Annual Congress of the European Association of Nuclear Medicine

October 12 – 16, 2019
Barcelona, Spain

eanm19.eanm.org
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Message</td>
<td>4</td>
</tr>
<tr>
<td>General Information</td>
<td></td>
</tr>
<tr>
<td>EANM Board &amp; Congress Committees</td>
<td>6</td>
</tr>
<tr>
<td>EANM19 Reviewers</td>
<td>6</td>
</tr>
<tr>
<td>EANM National Societies: Delegates &amp; Deputies</td>
<td>14</td>
</tr>
<tr>
<td>UEMS/EBNM National Delegates &amp; Deputies</td>
<td>14</td>
</tr>
<tr>
<td>UEMS/EBNM Committees</td>
<td>18</td>
</tr>
<tr>
<td>Information A-Z</td>
<td>20</td>
</tr>
<tr>
<td>Barcelona Information</td>
<td>24</td>
</tr>
<tr>
<td>Business Meetings</td>
<td>26</td>
</tr>
<tr>
<td>Floorplans</td>
<td></td>
</tr>
<tr>
<td>CCIB Barcelona</td>
<td>28</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td></td>
</tr>
<tr>
<td>Invited Speaker Sessions</td>
<td>32</td>
</tr>
<tr>
<td>Do.Mo.Re Track</td>
<td>40</td>
</tr>
<tr>
<td>M2M Track</td>
<td>41</td>
</tr>
<tr>
<td>EANM Young Daily Forum</td>
<td>42</td>
</tr>
<tr>
<td>Programme Overviews</td>
<td>43</td>
</tr>
<tr>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>(Incl. e-Poster Presentations)</td>
<td></td>
</tr>
<tr>
<td>Saturday, October 12, 2019</td>
<td>54</td>
</tr>
<tr>
<td>Sunday, October 13, 2019</td>
<td>59</td>
</tr>
<tr>
<td>Monday, October 14, 2019</td>
<td>99</td>
</tr>
<tr>
<td>Tuesday, October 15, 2019</td>
<td>140</td>
</tr>
<tr>
<td>Wednesday, October 16, 2019</td>
<td>173</td>
</tr>
<tr>
<td>e-Posters</td>
<td></td>
</tr>
<tr>
<td>Technologist e-Poster Presentation</td>
<td>111</td>
</tr>
<tr>
<td>e-Posters</td>
<td>185</td>
</tr>
<tr>
<td>Industry Programme</td>
<td></td>
</tr>
<tr>
<td>Satellite Symposia</td>
<td>292</td>
</tr>
<tr>
<td>List of Exhibitors</td>
<td>286</td>
</tr>
<tr>
<td>Exhibition Hall Floorplan</td>
<td>310</td>
</tr>
<tr>
<td>Company Profiles</td>
<td>312</td>
</tr>
<tr>
<td>Corporate Members</td>
<td>382</td>
</tr>
</tbody>
</table>
On behalf of the European Association of Nuclear Medicine, it is my great pleasure and honour to cordially invite you to the 32nd Annual EANM Congress in October 2019. This year, our congress will take place in Barcelona, Spain. The city is world famous for its hospitality, its cultural attractions and its culinary highlights.

Molecular imaging is continuously expanding; it is increasingly being combined with advanced technologies such as artificial intelligence and has become a principal component of medical imaging. In the therapy field, targeted radiopharmaceuticals have been demonstrated to be effective and are increasingly used in a variety of clinical settings, often integrated with other therapeutic options. The ultimate goal is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine clinical practice.

In the last three years, the status of the EANM annual meeting as the world-reference congress in nuclear medicine has been confirmed. In order to maintain the high level of excellence, the 2019 EANM Congress will build on the traditions that are highly appreciated by all attendees, with the expansion of newer features. A specific educational track, implemented with the collaboration of the European School of Multimodality Imaging and Therapy, will include up-to-date teaching sessions, enriched pitfalls seminars and Continuous Medical Education interactive sessions. In all these active learning conferences, attendees will have the possibility to enhance their knowledge of multimodality imaging. A careful evaluation procedure relating to the speakers will be implemented in order to gain feedback and ensure that future interactive sessions continue to enjoy a positive response. With similar pedagogic intent, numerous multidisciplinary joint symposia, organised by several EANM Committees in collaboration with our sister societies, will offer an integrative approach to various topics relevant to the state of the art of our discipline.

All these learning sessions will not impact adversely on the predominant role of our Congress, which is to enable oral and electronic poster presentations on the latest achievements in clinical nuclear medicine, science and technology. On the contrary, the oral sessions will be enriched. Rapid Fire sessions will draw attention to the highly rated abstracts in specific fields, with a panel of top-level presentations followed by extensive discussions; this will provide attendees with an integrated and coherent view on a wide variety of topics. Furthermore, the concept of featured oral sessions in which an invited speaker places the presentations into a broader perspective will be generalised to all the other oral presentations. The now well-established tracks M2M – Molecule to Man (basic and translational science) and Do.MoRe (radionuclide therapy and dosimetry) promise to promote high-quality research through interaction between basic and translational clinical scientists and to present the latest achievements and developments in the fields of clinical molecular imaging and nuclear medicine therapy. During plenary lectures, distinguished speakers will address the state of the art and new developments in clinical and allied sciences, covering a broad range of topics with the goal of fostering the provision of the best possible care for our patients. I am particularly delighted that two young but very motivated and highly respected members of our European Nuclear Medicine community, Dr. Valentina Garibotto from Geneva, Switzerland, and Dr. Sarah Schwarzenböck from Rostock, Germany, will provide the traditional Highlights lecture.

For all these reasons, I cordially invite you to EANM’19 to actively participate in our 32nd Annual Congress, to meet and interact with friends and colleagues from all over the world, to discuss science, to learn about the exciting developments in nuclear medicine, to break away from the daily routine and to enjoy everything that the city of Barcelona has to offer.

Francesco Giammarile
EANM Congress Chair 2017-2019
Board & Congress Committees

EANM BOARD

President 2019 – 2020
W.J.G. Oyen (Netherlands)

President Elect 2019 – 2020
J. Kunikowska (Poland)

Committee Coordinator 2019 – 2020
R. Hustinx (Belgium)

Congress Chair 2017 – 2019
F. Giammarile (Austria)

Education Chair 2017 – 2019
J. Pruim (Netherlands)

Secretary/Treasurer 2019 – 2020
W. Wadask (Austria)

Scientific Liaison Officer 2019 – 2020
M. Lasimann (Germany)

ADVISORY COUNCIL

The EANM Advisory Council is composed of the members of the Board and of the Committee Chairs:

Bone & Joint Committee
F. Paycha (France)

Cardiovascular Committee
H. Verberne (Netherlands)

Dosimetry Committee
M.W. Konijnenberg (Netherlands)

Drug Development Committee
J. Vercoullie (France)

Ethics Committee
W. Knapp (Germany)

Inflammation & Infection Committee
A. Glaudemans (Netherlands)

Neuroradiology Committee
I. Law (Denmark)

Oncology & Theranostics Committee
K. Herrmann (Germany)

Paediatrics Committee
Z. Bar-Sever (Israel)

Physics Committee
C. Hindorf (Sweden)

Radiation Protection Committee
S. Holm (Denmark)

Radiopharmacy Committee
M. Patt (Germany)

Technologist Committee
A. Santos (Portugal)

Thyroid Committee
M. Luster (Germany)

Translational Molecular Imaging & Therapy Committee
F. Van Leeuwen (Netherlands)

SCIENTIFIC PROGRAMME COMMITTEE

Chair
F. Giammarile (Austria)

Members
K. Bashir (Belgium)
M.W. Konijnenberg (Netherlands)
T. Kusser (Germany)
A. Santos (Portugal)
G. Treglia (Switzerland)
J. Vercoullie (France)
P. Zucchetta (Italy)
D. Visvikis (France)
K. Herrmann (Germany)
I. Iakovou (Greece)
P. Laveran (Netherlands)
F. Van Leeuwen (Netherlands)
F. Hyafil (France)
S. Morbelli (Italy)

SESSION COORDINATORS

V. Ambrosini
L. Antunovich
J. Arbizu
M. C. Attard
M. Bajc
S. Balogova
H. Barthel
M. Béhé
L. Bassorin
L. Cariani
F. Caobelli
P. Castellucci
N. Choun
L. de Geus-Oei
M. de Jong
R. Delgado Bolton
U. Eberlein
P. A. Erba
L. Evangelista
G. Flux
P. Fragnoi Costa
M. Gabriel
V. Garibotto
J. Gear
F. Gammarile
L. Giovanna
A. Glaudemans
G. Granavoglia
K. Herrmann
F. Hyafil
I. Iakovou
J. Kampen
C. Kobe
M. Konijnenberg

L. Kurch
A. Lamertsma
P. Laverman
I. Law
M. Ljungberg
E. Lopci
M. Luster
T. Lynch
M. Mada
T. Mogiatti
S. Morbelli
S. Nekolla
M. Olak
F. Paycha
A. Piccaro
S. Rac
L. Ribah-Vidal
S. Rep
D. Rubello
A. I. Santos
A. Santos
B. Santier
M. Schottelius
F. Semah
K. Spigregi Glessner
L. Stringari
J. H. Talbot
C. Tervanghe
G. Treglia
F. Van Leeuwen
J. Vercoullie
D. Visvikis
S. Zerdoud
EANM’19 Reviewers

A
- Erik Aarnitzen (Norway)
- Ronan Abgral (France)
- Wandi Acampa (Iceland)
- Judit Adam (Austria)
- An Aerts (Belgium)
- Denis Agostini (Paraguay)
- Nicolas Ajd (France)
- Rengard Maria Aigner (Austria)
- Umut Özgür Akdemir (Turkey)
- Nathalie Lisa Albert (Germany)
- Luigi Aloj (United Kingdom)
- Valentina Ambrosini (Italy)
- Marie Claire Attard (Netherlands)

B
- Lazlo Balkay (Hungary)
- Sona Bologova (Bosnia and Herzegovina)
- Ziú Bar-Sever (Israel)
- Manuel Barlitis (France)
- Henrik Barthel (Germany)
- Matteo Bauckneht (Italy)
- Martin Behr (Switzerland)
- Mohsen Beheshti (Germany)
- Simona Ben-Haim (Israel)
- Monique Bemnen (Norway)
- Valentina Bert (Italy)
- Andrea Bianchi (Italy)
- Lorenzo Bassors (United Kingdom)
- Angelika Bischof Deliakye (Ukraine)
- Jan Booj (Netherlands)
- Katalin Barabás (Hungary)
- Lise Borgwardt (Sweden)
- Maria Filomena R. Botelho (Portugal)
- David Briani (Switzerland)
- Matthias Broom (Ireland)
- Jan Bucerus (Netherlands)

C
- Carmelo Baldarelli (Italy)
- Luca Camoni (Italy)
- Federico Casbetti (Switzerland)
- Sofia Carriuho Vaz (Portugal)
- Ignasi Carrion (Spain)
- Paolo Castellucci (Italy)
- Chris Cavethome (Belgium)
- Diego Cecchini (Italy)
- Julianno Cerec (Italy)
- Riddhika Chakravartty (United Kingdom)
- Carlo Chiesa (Italy)
- Arturo Chi (Italy)
- Nicolas Chouin (France)
- Renaud Capuccion (Belgium)
- Francesco Ciccoricco (Italy)
- Bart Cornelissen (United Kingdom)
- Peter Covenys (United Kingdom)
- Alberto Cuscelo (Italy)
- David Currat (Ireland)

D
- Simone Dalmi (Netherlands)
- Doumit Daou (France)
- Peter De Bebi (Belgium)
- Lrce-FrÈDe Geor-Op (Netherlands)
- Claire De Labriolle-Vaylet (Paraguay)
- Diego De Palma (Italy)
- Jan de Swart (Netherlands)
- Erik F.J. de Wies (Netherlands)
- Clemens Decristoforo (Austria)
- Alberto Del Guerra (Switzerland)
- Roberto Carlos Delgado-Bolton (Spain)
- Christophe Deroose (Belgium)
- Winnie Deuthe-Conrad (Germany)
- John Dickib (United Kingdom)
- Audri Driez (Belgium)
- Lawrence Oliver Driewick (Paraguay)
- Miroslav Dzulk (Poland)

E
- Uta Eberlein (Germany)
- Michael Eisenhut (Germany)
- Philip Hein Eisinga (Netherlands)
- Paola A. Erba (Italy)
- Bekki Vance-Edda (Turkey)
- Turkak Entay (Turkey)
- Markus Essler (Germany)
- Laura Evangelista (Italy)
- Hendrik Everaert (Belgium)
- Samer Ezzidim (Finland)

F
- Melpomenu Fani (Belgium)
- Stefano Fant (Italy)
- Andrea Faro (Italy)
- Mohsen Faraad (France)
- Antonin Fikle (Czech Republic)
- Albert Flores-Giral (Spain)
- Glenn Flux (United Kingdom)
- Ivan Foldes (Hungary)
- Flavio Forrer (Sweden)
- Santa Forbas (United Kingdom)
- Pedro Fragoso Costa (Spain)
- Majo Franceschi (Croatia)
- Savvas Frangos (Spain)
- Christiane Franzius (Germany)

G
- Simona Gabrescoc (Switzerland)
- Michael Gabriel (Ireland)
- Andrei Gafita (Germany)
- Hans-Jürgen Gallowsitz (Austria)
- Lalitz Galuska (Hungary)
- Aria M. Garcia-Vicente (Spain)
- Valentina Garibotto (Switzerland)
- Jonathan Geurts (United Kingdom)
- Panagiotis Georgoulas (Greece)
- Oliver Grayem (Belgium)
- Nicholas Gillings (Ireland)
- Luca Giovannelli (Hungary)

H
- Uwe Haberkorn (Germany)
- Christin Haldin (Sweden)
- Mathieu Hart (France)
- Linda Heijmen (Netherlands)
- Karl Herholz (United Kingdom)
- Ken Hermann (Germany)
- Sven Hesloo (Germany)
- Cecilia Hindorf (Switzerland)
- Michael Hintereit (Austria)
- Martha Hoffmann (Austria)
- Soren Hofr (Denmark)
- Roger Haywood (United States of America)
- Alija Hubalewska-Dyjeczyk (Poland)
- Brian Hutton (United Kingdom)
- Fabien Hyafi (France)

I
- Ioannis Iakovou (Greece)
- Kenmo Ito (Japan)

J
- Marcel Janssen (Netherlands)
- Nina Jezherno (France)

K
- Wilm Uwe Kampert (Germany)
- Salim Kanaou (Morocco)
- Sina Karcz (Turkey)
- Margarita Kirenska (Italy)
- Anna Krizan (Slovenia)
- Rigobert Kleit (Austria)
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevena Manevska</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Venjamin Majstorov</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Theodosia Maina-Nock</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>ハンス・マイクリヒト</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Susanne Lütje</td>
<td>Germany</td>
</tr>
<tr>
<td>Moti Lorberboyn</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Lars Kurth</td>
<td>Germany</td>
</tr>
<tr>
<td>Jens Kurth</td>
<td>Germany</td>
</tr>
<tr>
<td>Torsten Kuwert</td>
<td>Germany</td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>Ada Lijanda Lammerstrom</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Charline Lasnari</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Michael Laszmann</td>
<td>Germany</td>
</tr>
<tr>
<td>Chiara Lauri</td>
<td>Italy</td>
</tr>
<tr>
<td>Peter Lavermant</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Edgar Anstides Lemos-Pereira</td>
<td>Portugal</td>
</tr>
<tr>
<td>Oliver Lindner</td>
<td>Germany</td>
</tr>
<tr>
<td>Michael Ljungberg</td>
<td>Sweden</td>
</tr>
<tr>
<td>Eggesta Lopici</td>
<td>Italy</td>
</tr>
<tr>
<td>Moti Lorberboyn</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Mark Lubbenink</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Susanne Lutje</td>
<td>Netherlands</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Marius Mada</td>
<td>Italy</td>
</tr>
<tr>
<td>Giuseppe Madeddu</td>
<td>Italy</td>
</tr>
<tr>
<td>Theodora Marina-Nock</td>
<td>Greece</td>
</tr>
<tr>
<td>Venjamin Majstorov</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Nevena Manevska</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Alain Manrique</td>
<td>France</td>
</tr>
<tr>
<td>Guillaume Mariani</td>
<td>Italy</td>
</tr>
<tr>
<td>Thibault Maurox</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Philipp M. Meyer</td>
<td>Germany</td>
</tr>
<tr>
<td>Jarina Mihalovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Renata Mikolajczak</td>
<td>Poland</td>
</tr>
<tr>
<td>Daniela Miladinova</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Elsa Milan</td>
<td>Italy</td>
</tr>
<tr>
<td>Thomas L. Mindt</td>
<td>Austria</td>
</tr>
<tr>
<td>Pablo Minguero Gallardo</td>
<td>Spain</td>
</tr>
<tr>
<td>Heddi Ralph Illari Mimi</td>
<td>Poland</td>
</tr>
<tr>
<td>Mercedes Mitjavila Casanovsik</td>
<td>Spain</td>
</tr>
<tr>
<td>Marina Monteiro</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Silvia Morbella</td>
<td>Italy</td>
</tr>
<tr>
<td>Felix Mattaghy</td>
<td>Germany</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>James Nagaranj</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Cristina Nanti</td>
<td>Italy</td>
</tr>
<tr>
<td>Carmela Nappi</td>
<td>Italy</td>
</tr>
<tr>
<td>Oliver Neel</td>
<td>Germany</td>
</tr>
<tr>
<td>Stephan Neffa</td>
<td>Germany</td>
</tr>
<tr>
<td>Flavia Nobili</td>
<td>France</td>
</tr>
<tr>
<td>Edel Nacriega</td>
<td>Spain</td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>Emine Meltem Ocak</td>
<td>Turkey</td>
</tr>
<tr>
<td>Anna Oltova</td>
<td>Sweden</td>
</tr>
<tr>
<td>Maria Teresa Ordu</td>
<td>Portugal</td>
</tr>
<tr>
<td>Arttis Ozlanski</td>
<td>Hungary</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Marco Pagani</td>
<td>Italy</td>
</tr>
<tr>
<td>Holger Palmen</td>
<td>Germany</td>
</tr>
<tr>
<td>Alfredo Palmen</td>
<td>Italy</td>
</tr>
<tr>
<td>Nikolaos Papathanasiou</td>
<td>Greece</td>
</tr>
<tr>
<td>Sabina Pappata</td>
<td>Italy</td>
</tr>
<tr>
<td>Claudio Pascali</td>
<td>Italy</td>
</tr>
<tr>
<td>Thomas Pascual</td>
<td>Austria</td>
</tr>
<tr>
<td>Marianne Patt</td>
<td>Germany</td>
</tr>
<tr>
<td>Frederic Pazcha</td>
<td>France</td>
</tr>
<tr>
<td>Lenka Perea Arias Hadzic</td>
<td>Germany</td>
</tr>
<tr>
<td>Petra Petranovic Ovcaricek</td>
<td>Hungary</td>
</tr>
<tr>
<td>Doina Piciu</td>
<td>Romania</td>
</tr>
<tr>
<td>Agata Karolina Pietrzak</td>
<td>Poland</td>
</tr>
<tr>
<td>Patrick Pilkington</td>
<td>Spain</td>
</tr>
<tr>
<td>Vasilios Prassopoulos</td>
<td>Greece</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>René Raëve</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Ian Rabiner</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sonja Rac</td>
<td>Greece</td>
</tr>
<tr>
<td>Zvezdana Rjakovac</td>
<td>Bosnia and Herzegovina</td>
</tr>
<tr>
<td>Ivo Rauch</td>
<td>Austria</td>
</tr>
<tr>
<td>Isabel Rauscher</td>
<td>Germany</td>
</tr>
<tr>
<td>Laila Rbah-Vidal</td>
<td>Jordan</td>
</tr>
<tr>
<td>Francesca Redondi</td>
<td>Italy</td>
</tr>
<tr>
<td>Sebastian Reip</td>
<td>Finland</td>
</tr>
<tr>
<td>Ana Cristina Revende Garau</td>
<td>Portugal</td>
</tr>
<tr>
<td>Mark Ripkeni</td>
<td>Germany</td>
</tr>
<tr>
<td>Christoph Aschipler</td>
<td>Germany</td>
</tr>
<tr>
<td>Margarida Rodrigues Radischat</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>Macarena Rodriguez-Fraile</td>
<td>Spain</td>
</tr>
<tr>
<td>Jan Roland</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Amanda-Ranger Rege</td>
<td>Finland</td>
</tr>
<tr>
<td>Sebastia Rubi</td>
<td>Spain</td>
</tr>
<tr>
<td>Edmond Rust</td>
<td>France</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Martin Samal</td>
<td>Cameroon</td>
</tr>
<tr>
<td>Ana Isabel Santos</td>
<td>Portugal</td>
</tr>
<tr>
<td>Andrea Santos</td>
<td>Portugal</td>
</tr>
<tr>
<td>Artti Saraste</td>
<td>Finland</td>
</tr>
<tr>
<td>Bernhard Sattler</td>
<td>Germany</td>
</tr>
<tr>
<td>Nikola Schafer</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Roger Schibli</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Andreas Schidlin</td>
<td>Germany</td>
</tr>
<tr>
<td>Erzhebet Schmidt</td>
<td>Portugal</td>
</tr>
<tr>
<td>Matthias Schmidt</td>
<td>Germany</td>
</tr>
<tr>
<td>Margret Schottelius</td>
<td>Germany</td>
</tr>
<tr>
<td>Markus Schwagert</td>
<td>Germany</td>
</tr>
<tr>
<td>Roberto Scaglia</td>
<td>Italy</td>
</tr>
<tr>
<td>Yann Semmler</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Franck Sematl</td>
<td>France</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Tereza Sena</td>
<td>Hungary</td>
</tr>
<tr>
<td>Stefivio Sestini</td>
<td>Italy</td>
</tr>
<tr>
<td>Gabriel Siclari</td>
<td>Italy</td>
</tr>
<tr>
<td>Reimer Sturti</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Graham Smith</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ciprian Stefanescu</td>
<td>Romania</td>
</tr>
<tr>
<td>Hans Steinert</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Caroline Stoikkel</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Marcel Stoikkel</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Lidia Stigtari</td>
<td>Finland</td>
</tr>
<tr>
<td>Klaus Strobel</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Anne Larsson Stromvall</td>
<td>Sweden</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Ana Ugurina</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Renato A. Valdes Olmos</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Elsemariene Van de Gessert</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Tim Van den Wijngaert</td>
<td>Belgium</td>
</tr>
<tr>
<td>Wouter Van der Bruggen</td>
<td>Belgium</td>
</tr>
<tr>
<td>Guus van Dongen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Martin van Essen</td>
<td>Sweden</td>
</tr>
<tr>
<td>Fuj Van Leeuwen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Sanne van Lith</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Jürgen Varga</td>
<td>Hungary</td>
</tr>
<tr>
<td>Nicolas Varmenot</td>
<td>Romania</td>
</tr>
<tr>
<td>Andrea Vareoni</td>
<td>Sweden</td>
</tr>
<tr>
<td>Patrick Veer-Habach</td>
<td>Canada</td>
</tr>
<tr>
<td>Hein J. Verbermen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Frederik Verburg</td>
<td>Germany</td>
</tr>
</tbody>
</table>
Johnny Vercouillie (France)
Annibale Versari (Italy)
Johan Frederik Verzijlbergen (Netherlands)
Sergi Vidal Sicart (Spain)
Liliana Vialante (Portugal)
Marina Vlajkovic (Serbia)
Alexis Vrachimis (Cyprus)
Dennis Vriens (Netherlands)

W
Stephan Walrand (Belgium)
Jochem Walz (France)
Michal Weiler-Sage (Israel)
Andy Welch (United Kingdom)

X
Catarina Xavier (Belgium)

Y
Ülkem Yararbas (Turkey)

Z
Katja Zaletel (Slovenia)
Katalin Zamba (Hungary)
Slimane Zerdoud (France)

EANM'19 at your fingertips!
Create your personal schedule!
Read scientific abstracts!
Get up to date information and much more...

Download it for free
## EANM National Societies: Delegates / Deputies

<table>
<thead>
<tr>
<th>Society</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenian Society of Nuclear Medicine</td>
<td>V. Barsegian</td>
<td>M. Grigoryan</td>
</tr>
<tr>
<td>Austrian Society of Nuclear Medicine</td>
<td>M. Hacker</td>
<td>I. Virgilini</td>
</tr>
<tr>
<td>Azerbaijani Society of Nuclear Medicine</td>
<td>F. Novruzov</td>
<td>A. Aliyev</td>
</tr>
<tr>
<td>Belgian Society of Nuclear Medicine</td>
<td>F. Jamar</td>
<td>N. Withofs</td>
</tr>
<tr>
<td>Bosnian Society of Nuclear Medicine</td>
<td>Z. Rajkovaçac</td>
<td>D. Roaç</td>
</tr>
<tr>
<td>British Nuclear Medicine Society</td>
<td>S. Vinjamuri</td>
<td>R. Graham</td>
</tr>
<tr>
<td>Bulgarian Society of Nuclear Medicine</td>
<td>V. Hadzyska</td>
<td>L. Chavdarova</td>
</tr>
<tr>
<td>Croatian Society of Nuclear Medicine</td>
<td>M. Franceschi</td>
<td>D. Šnejder</td>
</tr>
<tr>
<td>Cyprus Society of Nuclear Medicine</td>
<td>D. Kyprianos</td>
<td>R.K. Demetriadou</td>
</tr>
<tr>
<td>Czech Society of Nuclear Medicine</td>
<td>M. Simonek</td>
<td>P. Karanda</td>
</tr>
<tr>
<td>Danish Society of Clinical Physiology and Nuclear Medicine</td>
<td>L. Jensen</td>
<td>P. Hovind</td>
</tr>
<tr>
<td>Dutch Society of Nuclear Medicine</td>
<td>R. Bemink</td>
<td>M. Stokkel</td>
</tr>
<tr>
<td>Estonian Nuclear Medicine Society</td>
<td>S. Nazarzenko</td>
<td>K. Uist</td>
</tr>
<tr>
<td>Finnish Society of Nuclear Medicine</td>
<td>H. Mustalo</td>
<td>K. Timonen</td>
</tr>
<tr>
<td>Macedonian Society of Nuclear Medicine</td>
<td>A. Ugrinska</td>
<td>D. Miladinova</td>
</tr>
<tr>
<td>French Society of Nuclear Medicine</td>
<td>F. Cachin</td>
<td>J.-P. Vuiliez</td>
</tr>
<tr>
<td>German Society of Nuclear Medicine</td>
<td>B. Krause</td>
<td>K. Herrmann</td>
</tr>
<tr>
<td>George de Hevesy Hungarian Society of NM</td>
<td>T. Gyorke</td>
<td>L. Pavics</td>
</tr>
<tr>
<td>Georgian Nuclear Medicine Specialists Association</td>
<td>N. Shengela de Lange</td>
<td>K. Shamatava</td>
</tr>
<tr>
<td>Hellenic Society of Nuclear Medicine &amp; Biology</td>
<td>A. Fotopoulos</td>
<td>V.C. Prassopulos</td>
</tr>
<tr>
<td>Icelandic Society of Nuclear Medicine</td>
<td>to be announced</td>
<td>J. Gudjonsdottir</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Society</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irish Nuclear Medicine Association</td>
<td>M. O’Connell</td>
<td>R. Killeen</td>
</tr>
<tr>
<td>Israeli Society of Nuclear Medicine</td>
<td>Z. Bar-Sever</td>
<td>Z. Kedser</td>
</tr>
<tr>
<td>Italian Society of Nuclear Medicine</td>
<td>R. Giubbini</td>
<td>M.L. DeRemini</td>
</tr>
<tr>
<td>Latvian Society of Nuclear Medicine</td>
<td>D. Berzina</td>
<td>J. Kedrova</td>
</tr>
<tr>
<td>Lithuanian Society of Nuclear Medicine</td>
<td>D. Vajauskas</td>
<td>I. Kubakeiene</td>
</tr>
<tr>
<td>Luxembourg Society of Nuclear Medicine</td>
<td>C. Als</td>
<td>C.J. Picard</td>
</tr>
<tr>
<td>Maltese Association of Radiologists and Nuclear Medicine Physicians</td>
<td>M.A. Aquilina</td>
<td>A. Samuel</td>
</tr>
<tr>
<td>Norwegian Society of Nuclear Medicine</td>
<td>T.C. Adamsen</td>
<td>R. Sundset</td>
</tr>
<tr>
<td>Polish Society of Nuclear Medicine</td>
<td>R. Czepczynski</td>
<td>A. Sowa-Staszczak</td>
</tr>
<tr>
<td>Portuguese Society of Nuclear Medicine</td>
<td>G. Costa</td>
<td>A.P. Moreira</td>
</tr>
<tr>
<td>Romanian Society of Nuclear Medicine</td>
<td>R. Mititelu</td>
<td>V.C. Mazilu</td>
</tr>
<tr>
<td>Russian Society of Nuclear Medicine</td>
<td>P. Rumyantsev</td>
<td>V. Soukhov</td>
</tr>
<tr>
<td>Serbian Nuclear Medicine Society</td>
<td>D. Sobic-Saranovic</td>
<td>J. Mihalovic</td>
</tr>
<tr>
<td>Slovak Society of Nuclear Medicine</td>
<td>P. Pavnic</td>
<td>L. Kaliska</td>
</tr>
<tr>
<td>Slovenian Society of Nuclear Medicine</td>
<td>I. Zagar</td>
<td>K. Zatezal</td>
</tr>
<tr>
<td>Spanish Society of Nuclear Medicine</td>
<td>J.C. Alonso Farto</td>
<td>J.A. Vallejo Casas</td>
</tr>
<tr>
<td>Swedish Society of Nuclear Medicine</td>
<td>A. Sundin</td>
<td>A. Larson-Strömvalt</td>
</tr>
<tr>
<td>Swiss Society of Nuclear Medicine</td>
<td>T. Krause</td>
<td>M. Wissmeyer</td>
</tr>
<tr>
<td>Turkish Society of Nuclear Medicine</td>
<td>Z. Ozcan</td>
<td>L.O. May</td>
</tr>
<tr>
<td>Ukrainian Society of Nuclear Medicine</td>
<td>to be announced</td>
<td>to be announced</td>
</tr>
</tbody>
</table>
## UEMS/EBNM National Societies:
### Delegates / Deputies

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRIA</td>
<td>A. Kurttan</td>
<td>R. Lipp</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>K. Spaepen</td>
<td>G. Moulin-Romsee</td>
</tr>
<tr>
<td>BULGARIA</td>
<td>E. Piperkova</td>
<td>A.D. Tzanevski</td>
</tr>
<tr>
<td>CROATIA</td>
<td>D. Huic</td>
<td>S. Kusacic Kuna</td>
</tr>
<tr>
<td>CYPRUS</td>
<td>R.K. Demetriadou</td>
<td></td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>O. Lang</td>
<td>M. Kaminek</td>
</tr>
<tr>
<td>DENMARK</td>
<td>S. Hess</td>
<td>L.T. Jensen</td>
</tr>
<tr>
<td>ESTONIA</td>
<td>E. Kelk</td>
<td>A. Paksi</td>
</tr>
<tr>
<td>FINLAND</td>
<td>K. Timonen</td>
<td>J. Kemppainen</td>
</tr>
<tr>
<td>FRANCE</td>
<td>E. Gremillet</td>
<td>J.-E. Filmont</td>
</tr>
<tr>
<td>GERMANY</td>
<td>W. Brenner</td>
<td>M. Gotthardt</td>
</tr>
<tr>
<td>GREECE</td>
<td>I. Iakovou</td>
<td>S. Tsouris</td>
</tr>
<tr>
<td>HUNGARY</td>
<td>L. Pavics</td>
<td>I. Szilvasi</td>
</tr>
<tr>
<td>IRELAND</td>
<td>S. Skehan</td>
<td>M. O’Connell</td>
</tr>
<tr>
<td>ITALY</td>
<td>B. Palumbo</td>
<td>A. Carmiello</td>
</tr>
<tr>
<td>LATVIA</td>
<td>I. Vevere</td>
<td>A. Berzina</td>
</tr>
<tr>
<td>LITHUANIA</td>
<td>D. Vajauskas</td>
<td>N. Jurkene</td>
</tr>
<tr>
<td>LUXEMBOURG</td>
<td>P. Paulus</td>
<td>M. Doat</td>
</tr>
<tr>
<td>MALTA</td>
<td>A. Samuel</td>
<td>M. A. Aquilina</td>
</tr>
<tr>
<td>NETHERLANDS</td>
<td>R. J. Bennink</td>
<td>M. Stokkel</td>
</tr>
</tbody>
</table>

**nominated from full UEMS Member Countries**

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORWAY</td>
<td>T.M. Haslerud</td>
<td>M. Revheim</td>
</tr>
<tr>
<td>POLAND</td>
<td>M. Dzuk</td>
<td>B. Birkenfeld</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>L. Salgado</td>
<td>M. T. Ferreira</td>
</tr>
<tr>
<td>ROMANIA</td>
<td>G. Andres</td>
<td>R. Mititelu</td>
</tr>
<tr>
<td>SERBIA</td>
<td>V. Antiko</td>
<td>J. Mihailovic</td>
</tr>
<tr>
<td>SLOVAKIA</td>
<td>A. Vondrak</td>
<td>L. Kaliska</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>M. Grmek</td>
<td>D. Hristnik</td>
</tr>
<tr>
<td>SPAIN</td>
<td>J.C. Alonso Farto</td>
<td>F. Pons</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>E. Tiagjadh</td>
<td>P. Gryback</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>A. Boubaker</td>
<td>G. Goerres</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>S. Dzidarevic</td>
<td>T. Wagner</td>
</tr>
</tbody>
</table>

**nominated from UEMS Associate Member Countries**

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>TURKEY</td>
<td>Y. Yurekli</td>
<td>Z. Ozcan</td>
</tr>
</tbody>
</table>

**nominated from UEMS Observer Countries**

<table>
<thead>
<tr>
<th>Country</th>
<th>Delegate</th>
<th>Deputy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRAEL</td>
<td>A. Steinmetz</td>
<td>M. Quastel</td>
</tr>
</tbody>
</table>
UEMS/EBNM Committees

EXECUTIVE COMMITTEE

President  S. Mirzaei (Austria)
Secretary & Treasurer  S. Frangos (Cyprus)
Member  R. Hustinx (Belgium)

FELLOWSHIP EXAMINATION

Chair  A. Boubaker (Switzerland)
Members  I. Kulakienė (Lithuania)
Z. Özcan (Turkey)
J. R. García Garzón (Spain)
S. Vaz (Portugal)
Ex Office  S. Frangos (Cyprus)

EDUCATION & SYLLABUS

Chair  R. Hustinx (Belgium)
Members  J. Darcourt (France)
H. B. Sayman (Turkey)
D. Huic (Croatia)
T. V. Bogsrud (Norway)
P. Castellucci (Italy)

CME ACCREDITATION

Chair  M. Farsad (Italy)
Members  E. Lopci (Italy)
A. Haug (Austria)
S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair  J. Prior (Switzerland)
Members  A. García-Burillo (Spain)
N. Murtuza (Norway)
P. A. L. Van Boxem (Belgium)
M. L. Hall (United Kingdom)
Corresponding Members  F. Giesel (Germany)
A. Jiménez Heffernan (Spain)
J. Sippo-Tujunen (Finland)
N. G. Hartman (United Kingdom)
S. E. Bouayounef (Algeria)
A. Ciarmiello (Italy)
Ex officio  S. Mirzaei (Austria)

To obtain your CME/CTE credits (for single sessions as well as the congress itself) the respective evaluations are mandatory. Deadline: October 30, 2019. After this date, or without proper evaluation, no points will be accredited.

EVALUATION.EANM.ORG

EANM’19
CME/CTE CERTIFICATES

1) SCAN YOUR BADGE
Scan your badge at the beginning of each session when entering the room in order to acquire CME or CTE credits.

2) EVALUATE (Deadline - October 30, 2019)
A short evaluation has to be completed for each attended CME/CTE session until Oct 30, 2019.
Evaluation has to be done online at evaluation.eanm.org

3) DOWNLOAD YOUR CERTIFICATE
Once the steps above are completed, your certificate will be available within 24 hours in your vEANM area.
Information A - Z

AUDIO & VIDEO RECORDINGS
Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

BARCELONA INFORMATION DESK
The Barcelona Information Desk with a guide at the entrance level of the CCIB – Centre de Convencions Internacional de Barcelona will be open:
- Saturday, October 12, 2019: 10:00 – 19:00
- Sunday, October 13, 2019: 09:00 – 18:00
- Monday, October 14, 2019: 09:00 – 18:00
- Tuesday, October 15, 2019: 09:00 – 18:00
- Wednesday, October 16, 2019: 09:00 – 12:00

CERTIFICATE OF ATTENDANCE
To obtain your certificate of attendance please visit www.eanm.org, log in to your personal vEANM Area with your username and password and refer to the section «Confirmation > Congress related. The certificate(s) will be available within 24 hours after you have scanned your congress badge.

CME CREDITS & CERTIFICATES
The EANM’19 – 32nd Annual Congress of the European Association of Nuclear Medicine in Barcelona, Spain, 12/10/2019-16/10/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 31 European CME credits (ECMECs®).
To acquire CME credits, you are required to scan your congress badge at the congress bag distribution upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, you must complete an evaluation form for each one of the sessions attended. To obtain your CME certificate(s) please visit www.eanm.org, log in to the vEANM Area with your personal account information and refer to the section «Confirmation > Congress related. The certificate(s) will be available within 24 hours after you have scanned your congress badge.

CONGRESS APP
Maximise your connectivity and speed up your planning during the congress with the EANM’19 Congress App. Download it from the App Store and Play Store and benefit from the complete information in electronic way at your fingertips.
Browse through the Scientific Programme with the latest updates and create your personal schedule.
Stay up to date by receiving notifications.
Find your way to our industry partners by using the electronic floor plans.
Evaluate the sessions directly on your smart device to receive your CME Certificates.

CONGRESS VENUE
CCIB – Barcelona International Convention Centre
Placa de Willy Brandt, 11-14
08019 Barcelona, Spain
URL: http://www.ccib.es/home

The CCIB is a part of the newest section of Barcelona’s seafront, located in the heart of the technology and business district. This unique congress centre is known for the originality of its architecture and column free meeting halls with natural Mediterranean light. With a surface of 100,000 m² including the convention centre and forum auditorium the CCIB is a perfect location for creative congresses and meetings. It is in easy reach with the subway – line L4 (yellow line) until Maresme-Forum, tram and bus – lines 7 and H16 until Forum. There are also a lot of hotels in walking distance to the congress centre.
For further information about the lines connected to the CCIB, please visit http://www.ccib.es/getting-to-the-ccib/visitor-access

CONGRESS SELF CHECK-IN
Self Check-In stations will help you to collect your name badge without waiting queues. Please make sure to bring your QR code and a personal ID and visit our Self Check-In stations in the EANM Registration Area (Level 0, Entrance Hall).

CONGRESS OFFICE
The congress office is located at level P3, Room M212/212 & will be open during the following days and times:
- Saturday, October 12, 2019: 07:30 – 18:00
- Sunday, October 13, 2019: 07:30 – 18:00
- Monday, October 14, 2019: 07:30 – 18:00
- Tuesday, October 15, 2019: 07:30 – 18:00
- Wednesday, October 16, 2019: 07:30 – 12:00

CONGRESS LANGUAGE
The congress language is English. No simultaneous translation will be provided.

CONGRESS LANGUAGE
The congress language is English. No simultaneous translation will be provided.

CERTIFICATE OF ATTENDANCE
To obtain your certificate of attendance please visit www.eanm.org, log in to your personal vEANM Area with your username and password and refer to the section «Confirmation > Congress related. The certificate(s) will be available within 24 hours after you have scanned your congress badge.

EANM MEMBERS’ ASSEMBLY
The Members’ Assembly will be held on Saturday, October 12, 2019 from 16:30 – 18:30 | Lecture Hall 312, Level P3.
Please note: Only EANM members in good standing (having paid their membership dues for the year 2019) are eligible to attend the Members’ Assembly.

e-POSTER AREA
The e-Poster Area features 40 computers where you can check all uploaded e-Posters of EANM’19.
You can search for authors, topics and keywords.
The e-Poster Area is located in Level P3, next to the Review Centre and is open during the congress opening times.

INSURANCE & LIABILITY
Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

INTERNATIONAL MEETINGS AND ANNOUNCEMENT BOARD
Visit the Exhibition Hall to get information on upcoming events in nuclear medicine and more.
INTERNET CORNER
EANM provides free internet access at stations within the industry exhibition (SUN'TUBE) incl. a printing possibility. Please limit the viewing time to max. 5 minutes per person.

INTERNET / WI-FI
Free Wi-Fi is offered throughout the meeting (within the premises).
Network: EANM
Password: eanm2019

LOST & FOUND
A lost and found service will be provided at the EANM Registration desk for the duration of the congress.

MEDIA
By attending the event, you acknowledge and agree to grant EANM the right at the congress to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed, and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to you or any of your representatives.

MEDICAL FACILITIES
Medical assistance and an ambulance service will be available throughout the congress.

MOBILES
Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should be put to silent mode at all times when you are in the Congress Centre.

MUSEUMS
Barcelona has a huge variety of museums, which can easily suit every taste and fancy. Some museums are mainly to appeal to tourists, whereas others contain some of the biggest art collections of some style and yet others have education as their main purpose.

NAME BADGES
The badges for the congress will only be issued on-site between October 12 and October 16, 2019. The badges must be collected in person.
A confirmation email including a QR code will be issued upon successful completion of registration. With this QR code, along with a valid photo ID, the name badge can be printed onsite at the registration.

OPENING CEREMONY & WELCOME RECEPTION
All registered delegates and accompanying persons are cordially invited to the Opening Ceremony & Welcome Reception on Saturday, October 12, 2019 | 19:30 – 23:00
The Opening Ceremony will be held at the Auditorium of the CCIB and the subsequent Welcome Reception at Level 0 of the CCIB, in the Entrance Hall.
CCIB — Barcelona International Convention Centre
Plaça de Wili Branda, 11-14
08019 Barcelona, Spain
Please note: As of 22:00 only persons holding a valid congress name badge will be permitted to enter the congress venue. Anyone who has not picked up his/her badge from the registration desk until 22:00, or has not yet registered, or has lost/ forgotten his/her badge can no longer be granted entry into the congress venue due to security reasons. Registration will re-open on Sunday morning at 07:30.

PARKING
Private cars can be parked at additional cost in the parking areas P1 Pl. Forum, P2 Garcia Faria and P3 C.C. Diagonal Mar. The costs for a day are between € 10.00 and € 25.00. You can also reserve a parking space online on the following website: www.parclick.com.

PROGRAMME PLANNER & MYSCHEDULE
Browse through the EANM19 programme, plan your personal itinerary or search for dedicated sessions, abstracts or posters. Mark your favourite items by clicking on the star icon to add them to MySchedule. Make sure to login with your eEANM account before to have MySchedule synchronized on all your devices.

PUBLIC TRANSPORTATION TICKET
In case you have booked your hotel through the online registration page of EANM which is more than a 15 minutes’ walk away from the congress venue you will receive a complimentary public transportation ticket upon check-in at the hotel. In case you haven’t received it, please contact the Accommodation Desk in the Registration Area.
The PTT is not valid for the return transfer to the airport by public transport.
For further information on the public transportation system please visit https://www.tbmcat/en/home

SOCIAL MEDIA
The EANM is represented on several social media platforms to keep members, fans, followers and subscribers up to date on offers and activities of the EANM.
Follow us and share your experiences by using the hashtags #EANM and #EANM19!
Subscribe to become one of over 2.000 viewers and enjoy exclusive interviews, photos and videos, up-to-date information and much more.

REVIEW CENTRE
The Review Centre features 40 computers where you can check the PowerPoint presentations which have been already presented during EANM19. So in case you have missed a session, you can review the slides here afterwards.
The Review Centre is located in Level 3, next to the e-Poster Area and is open during the congress opening times.

REGISTRATION DESK
The registration desk at the entrance level of the CCIB will be open
Saturday, October 12, 2019: 07:30 – 22:00
Sunday, October 13, 2019: 07:30 – 18:00
Monday, October 14, 2019: 07:30 – 18:00
Tuesday, October 15, 2019: 07:30 – 18:00
Wednesday, October 16, 2019: 07:30 – 12:00

World Leading Meeting
Final Programme
Barcelona, Spain | October 12 – 16, 2019
Barcelona Information

BANKS, CREDIT CARDS & ATM’s
Banks are usually open from 09:00 - 16:00 (Monday-Friday) – closed during the weekends.
There will be ATMs (Automatic Teller Machine) at the nearby shopping mall and all over the city of Barcelona. At the airport and main station and along the main streets you first currency exchange offices as well. All major credit cards, including Eurocard, Diners, Visa and MasterCard are accepted in most of the establishments such as restaurants, hotels and shopping-centres and stores.
Travel checks can be cashed in most of the banks and exchange offices.
When paying by credit card for your shopping, you will be asked to show an identification. Please have your ID card or passport with you all the time, otherwise they may refuse to accept your credit card as payment.

CHURCHES, SYNAGOGUES, MOSQUES
Although Barcelona (like the rest of Spain) is basically catholic, all religions are allowed and practiced by many citizens. Please contact your hotel concierge for current times of services or nearby churches.

CITY TAX
In 2012 the Catalan Government approved a new tax on stays. The amount of the city tax depends on the category of the hotel and varies between 0,75 € and 2,50 € per person and night. This fee applies for the first seven nights. For any additional nights there will be no charge anymore.

CLIMATE
Barcelona enjoys a Mediterranean climate, with short cool winters and hot summers. The location of the city besides the sea increases the humidity level. Generally, it rains with more intensity during spring and autumn. In September and October, thunderstorms are frequent. In October the temperatures are mostly very nice with sunny autumn days while temperatures are decreasing radically at night.

CURRENCY
The official currency in Spain is Euro (€). You can exchange your currency without any limits for total amount at all banks as well as many exchange offices in Barcelona. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

ELECTRICITY
The power supply in Spain is 220/240 V. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British ones an adaptor for the two-pin sockets in use in Spain.

RESTAURANTS & NIGHTLIFE
One of the main characteristics of Barcelona is its nightlife. The good weather contributes to sit at the terraces of the coffee-shops, bars and restaurants which are open until very late.
Downtown restaurants normally open for lunch from 11:00 to 15:00 and for dinner from 19:30 to 23:00. Cafes and breakfast bars may open already at 08:00 or even earlier.
There is a great number of “tapas-bars” where you can enjoy a drink and small “tapas” or “pinchos” to eat any time of the day.
Fast food, kebabs and take-away pizza stalls usually serve food all day long, and some of them stay open till midnight. Bars, night clubs and discotheques usually open from 22:00 – 04:00 (some even longer).

SAFETY TIPS / PICK-POCKETS
Barcelona is very safe from violent crime - ranking sixth in the EU accordingly to the ’Safe Cities Index 2017’ by The Economist Intelligence Unit (EIU). But there are many pick-pockets and bag thieves in areas with popular tourist attractions (especially on Las Ramblas street & La Sagrada Familia), in the central subway, and the Sants train station.
Therefore, please do not carry your name badge outside the COB – it would clearly mark you as tourist. Do not put your wallet in your back pocket - but in a pocket with a zipper which you can see. Do not put phones, cameras etc. on tables at cafes and keep your belongings always on your lap. Carry your rucksack or shoulder bag in crowded areas or on street shows always in front of you so you can see it. Put the strap of your shoulder bag not just over your shoulder, but across your body. Be wary of strangers approaching or touching you and do not play any street games. Do not carry all cash money, credit card and ID documents all together in one bag/pocket. Keep a copy of your ID card as payment.

TAXES
Barcelona taxi colours are black and yellow. Taxis are an affordable alternative to the public transportation. A 15 minutes journey will cost about 10,00 € depending on the traffic. It is not recommended to use taxis in the inner city as a lot of the streets are pedestrian areas and the traffic is quite high. The rates will be shown on the meter next to the driver. The minimum rate for a taxi is 2,10 € plus 1,07 € to 1,30 € per kilometre depending on the time.
Possible taxi numbers are: Ràdio Taxi: +34 933 033 033 / Servi Taxi: +34 933 030 300 / Fono Taxi: +34 933 001 100 / Radio Taxi Maramar: +34 934 331 020.

TIME ZONE
Barcelona is located in the Central European Time Zone (CET), i.e one hour ahead of Greenwich Mean Time (GMT+1).
# Business Meetings during EANM’19

## EANM ASSEMBLIES

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Delegates Assembly</td>
<td>Sat. Oct. 12</td>
<td>13:45-16:15</td>
<td>Lecture Hall 312</td>
<td>P3</td>
</tr>
<tr>
<td>EANM Members Assembly</td>
<td>Sat. Oct. 12</td>
<td>16:30-18:30</td>
<td>Lecture Hall 312</td>
<td>P3</td>
</tr>
</tbody>
</table>

## EANM COMMITTEE INTEREST GROUP MEETINGS

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Translational Molecular Imaging &amp; Therapy Committee Interest Group Meeting</td>
<td>Sun. Oct 13</td>
<td>13:00-14:30</td>
<td>Meeting Room 130</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Oncology &amp; Thranostics Committee Interest Group Meeting</td>
<td>Sun. Oct 13</td>
<td>16:15-17:45</td>
<td>Meeting Room 131/132</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Neuroimaging Committee Interest Group Meeting</td>
<td>Mon. Oct 14</td>
<td>10:00-11:00</td>
<td>Meeting Room 123</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Thyroid Committee Interest Group Meeting</td>
<td>Mon. Oct 14</td>
<td>10:00-11:15</td>
<td>Meeting Room M220</td>
<td>P2</td>
</tr>
<tr>
<td>EANM Physics Interest Group Meeting</td>
<td>Mon. Oct 14</td>
<td>10:30-11:15</td>
<td>Meeting Room 131/132</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Drug Development Committee Interest Group Meeting</td>
<td>Mon. Oct 14</td>
<td>13:00-14:30</td>
<td>Meeting Room 123</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Paediatrics Committee Interest Group Meeting</td>
<td>Mon. Oct 14</td>
<td>13:45-15:00</td>
<td>Meeting Room 129</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Bone and Joint Committee Interest Group Meeting</td>
<td>Tue. Oct 15</td>
<td>11:30-13:00</td>
<td>Meeting Room M221</td>
<td>P2</td>
</tr>
<tr>
<td>EANM Dosimetry &amp; Radiation Protection Committee Interest Group Meeting</td>
<td>Tue. Oct 15</td>
<td>11:30-13:00</td>
<td>Meeting Room 131/132</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Technologist Committee Interest Group Meeting</td>
<td>Tue. Oct 15</td>
<td>13:00-14:30</td>
<td>Hall 117</td>
<td>P1</td>
</tr>
<tr>
<td>EANM Radiopharmacy Committee Interest Group Meeting</td>
<td>Tue. Oct 15</td>
<td>16:30-17:30</td>
<td>Meeting Room 131/132</td>
<td>P1</td>
</tr>
</tbody>
</table>

## EANM COMMITTEE INTEREST GROUP MEETINGS

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Executive &amp; Committee Chairs Meeting</td>
<td>Sun. Oct 13</td>
<td>08:00-10:00</td>
<td>Meeting Room M220</td>
<td>P2</td>
</tr>
<tr>
<td>EANM Delegates Assembly</td>
<td>Sun. Oct 13</td>
<td>16:00-17:30</td>
<td>Meeting Room 130</td>
<td>P1</td>
</tr>
</tbody>
</table>

## FEBNM EXAM DATES

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEBNM Preparation Session</td>
<td>Fri. Oct. 11</td>
<td>09:00-10:00</td>
<td>Room 124</td>
<td>P1</td>
</tr>
<tr>
<td>FEBNM Oral Exam</td>
<td>Fri. Oct. 11</td>
<td>10:30-15:00</td>
<td>Room 125</td>
<td>P1</td>
</tr>
</tbody>
</table>

## WFNMB MEETING

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>WFNMB Delegates Assembly</td>
<td>Mon. Oct. 14</td>
<td>11:30-13:00</td>
<td>Meeting Room 129</td>
<td>P1</td>
</tr>
</tbody>
</table>

## EANM EXHIBITORS MEETING

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Time</th>
<th>Room</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>EANM Exhibitors Meeting</td>
<td>Tue. Oct 15</td>
<td>10:00-11:30</td>
<td>Meeting Room 118/119</td>
<td>2</td>
</tr>
</tbody>
</table>
# Scientific Programme

on the occasion of the 32nd Annual Congress of the European Association of Nuclear Medicine  
CCIB Barcelona, Spain | October 12 – 16, 2019

<table>
<thead>
<tr>
<th>Section</th>
<th>Dates</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invited Speaker Sessions</td>
<td>Saturday, October 12, 2019</td>
<td>Page 32</td>
</tr>
<tr>
<td>Programme Overviews</td>
<td>Saturday, October 12, 2019</td>
<td>Page 44</td>
</tr>
<tr>
<td></td>
<td>Sunday, October 13, 2019</td>
<td>Page 46</td>
</tr>
<tr>
<td></td>
<td>Monday, October 14, 2019</td>
<td>Page 48</td>
</tr>
<tr>
<td></td>
<td>Tuesday, October 15, 2019</td>
<td>Page 50</td>
</tr>
<tr>
<td></td>
<td>Wednesday, October 16, 2019</td>
<td>Page 52</td>
</tr>
<tr>
<td>Pre-Congress Symposia</td>
<td>Saturday, October 12, 2019</td>
<td>Page 54</td>
</tr>
<tr>
<td>Oral Presentations (Incl. e-Poster Presentations)</td>
<td>Sunday, October 13, 2019</td>
<td>Page 59</td>
</tr>
<tr>
<td></td>
<td>Monday, October 14, 2019</td>
<td>Page 99</td>
</tr>
<tr>
<td></td>
<td>Tuesday, October 15, 2019</td>
<td>Page 140</td>
</tr>
<tr>
<td></td>
<td>Wednesday, October 16, 2019</td>
<td>Page 173</td>
</tr>
<tr>
<td>e-Posters</td>
<td>Technologist e-Poster Presentation</td>
<td>Page 111</td>
</tr>
<tr>
<td></td>
<td>e-Posters</td>
<td>Page 185</td>
</tr>
<tr>
<td>Technologists e-Poster Presentations</td>
<td>Monday, October 14, 2019</td>
<td>Page 113</td>
</tr>
</tbody>
</table>
INVITED SPEAKER SESSIONS

PRE-CongRESS SYMPOSIA

1. Saturday, October 12, 09:00 – 12:00
   Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (DTA)
   Inflammation & Infection Committee

2. Saturday, October 12, 09:00 – 12:00
   Quantification of Myocardial Blood Flow - Ready for Daily Practice?
   Cardiovascular Committee / EACVI

3. Saturday, October 12, 09:00 – 12:00
   Alpha Therapy - Practical Aspects on Chemistry and Applications
   Radiopharmacy + Oncology & Theranostics + Dosimetry Committee

4. Saturday, October 12, 09:00 – 12:00
   We can’t make it cool, but we can make it easier…
   Translational Molecular Imaging and Therapy + Drug Development + Radiopharmacy Committee

5. Saturday, October 12, 09:00 – 12:00
   Dosimetry from Image Reconstruction with Monte Carlo Modelling
   Dosimetry + Physics Committee

6. Saturday, October 12, 13:00 – 16:00
   An Update on Differentiated Thyroid Cancer (DTC) - Overview of Management
   Thyroid Committee / ESIT

7. Saturday, October 12, 13:00 – 16:00
   Reserve, Resilience and Protective Factors in AD - Contribution of Molecular Imaging
   Neuroimaging Committee

8. Saturday, October 12, 13:00 – 16:00
   PSMA Theranostics and Beyond
   Oncology & Theranostics Committee / EAU

9. Saturday, October 12, 13:00 – 16:00
   Advances in Image Processing Techniques
   Physics + Dosimetry Committee

10. Saturday, October 12, 13:00 – 16:00
    European Projects for Clinical Implementation of Dosimetry in Molecular Radiotherapy
    Radiation Protection + Dosimetry Committee

PLENARY SESSIONS

1. Sunday, October 13, 10:00 – 11:15
   Radiomics and Artificial Intelligence (incl. Marie Curie Lecture)

2. Monday, October 14, 10:00 – 11:15
   Prostate Cancer - Reload

3. Tuesday, October 15, 10:00 – 11:15
   Next Generation PET Technology in the Clinical Setting

   Highlights Lecture

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1. Sunday, October 13, 08:00 – 09:30
   An Educational Trip from Organ to Voxel-Based to Small Scale Dosimetry
   Dosimetry Committee

2. Sunday, October 13, 11:30 – 13:00
   NET - PRRT and More
   Oncology & Theranostics Committee

3. Sunday, October 13, 14:30 – 16:00
   Metrological Aspects on the Implementation of Dosimetry in Radionuclide Therapy
   Radiation Protection + Dosimetry Committee

4. Monday, October 14, 11:30 – 13:00
   Molecular Imaging Technologies for Infectious Diseases
   Inflammation & Infection + Translational and Molecular Imaging Therapy + Radiopharmacy Committee

5. Monday, October 14, 11:30 – 13:00
   Molecular Imaging for Infectious Diseases
   Inflammation & Infection + Translational and Molecular Imaging Therapy + Radiopharmacy Committee
CONTINUING TECHNOLOGIST EDUCATION (CTE) SESSIONS

1. Sunday, October 13, 08:00 – 09:30
   Technologist Approach to Global Dose Optimization
   Technologist Committee - ANZSNM / CAMRT

2. Sunday, October 13, 11:30 – 13:00
   Risk and Incidents - Interactive
   Technologist + Radiation Protection Committee

3. Monday, October 14, 14:30 – 16:00
   Preclinical Studies, from Bench to Bedside
   EANM/EAN Recommendations for the Use of Brain 18F-FDG-PET in Neurodegenerative Cognitive Impairment and Dementia
   Neuroimaging Committee / EAN

4. Monday, October 14, 16:30 – 18:00
   Technologist’s Guide Launch – Radiopharmacy: An Update
   Technologist Committee / SNMMI

5. Tuesday, October 15, 14:30 – 16:00
   Patient Communication - Interactive
   Technologist Committee

6. Tuesday, October 15, 16:30 – 18:00
   Parathyroid Imaging
   Technologist Committee

7. Wednesday, October 16, 10:00 – 11:30
   Updates in Lung Imaging
   Technologist Committee

In addition to the CTE Sessions the Technologist Track includes 3 Mini Courses:

1. Sunday, October 13, 14:30 – 15:30
   Research Methodology
   Technologist Committee

2. Sunday, October 13, 15:45 – 16:45
   Stress Testing for Technologists - Interactive
   Technologist Committee

3. Sunday, October 13, 17:00 – 18:00
   Theranostics - Fundamental
   Technologist Committee
JOINT SYMPOSIA

1. Bone Imaging in Chronic Inflammatory Joint Conditions
   Bone & Joint + Inflammation & Infection Committee / EULAR

2. New Approaches for the More Specific Detection of Inflammatory Cells than FDG
   Cardiovascular + Translational and Molecular Imaging Therapy + Inflammation & Infection Committee / ESMI

3. Role of Bone SPECT/CT in the Paediatric Population
   Bone & Joint + Paediatrics Committee / EPOS

4. New Development in Nuclear Cardiology - Ready for Prime Time?
   Cardiovascular Committee / ASNC

5. The Future of Medical Imaging in Precision Medicine
   Oncology & Theranostics Committee / EORTC

6. Imaging Inflammation as Major Determinant of Cardiovascular Diseases - New Tracers and Clinical Applications
   Translational and Molecular Imaging Therapy + Cardiovascular + Inflammation & Infection Committee / AHA

7. Interventional Nuclear Medicine
   Physics + Dosimetry Committee / AAPM

8. Which Strategy for the Evaluation of Patients at the Time of Multi-Modality Cardiac Imaging?
   Cardiovascular Committee / ESCM

9. Clinical Use of Brain Imaging for Patients with Epilepsy
   Neuroradiology Committee / IAN

10. What is Molar Activity and When Does it Impact PET Imaging?
    Drug Development / IRS

11. New Applications for Hybrid Brain PET/MRI
    Neuroradiology Committee / ISCBFM

12. Digital Detection in Clinical NM (PET & SPECT)
    Physics Committee

13. Low Grade Glioma
    Neuroradiology Committee / EANON

14. Radiological Protection in Therapy with Radiopharmaceuticals
    Dosimetry + Radiation Protection Committee / ICPR

15. Immunological Landscape in Solid Tumours and its Implications in Response to Immunotherapy
    Oncology & Theranostics Committee / ESMO

16. Dosimetry in Preclinical Setting to Determine Dose Limits and Extrapolation to Clinical Dosimetry
    Dosimetry + Translational and Molecular Imaging Therapy Committee / ESTRO

17. Challenge Pancreatic Cancer
    Oncology & Theranostics Committee / AIO

18. Imaging on Thyroiditis
    Thyroid + Inflammation & Infection Committee / ETA

19. PET/CT Guided Treatment in Non-Hodgkin Lymphoma
    Oncology & Theranostics Committee / EHA

20. Thyroid Cancer Imaging and Biomarkers
    Thyroid Committee / EANM / EFSUMB

21. Ovarian Cancer
    Oncology & Theranostics Committee / ESGO

22. Martinique 2018 Multilateral DTC (MMDTC) Conference Results
    Thyroid Committee / American Thyroid Association (ATA) / European Thyroid Association (ETA) / Society of Nuclear Medicine and Molecular Imaging (SNMMI)

23. Theranostic in NEN - What is New?
    Oncology & Theranostics Committee / ENS

24. Image Guided Therapies for Prostate Cancer
    Translational and Molecular Imaging Therapy + Oncology & Theranostics Committee / EAU / ERUS

25. Implementation of the new EANM Guideline for Pulmonary Embolism and Beyond
    Radiation Protection Committee / JSNM

26. Lessons from Fukushima - Low Dose Radiation from Environment Radioisotope
    Radiation Protection Committee / JSNM

27. Translational Aspects of PSMA Targeting
    Translational and Molecular Imaging Therapy + Oncology & Theranostics Committee / WMI
SPECIAL SESSIONS

1. Monday, October 14, 08:00 – 09:45
   UEMS/EBNM: Clinical Audit Session & New Fellows of EBNM

2. Monday, October 14, 14:30 – 16:00
   Tomorrow’s Experts Session – Best-Ranked Papers from the Under-30s

PITFALLS & ARTEFACTS SESSIONS

1. Sunday, October 13, 08:00 – 09:30
   ICC*: Pitfalls and Artefacts in Paediatric Nephro-Urology
   Paediatrics Committee

2. Sunday, October 13, 11:30 – 13:00
   ICC*: From Imaging to Dosimetry - Step-by-Step Patient Dosimetry
   Dosimetry Committee

3. Monday, October 14, 08:00 – 09:30
   ICC*: Tips and Tricks in the Interpretation of Cardiac PET
   Cardiovascular + Inflammation & Infection Committee

4. Monday, October 14, 11:30 – 13:00
   ICC*: PSMA Imaging
   Oncology & Theranostics Committee

5. Tuesday, October 15, 08:00 – 09:30
   ICC*: Brain PET and SPECT - Patients’ Preparation and Acquisition
   Neuroimaging + Technologists Committee

6. Tuesday, October 15, 11:30 – 13:00
   ICC*: Pitfalls & Artefacts in Cardiac Imaging
   Cardiovascular Committee

7. Wednesday, October 16, 08:00 – 09:30
   ICC*: NET Imaging - Multiple Endocrine Neoplasias (MEN)
   Oncology & Theranostics Committee

*ICC = Interactive Clinical Cases

TEACHING SESSIONS

1. Sunday, October 13, 14:30 – 16:00
   ICC*: Management of Thyroid Cancer in Children
   Paediatrics + Thyroid + Translational and Molecular Imaging Therapy Committee

2. Sunday, October 13, 16:30 – 18:00
   ICC*: Imaging of Immune Cells
   Radiopharmacy + Inflammation & Infection + Oncology & Theranostics Committee

3. Monday, October 14, 14:30 – 16:00
   ICC*: Radiological Aspects of Thoracic Anatomy

4. Monday, October 14, 16:30 – 18:00
   ICC*: Chemical Entities that can Induce a Therapeutic Response in Vivo - Light vs Radioisotopes
   Translational and Molecular Imaging Therapy + Drug Development Committee

5. Tuesday, October 15, 14:30 – 16:00
   ICC*: Neuroimaging - Before Reading PET Scans
   Neuroimaging Committee

6. Tuesday, October 15, 16:30 – 18:00
   ICC*: Radiological Aspects of Abdominal Anatomy

7. Wednesday, October 16, 10:00 – 11:30
   ICC*: Reading with the Experts - PET/CT in Neuroendocrine Tumours
   ESMIT
Do.MoRe Track

10TH INTERNATIONAL SYMPOSIUM ON DOSIMETRY AND MOLECULAR RADIOTHERAPY

The format of the dosimetry and therapy meeting has evolved from a series of interesting and important radiopharmaceutical and dosimetry symposia held approximately every 5 years since 1970. This series was continued at the EANM Congress 2004 (Helsinki) and the SNM Congress 2009 (Toronto). These symposia were formerly known as ISTARD: “International Symposium on Targeted Radiotherapy and Radiopharmaceutical Dosimetry.” Since 2015 the symposia have been organised annually in parallel with the EANM Congress and the name has been changed to Do.MoRe, emphasising both the importance of dosimetry and the more regular organisation.

The Do.MoRe Track consists of the following sessions:

- Do.MoRe - Rapid Fire Session: Data Analysis
- Do.MoRe - Parallel Session: Diagnostic Dosimetry
- Do.MoRe - Parallel Session: Image Reconstruction
- Do.MoRe - Parallel Session: 177Lu-PRLRT and other Preclinical & Clinical Dosimetry
- Do.MoRe - Parallel Session: Preclinical Dosimetry - What is the Future?
- Do.MoRe - Parallel Session: Clinical Dosimetry and Modeling
- Do.MoRe - Parallel Session: Artificial Intelligence in Image Processing
- Do.MoRe - Parallel Session: Dosimetry for PSMA Radiopharmaceuticals
- e-Poster Presentation Session 7 - Do.MoRe: Image Reconstruction & Data Analysis
- Do.MoRe - Parallel Session: 131I-Dosimetry and DNA Damage during Different Therapies
- Do.MoRe - Parallel Session: Performance, Standardisation & Quality Control
- Do.MoRe - Parallel Session: SPECT/CT Quantification & Data Analysis
- e-Poster Presentation Session 9 - Do.MoRe: Dosimetry
- Do.MoRe - Parallel Session: Radiobiology and Dosimetry for Radioembolisation Therapy
- Do.MoRe - Parallel Session: New Concepts, Harmonisation and Standardisation in Radiomics
- Do.MoRe - Parallel Session: PET/CT & SPECT/CT Instrumentation
- Do.MoRe - Parallel Session: PET/MR Physics

M2M Track

THE 6TH “FROM MOLECULE TO MAN” TRACK, COVERING TRANSLATIONAL DEVELOPMENTS IN IMAGING AND THERAPY

The M2M track actively stimulates multidisciplinary interplay between the various scientific disciplines concerned with molecular imaging and therapy, namely chemistry, engineering, physics, biology and medicine. The M2M track comprises a series of plenary lectures, CME sessions, symposia and focused scientific sessions, all of which have the aim of connecting fundamental research with unmet medical needs and vice versa.

The M2M Track consists of the following sessions:

- M2M - Parallel Session: Improvement of PSMA Ligands
- M2M - Parallel Session: Radionuclide Production
- M2M - Parallel Session: Antibody-Based Radionuclide Therapy
- M2M - Parallel Session: Radiolabelled Peptides and Proteins
- M2M - Parallel Session: Innovations in Bio-Nanotechnology
- M2M - Parallel Session: PET Radiosynthesis
- M2M - Parallel Session: Neurodegeneration and Neuroinflammation
- M2M - Parallel Session: Tumour Microenvironment & Cancer Biomarkers
- M2M - Featured Session: Immune Therapy
- M2M - Parallel Session: Preclinical Developments in Infectious Diseases
- M2M - Parallel Session: Targeting the Brain
- M2M - Parallel Session: Preclinical Models in Translational Science
- M2M - Parallel Session: Radiolabelled Peptides
- M2M - Parallel Session: Peptide-Based Radionuclide Therapy
EANM Young Daily Forum

The EANM Young Daily Forum is the ideal platform for all young talents attending the EANM congress. The Young Daily Forum consists of a series of lunch-time sessions open to all participants, particularly those who are at the beginning of their career. Each 1.5 hours’ time slot (Sunday-Tuesday, 13:00-14:30) will focus on a different topic, moderated in an interactive way by the professional facilitator Roy Sheppard. Participants will not only benefit from Roy’s vast experience as moderator and professional speaker, but will also have the opportunity to get to know new people in a relaxed atmosphere.

YDF 1: How to Meet More Great People at the EANM Congress
Sunday, October 13, 13:00 – 14:30

Attending the EANM congress is not only about learning from world-class thought-leaders. It also provides brilliant opportunities to meet and connect with high-calibre professionals. Those connections have the power to help your future career. (And for you to help the careers of others). But how do you start meaningful conversations with strangers, especially if you tend to be a quiet or shy person?

This highly entertaining session is always well attended because Roy shares so many practical ideas and techniques to help you meet lots of new people in professional and respectful ways.

YDF 2: Presentation Skills for Medical Professionals
Monday, October 14, 13:00 – 14:30

Standing up in front of an audience fills most people with fear and anxiety. That’s quite normal. However, an ability to clearly present your ideas and research is possibly the single biggest non-medical skill you can develop to further your career.

Roy has coached tens of thousands of medical professionals to give more impactful, effective and engaging presentations. He will explain every stage of presentation planning and structure. And, based on his 40 years’ presenting experience, will share priceless tips on how to deliver more relevant and engaging talks that help your audiences become better informed about your important work.

YDF 3: Be Stronger – Managing Work Stress and Building Your Resilience
Tuesday, October 15, 13:00 – 14:30

You love your work. Yet workloads continue to increase, the daily pressure keeps intensifying. How do you currently cope with work stress? In this workshop, Roy will show you how to build resilience and an inner strength to help you thrive during these challenging times. This session is practical, thought
**Programme Overview**
Saturday, October 12, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Location/Room</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:50</td>
<td>Auditorium</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 111</td>
<td>EANM Advisory Council Meeting (11:00 - 13:30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-Symposium 1: Inflammation &amp; Infection Committee</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 112</td>
<td>Pre-Symposium 2: Cardiovascular Committee / EACVI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-Symposium 3: Radiopharmacy + Oncology + Dosimetry Committee</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 113</td>
<td>Pre-Symposium 4: Translational Molecular Imaging and Therapy + Drug Development</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-Symposium 5: Dosimetry + Physics Committee</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 114</td>
<td>Pre-Symposium 6: Thyroid Committee / ESES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-Symposium 7: Neuroimaging Committee</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 115</td>
<td>Pre-Symposium 8: Oncology + Theranostics Committee / EAU</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre-Symposium 9: Physics + Dosimetry Committee</td>
</tr>
<tr>
<td>08:30-12:30</td>
<td>Room 116</td>
<td>Pre-Symposium 10: Radiation Protection + Dosimetry Committee</td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 111</td>
<td>EANM Delegates’ Assembly (13:45 - 16:15)</td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 112</td>
<td>EANM Members’ Assembly (16:30 - 18:30)</td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 113</td>
<td></td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 114</td>
<td></td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 115</td>
<td></td>
</tr>
<tr>
<td>13:00-16:15</td>
<td>Room 116</td>
<td></td>
</tr>
</tbody>
</table>
Programme Overview
Sunday, October 13, 2019

**Scientific Programme**

**Room 111**

08:00 - 08:30

CME 1  Do.MoRe - Rapid Fire Session Data Analysis

08:30 - 09:00

CME 3  Pitfalls & Artefacts - 1  ICC* Dosimetry Committee - Do.MoRe Do.MoRe Do.MoRe

09:00 - 09:30

CME 2  Pitfalls & Artefacts - 2  ICC* Dosimetry Committee - Do.MoRe Do.MoRe Do.MoRe

09:30 - 10:00

CME 4  Clinical Oncology - Rapid Fire Session - Do.MoRe: Prostate - BCR only

10:00 - 10:30

CME 5  Clinical Oncology - Rapid Fire Session - Do.MoRe: Thyroid - Rapid Fire Session

10:30 - 11:00

CME 6  Clinical Oncology - Rapid Fire Session - Do.MoRe: Neuroimaging - Rapid Fire Session

**Room 112**

11:00 - 11:30

CME 7  Clinical Oncology - Rapid Fire Session - Do.MoRe: Cardiovascular - Parallel Session

11:30 - 12:00

CME 8  Paediatrics & Other Clinical Studies - Rapid Fire Session

12:00 - 12:30

CME 9  Paediatrics & Other Clinical Studies - Parallel Session

**Room 113**

12:30 - 13:00

CME 10  Paediatrics + Thyroid Cancer in Children - Parallel Session

13:00 - 13:30

CME 11  Paediatrics & Other Clinical Studies - Rapid Fire Session

13:30 - 14:00

CME 12  Paediatrics & Other Clinical Studies - Parallel Session

**Room 114**

14:00 - 14:30

CME 13  Paediatrics & Other Clinical Studies - Rapid Fire Session

14:30 - 15:00

CME 14  Paediatrics & Other Clinical Studies - Parallel Session

15:00 - 15:30

CME 15  Paediatrics & Other Clinical Studies - Rapid Fire Session

15:30 - 16:00

CME 16  Paediatrics & Other Clinical Studies - Parallel Session

16:00 - 16:30

CME 17  Paediatrics + Thyroid Cancer in Children - Rapid Fire Session

16:30 - 17:00

CME 18  Paediatrics + Thyroid Cancer in Children - Parallel Session

**Room 115**

17:00 - 17:30

CME 19  Paediatrics + Thyroid Cancer in Children - Rapid Fire Session

17:30 - 18:00

CME 20  Paediatrics + Thyroid Cancer in Children - Parallel Session

*ICC = Interactive Clinical Cases*
Programme Overview
Monday, October 14, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 112</th>
<th>Room 113</th>
<th>Room 114</th>
<th>Room 115</th>
<th>Room 116</th>
<th>Room 117</th>
<th>Room 118</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>CME 5</td>
<td>Pitfalls &amp; Artifacts 3 - ICC</td>
<td>Clinical Oncology - Parallel Session</td>
<td>Paediatrics - Parallel Session</td>
<td>Endoclinic - Parallel Session</td>
<td>e-Poster Presentation Session 5</td>
<td>CME Overview</td>
</tr>
<tr>
<td>08:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Cardiovascular &amp; Infection Committee</td>
<td>Implementing Radiation Therapy Techniques and Technology</td>
<td>Neuroendocrine Malignancies</td>
<td>e-Poster Presentation Session 6</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Joint Symposium 9 Neuroradiology Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Oncology e-Poster Session</td>
<td>e-Poster Presentation Session 7</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>CME 10</td>
<td>Pitfalls &amp; Artifacts 4 - ICC</td>
<td>CME 6</td>
<td>Plenary 2</td>
<td>Thymus - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Joint Symposium 10 Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Oncology &amp; Theranostics + Bone &amp; Cancer Therapy Committee / IAEA</td>
<td>Clinical Oncology - Featured Session</td>
<td>Plenary 2</td>
<td>Thyroid - Rapid Fire Session</td>
<td>CME - Posters Overview</td>
<td></td>
</tr>
</tbody>
</table>
Programme Overview

Tuesday, October 15, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 111</th>
<th>Room 112</th>
<th>Room 113</th>
<th>Room 114</th>
<th>Room 115</th>
<th>Room 116</th>
<th>Room 136/134</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>CME 9</td>
<td>CME 9</td>
<td>CME 9</td>
<td>CME 9</td>
<td>CME 9</td>
<td>CME 9</td>
<td>CME 9</td>
</tr>
<tr>
<td>09:00</td>
<td>CME 10</td>
<td>CME 10</td>
<td>CME 10</td>
<td>CME 10</td>
<td>CME 10</td>
<td>CME 10</td>
<td>CME 10</td>
</tr>
<tr>
<td>09:30</td>
<td>CME 11</td>
<td>CME 11</td>
<td>CME 11</td>
<td>CME 11</td>
<td>CME 11</td>
<td>CME 11</td>
<td>CME 11</td>
</tr>
<tr>
<td>10:00</td>
<td>CME 12</td>
<td>CME 12</td>
<td>CME 12</td>
<td>CME 12</td>
<td>CME 12</td>
<td>CME 12</td>
<td>CME 12</td>
</tr>
<tr>
<td>10:30</td>
<td>CME 13</td>
<td>CME 13</td>
<td>CME 13</td>
<td>CME 13</td>
<td>CME 13</td>
<td>CME 13</td>
<td>CME 13</td>
</tr>
<tr>
<td>11:00</td>
<td>CME 14</td>
<td>CME 14</td>
<td>CME 14</td>
<td>CME 14</td>
<td>CME 14</td>
<td>CME 14</td>
<td>CME 14</td>
</tr>
<tr>
<td>11:30</td>
<td>CME 15</td>
<td>CME 15</td>
<td>CME 15</td>
<td>CME 15</td>
<td>CME 15</td>
<td>CME 15</td>
<td>CME 15</td>
</tr>
<tr>
<td>12:00</td>
<td>CME 16</td>
<td>CME 16</td>
<td>CME 16</td>
<td>CME 16</td>
<td>CME 16</td>
<td>CME 16</td>
<td>CME 16</td>
</tr>
<tr>
<td>12:30</td>
<td>CME 17</td>
<td>CME 17</td>
<td>CME 17</td>
<td>CME 17</td>
<td>CME 17</td>
<td>CME 17</td>
<td>CME 17</td>
</tr>
<tr>
<td>13:00</td>
<td>CME 18</td>
<td>CME 18</td>
<td>CME 18</td>
<td>CME 18</td>
<td>CME 18</td>
<td>CME 18</td>
<td>CME 18</td>
</tr>
<tr>
<td>13:30</td>
<td>CME 19</td>
<td>CME 19</td>
<td>CME 19</td>
<td>CME 19</td>
<td>CME 19</td>
<td>CME 19</td>
<td>CME 19</td>
</tr>
<tr>
<td>14:00</td>
<td>CME 20</td>
<td>CME 20</td>
<td>CME 20</td>
<td>CME 20</td>
<td>CME 20</td>
<td>CME 20</td>
<td>CME 20</td>
</tr>
<tr>
<td>14:30</td>
<td>CME 21</td>
<td>CME 21</td>
<td>CME 21</td>
<td>CME 21</td>
<td>CME 21</td>
<td>CME 21</td>
<td>CME 21</td>
</tr>
<tr>
<td>15:00</td>
<td>CME 22</td>
<td>CME 22</td>
<td>CME 22</td>
<td>CME 22</td>
<td>CME 22</td>
<td>CME 22</td>
<td>CME 22</td>
</tr>
<tr>
<td>15:30</td>
<td>CME 23</td>
<td>CME 23</td>
<td>CME 23</td>
<td>CME 23</td>
<td>CME 23</td>
<td>CME 23</td>
<td>CME 23</td>
</tr>
<tr>
<td>16:00</td>
<td>CME 24</td>
<td>CME 24</td>
<td>CME 24</td>
<td>CME 24</td>
<td>CME 24</td>
<td>CME 24</td>
<td>CME 24</td>
</tr>
<tr>
<td>17:00</td>
<td>CME 26</td>
<td>CME 26</td>
<td>CME 26</td>
<td>CME 26</td>
<td>CME 26</td>
<td>CME 26</td>
<td>CME 26</td>
</tr>
<tr>
<td>17:30</td>
<td>CME 27</td>
<td>CME 27</td>
<td>CME 27</td>
<td>CME 27</td>
<td>CME 27</td>
<td>CME 27</td>
<td>CME 27</td>
</tr>
<tr>
<td>18:00</td>
<td>CME 28</td>
<td>CME 28</td>
<td>CME 28</td>
<td>CME 28</td>
<td>CME 28</td>
<td>CME 28</td>
<td>CME 28</td>
</tr>
</tbody>
</table>
## Programme Overview

**Wednesday, October 16, 2019**

<table>
<thead>
<tr>
<th>08:00</th>
<th>Room 311</th>
<th>08:00 - 08:30</th>
<th>CME 13</th>
<th>Drug Development + Radiopharmacy Committee</th>
<th>Implementation of the new EANM Guideline for Pulmonary Embolism and Beyond</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Room 312</td>
<td>08:00 - 08:30</td>
<td>EANM Symposium 26</td>
<td>Current and Future of Radiopharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Room 117</td>
<td>08:30 - 09:00</td>
<td>M2M - Parallel Session</td>
<td>Radiolabelled Peptides</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Room 111</td>
<td>09:00 - 09:30</td>
<td>Scientific Programme Overview</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Room 111</td>
<td>10:00 - 10:30</td>
<td>CME 14</td>
<td>Bone &amp; Joint Committee / IASP</td>
<td>The Diagnosis is Complex Regional Pain Syndrome (CRPS-I) or is it?</td>
</tr>
<tr>
<td>10:30</td>
<td>Room 109</td>
<td>10:30 - 11:00</td>
<td>Joint Symposium 27</td>
<td>Radiation Protection Committee / EANM Lessons from Fukushima - Low Dose Radiation from Environment Radiosources</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Room 110</td>
<td>11:00 - 11:30</td>
<td>Joint Symposium 28</td>
<td>Translational and Molecular Imaging Therapy + Oncology &amp; Theranostics Committee / WMESS Translational Aspects of PSMA Targeting</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Room 111</td>
<td>11:30 - 12:00</td>
<td>CTE 7</td>
<td>Technologist Committee</td>
<td>Updates in Lung Imaging</td>
</tr>
<tr>
<td>12:00</td>
<td>Room 112</td>
<td>12:00 - 12:30</td>
<td>M2M - Parallel Session</td>
<td>Peptide-Based Radiopharmaceutical Therapy</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Room 113</td>
<td>12:30 - 13:00</td>
<td>Joint / EANM Symposia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Room 114</td>
<td>13:00 - 13:30</td>
<td>EANM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Room 115</td>
<td>13:30 - 14:00</td>
<td>Scientific Programme Overviews</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Plenary Sessions
- Marie Curie Award (11:45 - 12:15)
- Plenary 4: Highlights Lecture (12:15 - 12:45)
- Closing (12:45 - 13:00)

### Scientific Programme Overviews
- Further Parallel / Featured / Rapid Fire Sessions
- e-Poster Presentation Sessions

### Scientific Programme
- CME Sessions
- Joint / EANM Symposia
- Technologist's Track
- Do.MoRe Track
- M2M Track
- Pitfalls & Artefacts / Teaching Sessions
- Clinical Oncology Track

### Do.MoRe - Parallel Session
- PET/CT & SPECT/CT Instrumentation
- Clinical Oncology - Featured Session
- Radiation Protection - Parallel Session

### Pitfalls & Artefacts - ICC
- Drug Development + Radiopharmacy Committee
- Implementation of the new EANM Guideline for Pulmonary Embolism and Beyond

### M2M - Parallel Session
- Radiation Protection - Standards, Tools and Model
- PET/CT & SPECT/CT Instrumentation
- Clinical Oncology - Featured Session

### Do.MoRe - Parallel Session
- PET/CT & SPECT/CT Instrumentation
- Clinical Oncology - Featured Session
- Radiation Protection - Parallel Session

### Pitfalls & Artefacts - ICC
- Drug Development + Radiopharmacy Committee
- Implementation of the new EANM Guideline for Pulmonary Embolism and Beyond

### M2M - Parallel Session
- Radiation Protection - Standards, Tools and Model
- PET/CT & SPECT/CT Instrumentation
- Clinical Oncology - Featured Session

### Do.MoRe - Parallel Session
- PET/CT & SPECT/CT Instrumentation
- Clinical Oncology - Featured Session
- Radiation Protection - Parallel Session
**Pre-Congress Symposium 1 - Inflammation & Infection Committee: Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (DTA)**

*Chair:* R. Sadeghi, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

*Presenters:*
- G. Treglia, Barcelona, SPAIN
- Y. Takwoingi, Birmingham, UNITED KINGDOM.

**Pre-Congress Symposium 2 - Cardiovascular Committee / EACVI: Quantification of Myocardial Flow Reserve - Ready for Daily Practice?**

*Chair:* G. Pontone, Milan, ITALY

*Presenters:*
- T. van de Hoef, Department of Cardiology, Academic Medical Centre, Amsterdam, NETHERLANDS.
- M. Luebberink, PET Centre, Uppsala University Hospital, Uppsala, SWEDEN.

**Pre-Congress Symposium 3 - Radiopharmacy + Oncology & Theranostics + Dosimetry Committee: Alpha Therapy - Practical Aspects on Chemistry and Applications**

*Chair:* E. M. Oacak, Istanbul, TURKEY

*Presenters:*
- M. Konijnenberg, Erasmus MC, Rotterdam, NETHERLANDS.
- D. A. de Jong, CHUV, Lausanne, SWITZERLAND.
- R. Schottelius, CHUV, Lausanne, SWITZERLAND.

**Pre-Congress Symposium 4 - Translational Molecular Imaging and Therapy + Drug Development + Radiopharmacy Committee: We can’t make it cool, but we can make it easier?**

*Chair:* M. De Jong, CA ROTTERDAM, NETHERLANDS

*Presenters:*
- M. Schottelius, Department of Nuclear Medicine, University Medical Center Mainz, Mainz, GERMANY
- O. Neels, Department of Radiopharmaceutical Chemistry, Heidelberg, GERMANY
- F. Bruchertseifer, AZ AMSTERDAM, NETHERLANDS

**Pre-Congress Symposium 5 - Radiopharmacy Committee: We can’t make it cool, but we can make it easier?**

*Chair:* W. Deuther-Conrad, CHUV, Lausanne, SWITZERLAND

*Presenters:*
- E. M. Ocak, Istanbul, TURKEY
- F. Bruchertseifer, AZ AMSTERDAM, NETHERLANDS
- W. Deuther-Conrad, CHUV, Lausanne, SWITZERLAND

---

**PS 10: Pathophysiology of Coronary and Myocardial Flow Reserve**

*Presenter:* T. van de Hoef, Department of Cardiology, Academic Medical Centre, Amsterdam, NETHERLANDS

**PS 11: How to Quantify MBF?**

*Presenters:* M. Luebberink, PET Centre, Uppsala University Hospital, Uppsala, SWEDEN; A. Manrique, Hospital/Institute, Turku, FINLAND.

**PS 12: MBF Quantification Based on SPECT**

*Presenters:* A. Manrique, Com University Hospital, Department of Nuclear Medicine, Com, FRANCE; M. Saraste, University of Turku, Heart and PET Centre Hospital, Institute, Turku, FINLAND.

**PS 13: COFFEE BREAK**

---

**PS 14: MBF Quantification Based on PET**

*Presenters:* M. Saraste, University of Turku, Heart and PET Centre Hospital, Institute, Turku, FINLAND; G. Pontone, Centro Cardiologico Monzana, IRCCS, University of Milan, ITALY.

**PS 15: MBF Quantification Based on CT**

*Presenters:* G. Pontone, Centro Cardiologico Monzana, IRCCS, University of Milan, ITALY; H. Verberne, AZ AMSTERDAM, NETHERLANDS.

**PS 16: How to Implement MBF in Clinical Practice?**

*Presenters:* A. Saraste, University of Turku, Heart and PET Centre Hospital, Institute, Turku, FINLAND; G. Pontone, Centro Cardiologico Monzana, IRCCS, University of Milan, ITALY.

**PS 17: Discussion**

---

**PS 18: An Overview of Production and Radiochemistry of Alpha-Emitting Radionuclides**

*Presenters:* F. Bruchertseifer, Europäische Kommission, Institut für Transuran, Nuklearchemie, Karlsruhe, GERMANY; F. Buchertseifer, Klinik für Klinis Fysiolog, Nuklärmedizin & PET, Copenhagen, DENMARK.

**PS 19: Safe Handling of Alpha-Emitting Radionuclides During Preparation and Application of Radiopharmaceuticals**

*Presenters:* M. Benesova, German Cancer Research Center, Heidelberg, GERMANY; S. Holm, Klinik für Klinis Fysiolog, Nuklärmedizin & PET, Copenhagen, DENMARK.

**PS 20: Stability of Alpha-Emitting Radiopharmaceuticals - Impact on TATs**

*Presenters:* M. Schottelius, Department of Nuclear Medicine, University Medical Center Mainz, Mainz, GERMANY; D. A. de Jong, CHUV, Lausanne, SWITZERLAND.

**PS 21: COFFEE BREAK**

---

**PS 22: Recall Effect and its Impact on TATs Dosimetry**

*Presenters:* N. Chouin, French Institute of Health and Medical Research, Nanterre, FRANCE; S. Heskamp, Radiobod Institute for Molecular Life Sciences, Nijmegen, NETHERLANDS.

**PS 23: Antibody Derivatives as a Vehicle for TAT - Advantages, Disadvantages, Future Prospects**

*Presenters:* H. Verberne, AZ AMSTERDAM, NETHERLANDS; M. Miederer, Department of Nuclear Medicine, University Medical Center Mainz, Mainz, GERMANY.

**PS 24: Future Directions for Targeted Alpha Therapy Beyond Prostate Cancer**

*Presenters:* M. Niederer, Department of Nuclear Medicine, University Medical Center Mainz, Mainz, GERMANY; W. Deuther-Conrad, CHUV, Lausanne, SWITZERLAND.
PS 33  Statistical Reconstruction Methods - Principles
J. Gustafsson, Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.

PS 34  An Introduction to Monte Carlo Calculations for Imaging and Dosimetry
M. Ljungberg, Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.

PS 35  COFFEE BREAK

PS 36  Problems Related to Dosimetry for Therapy Based on Quantitative SPECT Imaging
P. Minguez Gabina, Department of Medical Physics and Radiation Protection, Guretzeta Basque University Hospital, Barakaldo, SPAIN.

PS 37  Examples of the Usefulness of Monte Carlo Modelling within a Reconstruction Process
H. de Jong, Department of Radiology, University Medical Centre Utrecht, UMC, Utrecht, NETHERLANDS.

PS 38  Discussion and Concluding Remarks

PS 39  Surgical Strategy at Initial Diagnosis
F. Sebag, Assistance Publique Hôpitaux de Marseille, Endocrine and Metabolic Surgery, Marseille, FRANCE.

PS 40  Strategies and Concepts Regarding Post-Surgery Radioiodine Treatment of DTC
E. Hindie, CRAH Hôpitaux de Bordeaux Service Médecine Nucléaire, Bordeaux, FRANCE.

PS 41  Multiscale Prognostic Factors for the Management of DTC
L. Giovanella, Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine, Bellinzona, SWITZERLAND.

PS 42  COFFEE BREAK

PS 43  Radioiodine Treatment for Metastatic DTC - How Much? How Many? How Often?
M. Luster, University of Marburg, Department of Nuclear Medicine, Marburg, GERMANY.

PS 44  Redifferentiation of Radioiodine Refractory DTC
S. Léboulleux, Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Paris Sud Cachan, Villejuif, FRANCE.

PS 45  Discussion

PS 46  Reserve and Resilience in AD - Evolution of the Concept
P. Vemuri, Department of Radiology, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

PS 47  Multimodal Interventions and Dementia Prevention
S. Sindl, Karolinska Institutet, Department of Neurobiology, Stockholm, SWEDEN.

PS 48  Functional Networks Underlying Cognitive Reserve
S. Morbelli, San Martino Hospital, Nuclear Medicine, Genoa, ITALY.

PS 49  Discussion

PS 50  COFFEE BREAK

PS 51  Should we Consider Education as a Confounder on FDG-PET Diagnostic Accuracy in Alzheimer’s Disease?
V. Garibotto, Nuclear Medicine and Molecular Imaging Division, Geneva University Hospitals, Geneva, SWITZERLAND.

PS 52  Contribution of Amyloid and Tau PET to the Understanding of Cognitive Reserve
M. Höning, Department of Nuclear Medicine, University Hospital Cologne, Cologne, GERMANY.

PS 53  Meditation in the Ageing Population to Foster Reserve and Prevent Dementia
G. Chételat, Inserm UMR-S U1337, Normandie Univ, UNICAEN, GP Cytéren, Caen, FRANCE.

PS 54  Discussion
EANM'19
FINAL PROGRAMME
WORLD LEADING MEETING

October 12
Oral Presentations

P59
Pre-Congress Symposium 9 - Physics + Dosimetry Committee: European Projects for Clinical Implementation of Dosimetry in Molecular Radiotheraphy
Chair: D. Viskvik; USOS INSERM, LaTIM - I35, CHU MORVAN, Bar 2 8th, BREST, FRANCE.
Saturday, October 12, 2019, 13:00 - 16:00 Lecture Hall 115

P510
Pre-Congress Symposium 10 - Radiation Protection + Dosimetry Committee: European Projects for Clinical Implementation of Dosimetry in Molecular Radiotheraphy
Chair: U. Eberlein; Klinik fuer Nuklearmedizin, Universitaetsklinikum Wurzburg, Wurzburg, GERMANY.
Saturday, October 12, 2019, 13:00 - 16:00 Lecture Hall 115

PS-63
Principles and Developments of Deep Learning Techniques in NM Image Processing
A. McMillan; University of Wisconsin, Department of Radiology, Madison, WI, UNITED STATES OF AMERICA.
PS-64
Whole Body Parametric PET/CT Imaging
N. Karakatsanis; Mount Sinai Hospital, Cornell University, New York, UNITED STATES OF AMERICA.
PS-65
COFFEE BREAK

PS-66
Functional Volume Segmentation - State of the Art
M. Hatt; INSERM, LaTIM, University of Western Brittany, Brest, FRANCE.
PS-67
Quantitative SPECT/CT Imaging
I. Armstrong; Nuclear Medicine Department, Manchester University Hospital NHS Trust, Manchester, UNITED KINGDOM.
PS-68
MC vs Non-MC Dose Estimation for Radionuclide Therapy
M. Ljungberg; Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.
PS-69
Calibration Protocols for Quantitative Imaging Developed Within the MRTDosimetry Project
A. Robinson; National Physical Laboratory, Teddington, UNITED KINGDOM.
PS-70
Multicentre Quantitative Imaging Exercises and Dosimetry Tool Intercomparison in the MRTDosimetry Project
J. Tran-Gia; University of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.
PS-71
Multicentre Quantitative Imaging Exercises and Dosimetry Tool Intercomparison in the MRTDosimetry Project
N. Calvert; The Christie NHS Foundation Trust, Joint Department of Physics, Sutton, UNITED KINGDOM.
PS-72
Discussion
PS-73
COFFEE BREAK
PS-74
Intercomparison for Lu-177 Imaging in the Netherlands
S. Peters; Radboudumc, Radiologie & Nucleaire Geneeskunde, Nijmegen, NETHERLANDS.
PS-75
The Role of CT in Image-Based Dosimetry
K. Sjögreen-Gleisner; Lund University, Medical Radiation Physics, Lund, SWEDEN.

PS-76
Mediram I-131 Multicentre Trial Set-Up
F. Leek; Royal Marsden Hospital, Joint Department of Physics, Sutton, UNITED KINGDOM.
PS-77
Discussion
DC
Opening Ceremony
Saturday, October 12, 2019, 19:30 - 20:30 Auditorium

OP-001
Organ Level Dosimetry
J. Gear; Royal Marsden NHS Foundation Trust, Joint Department of Physics, Sutton, UNITED KINGDOM.
OP-002
Voxel Level Dosimetry
N. Chouin; French Institute of Health and Medical Research, Nantes, FRANCE.
OP-003
Small Scale Dosimetry - Not so Appealing, but... It’s just Dosimetry
P. Bernhardt; University of Gottingen, Department of Radiation Physics, Gothenburg, Sweden.

101
CME 1 - Dosimetry Committee: An Educational Trip from Organ to Voxel-Based to Small Scale Dosimetry
Sunday, October 13, 2019, 8:00 - 9:30 Auditorium
Chair: M. Bardies; I35 1037 INSERM / U57, Centre de Recherche en Cancérologie de Toulouse, Toulouse, FRANCE.
Chair: G. Flux; Joint Department of Physics, Royal Marsden NHS Trust & Institute of Cancer Research, Sutton Surrey, UNITED KINGDOM.

OP-004
Bone SPECT/CT Versus MRI in Rheumatologic Patients
H. Palmedo; Institute for Radiology and Nuclear Medicine, Bonn, GERMANY.
OP-005
Small Scale Dosimetry - So Appealing, but... It’s just Dosimetry
P. Bernhardt; University of Gottingen, Department of Radiation Physics, Gothenburg, Sweden.

102
Joint Symposium 1 - Bone & Joint + Inflammation & Infection Committee / EULAR: Bone Imaging in Chronic Inflammatory Joint Conditions
Sunday, October 13, 2019, 8:00 - 9:30 Lecture Hall 311
Chair: X. Baraliakos; Henne, GERMANY.
Chair: W. Kamper, Nuklearmedizin Spitalerhof, HAMBURG, GERMANY.
OP-006
Bone SPECT/CT Versus MRI in Rheumatologic Patients
H. Palmedo; Institute for Radiology and Nuclear Medicine, Bonn, GERMANY.
OP-007
Impact of FDG-PET/CT in Patients with PMR
O. Gheyysens; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, Leuven, BELGIUM.
OP-028 Imaging of Osteoblast-/Osteoclast, Activity in New Bone Formation in Rheumatologic Patients X. Baraliakos, Rheumazentrum Ruhrgebiet, Herne, GERMANY.

OP-029 Device Infection F. Caobelli, Department of Nuclear Medicine, University hospital Basel, Basel, SWITZERLAND.

OP-030 Cardiac Remodeling J. Thackeray, Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

OP-031 Atherosclerosis J. Bucerius, Klinik für Nuklearmedizin, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, GERMANY.

OP-032 Myocarditis C. Rischpler, University Hospital Essen, Essen, GERMANY.

OP-033 Discussion

104 CTE 1 - Technology Committee / ANZSNM / CAMRT: Technology Approach to Global Dose Optimization Sunday, October 13, 2019, 8:00 - 9:10 Lecture Hall 117 Chair: L. Camoni, UNIVERSITA’ E SPEDALI CIVILI DI BRUSCEL/ BRESSO, BRESSO, ITALY
Chair: P.A. Fragoso Costa, Clinic for Nuclear Medicine, Essen, GERMANY.

OP-014s Opening A. Santos, Hospital CuDescobertas, Nuclear Medicine Department, Lisbon, PORTUGAL.

OP-014b Dose Optimization Principles P. Fragoso Costa, University Hospital Essen, Clinic for Nuclear Medicine, Essen, GERMANY.

OP-015 Dose Reference Levels in Nuclear Medicine E. Bailey, Royal North Shore Hospital, Department of Nuclear Medicine, Sydney, AUSTRALIA.

OP-016 PET/CT Dose Optimization and Occupational Exposure T. Alden, BC Cancer Agency, Vancouver, BC, CANADA.

OP-017 Cardiac Imaging Methods for Dose Reduction L. Camoni, Università & Spedali Civili di Brescia, Brescia, ITALY.

OP-015s Sunday, October 13, 2019, 8:00 - 9:10 Lecture Hall 111 Chair: C. Decristoforo, Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Innsbruck, AUSTRIA.
Chair: O. Neels, Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY.

OP-018 Novel 18F-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and superior tumor-to-kidney therapeutic index H. Kuo, J. Zhang, C. Urbe1, H. Merkens, C. Zhang, F. Bénaud, K. Lou1; 1Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA; 2Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

OP-019 Development of a new class of albumin-binding PSMA radioligands C. Mueller, J. Debek, C. A. Umbrecht, M. Benezoua, F. Bongni, V. J. Tichan, K. Thennoseva, R. Schell2; 1Paul Scherrer Institute, Villigen-PSI, SWITZERLAND; 2ETH Zurich, Zurich, SWITZERLAND, YTG Gmbh, Garching, GERMANY.

OP-020 A Sarcophagine Containing PSMA Ligand for Targeting Prostate Cancer with 111In/Cu J. M. Kelly, S. Panmali, A. Nikolopoulos1, N. Ziel, C. Williams Jr., P.S. Denny, J. W. Baitch; Well Comel Medical, New York, NY, UNITED STATES OF AMERICA; University of Melbourne, Melbourne, AUSTRALIA.

OP-021 In vitro and in vivo evaluation of the new 18F-labeled PSMA agents for prostate cancer diagnosis M. Maurin, A. E. Silido, M. Oreetwo1, U. Kerschmann, P. Gussnu1; 1National Centre for Nuclear Research Radiosotope Centre POLATOM, Chwów, POLAND; 2National Centre for Nuclear Radiosotope Centre Radiosotope Centre POLATOM, Chwów, POLAND.

OP-022 Sensitivity and specificity of 18F DCFPyL (PSMA agent) compared to MR in biochemically recurrent prostate cancer patients L. Lindenberg1, E. Menis Gonzalez1, B. Turkley1, L. Lim1, P. McVie1; L. Weaver, P. Eland1, A. Forest, A. Hanky1, A. Couvillon1, E. Schott1, W. Dahut2, D. Cnidy1, S. Harmon1, E. Berg1, A. Lindenberg1, A. Tor1, S. Adler1, J. Eary3, P. Choyke1; 1Molecular Imaging Program, National Caner Institute, NIH, Bethesda, MD, UNITED STATES OF AMERICA; 2Division of Hematology-Oncology, Department of Medicine, Betheseda, MD, UNITED STATES OF AMERICA; 3Health Sciences, Bethesda, MD, UNITED STATES OF AMERICA; 4Radboud university medical center, Nijmegen, NETHERLANDS; 5Radboud university, Nijmegen, NETHERLANDS; 6University Hospital Bonn, Bonn, GERMANY.

OP-023 ‘[18F]-PSMA: A Novel Class of Radiolabeled PSMA Inhibitors D. Di Carlo, V. Prasad, A. Beert, H. Wente1; Technical University of Munich, Garching bei München, GERMANY; 2Ulmer Medical Center Ulm, Ulm, GERMANY.

OP-024 [18F]-IRDye700DX-PSMA ligands for targeted photodynamic therapy of PSMA-expressing tumors Y. H. W. Derks1, H. I. V. Amato-Grein1, A. Hop1, G. M. Franssen1, J. K. van der Kamp2, D. W. P. M. Law1, G. C. Boehm1, M. Rijpermans1, S. Lajet1, S. Heskin1; Radboud university medical center, Nijmegen, NETHERLANDS; 2Radboud university, Nijmegen, NETHERLANDS; 3University Hospital Bonn, Bonn, GERMANY.

OP-025 Assessment of in vivo biodistribution and treatment efficacy of [18F]-PSMA-R2 and [18F]-PSMA-617 on mice bearing prostate cancer tumors V. Musio1, L. Ravasi1, L. Sacchetti1, L. Fugazza1, S. Bocat1, M. Debois1, A. Ahmad1, C. Mentegana1, C. Greata1, A. Brossat1; 1Advanced Accelerator Applications, a Nuvantis company, Geneva, SWITZERLAND, 2Univ. Grenoble Alpes, Inserm, CEA Grenoble Alpes, Grenoble, FRANCE.

106 DoMo-Re: Rapid Fire Session: Data Analysis Sunday, October 13, 2019, 8:00 - 9:10 Lecture Hall 112 Chair: J. Dickson, Institute of Nuclear Medicine, University College Hospital, LONDON, UNITED KINGDOM.
Chair: M. Lubbren, PET centre, Department of Radiology, Oncology and Radiation Science, Uppsala, SWEDEN.

OP-026 Standardized Radionuclides of Clinical Myocardial Perfusion Stress SPECT Images to Determine Coronary Artery Calcification Score S. Adafmat, P. Dalal1, M. Salesh Sadagopan1, H. Schandler2, M. G. Pomper1, A. Rahmitt1; 1Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA; 2Washington University at St. Louis, St. Louis, MO, UNITED STATES OF AMERICA; 3University of British Columbia, Vancouver, BC, CANADA.
A novel myocardial perfusion phantom-performing ground truth flow measurements to evaluate accuracy of flow quantification with SPECT

M. E. Kampbuis, G. van der Vle; M. Saadikh; J. Verschoor; A. Apolito; M. J. W. Greuter; C. H. Stumpf; R. H. J. A. Stal; University of Twente, Enschede, NETHERLANDS; Ziekenhuisgroep Twente, Hengelo, NETHERLANDS; University Medical Center Groningen, Groningen, NETHERLANDS.

Oral

OP-028 Initial evaluation of an automated high temporal resolution data-driven motion correction for rubidium cardiac relative perfusion PET

I. Armstrong, C. Hadjan; P. Anumagum; 'Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM; Siemens Medical Solutions USA, Inc., Annapolis, TN, UNITED STATES OF AMERICA.

OP-029 Volume split Digital PET in Myocardial Perfusion Imaging Using Rubidium-82 PET

S. S. Koenders, J. A. van Dolen; P. J. Berger; S. Knollem; J. R. Timmer; C. H. Stumpf; J. D. van Dijk; 'Isala hospital, Department of Nuclear Medicine, Zwolle, NETHERLANDS; Technical Medical Centre, University of Twente, Enschede, NETHERLANDS; 'Isala hospital, Department of Medical Physics, Zwolle, NETHERLANDS; 'Isala hospital, Department of Cardiology, Zwolle, NETHERLANDS.

OP-030 Cross validation of quantitative assessment of global cardiac function through hybrid PET/MR images

A. Villagran Asaiero; T. Wadello; J. Cabello; T. Wurhun; S. Nelas; Nuclear Medicine Department, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, GERMANY; 'Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM, Munich, GERMANY.

OP-031 Effect of collimator characteristics on 112m-MIBG phantom imaging using Monte Carlo simulation

K. Okuda, R. Nakajima; C. Imaizumi; Y. Kinoshita, J. Tak, M. Hashimoto; S. Kinoya; Kanazawa Medical University, Kanazawa, JAPAN; 'Kanazawa University, Kanazawa, JAPAN; FUJIFILM Toyama Chemical Co., Ltd, Tokyo, JAPAN.

OP-032 Impact of deep learning artificial intelligence approaches on amyloid PET diagnosis

M. Schüller, K. T. Chery; T. Jachsmies, M. Rallmann; M. Par; S. Topali; M. Schmert; C. Wensel; D. Saur; G. Zehathali; D. Sabo; H. Barthelet; Department of Nuclear Medicine, University of Leipzig Medical Center, Leipzig, GERMANY; Radiology, Stanford University, Stanford, CA, UNITED STATES OF AMERICA; 'Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY; Department of Neurology, University of Leipzig Medical Center, Leipzig, GERMANY.

OP-033 DASiC's software: a scintigraphic tool able to evaluate the scintigraphic load of bone disease as a survival predictor in mCRPC

R. Fantellizzi; M. D. Apolito; M. Conte; G. De Vincenzo; San Paolo University of Rome, Rome, ITALY.

OP-034 Impact of PET/CT image reconstruction parameters on patient dose distributions for quantitative 18F liver radioembolization

X. Hou, H. Mei; P. Esquinas; S. Tohurs; F. Brand; D. Liu; A. Celler; Radiology Department, University of British Columbia, Vancouver, BC, CANADA; Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA; 'IBM Watson Health Imaging, Mississauga, ON, CANADA; 'Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA.

OP-035 Impact of high energy co-emitted gamma quanta on quantification of Sc-44

F. Rosar, H. G. Buchhalz; M. Pet; F. Rösch; M Schreienberger; Department of Nuclear Medicine, Saarland University Medical Center, Homburg, GERMANY; Department of Nuclear Medicine, Johannes Gutenberg-University, Mainz, GERMANY; Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

OP-036 Dynamic Renal Scintigraphy

A. Santos; Hospital Garcia de Orta, LE, Nuclear Medicine Department, Almada, PORTUGAL.

OP-037 Static Cortical Scintigraphy

Z. Bar-Sever; Schneider Children’s Medical Center, Department of Nuclear Medicine, Petach Tikva, ISRAEL.

OP-038 Radionuclide Cystography

L. Blassoni; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Radiology, London, UNITED KINGDOM.

Clinical Oncology - Rapid Fire Session: Prostate - BCR and More

OP-039 Impact of application of fuosmeid combination with hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder in Ga PSMA-11 PET/CT

C. Uprum; A. Krass; B. Nilsz; H. Svendsen; F. Elsingmar; C. Deconsolator; E. Guggengm; G. de Santa; J. Vargane; 'Medical University of Innsbruck, Innsbruck, AUSTRIA; 'Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-040 Next-generation PET is a sensitive and reproducible biomarker of early CRPC

M. M. Weber, C. E. Kure, F. Barbato, C. Rischpler, M. Eiber, T. Maurer, B. Hadadchi, K. G. Hermeren, A. Wetter, F. P. Wallengren; University Clinic Essen, Department of Nuclear Medicine, Essen, GERMANY; University Clinic Essen, Department of Nuclear Medicine, Essen, GERMANY; 'Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, GERMANY; 'MariniClinic and Department of Urology, University Clinic Hamburg-Eppendorf (UK), Hamburg, GERMANY; 'Department of Urology, University Hospital Essen, Essen, GERMANY; 'Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY.

OP-041 Benefit of CT urography in Ga-PSMA-11 PET with low dose CT

F. Rosar, M. Hägle, M. R. Ri; S. Mou; S. Bartholome, T. Stenier, H. Bahnberger, P. Fries, F. Krenet; S. Ezadin; 'Department of Nuclear Medicine, Saarland University Medical Center, Homburg, GERMANY; 'Department of Radiology, Saarland University Medical Center, Homburg, GERMANY.

Prospective intra-patient comparison of F-Fluorochrome and Ga-PSMA-11 PET/CT in biochemical recurrence of prostate cancer after definitive therapy

B. Permtshler, H. Kusters, R. Kulm, C. Gatterner, R. M. Aigner; Medical University Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.

Impact of late pelvic acquisition on Ga-PSMA-11 PET/CT positive rate and inter-rater reliability analysis

D. Nicolotti, F. Ce, R. Plati, B. Diario, C. Led, M. Finni, V. Liberti, R. Passera, G. Bis, D. Deandrea; Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.
Evaluation of [18F]Florbetapir brain PET in therapy response assessment of prostate-targeted radionuclide therapy in patients with castration resistant prostate cancer

J. Kurth, J. Kretzschmar, M. Heuschkel, G. Kunat, O. W. Hakenberg, B. J. Krause; Rostock University Medical Center, Rostock, GERMANY.

Impact of [18F]PSMA-1007 Ligand PET/CT in Multimodal Imaging of Recurrent Prostate Cancer

L. Dronka1, M. Radzinska1, M. Triane2, L. Zemienie, M. Kalnin1, E. L. Remmers1, V. Lutsiewiet1, A. Freimann1, E. Vajters1. 1Institute of Radiology, Paaul Stradius University Clinical University Hospital, Riga, LATVIA; 2Riga Stradius University Radiology Research Laboratory, Riga, LATVIA.

Detection of biochemical recurrence of prostate cancer following radical prostatectomy through 18F-fluorodeoxyglucose positron emission tomography

L. Ulbrich, M. Eremenko, A. Mazurov, T. Horn3, H. Weister, W. Weber, M. Ebert. 1MRI/TUM, Munich, GERMANY; 2Department of nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY; 3Chair of PharmaceuticaL Radiationpharmacy, TUM, Munich, GERMANY; 4Martin-Luther-Klima, UKE, Hamburg, GERMANY; 5Santecor Sem GmbH, Fuerstenfeldbruck, GERMANY.

Preliminary results on response assessment using PSMA molecular imaging in patients with metastatic prostate cancer undergoing abiraterone

C. Liu, S. Hua, X. Xu, S. Song, Y. Zhang. Fudan University, Shanghai, CHINA.

Monocentric Intraindividual Comparison of [18F]Florbetapir and [18F]FDG PET/CT in MCRPC

M. Heuschkel, J. Kurth, O. W. Hakenberg, S. Nitsch, S. M. Schwazenbeek, B. J. Krause; Rostock University Medical Center, Rostock, GERMANY.

Localizing biochemical recurrence of prostate cancer using 68 Ga-PSMA-11 PET/CT and 11C-acetate PET/CT

N. Regula, V. Kostans, S. Johansson, C. Pulda, E. Lindstroem, M. Lubben, J. Veliky, S. Sorensen; Uppsala University Hospital, Upplands, SWEDEN.

Impact of [4F]-PSMA-1007 Ligand PET/CT in Multimodal Imaging of Recurrent Prostate Cancer

L. Dronka1, M. Radzinska1, M. Triane2, L. Zemienie, M. Kalnin1, E. L. Remmers1, V. Lutsiewiet1, A. Freimann1, E. Vajters1. 1Institute of Radiology, Paaul Stradius University Clinical University Hospital, Riga, LATVIA; 2Riga Stradius University Radiology Research Laboratory, Riga, LATVIA.

Propagator power of psosas muscles structure and metabolism in amyotrophic lateral sclerosis

A. Misceti, M. Danegam1, R. Lo1, S. Morbel1, V. Cominci, A. Bomb2, S. Rauff2, M. Bauchkhett1, S. Captar1, C. Camp2, G. Sambuceti1, M. Pama1, C. Marin2, OSSC University of Genoa, Genoa, ITALY; 3Santecor Sem GmbH, Fuerstenfeldbruck, GERMANY; 4H. Wakabayashi, K. Nakajima, S. Watanabe1, R. Lai, M. González1, M. Brell2, C. Peña2, M. Lai1, S. Morbelli1; IRCCS Policlinico San Matteo, Genova, ITALY; 5Santecor Sem GmbH, Fuerstenfeldbruck, GERMANY; 6Lewy body diseases artificial neural network: possible application to Lewy body diseases

I. Sundström Poromaa, H. Wilking1, H. Lai, S. Morbelli1; Siemens Medical Solutions USA, Charlotte, USA.

Intraobserver and interobserver agreement of Evaluation of [68 Ga]Ga-PSMA-PET/CT in therapy response assessment of prostate-targeted radionuclide therapy in patients with castration resistant prostate cancer

S. Güven Mese, A. Aina3, M. Rezende1, L. Zemienie, S. Misut1, M. Kalnin1, E. L. Remmers1, V. Lutsiewiet1, A. Freimann1. 1Institute of Radiology, Paaul Stradius University Clinical University Hospital, Riga, LATVIA; 2Riga Stradius University Radiology Research Laboratory, Riga, LATVIA; 3University of Twente, Enschede, NETHERLANDS.

ViQuant: an open-source PET/MRI pipeline for non-invasive determination of cerebral metabolic rate of glucose

L. Shiyam Sundar2, O. Muszki, L. Rischke, A. Hahn1, R. Lanneberg1, M. Hietaniemi, M. Bauer1, J. Rauch1, E. Patanasri1, J. Reub-Meulenberg1, T. Beyer1; 1Medical University of Vienna, Vienna, AUSTRIA; 2Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA.

How to convert F18-Flutemetamol centiloid values to Centiloid scale values - A simple-method using PNEURO 3.9 software

R. Lhomme1, B. Horsens1, V. Malotaux2, J. Cermai1, A. Ivanov2; 1Cliniques Universitaires Saint-Luc; UCLouvain, Brussels, BELGIUM; 2Institute of Neuro-Science (IONS), UCLouvain, Brussels, BELGIUM.

Multi-center PET data harmonization on the classification performance of deep learning networks in neuroimaging

R. Fahmi1, S. Schel, Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

The impact of multi-center PET data harmonization on the classification performance of deep learning networks in neuroimaging

R. Fahmi1, S. Schel, Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

How to convert F18-Flutemetamol centiloid values to Centiloid scale values - A simple-method using PNEURO 3.9 software

R. Lhomme1, B. Horsens1, V. Malotaux2, J. Cermai1, A. Ivanov2; 1Cliniques Universitaires Saint-Luc; UCLouvain, Brussels, BELGIUM; 2Institute of Neuro-Science (IONS), UCLouvain, Brussels, BELGIUM.

OP-049

Impact of [4F]-PSMA-1007 Ligand PET/CT in Multimodal Imaging of Recurrent Prostate Cancer

L. Dronka1, M. Radzinska1, M. Triane2, L. Zemienie, M. Kalnin1, E. L. Remmers1, V. Lutsiewiet1, A. Freimann1, E. Vajters1. 1Institute of Radiology, Paaul Stradius University Clinical University Hospital, Riga, LATVIA; 2Riga Stradius University Radiology Research Laboratory, Riga, LATVIA.

OP-050

Detection of biochemical recurrence of prostate cancer following radical prostatectomy through 18F-fluorodeoxyglucose positron emission tomography

L. Ulbrich, M. Eremenko, A. Mazurov, T. Horn3, H. Weister, W. Weber, M. Ebert. 1MRI/TUM, Munich, GERMANY; 2Department of nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY; 3Chair of Pharmaceutical Radiationpharmacy, TUM, Munich, GERMANY; 4Martin-Luther-Klima, UKE, Hamburg, GERMANY; 5Santecor Sem GmbH, Fuerstenfeldbruck, GERMANY.

OP-051

Classification of [18F]Florbetapir brain PET studies in cognitively normal subjects using a Convolutional Neural Network

R. Boellaard, B. de Vries, T. Timmers, J. Ebenau, S. Verfaillie, F. Heeman, M. Cysouw, W. van der Flier, B. van Berckel, M. Haays, S. Goda; Amsterdam University Medical Center, VUMC, AMSTERDAM, NETHERLANDS.

OP-052

Machine-learning based interpretation of 11C-Florbetapir PET/CT scans allows high-accuracy detection of Parkinson's Disease

M. Dotinga1, J. D. van Dyk1, B. N. Vemeld1, C. H. Slump1; 1University of Twente, Enschede, NETHERLANDS.
OP-055
Low-dose Dynamic Myocardial Perfusion Imaging by CZT-SPECT in the Identification of Obstructive Coronary Artery Disease

OP-056
Comparison of SPECT Myocardial Blood Flow Quantification and MPI for Detection of Myocardial Ischemia in Patients with Intermediate Coronary Stenosis Disease
L. Wang, R. Ma, M. Wang, B. Hu, W. Fang, 1 Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA. 2 University of Missouri-Columbia, Columbia, MO, UNITED STATES OF AMERICA.

OP-057
Diagnostic performance of myocardial perfusion imaging with conventional and CZT single photon emission computed tomography in detecting coronary artery disease: a meta-analysis

OP-058
Impact of spline fitting of dynamic CZT SPECT data on the assessment of myocardial blood flow and flow reserve
N. Courdaux, C. Agostini, C. Nguyen, M. Bouthdra, P. Yogev, V. Roda, N. Rat, F. Beygui, A. Mannique, 1 CHU Côte de Nacre, Caen, FRANCE. 2 Normandy University, EA 4650, Caen, FRANCE. 3 Spectrum Dynamics Medical Ltd, Casarea, ISRAEL. 4 Cerenium PET Center, Caen, FRANCE.

OP-059
Evaluation of global and regional coronary flow reserve by routine perfusion SPECT, without first pass study
L. Philipppe, C. Pruner-Aesch, Y. El Yassaouli, Medicine Nucleaire Toulansgelle, Chambay-le-Tours, FRANCE.

OP-060
Absolute myocardial blood flow and coronary flow reserve derived by dynamic single photon emission computed tomography: correlation with invasive coronary angiography results in patients with multivessel coronary artery disease
K. Zavadovsky, A. Mochula, A. Ivan, A. Malthea, S. Andreu, Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.
**Presentations**

**Sunday, October 13, 2019**

10:00 - 11:15 Auditorium

**Chair**: I. Vigliani

**Venue**: Vienna, AUSTRIA

---

**EPS-005**

The evaluation of tumor response to neoadjuvant chemotherapy for esophageal cancer using PERCIST 1.0-multicenter study

H. Kaida, K. Kitajima, M. Nakajo, M. Ishibashi, R. Minamimoto, K. Hisa, K. Nakatsui, T. Kusuda, K. Ishii; Kinki University Faculty of Medicine, Osaka-Sayama, JAPAN, **Jyuga College of Medicine, Nishinomiya, JAPAN, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JAPAN, School of Medicine, Tottori University, Yonago, JAPAN, National Center for Global Health and Medicine, Tokyo, JAPAN**

**EPS-006**

**Oral**

- **EPS-006** 18F-FDG PET/CT metabolic/volumetric parameters evaluation to predict response to neoadjuvant chemotherapy (NAC) and prognostic value in patients with triple-Negative breast cancer (TNBC)
  - G. Paone, S. Di Lazzaro, F. Quattracchi, T. Ruberto, G. Treglia, L. Cenani, L. Giavonetti; **Department of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Lugano-Bellinzona, SWITZERLAND**
  - S. Tisserand, S. Kanou, J. Blanc, B. Gaudert, A. Bennio-Riedinger, F. Cachin, L. Champion, O. Humbert, P. Salard, T. Mognet, K. Kerkau; **Centre Georges François Leclerc, Dijon, FRANCE**
  - E. Verrou, E. Katodritou, P. Mitsakis, J. Blanc, B. Gaudert; **Centre Pierre Laguesse, Université de Lyon, Lyon, FRANCE**
  - J. Pruim, J. Lopez Urdaneta; **Department of Nuclear Medicine, Gothenburg, SWEDEN**

**EPS-007**

18F-FDG PET/CT: early prediction of response to neoadjuvant therapy in HER2+ breast cancer: validation in a multicentric population

S. Tisserand, S. Kanou, J. Blanc, B. Gaudert, A. Bennio-Riedinger, F. Cachin, L. Champion, O. Humbert, P. Salard, T. Mognet, K. Kerkau; **Centre Georges François Leclerc, Dijon, FRANCE**

**EPS-008**

Clinical Efficacy of Radiosynoviorthesis (RSV) in Elbow Joint Systemic Arthritis

I. Iakovou, T. Kottotzio, E. Gournsoul, M. Koliaszoglou, C. Zachekakis, G. Avouris; **Academic Dept Of Nuclear Medicine, Papageorgiou Hosp, Thessaloniki, GREECE**

**EPS-009**

Bone marrow FDG uptake and correlation with bone marrow plasma cell infiltration rate and plasma cell morphology in Multiple Myeloma patients

A. Paschali, E. Panagiotidi, P. Mitsakis; **Department of Nuclear Medicine, Health Promotion Center, H Padi New Yang-A Hosp, Department of Nuclear Medicine, Chul General Hospital, Seoul, KOREA, REPUBLIC OF**

**EPS-010**

Pathologic neck metastasis in Patients With Gynecologic Malignancy with neck node uptake on the F-18 FDG PET/CT

S. Yoon; **Department of Nuclear Medicine, Health Promotion Center, H Padi New Yang-A Hosp, Department of Nuclear Medicine, Chul General Hospital, Seoul, KOREA, REPUBLIC OF**

**EPS-011**

Bone marrow FDG uptake and correlation with bone marrow plasma cell infiltration rate and plasma cell morphology in Multiple Myeloma patients

A. Paschali, E. Panagiotidi, P. Mitsakis, N. Rapaportoulos, T. Trinatayafllis, E. Gournsoul, M. Koliaszoglou, E. Vemou, P. Konstantinidou, V. Chataspidou, E. Katodritou; **Department of Nuclear Medicine, Therapeia Cancer Hospital, Thessaloniki, GREECE**

**EPS-012**

“4Ga-PSMA PET/CT whole-body tumor burden in patients with biochemical recurrence of prostate cancer

A. Biggi Mattioli, M. C. L. Lima, M. Camacho, C. D. Ramos, A. G. Santos, E. Echternach; **Medicina Nuclear de Campinas, Campinas, BRAZIL**

**EPS-013**

Retrospective cohort study to assess the prognostic value of baseline necrosis on PET-CT imaging in Hodgkin lymphoma

I. Chen, M. Borges, L. Winn, W. Osborne, G. Petrides; **Freeman Hospital, Newcastle Upon Tyne, UNITED KINGDOM**

**EPS-014**

Metabolic Tumor Volume Predicts Short-Term Progression After Immunotherapy in Non Small Cell Lung Cancer

D. Chardin, M. Puquet, J. Darcourt, J. Otto, O. Humbert; **Centre Antoine Lacassagne, Nice, FRANCE**

**EPS-015**

GaGa-PSMA-11 PET/CT For Monitoring Response to Treatment in Metastatic Prostate Cancer - is there an Added Value over Standard Follow-up?

J. Kuten, D. Sand, O. Yossopoulos, N. J. Mathiopoulos, E. E. Saps; **Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL**

**EPS-016**

Artificial intelligence can discriminate between focal and normal bone/bone marrow uptake in lymphoma patients staged with FDG-PET/CT: a descriptive study

M. Sadik, A. Krijn, A. Duda, J. Lopez Uriñandez, J. Uñiri, A. Enquist, P. Andrea, L. Edendbrant; **1 Nuclear Medicine, Gothenburg, SWEDEN, 2 department of Hematology, Chalmers University of Technology, Gothenburg, SWEDEN, 3 Department of Hematology, Gothenburg, SWEDEN**

201904

**Plenary 1: Radiomics and Artificial Intelligence (incl. Marie Curie Lecture)**

Sunday, October 13, 2019, 10:00 - 11:15

**Chair**: F. Giammarile

**Venue**: Vienna, AUSTRIA

**EPS-068**

Radiomics - Predictive and Prognostic Modelling using Multimodality Imaging

D. Vissvik; **INSERM UMR101, LaTIM, CERME, Marseille, FRANCE**

**OP-069**

Artificial Intelligence in Nuclear Oncology

R. Hustinx; **Centre Hospitalier Universitaire, Service de Médecine Nucléaire, Liège, BELGIUM**

**OP-070**

Marie Curie Lecture: Artificial Intelligence in Brain Imaging

M. Forsting; **UK Essen, Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Essen, GERMANY**

**OP-071**

PET/CT Imaging of PPGL in the Era of Genomic Disease Characterization (EANM/SNMII 2019 Guidelines)

D. Taieb; **Department of Nuclear Medicine, La Timone University Hospital, CERME, Aix-Marseille University, Marseille, FRANCE**

**OP-072**

Long-Term Outcome of PRRT and Predictors of Outcome

M. Gabriel; **Allgemeines Krankenhaus Linz, Institut für Nuklearmedizin und Endokrinologie, Linz, AUSTRIA**

**OP-073a**

PRRT - Individualized Dosimetry vs. Fixed Dose Scheme

A. Haug; **University Clinic of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA**

**OP-074a**

PRRT Treatment Sequencing and Combinations

R. Hicks; **Department of Nuclear Medicine and PET, Peter MacCallum Cancer Institute, Melbourne, AUSTRALIA**
302
Joint Symposium 3 - Bone & Joint + Paediatrics Committee / EPOS: Role of Bone SPECT/CT in the Paediatric Population
Sunday, October 13, 2019, 11:30 - 13:00 Lecture Hall 311
Chair: D. Eastwood, London W1N 3JH, UNITED KINGDOM
Chair: L. Antunovic, Raccozana, ITALY

OP-074
Bone Scan with SPECT/CT in the Assessment of Bone Viability
I. Roca, Vall d’Hebron University Hospital, Pediatric Nuclear Medicine Unit, Nuclear Medicine Department, Barcelona, SPAIN.

OP-075
SPECT/CT of the Jaw in Condylar Hyperplasia
K. Strobel, Luezer Kantons spit (LUKS), Department of Radiology and Nuclear Medicine, Lucerne, SWITZERLAND.

OP-076
Complex Adolescent Foot Pain - Clinical Scenarios and Management
D. Eastwood, Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Orthopaedics, London WC1N 3JH, UNITED KINGDOM.

OP-077
SPECT/CT in Complex Adolescent Foot Pain - Initial Experience
L. Biaisoni, great Ormond Street Hospital for Children NHS Foundation Trust, Department of Radiology, London, UNITED KINGDOM.

303
Joint Symposium 4: Cardiovascular Committee / ASNC: New Development in Nuclear Cardiology - Ready for Prime Time?
Sunday, October 13, 2019, 11:30 - 13:00 Lecture Hall 312
Chair: P. Hyafil, Nuclear Medicine, AP-Hôp PARIS, FRANCE
Chair: R. Soman, Pittsburgh, PA, UNITED STATES OF AMERICA.

OP-078
Whole-Body CZT Camera for Cardiac Imaging
D. Agostini, Department of Nuclear Medicine, Caen University Hospital, Caen, FRANCE.

OP-079
Quantification of Myocardial Blood Flow with SPECT
R. Nikoulou, Department of Nuclear Medicine, University Hospital Geneva, Geneva, SWITZERLAND.

OP-080
Measurement of Left Ventricular Dysynchrony
P. Soman, University of Pittsburgh Medical Center, Division of Cardiology and The Heart and Vascular Institute, Pittsburgh, UNITED STATES OF AMERICA.

OP-081
Artificial Intelligence and Deep Learning
P. Slomka, University of Wisconsin Madison, Madison, WI, UNITED STATES OF AMERICA; University of Alberta, Edmonton, ALBERTA, CANADA; University of British Columbia, Vancouver, BC, CANADA.

304
CTE 2 - Interactive - Technologist + Radiation Protection Committee: Risk and Incidents
Sunday, October 13, 2019, 11:30 - 13:00 Lecture Hall 117
Chair: S. Rep, Department of Nuclear Medicine, University Medical Centre Ljubljana, LJUBLJANA, SLOVENIA
Chair: G. Testanera, Department of Nuclear Medicine, Barts Health NHS Trust, London, UNITED KINGDOM.

OP-082a
Risks and Incidents in Nuclear Medicine - A Medical Physics Perspective
K. Bacher, Ghent University, Department of Medical Physics, Ghent, BELGIUM.

OP-082b
Discussion

OP-083a
Potential Risk and Incidents in HotLab
A. Socan, University Medical Centre, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

OP-083b
Discussion

OP-084a
Management of Risks and Incidents in Nuclear Medicine
G. Testanera, St Bartholomew’s Hospital, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-085
Discussion

305
M2M - Parallel Session: Radiouclide Production
Sunday, October 13, 2019, 12:30 - 14:30 Lecture Hall 312
Chair: G. Luurtsema, NETHERLANDS
Chair: M. Papbiti, ATHENS, GREECE.

OP-085a
Cyclotron Production of 68Ga Using Enriched 68Zn Foils
J. Silikan, E. Jussing1, S. Molitor, C. Steiger, J. Uilenborgh1, T. Tran1, S. Stamey1, Karolinska University Hospital, Department of Medical Radiation Physics and Nuclear Medicine, Stockholm, SWEDEN; Karolinska University Hospital, Department of Radiopharmacy, Stockholm, SWEDEN; Karolinska Institute, Department of Clinical Neuroscience, Stockholm, SWEDEN.

OP-085b
Cyclotron Production of 68Ga Using Enriched 68Zn Foils
J. Silikan, E. Jussing1, S. Molitor, C. Steiger, J. Uilenborgh1, T. Tran1, S. Stamey1, Karolinska University Hospital, Department of Medical Radiation Physics and Nuclear Medicine, Stockholm, SWEDEN; Karolinska University Hospital, Department of Radiopharmacy, Stockholm, SWEDEN; Karolinska Institute, Department of Clinical Neuroscience, Stockholm, SWEDEN.

OP-086
Multi-Cure Production of Gallium-68 on a Biomedical Cyclotron
J. Kumlin, J. H. Dam1, C. J. Chuai, S. Bagyan, A. Kassan, B. Hosi, S. Zeleier, P. Schaffter, M. Thoegersen1, ARTMS, Vancouver, BC, CANADA; Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK; Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.

OP-087
Characterization of TriskEm Actinide resin for production of 68Ga using enrichment to 2,3,1
K. Barrett, 1Department of Medical Radiation Physics and Nuclear Medicine, Odense University Hospital, Odense, DENMARK; 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK; 3Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-088
Characterization of TriSKem Actinide resin for production of 68Ga using enrichment to 2,3,1
K. Barrett, 1Department of Medical Radiation Physics and Nuclear Medicine, Odense University Hospital, Odense, DENMARK; 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK; 3Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-089
The development of 151Tb production and its characterization towards clinical application

OP-090
Target development and chemical separation for radioantimony production
A. Olson, P. A. Elivon, E. Alucio-Sarduy1, T. Kostelnik, J. Myners, T. E. Banhart1, R. J. Nickles1, V. Rodickenh1, J. W. Engels1; Department of Medical Physics, University of Wisconsin Madison, Madison, WI, UNITED STATES OF AMERICA; Medical Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA; Life Sciences Division, TRUIME, Vancouver, BC, CANADA.

306
Du Morfe - Parallel Session: Diagnostic Dosimetry
Sunday, October 13, 2019, 11:30 - 12:45 Lecture Hall 312
Chair: J. Tran-Gia, Würzburg, GERMANY
Chair: M. Abu Qbeitat, Istanbul, TURKEY.

OP-091
Radiation Dosimetry of 18F - AzaFol as the first Folate Receptor-alpha (FRα) directed PET-Tracer
S. Gnesis, J. Mueller, J. Burger, A. Mense1, M. Chorschuck, C. Mueller, R. Schöfl, S. M. Ananthamoney1, J. O. Prior, N. Schraer1; Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND; Department of Radiology and Nuclear Medicine, Cantonal Hospital St Gallen, St. Gallen, SWITZERLAND; Department of Nuclear Medicine, Kantonspital Baden, Baden, SWITZERLAND; Department of Internal Medicine - Hematology & Oncology, Stadtpital Waad, Zurich, SWITZERLAND; Institute for Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, SWITZERLAND; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, Villigen, SWITZERLAND; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.
OP-092
Biodistribution and radiation dosimetry study of [68Ga]-FAPI-46 PET imaging in patients with various cancers
C. Meyer1, M. Dahlborn1, J. Cemmi2, S. Vaurou3, T. Lindeberg4, K. Halberkorn5, J. Calais6, Physics & Biology in Medical Interdepartmental Graduate Program, UCL, Los Angeles, CA, UNITED STATES OF AMERICA, 1Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2DOSuit SA, Cachan, FRANCE, 3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY.

OP-093
Patient-Specific Estimates of Organ Dose in Pediatric [18F]FDG PET/CT Imaging Studies
F. Fahey1, C. Kottler2, B. Sexton-Satalone3, R. Reddy4, R. MacDougall5, W. Bolch6, Boston Children’s Hospital, Boston, MA, UNITED STATES OF AMERICA, 1Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, 2Cayman Point Family Dept. of Biomedical Engineering, University of Randa, Gainesville, FL, UNITED STATES OF AMERICA.

OP-094
Dosimetric Impact of Modeling the Epiphysial Plates in Pediatric [18F]FDG PET/CT Studies
J. L. B. Brown1, Y. V. B. Sexton-Satalone2, R. Cao3, D. Pijak4, E. C. Frey5, S. P. Tenes6, T. H. Fahey4, G. Sgouros4, W. E. Bolch4, University of Florida, Gainesville, FL, UNITED STATES OF AMERICA, 1Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 2Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.

OP-095
Dosimetry of Radioembolisation with 90Y Microspheres
C. Chiesa: Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumor, Milan, ITALY.

OP-096
Dosimetry for Radioembolisation with 90Y Microspheres
M. Lindner, P. Plyku, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 1Pediatric 18 FDG PET/CT Imaging Studies.

OP-097
Dosimetry for [111In]LuLu-PSMA Therapy
G. Böning: Ludwig-Maximilians-University - University Hospital, Department of Nuclear Medicine, Munich, GERMANY.

OP-098
Dosimetry for [111In]LuLu-PSMA Therapy
H. Illhan: Ludwig-Maximilians-University - University Hospital, Department of Nuclear Medicine, Munich, GERMANY.

OP-099
Dosimetry for Alpha-Particle Emitters
C. Hindorf: Södertörn University Hospital, Department of Radiation Physics, Lund, SWEDEN.

OP-100
Step by Step Estimation of Uncertainty on Absorbed Dose
J. Gear: Royal Marsden NHS Foundation Trust, Joint Department of Physics, Sutton, UNITED KINGDOM.

308
Clinical Oncology - Rapid Fire Session: Prostate - BCR only
Chair: K. Herrmann: Nuclear Medicine, Universitätsklinikum Essen, Essen, GERMANY.

309
Clinical Oncology - Rapid Fire Session: Prostate - BCR only
Chair: M. Abuqubaitah: Nuclear Medicine, Istanbul university, Istanbul, TURKEY.

• OP-101
68Ga-PSMA PET/CT in biochemical recurrent prostate cancer: an international multi-institutional prospective study promoted by the MAA
E. Estrada Lobato1, S. Fanti1, C. Cerci1: 1International Atomic Energy Agency, Vienna, AUSTRIA, 2Università di Bologna, Bologna, ITALY, 3Quanta Diagnostica e Terapia, Curitiba, BRAZIL.

• OP-102
“Ga-PSMA-PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 1000 patients
P. Caroli1, U. De Gregori2, M. Celli3, L. Fanin4, A. Moretti5, R. Cala6, V. Di Volo7, F. Ferroni7, A. Romeo7, M. Caracciolo6, G. Paganelli8, F. Mattucci8, 1RCCEM RIST, Milano, ITALY, 2Ospedale Maggiore-Piemontese, Forlì, ITALY, 3Ospedale S. Anna, Ferrara, ITALY.

• OP-103
The impact of clinical factors and inter-site variation on detection of recurrent prostate cancer with [18F]fluociclovine PET/CT and subsequent management decisions: data from the FALCON trial
G. Cook, Falcon study group, King’s College London, London, UNITED KINGDOM.

• OP-104
“Ga-PSMA-11 PET localizes residual prostate cancer after salvage lymph node dissection in a multicenter retrospective study
A. Farollo1, M. Weber1, F. Barbato1, H. Khan2, A. Gafita3, M. Eber1, J. Calais1, A. Afshar-Oromieh1, A. Wetter1, B. Hadadchitz1, D. Penoni1, S. Fanti1, U. Habermann1, K. Herrmann1, W. Weber1: Nuclear Medicine Department, S. Croce Hospital, Bologna, Bologna, ITALY, 1Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, 2Department of Nuclear Medicine, University Hospital Munich, Ludwig-Maximilians-Universität (LMU), Munich, GERMANY, 3Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY, 4Mammion Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA, 5Department of Nuclear Medicine, Ben University Hospital Bern, SWITZERLAND, 6Department of Radiology, University Hospital Essen, Essen, GERMANY, 7Department of Urology, University Hospital Essen, Essen, GERMANY, 8Department of Biomedical and Neuroradiology Sciences, University of Bologna, Bologna, ITALY, 9Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY.

• OP-105
Prostate-Specific Membrane Antigen Positron-Emission Tomography (PSMA-PET/CT) in High-Risk Nonmetastatic Castration-Resistant Prostate Cancer (mmCRPC): SPARTAN-like Patients Negative by Conventional Imaging
W. Fendler1, M. Weber2, A. Ivanov3, M. S. Hoffman4, J. Calais1, J. Czernin1, H. Khan1, E. J. Small5, M. A. Smith1, M. P. Perez6, A. Hope7, J. Ruschau8, A. Landhe1, 1Janssen Research & Development, Los Angeles, CA, UNITED STATES OF AMERICA, 2Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 3Department of Nuclear Medicine, Ludwig Maximilian University, Munich, GERMANY, 4Centre Hospitalier de l’Université de Montréal, Universitat de Montreál, Montréal, QC, CANADA, 5Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, 6Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, 7Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY, 8Janssen Research & Development, Titusville, NJ, UNITED STATES OF AMERICA, 9Janssen Research & Development, Los Angeles, CA, UNITED STATES OF AMERICA, 10Janssen Research & Development, Ranson, NY, UNITED STATES OF AMERICA, 11Department of Urology, Department of Urology and Translational Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Essen, GERMANY.

• OP-106
Prognostic value of PSMA PET-derived skeleton tumor burden parameters for overall survival in patients undergoing radium-223 treatment
A. Gafita1, W. Wang1, M. Krönke1, W. Weber1, R. Tauber1, M. Eber1, 1Technical University Munich, School of Medicine, Department of Urology, Munich, GERMANY, 2Technical University Munich, School of Medicine, Department of Urology, Munich, GERMANY.

308
Clinical Oncology - Rapid Fire Session: Prostate - BCR only
Chair: K. Goffin: Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, BELGIUM.

309
Clinical Oncology - Rapid Fire Session: Prostate - BCR only
Chair: K. Goffin: Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, BELGIUM.
OP-107 Prediction Nomogram for 
**Ga-PSMA-11 PET/CT** in different clinical settings of PSA failure after radicular treatment for prostate cancer

F. Ceci1, L. Bianchi, M. Borga2, G. Palermo3, A. Brignone1, A. Ferrini1, R. Schuwer1, E. Brunaccini1, F. Castellucciu, S. Fanini2; 1University of Turin, Turin, ITALY, 2Metropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 3Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, *Unit of Urology/ Division of Oncology, Urological Research Institute, IRCSS San Raffaele Hospital, Milan, ITALY.

OP-108 Ga-PSMA-11 PET/CT in hormone-naïve recurrent prostate cancer: a prospective, single-center study in patients eligible for salvage therapy

F. Ceci1, D. G. Nicolato2, E. Piau2, A. Guarenni3, B. Luka1, R. Pasquali1, V. Liberman1, M. Finessi1, M. Mell1, P. Gontier1, L. Ricardi2, D. Deandreis1; 1Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY, 2Radiation Oncology, Department of Oncology, University of Turin, Turin, ITALY, 3Urology, Department of Surgery, University of Turin, Turin, ITALY.

OP-109 Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: impact on therapeutic decision-making and biomarker changes

C. Rousselau1, A. Michaud2, M. Barbaud3, C. Mandrand2, B. Mouchère2, M. Le Thiec2, D. Baru2, A. Morel3, V. Ferlay1, M. Colombel1, A. Rauscher1, M. Fréde2, P. Baumeister2, N. Ferrier2, L. Campion3, F. Krämer-Bödeker2; 1ICO Cancer Center, Nuclear Medicine Unit, St Herblain, FRANCE, 2SERCINA, University of Nantes, UFR SM UMR1232, CNRS-ERL6001, Nantes, FRANCE, 3ICO Cancer Center, Pharmacy Unit, St Herblain, FRANCE, 4ICO Cancer Center, DRC, St Herblain, FRANCE, 5ICO Cancer Center, Biometrics Unit, St Herblain, FRANCE.

OP-110 Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 105 cases

M. Behebti1; 1Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC.

OP-111 The role of thyroid scintigraphy with Tc-99m in the era of FNAC and molecular markers

S. Sophocleous1,2; 1Nuclear Medicine, Innsbruck University Hospital, RWTH University, Aachen, GERMANY, 2Nuclear Medicine, Paracelsus Medical University, Salzburg, AUSTRIA.

OP-112 Is there a role for semiquantitative parameters to characterize incidental focal thyroid uptake on (18)F-FDG PET/CT study?

R. Durmo1; 1D. Albano2, M. Bonsaccia1, M. Gazzani1, E. Cenideli1, F. Dondi2, A. Mazzarotto2, P. Bellini2, F. Bertaglia2, R. Guibbini2; 1Nuclear Medicine, Spezialklinik di Brescia, Brescia, ITALY, 2Nuclear Medicine, University of Brescia and Spezialklinik di Brescia, Brescia, ITALY.

OP-113 Technetium-99m MIBI Scintigraphy Contribution In The Assessment Of Cold Thyroid Nodules

A. Chehbouni1; 1D. Fouladi1, O. Naïli2, M. Serré1, L. Bougmati1, L. Grenier1, S. E. Benni1, S. Masmoun-Zergoui1; 1Endocrinology Unit-Pierre and Marie Curie Center, Algiers, ALGERIA, 2Radiology Unit-Pierre and Marie Curie Center, Algiers, ALGERIA, 3Harmonisation Unit-Pierre and Marie Curie Center, Algiers, ALGERIA.

OP-114 Diagnostic performance of technetium-99m (99mTc) methoxy-isobutyl-isonitrile (MIBI) for differentiation of malignant from benign thyroid nodules with indeterminate or non-diagnostic fine needle aspiration cytology (FNAC)

I. Iakovou1, E. Giammola1, A. Katsatzoglou2, V. Mpsalos2, X. Michalis2; 1Academic Dept Of Nuclear Medicine, Papageorgiou General Hospital, Thessaloniki, GREECE.

OP-115 Comparison of (F) fluoro-choline PET-CT to (18)F-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism

C. Mathey1; 1Keyzer, V. Van Simons1, N. Thibault1, S. Larcine1, B. Corvisol1, S. Goldman1, B. Monma-Reyes; 1Exerre hospital, Bruxelles, BELGIUM.

OP-116 Added Value Of Fluorocholine (FC) PET/CT To Tc-99m MIBI Scintigraphy/SPECT (Sc) And Ultrasoundography (US) For Preoperative Detection Of Hyperfunctioning Parathyroid (PT) Glands In Patients With Hyperparathyroidism (HPT) And Chronic Kidney Disease (CKD)

J. Talbot1; 1J. Zhang-Yin2, T. Delbart1, M. Assar1, J. Anton2, S. Balogov1, F. Montazer1, P. Haymann1, S. Ahin1, M. Gauthé2, G. Guizou1; 1Hospital Tenon, Paris, FRANCE, 2Hospital Tenon, Nuclear Medicine, Paris, FRANCE, 3Hospital Cochin, Nuclear Medicine, Paris, FRANCE, 4Hospital Tenon-Radiology, Paris, FRANCE, 5Hospital Tenon, Endocrine Surgery, Paris, FRANCE.

OP-117 Contribution of dual time point F-18 fluorocholine PET/CT for challenging pre-operative parathyroid imaging in primary hyperparathyroidism

L. M. Vija1; 1E. Gabach2, P. Piscali2, S. Kanu1, J. Demirski1, C. Renaud1, B. Jeant1, B. Herbaud-Balare3, S. Brikouet1, S. Gréneval4, M. Violant5, P. Caron6, F. Courbot7; 1Nuclear Medicine/Institut Universitaire de Cancérologie IUCT, IRC, Toulouse, FRANCE, 2Nuclear Medicine, Institut Universitaire de Cancérologie IUCT, IRC, Toulouse, FRANCE, 3Thoracic Surgery, University Hospital-CRU, Toulouse, FRANCE, 4Pathology, Institut Universitaire de Cancérologie IUCT, IRC, Toulouse, FRANCE, 5Institut Universitaire de Cancérologie IUCT, IRC, Toulouse, FRANCE, 6Endocrinology, University Hospital-CRU, Toulouse, FRANCE.

EP-017 Possible pharmacological treatment interactions in autologous leucocytes labelling technique with 99mTc-HMPAO in patients with knee/hip prosthesis

E. Debra2; 1Maritza de Miguel, E. Orhue2; 1V. Menéndez-Barcena, H. Garcia-Ruiz, E. Martinez-Montañés; 1Hospital Universitario La Paz, Madrid, SPAIN.
Diagnostic impact of Ga-PECT/CT using quantitative analysis for patients with lower-limb osteomyelitis
Y. Nishikawa, Y. Fukushi, M. Kodani, G. Takagi, M. Miyamoto, S. Kamata, Nippon Medical School Hospital, Tokyo, JAPAN.

Diagnostic accuracy of 18F-FDG digital PET/CT in the detection of infective endocarditis on native and prosthetic valves and intracardiac devices: Preliminary results in a reference medical center
M. Mallén Araujo, E. Abou Jokh, V. Pubul Núñez, M. Pombo Pavin, M. Garrido Pumar, L. Garcia Bernardo, A. Martínez-Moránns, A. Martínez de Alegría Alonso, A. Rubial Morell, CHUS, Santiago De Compostela, SPAIN.

Aortic valve prosthesis infection: value of 18F-FDG PET/CT
D. Ortega-García, M. C. Fuentes, M. G. Calvo, M. R. Castaño, M. I. Martín, M. A. Villa Carballada, A. E. Toribio, Hospital Universitario de Malaga, Malaga, SPAIN.

Diagnostic accuracy of 18F-galactonate PET/CT in the detection of infective endocarditis in patients with prosthetic valves and implantable cardiac devices
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>OP-119</td>
<td>Introduction</td>
<td>K. Sjögreen Gleisner</td>
<td>Lund University, Medical Radiation Physics, Lund, SWEDEN.</td>
</tr>
<tr>
<td>OP-120</td>
<td>Requirements for the Dosimetry-Guided, Multi-Center Clinical Trial</td>
<td>J. Wadsley</td>
<td>Weston Park Cancer Centre, Sheffield, UNITED KINGDOM.</td>
</tr>
<tr>
<td>OP-121</td>
<td>Priorities of Dosimetry in Clinical Radionuclide Therapy: The Italian Agreement Between National Nuclear Medicine and Medical Physics Associations</td>
<td>C. Chiesa</td>
<td>Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.</td>
</tr>
<tr>
<td>OP-122</td>
<td>European Initiatives to Ensure Traceable Dosimetry Across Countries and Centers</td>
<td>M. Lassmann</td>
<td>Universitätsklinikum Würzburg, Klinik für Nuklearmedizin, WURZBURG, GERMANY.</td>
</tr>
<tr>
<td>OP-123</td>
<td>Joint Symposium 5 – Oncology &amp; Theranostics Committee / EORTC: The Future of Medical Imaging in Precision Medicine</td>
<td>D. de Geus-Oei</td>
<td>Leiden University Medical Center, Leiden, NETHERLANDS.</td>
</tr>
<tr>
<td>OP-124</td>
<td>Companion Diagnostics in Drug Development</td>
<td>G. van Dongen</td>
<td>Amsterdam University Medical Center, Department of Radiology &amp; Nuclear Medicine, Amsterdam, NETHERLANDS.</td>
</tr>
<tr>
<td>OP-125</td>
<td>Total Body PET-CT for Pharmacokinetic Analysis</td>
<td>S. Vandenbergh</td>
<td>University of Ghent, Department of Electronics and information systems, Gent, BELGIUM.</td>
</tr>
<tr>
<td>OP-126</td>
<td>The Use of Artificial Intelligence in Precision Medicine</td>
<td>I. Buvač</td>
<td>Unif. Imageorges Moleculaire In Viva, CEA/DRF/Service Hospitalier Informat, Joliot, Orsay, FRANCE.</td>
</tr>
<tr>
<td>OP-127</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OP-128</td>
<td>Joint Symposium 6 – Translational and Molecular Imaging Therapy + Cardiovascular + Inflammation &amp; Infection Committee / AHAG: Imaging Inflammation as Major Determinant of Cardiovascular Diseases – New Tracers and Clinical Applications</td>
<td>J. Thackeray</td>
<td>Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover, GERMANY.</td>
</tr>
<tr>
<td>OP-129</td>
<td>New Concepts, New Targets</td>
<td>J. Thackeray</td>
<td>Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.</td>
</tr>
<tr>
<td>OP-130</td>
<td>SPECT and PET in Cardiac Infection and Inflammation</td>
<td>C. Lauri</td>
<td>Department of Nuclear Medicine and Molecular Imaging, Sapienza University of Rome - Sant’Andrea Hospital, Rome, ITALY.</td>
</tr>
<tr>
<td>OP-131</td>
<td>Preclinical Perspective</td>
<td>V. Taqueti</td>
<td>Cardio Simes Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, UNITED STATES OF AMERICA.</td>
</tr>
<tr>
<td>OP-132</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OP-133</td>
<td>Research Methodology</td>
<td>C. Malamanthang</td>
<td>Division of Nuclear Medicine, University of Cambridge, Cambridge, UNITED KINGDOM.</td>
</tr>
<tr>
<td>OP-134</td>
<td>Targeted alpha therapy with $^{212}$Pb-NNV003 is efficient in treatment of irinotecan-resistant chronic lymphocytic leukaemia in preclinical models</td>
<td>A. Saidi</td>
<td>1. Heyerdahl, 2. A. Johan, 3. J. Torgue, 4. Orano Med LLC, Plano, TX, UNITED STATES OF AMERICA.</td>
</tr>
<tr>
<td>OP-138</td>
<td>In vitro and in vivo evaluation of bismuth-213 labelled anti-HER2 nanobodies</td>
<td>Y. Dekempeneer</td>
<td>Vrije Universiteit Brussel, Brussel, BELGIUM.</td>
</tr>
</tbody>
</table>
OP-143

Biodistribution and Therapeutic Efficacy of 151At-labelled Farletuzumab in a Disseminated Ovarian Cancer Mouse Model
S. Palm, E. Anhede1, T. Black1, A. Halkquist2, R. Hultbom, L. Jacobsen1, H. Jenney, S. Lindgren1, P. Albertsson1; 1University of Gothenburg, Gothenburg, SWEDEN, 2Rigshospitalet, Copenhagen, DENMARK.

OP-144

Systematic inaccuracies in the timing offset calibration may lead to large reconstructed transaxial asymmetries in the GE SIGNA PET/MR MP24

OP-145

Quantitative Optimization of High Definition Neurologic Imaging for Digital PET/CT
K. Binzel, A. Akinadi, J. Zhang, M. V. Knoop; The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA.

OP-146

Clinical impact of Spatially Variant Positon Range Correction for "Ga-DOTATATE and "Ga-PSMA PET/CT
A. Berger, J. Cal-Gonzalez, S. Rassu, M. Hoesker, M. Grateanou, R. A. Lath, G. Schernh, J. Rausch, T. Beyer, P. Kirsch; QMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, 2Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, 3Discipline of Medical Radiation Science and Brain and Mind Science, Faculty of Health Sciences, The University of Sydney, NSW, AUSTRALIA.

OP-147

Feasibility of Quantitative SPECT of Radionuclides used in Targeted Alpha Therapy
M. Ghaly1, B. He2, Y. Du3, G. Sprouse2, E. C. Frey2; 1Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 2Radiopharmaceutical Imaging and Dosimetry (Rapid), LLC, Baltimore, MD, UNITED STATES OF AMERICA.

OP-148

Artefacts reduction in cardiac SPECT images by using a novel reconstruction algorithm
M. Denisova1, A. Anhof, L. Sjogren1, H. Kertesz2, T. Beyer, J. Kilininski1; 1Institute of Theoretical and Applied Mechanics, Novosibirsk, RUSSIAN FEDERATION, 2National Medical Research Center of Cardiology, Moscow, RUSSIAN FEDERATION, 3Medical University of Vienna, Vienna, AUSTRIA, 4Novosibirsk State University, Novosibirsk, RUSSIAN FEDERATION.

OP-149

Dependence Of Error Propagation Due To An Incorrect Attenuation Map On PET Time-of-Flight Resolution
E. C. Emond1, A. Bousse2, A. M. Gover3, B. F. Hudson1, K. Thelemann3; 1University College London, London, UNITED KINGDOM, 2Université de Bretagne Occidentale, Brest, FRANCE.

407

Teaching Session 1 – Interactive Clinical Cases - Paediatric + Thyroid + Translational and Molecular Imaging Therapy Committee: Management of Thyroid Cancer in Children
Sunday, October 13, 2019, 14:30 - 16:00; Lecture Hall 113
Chair: L. Kurch; Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY.

OP-150

Paediatric DTC Management
A. Piccardo, E.O. Odedokun-Galiera; Department of Nuclear Medicine, Genoa, ITALY.

OP-151

Molecular Imaging in Paediatric DTC
F. Van Leeuwen; Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

OP-152

Radiodine Dosimetry and Therapy in Paediatric DTC Patients
M. Luster; University of Marburg, Department of Nuclear Medicine, Marburg, GERMANY.

OP-153

Radiomics from [18F]PSMA PET-CT with machine learning as a novel biomarker in primary prostate cancer
M. Cysouw1, B. H. Jansen1, K. C. van der Zande1, B. M. de Vries1, R. J. van Meetsma1, A. N. Vos1, G. S. Hoekstra1, T. van der Bruij2, D. E. Oesper-Lager3, R. Boellaard4; 1Amsterdam UMC, Vrije Universiteit Amsterdam, dept. of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS, 2Amsterdam UMC, Vrije Universiteit Amsterdam, dept. of Urology, Amsterdam, NETHERLANDS.

OP-154

Comparison Of Ga-68 PSMA PET/MR With Textural Analysis Data In Translational Zone Prostate Tumors: Preliminary Results Of An On-Going Study
L. L. Uslu1, S. Tuner2, B. Baker3, S. Gazi Hiday4, C. Demiray5, E. Guıı6, S. Sager7, H. K. Sayın8, K. Sonmezoglu9; 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, 2Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, TURKEY, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Urology, Istanbul, TURKEY, 4Health Sciences University, Bahirkapi Sadi Kanuk Training and Research Hospital, Department of Urology, Istanbul, TURKEY.

OP-155

Preliminary evaluation of PSMA PET/MR radiomics for primary staging in patients with prostate cancer
E. Solari; A. Gaffda1, B. Laurent1, T. Amire2, R. Tauber3, D. Vyskoce1, W. Weber, M. Eiber, M. Hatt, S. G. Neto1, 1Department of Nuclear Medicine, Klinikum rechts der Isar, Munich, GERMANY, 2Department of Nuclear Medicine, School of Medicine, Technical University Munich, Munich, GERMANY, 3LaTIM, INSERM, UMR 1101, Univ. Brest, Brest, FRANCE, 4Department of Urology, School of Medicine, Technical University Munich, Munich, GERMANY.

408

Clinical Oncology – Rapid Fire Session: New Tracers and Machine Learning
Sunday, October 13, 2019, 14:30 - 16:00; Lecture Hall 114
Chair: I. Buvat; Paris 7 and Paris 11 Universities, ORSAY, FRANCE.

Chair: M. Gotthardt; Radiatiod University Nijmegen Medical Centre, GA NIJMEGEN, NETHERLANDS.
OP-156 Machine Learning to Detect Prostate Cancer Recurrence using 18F-Fluciclovine PET

G. A. Davidson, J. Lee, H. Yang, H. Song, C. Hansaraz, A. Iagaru, *Stanford University, Stanford, CA, UNITED STATES OF AMERICA; Vam Medical Center University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF; Dimensional Mechanics, Seattle, WA, UNITED STATES OF AMERICA.

OP-157 **Ga-NODAGA-exendin-4 PET/CT for the diagnosis and localization of focal congenital hyperinsulinism

M. Boss, *P. Shah, W. Brenner, D. Blankenstein, C. Rottenburger, M. Brom, A. Eek, M. Buttinga, M. Gotthardt, *Radioboudumc, Nijmegen, NETHERLANDS, **Amsterdam University Medical Center, Amsterdam, NETHERLANDS, *Erasmus Medical Center, Rotterdam, NETHERLANDS, *Erasmus University Medical Center, Rotterdam, NETHERLANDS, *Julius Center for Health Sciences and Primary Care, Utrecht, NETHERLANDS, *University Medical Center Groningen, Groningen, NETHERLANDS, *Anton van Leeuwenhoek, Amsterdam, NETHERLANDS, *Rijnstate Arnhem, Arnhem, NETHERLANDS, *Humanitas University, Milan, ITALY.

OP-158 ([Ga]$^{68}$Ga-DOTA-exendin-4 PET/CT for the localization of insulinomas


OP-159 Lesion detection by $[^{22}R]$-DOG-girentuximab and $[^{18}F]$FDG-PET in patients with newly diagnosed metastatic renal cell carcinoma


OP-160 Thracostin (18F)Cu/SARATE Clinical Trial - Uptake and retention of (18F)Cu/SARATE within meningioma

G. P. Schembri, *C. Wyk, K. Willows, *A. Heft, J. Lengelou, *M. Parker, C. Biggin, M. Harris, *Royal North Shore Hospital, St Leonards, AUSTRALIA, **Flinders University, Adelaide, AUSTRALIA.

OP-161 Results of a Phase I/la study using $[^{68}$Ga-NeOBM$^1_8$ in oligometastatic GIST


OP-162 The role of FAPI-PET/CT in patients with lower gastrointestinal malignancies - first clinical experience

S. A. Koerber, *F. Staudinger, C. Kratochwil, S. A. Koerber, T. Lindner, D. Wild, *Max Delbrueck Center for Molecular Medicine, Berlin, GERMANY, **Max Delbrueck Center for Molecular Medicine, Berlin, GERMANY, ***National Center for Tumor Diseases (NCT), Heidelberg, GERMANY, ****Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY, *****Clinical Cooperation Unit Radiation Oncology, Heidelberg Cancer Research Center (DKZK), Heidelberg, GERMANY, ******Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKZK), Heidelberg, GERMANY, *******German Cancer Consortium (DKTK), Heidelberg, GERMANY.

OP-163 Non-invasive imaging of tumor-associated fibroblasts by $[^{68}$Ga-FAPINPET/CT - first experience in head and neck cancer

S. Seering, *Y. Zhu, A. Schirbe, T. Lindner, A. Schersch, S. Haberkorn, G. Endhardt-Hartmann, U. Haberkorn, C. Lapa, A. Buck, *Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, **Department of ENT, University Hospital Würzburg, Würzburg, GERMANY, ***Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ****Department of Pathology, University Hospital Würzburg, Würzburg, GERMANY, *****Department of Pathology, University Hospital Würzburg, Würzburg, GERMANY.

OP-164 A Pilot Study of Anti-HER2 Affibody Molecule

$[^{68}$Ga-MZHER2 in HER2-positive Gastric Cancer Patients

X. Guo, W. Zhou, H. Zhu, Z. Yang, Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-165 Thyroid Imaging Reporting And Data System (TIRADS) and 18F-MIBI-scintigraphy for the assessment of differentiated thyroid carcinomas and follicular neoplasms

S. Schenke, *R. Klett, P. Wagner, M. Zimny, *M. C. Kretz, **Department of Radiology and Nuclear Medicine, University Hospital Magdeburg A.O.R., Magdeburg, GERMANY, ***UGAG Nuclear Medicine Hanau, GERMANY, ****Department of Radiology and Nuclear Medicine, University Hospital Magdeburg A.O.R., Magdeburg, GERMANY, *****UGAG Nuclear Medicine Hanau, GERMANY.

OP-166 Variations in radiodine ablation - decision making after total thyroidectomy

O. C. Maas, *M. Maas, *P. Matzner, C. Marje, P. Blaufuss, *Medical University of Innsbruck, Innsbruck, AUSTRIA, **University of Innsbruck, Innsbruck, AUSTRIA, ***Medical University of Innsbruck, Innsbruck, AUSTRIA, ****Medical University of Innsbruck, Innsbruck, AUSTRIA, *****Medical University of Innsbruck, Innsbruck, AUSTRIA, ******Medical University of Innsbruck, Innsbruck, AUSTRIA, *******Medical University of Innsbruck, Innsbruck, AUSTRIA, ********Medical University of Innsbruck, Innsbruck, AUSTRIA.
OP-167  
First V600E mutation analysis in low and intermediate risk papillary thyroid carcinoma
I. López Villar, T. Navarro Martínez, P. Jane Soler, J. Bonilla Plaza, A. Martínez Lorca, J. Pérez Isuela, M. Corbura Díaz, Ramón y Cajal University Hospital, Madrid, SPAIN.

OP-168  
Addition of V11 of 18F-SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
I. Marin1,2, M. Mussat1, G. Petros2, M. Salvatori1.
1Unita Operativa Complessiva di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY; 2Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Roma, ITALY.

OP-169  
Thirteen-year Outcome of a Prospective Randomized Phase III study: 1.1 GBq and 3.7 GBq of Radioiodine Are Equally Effective in Ablation Therapy for Papillary and Follicular Thyroid Cancer
V. Ahtilaïnen, I. Vuolaiti, M. Tenhunen, H. Jomaa2, H. Minimalgia, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, FINLAND.

OP-170  
Predictive factors of recurrence in patients with indeterminate or incomplete biochemical response after radio-iodine therapy in patients followed for differentiated thyroid carcinoma
M. Chafai El Alaoui1,2, C. Valla3,4, F. Cachin1, B. Lardet1, A. Kelly1.
1Université de Nice Sophia Antipolis, Centre hospitalier universitaire, Nice, FRANCE; 2Neuroendocrinologie de l’hypophyse, Centre hospitalier universitaire, Nice, FRANCE; 3Médicament et Biologie, Université de Nice Sophia Antipolis, Nice, FRANCE; 4Centre de Référence des Tumeurs Hypophysaires, Centre hospitalier universitaire, Nice, FRANCE.

OP-172  
SensormiRNAs measurements and diagnostic radioiodine whole body scintigraphy can be useful diagnostic tool in early identifying of persistent disease in differentiated thyroid cancer (DTC) patients with uninformative IgG values
A. Campenni1,2, M. Agnenuozzi1, A. Vento1, F. Polato1, A. Di Cammi1,2, R. M. Di Gregorio1, F. Parini1, R. M. Ruggieri1, S. Baldani1,2, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY; 3Department of Clinical and Experimental Medicine, Unit of Neuroradiology, University of Messina, Messina, ITALY; 4Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, ITALY.

OP-174  
A comparison of quantitative and qualitative assessment for the diagnosis of malignancy in solitary pulmonary nodules using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET-CT) in the multicentre SPUn Nik trial
S. Dzidarevic1, J. R. Wier-McCay1,2, S. Hams3, L. A. Little1, J. J. Jones1, K. A. Miles1, R. C. Richman4, N. R. Qureshi1, J. M. Madden1, K. Echourouf5, L. Durcan4, K. Czarnik1, P. Lié6, D. Sinclair7, R. Eaton8, A. Shah9, L. Brindle1, A. Cook10, S. George11, on behalf of the SPUn Nik Investigators, F. Gilher; Imaging and Nuclear Medicine Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM; Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge, UNITED KINGDOM; ‘Public Health Sciences and Medical Statistics, University of Southampton, Southampton, UNITED KINGDOM; Southampton Clinical Trials Unit, University of Southampton, Southampton, UNITED KINGDOM; ‘Centre for Innovation and Leadership in Health Sciences, University of Southampton, Southampton, UNITED KINGDOM; Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM; Department of Thoracic Oncology, Papworth Hospital, Cambridge, UNITED KINGDOM; Department of Radiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UNITED KINGDOM; Division of Imaging Sciences and Biomedical Engineering, King’s College London, London, UNITED KINGDOM; Radiation Protection Department, East and North Hampshire NHS Trust, Stevenage, UNITED KINGDOM; Faculty of Health Sciences, University of Southampton, Southampton, UNITED KINGDOM.

OP-177  
Assessment of Pulmonary Lobar Perfusion Fraction and Prediction of Postoperative Function in Lung Cancer Patients
1Dept. of Clinical Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, DENMARK; 2Dept. of Clinical Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK.

OP-178  
First comparison of (18F)-FMISO and (18F)-FAZA for PET imaging of hypoxia in lung cancer before surgery
S. Therreau1,2, N. Pitar1, P. Gouat1, R. Modart2, A. Dujon1, J. Baxter, J. Meili, P. Riviere, C. Pellerin, S. Hagdry, J. Sabouarin, J. Pacquet, P. Bohm, P. Véret1, Department of Radiation Oncology, Henri Becquerel Cancer Center and Rouen University Hospital, & Quargri – LTSU EA 4198, Rouen, FRANCE; Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, & Quargri – LTSU EA 4198, Rouen, FRANCE; Department of Pathology and Normandie University, UNIROUEN, Inserm U145, Rouen University Hospital, Rouen, FRANCE; Clinic of Chest, Rouen, FRANCE; 1Dept. of General and Thoracic Surgery, Rouen University Hospital, Rouen, FRANCE; 2Department of Pathology, Henri Becquerel Cancer Center, Rouen, FRANCE.

OP-179  
18 Fdg Pet Cta Therapeutic And Pronostic Impact In The Initial Assessment Of Head And Neck Squamous Cell carcinomas A Retrospective Study Of 477 Patients
J. Leclerc1, O. Delcroix1, P. Robin1, S. Quenel1, R. Le Roux1, C. Guezennece1, L. Ollivier1, J. Schick1, J. Roussat2, G. Valette1, R. Abgral1, Department of Head and Neck Surgery, Brest University Hospital, Brest, FRANCE; Department of Nuclear Medicine, Medical Center of the University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY; Department of Thoracic Surgery, Medical Center of the University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.

OP-180  
*F* -FDG-PET/CT for the assessment and prognostication Cardiac Tumors
J. Meng, X. Li, H. Zhao, M. Yan, W. Dong1, M. Kresov1, X. Zhang1, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA; Medical University of Vienna, Vienna, AUSTRIA; Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA; University Hospital Magdeburg, Magdeburg, GERMANY.
**OP-180**
Metabolic Behavior And Prognostic Role Of Pretreatment 6F-DFG PET/CT In GIST
D. Albano1, M. Bonacina1, R. Dumont1, E. Carugati2, M. Gazelli4, F. Donati6, A. Mazzoleni1, P. Belloni1, F. Bertaglia3, R. Guide2
1Spedali Civili Brescia, Brescia, ITALY, 2University of Brescia, Brescia, ITALY, 3Spedali Civili Brescia and University of Brescia, Brescia, ITALY.

**ORAL**
October 13
EANM'19 EANM'19

**EANM'19**
**EANM'19**
**October 13**
**Oral**
M. Gazzilli
Barcelona, SPAIN,
Martinez-Lage
Sebastian, SPAIN.
Madrid, SPAIN,
Valencia, SPAIN,
SPAIN,
Pau, Barcelona, SPAIN,
SPAIN,

**411**
e-Poster Presentation Session 3 –
Neuroimaging: Neurodegeneration, Amyloidosis and Neuroinflammation
Sunday, October 13, 2019, 14:30 - 16:00
Room 139/140
Char. J. Arbizu, Nuclear Medicine, University of Navarra, PAMPLONA, SPAIN.
Char. F. Nobili, Dept. of Neuroscience, Ophthalmology and Genetics (DINOG), Clinical Neuroradiology, GENOA, ITALY.

**EPS-034**
Clinical outcome of Amyloid PET: interim analysis of the Spanish Registry of amyloid PET
J. Arbizu1, G. Martí1, C. Lomar-Basquet2, C. Gamo3, M. Gómez-Rod1, C. Marató4, M. Balsa4, B. Rodríguez-Alfonso5, A. Garcia-Viñére7, R. Lumbreras6, E. Caballero1, A. Gamar-Grande6, P. Sagona3, L. Dominguez-Gadea6, A. Rieger1, V. Camacho1, J. Boix1, P. Tamayo1, A. Persinotti4, I. Perelias2, C. Gamo3, P. Martinez-Lage1, I. Carrión1, on behalf of the Spanish Registry of Amyloid PET and PET AD/AD Consortium.
1Clnica Universitària de Navarra, Pamplona, SPAIN,
2Hospital Universitario Vall d’Hebron, Barcelona, SPAIN,
3Hospital Universitario de Bellvitge, Barcelona, SPAIN,
4Hospital Universitario Gregorio Marañón, Madrid, SPAIN,
5Hospital Universitario Puerta de Hierro, Madrid, SPAIN,
6Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, SPAIN,
7Hospital Ruber Internacional, Madrid, SPAIN.

**EPS-035**
Simultaneous 3T Quantitative Susceptibility Mapping MRI and Amyloid PET in Dementia
M. Rümmeli1, S. Topa1, A. Schäfer1, T. H. Jochimsen2, M. L. Schröter3, M. Patt4, O. Sabat1, H. Barthel1.
1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY,
3Siemens Healthcare GmbH, Diagnostic Imaging, Magnetic Resonance, Research & Development, Erlangen, GERMANY.

**EPS-036**
Validation of a pseudorefERENCE region approach using [18F]DPA714 in ALS patients
D. Van Weehaeghe1, N. Zürcher1, C. Teng1, M. Koole1, M. Aishboker1, J. Hooker1, J. De Vecker1, P. Van Damme1, K. Van Laer1, N. Assay2.
1Department of nuclear medicine and biomedical imaging, University Hospital Leuven, Leuven, BELGIUM, 2Athensoulas A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,
3Neuroradiological Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,
4Department of Neurology, University Hospital Leuven, Leuven, BELGIUM.

**EPS-037**
Influence of APOE genotype on e482 nicotinic acetylcholine receptor binding in mild Alzheimer’s disease as assessed by [11C]Flutabine PET
P. M. Meyer1, S. Wilker1, S. Hesse1, G. Becker1, M. Rümmeli1, M. Patt2, J. Luft2,3, G. Wagenknecht1,2, A. Hiepping1, R. Smith2, B. Satter2, S. Topa1, W. Duerstral-Conrad1, H. Barthel1, P. Scherneck1, P. Brust1, O. Sabat1, 1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2Integrated Research and Treatment Centre (IRCT) Adiposity Diseases, University of Leipzig, Leipzig, GERMANY, 3Electronic Systems (ZEA-2), Central Institute for Engineering, Electronics and Analytics, Research Center Juelich, Juelich, GERMANY, 4ABB advanced biochemical compounds GmbH, Radeberg, GERMANY, 5Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Leipzig, GERMANY, 6Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, GERMANY.

**EPS-038**
Assessment of Centiloid [18F]Flutemetamol values relative to CERAD-style pathology categories from a well characterised autopsy cohort
C. J. Buckley1, M. Battle3, G. Fanari2, C. Foley4, A. Smith2, D. Thal4.
1GE Healthcare Pharmaceutical Diagnostics, Amersham, UNITED KINGDOM,
2Department of Neurosciences, IU Leuven, Leuven, BELGIUM,
3Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY,
4Peking University First Hospital, Beijing, CHINA.

**EPS-039**
Sex Modulates the ApoE ε4 Effect on Tau Brain Deposition measured by [18F]AV-1451 PET in Individuals with Normal Aging and Mild Cognitive Impairment
R. Wang1, M. Li1, X. Chen1, Y. Zhou1.
1Peking University Hospital, Beijing, CHINA, 2Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

**EPS-041**
At first sight - Can grey matter/white matter boundary delineation or partial volume effect correction enhance the visual read of [18F]Florbetaben PET images?
M. Rümmeli1, S. Topa1, K. Messerschmidt1, T. Gerhardt1, M. Schurer2, S. Hesse1, D. Sauter1, C. Meiser1, M. L. Schroeter1, J. Claessen1, O. Sabat1, H. Barthel1.
1Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, 2A8 Alzheimer Disease, Leipzig University Medical Center, Leipzig, GERMANY,
3Department of Radiological Imaging, Memory Clinic, Skåne University Hospital, Malmö, SWEDEN.

**EPS-042**
Baseline Assessments of Striatal Amyloid Plaque Load, Hippocampal and Ventricular Volumes via [18F]Flutemetamol PET and MRI Imaging Predicts Clinical Progression to AD in a 3-year observational AMCoT Cohort Study
L. Chedumbarum Pillay1, P. Wilkens1, C. J. Buckley1.
1University of Oxford, Oxford, UNITED KINGDOM,
2GE Healthcare, Marlborough, MA, UNITED STATES OF AMERICA, 3GE Healthcare, Amersham, UNITED KINGDOM.

**EPS-043**
Direct quantification of native-space amyloid PET via end-to-end training of a deep learning J. Kim, H. Choo, J. Paeng, G. Choon, K. Kang, D. Lee, Department of Nuclear Medicine, Seoul National University, Seoul, KOREA, REPUBLIC OF.

**EPS-044**
Comparison of Centiloid Scaling Values with Visual Read Assessment in a Pathology Verified Amyloidosis Cohort
M. Battle1, C. Buckley1, A. Smith2, G. Fanari2, D. R. Thal1, J. Molineux1, O. Hansson1.
1GE Healthcare, Amersham, UNITED KINGDOM, 2Department of Neuroradiology, IU Leuven, Leuven, BELGIUM,
3Barcelona Brain Research Centre, Barcelona, SPAIN,
4Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, SWEDEN,
5Memory Clinic, Skåne University Hospital, Malmö, SWEDEN.

**EPS-045**
Validation of a Visual Assessment Strategy for 18F-Florbetapir PET
A. Dodich1, A. Rochat1, J. Manto1, C. Naert1, P. Andryszak2, B. Rakicamianramo3, G. B. Pospisil1, V. Ganbatov1.
1NIMThA, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, SWITZERLAND, 2Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND,
3Memory Center and LANVIE - Laboratory of Neuroimaging and Genomics, Geneva University Hospitals, Geneva, SWITZERLAND.
Oral Presentations

EANM'19 EANM'19

C. Moro
Lammertsma
Farrar
C. J. Buckley
and Centiloid analysis
florbetaben images including regional SUVR
EPS-046

Korman
Landau
Molecular Imaging, Berlin, GERMANY,
of Geneva, Geneva, SWEDEN,
of Neuroimaging of Aging (LANVIE), University of
Healthcare Pharmaceutical Diagnostics, Amersham,
Berkeley, CA, UNITED STATES OF AMERICA.

Evaluation of a visual interpretation method for
EPS-047

University of California, Los Angeles, CA,
O. H. Lesman-Segev
S. Bullich
I. Lopes-Alves
Berkeley, CA, UNITED STATES OF AMERICA.

Department of Nuclear Medicine and Molecular Imaging, University Hospitals of
Geneva, SWEDEN,
Centre for Medical Image Computing, UCL, London, UNITED KINGDOM,
*Geminist Research Centre, London, UNITED KINGDOM.

1,2

EPS-049

Soliman
L. Beyer
M. Assal
11
2
M. Marques da Silva
1
11

[11 C]PK11195 PET Quantification Analysis
EPS-050

M. Roos
1

Role of Extracellular Matrices in Cancer and
Oncology & Theranostics Committee:
Molecular Imaging Therapy +
Committee: Stress Testing for Technologists
Minicourse 2 - Interactive - Technologist
Other Diseases
Role of Extracellular Matrices in Cancer and
Oncology & Theranostics Committee:
Molecular Imaging Therapy +
Committee: Stress Testing for Technologists
Minicourse 2 - Interactive - Technologist

BARCELONA, SPAIN | OCTOBER 13 – 16, 2019
BARCELONA, SPAIN | OCTOBER 13 – 16, 2019
OP-190 Which Role for Cardiac CT(A) in CAD?
D. Andreini, Centro Cardiologico Monzino, Milan, ITALY.

Sunday, October 13, 2019, 16:30 - 18:00 Lecture Hall 111

M2M - Parallel Session: Radiolabelled Peptides and Proteins

Chair: L. Aloj, NUCLEAR MEDICINE, CAMBRIDGE UNIVERSITY HOSPITALS, CAMBRIDGE, UNITED KINGDOM.

OP-195 Comparison Of Affibody- And Antibody Fragments-based Caix Imaging Probes In Mice Bearing Renal Cell Carcinoma Xenografts
J. Garousi, F. Huang2, A. Vorobyeva3, B. Mitran4, K. Andreus5, C. Dathuesen Lettea6, F. Frey7, J. Lofbom7, J. Businski, A. Orlow1, V. Skarpmént1, 1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN; 2Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS; 3Department of Medical Chemistry, Uppsala University, Uppsala, SWEDEN; 4Department of Protein Science, KTH Royal Institute of Technology, Stockholm, SWEDEN; 5Department of Radiology and nuclear medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-196 Pharmacodynamic changes of FAP-targeted IL2 variant immunotherapy assessed with [18F] Ga-DOTA-Siglec-9 in B16-FAP melanoma mice
R. Sittonen1, I. H. Väinen2, H. L. Liljenklock3, O. Moso1, X. Li1, C. Klein4, T. Naito1, S. Jalkanen1, A. Roivainen1; 1Turku PET Centre, University of Turku, Turku, FINLAND; 2Turku Center for Drug Discovery Modeling, University of Turku, Turku, FINLAND; 3Rochio Pharma Research and Early Development, Roche Innovation Center Basel, Basel, SWITZERLAND; 4MedCity Research Laboratory, University of Turku, Turku, FINLAND.

OP-199 EPI-PGD-DOTA: Novel androgen receptor ligand as an alternative to PSMA ligands
F. Braun1, S. Meurath, V. Mammel, H. Endopoli, M. von Brandenstein1, M. Peters2, A. Drasch3, K. Schmacher1; 1University of Cologne, Clinic of Nuclear Medicine, Cologne, GERMANY; 2University of Cologne, Clinic of Urology, Cologne, GERMANY; 3University of Cologne, Institute of Pharmacology, Cologne, GERMANY.

OP-200 Evaluation of Bivalent GPR1 Radioligands for Targeting Prostate Cancer
N. Romantini1, S. Dabad, M. Alam1, M. Spillmann1, R. Schol1, X. Deup1, H. Wenneers1, P. Berger1, M. Reha; 1Paul Scherrer Institute, Villigen, SWITZERLAND, 2Teaal Institute of Technology (ETH), Zurich, SWITZERLAND.

OP-201 Imaging of Prostate Cancer in Therapy-Naive Patients Using the GRPr Antagonist [68 Ga]68Ga-SB3
1. L. Bakker1, A. C. Feijer1; 1B. van der Sluij1, J. E. Zeltingben1, M. Konijnenberg1, J. Schuur1; 1L. M. van Leuven1, E. de Blas1, J. W. M. van Weenden1, T. Maina1; 2A. Noë1, M. de Jong1; 3Exssus MC, Rotterdam, NETHERLANDS; 4WAVEST, INSTM “Demokritos”, Athens, GREECE.

506 Do Me - Parallel Session: 111Lu-PRRT and other Preclinical & Clinical Dosimetry

Chair: M. Bardies, UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, FRANCE; 2INRASTES, NCSR ‘Demokritos’, Athens, GREECE.

OP-202 In vitro dose-response comparison of [177Lu] Lu-labelled somatostatin receptor agonist and antagonist
G. Tamborini1, M. De Sant’Hubert1, L. Struëns1, S. Dalim2, E. Rugnak, M. de Jong3, J. Nonnenmacher1, M. W. Konijnenberg4; 1Research in Dosimetry, Applications, Belgian Nuclear Research Centre (SCK•CEN), Mol, BELGIUM; 2Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NETHERLANDS; 3Department of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NETHERLANDS.

OP-203 Absorbed doses to kidneys based on one or two SPECT measurements versus three SPECT measurements in 777 patients with neuroendocrine tumours receiving 177Lu-DOTATATE therapy
M. Sandstrom1, D. Granberg1, A. Sundin1, M. Lubenink1, 2Nuclear medicine & PET, Uppsala University, Uppsala, SWEDEN, 3Medical physics, Uppsala University Hospital, Uppsala, SWEDEN.

OP-204 Quantitative SPECT/CT voxel-based dosimetry in 177Lu-octreotate PRRT: the selection of the reference timepoint for deformable CT registration impacts on the calculated absorbed dose to target tissues
A. Dasy1, G. F. Boer1, D. Mandre2, A. S. Nelson3, J. M. Baumgard1, 2Department of Medical Imaging and Oncology Division of Research Center, CHU de Quebec – Universite Laval, Quebec City, QC, CANADA, 3Department of Radiology and Nuclear Medicine and Cancer Research Center, Universite Laval, Quebec City, QC, CANADA, 4MIM Software Inc., Cleveland, OH, UNITED STATES OF AMERICA.

OP-205 Personalized OAIR dosimetry in patients with NET: preliminary results of a Phase II study
E. Tonini1, M. Lang1, S. Di Bari2, A. Barone2, A. Turra3, L. Longo3, G. Di Domenico4, L. Uccelli5, S. Panareo1, C. Citton1, S. Santì1, I. Rambaldi1, M. Bardies1, 2Arcispedale Sant’Anna Hospital, Medical Physics Unit, Ferrara, ITALY, 3Sapienza University of Rome, Ph. D. Program in Morphogenesis & Tissue Engineering, Rome, ITALY, 4Department of Radiotherapy and Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NETHERLANDS, 5Department of Medical Physics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NETHERLANDS.

OP-206 Absorbed dose calculation considering organ mass variation for patients treated with Lutathera
E. Mora Ramirez1, A. Vergara-Gutiérrez1, J. Ocampo-Ramos2, J. Rouquet3, P. Kostta4, J. Sandoval5, M. Deshayes1, 2M. Bardies3; 1CRT-UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, FRANCE, 2Universidad de Costa Rica, Escuela de Física, OCNAN, San José; 3INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTEPELLIER, MONTEPELLIER, FRANCE, 4Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, Montpellier, FRANCE.

*EANM’19*  
BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

---

**Barcelona, Spain | October 12 – 16, 2019**
Cellular dose-response models for [177Lu] OP-207
L. Jiménez-Franco, S. Donatiello, Pizzoferro
Dresden, GERMANY, Erasmus MC, University Medical Center Rotterdam, The Netherlands, Rotterdam, NETHERLANDS.

Preliminary dosimetric study with [177-Lutetium OP-208
G. Tamborino, B. Cassano
Roesch & PET/CT Positronmed, Santiago de Chile, CHILE, Molecular Medicine Department, Rome, ITALY.

Biodistribution and dosimetry of a single dose of [111In]Lu-DOTA-Tyr3,octreotate radionuclide therapy OP-209
B. Carrasso, E. Genovese, C. Palao, M. Longo, S. Donatiello, A. Napolitano, T. Insero, S. Valeri, M. Pozzolenti, A. Semis, M. C. Gangarossa, V. Cannata, IRCCS Bambino Gesù Children’s Hospital, Medical Physics Unit, Rome, ITALY, Sapienza University of Rome, Molecular Medicine Department, Rome, ITALY, Assisicopianti Sant’Anna Hospital, Medical Physics Unit, Ferrara, ITALY, Sapienza University of Rome, Ph. D. Program in Morphogenesis & Tissue Engineering, Rome, ITALY, Tor Vergata Postgraduate School of Medical Physics, Rome, ITALY.

Biodistribution and dosimetry of a single dose of [111In]Lu-DOTA-Tyr3,octreotate radionuclide therapy OP-209

Imaging of Immune Cell - From Preclinical to Clinical OP-213
M. Knellling, Eberhard Karls University, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiotherapy, Department of dermatology, Tubingen, GERMANY.

Influence of Pretreatment with Everolimus and/or Sorafenib on the Acute Hematotoxicity of [177Lu]DOTATATE PRRT OP-217
J. Zhang, O. Lui, H. R. Kulikarni, A. Singh, C. Schuchardt, M. Pavel, P. Broberg, A. Wegener, R. Hicks, A. Demange, K. Oberg, P. Puzmic, J. Vaneechoutte; Theranostics Center for Molecular Radiopharmacy & Precision Oncology, ENETS Center of Excellence, Zentrumklinik Bad Berka, Bad Berka, GERMANY, Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, CHINA.

Clinical Oncology - Rapid Fire Session PRRT 4.07 OP-215
L. Bodei, New York, NY, UNITED STATES OF AMERICA.

Preliminary dosimetric study with [177-Lutetium OP-210
P. Laverman, Radboud University Nijmegen Medical Centre, Department of Radiology & Nuclear Medicine (FS7), Nijmegen, NETHERLANDS.

Basics of Immune Cells - Expression, Role and Targeting Possibilities OP-211
E. Aamtszen, Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

Methods for Immune Cell Radiolabelling OP-212
R. Torres Martin de Rosales, Sr Thomas’ Hospital / Kings’ College London, School of Biomedical Engineering & Imaging Sciences, London, UNITED KINGDOM.

Analysis of patient diaries in the NETTER-1 Study OP-219

Prognostic value of [18F]FDG PET/CT in a large cohort of 495 patients with advanced neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT) OP-216
J. Zhang, O. Lui, H. R. Kulikarni, A. Singh, C. Schuchardt, K. Nkusu, R. P. Baum; Theranostics Center for Molecular Radiopharmacy & Precision Oncology, ENETS Center of Excellence, Zentrumklinik Bad Berka, Bad Berka, GERMANY, Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, CHINA.

First Results of Targeted Alpha Peptide Receptor Radionuclide Therapy Using Ac-225 DOTATOC for Progressive Metastatic Neuroendocrine Neoplasms OP-220
H. R. Kulikarni, J. Zhang, A. Singh, C. Schuchardt, R. P. Baum; Theranostics Center for Molecular Radiopharmacy and Precision Oncology, Zentrumklinik Bad Berka, Bad Berka, GERMANY.

Predictive factors for short-term haematotoxicity during peptide receptor radionuclide therapy OP-221
OP-222  Amino Acid Solutions in Premedication Peptide Receptor Radionuclide Therapy (PRRT) with LuAtthera®: A Tolerability Study  
K. Fröss-Baron, B. Bouzehouane, J. Bour, E. Leongemasu, C. Bolier, C. Baunaud, hôpital Civils de Lyon, Groupement Hospitalier Est, Bron, FRANCE; Université Lyon 1; Claude Bernard Lyon, FRANCE.

OP-223  Favourable outcome in patients with metastatic pheochromocytomas and paragangliomas treated with “Lu-DOTATATE”  
A. Vyakaranam, M. H. Conn, E. Thois-Evenser, P. Hellman, G. Nolet, B. Granberg, U. Garske-Román, K. Fos-Aban, M. Sandström, A. Sundin, Uppsala University, Uppsala, SWEDEN; Akademia Sjuktunet, Uppsala, SWEDEN; Oslo Metropolitan University, Oslo, NORWAY; Department of Nuclear Medicine, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-224  A standardized and simplified dosimetric approach for PRRT in patients with neuroendocrine tumor  
E. Tonini, S. Di Biaso, M. Longo, A. Barbetti, A. Turni, L. Uccelli, S. Pandareo, C. Cittadini, M. Bartolomei, Arcispedale Sant’Anna Hospital, Medical Physics Unit, Ferrara, ITALY; Dipartimento di Fisica e Scienza della Terra, Ferrara University, Ferrara, ITALY; Sapienza University of Rome, Ph. D. Program in Morphogenesis & Tissue Engineering, Rome, ITALY; Arcispedale Sant’Anna Hospital, Nuclear Medicine Unit, Ferrara, ITALY.

OP-225  177Lu-DOTATATE in advanced neuroendocrine tumours: real world data from SEPTRALU registry  
M. Mitjavila Casanova, C. Felda, P. Baldo, Z. Nogradi, S. Sasner, L. Galmé-Caramasqui, J. Adur, A. Rivero, P. Gaia, M. Castellví, M. Mura, A. Teule, A. Repeto, M. Miguel Martínez, M. Eistol, P. Jimenez-Forcada, A. Cammona-Bayona, Nuclear Medicine HU Puerta de Hierro Magdalena, Madrid, SPAIN; Nuclear Medicine Hôpitaux de Madrid, Madrid, SPAIN; Nuclear Medicine, HU La Fe, Valencia, SPAIN; Nuclear Medicine, HU Luca Augusto, Lugo, SPAIN; Nuclear Medicine, Hôpitaux de Madrid, Madrid, SPAIN; Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN; Nuclear Medicine, Hospital Universitari d’Ogdena Marion, Madrid, SPAIN; Medical Oncology, HU Ramón y Cajal, Madrid, SPAIN; Nuclear Medicine, HU Vegen de la Aximca, Murcia, SPAIN; Nuclear Medicine HU Vegen de Las Nieves, Granada, SPAIN; Medical Oncology, ICO-Elvabe, Barcelona, SPAIN; Nuclear Medicine, HU San Esteban, Palma de Mallorca, SPAIN; Nuclear Medicine HU Burgos, Burgos, SPAIN; Nuclear Medicine HU Sant Pau, Barcelona, SPAIN; Medical Oncology, Hospital Universitari Central de Asturias, Oviedo, SPAIN; Medical Oncology, Hospital Universitario Morares, Meseguer de Murcia, Universidad de Murcia, UMU; MB, Murcia, SPAIN.

509  Neuroimaging - Parallel Session: Movement Disorders and Neurotransmission  
Sunday, October 13, 2019, 16:30 – 18:00  
Chair: D. Cechin, Nuclear Medicine Service, Diagnostic Medical Sciences, PADOVA, ITALY; Chair: E. van de Giessen, Nuclear Medicine, University of Amsterdam, Amsterdam, NETHERLANDS.


OP-227  A Multiple-modality Pattern of Multiple System Atrophy Based on FDG PET/CT and MRI  
L. Li, S. Peng, P. Wu, J. Ge, J. Lu, J. Wang, Y. Mei, Huashan Hospital, Shanghai, CHINA, Fenestra Institute for Medical Research, New York, NY, UNITED STATES OF AMERICA.

OP-228  Variability of Dopaminergic Degeneration Patterns in Multiple System Atrophy: Data-driven Approaches of Dopamine Transporter PET  
R. Lee, J. Shin, H. Cho, H. Kim, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-229  Differential Diagnosis of Parkinsonism using a 3D Deep Residual Convolutional Neural Network based on 18F-FDG PET Imaging  
P. Wu, Y. Zhao, J. Wang, N. Novati, I. Yakushev, W. Wibertz, M. Schwager, S. Huang, P. Cumming, A. Rominger, C. Zuo, X. Shi, PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA; Department of Computer Science, Technische Universität München, Munich, GERMANY; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA; Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, Department of Nuclear Medicine, University of Bern, Bern, SWITZERLAND.

OP-230  High-PI PET references from values with subjects with non-degenerative Parkinsonism, comparable to values from healthy volunteers  
C. Scheiber, G. Plasch, G. Gourtou, S. Thobois, S. Zeltwanger, P. Fahrenholz, H.-C. Groupement Hospitalier Est, Lyon, FRANCE, Siemens AG Healthcare, Erlangen, GERMANY; Hospital Neurologique, Lyon, FRANCE, Siemens Medical Solutions USA, Inc, Knoxville, TN, UNITED STATES OF AMERICA.

OP-231  Neuroprogressive character of sigma-1 receptor pathophysiology in undiagnosed patients with acute major depressive disorder as investigated by [-][18F]Fluspiride PET  
P. Meyer, M. Stauusi, G. Becker, S. Hesse, K. Beboshaghi, E. Helrich, S. Wilt, F. Zentek, M. Rülke, M. Luther, S. Fischer, A. Palt, B. Wünsch, P. Bruix, O. Sahn, Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY; Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, GERMANY, Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Leipzig, GERMANY; Institute for Pharmaceutical and Medical Chemistry, University of Munster, Munster, GERMANY.

OP-232  [18F]Fluspiride and [18F]Jallypride PET study to evaluate sigma-1 receptor (S1R) and dopamine 2 / dopamine 3 receptor (D2/3R) occupancy by pridopidine in healthy volunteers (HV) and patients with Huntington disease (HD)  
OP-233  Simultaneous Sigma-1 Receptor PET/ Multimodality MRI of the Effect of Pridopidine in Huntington Disease Patients and Healthy Volunteers
H. Barthel1, P.M. Meyer1, M. Rüllmann1, G. Becker1, M. Brostizel2, D. Mestelser1, G. Pust1, O. Vager1, L. Raboinovitch1, H. Knobloch2, F. Stademann1, S. Ruhland1, M. Seidel1, M. Hentschel1, P. Kahle1, S. Hauke1, M. Stöger1, G. Eichhorn1, M. Schober1, S. Bartl1, M. A. Rabinovich1, B. Sattler1, M. Patt1, E. Strauss1, A. Kugler1, J. Sava1, M. F. Gordon2, M. Gerst1, H. Hess1, M. Haydon3, I. G. Griesch1, O. Sabri3, 1University Hospital Leipzig, Leipzig, Germany, 2ABK-CRC, Dresden, Germany, 3Teva Branded Pharmaceutical Products RLD, Frazer, PA, UNITED STATES OF AMERICA, 4Artemisstiftungchor Lepzig, Leipzig, Germany, 5Prelina Therapeutics Development, Heilbronn, Germany, 6Guide Pharmaceutical Consulting, Mississauga, ON, UNITED STATES OF AMERICA.

S10  Cardiovascular - Parallel Session: Cardiac Imaging - More than Perfusion
Sunday, October 13, 2019, 16:30 - 18:00; Lecture Hall 116
Chair: E. Reyes, Horefield, UNITED KINGDOM.

OP-234  Detection of Thrombus inside LVADs using 18F-GP1 PET/CT - Preliminary Results
V. Hugenberg1, A. Brucher2, R. Reuß3, N. Kögler2, M. Berndt1, A. Stepans1, C. Feldmann1, A. Kasner1, M. Melting1, 1Institute for Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetic Center North Rhein Westphalia, University Hospital, Ruhr University Bochum, Bad Oeynhausen, Germany, 2Life Molecular Imaging GmbH, Berlin, Germany, 3Department of Cardi thoracic, Transplantation and Vascular Surgery (HTIG), Hannover Medical School, Hannover, Germany, 4Clinic for Thoracic and Cardiac Surgery, Enich & Hanna Kressmann Institute, Heart and Diabetes Center North Rhein Westphalia, University Hospital, Ruhr University Bochum, Bad Oeynhausen, Germany.

OP-235  Sex Hormones Preserve Cardiac Sympathetic Integrity Following Myocardial Injury
A. Haider1, S. Benga1, M. Marendzik2, A. Porrmann1, G. Warnock1, F. Montecucc1, A. Alkhoday1, A. Müller Hendel1, C. Keller1, S. D. Köser1, A. Schröf1, L. Mün1, P.A. K. Mau1, S. M. Ametamy1, C. Gebhart1, 1University Hospital Zurich, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland, 3University of Genoa, Genoa, Italy, 4ETH Zurich, Zurich, Switzerland.

OP-236  Early inflammatory changes of myocardial ischemia-reperfusion injury can be detected with vascular adhesion protein-1-targeting PET imaging
A. Autio1, S. Uotila1, V. Kyhti1, M. Kijger1, H. Liljendahl2, A. Saarialho1, J. Naumenko3, S. Jaakinen4, A. Saraste1, A. Rovainen5, 1Turku PET Centre, Turku, Finland, 2University of Turku, MedRey Research Laboratory, Turku, Finland, 3Heart Center, Turku University Hospital and University of Turku, Turku, Finland, 4Turku Center for Disease Modeling, University of Turku, Turku, Finland.

OP-237  Comparison of a new 99mTc-radiolabelled PET imaging agent sc146 and RGD peptide for non-invasive evaluation of angiogenesis in mouse model of myocardial infarction
M. Anais1, P. Garesse1, S. Fernandez1, E. Hubert1, L. Balasse1, P. Brige1, A. Bouhlel1, G. Hache1, M. Blot Chabaud1, F. Rochais1, F. Dignat-George1, B. Guillet1, A. Vanmaele2, University of Flanders, Belgium.

OP-238  Feasibility and potential time reduction of simultaneous 99mTc-tetrofosmin and 123I-BMIPP dual-tracer imaging with cadmium-zinc-telluride detectors in patients with acute myocardial infarction
S. Nakano1, Y. Yamada1, T. Muramatsu1, S. Nishimura1, N. Okano1, J. Matsumori1, K. Fukushima1, 1Department of Cardiology, International Medical Centre, Saitama Medical University, Hidaka, Saitama, Japan, 2Department of Nuclear Medicine, Radiation and Biomedical Science, Saitama Medical University, Moro, Saitama, Japan, 3Department of Nuclear Medicine, International Medical Centre, Saitama Medical University, Hidaka, Saitama, Japan.

OP-239  Low septal to lateral wall 18F-FDG ratio is a marker of mechanical dysynchrony in non-ischemic CRT candidates
G. Degtjareva1, P. Claus1, J. Duchenne1, M. Cucq1, M. J. Verbeken1, G. Schramm1, J. Nytko1, J. Vagner1, O. Gheysens2, 1Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium, 2Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium, 3Cardiovascular Sciences, Cardiovascular Imaging and Dynamics, KU Leuven, Leuven, Belgium, 4Cardiovascular Disease, University Hospitals Leuven, Leuven, Belgium, 5Cardiovascular Sciences, Cardiology, KU Leuven, Leuven, Belgium, 6Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, Netherlands.

OP-240  Cardiac 111InMBG scintigraphy as a tool to optimize CRT patient selection
D. O. Verschure1, E. Paet1, V. Frontezki1, G. De Vincenzo1, O. Gheysens2, J. H. de Grooth1, M. Verbeken3, 1Amsterdam University Medical Center, Amsterdam, Netherlands, 2Sapporo - University of Rome, Rome, Italy, 3University Hospitals Leuven, Leuven, Belgium.

OP-241  Prediction of cardiac death using 123I-MIBG: comparison between statistical and machine learning models for serious arrhythmic events and heart failure death
K. Nakajima1, T. Nakata1, T. Dav1, K. Murayama1, 1Kansazawa University, Kanzazawa, Japan, 2Kanazawa Goryokaku Hospital, Kanazak, Japan, 3Tone Kosuge Hospital, Sapporo, Japan, 4Walsh Research Inc, Tokyo, Japan.

OP-242  Impact of 18F-FDG PET/CT in Therapy Management of Pediatric Patients with Bone and Soft Tissue Sarcomas
E. Riera1, S. Orzi1, P. Bassol1, M. Soler1, P. Perea1, M. Gama2, E. Inamori1, J. Barber1, J. Giralda2, CETIR, ASCORES, Barcelona, Spain, 3Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

EANM'19  FINAL PROGRAMME  BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

WORLD LEADING MEETING  FINAL PROGRAMME  BARCELONA, SPAIN | OCTOBER 12 – 16, 2019
EPS 054
Normal (11C)-metionine PET uptake in the brain in children before and after treatment
D. Susin, T. Skvortsova; N.P. Bcheleva Institute of Human Brain, Saint-Petersburg, RUSSIAN FEDERATION.

EPS 057
Hepatobiliary scintigraphy for pediatric biliary atresia: a single-institution experience
W. Wong, X. Chu, B. Kang, T. Au Yang, Nuclear Medicine and Clinical PET Centre, Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EPS 058
Age & puberty are major determinants of response to radioiodine in children and adolescents with differentiated thyroid cancer
S. S. Singh, A. Goad, A. Bhatcharaya, B. R. Mitra, G. Kumar, A. S. Shekhawat, Post graduate institute of medical education and research (PGIMER), Chandigarh, INDIA.

EPS 059
Predictors Of Radiodiagnosis Therapy Effectiveness In Children And Adolescents With Graves’ Disease
P. O. Rumyantsev, D. Dreysova, A. Tkachin, M. Sharavetina, V. Vaschenyua, K. Satschuk, M. Deytseva, S. Serezhkina, Y. Sirota, V. Nikitaya; Endocrinology Research Center, Moscow, RUSSIAN FEDERATION.

EPS 060
Will pulmonary embolism diagnosis still be made with ventilation/perfusion imaging?

EPS 061
Findings in Lung Perfusion and Ventilation-Perfusion Scintigraphy in patients with suspicion of Chronic Thromboembolic Pulmonary Hypertension
G. Guzmán, M. Calomón, L. Nieto, M. Falgués, P. Navas, M. Sanz, S. Álvarez, L. De la Cuerva, D. Abós; Hospital Universitari a Miguel Servet, Zaragoza, SPAIN.

EPS 062
Differences in Pulmonary Ventilation / Perfusion Scintigraphic in Patients with Chronic Thromboembolic Disease with or without Pulmonary Hypertension

EPS 063
Scintigraphic quantification of pulmonary perfusion - comparison between planar and tomographic acquisition
M. Víctor, S. Carmona, S. Chín, A. I. Santos; Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

EPS 064
Lung Aerosol Scintigraphy in Diabetic Patients Without Pulmonary Symptoms
K. Kata, N. Pandit; JIPMER, Pondicherry, INDIA.

EPS 065
Utility Of 99mTc-MAA Scintigraphy And SPECT / CT For The Diagnosis Of Peritoneal Leakage In Dialyzed Patients With End Stage Kidney Disease
B. Pérez López, P. J. Turbay Eljach, J. Gómez Hidalgo, N. Álvarez Memo, S. Sanz Ballesteros, M. A. Ruiz Gómez, C. Garnatas Lehmen, M. Alonso Rodriguez, M. J. González Soto, A. Sanz Esteban, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EPS 066
Replacing the 3 hours imaging in 99mTc-SehCAT bile acid malabsorption investigations with a calculated value
L. Duchstein, C. Härdesfeldt, J. Nielsen, A. Flinsborg; Biopolymers and Frederiksberg Hospital, Dept. of Clinical Physiology and Nuclear Medicine, Copenhagen NV, DENMARK.

004C
Mini Course 3 - Technologist Committee: Theranostics - Fundamental
Sunday, October 13, 2019, 17:00 - 18:00; Lecture Hall 157.
Chair: S. Rac, Nuclear Medicine, ABC Ryjka, RJEWA, CROATIA.
Chair: S. Rep, Department of Nuclear Medicine, University Medical Centre Ljubljana, LJUBLJANA, SLOVENIA.

OP 242
General Aspects of Theranostics in Nuclear Medicine
S. Mirzaei; Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, AUSTRIA.

OP 243
Theranostics for Technologists in the Context of NET
N. Gulliver; Department of Nuclear Medicine & PET-CT, King’s College Hospital NHS Foundation Trust | Denmark Hill, London, UNITED KINGDOM.

601
CMES - Oncology & Theranostics + Bone & Joint Committee: Radionuclide Molecular Imaging in Bone Tumours and Multiple Myeloma - Pearls, Patterns & Pitfalls
Monday, October 14, 2019, 8:00 - 9:30; Auditorium.
Chair: G. Gnanasegaran, NUCLEAR MEDICINE, LONDON, UNITED KINGDOM.
Chair: F. Paycha, Summers, FRANCE.

OP 244
Radionuclide Molecular Imaging in Primary Bone Tumours
T. Van den Wyngaert; Antwerp University Hospital, Nuclear Medicine, Edegem, BELGIUM.

OP 245
Radionuclide Molecular Imaging of Bone Metastases
G. Gnanasegaran, Royal Free Hospital, Nuclear Medicine, London, UNITED KINGDOM.

OP 246
Radionuclide Molecular Imaging of Multiple Myeloma
C. Nanni; S. Orsola-Malpighi Hospital, Piacenza; S. Orsola Malpighi Bologna, Nuclear Medicine, Bologna, ITALY.

062
Joint Symposium 9 - Neuroimaging Committee / IAE: Clinical Use of Brain Imaging for Patients with Epilepsy
Monday, October 14, 2019, 8:00 - 9:30; Lecture Hall 311.
Chair: P. Federico, Calgary, AB, CANADA.
Chair: F. Semah; Service Central de Médecine Nucléaire et imagerie fonctionnelle, CHU de Lille, LILLE, FRANCE.

OP 247
The Use of MRI for Patients with Epilepsy and the Need of Multimodal Imaging for the Clinician
P. Federico; Hoartshick Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, CANADA.

OP 248
FDG-PET for Partial Epilepsy Revisited
F. Chassoux; Sainte-Anne Hospital, Neurosurgery Department, Paris, FRANCE.

OP 249
The Role of Ictal SPECT in the Presurgical Evaluation of Patients with Drug-Resistant Epilepsy
V. Van Paesschen; KU Leuven, Neurology Department, Leuven, BELGIUM.

603
Joint Symposium 10 - Drug Development Committee / SRS: What is Molar Activity and When does it Impact PET Imaging?
Monday, October 14, 2019, 8:00 - 9:30; Lecture Hall 312.
Chair: A. Gee; Imaging Sciences Rayne Institute, Kings College London, London, UNITED KINGDOM.
Chair: P. Payoux; Nuclear Medicine Department, CHU Purpan, TOULOUSE, FRANCE.

OP 250
What do I Need to Know? Basic Concepts of Mass in Radionuclide Imaging
S. Bongarzone; King’s College London, Division of Imaging Sciences and Biomedical Engineering, London, UNITED KINGDOM.
Presentations
Oral
Chair; Karolinska Institute, Department of Neuroscience

Mass Effect of PET Radioligands for Oncology, Radiology and Clinical Immunology,
OP-251

October 14, 2019, 8:00 - 9:30 Lecture Hall 111
M2M - Parallel Session: Innovations in Bio-Nanotechnology
Chair; P. Torres Martin de Rosales, School of Biomedical Engineering & Imaging Sciences, King’s College London, London, UNITED KINGDOM.

OP-265
Radioiodinated endothelial microspheres and evaluating their in vivo biodistribution in healthy and ischemic mice
P. Garrigue, R. Graud, A. Myeon, V. Nall, S. Simoncini, J. Balsavet, S. Fernandez, A. Bruhle, F. Dgnat-Georgi, B. Gault, F. Sabatier; CNIM INSEEM 1263 INRA 1260 CERME4 Avix-Marseille Université APHM, Marseille, FRANCE, CNIM Avix-Marseille Université APHM, Marseille, FRANCE, CNIM INSEEM 1263 INRA 1260 CERME4 Avix-Marseille Université, Marseille, FRANCE, CERME4 Avix-Marseille Université, Marseille, FRANCE, CNIM INSEEM 1263 INRA 1260 CERME4 Avix-Marseille Université, Marseille, FRANCE.

OP-266
Novel radiolabeled silicon dyes for bimodal scintigraphic and optical imaging
T. Kanagasundaram, M. Schiller, K. Koss, E. Bana, R. Ropp, J. German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 288, Heidelberg, GERMANY, Institute of Inorganic Chemistry, Heidelberg University, Heidelberg, GERMANY, Stony Brook University, Department of Chemistry, New York, NY, UNITED STATES OF AMERICA.

OP-267
A Reinvestigation Study of Sn-117m Colloid to Treat Canine Osteoarthritis Shows Safety and Efficacy
C. A. Doerner, J. M. Donecker, N. R. Stevenson, G. R. Gonzales, J. C. Lattimer; Serene LLC, The Woodlands, TX, UNITED STATES OF AMERICA, University of Missouri, Columbia, MO, UNITED STATES OF AMERICA.

OP-268
“Ga-labeled carbon nanoparticles for ventilation PE/T/CT imaging: physical properties study and comparison with Technegas”
F. Blanc-Béguin, P. Eleyer, N. Kervarec, P. Robin, R. Tripier, E. Clement, E. Kervarec, P. Robin, F. Blanc-Béguin, P. Eleyer; *Brest University Hospital, Brest, FRANCE, †Brest University Hospital, Brest, FRANCE.
OP-269  
Recoil retention and therapeutic efficacy of $^{123}$I-ac containing polymersomes  

OP-270  
NM600, a theranostic allylphosphocholine chelate, shows promise as a universal tumor-targeting agent  

OP-271  
Pharmacokinetic variability of vector labeled Actinium-225 and the in vivo generated decay daughters Francium-221 and Bismuth-213 in murine models  
A. Josefsson, J. R. Neshov, S. R. Banerjee, M. G. Pomper, G. Spassov, R. F. Habib, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-272  
Organic melanin nanoparticles targeting prostate-specific membrane antigen (PSMA) and multimodality imaging for human prostatic cancer xenograft model  
L. Xia, Z. Cheng, H. Zhu, Z. Yang; Peking University cancer hospital, Beijing, CHINA, Stanford University, San Francisco, CA, UNITED STATES OF AMERICA.

OP-273  
Direct Comparison of Theranostic [123I(+II)]-NM404 and [124I(+III)]-MIBG Dosimetry in a Murine Xenograft Model of Neuroblastoma  

OP-274  
Demonstration of significantly heterogeneous intratumoral [177Lu]-PSMA-617 dose deposition in a preclinical model of prostate cancer using ex vivo digital autoradiography  

OP-275  
Similarities and differences of dosimetry between meta-[123I]Atlastatabenzyguanidine ([123I]At-MABG) and meta-[124I]iodobenzyguanidine ([124I]MIBG) as companion diagnostic drug  
N. Ukon*, S. Zhao, K. Vashaghi*, K. Washino*, M. Askì*, K. Nishiyama*, S. Shimayama*, C. Tan*, K. Washiyama*, N. Ouchi*, K. Takahashi*, T. Higashi*, H. Ito*; Advanced Clinical Research Center, Fukushima Medical University, Fukushima, JAPAN, National Institute of Radiological Sciences, Chiba, JAPAN, Department of Molecular Imaging and Theranostics, National Institute for Quantum and Radiological Sciences and Technology (QST), Chiba, JAPAN, Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, JAPAN.

OP-276  
Radiation doses from terbium-161 compared to lutetium-177 in single tumor cells and micrometastases  
E. Hindie, M. E. Alcocer-Avila1, C. Morati1, C. Champion1; Bordeaux University Hospital, Bordeaux, FRANCE, Centre Lucien Intermes et Applications, Bordeaux University, Talence, FRANCE.

OP-277  
Pitfalls & Artefacts 3 - Interactive Clinical Cases - Cardiovascular + Inflammation & Infection Committee: Tips and Tricks in the Interpretation of Cardiac PET  
Monday, October 14, 2019, 8:00 - 9:30 Lecture Hall 113 Chair: W. Acampa, Naples, ITALY. Chair: P. Georgoulas, Larissa, GREECE.

OP-278  
Visibility  
A. Saraste; University of Turku, Heart and PET Centre Hospital/Institute, Turku, FINLAND.

OP-279  
Endocarditis  
F. Rouzet; Bichat Hospital, Paris, FRANCE.

OP-280  
Sarcoidosis  
L. Leccisotti; Fondazione Poli/Univ Versitario A. Gemelli, RICS, Rome, ITALY.

OP-281  
Predictive value of Visceral Fat Activity Assessed by Preoperative F-18 FDG PET/CT for omental Metastasis in Patients with Epithelial Ovarian Cancer  
S. Choi1, J. Eo1, E. Lee2, S. Kim1, Korea University Guro Hospital, Seoul, KOREA, REPUBLIC OF, Korea University Anam Hospital, Seoul, KOREA, REPUBLIC OF.

OP-282  
Imaging in breast cancer staging: MRI of the breast versus dedicated breast PET and whole body PET/CT  
D. Grigolato; A. Invento1, P. Pellet1, M. Zuffanetti, M. Curca, E. Biggi*, F. Padovan*, M. Nazari, E. Fano*, Q. Rubello*, G. P. P. Polini, M. Forghani; Nuclear Medicine Dept, Azienda Ospedaliera di Verona, Verona, ITALY, Oncologic Surgery Department, Complex Operative Unit of Breast Surgery - Breast Unit, Azienda Ospedaliera di Verona, Verona, ITALY, Department of Diagnostic and Pathology, Azienda Ospedaliera di Verona, Verona, ITALY.
OP-284
First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormone therapy in estrogen receptors positive metastatic breast cancer patients
B. Maucherat; A. Leduc-Pennec; N. Fleury; I. Feller; E. Bouchouleurs; H. Simon; M. Le Thiec; D. Rau; V. Fleury; M. Colombier; A. Morel; F. Kraebel-Bodere; L. Campion; C. Rousseau; "ICD Cancer Center, Nuclear Medicine Unit, Saint Herblain, FRANCE, 2 University Hospital, Nuclear Medicine Unit, Brest, FRANCE, 3 ICD Cancer Center, Oncology Unit, Saint Herblain, FRANCE, 4 ICD Cancer Center, Physics Unit, Saint Herblain, FRANCE, 5 IRCVac, University of Nantes, INSERM UMR1322, CURES-ERL001, Nantes, FRANCE, 6 ICD Cancer Center, Oncology Unit, Saint Herblain, FRANCE, 7 ICD Cancer Center, Biometrics, Saint Herblain, FRANCE.

OP-285
Frequency Of Incidental Focal Breast Lesions Identified By 18F-FDG PET/CT
L. Petersen; J. D. Andersen; H. D. Zacho; Department of Nuclear Medicine, Aalborg University Hospital, DENMARK.

OP-286
To evaluate the role of F-18 FDG PET/CT in different molecular subtypes of breast cancer for prognostication
R. Kumar; S. Arora; A. Prashanth; A. Passah; A. Prashanth; N. Mohan; R. Kumar; "University of Milano Bicocca, Milan, ITALY, 2 MRI Center, Physics Unit, Brest, FRANCE, 3 Clinical Trial Research Unit, Galliera Hospital, Genoa, ITALY, 4 Nuclear medicine unit, Pavia, ITALY, 5 Department of Nuclear Medicine, Galliera Hospital, Genoa, ITALY, 6 Center for Innovative Medical Technology, Odense University Hospital, Odense, Denmark, 7 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

609
Paediatrics - Parallel Session Paediatrics
Monday October 14, 2019, 8:00 - 9:30
Chair: L. Biassoni, Radiology, LONDON, UNITED KINGDOM.
Chair: D. De Palma, Serv. di Medicina Nucleare, Ospedale di Circolo, VARESE, ITALY.

OP-288
Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer: Interater Agreement and Reliability of PERCIST and Visual Assessment
J. Sorensen; J. M. H. Hestbaek; J. Holmer; M. Vagen 1,2,11, J. Bulow; L. Jorgensen; M. G. Hildemand 12, Q. Gerke 12; "Department of Clinical Research, University of Southern Denmark, Odense, DENMARK, 2 Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, 3 Department of Oncology, Odense University Hospital, Odense, DENMARK, 4 Center for Innovative Medical Technology, Odense University Hospital, Odense, Denmark, 5 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

OP-289
"F-FET PET/MRI for CNS-Tumors in Children and Adolescents
L. Marner; K. Nyvad; A. Serestead; L. Borgwardt; R. Mathiassen; R. Mathiassen; P.S. Wehrens; D. M. Henrikse; L. Mundermann; C. Thomsen; L. Bageskov; S. Jiskjat-Rasmussen; H. Broholm; D. Schene; M. Juhler; J. Hegedal; J. Leue; "Department of Clinical Physiology and Nuclear Medicine, University Hospital Aarhus, Aarhus, DENMARK, 2 Department of Clinical Radiology, Odense University Hospital, Odense, DENMARK, 3 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 4 Department of Clinical Radiology, Odense University Hospital, Odense, Denmark, 5 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 6 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 7 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

OP-290
Diagnostic and Prognostic Role of 18F-DOPA PET/CT in children affected by Neuroblastoma: Comparison with 123I-mIBG scan
G. Bottoni; G. Fornazzari 1; A. Cistoni; G. Puntaroli; G. Massari; S. Sommerness; A. Zucchetti; M. Ugolini; M. Coner; M. Persotto; M. Latussa; A. Garavanter; L. Giovannelli; L. E. Dogi; "Nuclear medicine unit, Ospedali Galliera, Genova, ITALY, 2 Nuclear medicine unit, Pavia, ITALY, 3 Department of Nuclear Medicine, Galliera Hospital, Genoa, ITALY, 4 Clinical Trial Research Unit, Galliera Hospital, Genoa, ITALY, 5 Neuroradiology Unit, IRCVCS Institute Giamma Gaioni, Genoa, ITALY, 6 Unit of Pediatric Oncology, IRCVCS, G. G. Gaslini, Genoa, ITALY, 7 Department of Nuclear Medicine, University Hospital of Padova, Padova, ITALY, 8 Medical Physics Department, Galliera Hospital, Genoa, ITALY, 9 Anesthesiology Department, Galliera Hospital, Genoa, ITALY, 10 Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, SWITZERLAND, 11 Department of Nuclear Medicine, Humanitas Research Hospital, Rozzano, ITALY, 12 Nuclear medicine unit, Galliera Hospital, Genoa, ITALY.

OP-291
Metastatic differentiated thyroid cancer in paediatric patients - radioiodine treatment after thyroid hormone withdrawal or rHSTH stimulation
D. Handkiewicz-Junak; A. Kropinska; A. Kropinska; A. Ledwon; J. Skjøth-Rasmussen; L. Biassoni; L. Højgaard; C. Thomsen; P. S. Wehner; "Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 2 Department of Oncology, Odense University Hospital, Odense, Denmark, 3 Department of Pediatrics and Adolescent Medicine, Odense University Hospital, Odense, Denmark, 4 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 5 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark, 6 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.

OP-292
– Cancer Center Gliwice Branch, Gliwice, POLAND.

OP-293
Prognostic value of interim-PET in paediatric Hodgkin lymphomas: the role of qPET
S. Pacella; C. Cardani; M. Avra; E. De Ponti; S. Marzetti; C. Civenlano; F. Elvano; M. Spinetti; A. Salde; L. Guerra; "University of Milano Bicocca, Milan, ITALY, 2 Nuclear Medicine Department, ASST Monza San Gerardo Hospital, Monza, ITALY, 3 Medical Physics Department, ASST Monza San Gerardo Hospital, Monza, ITALY, 4 Fondazione MBBM ASST Monza San Gerardo Hospital, Monza, ITALY.

OP-294
–FDG-PET-CT in Paediatric Langerhans Cell Histiocytosis: Extension, Diagnosis, Recurrence and Treatment Response Evaluation
J. Alors-Ruiz; C. Sabado-Navarro; A. A. Cardoso-Salvador; I. Roca-Beltrau; A. Garcia-Beltrau; J. Castell-Carles; "Nuclear Medicine Department, Hospital Clinica Universitaria Véganz de la Victoria, Málaga, SPAIN, 2 Paediatric Oncology and Haematology Department, Hospital Universitari Vall d’Hebron, Barcelona, SPAIN, 3 Nuclear Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, SPAIN.

OP-295
Might STAGING 18FDG-PET stratify prognosis in Osteosarcoma and Ewing sarcoma?
C. Oliani; R. Di Dato; M. Agheddi; A. Tamburini; C. Caporossi; R. Scaglì; "University Hospital of Careggi, Florence, ITALY, 2 University Hospital Meyer, Florence, ITALY.

OP-296
Assessment of future remnant liver function in pediatric patients with liver malignancies
Y. Likar; K. Chauxsoy; E. Kireeva; I. Vdovina; M. Chirchikova; D. Alkhazov; Ditya-Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.
Endocrine - Parallel Session: Neuroendocrine Malignancies

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

[107]

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations

EANM'19

Lecture Hall 116

Chair: R. Haug, Department of Nuclear Medicine, University of Munich, Munich, GERMANY.

Chair: M. Michaelovic, Institute of Oncology, Sremska Kamenica, SERBIA.

Oral Presentations
EPS-074
Assessment Of Abdominal Resectability With FDG-PET/CT In Locally Advanced Ovarian Cancer
A. Careas Aréstegui, J. Del Riego Ferrant, Y. García García, L. Nebol Lumer, B. Morillas Oliveras, J. Costa Tranchesi, J. Martín Miramon, A. Rodríguez Resueyro, M. Moragas Salanes, Z. Brava Ferrer, J. Antoni Vives, L. Berra Roqueta, "Nuclear Medicine Department, Parc Taulí Hospital Universitari, Sabadell, SPAIN; "Radiology Department, Parc Taulí Hospital Universitari, Sabadell, SPAIN; "Oncology Department, Parc Taulí Hospital Universitari, Sabadell, SPAIN; "Gynecology Department, Parc Taulí Hospital Universitari, Sabadell, SPAIN; "Pathology Department, Parc Taulí Hospital Universitari, Sabadell, SPAIN.

EPS-075
TNF alpha therapy and radiosynoviorthesis in patients with rheumatoid arthritis

EPS-076
18F-FDG PET/CT based BRAFV600 prediction in personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma - final results

EPS-077
Phase I clinical trial using a novel CCK2 receptor-localizing radiolabelled peptide probe for CT imaging of the brain sentinel node imaging? for reducing the false positive rate of 18F-FDG PET/CT diagnosis in patients with suspected lung cancer
F. Kang, W. Mui, J. Gong, W. Qiu, J. Tian, J. Wang. "Department of Nuclear Medicine, Xijing Hospital, Xi’an, CHINA; "Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, CHINA; "Life Sciences Research Center, School of Life Sciences and Technology, Xi’an University, Xi’an, CHINA.

EPS-078
Impact of Metabolic Switch in HCC Patients Treated with Sorafenib - A Proof-of-concept Trial
E. Lopci, A. Castello, N. Feronen, T. Preusser, V. Smržová, E. Mažurek, J. Jámašová. "Humanitas Clinical and Research Hospital - IRCCS, Milova, ITALY.

EPS-079
Diagnosis of Pelvic Insufficiency Fractures in Oncology Patients: Radiological Findings and Role of Tc99m MDP SPECT/CT imaging
V. Sabaliauskas. "Tuvėnų Kėdainių Oncological Clinic, TUVINĖ, LITHUANIA.

EPS-080
Meet 99mTc-tilmanocept as next generation radiotracer with the requirements for improved sentinel node imaging?
D. Rietbergen, L. Perena Anas-Bouja, J. vd Hage, R. Valdes Clérons, Lunds Universitet Medscenter Centrum (LUMC), Liden, NETHERLANDS.

EPS-081
Integrating Clinical Experience Into Radiomics For Reducing The False Positive Rate Of 18F-FDG PET/CT Diagnosis In Patients With Suspected Lung Cancer
F. Kang, W. Mui, J. Gong, W. Qiu, J. Tian, J. Wang. "Department of Nuclear Medicine, Xijing Hospital, Xi’an, CHINA; "Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, CHINA; "Life Sciences Research Center, School of Life Sciences and Technology, Xi’an University, Xi’an, CHINA.

EPS-083
EPS-082
EPS-080
**OP-310**
Introduction
S. Fantl, Policlinico S. Orsola, University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

**OP-311**
[18F]PSMA-1007
F. Giesel, University of Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

**OP-312**
[68 Ga]Ga-PSMA-11
M. Eiber, Center for Biomedical Imaging, Boston.

**OP-313**
[18F]PSMA-1007
J. Kunikowska, Warsaw, POLAND.

**OP-314**
[18F]PSMA-1007
S. Fanti, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

**OP-315**
[18F]PSMA-1007
Kim, Seoul National University Bundang hospital, CHINA.

**OP-316**
[18F]PSMA-1007
Zhang, nucléaire, Brussels, BELGIUM.

**OP-317**
Imaging of Bacterial and Pathogen Infections, Infectious Disease Specialist’s Point of View
M. Roestenberg, Leiden University Medical Center, Department of Infectious diseases and parasitology, Leiden, NETHERLANDS.

**OP-318**
Imaging of Bacterial and Pathogen Infections, Nuclear Medicine's Point of View
M. Sathekge, Steve Biko Academic Hospital, University of Pretoria, Department of Nuclear Medicine, Pretoria, SOUTH AFRICA.

**OP-319**
Novel Approaches to Image the Pathogen, Radiopharmacy's Point of View
C. Decristoforo, Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

**OP-320**
The Clinical Aspects of Large FOV CZT Detection
A. Verger, Centre Hospitalier Universitaire de Nancy, service de médecine nucléaire, Nancy, FRANCE.

**OP-321**
Brain PET/MRI in Epilepsy
M. Koepf, University College London, Institute of Neurology, London, UNITED KINGDOM.

**OP-322**
Brain PET/MRI in Epilepsy
M. Lemos Pereira, Department of Nuclear Medicine, NuclearMed - Hospital Paticular Almada, ALMADA, PORTUGAL.

**OP-323**
Quantification and Standardization in Brain PET/MRI
R. Boellaard, Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam, NETHERLANDS.

**OP-324**
The Physics of Large FOV CZT Detection
W. Hongyong, PET-MF-2V-IT-I Module With SPE Purification and Molecular Imaging, University Medical Center location VUMC, Amsterdam, NETHERLANDS.

**OP-325**
The Physics of SiPM PET Detection
M. Luberink, PET centre, Department of Radiology, Oncology and Radiation Science, Uppsala, SWEDEN.

**OP-326**
The Physics of Large FOV CZT Detection
L. Imbert, Centre Hospitalier Universitaire de Nancy, service de médecine nucléaire, Nancy, FRANCE.

**OP-327**
Summary and General Discussion

**OP-328**
TEPS-01 Development of a M4 PAM PET radioligand - ([18F]PF-06885190 – for a study in nonhuman primates

**OP-329**
E. Poel, M. F. Lam, Y. Chahid, Amsterdam UMC, location AMC, Amsterdam, NETHERLANDS.

**OP-330**
TEPS-03 Quality assurance audit of in-house prepared 68Ga labelled radiopharmaceuticals: 5 years of institutional experience
B. S. Shetye, P. Monteiro, M. Pathan, S. Mitthun, A. Jha, V. Rangaswai, Tata Memorial Hospital, Mumbai, INDIA.

**OP-331**
W. Hongyong, P. Zhou, M. Xie, Y. Liu, J. Wu, H. Wu, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, CHINA.

**OP-332**
TEPS-05 Outstanding clearing method for the reliability of the automated synthesis module with non-cassette type
TEPS-06 Determination of Aluminum in Pertechnetate and Perhenate Solution in eluate of $^{99m}$Tc and $^{99m}$Tc and $^{99}$Tc Generator
M. Karamanov, F. Farbakhshmamaghani, M. Dastpanah - Pari Isotope Co, Tehran, IRAN, ISLAMIC REPUBLIC OF; Pari Isotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

TEPS-07 The "Radiopharmacy of errors": a serious game to strengthen quality
T. Martin, C. Mauré, N. Sapin, I. Benard-Thiery - Radiopharmacy department, Centre Antoine Lacassagne, Nice, FRANCE.

TEPS-08 Quality Improvement of Patient Safety and Images through Analysis and Compliance with Standard Operating Procedures in $^{18}$F-FDG PET/CT scan
S. Yoon, J. Pyo, Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

TEPS-09 Appreciation of patients' feeling about the environment of a new digital PET-CT room
M. Pappon, P. Genoud, M. Meyer, J. Pior, CHUV, Lausanne, SWITZERLAND.

TEPS-10 One instruction for all-managing pediatric protocols across departments
H. Segaard, P. N. H. B. Christensen, Aarhus University Hospital, Aarhus, N, DENMARK.

TEPS-12 Managing patients and working spaces during facilities upgrade: a single-center experience
M. Macagnani, O. Pedrali, A. Fanna, A. Lamberti, S. Fantini, S. Barbieri - Nuclear Medicine Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY; Technical Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY; Department of Anesthesia Intensive Care, University of Padova, Padova, ITALY.

TEPS-13 Discovery, A New Zealand Nuclear Medicine Department voyage that has made a real difference
P. E. Lamerton, Hawkes Bay District Health Board, Hastings, NEW ZEALAND.

TEPS-14 Tracer extravasation in PET/CT: could we predict it?
M. Trevisan, A. Biscotto, F. Linzetta, M. De Rossi, F. Ruffo, P. Recchia, A. Cervino, M. Burn, L. Cuppari, A. Canars, L. Evangelista - Nuclear Medicine Unit, Veneto Institute of Oncology XV - IRCCS, Padua, ITALY.

TEPS-15 Lutetium (177)Lu Ossodroretroide Therapy - Increasing Capacity and Demand
E. Seal - University Hospital Birmingham, Birmingham, UNITED KINGDOM.

TEPS-16 Estimate of thyroid volume aimed at radiometabolic treatment of hyperthyroidism

TEPS-17 Biodistribution Mapping of $^{90}$Radium Dichloride during the course of Treatments 2 to 6. A Patient Case Study
J. Weekes, I. Sayers, M. Foley; New Cross Hospital, Wolverhampton, UNITED KINGDOM.

TEPS-18 Referral Rates and Overall Survival of Patients Receiving Ra223 Therapy for mCRCP at the Beatson West of Scotland Cancer Centre
I. Kerr - C. Braun, C. Findlay, G. Buchanan; Beatson West of Scotland Cancer Centre, Glasgow, UNITED KINGDOM.

TEPS-19 Impact of TOF(Time of Flight) reconstructions on SUV(max)(Standard uptake value) in AD(Alzheimer Disease) (PD) Parkinsonism Disease) patients using of $^{18}$F-FDG, $^{11}$C-CT and $^{11}$C-PiB
D. Wimalarathne, N. Jani, B. Kim, W. Ruan, R. An, X. Lan, A. Bai; Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

TEPS-20 Validation of Standardized Uptake Value about Hardware Components in Integrated PET/MRI
B. Kim, M. Kim, J. Moon, H. Lee, G. Nah; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF; Department of Radiology, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

TEPS-21 Optimization of Bayesian penalized likelihood reconstruction parameters for quantitative brain Positron Emission Tomography (PET) imaging

TEPS-22 Correlation of the Standardized Uptake Value(SUV) and the Apparent Diffusion Coefficient(ADC) Value in Breast Carcinoma with Simultaneous (18)F-FDG PET/MRI
M. Kim, B. Kim, H. Jung, Y. Bang; Department of Radiology, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

TEPS-23 Case-by-case Evaluation of Clearance of Waste contaminated with Residues of the Radio pharmaceutical Xefo
O. Nittsche, S. Thelenfeld, R. Kunz, K. Wittke; Brink Systemplanung Gmbh, Aachen, GERMANY; Bayer AG, Wuppertal, GERMANY.

TEPS-24 A sensitive analytical method for the determination of the long-lived impurity $^{227}$Ac in production batches of Xefo has been developed in order to allow for unconditional release of clinical waste after decay-in-storage
J. Gay, I. Hurnest, A. K. Pearce, P. Ivanov, K. Wittke, Bayer AG, Berlin, GERMANY; Bayer AG, Cisd, NORSWAY, National Physical Laboratory, Teddington, UNITED KINGDOM; Bayer AG, Wuppertal, GERMANY.

TEPS-25 Differentiated thyroid cancer patients treated with radioiodine-therapy and individualized recommendation of radioprotection
C. Moises-Guia, A. Sabri, C. Penteas, C. Cecin, C. Cianu, D. Piuic; Oncological Institute of Cluj-Napoca, Cluj-Napoca, ROMANIA.

TEPS-26 A Phantom Study on Radiotracer Dose Reduction in Integrated PET/MRI System
J. Zhuang - M. Bas, Xiaoxiu Hospital, Capital Medical University, Beijing, CHINA.

TEPS-27 Examination of the Correlation between patient-dependent parameters and radiation dose rates measured around patients undergoing PET/CT imaging using 18F-FDG
S. Alqahtani, K. Saliman; A. Almenzi; PSMMC, Riyadh, SAUDI ARABIA, Medical Physics Department, PSMMC, Riyadh, SAUDI ARABIA, Faculty of Applied Medical Sciences, KSU, Riyadh, SAUDI ARABIA.

TEPS-28 Typical patient doses from CT part of PET/CT examinations in Slovenia and comparison with other countries
J. Peric, I. Zagar, D. Zontar - Institute of Oncology, Ljubljana, SLOVENIA, Faculty of Health Sciences, University Ljubljana, Ljubljana, SLOVENIA, Slovenian Radiation Protection Administration, Ljubljana, SLOVENIA.

TEPS-29 CT Dose Optimization
B. Gillman; British Columbia Institute of Technology, Vancouver, BC, CANADA.
TEPS-30 Evaluation of animal imaging of the new generation of pre-clinical all-digital PET/CT
W. Xiao, A. Yan, L. Wan, Q. Xie, Huzhouhang University of Science & Technology, Wuxun, CHINA, 1Wuhan Raydata Technology Co., Ltd, Wuxun, CHINA

TEPS-31 Conventional vs. digital Philips PET/CT: evaluation of phantom data
A. Ebba, T. Nguyen, E. Marter, B. J. de Wit-van der Veen, Netherlands Cancer Institute, Amsterdam, NETHERLANDS

TEPS-32 PET-CT acquisition protocol optimization with a new digital PET-CT
S. Cola, F. Fournet, A. Palmeri, 1Nuclear Medicine S. Maria Nuova Hospital, Reggio Emilia, ITALY, 2Physical Department S. Maria Nuova Hospital, Reggio Emilia, ITALY

TEPS-33 Quantitative harmonization of Biograph mCT systems using post-reconstruction filter (EQ Filter) and its validation in clinical studies for whole body “FF–FDG
A. Hurtado de Mendoza, C. Sasa, J. Flores, S. Lopez, J. Spuler, H. Amaral, Center for Nuclear Medicine & PET/CT Postnared, Santiago, CHILE

TEPS-34 Image quality of 18F-FDG for patients with a high body mass index examined on Si-photomultiplier based PET
B. Olsson, J. Kjörg, E. Targarona, J. Oddberg, 1Clinical Physics and Nuclear Medicine, Skåne University Hospital and Lund University, Malmö-Lund, SWEDEN, 2Department of Radiology, Central Hospital, Kristianstad, SWEDEN, 3Radiation Physics, Skåne University Hospital and Lund University, Malmö-Lund, SWEDEN

R. Oto, N. Fujiy, C. Hasegawa, Y. Ito, T. Tasaki, A. Murayama, Y. Tsubura, J. Odagawa, M. Tamura, S. Aki, K. Kato, 1Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, 2Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN

TEPS-36 Evaluation of acquisition condition in dynamic imaging using continuous bed motion PET/CT
T. Umezawa, T. Ino, T. Murata, K. Sawada, Y. Masuda, T. Ueno, Osaka University Hospital, Osaka, JAPAN

TEPS-37 Evaluation of Respiratory Motion Correction on Liver Kinetic Analysis for Dynamic PET Imaging
Y. Shao, J. Wang, X. Wang, J. Cu, N. Li, J. Hao, H. Zhang, 1Department of Biomedical Engineering, Tonghua University, Beijing, CHINA, 2Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing, CHINA, 3SinoUnion (Beijing) Healthcare Technologies Co., Ltd, Beijing, CHINA

TEPS-38 Bayesian penalized-likelihood reconstruction algorithm in the advanced digital PET/CT system for 18F-NaF PET/CT in morbidly obese patients
M. Al-Daas, L. Ali, A. Sawkumar, A. Essma, F. Marafi, 1Jaber Al-Ahmad Center for Molecular Imaging, Shuwaikh, KUWAIT, 2Kuwait University, Shuwaikh, KUWAIT, 3Jaber Al-Ahmad center for molecular Imaging, Shuwaikh, KUWAIT

TEPS-39 Influence of statistical fluctuation on the accuracy and stability of SUV and TBR - A phantom study
X. Xie, M. Yun, H. Mi, Y. Zhang, 1Department of Nuclear Medicine, Beijing Anzhen Hospital, Beijing, CHINA

TEPS-40 Optimization of image reconstruction for rapid image acquisition by “FF–NaF bone PET: Comparison of OSEM and Bayesian penalized likelihood algorithms
T. Yoshii, K. Mower, K. Watanabe, M. Yamaguchi, M. Suga, Y. Kamitani, T. Tamao, S. Harasuka, 1International University of Health and Welfare, Tokyo, JAPAN, 2Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN

TEPS-41 Development of a fully automatic analytical program for the 18F–MIBG myocardial uptake measurement method
R. Sako, Y. Uchijima, K. Kamiyama, S. Ito, 1Graduate school of health sciences, Kumamoto University, Kumamoto, JAPAN, 2Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, 3Chibana Clinic, Okinawa, JAPAN

TEPS-42 Accuracy of Planar Scan based and SPECT/CT based Quantification Methods in Bone Scintigraphy
D. Sercie, A. Doma, I. Zagar, D. Skr, 1Institute of Oncology Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Health Sciences, University of Ljubljana, Ljubljana, SLOVENIA, 3Slovenian Radiation Protection Administration, Ljubljana, SLOVENIA

TEPS-43 Evaluation of cingulate island sign ratios for the differentiation of dementia with Lewy bodies versus Alzheimer’s disease using 18F-IMP SPECT
N. Hayashi, T. Murata, A. Ito, Y. Hagi, H. Sawa, K. Tor, H. Ina, T. Yamagami, Kochi Medical School Hospital, Kochi, JAPAN

TEPS-44 Introduction of a New 3D Analysis for the DATscan and the Realisation of a larger and more up to date Reference Set
A. Gelderblom, P. Brink, J. Habraken, J. Lavallée, 1University of Cambridge, Cambridge, UNITED KINGDOM, 2Jabriya, Kuwait, 3Jordan University of Science and Technology, Irbid, JORDAN

TEPS-45 The Evaluation of the impact of 99mTc gamma rays on x-ray detectors during a CT low dose acquisition
A. Resende Geao, A. Santos; Hospital Clínic Mexicans, Lisboa, PORTUGAL

TEPS-46 The effect of metal artifact reduction on quantitative SPECT/CT imaging
T. Konishi, T. Shibutani, K. Nishida, H. Yoneyama, R. Moribe, M. Chaguchi, K. Nakajima, S. Kinuya, 1Department of Radiology, Kanazawa University Hospital, Kanazawa City, JAPAN, 2Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa City, JAPAN, 3Department of Physics, Kanazawa Medical University, Kohnakumi, JAPAN, 4Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa City, JAPAN, 5Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa City, JAPAN

TEPS-47 Usefulness of partial volume effect correction in 111In/123I dual-isotope myocardial SPECT on CZT–SPECT camera
D. Ishieka, S. Shuang, S. Tomiyachi, 1Graduate School of Health Science, Kumamoto, JAPAN, 2Kumamoto University Hospital, Kumamoto, JAPAN, 3Faculty of Life Sciences, Kumamoto, JAPAN

TEPS-48 The Evaluation of the impact of 99mTc gamma rays on x-ray detectors during a CT low dose acquisition
A. Resende Geao, A. Santos; Hospital Clínic Mexicans, Lisboa, PORTUGAL

TEPS-49 The effect of metal artifact reduction on quantitative SPECT/CT imaging
T. Konishi, T. Shibutani, K. Nishida, H. Yoneyama, R. Moribe, M. Chaguchi, K. Nakajima, S. Kinuya, 1Department of Radiology, Kanazawa University Hospital, Kanazawa City, JAPAN, 2Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa City, JAPAN, 3Department of Physics, Kanazawa Medical University, Kohnakumi, JAPAN, 4Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa City, JAPAN, 5Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa City, JAPAN

TEPS-50 Performance Evaluation of a New Collimator Optimized for “Lu Preclinical SPECT Imaging
N. Colpo, C. Ulbr, J. Rousseau, K. Kamphuis, F. Beekmann, F. Bénard, 1BC Cancer, Vancouver, BC, CANADA, 2University of British Columbia, Vancouver, BC, CANADA
TEPS-51 Repeatability and stability evaluation of Lutetium quantification
M. C. Dekker, D. M. V. Hauk, B. J. De Wit - van der Veen, Anton van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TEPS-52 Agreement between functional parameters of myocardial perfusion assessed with gated IQ-SPECT and conventional SPECT/CT
W. Martinez, I. Pelebete García, E. Noriega Álvarez, E. Cañas Sigurado, A. García Vicente, A. Sonano, Service de Medicina Nuclear, Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

TEPS-53 Development of cardiac phantom for evaluation of fusion image of Myocardial perfusion imaging and CT-A
A. Kikuchi, Y. Homma, H. Homma, A. Andou, M. Kiyama, G. Okuyama, Department of Radiological Technology Faculty of Health Sciences, Sapporo, JAPAN, Oino Memorial Hospital, Sapporo, JAPAN.

TEPS-54 mcARM An Automated Motion Correction Algorithm For MPI SPECT
A. Szucs, I. Z. Fegyvari, B. Kari, O. Pártos, István Loránd University, Budapest, HUNGARY, Media Medical Imaging Systems, Budapest, HUNGARY, Semmelweis University, Department of Radiology, Budapest, HUNGARY, Semmelweis University, Nuclear Medical Centre, Budapest, HUNGARY.

TEPS-55 The use of effervescent granules in myocardial perfusion imaging: the full secret to a man’s heart
J. Goh, Y. Ng, M. Chang, K. Tari, Y. Wong, Z. Huang, J. Tari, X. Tang, Sengkang General Hospital, Singapore, SINGAPORE, Singapore General Hospital, National Heart Centre, Singapore, SINGAPORE, Singapore General Hospital, Singapore, SINGAPORE.

TEPS-56 Diagnostic utility of 99mTc-DPD scintigraphy in patients with suspected cardiac amyloidosis
E. N. Andersen, A. Hohti, E. Gude, T. Bach-Gansmo; The University of Tromsø, Tromsø, NORDIC, Department of Radiology and Nuclear Medicine, Oslo, NORWAY, Oslo University Hospital Rikshospitalet, Department of Cardiology, Oslo, NORWAY.

TEPS-57 Repositioning and stability evaluation of Lutetium quantification
M. C. Dekker, D. M. V. Hauk, B. J. De Wit - van der Veen, Anton van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TEPS-58 Analysis of Influence Factors And Correlation For Quality Of Wholebody Bone Scan Imaging
T. Lu. G. Yang, Shandong Cancer Hospital affiliated to Shandong University, Jinan in Shandong province, CHINA.

TEPS-59 Repeatability and stability evaluation of Lutetium quantification
M. C. Dekker, D. M. V. Hauk, B. J. De Wit - van der Veen, Anton van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

TEPS-60 Quantitative accuracy of standardized uptake value (SUV) for xSPECT Bone technology using new supine phantom
T. Shibutani, M. Onoguchi, T. Konoishi, H. Yoneyama, H. Ichikawa, K. Okada, K. Nishiyama; Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, JAPAN, Department of Radiological Technology, Kaiyoshiji Municipal Hospital, Toyohashi city, JAPAN, Department of Physics, Kanazawa Medical University, Kanazawa city, JAPAN, Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa city, JAPAN.

TEPS-61 Creation Of A Labeled Technetium-99m Colloid Drug For The Detection Of Guarding Lymph Nodes
A. Rogov, E. Stasyuk, E. Nesterov, E. Yampolsky, E. Nesterov; National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

TEPS-62 Lymphoscintigraphy and sentinel node localization in gynaecological cancers into practice: a UK single-centre protocol
L. Pereira, R. Brook, T. Barnard, O. Devaja, A. Coniglini; Mansfield and Tunbridge Wells NHS Trust, Mansfield, UNITED KINGDOM.

TEPS-63 Net Administered Activity As A Surrogate Quality Control Indicator For Non-Imaging Breast SLNB Procedures
L. Wason, A. Neit, J. Dennis, C. Flynn; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

TEPS-64 Clinical Effectiveness Of Sentinel Node Biopsy In Early Oral Cavity Carcinoma
Y. Herrera-Martínez, A. Bonilla De Damidó, V. Paclón Gamudo, D. Tamayo Canabarro, A. Álvarez Pérez, J. Jiménez-Hoyuela García, Hospital Universitario Virgen del Rocío, Seville, SPAIN.

TEPS-65 Quantitative evaluation of the renal tubular function with 99mTc-MAG3: comparative software approach using two methods in a pediatric population

TEPS-66 Comparison of Single and Dual Isotope Imaging for 3D Lung Lesar Quantification with SPECT CT
T. Sousa, G. Gregg, K. Mecklenber; Royal Brompton and Harefield Foundation Trust, Harefield Hospital, London, UNITED KINGDOM.

TEPS-67 Assessment of 2-hour images for 99mTc-HYNIC-TOC Studies Using Image Interpretation and Image Analysis
S. Tavares; M. Jessop, D. Pencharz, E. Manzar, N. Singh; S. Siqueira; Royal Sussex County Hospital, Brighton, UNITED KINGDOM, ‘Lisbon School of Health Technology, Lisbon, PORTUGAL.

TEPS-68 Quantification Of Technetium-99m Septamibi Thyroid Scintigraphy In Air Type I and II
K. Erenbrang, M. V. Klette, J. Lawaluyi, J. Hafbraker, St. Antonius Hospital, Nieuwegein, NETHERLANDS.

TEPS-69 Serum creatinine measurement as a predictor for single sample GFR using 99mTc-DTPA
G. Hilland, A. Matsos, C. Findlay; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

TEPS-70 End of Chromium-51 availability: Setting-up of a new protocol, validation and impact analysis
S. A. Figueiredo, G. Afsharazad, J. D. Prior, J. Delage, J. Coster, CHU, Louvain, SWITZERLAND.

TEPS-71 Glomerular filtration rate: Comparison of two tracers
L. Janus, T. Andersen, K. Thilings-Hanssen, D. Rohald, C. Led, P. Andersen, H. Thomsen, O. Gerke, P. Håkland-Carlsen, J. Simonsen; Odense University Hospital, Odense C, DENMARK.

TEPS-72 Association between TNM staging and primary tumor parameters assessed in 99mTc-FDG PET/CT study in NSCLC patients
K. Pietrasz, P. Ceglar, K. Wikowski, R. Czapczynski, M. Bory, W. Cholewinski, Departments of Radiology, Greater Poland Cancer Centre, Poznan, POLAND, Affiliated Medical Center, Poznan, POLAND. "Oncotherapy Department at Regional Centre of Lung Diseases in Poznan and Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, POLAND, "Chair and Department of Endocrinology, Metropolitan and Internal Medicine, Poznan University of Medical Sciences, Poznan, POLAND, "Chair and Department of Gastroenterology, Poznan University of Medical Science, Poznan, POLAND.

TEPS-73 Assessment of 99mTc-PET/CT texture analysis to discriminate NSCLC from radiation pneumonitis after CRT

TEPS-74 Serum creatinine measurement as a predictor for single sample GFR using 99mTc-DTPA
G. Hilland, A. Matsos, C. Findlay; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

TEPS-70 End of Chromium-51 availability: Setting-up of a new protocol, validation and impact analysis
S. A. Figueiredo, G. Afsharazad, J. D. Prior, J. Delage, J. Coster, CHU, Louvain, SWITZERLAND.

GEP-71 Glomerular filtration rate: Comparison of two tracers
L. Janus, T. Andersen, K. Thilings-Hanssen, D. Rohald, C. Led, P. Andersen, H. Thomsen, O. Gerke, P. Håkland-Carlsen, J. Simonsen; Odense University Hospital, Odense C, DENMARK.

TEPS-72 Association between TNM staging and primary tumor parameters assessed in 99mTc-FDG PET/CT study in NSCLC patients
K. Pietrasz, P. Ceglar, K. Wikowski, R. Czapczynski, M. Bory, W. Cholewinski, Departments of Radiology, Greater Poland Cancer Centre, Poznan, POLAND, Affiliated Medical Center, Poznan, POLAND. "Oncotherapy Department at Regional Centre of Lung Diseases in Poznan and Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, POLAND, "Chair and Department of Endocrinology, Metropolitan and Internal Medicine, Poznan University of Medical Sciences, Poznan, POLAND, "Chair and Department of Gastroenterology, Poznan University of Medical Science, Poznan, POLAND.

TEPS-73 Assessment of 99mTc-PET/CT texture analysis to discriminate NSCLC from radiation pneumonitis after CRT

TEPS-74 Serum creatinine measurement as a predictor for single sample GFR using 99mTc-DTPA
G. Hilland, A. Matsos, C. Findlay; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.
Correlation of HPV status and biological parameters assessed in 18 F-FDG-PET/CT study in head and neck cancer patients

A. Kedves, Z. Tátrai, T. Petéter, B. Sándor, Z. Czélár, V. Kocák, D. Sipas, F. Omán, G. Baják, J. Hadávy, L. Repai, M. Mészáros, A. Kocsás: 1Department of Medical Imaging, Faculty of Health Sciences, University of Pécs, Kapuvár, HUNGARY; 2Department of Radiology, Centre for Radiology, Moritz Kaposi Teaching Hospital, Kapuvár, HUNGARY; 3Department of Health Economics and Health Care Management, University of Pécs, Pécs, HUNGARY; 4PET Medicus Nonprofit Ltd, Moritz Kaposi Teaching Hospital, Kapuvár, HUNGARY; 5Department of Health Promotion and Public Health, University of Pécs, Pécs, HUNGARY; 6Moritz Kaposi Teaching Hospital, Kapuvár, HUNGARY.

The addition of late PSMA-ligand PET/CT imaging for the differentiation between benign and malignant PSMA uptake

A. Dijkstra, E. Stegger, M. Scharfs, B. Nato: Department of Nuclear Medicine, Münster, GERMANY.

Correlate assessment of lumbar intervertebral disc degeneration in alkalopnia patients using quantitative analysis in 18F-NaF PET/CT and MRI grading systems

E. H. Alawadhi, A. Mistry, S. Vinyamuri, J. Gallagher, R. Lakshminarayan: 1Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 2Department of Radiology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UNITED KINGDOM; 3Department of Nuclear Medicine Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 4Liverpool Clinical Laboratories, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UNITED KINGDOM. 5Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 6Department of Nuclear Medicine Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 7Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM.

The results of 18 F-Ga-PSMA-11 PET/CT study in patients with recurrence of prostate cancer

L. Dijkstra, B.Grego, L. M. P. M. van Goor, R. H. J. A. Slart: 1Department of Nuclear Medicine, RUG, Groningen, NETHERLANDS, 2Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM, 3Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 4Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 5Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 6Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 7Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM.

Influence of intravenous diuretics on the detectability of local prostate cancer recurrence in Ga-PSMA-11 PET/CT

L. Dijkstra, L. M. P. M. van Goor, R. H. J. A. Slart: 1Department of Nuclear Medicine, RUG, Groningen, NETHERLANDS, 2Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 3Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 4Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 5Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 6Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 7Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM.

805 Pd catalyzed cross coupling of [11 C]MeLi and its application in the synthesis and evaluation of a potential tracer for vesicular acetylcholine transporter (VACHT)

H. Helbert, B. Wenzel, W. Deuthe-Canasad, G. Luurtsema, S. Wszynska, P. Bruin, B. Fennegel, R. Dierer, P. Elsinga: 1UMCG, Groningen, NETHERLANDS, 2Institute of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM, 3Institute of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 4Department of Nuclear Medicine, RUG, Groningen, NETHERLANDS, 5Institute of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 6Heimholtz-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.

Influence of intravenous diuretics on the detectability of local prostate cancer recurrence in Ga-PSMA-11 PET/CT

L. Dijkstra, L. M. P. M. van Goor, R. H. J. A. Slart: 1Department of Nuclear Medicine, RUG, Groningen, NETHERLANDS, 2Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 3Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 4Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 5Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 6Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 7Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM.

Correlate assessment of lumbar intervertebral disc degeneration in alkalopnia patients using quantitative analysis in 18F-NaF PET/CT and MRI grading systems

E. H. Alawadhi, A. Mistry, S. Vinyamuri, J. Gallagher, R. Lakshminarayan, J. Dillon: 1Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 2Department of Radiology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UNITED KINGDOM; 3Department of Nuclear Medicine Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 4Liverpool Clinical Laboratories, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UNITED KINGDOM; 5Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 6Department of Nuclear Medicine Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM; 7Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 8Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 9Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM; 10Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UNITED KINGDOM.

Optimization of manufacturing process of [11 C]ODMPA for phase II clinical study

S. Krajewski, J. Sikora, J. Ambrosias, J. Radwanska, P. Kalmierczak, G. Shamoy, S. Cohen, E. Mihalik, J. Wlóstowski: 1Research & Development Centre, Syntelik S.A., Warsaw, POLAND, 2Faculty of Pharmacy, Medical University of Warsaw, Warsaw, POLAND, 3Cyklotron/Radiochemistry/MicroPET Unit, Hadassah Hebrew University Hospital, Hadassah Medical Organization, Jerusalem, ISRAEL.

Selection Of The Optimal Macrocyclic Chelators For Labelling With 11 C And 18 F: An Improves Contrast Of Her2 Imaging Using Engineered Scaffold Protein Adapt6

J. Garoulian, W. Wittring, S. Linabo, A. Vareyeva, M. Håås, M. Oonjuyen, B. Mitrani, A. Ostvald, S. Hober, P. Tomaioch: 1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, 2Department of Protein Science, KTH Royal Institute of technology, Stockholm, SWEDEN, 3Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, 4Department of Protein Science, KTH Royal Institute of technology, Stockholm, SWEDEN.
Fluorescein-based 18F labeled probe for pre-targeted PET imaging of cancer cells


Radio pharmacological Evaluation of Cyclohexanediamine-Triazole-Peptide Conjugates Labeled via the AlF3-Approach


In vivo evaluation of ([18F]5-fluoroamino-subaric acid ([18F]FASu) isomers as PET imaging agents targeted PET imaging of cancer cells


Image quality of a 3D pretreatment procedure for radioembolisation


DoMoRe - Parallel Session: Clinical Dosimetry and Modeling

Monday, October 14, 2019, 11:30 - 12:45 Lecture Hall 112

Chair: J. Tran-Gia, Würzburg, GERMANY.

Influence of affinity and total ligand amounts on pharmacokinetics and absorbed doses of PSMA-specific ligands: a simulation study

N. Begum, G. Gärtner, M. Elter, A. Beer, P. Kletting, Ulm University, Ulm, GERMANY, Technical University of Munich, Munich, GERMANY.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Humanitas University, CHRU Morvan, France.

OP 339

Towards a Patient-Specific Kidney Dosimetry in Radiooncology Therapy

J. Tran-Gia, M. Lassmann, University of Würzburg, Würzburg, GERMANY.

OP 340

Image quality of a 3D pretreatment procedure for radioembolisation


OP 341

TOF-PET/CT enables valuable EUD estimations in heterogeneous 18F distributions

M. Hesse, S. Wohlhart, F. Lam, F. J. van der Heide, F. J. van der Sluijs, J. J. M. Scholten, J. A. F. van den Berg, University of Amsterdam, Amsterdam, NETHERLANDS, Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP 342

Personalized dosimetry for liver cancer radioembolization using computational fluid dynamics

E. Roncalli, A. Tarchi, M. Rusnak, B. Spencer, D. Caulee, C. Foster, T. T. Yu, University of California, Davis, CA, UNITED STATES OF AMERICA.

OP 343

Improving resolution recovery factors using 3D printed phantoms and Monte Carlo for quantitative imaging and dosimetry

J. Gear, F. Leek, G. Flux, Royal Marsden NHSFT, Sutton, UNITED KINGDOM.

OP 344

Quantification of the Trabecular Bone Volume Fraction with Dual Energy Quantitative CT to Calculate Patient-Specific Radionuclide S Values for Bone Marrow Dosimetry


OP 345

Towards a Patient-Specific Kidney Dosimetry in Radiooncology Therapy

J. Tran-Gia, M. Lassmann, University of Würzburg, Würzburg, GERMANY.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.

Clinical Oncology - Featured Session: Implementing Radiomics into Technical Practice

Monday, October 14, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: C. Lasnon, Nuclear Medicine, Caen, FRANCE.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>OP-354</td>
<td>Contribution of tumour blood-flow for prediction of response to neoadjuvant chemotherapy in breast cancer using 18F-FDG PET/CT</td>
<td>N. Payan, B. Presley, J. M. Vignaud, I. A. Cochel; 114Vascular Laboratory, UT Southwestern Medical Center, Dallas, TX, USA; 2Department of Nuclear Medicine, Georges-François Leclerc Cancer Centre, Dijon, FRANCE.</td>
</tr>
<tr>
<td>OP-355</td>
<td>Radiometric features of glucose metabolism enable prediction of bone marrow involvement in mantle cell lymphoma</td>
<td>M. Mayerhofer, C. Riedl, H. Schöder; Department of Nuclear Medicine, Institute of Medical Radiobiology, University Hospital, ND, Germany.</td>
</tr>
<tr>
<td>OP-357</td>
<td>Contrast-Enhanced 18F-FDG PET/CT in Detection of Recurrent/Metastatic Radiodine Negative Differentiated Thyroid Carcinomas</td>
<td>R. Koranda, H. Polzerová, L. Quinn, E. Burianková, R. Formánek, M. Halenka, M. Macháčková, M. Kramírek; 1Dept. of Nuclear Medicine, UJvana, Brno, Czech Republic, 2Dept. of Internal Medicine II, Univ. Hospital, Olomouc, Czech Republic, 3Czech Republic.</td>
</tr>
<tr>
<td>OP-358</td>
<td>Prognosis of high-risk papillary thyroid cancer patients with pre-ablation stimulated Tg &lt;1 ng/mL</td>
<td>T. Tian, P. Kou, R. Huang, B. Liu, West China Hospital, Sichuan University, Chengdu, CHINA.</td>
</tr>
<tr>
<td>OP-359</td>
<td>Comparisons between Thyroid Hormone Withdrawal and Recombinant Human Thyroid-stimulating Hormone Administration for Radiodine Ablation in Patients with Intermediate-risk to High-risk Differentiated Thyroid Cancer</td>
<td>Y. Iizuka, T. Kataoka, O. Oguma, M. Inoue, K. Nakamura, T. Miasawaki, Kyoto University, Kyoto, JAPAN.</td>
</tr>
<tr>
<td>OP-360</td>
<td>Interleukin-6 is over-expressed in differentiated thyroid cancer and could act as the prognostic factor for disease persistence or recurrence</td>
<td>Z. Guo-Qiang, Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, CHINA.</td>
</tr>
<tr>
<td>OP-362</td>
<td>Contrast-Enhanced 18F-FDG PET/CT in Detection of Recurrent/Metastatic Radiodine Negative Differentiated Thyroid Carcinomas</td>
<td>R. Koranda, H. Polzerová, L. Quinn, E. Burianková, R. Formánek, M. Halenka, M. Macháčková, M. Kramírek; 1Dept. of Nuclear Medicine, UJvana, Brno, Czech Republic, 2Dept. of Internal Medicine II, Univ. Hospital, Olomouc, Czech Republic, 3Czech Republic.</td>
</tr>
<tr>
<td>OP-363</td>
<td>Course of disease and outcome in patients with poorly differentiated thyroid cancer: a single center study</td>
<td>F. Alhamady, Y. W. Stenström, S. L. Lehrer, H. J. Khan, A. Tadod, Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.</td>
</tr>
<tr>
<td>OP-364</td>
<td>A Prospective Study of the Effect of Radioiodine Therapy on Ovarian Reserve Function in Patients with Differentiated Thyroid Carcinoma</td>
<td>W. Miao, R. Lin, The First Affiliated Hospital of Fujian Medical University, Fuzhou, CHINA.</td>
</tr>
<tr>
<td>OP-365</td>
<td>Clinical study on the effect of TSH suppression on left ventricular systolic synchrony in patients with DTC</td>
<td>W. Wang, J. Yang, J. J. J. Wu, X. Han, Y. Liu, J. Liu, Nuclear Medicine Department, The First Affiliated Hospital of Zhejiang University, Zhejiang, CHINA.</td>
</tr>
<tr>
<td>OP-366</td>
<td>Imaging of Immunological Targets</td>
<td>W. Weber, Nuclear Medicine Department, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, GERMANY.</td>
</tr>
<tr>
<td>OP-367</td>
<td>Current State of Imaging in Assessment of Immunotherapy</td>
<td>C. Bodet-Millin, Nuclear Medicine Department, University Hospital, CRONA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, FRANCE.</td>
</tr>
<tr>
<td>OP-368</td>
<td>Emerging Imaging Concepts in Immunoncology</td>
<td>M. Schottelius, CHUV, Lausanne, SWITZERLAND.</td>
</tr>
</tbody>
</table>
OP-375 How to Develop the Ideal Radiopharmaceutical G. Bormans; UZ Leuven, Radiopharmacy Department, Leuven, BELGIUM.

OP-376 Preclinical PET Imaging and Quantification M. Koole; UZ Gasthuisberg, Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

OP-377 Nanobodies Applications for Radionuclide Imaging and Therapy - Process from Camel to Patient M. Keyaerts; UZ Brussels, Nuclear Medicine, Brussels, BELGIUM.

OP-379 Discovery and preclinical characterization of [18F]PiB-2620, a new generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies A. Mueller; K. Kroth; F. Golzi; F. Capostiti; M. Bender; J. Möderle; H. Schaeferstein; V. Darmenzy; J. Castellano-Mellon; E. Volski; H. Schmitz-Wilke; D. Hickmann; A. Pfeffer; S. Poli; H. Denekberg; A. Stephens; Life Molecular Imaging, Berlin, GERMANY; AC Immune SA, Lausanne, SWITZERLAND.

OP-380 Characterization of the Sorafenin 2A receptor selective PET tracer [(18)F]HFU-137218 in the human brain V. Kramer; A. Duszniewski; J. Fleuri; C. Szabo-Ried; J. Ressch; G. Moos Knudsen; H. Amalberti; M. Hestel1; Postnuclear Pharma SA, Santiago de Chile, CHILE; Center for Nuclear Medicine & PET/CT Postnuclear, Santiago, CHILE; Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, DENMARK; Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, GERMANY; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, DENMARK; Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, DENMARK.

OP-381 A minimally-invasive approach to quantify P2X7 receptor occupancy using [(18)F]64413719 dynamic PETMR and MRI-driven image-derived input function N. Mertens; M. Schmidt; A. Hjerm; P. Ravenstein; K. Van Laere; M. Koole; University Hospital and KU Leuven, Leuven, BELGIUM; Janssen Research & Development, Beerse, BELGIUM.

OP-382 The influence of high-fat diet on neuroinflammation and D2 receptor availability in a rat model of Parkinson’s disease L. Reali Nazario; A. Deliš; J. Marigo-Amaro; B. Lima Gascoito; A. Schild; R. A. J. O. Dencks; C. Mana Manguchi Jekett; R. Souza da Silva; J. Deoandun; E. F. J. de Vries1; University Medical Center Groningen, Groningen, NETHERLANDS; Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, BRAZIL; University of Groningen, Groningen, NETHERLANDS.

OP-383 Synthesis Of A Potential Cannabinoid Receptor Subtype 2 (CB2) Receptor Binding Ligand, Nucleophile [(3H)Flourination and First Preclinical Results D. Modemann; C. Buter; A. Keyersschmidt; C. Breuing; D. Stapke; J. Wittling; C. Salthmann; Y. Buter; B. Meiler; Georg-August University Göttingen, Göttingen, GERMANY.

OP-384 TSPD-targeting [(18)F]CB251 PET/MR in an intracranial LPS induced neuro-inflammation model: comparative analysis with biomolecules imaging of peripheral immune cells K. Kim1, H. Kim2, S. Bae3, Y. Kim1, J. Na1, C. Lee1, M. Lee4, G. Ko1, K. Kim1, J. Paeng1, G. Cheon1, K. Kang4, S. Kim3, J. Chung3, L. Kim3, L. Bae1, M. Han1; Samsung cancer institute, Seoul, KOREA, REPUBLIC OF; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF; Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF.

OP-385 DoMoRe - Parallel Session: Artificial Intelligence in Image Processing Monday, October 14, 2019, 14:30 – 16:00 Lecture Hall 152 Chaired by D. Wörlis; UISO INSERM, LaTIM - I35, CHU Milétrie, Brest, FRANCE; A. Mervoyer; University Hospital of Brest, Brest, FRANCE; C. Meller; Georg-August University Göttingen, Göttingen, GERMANY.

OP-386 Deep Learning segmentation of planar thyroid scintigraphy: application of U-net for cold nodules detection F. Hanin; M. Derenne; J. Marquette-Timade; J. Mathieu; B. Willems; C. Uchiyama; N. Namur, Namur, BELGIUM; Anvoly Diagnostics, Brussels, BELGIUM.

OP-387 Automated Cervical Primary Tumor Functional Volume Segmentation in PET Images A. Jantsen; J. Louw; E. Fischer; F. Bonnemains; I. Masson; A. Merjono; C. Renfrida; P. Louvassos; R. Husman; M. De Cuyper; F. Kindler; J. Schick; D. Vuylsteke; M. Hart; Palatia, UMR 1102, University of Fribourg, Brest, FRANCE; Palatia, University Hospital of Brest, Brest, FRANCE; Palatia, University Hospital of Lille, Lille, BELGIUM; Department of Radiology, McGill University Health Centre (MUHC), Montreal, QC, CANADA; Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Nantes, FRANCE.

OP-388 Fully automated computations of putamen and caudate-based clinical measures in [(18)F]-FE-2021/PET/CT dopamine transport imaging using deep learning segmentation L. Andersen; Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK; Palatia, University Hospital of Brest, Brest, FRANCE; Palatia, University Hospital of Lille, Lille, BELGIUM; Department of Clinical Physiology and Nuclear Medicine and PET, Rigshospitalet, Copenhagen, DENMARK; Department of Clinical Physiology and Nuclear Medicine, University Hospital of Bypelberg and Fredriksberg, Copenhagen, DENMARK.

OP-389 Performance assessment of Artificial Intelligence-supported lesion classification in a heterogeneous 18F-FDG PET/CT population C. Von Gall; D. Thomas; Y. Shah; L. Sible; B. Sportswood; Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-390 Consensus of machine learning pipelines for outcome prediction relying on clinical and radiomics features from [(18)F]-FDG-PET/CT images in non-small cell lung cancer M. Hatt; S. Sephen1, T. Upadhaya, D. Visvikis; C. Cheze Le Riec2, INSERM, Brest, FRANCE; CHU Maitre, Poitiers, FRANCE.
OP-393 Radiogenomics analysis of PET/CT images in lung cancer patients: Conventional radiomics versus deep learning
I. Shin1, G. Hasanpour1, S. Ashrafi1, J. Jenabi1, M. Oveis1, A. Rahmani1, 1Department of Biomedical and Health Informatics, Rajaee Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF IRAN, 2Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 3Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 4Research Center for Nuclear Medicine, Shahnaz Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF IRAN, 5Department of Computer Science, University of British Columbia, Vancouver, BC, CANADA, 6Department of Radiology and Physics & Astronomy, University of British Columbia, Vancouver, BC, CANADA, 7Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-392 Towards fully automated image processing in the clinic
J. Taylor1, P. Meherati1, Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM.

OP-391 Clinical Oncology - Featured Session: Evaluating Immunotherapy - Where do we stand?
Monday, October 14, 2019, 14:30 - 16:00 Lecture Hall 114
Chair: N. Aide, Centre Régional de lutte contre le cancer François Baccetix, Caire Cedex 05, FRANCE.
Chair: V. Grünwald, Essen, GERMANY.

OP-396 Immunotherapy for Dummies - Where do we stand?
V. Grünwald, UK Essen, Dept. Of Urology, Essen, GERMANY.

OP-395 Total Metabolic Tumor Volume (TMTV) correlates with treatment failure after CD19 CAR T-cell therapy in patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL)
L. S. Vercellino1, I. Jassal2, A. Marti-Bune3, S. Chevet1, R. Di Blasi1, S. Bernard1, E. De Kerviler4, V. Megnain5, M. Megnain6, P. Merlot1, C. Thebault1, 1Hospital Saint Louis, Paris, FRANCE, 2VISA Imaging, Henri Mondor University Hospitals, Creteil, FRANCE.

OP-394 Value of FDG-PET/CT radiomic features in predicting response to anti-programmed death 1 (PD-1) antibodies treatment in refractory Hodgkin Lymphoma patients
M. Sollini1, M. Kriken2, L. Cozzi2, C. Torni2, L. Antonioli3, E. Tabacci2, L. Calabrò2, C. Nanni3, A. Alexis1, E. Serenga1, S. Fant1, A. Guadita3, F. Rizzo1, P. Coradini1, P. Zannini1, C. Carlo-Stella1, A. Chiti2, 1Humanitas University, Pieve Emanuele, ITALY, 2Humanitas Clinical and Research Center, IRCCS, Rozzano, ITALY, 3 Policlinico S Orsola – University of Bologna, Bologna, ITALY, 4 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, 5 University of Milan, Milan, ITALY.

OP-393 Combined Pre-Treatment Metabolic Tumor Burden on 18F-FDG PET/CT and Derived Neutrophils to Lymphocytes Ratio as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
R. Seban1, L. Mezquita1, L. Champion1, A. Benettamour1, A. Bontecalle1, C. Le Hédouc1, C. Canamé1, L. Gabriel1, M. Massani2, J. Dezde1, S. Gémard1, S. Leboulleux2, N. Girard2, B. Besse2, 1Institut Curie – René Huguenin, Saint-Cloud, FRANCE, 2Gustave Roussy, Villejuif, FRANCE, 3 Institut du Thorax Côte-Montsouris, Paris, FRANCE.

OP-392 Synthesis and Preclinical Evaluation of GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
A. Abouzayed1, C. Yim1, B. Mitran1, S. Rinne1, V. Tilmalm1, M. Lehted1, U. Rosmolin1, R. Olofsson1, Uppsala University, Uppsala, SWEDEN.

OP-391 Parameterized Mathematical Modelling of Positron Range Effects in PET/MRI
A. Berger1, J. Cal-Gonzalez1, J. Rausch2, H. Kesten3, J. Heraza1, A. López-Montes1, M. Corti1, T. Beyer1, 1QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA, 2Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Institute of Medical Physics, Stuttgart, GERMANY, 3University Medical Center, Hamburg-Eppendorf, HAMBURG, GERMANY.

OP-390 CFDA PET/CT Imaging Of Immune-related Adverse Effects in Patients With Cutaneous Melanoma Treated With Pembrolizumab
A. Sabaté-Llobera1, P. Nastas1, M. Martínez de Buena1, J. Jiménez-Camallor1, J. Martin-Lubera1, M. Carrió-Ramos1, J. Marcoval1, J. L. Vernet-Cangas1, C. Gálvez-Ceniza1, 1PET Unit, Department of Nuclear Medicine, CHU Saint-Louis, Paris, FRANCE, 2PET Unit, Department of Nuclear Medicine, Institut Curie, Paris, FRANCE, 3PET Unit, Department of Nuclear Medicine, Institut Curie, Paris, FRANCE, 4Department of Medical Oncology-CHU, Skin Cancer Multidisciplinary Team, Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN, 5Department of Medical Oncology-CHC, Skin Cancer Multidisciplinary Team, Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN, 6Department of Dermatology, Skin Cancer Multidisciplinary Team, Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN.

OP-398 Clinical Oncology - Featured Session: Evaluating Immunotherapy - Where do we stand?
Monday, October 14, 2019, 14:30 - 16:00 Lecture Hall 114
Chair: N. Aide, Centre Régional de lutte contre le cancer François Baccetix, Caire Cedex 05, FRANCE.
Chair: V. Grünwald, Essen, GERMANY.

OP-397 Towards fully automated image processing in the clinic
J. Taylor1, P. Meherati1, Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM.

OP-396 Value of FDG-PET/CT radiomic features in predicting response to anti-programmed death 1 (PD-1) antibodies treatment in refractory Hodgkin Lymphoma patients
M. Sollini1, M. Kriken2, L. Cozzi2, C. Torni2, L. Antonioli1, E. Tabacci1, L. Calabrò1, C. Nanni1, A. Alexis1, E. Serenga1, S. Fant1, A. Guadita3, F. Rizzo1, P. Coradini1, P. Zannini1, C. Carlo-Stella1, A. Chiti2, 1Humanitas University, Pieve Emanuele, ITALY, 2Humanitas Clinical and Research Center, IRCCS, Rozzano, ITALY, 3 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, 4 University of Milan, Milan, ITALY.

OP-395 Combined Pre-Treatment Metabolic Tumor Burden on 18F-FDG PET/CT and Derived Neutrophils to Lymphocytes Ratio as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
R. Seban1, L. Mezquita1, L. Champion1, A. Benettamour1, A. Bontecalle1, C. Le Hédouc1, C. Canamé1, L. Gabriel1, M. Massani2, J. Dezde1, S. Gémard1, S. Leboulleux2, N. Girard2, B. Besse2, 1Institut Curie – René Huguenin, Saint-Cloud, FRANCE, 2Gustave Roussy, Villejuif, FRANCE, 3 Institut du Thorax Côte-Montsouris, Paris, FRANCE.

OP-394 Parameterized Mathematical Modelling of Positron Range Effects in PET/MRI
A. Berger1, J. Cal-Gonzalez1, J. Rausch2, H. Kesten3, J. Heraza1, A. López-Montes1, M. Corti1, T. Beyer1, 1QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA, 2Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Institute of Medical Physics, Stuttgart, GERMANY, 3University Medical Center, Hamburg-Eppendorf, HAMBURG, GERMANY.

OP-393 Synthesis and Preclinical Evaluation of GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
A. Abouzayed1, C. Yim1, B. Mitran1, S. Rinne1, V. Tilmalm1, M. Lehted1, U. Rosmolin1, R. Olofsson1, Uppsala University, Uppsala, SWEDEN.

OP-392 Parameterized Mathematical Modelling of Positron Range Effects in PET/MRI
A. Berger1, J. Cal-Gonzalez1, J. Rausch2, H. Kesten3, J. Heraza1, A. López-Montes1, M. Corti1, T. Beyer1, 1QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA, 2Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Institute of Medical Physics, Stuttgart, GERMANY, 3University Medical Center, Hamburg-Eppendorf, HAMBURG, GERMANY.
EANM'19
BARCELONA, SPAIN | OCTOBER 12 – 16, 2019
BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

128

129

Oral Presentations

October 14

OP-407
Histologically-confirmed diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for lymph node staging of patients with high risk primary prostate cancer
L. Joos1, H. Kaeker1, A. Wüster1, K. Schweabøm2, L. Uebelhoer1, T. Mauser1, S. Kropp1, T. Haim1, B. Halter1, H. Wester1, W. Werbel1, M. Euler1, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY; 1Chair of Pharmaceutical Radiopharmacy, TUM, Munich, GERMANY; 2Institute of Pathology, TUM, Munich, GERMANY; 3Marien-Klinik, UK, Hamburg Eppendorf, GERMANY; 4Scintomics GmbH, Fuerstenfeldebruck, GERMANY; 5Department of Radiology, Klinikum rechts der Isar, TUM, Munich, GERMANY; 6Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, TUM, Munich, GERMANY.

910

Inflammation & Infection - Parallel Session: PET in Vascular Infection and Myocardial Inflammation

Monday, October 14, 2019, 14:30 - 16:00 Lecture Hall 116.
Chair: V. Artikov, Center for Nuclear Medicine, Clinic Center of Serbia, BELGRADE, SERBIA.
OP-410
18F-FDG-PET accuracy for diagnosis of Infective Endocarditis compared to Duke echocardiographic criteria
M. Gazzelli1, R. Durmus1, D. Albano1, E. Cerulli1, M. Bonacini1, F. Donad1, A. Mazzetti1, P. Bellini1, F. Bertagnolli1, R. Gubbiani1, A. Societa Socian Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY; 2Università di Brescia, Brescia, ITALY.

OP-413
Advanced texture features analysis of [18F]FDG-PET/CT imaging in patients with infective endocarditis
R. Zanca1, A. Manciano1, F. Barrai1, S. Vatal1, A. Di Caro1, E. Di Lavore1, R. Slatt1, J. Bonnet1, R. Slatt1, A. Guadennan1, P. Erba1, Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and AOUP, Pisa, ITALY; 3Unit of Infectious Diseases, University of Pisa and AOUP, Pisa, ITALY; 4Division of Cardiology, University of Pisa and AOUP, Pisa, ITALY; 5Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Pisa, ITALY.

OP-414
Effect of image artifacts on texture analysis in mechanical prosthetic valve endocarditis
R. Zanca1, A. Manciano1, F. Barrai1, S. Vatal1, E. Leazen2, R. Slatt1, A. Guadennan1, P. Erba1, Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and AOUP, Pisa, ITALY; 3Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-415
18F-Fluorodeoxyglucose uptake by PET/CT for quantitative analysis of 18F-FDG PET/CT and Radiolabeled Leukocyte Scintigraphy for the Diagnosis of Infected Aortic Anaerysm
M. P. Mention1, J. Brosseau1, 2, J. Min2, L. Riou2, A. Marciano1, 2, F. Thibault3, 1, 2, 3Institute Henri Bergon, Centre Henri Bergon, CHRU Tours, Tours, FRANCE.

OP-416
Reference values for abnormal uptake of 68Ga-DOTATOC in patients with myocardium inflammation
S. Boughdad1, M. Luther2, E. Pruvot2, P. Pascale1, K. Schwamborn1, 2Chair of Pharmaceutical Radiopharmacy, TUM, Munich, GERMANY; 3Institute of Pathology, TUM, Munich, GERMANY.

OP-417
Comparison of 68Ga-DOTANOC PET/CT with cardiac MRI for imaging inflammation in cardiac sarcoidosis
P. Kauschke1, C. Patta1, G. Vulati1, S. Sonth1, P. Parakh2, R. Kumar1, R. Gulema1, C. Bail1, All India Institute of Medical Sciences, New Delhi, INDIA.

OP-408
SUV-based interpretation is better for prognostic response than Deauville Score in Hodgkin Lymphoma patients
E. Texte1, J. Lequesne2, P. Verdu2, A. Starmatoulia-Bastand2, S. Becker2, 1Centre Henri Becquerel, Nuclear Medicine Dept, Rouen, FRANCE; 2Centre Henri Becquerel, Haematology Dept, Rouen, FRANCE.

OP-409
Integrating radioguidance during robot-assisted laparoscopic surgery - In human evaluation of a DROP-IN gamma probe
M. N. van Oosterom1, P. Dott2, 2, P. Meershoek1, T. Mauser1, P. I. van Leeuwen3, E. M. W. W. H. G. van der Poel4, F. W. B. van Leeuwen5, 2, 5, 6, 1Innternational Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS; 2Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS; 3ORSI Academy, Melle, BELGIUM; 4Marine-Clinic University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

OP-411
Quantitative analysis of 18F-Fluorodeoxyglucose uptake by PET/CT for detection infective endocarditis
M. Gazzelli1, R. Durmus1, D. Albano1, E. Cerulli1, M. Bonacini1, F. Donad1, A. Mazzetti1, P. Bellini1, F. Bertagnolli1, R. Gubbiani1, A. Societa Socian Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY; 2Università di Brescia, Brescia, ITALY.

OP-412
Diagnostic and therapeutic impact of wholebody 18F-FDG PET/CT in patients suspected of infective endocarditis on native or prosthetic valve: the prospective multicenter TEPVENDO study
F. Rouzet1, B. Mahida1, S. Tulaba1, M. Episosto2, Fanele1, E. Ilc-Habolini1, A. Baudron1, E. Cherwaler1, H. Dierickx1, A. Piron1, G. Marel2, O. Humbert1, A. Devillers1, B. Gérodet1, E. Lavau1, B. Jung1, X. Eluot2, Bichat Hospital, Paris, FRANCE; 2Lapeyronie Hospital, Montpellier, FRANCE; 3Nancy hospital, Nancy, FRANCE; 4Nantes hospital, Nantes, FRANCE; 5Besançon hospital, Besançon, FRANCE; 6Olyon hospital, Dijon, FRANCE; 7Centre Eugène Marquis, Rennes, FRANCE; 8Hospices Civils de Lyon, Lyon, FRANCE.

ePoster Presentation Session 6 - Cardiovascular Searching for Myocardial Ischemia
Monday, October 14, 2019, 14:30 - 16:00 Room 333/334.
Chair: A. Flotats Giralt, Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, BARCELONA, SPAIN.
Chair: P. Georgoulis, Larissa, GREECE.

EPS-086
SPECT Myocardial Blood Flow measurement with a dedicated cardiac CZT camera for Coronary Artery Disease screening: correlation with cardiovascular risk
M. Bailly1, F. Thibault2, M. Courtheoux2, G. Metard3, M. Ribiero1, CHU Orleans, Orleans, FRANCE; 2CHU Tours, Tours, FRANCE.

EPS-085
Correlation Of Coronary Calcium Burden And Myocardial Perfusion Assessed By Myocardial Perfusion SPECT/CT
S. Cho1, J. Kwon1, S. Yang2, S. Kwon1, J. Min1, H. Song1, H. Bori1, Chonnam National University Hospital, Gwang-Ju, KOREA, REPUBLIC OF; 3Chonnam National University Hwasun Hospital, Jeollanam-do, KOREA, REPUBLIC OF.

EPS-086
SPECT Myocardial Perfusion Imaging Reveals Increased Myocardial Perfusion Entropy in a Rodent Model of Type 2 Diabetes Prone to Coronary Microvascular Dysfunction
A. Carabelli1, M. Larur, A. Frugue-Rubor2, J. Loenhardt2, A. Besart1, J. Miranda3, G. Vancetter3, D. Fagert4, M. Desvigne1, L. Djaloe1, C. Ghazii5, G. Barone-Ricohette6, L. Riau1, Grenoble; Alpes University Hospital - Cardiology Dept, Grenoble, FRANCE; 2GIRER-IDUT155 Radiopharmaceutiques Biocliniques, Grenoble, FRANCE; 3Grenoble - Alpes University Hospital - Nuclear Medicine Dept, Grenoble, FRANCE; 4GIRPSA Lab, UMR CNRS 5216, Grenoble, FRANCE.

118
119
EPS-087 Prognostic value of myocardial perfusion entropy quantified from SPECT myocardial perfusion images

EPS-088 Significance of microalbuminuria in predicting silent myocardial ischaemia (SMI) in patients with type 2 diabetes using myocardial perfusion imaging
M. Assadi, T. Emini, Z. Nazemi, A. Sabzikar, D. Hanpour, M. Kaktarhormooz, A. Azmohammadi, E. Jafar, Bushehr University of Medical Sciences

EPS-089 Prognostic value of coronary artery calcium and myocardial perfusion reserve in patients with and without diabetes mellitus
R. Assante, W. Acampa, E. Zampella, C. Nappe, T. Mannarino, V. Gaudieri, M. Parrao, V. Cantonii, R. Green, M. Petretta, M. Memmott, P. Asmugam, A. Cuculo

EPS-090 Prospective diagnostic performance of semi-conductor SPECT myocardial perfusion imaging: wall thickening analysis overcomes the lack of prone acquisition

EPS-091 Comparison of the prognostic value of PET and SPECT in patients with coronary artery disease: A meta-analysis
H. Chen, R. Wang, J. Wen, C. Fan, West China Hospital of Sichuan University, Chengdu, Sichuan, China

EPS-092 Predictability of Coronary Flow Reserve and Geriatric Nutritional Risk Index for poor prognosis in the Patients with Dialysis dependent End-Stage Renal Disease
S. Ohshima, H. Umemoto, R. Ito, T. Sakakibara, H. Haru, T. Morohara, Nagoya Kyoritsu Hospital, Nagoya, Japan, Ichinomiya Municipal Hospital, Ichinomiya, Japan, Nagoya University Graduate School of Medicine, Nagoya, Japan

EPS-093 Prognostic value of coronary flow reserve in patients with suspected or known coronary artery disease referred to myocardial perfusion imaging by positron emission tomography: a meta-analysis
V. Cantonii, R. Green, T. Mannarino, R. Assante, V. Gaudieri, E. Zampella, C. Nappe, G. Agliata, M. Petretta, W. Acampa, A. Cuculo, University Federico II, Naples, Italy

EPS-094 Performance of Attenuation Corrected Myocardial Perfusion Imaging for Coronary Artery Disease: A Meta-analysis of Vessel-based Data
J. Huang, C. Huang, R. Yen, K. Ko, L. Lu, J. Chen, Y. Wu, Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Department of Nuclear Medicine, and Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan

EPS-095 Comparison between computer-based analysis and expert reading in the interpretation of MPI studies

EPS-096 Causative factors of prolonged myocardial ischemic damage shown on hybrid cardiac fatty-acid metabolism SPECT/CT in patients with coronary artery disease after coronary artery bypass grafting
Y. Fukushima, Y. Ishii, T. Kinoya, T. Nitta, S. Kumita, Nippon Medical School, Tokyo, Japan

EPS-097 Deterministic Effects of Radioiodine Treatment
P. Spaniol, University Hospital, University of Geneva, Department of Nuclear Medicine, Geneva, Switzerland

EPS-098 Stochastic Adverse Effects of Radioiodine Treatment
P. Radojevski, Charité – Universitätsmedizin Berlin, Klinik für Nuklearmedizin, Berlin, Germany, University Hospital, University of Geneva, Department of Nuclear Medicine, Geneva, Switzerland

1001 Joint Symposium 15 - Oncology & Theranostics Committee / ESMO: Immunological Landscape in Solid Tumours and its Implications in Response to Immunotherapy
Monday, October 14, 2019, 16:00 - 18:00 Lecture Hall 311
Chair: J. Haanen, Amsterdam, Netherlands
Chair: E. Lopci, Nuclear Medicine, Istituto di Ricerca e Cura a Carattere Scienfifico (IRCCS), Milano, Italy

OP-421 Prognostic and Predictive Role of Tumour Immune Landscape
J. Haanen, Medical Oncology and Molecular Oncology & Immunology Divisions, The Netherlands Cancer Institute, Amsterdam, Netherlands

OP-422 Immunoscore and its Introduction in Clinical Practice
J. Galon, INSERM, Laboratory of Integrative Cancer Immunology (Team 15), Cordeliers Research Centre, Paris, France

OP-423 Advanced Techniques for the Assessment of Tumour Immunological Profile
E. Lugli, Laboratory of Translational Immunology, Humanitas Clinical and Research Center, Rozzano, Italy

OP-424 Immune-PET, Tumour Metabolism and Patterns of Response to Immunotherapy
E. Lopci, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Humanitas (Rozzano), Nuclear Medicine, Milan, Italy
**Oral Presentations**

**October 14**

**EANM'19**

**Final Programme**

---

**OP-425**

**Discussion**

---

**1003**

**Joint Symposium 16 - Dosimetry + Translational and Molecular Imaging Therapy Committeee / ESTRO: Dosimetry in Preclinical Setting to Determine Dose Limits and Extrapolation to Clinical Dosimetry**

- **Monday, October 14, 2019, 16:30 - 18:00**
- **Lecture Hall 312**
- **Chair:** L. Strigari, Laboratory of Medical Physics, Regina Elena Institute F.G. Rame, ITALY
- **Chair:** E. Toma-Dassa, Stockholm, SWEDEN

---

**OP-426**

**Variable Proton RBE - Is it Time to Consider the Dose Limits for Normal Tissues?**

- **Monday, October 14, 2019, 16:30 - 18:00**
- **Lecture Hall 312**
- **Chair:** I. Toma-Dassa, Stockholm University and Karolinska Institutet, Medical Radiation Physics, Stockholm, SWEDEN

---

**OP-427**

**The Physics of Radiobiology for Alpha-Particle Radionucleide Therapy Effects**

- **R. Hobs,** Johns Hopkins University, Radiation Oncology, School of Medicine, Baltimore, Baltimore, UNITED STATES OF AMERICA

---

**OP-428**

**The Biology of Radiobiology Markers for Dose-Effects in Radionucleide Therapy**

- **J. Nonnekens,** Ernst M. CC, Radiology & Nuclear Medicine and Genetics, Rotterdam, Rotterdam, THE NETHERLANDS

---

**1004**

**CTE 4 - Technologist Committee / SNMML: Technologist's Guide Launch - Radiopharmacy: An Update**

- **Monday, October 14, 2019, 16:30 - 18:00**
- **Lecture Hall 117**
- **Chair:** M. Attard, Nuclear Medicine, Isola Kliniek, Zwaal, NETHERLANDS
- **Chair:** M. Crossrothwaite, Richmond, VA, UNITED STATES OF AMERICA

---

**OP-429**

**Technologist's Guide Launch**

- **M. Attard:** Isola, Radiology and Nuclear Medicine Department, Zwaal, NETHERLANDS

---

**OP-430**

**Generators used in Nuclear Medicine**

- **M. Crossrothwaite:** Virginia Commonwealth University, Richmond, UNITED STATES OF AMERICA

---

**OP-431**

**Theoretical Basics of Radiopharmacy**

- **Z. Wimana,** Institute Jules Bordet, Nuclear Medicine/Radiopharmacy, Brussels, BELGIUM

---

**1005**

**M2M - Parallel Session: Tumour Microenvironment & Cancer Biomarkers**

- **Monday, October 14, 2019, 16:30 - 18:00**
- **Lecture Hall 111**
- **Chair:** B. Singh, Department of Nuclear Medicine, KGMR, CHANDIGARH, INDIA

---

**OP-432**

**The Case for SUV75 as an Imaging Biomarker of Response to Therapy in FDG-PET Imaging of Triple Negative Breast Cancer (TNBC) Patient-Derived Tumor Xenografts (PDX)**

- **K. Shoqri,** L. L. T. Whithead, S. Roy, L. Strong, N. Jettig, R. Walsh, M. Savarikar, Washington University School of Medicine, St. Louis, MO, UNITED STATES OF AMERICA

---

**OP-433**

**First-in-humans Evaluation of [182mTc]-ADAPT6, A Novel Scafold Protein for Visualization of HER2 Expression**

- **V. Tolmachev,** O. Bogaart, E. van Wingen, J. Garauas, R. Zielchans, I. Sinikin, A. Medvedeva, A. Eranon-Hekken,** A. Vanycheva, S. Lindbom, J. Bonni,* N. Tarabanovskaya,** S. Hobert, V. Chernov,** Uppsala University, Uppsala, SWEDEN, "Tomk National Research Medical Center of the Russian Academy of Science, Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, "VTH Royal Institute of Technology, Stockholm, SWEDEN.

---

**OP-434**

**Enhanced apoptosis in response to glucose metabolism and oncogene driver co-targeting in non-small cell lung cancer**

- **V. De Rosa,** C. Terza, F. Rezzani, E. Leggiero,** L. Passeri,** S. Del Vecchio,** Instutute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, "Department of Advanced Biomedical Sciences, University of Naples "Federico II," Naples, ITALY, "CEIDE - Advanced Biotechnologies, Naples, ITALY, "Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II," Naples, ITALY

---

**OP-435**

**[90Y]NIT00 targeted radionucleide therapy immunomodulates the tumor microenvironment of prostate tumors**

- **R. Hernandez,** C. Zahn, E. Alucic-Sanjay, H. Poduri, J. Guzman, C. Massey, A. Bitton, J. Engle, D. McNeil, J. Weichert, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA

---

**OP-436**

**Podophytoxin, a new target for radioimmunotherapy of pancreatic cancers**


---

**OP-437**

**Fluorine-18 Labeled FAPI-Tracers For PET Imaging**


---

**OP-438**

**Theranostics targeting fibroblast activation protein-a (FAP) -Targeted Theranostics**

- **J. M. Kelly,** S. Pannala,** T. M. Jentner,** A. Nikolopoulou,** C. Williams,** B. Hu,** J. W. Babich,** Well Cornell Medicine, New York, NY, UNITED STATES OF AMERICA

---

**OP-440**

**Patient-specific 3D Monte-Carlo-based bone marrow dosimetry for Lu-177 PSMA therapy and the potential value of Tr-99m-anti-granulocyte antibody SPEC1/Tc for image-based 3D active bone marrow localisation**

- **A. Gosiewski,** H. Rathi,** S. Tattertenger,** A. Maziarz,** K. Parodi,** J. Bresch,** J. Kasier,** F. Gieldeharr,** A. Todrik,** S. Ziegler,** P. Bartenstein,** G. Böning,** "Department of Nuclear Medicine, University Hospital Munich, Munich, GERMANY, "Heidelberg Ion Beam Therapy Center, University Hospital Heidelberg, Heidelberg, GERMANY, "Department of Medical Physics, Ludwig-Maximilians-Univeristät München, Munich, GERMANY.

---

**OP-441**

**A Small Molecule Trifunctional Ligand for Fibroblast Activation Protein-a (FAP) -Targeted Theranostics**

- **J. M. Kelly,** S. Pannala,** T. M. Jentner,** A. Nikolopoulou,** C. Williams,** B. Hu,** J. W. Babich,** Well Cornell Medicine, New York, NY, UNITED STATES OF AMERICA

---

**OP-442**

**Theranostics targeting fibroblast activation protein in the tumor stroma: [11Cu] and [11Ac] labelled FAPI-04 in pancreatic cancer xenograft mice**

- **T. Watabe,** Y. Shikami,** K. Karedo-Nakashima,** Y. Liu,** T. Lindner,** K. Doer,** A. Tayshikhim,** S. Nakai,** E. Shimosegawa,** U. Haberkorn,** F. Genet,** J. Hatazuwa,** "Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, "Institute for Radiosciences, Osaka University, Suita, Osaka, JAPAN, "Osaka University Graduate School of Science, Suita, Osaka, JAPAN, "University Hospital Heidelberg, Heidelberg, GERMANY, "Osaka University Hospital Suita, Osaka, JAPAN, "Research Center for Nuclear Physics, Osaka University, Suita, Osaka, JAPAN.

---

**OP-443**

**For NM900 targeted radionucleide therapy immunomodulates the tumor microenvironment of prostate tumors**

- **R. Hernandez,** C. Zahn, E. Alucic-Sanjay, H. Poduri, J. Guzman, C. Massey, A. Bitton, J. Engle, D. McNeil, J. Weichert, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA.
October 14
Oral Presentations

OP-445
Fully hybrid PET/MRI with 18F-FDG in preoperative staging of endometrial cancer: initial experience
P. Mapelli (1), G. Ioni (1), A. Bergamin (1), F. Falconar (1), L. Biscocetti (1), P. Sorof (2), V. Bertinardi (2), R. Cordi (3), G. Taccogna (4), M. Petrino (2), E. Babbottini (5), L. Giammài (5), P. De Ceutelisii (2), P. Poccio (5), A. Vita-Salute San Raffaele University, Milan, ITALY; (2) Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY; (3) Radiology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY; (4) Unit of Obstetrics and Gynecology, IRCCS San Raffaele Scientific Institute, Milan, ITALY; (5) Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-454
The role of PET/MR imaging, PSA and patient age in risk prediction for lesions from prostate cancer
L. Pagg (1), C. P. Spiekogen (1), M. Grahovac (1), T. Beyer (1), M. Hacker (1), QIMP team; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA; (2) Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, AUSTRIA; (3) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

OP-455
Ga68 PSMA PET/MRI in newly diagnosed prostate cancer patients: Correlation of Ga68 PSMA uptake in intraprostatic lesion with disease stage
U. Aydos (1), U. Adlam (2), S. Guibahan (1), J. Gonsal (2), N. Karabacak (2), A. Tlabay (2), L. Ray (2), (1) Gazi University Medical Faculty Department of Nuclear Medicine, Ankara, TURKEY; (2) Gazi University Medical Faculty Department of Urology, Ankara, TURKEY.

OP-456
Can the number of tumour feeding vessels predict hypoxia in breast cancer? A study using combined “FF-FMISO PET-MRI”
J. Carmona-Bozo (1), R. Manovski (2), G. Barret (1), R. Waitek (1), A. Patterson (2), E. Proenza (3), T. Freyer (1), M. Graeser (1), P. Gilbert (1), University of Cambridge, Cambridge, UNITED KINGDOM; (2) Cambridge University Hospitals NHS Foundation Trust, Cambridge, UNITED KINGDOM; (3) Cambridge University Hospitals, Cambridge, UNITED KINGDOM.

P. Veit-Haibach (1), University of Toronto, Department Medical Imaging, Toronto, ON, CANADA.

OP-451
Texture analysis of 2-point Dixon images acquired during PET/MRI: Technique and Initial Experience in Colorectal Cancer
B. Ganeshan, D. Wall, L. Hoy, S. Wam, K. Miles, A. Graves, University College London Hospital, London, UNITED KINGDOM.

OP-452
“FF-FDG PET/MRI in discriminating between malignant and benign pancreatic cystic lesions (PCNs)
H. Xue (1), B. Hou (1), W. Zhu (1), H. Ding (1), X. Li (1), Y. Hu (1), H. Xue (1), F. Feng (2), K. Li (1), X. Wu (1), F. Li (1), Z. Ai (1), D. Li (1), L. Hua (1), Y. Zhao (1), Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA; (2) Peking University Medical Center, Beijing, CHINA.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 114
Chair: T. Buckle, Radiology, LJMC, Leiden, NETHERLANDS.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 113
Chair: L. Aloj, NUCLEAR MEDICINE, CAMBRIDGE UNIVERSITY HOSPITALS, CAMBRIDGE, UNITED KINGDOM.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 112
Chair: H. Amaral, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Villingen, SWITZERLAND, Th. Buckle: NUCLEAR MEDICINE, CAMBRIDGE UNIVERSITY HOSPITALS, CAMBRIDGE, UNITED KINGDOM.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 111
Chair: J. Carmona-Bozo, Radiology, LJMC, Leiden, NETHERLANDS.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 110
Chair: T. Beyer, Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA; (2) Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, CHINA; (3) Center for Biomedical Imaging Research, Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, CHINA; (4) Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA; (5) Department of Thoracic Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, CHINA.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 109
Chair: G. Baxter, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY, (2) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA; (3) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA; (4) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 108
Chair: F. L. Giesel, NUCLEAR MEDICINE, CAMBRIDGE UNIVERSITY HOSPITALS, CAMBRIDGE, UNITED KINGDOM.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 107
Chair: F. Fallanca,1,2,1,2 Erasmus MC, Radiology and Molecular Imaging, Bad Bents, GERMANY; (2) Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, GERMANY.

Monday, October 14, 2019, 16:30 - 18:00 Lecture Hall 106
Chair: E. Mezzenga, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Raffaele Scientific Institute, Milan, ITALY, (2) Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA; (3) Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, CHINA; (4) Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, CHINA; (5) Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, CHINA; (6) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA; (7) Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.
1009
Neuroimaging - Parallel Session: TAU Imaging

Monday, October 14, 2019, 16:30 - 18:00
Lecture Hall 115
Chair: A. Dodich, Geneva University Hospitals, Geneva, SWITZERLAND.
Chair: V. Gariibotto, Medical Imaging, University Hospital of Geneva, Geneva, SWITZERLAND.

OP-457 Tau-PET Correlates with Neuropathology Findings


MAYO Clinic, Rochester, MN, UNITED STATES OF AMERICA, 1Mayo Clinic, Jacksonville, FL, UNITED STATES OF AMERICA.

OP-458 Changes in synaptic density in relation to tau deposition in prodromal Alzheimer’s disease: a dual protocol PET-MR study

H. R. J. Vanhaute, L. Ceccarini, J. Ceccarini, 1S. A. Przybelski, 2H. R. J. Vanhaute, J. Ceccarini, 1S. A. Przybelski, 1Department of Neurology, University Hospitals Leuven, Leuven, BELGIUM, 2Department of Neurology, VIB-KU Leuven, Leuven, BELGIUM.


OP-459 18F]Flortaucipir PET strongly correlates to cognition across the clinical Alzheimer’s disease continuum, independently of CSF tau


OP-460 Cortical Binding Characteristics of [18F]-PI-2620 Differentiate the Clinically Predicted Tau Inform in Suspended 3/4-Repeat and 4-Repeat Tauopathies


OP-461 Amyloid and tau PET relate to memory loss in cognitively normal individuals: the SCIENCe project

E. Wolters, T. Timmers, R. Ossenkoppele, S. C. J. Verfaillie, D. Visser, P. Scheltens, M. E. Schmidt, K. van den Bosch, R. Roelbaard, S. S. V. Golla, W. M. van der Flier, B. N. M. van Berckel, VUmc, Amsterdam, NETHERLANDS, Janssen Research and Development, Beerse, BELGIUM.

OP-462 Longitudinal Dynamic [18F]Flortaucipir PET Reveals Increased Early Stage Tau Pathology in Individuals with Subjective Cognitive Decline

D. Visser, R. Ossenkoppele, S. C. J. Verfaillie, T. Timmers, E. E. Wolters, E. M. Goormans, M. E. Schmidt, R. Roelbaard, B. Windhorst, P. Scheltens, W. M. van der Flier, B. N. M. van Berckel, VUmc, Amsterdam, NETHERLANDS, Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, Clinical Memory Research Unit, Lund University, Lund, SWEDEN, Janssen Research & Development, Beerse, BELGIUM, Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS.

136
BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

Get your proof of concept audit in 2020!

Professional auditor
Qualified subject matter experts
EU-legislation compliant
High-quality audits
OP-463 The incremental Value Of Tau Burden Quantified By 18F-AV-1451 PET/CT Over Conventional 11C-PiB And 18F-FDG PET/CT For Alzheimer’s Disease S. Chen, Y. Leung, L. Li, Y. Lai, V. Mak, C. Ha; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG, The Chinese University of Hong Kong, Hong Kong, HONG KONG.


1010 Cardiovascular - Parallel Session: Myocardial Blood Flow Quantification with PET Monday, October 14, 2019, 15:30 - 16:30 Lecture Hall 116 Chair: A. Kjaer; Nuclear Medicine & PET, KP, Technical Medicine Centre, Enschede, Rijksuniversiteit, COPENHAGEN, DENMARK.
Chair: J. O. Prior, Médecine nucléaire, Lausanne, SWITZERLAND.

OP-465 Association between pericoronary fat thickness and coronary vascular function in patients with suspected coronary artery disease and normal myocardial perfusion imaging C. Nappi, V. Gaudenzi, A. Assante, E. Zampella, G. De Simini, A. Gardano, T. Mannarino, A. D’Antona, R. Greiner, V. Cantori, M. Petretta, W. Acampa, A. Cucciolì, Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY; Department of Translational Medical Sciences, University Federico II, Naples, ITALY.

OP-466 Quantitative myocardial perfusion 99mTc-PET assessed by hybrid PET/CT: normal values and diagnostic performance M. T. Freitag, J. Bremenich, D. Wild, P. Haaf, M. J. Zeltwegger, K. Caserelli, University Hospital Basel, Basel, SWITZERLAND.

OP-467 Prognostic value of coronary vascular dysfunction assessed by hybrid rubidium-82 PET/CT imaging in patients with resistant hypertension V. Gaudenzi, W. Acampa, R. Assante, E. Zampella, C. Nappi, T. Mannarino, M. Petretta, A. D’Antona, M. Raddi, M. Petretta, M. Memmott, P. Arumugam, A. Cucciolì, Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY; Institute of Biotrastructure and Bioimaging, National Council of Research, Naples, ITALY; Department of Translational Medical Sciences, University Federico II, Naples, ITALY; Technical Medicine Centre, Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM.

OP-468 Quantitative PET with [113m]I-Ammonia in the Detection of Functional Significance of Intermediate Stenoses of Coronary Arteries D. Ryzhkova, D. Zverev, National Research Medical Centre, St. Petersburg, RUSSIAN FEDERATION.

OP-469 Combined evaluation of regional coronary artery calcium and myocardial perfusion by 99mTc-PET/CT in predicting lesion-related outcome E. Zampella, W. Acampa, R. Assante, T. Mannarino, A. Genaro, C. Nappi, A. D’Antona, V. Gaudenzi, M. Petretta, P. Arumugam, A. Cucciolì, Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY; Institute of Biotrastructure and Bioimaging, National Council of Research, Naples, ITALY; Department of Translational Medical Sciences, University Federico II, Naples, ITALY; Technical Medicine Centre, Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM.

OP-470 Evaluation Of Quantitative Cmr Perfusion Imaging By Comparison With Simultaneous15O-water pet T. Kero, J. Johannsson, M. Ingstrom, K. Eggert, J. Johannsson, H. Ahlstrom, M. Lubbern, Uppsala University, Uppsala, SWEDEN; Aarhus University, Aarhus, DENMARK.

OP-471 Appropriate Coronary Revascularization Can Be Accomplished If Myocardial Perfusion Is Assessed With Cardiac PET Prior To Treatment Decision S. Akil, F. Hedder, J. Oddtgaj, T. Olson, J. Jägi, D. Ehringer, M. Carlsson, H. Ahlsten, C. Kindorf, H. Engblom; Lund University, Lund, SWEDEN; Princess Noorah Bint Abdullatif University, Riyadh, SAUDI ARABIA.

OP-472 Preserved stress myocardial flow can predict improvement of contractile function in the patients with non ischemic dilated cardiomyopathy E. Kong, J. Cho, C. Lee, D. Shin, Yeoungnam university Hospital, Daegu, KOREA, REPUBLIC OF.

EPS-105
Detectability of small objects in positron emission tomography/computed tomography images with Bayesian penalized likelihood reconstruction
M. Macnab, F. J. Biggervili, F. I. Moksidet, M. J. Pether; J. J. Smiton, R. T. Staff; NHS Grampian, Aberdeen, UNITED KINGDOM; IVIS Tayside, Dundee, UNITED KINGDOM.

EPS-106
NEMA NU 2-2007 Measurements and GATE Monte Carlo Simulations of GE Signa integrated PET/MR for Pure and Non-Pure Positron Emitters
P. R. R. V. Carbie, M. Koole, A. Diagry, Y. D’Asselet, T. Dellet, S. Vandenberghe; ‘Medical Imaging and Signal Processing – MEDISP’ Ghent University, Ghent, BELGIUM; Division of Nuclear Medicine and Molecular Imaging – UZ/KU Leuven, Leuven, BELGIUM; Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL; ‘GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

EPS-107
Relying on deep convolutional neural networks on PET/CT images for stage II and III non-small cell lung cancer outcome prediction
M. Ibrahim, D. Visvikis, C. Chez Le Rest, M. Hatt; Laboratory of Medical Information Processing, Brest, FRANCE; 1101 Joint Symposium 17 - Oncology & Theranostics Committee / AIO: Challenge Pancreatic Cancer

EPS-108
Fuzzy Radiomics: A novel approach to minimizing the effects of target delineation on radiomic models for PET
L. Papp, J. Rauchz; M. Hacker, T. Beyer; QIMM team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA; Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EPS-109
Towards automated whole-body MTV/TLG calculation using artificial intelligence upstack classification
C. Von Gail, D. Thomas, L. Sibille, V. Shah, B. Spotnwoode; Siemens Medical Solutions USA Inc, Knoxville, TN, UNITED STATES OF AMERICA.

EPS-110
A Deep Learning Model to Predict a Classification of Tc-99m ECD SPECT of the Brain by Using Different Pre-trained Models
Z. Lin, F. P. Tseng, Y. C. Ni, Y. P. Chia, G. L. Hung; M. C. Pari; Institute of Nuclear Energy Research, Taoyuan, TAIWAN; Show Chwan Memorial Hospital; Changhua, TAIWAN; Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN; National Cheng Kung University Hospital, Tainan, TAIWAN.

EPS-111
Integrating respiratory gating into PET/CT and PET/MR: evaluating an improved clinical workflow

EPS-112
Quantitative Characterization Of Tumors In PET: A Comparison Of Three Texture Analysis Software Packages
M. Larobina, R. Solga, R. Megna; Institute of Biostatistics and Biostatistics, National Research Council, Naples, ITALY.

EPS-113
Accuracy of 18F-FDG brain activity quantification on the GE SIGNA PET/MR system with MR derived attenuation correction
P. Braad; T. I. Andersen; P. Gruner; ‘Department of Nuclear-Medicine, Odense, DENMARK; Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.

EPS-114
OP-473
When and How Should I Look for Myocardial Ischemia or Viability?
F. Hyasit; Department of Nuclear Medicine, Bichat University Hospital, Paris, FRANCE.

OP-474
When and How Should I Look for Cardiac Amyloidosis?
R. Slat; University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.

OP-475a
When and How Should I Look for Cardiac Dysynchrony?
M. Hacker; Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.

OP-475b
When and How Should I Look for Cardiac Innovation?
H. Verberne; Academic Medical Center, Department of Nuclear Medicine, Amsterdam, NETHERLANDS.

1102
Joint Symposium 17 - Oncology & Theranostics Committee / AIO: Challenge Pancreatic Cancer

EPS-476
Diagnostic Challenges of PDAC
A. Scarp; University of Verona, Department of Pathology and Diagnostics, Verona, ITALY.

EPS-477
Treatment Algorithm of PDAC
J. Siveke; Universitätsklinikum Essen, Essen, GERMANY.

EPS-478
Challenge Diagnostic Imaging of PDAC
P. Veit-Haibach; University of Toronto, Department Medical Imaging, Toronto, CANADA.

EPS-479
Is PDAC an Indication for Radioligand Therapy?
F. Giesel; University of Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

EPS-480
Thyroiditis - Clinical Appraisal and Ultrasound Features
C. Buffet; Hospital Pitie Salpetriere, Thyroid Unit, Paris, FRANCE.

EPS-481
Thyroid Scintigraphy and Uptake in Patients with Thyroiditis - Is there a Current Role?
L. Giovannella; Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine, Bellinzona, SWITZERLAND.

1103
Chair: P. Costa; Nuclear Medicine Department, High Institute for Allied Health Technologies of Porto - Polytechnic Institute of Porto, Vila Nova de Gaia, PORTUGAL.

1104
Chair: G. Testanera; Department of Nuclear Medicine, IRCCS Policlinico San Donato, Milan, ITALY.

EPS-482
Thyroiditis at PET Imaging with Different Tracers - Interpretation Criteria and Reporting
G. Treglia; Imaging Institute of Southern Switzerland and Health Technology Assessment Unit, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND.

Chair: G. Testanera; Department of Nuclear Medicine, IRCCS Policlinico San Donato, Milan, ITALY.
Oral Presentations

**OP-483**
Prevention of activated brown adipose tissue in F-18-FDG PET imaging in children and adolescents - Which measures are effective?

C. Pötzsch, S. Naumann, L. Künzle, T. W. Georgi, M. Weickesser, S. Klummann, D. Schmid, H. Herrmann, J. Schodl, H. Hasseleer, C. Mauz, H. Köhl, D. Köhl, O. Sabri, R. Kluge; Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY; Department of Nuclear Medicine, University Hospital Eppendorf, Hamburg, GERMANY; Department of Nuclear Medicine, University of Augsburg, Augsburg, GERMANY; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, GERMANY; Department of Pediatric, Haematology and Oncology, University of Giessen, Giessen, GERMANY.

---

**OP-484**
Combined 18F-Fluorocholine and 11C-Methionine PET-CT for parathyroid adenoma localization: a pilot acquisition protocol

A. Pereira Gomes, L. Silva, Ermisse Hospital, Anderlecht, BELGIUM.

---

**OP-485**
Dual time-point 18F-Fluorometabol PET protocol for the imaging of neurodegenerative and amyloid biomarkers in mild cognitive impairment

A. Ruzza, L. Filippi, G. Cicco, P. Basile, R. Pirisino, O. A. Ruzza; Santa Maria Goretti Hospital, Latina, ITALY.

---

**OP-486**
Further Reduction Of [18 F]-fDG Activity Applied In Clinical Routine For State-of-the-art 3d ToF PET/ct Systems: Is It Feasible?

J. Pilz, L. Heiswether, J. Holzmannhofer, G. Schweighauser-Zürn, C. Fisch, Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA.

---

**OP-487**
Automated preparation and dispensation of "Ga-DOTATOC on the same synthesizer - impact on the dosimetric exposure of technologists compared to manual practice

M. Frindel, N. Varmenot, A. Rauchser, P. Baumgartner, F. Debuyç, C. Rousseau, F. Kraebel-Bodner; Institut de Cancérologie de l'Ouest, Saint-Herblain, FRANCE, CHU de Nantes, Nantes, FRANCE.

---

**OP-488**
PET/CT SPM: Feasibility of a breath-hold acquisition in a clinical routine

J. Paggan, M. Jinge, C. Bergöman, P. Genzov, J. Prior, CHU, Louvainse, SWITZERLAND.

---

**OP-489**
Clinical Benefit Of Routine True-whole-body 18F-fdg Pet/ct For Patients With Malignant Melanoma

A. M. van den Berk, J. P. Essen, Meander Medical Center, Amersfoort, NETHERLANDS.

---

**OP-490**
The role of ultra-low dose (0.04mCi/kg) 18F-Sodium Fluoride (NaF) PET/CT in the evaluation of metastatic bone disease

M. Al-Daas, T. Al-Ahmad, A. Esmail, S. Usmani, F. Marashi; Sahar Al-Ahmad Center for Molecular Imaging, Shuwaikh, KUWAIT.

---

**OP-491**

M. Szoliková, E. Richetta, F. Garbaccio; Klinik für Nuklearmedizin, University Hospital Eppendorf, Hamburg, GERMANY.

---

**OP-492**
Immunotherapy

M. Kneillling; Eberhard Karls University, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Department of Dermatology, Tubingen, GERMANY.

---

**OP-493**
In vivo Cell Tracking with a Cell Membrane Thiol Targeting Dual PET and Fluorescent Bioconjugation Reagent

T. T. Pham, C. Davis, J. Maher, R. Yan; King’s College London, London, UNITED KINGDOM.

---

**OP-494**
Evaluation of [18F]FDG uptake after anti PD-1 therapy in mice

M. Ogawa, M. Toma, H. Yasu, K. Higashikawa, K. Nakajima, T. Shiga, Y. Kuge; Hokkaido University, Sapporo, JAPAN.

---

**OP-495**
[18F]AF-RESCA IL2 for imaging activated T-cells

I. Antunes: E. L. van der Veen, F. V. Suurin, F. Cremers, G. Bormans, R. L. Elzinga, R. A. J. D. Deeren; M. N. Lub-de Hooge, E. G. De Vries, E. J. F. De Vries; University of Groningen, University of Medical Center of Groningen, Dept. of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS; University of Groningen, University of Medical Center of Groningen, Dept. of Medical Oncology, Groningen, NETHERLANDS; University of Leuven, Dept. of Pharmacy and Pharmacology, Laboratory for Radiopharmaceutical Research, Groningen, NETHERLANDS; University of Groningen, University of Medical Center of Groningen, Dept. of Hospital and Clinical Pharmacy, Groningen, NETHERLANDS.

---

**OP-496**
Imaging CD8+ T cell tumor infiltration following radiotherapy

P. Wieserba, F. Raquel, G. Sandker, M. Boswinkel, C. Watmough-Kuimet, E. Aarntzen, S. Heskamp; Radboudumc, Nijmegen, NETHERLANDS.

---

**OP-497**
PET Imaging For Tracking Immunoologically Competent Cells With Zirconium-89 Labeling Method In Murine Syngeneic Transplantation Model


---

**OP-498**
Is [18F]FDG-PET a useful tool to capture an immune response to oncolytic virotherapy?

J. Hoebart, C. Da-Pere, P. Rao, D. M. Colado, G. Smith, A. Melchez, K. J. Harding, G. Kramer-Marék; The Institute of Cancer Research, London, UNITED KINGDOM.

---

**OP-499**
Lesion dosimetry in metastatic thyroid cancer treated with [131I]-standardization of SPECT-TC calculation method with an in-house software tool and preliminary texture analysis results

E. Richetta, M. Poli, A. Renzo, D. Valentini, B. Petretti Paradisi, V. Garbuccio, F. Pelligra, A. Munti, D. Dearden; M. Stazi; AD Online Maunostana, Torino, ITALY; Orsiedele Civile Sant Antonio e Biagio e Cesare Aringa, Alessandria, ITALY; Completo Circa della Salute e della Scienza, Torino, ITALY.

---

**OP-500**
Retrospective evaluation of a single time point dosimetry method for radioiodine treatment of hyperthyroidism

E. Amato, A. Campennì, R. M. Ruggener, L. Audoto, S. Baldini; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ITALY, Istituto Nazionale di Fisica Nucleare, Catania, ITALY, Nuclear Medicine Unit, University Hospital “G. Martino”, Messina, ITALY; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, ITALY.
OP-501 Salivary gland dosimetry of differentiated thyroid cancer patients treated with ¹³¹I-Nal after near-total thyroidectomy
J. Tappeger, J. Leek, J. Garay, I. Mumpf, G. Flué; Hospital Universitari Germans Trias i Pujol, BADALONA, SPAIN.

OP-502 The MEDIRAD multi-national I-131 dosimetry study for thyroid ablation and adenoid therapy: current status

OP-503 Dosimetric analysis and clinical outcome for patient with High-Risk Neuroblastoma administered with high-activity therapy of 131I-mIBG
J. Carrasco1, J. Ramos-Mendar1, M. Avila-Rodriguez1, I. Casado Bover1, A. González-Be1, J. Garay, U. Eberleer, C. Lator, A. K. Buch; M. Lassmann; E. Morera, A. Vergara; M. Barnels; D. Valla; F. Courbon; J. V7; G. Flué, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UNITED KINGDOM; Barz Health NHS Trust, London, UNITED KINGDOM; University Hospital Manto, Marburg, GERMANY; University Hospital Würzburg, Würzburg, GERMANY; WISER, UAM 1037, Université Toulouse Paul Sabatier, Toulouse, FRANCE; Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, University of Costa Rica, Physics School, CICANUM, San Jose, COSTA RICA, Instituto Politécnico Nacional, CDMX, MEXICO, University of California, San Francisco, CA, UNITED STATES OF AMERICA, University of Copenhagen, I. Law.

OP-504 Imaging DNA Damage in vivo following [177 Lu] Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer

OP-505 Alpha Particles Induce DNA Damage in Leukocytes during Treatment with Ra-223
S. Schumann, M. Lassmann, C. Lapor, R. Muhtadi, H. Seuthe, E. Eberleer, Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY; Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

OP-506 Determination of S-values and characterization of direct damage to DNA induced by Auger electrons from Copper-64

OP-507 Challenges Related to Acquisition of Brain PET and SPECT in Patients with Neurological Diseases - A Technical Overview
M. Mada, IRC Cognition and Brain Sciences Unit, Cambridge, UNITED KINGDOM.

OP-508 Pitfalls and Artefacts Related to Preparation and Acquisition of Brain FDG PET
M. Baucknecht, Nuclear Medicine Unit, San Martino Hospital, University of Genoa, Genoa, ITALY.

OP-509 Pitfalls and Artefacts Related to Preparation and Acquisition of Dopaminergic Imaging
E. van de Giessen, Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS.

OP-510 Pitfalls and Artefacts Related to Preparation and Acquisition of PET AA Imaging in Brain Tumours
I. Law, Department of Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, DENMARK.

OP-511 Diagnostic values of real time F-18 FDG PET/CT guided metabolic biopsy for diagnosis of Lymphoma
B. Mittal, R. Kumar, H. Singh, A. Bhattacharyya, G. Prakash, P. Mathew, Postgraduate Institute of Medical Education & Research, Chandigarh, INDIA.

OP-512 Sentinel Lymph Node biopsy in breast cancer with **18**F-Tilmanocept (LYMPHOSEEK®): A descriptive analysis of our experience in 9 centers in Spain
S. Vidal Sicart, M. Riga-Martín, A. Prieto, E. Gentil, J. Gómez, M. Albalá, L. lumière, C. León, J. Gómez, Hospital Clinic Barcelona, Barcelona, SPAIN; Hospital Universitario Ramón y Cajal, MADRID, SPAIN; Hospital Puerta de Hierro, Madrid, Spain; Complejo Hospitalario de Navarra, Pamplona, SPAIN; Hospital General Universitario Gregorio Marañón, MADRID, Spain; Hospital Universitario Reina Sofia, Córdoba, Spain; Hospital Regional Universitario de Málaga, Málaga, SPAIN; Hospital Rey Juan Carlos, Madrid, Spain.

OP-513 Sentinel lymph node biopsy with **111**In-Tilmanocept in oral cavity cancer: Our experience
M. Albalá Gonzalez, A. Santos Bueno, A. Dean Ferrer, M. Esteve Semana, De La Cruz, M. Sanchez Frais, A. Acosta Collado, J. María Fernandez, J. Prieto Prieto, V. Guare Moorena, J. Valverde Casas, Hospital Universitario Reina Sofia, Córdoba, SPAIN.

OP-514 Image-guided Occult Lesion Localization for Non-Palpable Breast Cancer Tumors
J. R. Orroz Cortés, A. Badenes Romano, G. Garmiços Orpea, B. Cuesta Caridad, I. Latorre Agyme, P. Alonso, T. Mut, D. Balaguer, R. Vila, S. Pelsae, E. Caballero Calduag, M. Pionsca, M. Reyes, R. Martinez, Hospital Universitario De Perez, València, SPAIN.

OP-515 Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In Breast Cancer Patients; Correspondence With Molecular Subtypes
P. de la Riva Pérez, C. Calvo Moran, T. Cambal Molina, J. García Gómez, A. Ayudo Martínez, G. Sabatei Hernández, M. Molina Marco, Hospital Macarena, Sevilla, SPAIN.

OP-516 Sentinel lymph node status versus tumor characteristics, neutrophil to lymphocyte ratio, C-reactive protein levels and C-reactive protein to albumin ratio- prognostic factors for primary cutaneous melanoma
S. Stojanovski, M. Manevska, T. Makedona, D. Mladenova, Medical Faculty, Skopje, NORTH MACEDONIA.

OP-517 The value of **111**In-microcolloid reinjection in vulva cancer patients with non-visualisation of a contralateral sentinel node

WORLD LEADING MEETING
F I N A L  P R O G R A M M E
B A R C E L O N A, S P A I N | O C T O B E R  1 2 – 1 6, 2019

BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

145
OP-518 Head-to-head comparison of two radioisotopes with different particle size for sentinel lymph node imaging using lymphoscintigraphy and SPECT/CT
D. Rietbergen, P. Meershoek, M. Donwijk, M. Klap, R. Valdes Olmos, F. Van Leeuwen, J. vd Hage; Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

OP-519 Cardiovascular - Parallel Session: Imaging the Vessel Wall
Tuesday, October 15, 2019, 8:00 - 9:30 Lecture Hall 115
Chair: J. Bucur, University of Vienna, Austria

OP-521 The Presence Of Brown Adipose Tissue Protects Against Arterial Inflammation In Young Healthy Adults
O. Hedeslan, A. Gruber, C. T. Herz, M. E. Mayerhöfer, F. Langer, G. Prager, M. Haak, F. W. Kiefel, A. Haag; Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Austria.

OP-522 Fully-automated production of [18 F] ligands of Lipoprotein-associated phospholipase A2 for PET imaging of atherosclerosis
E. Jestin, F. Gobbaz, T. Bénard, J. Armari, F. Gérin, D. Menhir; GIP CYROI, Sainte Clotilde, France.

OP-523 Arterial Wall Inflammation, Increased Hematopoiesis and Macrophage Activation in Patients with Primary Aldosteronism

OP-524 Alterations of peripheral microcirculation in Diabetes mellitus and Obesity
M. Miko, J. Varga, E. Nagy, A. Ernő, M. Kaplan, A. Forgacs, I. Gata; Department of Medical Imaging, University of Debrecen, Debrecen, Hungary.

OP-526 Aorta Inflammation spatial heterogeneity in Erdheim-Chester Disease:
18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography

OP-527 Variability in NEMA NU 2-2012 performance measurements of all sixteen Discovery MI digital time-of-flight PET-CT systems in the Nordic countries

OP-528 Harmonisation of PET/CT Performance for Brain Studies
E. E. Verweer, S. V. S. Gokh, A. Kaspjer, M. Lubberink, F. H. P. van Velden, V. Bettmann, M. M. Yaqub, T. Seren, J. Rinneb, A. A. Lammertma, A. Boellaard; Amsterdam University Medical Centers, Location VUMc, Amsterdam, Netherlands, North East Scotland Medical Center Foundation, Tallinn, Estonia, Uppsala University Hospital, Uppsala, Sweden.

OP-529 Imaging performance of Siemens Vision 600 and GE Discovery MI-5 evaluated on phantoms with focus on detection and quantification of sub-centimeter lesions
O. L. Munk, L. P. Tolbod; Aarhus University Hospital, Aarhus, Denmark.

OP-531 Oral Presentations
EARN 19

OP-532 Oral Presentations
EARN 19

OP-533 Oral Presentations
EARN 19

OP-534 Oral Presentations
EARN 19

OP-535 Oral Presentations
EARN 19

OP-536 Oral Presentations
EARN 19
OP-530  Quality Control of PET/MRI systems: Consensus Recommendations from a European Network of Hybrid Imaging Sites (HYBRID)  
A. Valladares, S. Ahangari, T. Bayer, R. Baekhoud, Z. Chatzilampakis, C. Comtat, J. Daafouz, A. E. Hansen, M. Koled, J. MacKenzie, P. Manderop, J. Nuyts, S. Path, E. Salatik, I. Rauchh; *Medical University of Vienna, Vienna, AUSTRIA; †Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK; ‡Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, NETHERLANDS; §Service Hospitalier Frédéric Joliot, Villejuif, INSERM, CNRS, Univ. Paris-Sud, Orsay, FRANCE; ††Department of Nuclear Medicine, University Hospital, Leuven, LEUVEN, BELGIUM; ‡‡Department of Nuclear Medicine, University Hospital, Tuebingen, Tuebingen, GERMANY; ‡§Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY.

OP-534  Optimization of Yttrium-90 PET/CT Acquisition Time on a SiPM-PET/CT during Selective Internal Radiation Therapy  
J. Labour, A. Martin, P. Bussard, T. Bauduin, P. Veyrat-Durez, D. Delvaige, G. Samal, J. N. Baud; †Centre Leon Bérard, Lyon, FRANCE; #CREATIS, Lyon, FRANCE.

1111 e-Poster Presentation Session B - Bone & Joint: Bone SPECT/CT - Clinical Imaging Pattern and Quantification Tools  
Tuesday, October 15, 2019, 09:00 - 13:00  
Chair: L. Rustin, Rovigo, ITALY  
Chair: E. Rust, Medecine Nucleaire, Mulhouse, FRANCE.

OP-533  Dose optimization for pediatric FDG whole body PET/CT  
M. van Gent, V. C. Hamming, J. E. Schaaf, A. W. J. M. Glaudemans, A. T. M. Willemsen, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-113  Irradiated sciatic pain as an unusual presentation of osteoid osteoma in distal limb bone  
J. Uha, C. Alvarez-Gonzalez, C. Cardenas Negra, A. Vilela de Viera, F. de Leon Garcia, Servicio Comarca Salud, Santa Cruz de Tenerife, SPAIN.

EPS-123  Quantitative three-phase 99mTc-MDP scintigraphy in the assessment of loosening of total knee endoprostheses in patients with equivocal imaging findings  
M. Beheshhti, Z. Payam, R. Hormaei, C. Schiller, F. Fari, F. Massoum, J. Hochreiter, W. Langsteiger; †Nuclear Medicine, University Hospital, RWTH University, Aachen, GERMANY; ‡Nuclear Medicine, Pancreas Medical University, Salzburg, AUSTRIA; §Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN; ¶ISLAMIC REPUBLIC OF; #Orthopaedic surgery, Ondensklinikum, Linz, AUSTRIA; †§Nuclear Medicine, St. Vincenti’s Hospital, Ondensklinikum, Linz, AUSTRIA; ¶¶Orthopaedics Surgery, Tahb University of Medical Sciences, Tabriz, IRAN; ¶¶ISLAMIC REPUBLIC OF; ‡‡Orthopaedics surgery, Ondensklinikum, Linz, AUSTRIA.

EPS-124  Bone SPECT/CT in patients with persistent low back pain after lumbar spine stabilization  

EPS-125  Utility of SPECT-CT in the follow-up of patients undergoing cervical intersomatic arthrodesis  
M. Moreno-Caballero, A. Moreno-Florez, A. Martinez-Espin, P. Jiménez-Garrero, A. Colado-Rodriguez, J. Infante-de la Torre, J. Segarra-Vicente, J. Rojo-Madrid; †Department of Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, SPAIN; ‡Department of Neuroimaging, Hospital Universitario de Badajoz, Badajoz, SPAIN.

EPS-126  usefulness of bone SPECT/CT for the prediction of bone graft viability after maxillofacial reconstruction with vascularized bone grafts  
H. Kim, S. Han, J. Shin, J. Lee, K. Ahn, K. Byul; *Department of Nuclear Medicine, Asan Medical Center, Seoul, KOREA, REPUBLIC OF; †Department of oral and maxillofacial surgery, Asan Medical Center, Seoul, KOREA, REPUBLIC OF; ¶University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-117  Hypertrophic Osteoarthropathy as a warning in bone scintigraphy  
L. S. Torres, V. Aves, A. Oliveros, J. Perera; Centro Hospitalario Universitario S. Joda, Porta, PORTUGAL.

EPS-120  Comparison of conventional MDP bone scan and Somatostatin Receptor PET CT in detection of active Rheumatoid Arthritis  
S. Shamim, A. Behra, R. Gupta, G. Arora, S. Datta Gupta, C. Bab; All India Institute of Medical Sciences, Delhi, INDIA.

EPS-118  Mazabraud’s syndrome a new case report  
Z. Jemni, A. Ezine, H. Chekir, H. Boudriga, M. Ben Fredj, S. S. Mers, T. Darder, H. Charfi, R. Slaar, M. Nouiri, K. A. Chatti; †Nuclear medicine department, Sahllou University hospital, Toulouse, TUNISIA; §IRDES, University of Toulouse, Faculty of medicine of Toulouse, Toulouse, TUNISIA; ‡Imaging Department, Sahllou University hospital, Toulouse, TUNISIA.

EPS-119  Assessment of instability in thoracolumbar burst fractures using bone scintigraphy  
M. Seo, J. Choi, J. Kim, S. Park; †Ulsan University Hospital, Ulsan, KOREA, REPUBLIC OF; ¶Dongyang Medical Center, Ulsan, KOREA, REPUBLIC OF; ‡Ulsan University College of Medicine, Ulsan, KOREA, REPUBLIC OF.

EPS-121  Assessment of instability in thoracolumbar burst fractures using bone scintigraphy  
M. Seo, J. Choi, J. Kim, S. Park; †Ulsan University Hospital, Ulsan, KOREA, REPUBLIC OF; ¶Dongyang Medical Center, Ulsan, KOREA, REPUBLIC OF; ‡Ulsan University College of Medicine, Ulsan, KOREA, REPUBLIC OF.

EPS-122  Assessment of instability in thoracolumbar burst fractures using bone scintigraphy  
M. Seo, J. Choi, J. Kim, S. Park; †Ulsan University Hospital, Ulsan, KOREA, REPUBLIC OF; ¶Dongyang Medical Center, Ulsan, KOREA, REPUBLIC OF; ‡Ulsan University College of Medicine, Ulsan, KOREA, REPUBLIC OF.
EANM'19 | Final Programme

Oral Presentations

October 15

EANM'19 | Final Programme

BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

150

151
OP-553
Opening minds to Lean management in Nuclear Medicine
J. Lemos, D. Veira, N. Antunes, P. Costa; Nuclear Medicine Department, School of Health, Polytechnic Institute of Porto (ESP|Pporto), Porto, PORTUGAL.

OP-554
Barriers And Limitations For Nuclear Medicine Technologists’ Research In Spain
R. García Gorga1,2, C. Romero Magdalena1, N. Vega de Andrea1, L. Rincón Gayán1, I. Hernена Peco1, 1Sociedad Española de Graduados y Técnicos en Radiología, Madrid, SPAIN, 2Serv de Medicina Nuclear, Hospital Universitario 12 de Octubre, Madrid, SPAIN, 3Health Sciences College, Alfonso X El Sabio University, Madrid, SPAIN.

OP-555
Nuclear Medicine Technologists: Professional Identity - Can leadership profiles make a difference?
A. Martina1,2,1 J. Fari de Albuquerque3, G. Cunha3, 1Higher School of Health of the Portuguese Red Cross, Lisbon, PORTUGAL, 2Joaquim Chaves Saúde, Lisbon, PORTUGAL, 3Lisbon School of Health Technology, Lisbon, PORTUGAL, 4NOVA-SBE, Lisbon, PORTUGAL.

M2M - Parallel Session: Preclinical Developments in Infectious Diseases

Tuesday, October 15, 2019, 11:30 - 12:45 Lecture Hall 111
Chair: F. Caobelli, Basel, SWITZERLAND.
Chair: G. Treglia, Bellinzona, SWITZERLAND

OP-556
111In-PCTA-VRC07 a Radiolabeled Broadly Neutralizing Antibody For HIV Imaging in Mice
D. Viertl1, J. Denoël1, F. Ciccone1, C. Müller1, C. Fenwick1, C. Pantaleo1, J. O. Prior, 1Lisbon School of Health Technology, Lisbon, PORTUGAL, 2Hospital Universitari Parc Taulí, Sabadell, SPAIN, 3Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, 4University of Porto (ESS|Pporto), Porto, PORTUGAL, 5Faculty of Medicine, University of Porto, Porto, PORTUGAL.

OP-557
Imaging infections: evaluation of antimicrobial peptide 99mTc-DPAH-UBI29-41 as a specific agent
M. Zinkalova1, A. Persiano1, V. Udrudov1, V. Ivanov1, M. Laskina2, E. Stayakuly2, A. Roger2, A. Lushchiky2, N. Shvetsov1, V. Zavozdetskii1, 1Siberian State Medical University, Tomsk, RUSSIAN FEDERATION, 2National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Institute of Bioorganic Chemistry, Minsk, BELARUS.

OP-558
In vivo imaging of infection with 99mTc-Labelled Human Beta-Defensin-3 in a Rat Model
G. A. Follacchio1,2, A. Pakr1, S. Scaccianese1, F. Monteleone1, M. Liberatore1, 1Sapienza University of Rome, AOUClinico Umberto I, Nuclear Medicine Unit, Rome, ITALY, 2Department of Moleculare Medicine, Sapienza University, Rome, ITALY, 3Sapienza University of Rome, Department of Human Physiology and Pharmacology, Rome, ITALY.

OP-559
Multiplexing during host-guest mediated pre-targeting of bacteria
M. Welling1, N. Duzenko2,3, D. M. van Willigen1, W. K. Smith1, M. Roestenberg1, T. Buckle2, F. W. B. van Letwouwe1, 1Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, 2Department of Parasitology and Department of Infectious Diseases, Leiden University Medical Center, Leiden, NETHERLANDS, 3Department of Medical Microbiology, Section Experimental Bacteriology, Leiden University Medical Center, Leiden, NETHERLANDS, 4Laboratory of BioNanoTechnology, Department of Agronomy, Wageningen University & Research, Wageningen, NETHERLANDS.

OP-560
An animal model of foreign body infection for the development of quantitative infection imaging
B. Mahida1, R. Aid2, J. Antis1, F. Andreatta1, L. Loutard1, F. Chau1, F. Rouzet1, 1Department of Nuclear Medicine, Bichat University Hospital, Assistance Publique—Hôpitaux de Paris, FRANCE, 2INSERM Unité 1148 Bichat University Hospital, Paris, FRANCE, 3INSERM, Bichat University Hospital, Paris, FRANCE, 4University Paris Diderot-Paris 7, Paris, FRANCE, 5Department of Nuclear Medicine, Bichat University Hospital, Assistance Publique – Hôpitaux de Paris, University Paris Diderot-Paris 7, Inserm Unité Mixte de Recherche 1148, Paris, FRANCE.
OP-561

FDG uptake pattern can predict the success of bacterial cancer therapy

A. Chong1, J. Min1, H. Nguyen1, J. Ha2, K. Kim1, Chosun University Hospital, Gwangju, KOREA, REPUBLIC OF; 1Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF.

1306

DoMoRe - Parallel Session: SPECT/CT Quantification & Data Analysis

Tuesday, October 15, 2019, 11:30 - 12:45 Lecture Hall 112

Chair: L. Armstrong; Nuclear Medicine, MANCHESTER, UNITED KINGDOM.

Chair: J. Dickson; Institute of Nuclear Medicine, University College Hospital, LONDON, UNITED KINGDOM.

OP-562

Convolutional neural network-based denoising allows 67% reduction of scan time or tracer dose in dopamine transporter SPECT

M. Nazari1,2, S. Kmoer1, M. Ehrnhung1, A. Kluge1, R. Bucher1, ABX - CRO advanced pharmaceutical services, Dresden, GERMANY, 1TU-Dresden, Dresden, GERMANY; 2Pinax Pharma, Bad Liebenwerda, GERMANY.

OP-563

Deep Image Denoising in SPECT

M. Reymann1, T. Kuwof1, P. Hart1, B. Sempf1, M. Cachovan1, H. A. Vija1, A. Mav1, Friedrich-Alexander University Erlangen-Nuremberg, Pattern Recognition Lab, Erlangen, GERMANY, Erlangen Graduate School in Advanced Optical Technologies (SAOT), Erlangen, GERMANY; 1Clinic for Nuclear Medicine, University Hospital Erlangen, Erlangen, GERMANY, 1Siemens Healthineers, Erlangen, GERMANY; 1Siemens Medical Solutions USA, Inc., Malvern, PA, UNITED STATES OF AMERICA.

OP-564

Optimization of myocardial perfusion imaging protocol for digital SPECT/CT imaging system

R. Hirvilaammi1, M. Sepparan1,2, J. Kuusari1, T. Nepponen1,2, Department of Clinical Physiography and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 1Turku PET Centre, Turku University Hospital, Turku, FINLAND, 2Department of Medical Physics, Turku University Hospital, Turku, FINLAND.

OP-565

Optimisation Of A General Purpose CZT SPECT/CT For Tomography

N. Bird1, D. Gillett; Addenbrooke’s Hospital, Cambridge, UNITED KINGDOM.

OP-566

Lutetium-177 SPECT Quantification: A Multi-Center, Multi-Vendor Comparison

S. Meyer Vio1, M. M. Peters1, N. R. van der Werf1, F. H. P. van Velden1, N. de Jong2, M. Konijnenberg2, A. Meurs2, M. Gotthardt2, C. Benj3, H. W. A. M. de Jong3, M. Segberg4; IUMC Utrecht, Utrecht, NETHERLANDS, 1Radiotherapy, Nijmegen, NETHERLANDS; 2Erasmus MC, Rotterdam, NETHERLANDS, 3Leiden University Medical Center, Leiden, NETHERLANDS.

OP-567

Reproducibility and Accuracy for a Phantom with Lutetium-177 Filled Spherical Inserts Using two Different SPECT/CT Quantitation Methods; Implications for Tumour Dosimetry After 

15-Litiotametetrayaczetan Treatment

J. Blakkejsrud1, E. T. G. Mikalsen1, A. Landsalen1, C. Sokol1, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, 1Department of Physics, University of Oslo, Oslo, NORWAY, 2Faculty of Medicine, University of Oslo, Oslo, NORWAY, 3Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, NORWAY.

OP-568

Automated, robust and agile organ segmentation for voxel-based dose planning

M. Nazari1, A. Kluge1, S. Kmoer1, ABX - CRO advanced pharmaceutical services, Dresden, GERMANY, 1TU-Dresden, Dresden, GERMANY.

OP-569

SPECT/CT

C. Nappi; Institute of Biostatistics and Bioimaging, Naples, ITALY.

OP-570

PET/CT

R. Sciagra; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, ITALY.

OP-571

Cardiac-Centered Gamma Cameras

O. Lairiez; University Hospital Toulouse, Toulouse, FRANCE.

OP-572

Hybrid Imaging

C. Rischpler; University Hospital Essen, Essen, GERMANY.

OP-573

Value Of FDG PET/CT To Evaluate The Efficacy Of Regorafenib In Locally Advanced Non-Resectable/Metastatic Bilary Tract Tumors: The REACHIN Study

R. Lhommel1, L. Guillaume1, J. Borbash1, S. Goldman1, J. Van Lantersh2, A. Demoli2, Cliniques Universitaires Saint-Luc, ULouvain, Brussels, BELGIUM, 1Hospital Universitaire Erasme - ULB, Brussels, BELGIUM.

OP-574

18F-fluciclatide Pet As A Biomarker Of Response To Combination Therapy Of Pazopanib And Paclitaxel In Platinum-resistant/refractory Ovarian Cancer

R. Sharma; P.O. Vallet1, M. Inglesi1, D. Dubahi1, M. Chien1, H. Gaber1, A. Monteri2, A. Chahkapi3, M. Achan4, G. Thakaran5, E. Chambers1, T. Cole1, J. Laoro-Kuette1, T. D. Bawde1, E. O. Abagge1, 1Imperial College London, London, UNITED KINGDOM, 2Guys and St Thomas’ NHS Trust, London, UNITED KINGDOM.

OP-575

Combination of 18F-FDG PET/CT-based Metabolically Active Tumor Volume and Early Metabolic Response Significantly Improves Outcome Prediction in Metastatic Colorectal Cancer: results from two prospective development and one external validation cohort


OP-576

Multimodal Radiomic Imaging: Evaluation of 18F-FDG-PET and CE-CT as an early Imaging Biomarker for Prognostication and Response Prediction after Radiochemotherapy using Cetuximab in Head and Neck Squamous Cell Carcinoma

B. Sah1, M. Bogowrza2, T. Tanadini-Lang3, O. Rentzen1, C. Leising1, J. Heyerhagen1, G. Souder1, M. W. Hueler1, P. Ver-Halbach2, 1Department Nuclear Medicine, University Hospital Zurich and University of Zurich, Zurich, SWITZERLAND, 2Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, University of Bern, Bern, SWITZERLAND, 3Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, SWITZERLAND, 4Department of Radiation Oncology, University Hospital Zurich, Zurich, SWITZERLAND, 5Department of Radiotherapy, Kantonsspital Luzern, Luzern, SWITZERLAND, 6Department of Medical Imaging, University of Toronto, Toronto, ON, CANADA.

OP-577

Prediction Of Therapeutic Response and Long-Term Outcomes By EORTC Criteria And Percist in Breast Cancer Following Two Courses Of Neoadjuvant Chemotherapy

W. Lian, C. Liu, Z. Yang, S. Song, Y. Zhang, Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-580

Clinical Oncology - Parallel Session: Therapy Response Assessment - Conventional Criteria and More

Tuesday, October 15, 2019, 11:30 - 13:00 Lecture Hall 114

Chair: N. Aida; Centre Régional de lutte contre le cancer François Baclesse, Caen Cedex 05, FRANCE.

Chair: M. Lam, Utrecht, NETHERLANDS.

OP-581

Oral Presentations

Tuesday, October 15, 2019, 11:30 - 12:45 Lecture Hall 112

OP-582

Oral Presentations

Tuesday, October 15, 2019, 11:30 - 13:00 Lecture Hall 113

Chair: D. Agostini; Laboratoire de Biophysique Medecale Faculte de Medecine, Siemens Healthcare, CAIN, FRANCE.

Chair: A. Saraste; Turku, FINLAND.

OP-583

Oral Presentations

Tuesday, October 15, 2019, 11:30 - 13:00 Lecture Hall 113

Chair: D. Agostini; Laboratoire de Biophysique Medecale Faculte de Medecine, Siemens Healthcare, CAIN, FRANCE.

Chair: A. Saraste; Turku, FINLAND.

OP-584

Oral Presentations

Tuesday, October 15, 2019, 11:30 - 13:00 Lecture Hall 113

Chair: D. Agostini; Laboratoire de Biophysique Medecale Faculte de Medecine, Siemens Healthcare, CAIN, FRANCE.

Chair: A. Saraste; Turku, FINLAND.

OP-585

Oral Presentations

Tuesday, October 15, 2019, 11:30 - 13:00 Lecture Hall 113

Chair: D. Agostini; Laboratoire de Biophysique Medecale Faculte de Medecine, Siemens Healthcare, CAIN, FRANCE.

Chair: A. Saraste; Turku, FINLAND.
**EANM '19**

**ORAL PRESENTATIONS**

**October 15**

**EORTC versus PERCIST 1.0 Criteria in The Evaluation Of Response To Neoadjuvant Chemotherapy in Inoperable High-grade Serous Ovarian Carcinoma. Which One Best Predicts An Optimal Interval Surgery?**


EPS-129 Predictive value of 68mTc-MAA SPECT-CT-Based dosimetry before radioembolization of liver tumors

P. D'Abadie, R. Lhomme, S. Wahnant, M. Hesse, M. Amín, P. Goffette, I. Bobath, F. Jamar, Cliniques Universitaires Saint Luc, Brussels, BELGIUM.

EPS-130 Radiation Dosimetry for 177Lu-labeled PSMA-1686

S. Urbán, I. Farkas, Z. Beneky, L. Pakusza. University of Szeged, Szeged, HUNGARY.

EPS-131 Correlation between lesion absorbed dose and relative variation of the 18F-FDG lesion uptake before the first cycle and after the sixth cycle in patients treated for metastatic castration resistant prostate cancer with 223Ra

P. Minguéz Gabaiba, A. Gómez de Iriága Pino, A. Esteban-Figureueta, M. Nevares Heiner, R. Valverde Jorge, I. Fernando Teresa, I. Rodeno Ortiz de Zunaret, Ouklátzka, Bratislava, SLOVAKIA.

EPS-132 NCMM: an internal dosimetry software using ICRP and NCI pediatric and adult computational phantoms

D. Villoing, C. Lee, National Cancer Institute at the National Institutes of Health, Rockville, MD, UNITED STATES OF AMERICA.

EPS-133 Validation of a voxel based MRT dosimetry software module for 3D slicer

D. P. Rushforth, J. Jeur, I. Murray, G. Flux. The Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM.

EPS-134 Geant4/GATE ion source implementation for internal dosimetry applications

A. Vergara Gill: CIRCT, LBM 1073, INSEAN, Université Toulouse III, Paul Sabatier, Toulouse, FRANCE, “SCK CEN”, Belgian Nuclear Research Centre, Burelart, BELGIUM.

EPS-135 Customisation of Internal Dosimetry Phantoms by Using the OpenDose SAFs Generated for the ICRP Voxel Phantom

A. Malardöra, J. McKay, “St Vincent’s” Hospital Sydney, Sydney, AUSTRALIA, “St George Hospital”, Sydney, AUSTRALIA.

EPS-136 Feasibility study of using monocryalline silicon as a dosimeter for neutron capture therapy

M. Anikin, I. Lebedev, M. Smolnikov, A. Naymushin, National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

YDF3 EANM Young Daily Forum

Tuesday, October 15, 2019, 13:00 - 14:30

**WORLD LEADING MEETING**

**FINAL PROGRAMME**

**October 15**

**EANM Young Daily Forum**

Tuesday, October 15, 2019, 11:30 - 13:00 Room 133/134

Chair: M. Dewey. Charité, Radiology, Berlin, GERMANY.

1401 CME 11 - Physics + Cardiovascular Committee: Advances in Quantitative Cardiac Imaging

Tuesday, October 15, 2019, 10:30 - 16:00 Auditorium

Chair: M. Hacker. Vienna, AUSTRIA.

Chair: S. G. Nekolla. Nuklearmedizinische Klinik, Tübingen, Munchen, GERMANY.

OP-587 Quantification in CT - Current State and Perspectives

M. Hakulinen. Kuopio University Hospital, Imaging Centre, Department of Clinical Physiology and Nuclear Medicine, Kuopio, FINLAND.

OP-588 Quantification in SPECT - Current State and Perspectives

I. Armstrong. Nuclear Medicine Department, Manchester University Hospital NHS Trust, Manchester, UNITED KINGDOM.

OP-589 Quantification in PET - Current State and Perspectives

M. Rosendahl. Rigshospitalet - Copenhagen University Hospital, Copenhagen, DENMARK.

OP-590 Response Assessment with PET/CT and PET/MR - The Nuclear Medicine Physician's Point of View

R. Delgado Bolton. San Pedro Hospital - Centre for Biomedical Research of La Rioja (CIBIR), Servicio Riojano de Salud (SERIO), Logroño - La Rioja, SPAIN.

OP-586 Staging, Prognosis and Relapse Detection - The Clinician’s Point of View

A. Ferrero. Academic Division Gynaecology and Obstetrics - University of Torna, Masanuino Hospital, Torna, ITALY.

OP-585 Staging, Prognosis and Relapse Detection with PET/CT and PET/MR - The Nuclear Medicine Physician’s Point of View

R. Delgado Bolton. San Pedro Hospital - Centre for Biomedical Research of La Rioja (CIBIR), Servicio Riojano de Salud (SERIO), Logroño - La Rioja, SPAIN.

OP-581 Quantification in SPECT - Current State and Perspectives

M. Hakulinen. Kuopio University Hospital, Imaging Centre, Department of Clinical Physiology and Nuclear Medicine, Kuopio, FINLAND.

OP-582 Quantification in PET - Current State and Perspectives

N. Aide. University Hospital, Department of Nuclear Medicine and Medical Physics, Coen, FRANCE.

OP-583 Quantification in CT - Current State and Perspectives

M. Dewey. Charité, Radiology, Berlin, GERMANY.

Joint Symposium 21 - Oncology & Theranostics Committee / ESGO: Ovarian Cancer

Tuesday, October 15, 2019, 14:30 - 16:00 Lecture Hall 311

Chair: R. C. Delgado-Bolton. Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, Servicio Riojano de Salud (SERIO), Logroño - La Rioja, SPAIN.

Chair: F. Giammarile. Vienna, AUSTRIA.

OP-577 Staging, Prognosis and Relapse Detection - The Clinician’s Point of View

A. Ferrero. Academic Division Gynaecology and Obstetrics - University of Torna, Masanuino Hospital, Torna, ITALY.

OP-578 Staging, Prognosis and Relapse Detection with PET/CT and PET/MR - The Nuclear Medicine Physician’s Point of View

R. Delgado Bolton. San Pedro Hospital - Centre for Biomedical Research of La Rioja (CIBIR), Servicio Riojano de Salud (SERIO), Logroño - La Rioja, SPAIN.

OP-579 Response Assessment with Imaging - The Clinician’s Point of View

M. Rosendahl. Rigshospitalet - Copenhagen University Hospital, Copenhagen, DENMARK.

OP-576 Quantification in CT - Current State and Perspectives

M. Dewey. Charité, Radiology, Berlin, GERMANY.

OP-571 Staging, Prognosis and Relapse Detection - The Clinician’s Point of View

A. Ferrero. Academic Division Gynaecology and Obstetrics - University of Torna, Masanuino Hospital, Torna, ITALY.

OP-572 Staging, Prognosis and Relapse Detection with PET/CT and PET/MR - The Nuclear Medicine Physician’s Point of View

R. Delgado Bolton. San Pedro Hospital - Centre for Biomedical Research of La Rioja (CIBIR), Servicio Riojano de Salud (SERIO), Logroño - La Rioja, SPAIN.
OP-610 Modeling the biological effectiveness of non-uniform dose distributions delivered from selective internal radiation therapy
B. Bednarz, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA

OP-611 Voxel-based Dosimetry in the Liver: Yttrium-90 Microspheres Radioembolization After SBRT
P. Ferreira1, P.M. Oliveira2, R. Paradis2, J.S. Garito2, P.C. Caram2, O. Pares1, D.C. Costa1; 1Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, PORTUGAL; 2Memories Health, Lisbon, PORTUGAL; 3Instituto de Telecomunicações, Instituto Superior Técnico - Universidade de Lisboa, Lisbon, PORTUGAL

OP-612 Key role of personalized dosimetry in dose adjustment for selective internal radiotherapy: retrospective study of patients treated with yttrium-90 resin microspheres
C. Subreville1, J. Pinaquy2, J. Pinaquy2, R. Parafita1; 1Champalimaud Foundation, Lisbon, PORTUGAL; 2Fac. de medicina - UVSQ, 78035, Versailles, FRANCE

OP-613 Tumor control probability in the limit of high heterogeneity applied to Y-90 radioembolization therapy
P. Roberson, D. Devaas, Y.K. DeVargas; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA

OP-614 Inter-observer variability of 18F PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization
N. Meyers, A. Jutzi, C. Bernard, R. Hustinx; University Hospital of Liège (division of nuclear medicine and oncologic imaging), Liège, BELGIUM

1407
Teaching Session 3 - Interactive Clinical Cases - Neuroimaging Committee - Neuroimaging - Before Reading PET Scans
Tuesday, October 15, 2019, 14:30 - 16:00, Lecture Hall 113
Chair: Ö. Ekmeckioglu; Nuclear Medicine Dept., Istanbul, TURKEY

E. van de Giessen, Nuclear Medicine, University of Amsterdam, Amsterdam, NETHERLANDS

OP-615 Introduction to PET/CT Acquisition of the Brain
J. Dickson, University College Hospital, Institute of Nuclear Medicine, London, UNITED KINGDOM

OP-616 Quantification for Dummies
R. Boellaard, Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, location VUMC, Amsterdam, NETHERLANDS

OP-617 MRI and CT - Abnormal Findings Relevant for PET Reading
E. van de Giessen, Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS

1408
Clinical Oncology - Parallel Session: Therapy - PSMA and More
Tuesday, October 15, 2019, 14:30 - 16:00, Lecture Hall 114
Chair: S. Carrilho Vaz; Lisbon, PORTUGAL

S. Ezziddin, Nuclear Medicine, Saarland University, Homburg, GERMANY

OP-618 177Lu PSMA-617 in advanced castration resistant prostate cancer patients: dosimetry and preliminary evaluation of IRST 185.03 phase II prospective study
M. Sansonvili1, A. Sarre2, S. Smemi1, F. Foca1, M. Celi2, M. Mingi2, J. Nicolosi2, E. Tardelli1, F. Matteucci1, F. Foca1, M. Gigante2, V. Di Iacono2, U. De Giorgi1, E. Mavriopoulou1; 1IRST, Meldola (FC), ITALY; 2S. Zerdoud, Nuclear Medicine, Saarland University, Homburg, GERMANY

OP-619 Tandem PSMA Radioligand Therapy Using Ac-225 and Lu-177 in Advanced Prostate Cancer: Safety and Efficacy
H. R. Kulkarni1, J. Zhang2, A. Singh2, A. Mishra2, C. Schuchhardt3, R. P. Baum3; 1Theranostics Center for Molecular Radiotherapy and Precison Oncology, ZentraleKlinik Bad Berka, Bad Berka, GERMANY

OP-620 Prognostic Tumor Markers in Men With Prostate Cancer Undergoing 177Lu/Lu-PSMA-617 Treatment
A. Yordanova1, P. Linden2, S. Hauser3, G. Feldmann1, A. Ferrar2, M. Eckert1, S. Hollederer1, H. Ahmaddifar2; 1University Hospital Bonn, Bonn, GERMANY; 2Technical University of Munich, Munich, GERMANY

OP-621 Response evaluation of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH in 100 patients
H. Ratheke1, F. Holland-Letz2, W. Mier1, P. Fleischig3, E. Mavriopoulou1, M. Roehrich1, U. De Giorgi1; 1IRST, Meldola (FC), ITALY; 2Rochester University Hospital, School of Medicine, Rochester, NEW YORK, USA; 3University Hospital Bonn, Bonn, GERMANY

OP-622 Preliminary Evaluation of Tumor Uptake and Laboratory Parameters After a Single Dose of 177Lu-RM2 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
R. Fernández1, V. Kramer1, A. Hurtado de Alderama1, J. Flores2, H. Amarat2; 1Center for Nuclear Medicine & PET/CT, Positronm, Santiago, CHILE; 2Positronpharma SA, Santiago, CHILE

OP-623 Efficacy of radium 223 in radioactive iodine refractory bone metastases from thyroid cancer: Preliminary results of a single arm Phase II trial
S. Zerdoud1, D. Dearden1, A. Mailard2, J. Birger3; 1Institut Hassan II, Marrakech, MOROCCO; 2University of Kaiserslautern, Kaiserslautern, GERMANY; 3Department of Nuclear Medicine, Université Paris-Sud, Versailles, FRANCE

OP-624 Novel CT guided 188-ribenium Brachytherapy Device For Local Primary And Secondary Lung Malignancies
H. Belhadj Tahar1, J. Chen1, J. Zhao1, J. Song1, M. Ouari2, C. Li3, X. Gu4, G. Yang4, Y. Gao5, 1APRFAMED (French Association of Medical Research Advancement), Toulouse, FRANCE; 2Shanghai East Hospital, School of Medicine, Shanghai East Hospital (China), Shanghai, CHINA

OP-625 First Clinical Experience using 177Lu-Zedetronate for the Treatment of Skeletal Metastases in Breast Cancer: 68Ga-NODAGA-ZOL PET/CT imaging for patients eligibility and follow-up
F. Novruzov1, J. Alyiev1, S. Rahimzade2, R. Shukurov3, J. Smeele4, L. Melmetegyl5, I. Zaalikhanyev6, M. Mehdi; 1Department of Nuclear Medicine, National Centre Of Oncology, Baku, AZERBAIJAN; 2Department of General Surgery, National Centre Of Oncology, Baku, AZERBAIJAN; 3Department of Woman Health, National Centre Of Oncology, Baku, AZERBAIJAN; 4Isotop Technologies Garching GmbH, Garching, GERMANY; 5Department of Medical Oncology, Central Clinical Hospital, Baku, AZERBAIJAN
Prognostic utility of $^{18}$F-NaF PET/CT imaging for fractures in patients with fibrous dysplasia of bone
G. Z. Papadakis, G. C. Maniki, A. H. Karanantza, K. Mavri, U. Bagci, P. Paerement, M. T. Collin, A. Boyer. Department of Radiology, Medical School, University of Crete, Heraklion, GREECE; Department of Bone and Joint Surgery, Medical School, University of Crete, Heraklion, GREECE; Department of Nuclear Medicine and Molecular Imaging, University of Crete, Heraklion, GREECE; Department of Nuclear Medicine, University of Crete, Heraklion, GREECE; Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria di Parma, Parma, ITALY.

OP-629

Prognostic value of NaF-PET/CT in non-instrumental postero-lateral lumbar fusion
C. Constantinescu, A. Pirz, O. Gerke, M. Andersen, P. Haniel-Carlsten, M. Boyer. Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK; Department of Clinical Neurology, University of Southern Denmark, Odense, DENMARK; Department of Spine Surgery and Research, Nyhøj, Odense, DENMARK; Department of Nuclear Medicine and Molecular Imaging, University of Southern Denmark, Odense, DENMARK.

OP-630

The role of $^{18}$F-NaF PET/CT imaging in the assessment of patients undergoing spinal fusion surgery

OP-631

Effect of adenosine infusion on renal blood flow (RBF) during stress Rb-82 PET/CT
G. Allenbach, N. Testart, M. Meyer, N. Lalonde. Greater Nuclear Medicine - Parallel Session: New Vascular Imaging, University Hospital of Basel, Department of Orthopaedic Surgery, Basel, SWITZERLAND.

OP-632

Tailoring the sampling time of single-sample GFR according to renal function: is the proposal in the British Nuclear Medicine Society GFR guidelines practical and supported by evidence?

OP-633

Utility Of The Isotopic Renogram And SPECT/CT In The Urinary Leaks Diagnosis And Management In Patients With Renal Transplantation
J. Gómez Hidalgo, M. Ruiz Gómez, P. Turbay Eljach, N. Álvarez Mena, A. Sanz Esteban, M. Alonso Rodríguez, C. Gamallo Còhemin, B. Pérez López, M. González Soto, B. Rovira Pérez. Hospital Clinico Universitario de Valladolid, Medicina Nuclear, Valladolid, SPAIN.

OP-634

Quantification of pulmonary function using hybrid SPECT/CT in normal subjects
C. C. M. Fernandez, E. Silva, S. Rodriguez, A. Damian, R. Fernanda. Clinica Hospital, University of the Republic, Montevideo, URUGUAY.

OP-635

The Role of Tc-99m MAA SPECT-CT in Evaluation of Lung Lobar Perfusion in Patients with Chronic Obstructive Pulmonary Disease (COPD) Prior to Lung Volume Reduction Surgery (LVRS)
E. Trahar, E. Nowosinska, N. Szet, K. Loa, G. Sotropasou, A. Bilson, T. O'Shaughnessy, R. Williams, D. Walker, M. Burniston, Barts Health NHS Trust, London, UNITED KINGDOM.

OP-636
Oral Presentations

EANM'19

Tuesday, October 15, 2019, 14:30 - 16:00
Room 133/134

Oncology - Mixed Pickles

164 165

Tuesday, October 15, 2019, 14:30 - 16:00 Room 133/134
Oncology - Mixed Pickles

EPS-138
Is it reliable to perform radioguided surgery with Magnetic Resonance Imaging after neoadjuvant chemotherapy in patients with breast cancer?

EPS-139
PSMA Expression according to different Prostate Cancer Bone Metastases subtypes
P. i. d. P. Soeiro, R. Silvã, G. Catarost, J. Resiás de Lima,1,2 Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,1 Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL,2 Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EPS-141
Risk stratification of significant prostate cancer by 18F-choline PET/MRI is more accurate and cost-effective than multi parameter MRI alone
M. R. Pierf, M. S. Davenport, C. Barnett, J. L. Montgomery, E. Lee, K. X. Shao, L. P. Kuni, B. Denton1, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,2 RTI Health Solutions, Research Triangle Park, NC, UNITED STATES OF AMERICA,3 Department of Information and Statistics, Chungnam National University, Daejon, KOREA, REPUBLIC OF.

EPS-143
Prognostic role of the Total Metabolic Tumor Volume (TMTV) and the Total Lesion Glycolysis (TLG) in the definition of clinical outcome and response to therapy in Hodgkin's Lymphoma
M. Spallino1, M. Cuzzocrea2, E. De Pinto1, S. Bolis1, L. Casadei1, C. Landoni1, L. Guerra1, Nuclear Medicine Department, University of Milan Bicocca, Milan, ITALY,2 ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,3 Medical Physics Department, San Gerardo Hospital ASST, Milan, ITALY,4 Hematology Department, San Gerardo Hospital ASST, Monza, ITALY,5 Nuclear Medicine Department, San Gerardo Hospital ASST, Monza, ITALY.

EPS-144
Bone Marrow Evaluation in Initial Staging Of Follicular Lymphoma. 18F-FDG PET/CT Versus Bone Marrow Biopsy
M. Cortes Romera1, S. Mendes-da-Vitória1, A. Pilarma-Murúa2, A. Sabate-Llobes3, F. Climent-Estellier4, É. Lleras-Tello5, E. Gonzales-Barcó6, C. Gómez-Camano6, Unidad PET/CT (IDI)- Department of Nuclear Medicine, Hospital U. de Belvège-IDEBEL7, L'Hôpital De Llobregat (Barcelona), SPAIN,1 Department of Hematology, C. Hospital Duran i Reynals-IDIBELL8, L'Hôpital De Llobregat (Barcelona), SPAIN,2 Department of Pathology, Hospital U. de Belvège-IDEBEL7, L'Hôpital De Llobregat (Barcelona), SPAIN.

EPS-145
Impact of interim FDG PET/CT on Hodgkin Lymphoma adult patients at King Hussein Cancer Center (KHCC)
A. N. K. Al-Ibraheem1, F. Anwer, A. Khalaf2, King Hussein Cancer Center, Amman, JORDAN.

EPS-146
Usefulness of gradient tree boosting for predicting histological subtype and EGFRmutation status of non-small cell lung cancer on 18F-FDG PET/CT
S. Koyama1, M. Wakisaka2, H. Iida1, Y. Nakamutsu1, K. Yoshiba1, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN.

EPS-147
AI-based Detection of Lung Lesions in FDG-PET/CT From Lung Cancer Patients
L. Edenbrandt1, R. Kato2, S. Saitoh2, J. Uilen3, O. Enqvist2, P. Bomel4, Sahlgrenska University Hospital, Gothenburg, SWEDEN,5 Euphrasian, Mannheim, SWEDEN,6 Department of Electrical Engineering, Chalmers University of Technology, Gothenburg, SWEDEN.

EPS-148
Efficacy and toxicity profile of low dose 177 Lutetium- Ethylenediamine tetra methane phosphate (177Lu-EDTMP) for bone pain palliation in patients with skeletal metastases
A. S. O. Halasani1, N. Pandit1, M. Pannaszamy1, JIPMER, Pondicherry, INDIA.

EPS-149
Design of a Bimodal Ligand of Neurotensin Receptor 1 for 68 Ga-PET Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer
E. Renard1, P. A. Danger1, C. Portal2, F. Denat1, M. Pignon2, V. Gonzalvez2,1 Institut de Chimie Moléculaire de l'Université de Bourgogne, Université Bourgogne Franche Comête, Dijon, FRANCE,2 Kair Lus, Nancy, FRANCE,3 Edinburgh Molecular Imaging, Edinburgh, UNITED KINGDOM,4 Laboratoire d'Imagerie Moleculaire Postonise, Sorbonne Université, Paris, FRANCE.

EPS-150
PSMA-targeting hybrid tracers based on heterobifunctional cyanine spacer moieties - tuning the pharmacokinetic properties and exploring dye interaction with PSMA
A. Hensbergen1, T. Buckle2, D. M. van Willigen2, M. Schottelius1, M. M. Welling1, J. F. van der Wijl1, H. G. van der Roel3, T. Maurer4, H. W. W. B. Leuven1, Leiden University Medical Center, Leiden, NETHERLANDS,2 Technische Universität München, Garching, GERMANY,3 The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,4 Marinke Klinik, Hamburg, GERMANY.

EPS-152
Impact of Ga-68 PSMA PET/CT on diagnosis and staging of hepatocellular carcinoma
C. Gundogan1, M. Eguil2, M. S. Cakin2, A. Koca3, N. A. Krikiesmez1, T. E. Cermik1, University of Health Sciences, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY,4 University of Health Sciences, Istanbul Training and Research Hospital, Clinic of Radiology, Istanbul, TURKEY.

EPS-153
Texture analysis of 18F-choline uptake in prostate gland of patients with untreated cancer: relationship with the Risk Assessment Score, additional prostate biopsy findings and patient's outcome
M. Cuzzocrea1, L. Florimont1, V. Longari2, G. Santaguida3, E. Orunesu4, M. Castellani5, Nuclear Medicine Department, Fondazione RRC Ca Grandi Ospedale Maggiore Policlinico, Milan, ITALY,6 Università degli Studi di Milano, Milan, ITALY.

EPS-155
CME 12 - Paediatrics Committee
Response Evaluation of Paediatric Sarcomas
Chair: L. Borgwardt; Clin Clinical Phys. Nuclear Medicine & PET. Ag Hospitalet, Copenhagen. Univ. Hosp., COPENHAGEN, DENMARK.
Chair: N. Jehanno; Imaging Department, Nuclear Medicine, PARIS, FRANCE.

OP-641
Response of Paediatric Sarcomas - Does it Matter?
S. Bielack; Klinikum der Landeshauptstadt Stuttgart gKfo - Olgospital, Department of Paediatric Oncology, Stuttgart, GERMANY.

OP-642
Radiological Response Evaluation of Paediatric Sarcomas
T. von Kalle; Klinikum der Landeshauptstadt Stuttgart gKfo - Olgospital, Department of Paediatric Radiology. Stuttgart, GERMANY.

OP-643
Response Assessment in Paediatric Sarcomas - Value of Nuclear Medicine Techniques
M. Parisi; Seattle Children's Hospital, Department of Paediatric Radiology and Nuclear Medicine, Seattle.
1502
Joint Symposium 23 - Oncology & Theranostics Committee / ENETS: Theranostic in NEN - What is New?
Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 311
Chair: J. Kunikowska, Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND.
Chair: M. Pavel, Erlangen, GERMANY.

OP-644 Overview on NEN Treatment - Current Options and Clinical Needs
M. Pavel, Department of Medicine I Division of Endocrinology, Friedrich Alexander University Erlangen – Nürnberg, Erlangen, GERMANY.

OP-645 Overview on NEN Diagnosis
V. Ambrosini, University of Bologna, S.Orsola-Malpighi Hospital, Department of Experimental Diagnostic and Specialized Medicine, Nuclear Medicine, Bologna, ITALY.

OP-646 Update on PRRT - When and How
L. Bodei, Memorial Sloan Kettering Cancer Center, Department of Radiology, Targeted Radiouclide Therapy Molecular Imaging and Therapy Service, New York.

OP-647 New Treatment Options
D. Wild, University Hospital Basel, Division of Nuclear Medicine, Basel, SWITZERLAND.

OP-648 Discussion

1503
Joint Symposium 24 - Translational and Molecular Imaging Therapy + Oncology & Theranostics Committee / EAU / ERUS: Image Guided Therapies for Prostate Cancer
Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 312
Chair: S. Carrilho Vaz, Lisbon, PORTUGAL.
Chair: L. Evangelista, Medica Nuclear, Istituto Oncologico Veneto I R.C.C.S., Padua, ITALY.

OP-649 Hardware Development for Targeted Prostate Cancer Therapies
P. Collamatii, Istituto Nazionale di Fisica Nucleare, Department of Physics, Rome, ITALY.

OP-650 Molecular Targeting Strategies for Salvage Prostate Cancer Surgery
T. Maurer, University of Hamburg-Eppendorf (UAE), Mamm-Klinik Prostate Cancer Center, Hamburg, GERMANY.

OP-651 Focal Therapy for Prostate Cancer
J. Walz, Institut Paoli-Calmettes Cancer Center, Department of Urology, Marseille, FRANCE.

1504
CTE 6 - Technologist Committee: Parathyroid Imaging
Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 117
Chair: C. Pestean, Nuclear Medicine Department, Institute of Oncology, Cluj, ROMANIA.
Chair: S. Rep, Department of Nuclear Medicine, University Medical Centre Ljubljana, LJUBLJANA, SLOVENIA.

OP-652 Comparison of [11 C]Methionine PET-CT Imaging in Hyperparathyroidism
L. Lezaic, University Medical Centre, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

G. Pepe, Humanitas Research Hospital, Department of Nuclear Medicine, Milan, ITALY.

OP-654a The Role of a Technologist in the Preparation of Acquisition Protocols and the Processing of Image Data in Nuclear Medicine Parathyroid Imaging
S. Rep, University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

OP-654b Molecular imaging characterization of Distraction Osteogenesis model
L. Balasse, F. Rasere, A. Moyer, S. Fernandez, P. Gamir, G. Hache, M. Pithoux, B. Guillet, Aix Marseille Univ, CNR, CERMED, Marseille, FRANCE. Aix Marseille Univ, CNRS, ISM, Marseille, FRANCE. Aix Marseille Univ, APHM, CNRS, ISM, Sainte-Marguerite Hospital, Institute for Locomotion, Department of Orthopedics and Traumatology, Marseille, FRANCE. Aix Marseille Univ, CERMED, Marseille, FRANCE.

OP-655 124I-trastuzumab for noninvasive HER2 detection: From patient-derived xenograft models to gastric cancer PET imaging

OP-656 Characterization Of The Apolipoprotein E-deficient Rat As Novel Model For Atherosclerosis Imaging

1505
M2M - Parallel Session: Preclinical Models in Translational Science
Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 111
Chair: W. Deutcher-Conrad, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Heinrich-Zentrum Dresden-Rossendorf, Leipzig, GERMANY.
Chair: S. A. M. van Lith, Radionuclide, Nijmegen, NETHERLANDS.

OP-657 Prospective Theranostic Treatment Planning for Patient-Specific Low-Dose Molecules Targeted Radiotherapy to Enhance Immunotherapeutic Response

OP-660 PET imaging of the glucagon receptor in non-human primate

OP-658 Systemic effects of SGLT2 Inhibition in healthy mice
B. K. Geist, T. Balzer, B. Bugaychik, E. Kliebermaier, L. Neis, A. Pilinger, S. Rasch, H. Ingale, A. Zacher, M. Hacker; Medical University Vienna, Vienna, AUSTRIA.
OP-601 The Potential of PET/CT imaging as a clinical evidence method for the early detection of Duchenne muscular dystrophy (DMD) in female carriers: a study in genetically modified pigs M. J. Lindner, L. M. Fontenay, B. Kelller, A. Bollenbacher, E. Kenter, A. Staud, S. Nekollak, P. Bartienen, E. Wolf, S. Ziegler, 1 Department of Nuclear Medicine, University Hospital Munich, Munich, GERMANY; 2Gene Center and Department of Biochemistry, Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, GERMANY, 1Department of Nuclear Medicine at Technische Universität München, Munich, GERMANY.

OP-602 Phosphatidylserine phospholipid fractionation by function at the blood-brain barrier with [111In]MC2SP PET in non-human primates L. Garcia Varela, W. M. Anf, D. Vallez Garcia, T. Kasu, C. T. Cho, S. T. Hashima, T. Taga, P. H. Elsinga, H. Tsukada, N. A. Colabufo, R. A. J. D. Dieker, A. van Waarder, T. Toyohara, R. Boeddinghaus, G. Luu, 1Department of Nuclear Medicine, Groningen, NETHERLANDS; 2Central Research Laboratory, Hamamatsu Photonics KK, Hamamatsu, JAPAN, 3Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, 4University of Bas Aldo, Mori, Bari, ITALY.

OP-603 A Study of Radiomic Features Robustness for Ga-DOTATOC PET/CT in Neuroendocrine Tumors V. Liberini, E. Galli, O. Rampado, B. De Sante, B. Dionisi, F. C. Pietro, M. Finesi, M. Bello, G. Bisi, F. Molinari, D. Deardres, 1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY; 2Medical Physics Unit, AOU Città della Salute and della Scienza, Turin, ITALY, 3Biokart, Department of Electronics and Telecommunications, Politecnico di Torino, Turin, ITALY.

OP-604 Multi-level multi-modality fusion radiomics: application to PET and CT imaging for improved prognostication of head and neck cancer W. Lv, S. Ashrafina 1, J. Mal, L. Lu, A. Rahimn 1, 1School of Biomedical Engineering, Southern Medical University, Guangzhou, CHINA; 2Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, CANADA, 3Department of Electrical & Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 4Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 5Of Radiology and Physics, University of British Columbia, Vancouver, MD, CANADA.

OP-605 Comparison of machine learning-driven lesion classifiers in PET/MI images of prostate cancer patients L. Papp, C. P. Speijker, M. Graaa, T. Beyer, M. Hacker 1, SMP team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, 2Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, AUSTRIA, 3Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

OP-606 Multi-level multi-modality fusion radiomics: application to PET and CT imaging for improved prognostication of head and neck cancer W. Lv, S. Ashrafina 1, J. Mal, L. Lu, A. Rahimn 1, 1School of Biomedical Engineering, Southern Medical University, Guangzhou, CHINA; 2Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, CANADA, 3Department of Electrical & Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 4Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, 5Departments of Radiology and Physics, University of British Columbia, Vancouver, MD, CANADA.

OP-607 Harmonization strategies based on ComBat for multicentric radiomic studies R. Da-ano 1, F. Lucuar, M. Vallieres, P. Bonaffin, M. Massari, M. Merago, C. Reenhof, S. Schaik 1, D. Visviki 1, M. Hatt 1, LatIM, INSERM, IUMR 1101, Univ. Burgundy, Brest, FRANCE, 2Radiological Oncology department, University Hospital Brest, FRANCE, 3Department of Radiology, McGill University Health Centre (MUHC), Montreal, QC, CANADA, 4Department of Radiation Oncology, Institut de Cancérologie de lOuest, Nantes, FRANCE.

OP-608 Experimental Multicenter And Multivendor Evaluation Of Pet Radiomic Features Performance Using 3D Printed Phantom Inserts E. Pfaehler 1, J. Van Sluys, B. B. J. Meerman, P. Van Duyven, R. C. M. Berendsen, F. H. P. Van Den Wall, R. Boeddinghaus 1, University Medical Center Groningen, Groningen, NETHERLANDS, 2Zuidland Medical Center, Heerlen, NETHERLANDS, 3Leiden University Center, Leiden, NETHERLANDS, 4Y. V. Medical Center, Amsterdam, NETHERLANDS.

OP-609 Adding the Temporal Domain to PET Radiomic Features W. A. Noortman 1, D. Vreene, C. H. Stump, J. Balzoti 1, T. W. H. Meijer, 1, F. de Geus-Oei, 2, F. H. P. Van Sluys 1, 1Leiden University Medical Center, Leiden, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS, 3Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-610 Dose distribution radiomics: a new paradigm for assessment of radioligand therapy X. Hou, W. Lv, L. J. Buregard 1, A. Cellier, A. Rahimn 1, 1Radiology Department, University of British Columbia, Vancouver, BC, CANADA, 2Department of Biomedical Engineering, Southern Medical University, Guangzhou, CHINA, 3Department of Medical Imaging and Oncology Division of Research Center, CHU de Quebec – Universite Laval, Quebec, QC, CANADA, 4Institute of Radiology and Nuclear Medicine and Cancer Research Center, Quebec, QC, CANADA, 5Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-611 Teaching Session 6 - Interactive Clinical Cases - Radiological Aspects of Abdominal Anatomy Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 113 Chair: T. Lynch, Belfast, UNITED KINGDOM.


OP-613 Impact of personalized treatment in HCC patients treated with resin 90Y-microspheres: preliminary results of a randomized clinical trial L. Strigari 1, S. Unguida, S. Rent, A. Aroninazz 1, G. Pizzl, G. Vallet 1, G. Lacaccia 1, S. De Nicolao 1, R. Scifo 1, Regione Elba Institute IRCC, Rome, ITALY, 2St. Oronol Malpighi University Hospital, Bologna, ITALY.

OP-678 Prognostic value of FDG-PET/CT in recurrent/refractory CNS lymphoma receiving rituximab-based therapies

S. Krebs, J. Walla, I. Melinghoff, C. Grohmann, H. Schoder. Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-678 Prognostic value of FDG-PET/CT in recurrent/refractory CNS lymphoma receiving rituximab-based therapies

S. Krebs, J. Walla, I. Melinghoff, C. Grohmann, H. Schoder. Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-680 HCC Radioembolization with Yttrium-90 Polymer Beads (SIR-Spheres) in MAA SPECT/CT based dosimetry correlation with survival and tumor response


1509 Neuroradiology - Parallel Session: Brain Tumours

Tuesday, October 15, 2019, 16:30 - 18:00 Lecture Hall 115

Chair: L. Albert, Department of Nuclear Medicine, Munich, GERMANY.

Chair: L. Law, Dept of Clinical Physiology, Nuclear Medicine, and PET, Section SWS, COPENHAGEN, DENMARK.

OP-681 Prognostic value of dynamic 

F-FET PET in oligodendrogliomas

F. J. Vettermann, M. Unterrainer, B. Suchorska, J. Hemu, P Bartenstein, J. Tonn, N. L Albert; Ludwig-Maximilians-University, Munich, GERMANY.

OP-682 Prognostic value of FDG-PET/CT in recurrent/refractory CNS lymphoma receiving rituximab-based therapies

S. Krebs, J. Walla, I. Melinghoff, C. Grohmann, H. Schoder. Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-682 Dynamic 

Ga-DOTATATE PET/MRI and Patlak analysis for enhanced diagnosis of intracranial meningioma


OP-682 Determining the optimal segmentation method for assessing metabolic tumor volume in FDG-PET/CT scans in relapsed/refractory classical Hodgkin lymphoma

D. Jriesen, G. J. C. Zwetsenbreijer, J. S. Eerink, M. J. Keenen, G. S. Hoekstra, J. M. Zijlstra, R. Boelensd; 1Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LUMC (Lymphoma and Myeloma Center), Amsterdam, NETHERLANDS, 2Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 3Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NETHERLANDS.

OP-683 Biocumulative-volume in standards and early summation "F-FET PET images distinctly exceed contrast-enhancement patients with IDH-wildtype glioma"

M. Unterrainer; K. von Rohr, L. Kaiser, C. Dierkmann, V. Jürgens, H. P. Bartenstein, M. Niyaz, J. Tonn, N. L. Albert; University of Munich, Munich, GERMANY.

OP-684 The Role of "C-methionine PET in Patients with Negative/Undetermined Diffusion-Weighted Magnetic Resonance Imaging (DWI) Correlation with Histology and Molecular Biomarkers in Operated Glioma

A. Castello, A. Buzi, M. Avat, M. Rossi, F. Persina, B. Fernandez, M. Gnanfieldi, E. Mazzeotti, P. Navarria, L. Beini, P. Lohu, C. Le, Nuclear Medicine, Humanitas Clinical and Research Hospital, IRCCS, Rozzano (MI), ITALY; 2Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, ITALY; Oncological Neurosurgery, Humanitas Clinical and Research Hospital – IRCCS, Rozzano (MI), ITALY; Pathology, Humanitas Clinical and Research Hospital, Rozzano (MI), ITALY; Nuclear Medicine, Humanitas Clinical and Research Hospital, Rozzano (MI), ITALY; Nuclear Medicine, Humanitas Clinical and Research Hospital, Rozzano (MI), ITALY.

OP-684 Molecular-genetic and histologic differentiation of gliomas based on characteristics 

F-FET PET pharmacokinetics

L. Kaiser*, M. Unterrainer*, A. Holzgreve*, M. Grosch*, S. A. Altindag*, E. Millo*, A. Geweis*, J. Brosch*, B. Suchorska, J. C. Tonn*, S. Ziegler*, P. Bartenstein*, N. L. Albert*, G. Böning*, 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 2Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, 3Department of Neurology, University Hospital, LMU Munich, Munich, GERMANY.

OP-685 Dynamic 

Ga-DOTATATE PET/MRI and Patlak analysis for enhanced diagnosis of intracranial meningioma


OP-685 Prognostic role of baseline FDG-PET in patients with Richter Syndrome


OP-685 Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients with Richter Syndrome

R. Nakajima; A. J. Moskovitz, L. Michaels, A. Mauguen, H. Schödel; 1Memorial Sloan Kettering Cancer Center, Department of Radiology, Molecular Imaging and Therapy Service, New York, NY, UNITED STATES OF AMERICA, 2Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, New York, NY, UNITED STATES OF AMERICA, 3Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biomathematics, New York, NY, UNITED STATES OF AMERICA.

OP-686 Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly Hodgkin lymphoma

A. Mozolecki, D. Albanese, J. Dondi, M. Banacchia, A. Diamant, E. Ceravedda, M. Gazzini, P. Bellini, F. Bertagnoni, R. Guibbins; 1Università degli Studi di Brescia, Brescia, ITALY, 2Istituto Scientifico Civile di Brescia, Brescia, ITALY.

OP-686 Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly Hodgkin lymphoma

A. Mozolecki, D. Albanese, J. Dondi, M. Banacchia, A. Diamant, E. Ceravedda, M. Gazzini, P. Bellini, F. Bertagnoni, R. Guibbins; 1Università degli Studi di Brescia, Brescia, ITALY, 2Istituto Scientifico Civile di Brescia, Brescia, ITALY.

OP-689 Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients

Y. E Silva*, J. Reidering*, D. Ciavol*, M. Oehser*, J. Cones*, A. Goeth*, C. Taboare-Vidal*, Unicancer Georges François Leclerc Cancer Center, Dijon, DIJON, 1University Hospital Francois Mitterrand, Dijon, DIJON, 2Institut Universitaire du Cancer-Oncopole, Toulouse, FRANCE.

OP-689 Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients

Y. E Silva*, J. Reidering*, D. Ciavol*, M. Oehser*, J. Cones*, A. Goeth*, C. Taboare-Vidal*, Unicancer Georges François Leclerc Cancer Center, Dijon, DIJON, 1University Hospital Francois Mitterrand, Dijon, DIJON, 2Institut Universitaire du Cancer-Oncopole, Toulouse, FRANCE.

OP-689 Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients

Y. E Silva*, J. Reidering*, D. Ciavol*, M. Oehser*, J. Cones*, A. Goeth*, C. Taboare-Vidal*, Unicancer Georges François Leclerc Cancer Center, Dijon, DIJON, 1University Hospital Francois Mitterrand, Dijon, DIJON, 2Institut Universitaire du Cancer-Oncopole, Toulouse, FRANCE.

OP-690 Quantitative Assessment of FDG-PET Images in Patients with Hodgkin Lymphoma: Is It Affected by Contrast-Enhanced CT Attenuation Correction?

C. Volin, J. Meintel*, R. Boelens, G. Kuhnt**, M. Dieten**, P. Bornschann, A. Dietze**, C. Kibe*; 1University Hospital of Cologne, Cologne, GERMANY, 2University Medical Centre, Amsterdam, NETHERLANDS.
Effect of intramyocardial injection of erythropoietin stimulated autologous bone marrow cells on myocardial perfusion in patients with chronic myocardial ischemia - SPECT 99mTc-MIBI study

S. Minin, A. Fomichev, N. Nikitin, A. Chernyavskiy; Meshchanskii National Medical Research Center, Novosibirsk, RUSSIAN FEDERATION.

Detection of left ventricular dysynchrony in hypertensive patients using phase dysynchrony analysis in gated myocardial perfusion SPECT

S. Fatima, S. T. Biu, M. A. Saed, A. Ammar, K. B. M., N. Ahmed, Z. Chegah; Nuclear Medicine, Oncologic & Radiosurgery Institute (NORI), Islamabad, PAKISTAN; Gurnaq General Hospital, Al-Karajiy, IRAQ, ARABIA.

Effect of intramyocardial injection of erythropoietin stimulated autologous bone marrow cells on myocardial perfusion in patients with chronic myocardial ischemia - SPECT 99mTc-MIBI study

S. Minin, A. Fomichev, N. Nikitin, A. Chernyavskiy; Meshchanskii National Medical Research Center, Novosibirsk, RUSSIAN FEDERATION.

Detected left ventricular dysynchrony in hypertensive patients using phase dysynchrony analysis in gated myocardial perfusion SPECT

S. Fatima, S. T. Biu, M. A. Saed, A. Ammar, K. B. M., N. Ahmed, Z. Chegah; Nuclear Medicine, Oncologic & Radiosurgery Institute (NORI), Islamabad, PAKISTAN; Gurnaq General Hospital, Al-Karajiy, IRAQ, ARABIA.

The value of stress gated blood pool SPECT in prediction of early postoperative period course in patients with ischemic cardiomyopathy

V. Shipulin, K. Zavadovsky, S. Andreiev, A. Piyalkin, V. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

Relationship between myocardial cardiac fibrosis and myocardial denervation in non-ischemic idiopathic dilated cardiomyopathy


Assessment of chemotherapy-induced systolic and diastolic myocardial impairments using gated perfusion SPECT

A. A. Ansheles, F. A. Pus, E. J. Vasilchenko, I. V. Sergyanko, V. B. Sergyanko, National Medical Research Center of Cardiology, Moscow, RUSSIAN FEDERATION.

Correlation Between Left Ventricular Mechanical Dysynchrony And 18F-Metabolitybenzyguanidine Uptake In Pediatric Heart Disease Patients

M. Ota, Y. Kasamamura, K. Omo, Y. Tsubomota; Gifu Prefectural General Medical Center, Gifu, JAPAN; Nara Medical University Hospital, Kashihara, JAPAN; Awano Children’s Clinic, Gifu, JAPAN.

Potential of imaging modalities as gatekeeper in endomyocardial biopsy in patients suspected of cardiac sarcoidosis: Ga-67 SPECT vs F-18 FDG PET

K. Takamani, T. Takeda, Tohoku University Hospital, Sendai, JAPAN.

Mechanical Dyssynchrony And Correlation Between Left Ventricular Mechanical Dysynchrony And 18F-Metabolitybenzyguanidine Uptake In Pediatric Heart Disease Patients

M. Ota, Y. Kasamamura, K. Omo, Y. Tsubomota; Gifu Prefectural General Medical Center, Gifu, JAPAN; Nara Medical University Hospital, Kashihara, JAPAN; Awano Children’s Clinic, Gifu, JAPAN.

The value of stress gated blood pool SPECT in prediction of early postoperative period course in patients with ischemic cardiomyopathy

V. Shipulin, K. Zavadovsky, S. Andreiev, A. Piyalkin, V. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

Evaluation of F-18-Flutemetamol in hybrid PET-imaging of cardiac amyloidosis: A pilot study

A. Kessler, M. Papathanasou, A. Brainman, D. Kersten, P. Luecke, G. Weber, L. Campione, T. Hagemaker, P. Rauchfuss, K. Hermann, C. Rischpler; Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY; Department of Cardiology, University Hospital Essen, Essen, GERMANY; Department of Hematology, University Hospital Essen, Essen, GERMANY; Department of Neurology, University Hospital Essen, Essen, GERMANY.

The value of gated blood-pool SPECT-derived cardiac dysynchrony in the cardiac resynchronization therapy response prediction

V. Saushkin, A. Mishkhina, V. Shipulin, A. Machula, D. Lebedev, K. Zavadovsky; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

Evaluation of F-18-Flutemetamol in hybrid PET-imaging of cardiac amyloidosis: A pilot study

A. Kessler, M. Papathanasou, A. Brainman, D. Kersten, P. Luecke, G. Weber, L. Campione, T. Hagemaker, P. Rauchfuss, K. Hermann, C. Rischpler; Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY; Department of Cardiology, University Hospital Essen, Essen, GERMANY; Department of Hematology, University Hospital Essen, Essen, GERMANY; Department of Neurology, University Hospital Essen, Essen, GERMANY.

Potential of imaging modalities as gatekeeper in endomyocardial biopsy in patients suspected of cardiac sarcoidosis: Ga-67 SPECT vs F-18 FDG PET

K. Takamani, T. Takeda, Tohoku University Hospital, Sendai, JAPAN.

The value of gated blood-pool SPECT-derived cardiac dysynchrony in the cardiac resynchronization therapy response prediction

V. Saushkin, A. Mishkhina, V. Shipulin, A. Machula, D. Lebedev, K. Zavadovsky; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

Evaluation of F-18-Flutemetamol in hybrid PET-imaging of cardiac amyloidosis: A pilot study

A. Kessler, M. Papathanasou, A. Brainman, D. Kersten, P. Luecke, G. Weber, L. Campione, T. Hagemaker, P. Rauchfuss, K. Hermann, C. Rischpler; Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY; Department of Cardiology, University Hospital Essen, Essen, GERMANY; Department of Hematology, University Hospital Essen, Essen, GERMANY; Department of Neurology, University Hospital Essen, Essen, GERMANY.

The value of stress gated blood pool SPECT in prediction of early postoperative period course in patients with ischemic cardiomyopathy

V. Shipulin, K. Zavadovsky, S. Andreiev, A. Piyalkin, V. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

Comparison between 99mTc-sestamibi/123I-metiodobenzylguanidine Uptake In Pediatric Heart Disease Patients

M. Ota, Y. Kasamamura, K. Omo, Y. Tsubomota; Gifu Prefectural General Medical Center, Gifu, JAPAN; Nara Medical University Hospital, Kashihara, JAPAN; Awano Children’s Clinic, Gifu, JAPAN.

Relationship between myocardial cardiac fibrosis and myocardial denervation in non-ischemic idiopathic dilated cardiomyopathy


Effect of intramyocardial injection of erythropoietin stimulated autologous bone marrow cells on myocardial perfusion in patients with chronic myocardial ischemia - SPECT 99mTc-MIBI study

S. Minin, A. Fomichev, N. Nikitin, A. Chernyavskiy; Meshchanskii National Medical Research Center, Novosibirsk, RUSSIAN FEDERATION.

Mechanical Dyssynchrony And Correlation Between Left Ventricular Mechanical Dysynchrony And 18F-Metabolitybenzyguanidine Uptake In Pediatric Heart Disease Patients

M. Ota, Y. Kasamamura, K. Omo, Y. Tsubomota; Gifu Prefectural General Medical Center, Gifu, JAPAN; Nara Medical University Hospital, Kashihara, JAPAN; Awano Children’s Clinic, Gifu, JAPAN.

Detection of left ventricular dys synchrony in hypertensive patients using phase dysynchrony analysis in gated myocardial perfusion SPECT

S. Fatima, S. T. Biu, M. A. Saed, A. Ammar, K. B. M., N. Ahmed, Z. Chegah; Nuclear Medicine, Oncologic & Radiosurgery Institute (NORI), Islamabad, PAKISTAN; Gurnaq General Hospital, Al-Karajiy, IRAQ, ARABIA.

The value of stress gated blood pool SPECT in prediction of early postoperative period course in patients with ischemic cardiomyopathy

V. Shipulin, K. Zavadovsky, S. Andreiev, A. Piyalkin, V. Shipulin; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.
Novel radiolabelled neurotensin analogues containing silylated amino acid for improved neurotensin receptor-1 (NTS1) targeting.

E. von Guggenberg, 1 E. de Blois, 2 E. Garnuszek, 1 M. Kieć-Klimczak, 1

OP-709

Novel radiolabelled CCK2R Antagonists: Design, Synthesis and In Vitro Evaluation

D. Novak, 1 M. Anderluh, 2 P. Kolenc Peitl, 1 M. Akl, 2 T. Tomašič, 2 J. Baguna Torres, 1 M. Mosley, 3 P. Garnuszek, 1 R. Lugassi, 2 T. Maina, 1 V. Kersemans, 3 J. Zeisler, 1 C. Uribe, 1,2,3 J. Kennedy, 1 S. Balogova, 2 V. Keereman, 1,4 S. A. Zein, 2 S. A. Nehmeh, 2 Weill-Kennedy College of Medicine, New York, NY, UNITED STATES OF AMERICA.

OP-705

The Effect of a Cationic Linker on the Pharmacokinetics of ProBOMB2, a Novel Bombesin Derivative

I. Bratanovic, 1 C. Zhang, 1 Z. Zhang, 1 H. Kuo, 2 N. Colpo, 1 J. Pan, 1 R. Lin, 1 F. Behard, 1 British Columbia Cancer Research Centre, Vancouver, BC, CANADA.

OP-710

Evaluation of [18F]Ga-BL02 for Imaging the C-X-C Chemokine Receptor 4: Leveraging a Glutamate-based Linker

D. Kwon, 1 Z. Zhang, 1 J. Zeisel, 1 C. Obrle, 1 C. Zhang, 1 J. Lau, 1 K. Lin, 1 F. Behard, 1 Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA, 1 Functional Imaging, BC Cancer, Vancouver, BC, CANADA, 1 National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA, 1 Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

OP-711

Lower binding potential of GLP-1 receptor in the pancreas as a consequence of diet-induced obesity

C. Malbert, 1 A. Chauvin, 1 F. Le Gougec, 1 J. Georges, 1 M. Cimoz, 2 M. Hirszon, 2 INRA, Saint-Gilles, FRANCE; 2 INRA, Saint-Gilles, FRANCE.

OP-712

Head-to-head comparison of a Si-photomultiplier-based and a conventional photomultiplier-based PET-CT system

J. Odditt, 1 G. Balin, 2 E. Taagai, 2 D. Minasi, 2 Radiation Physics, Lund, SWEDEN, 2 Clinical Physics and Nuclear Medicine, Malmo, SWEDEN, 2 Radiation Physics, Malmo, SWEDEN.

OP-713

Comparison of Siemens Biograph Vision 600 and Biograph mCT PET-CT scanners

S. Eberl, 1 J. Voschuer, 1 A. Waugh, 1 A. Hughes, 2 M. J. Fulham, 1 Royal Prince Alfred Hospital, Sydney, AUSTRALIA.

OP-714

Continuous Bed Motion Acquisition for Clinical PET Systems With a Sparse Block Rings Configuration

N. A. Karakatsanis, 1 S. A. Zen, 2 S. Ahmed, 1 Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.

OP-715

PET2020 HRS: Maximization of sensitivity and resolution using axial extension and patient adaptive rings in a high resolution long axial FOV scanner

S. Vandenberge, 1 M. Gregoir, 1 E. Ethimous, 1 M. Stockhoff, 1 C. Thysens, 2 M. AH, 2 V. Keereman, 1 C. Vanhoore, 1 M. Kiel, 1 R. Vian Holen, 2 J. Karpi, 2 Universite Gent, GENT, BELGIUM, 2 University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, 2 University of Hull, Hull, UNITED KINGDOM, 2 KU Leuven, LEUVEN, BELGIUM.

OP-716

Digital SPECT: Collimator Design and CzT Crystal Thickness Affect General Purpose Solid State Camera Characteristics Facilitating Dual Isotope 99mTc/123I Quantitation

J. Kennedy, 1 R. Lugasi, 2 Z. Kneissl, 1 Rambam - Health Care Campus, Haifa, ISRAEL, 2 and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.

OP-717

Performance Evaluation of a Novel Multi-Pinhole Collimator for Dopamine Transporter SPECT

K. Tecklenburg, 1 Apostolova, S. Kluttman, B. Buchert, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

OP-718

Evaluation of general-purpose CZT SPECT/CT scanner for dual-isotope parathyroid imaging

E. T. Napolitano, 1 R. Hiviskari, 1 M. Steppen, 1 V. Tuninetti, 1 Department of Medical Physics, Turku University Hospital, Turku, FINLAND, 1 Department of Clinical Physics and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 1 Department of Clinical Physics and Nuclear Medicine, Satakunta Central Hospital, Pori, FINLAND.

OP-719

Slant-hole collimation system for high-resolution molecular imaging gamma tomosynthesis

M. Lango, 1 R. Parel, 1 P. Pellegati, 1 M. Crefi, 1 Frontallazzi, 1 G. De Vincenti, 1 Sapienza University of Rome, Ph. D. Program in Morphogenesis & Tissue Engineering, Rome, ITALY, 1 Azienda Ospedaliero-Universitaria di Trieste, Medical Physics Unit, Trieste, ITALY, 1 Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, ITALY, 1 Department of Molecular Imaging, Sapienza University of Rome, Rome, ITALY.

OP-720

Crystal Thickness Affect General Purpose Solid State Camera Characteristics Facilitating Dual Isotope 99mTc/123I Quantitation

J. Kennedy, 1 R. Lugasi, 2 Z. Kneissl, 1 Rambam - Health Care Campus, Haifa, ISRAEL, 2 and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.

OP-717

Performance Evaluation of a Novel Multi-Pinhole Collimator for Dopamine Transporter SPECT

K. Tecklenburg, 1 Apostolova, S. Kluttman, B. Buchert, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

OP-718

Evaluation of general-purpose CZT SPECT/CT scanner for dual-isotope parathyroid imaging

E. T. Napolitano, 1 R. Hiviskari, 1 M. Steppen, 1 V. Tuninetti, 1 Department of Medical Physics, Turku University Hospital, Turku, FINLAND, 1 Department of Clinical Physics and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, 1 Department of Clinical Physics and Nuclear Medicine, Satakunta Central Hospital, Pori, FINLAND.

OP-719

Slant-hole collimation system for high-resolution molecular imaging gamma tomosynthesis

M. Lango, 1 R. Parel, 1 P. Pellegati, 1 M. Crefi, 1 Frontallazzi, 1 G. De Vincenti, 1 Sapienza University of Rome, Ph. D. Program in Morphogenesis & Tissue Engineering, Rome, ITALY, 1 Azienda Ospedaliero-Universitaria di Trieste, Medical Physics Unit, Trieste, ITALY, 1 Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, ITALY, 1 Department of Molecular Imaging, Sapienza University of Rome, Rome, ITALY.

OP-720

Crystal Thickness Affect General Purpose Solid State Camera Characteristics Facilitating Dual Isotope 99mTc/123I Quantitation

J. Kennedy, 1 R. Lugasi, 2 Z. Kneissl, 1 Rambam - Health Care Campus, Haifa, ISRAEL, 2 and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.
OP-720 Genomics of MEN - Diagnostic Strategy and Pitfalls
M. North, Hôpital Cochin AP-HP Service de Genétique et Biologie Moléculaires, Paris, FRANCE.

OP-721 Imaging MEN 1
J. Talbot, Hôpital Tenon AP-HP & Sorbonne Université, Médecine Nucléaire, Paris, FRANCE.

OP-722 Imaging MEN 2
S. Balogova, K.Eriftzsch Oncology Institute, Cameron University of Bratislava, Nuclear medicine, Bratislava, SLOVAKIA.

OP-723 Scientific Programme
F. van Leeuwen, Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

OP-724 Bispecific anti-GRPR/PSMA heterodimer for PET and SPECT diagnostic imaging of prostate cancer
B. Mitran, Z. Varasdi, E. Pauwels, A. Abouzayed, S. S. Kim, T. Talmache, M. Lashë, U. Rosenstrom, A. Olova; Uppsala University, Uppsala, SWEDEN,
1Technische Universität München, München, GERMANY.

OP-725 Introduction of an amylase cleavable linker to PSMA-617 - a novel strategy for the reduction of salivary gland uptake in endoradiotherapy of prostate cancer
A. Baranski, T. Lindner, T. Riesenmann, P. T. Meyer, W. Mier, M. Eder; 1Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, GERMANY, 2Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Freiburg im Breisgau, GERMANY, 3Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY.

OP-726 68 Ga-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
A. Jagara, L. Bozzato, H. Duan, N. Hataami, C. Man, G. Davison; Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA.

OP-727 Oral Presentations
Wednesday, October 16, 2019, 8:00 - 9:30
Lecture Hall 114
Chair: R. A. Burger, University Hospital Zurich, ZURICH, SWITZERLAND.
Chair: F. van Leeuwen, Leiden, NETHERLANDS.

OP-728 High Repeatability Of Dynamic 82Rb-PET/CT For Tumor Blood Flow Imaging In Prostate Cancer – a Test-Repeat Study
M. Jochemsen, J. K. B. Nielsen, M. Bonnet, J. Eastman, J. Jiang, J. P. Talbot, 1Aarhus University Hospital, Dept. of Nuclear Medicine and PET-Centre, Aarhus, DENMARK, 2Aarhus University, Dept. of Clinical Medicine, Aarhus, DENMARK, 3Aarhus University, Dept. of Public Health, Section for Biostatistics, Aarhus, DENMARK, 4Aarhus University Hospital, Dept. of Radiology, Aarhus, DENMARK.

OP-729 Prospective comparison of 68Ga-RM2 PET/CT and 68Ga-PSMA PET/CT for initial staging of prostate cancer

OP-730 Reporting Incidents In Therapeutic Nuclear Medicine. A New IAEA Tool
M. Marengo, O. Galletandre, B. Thomassen, T. Ell; 1Children’s Hospital and Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, 2MRC Cyclotron and Radiochemistry Unit, University College London, London, UK, 3MRC Cyclotron and Radiochemistry Unit, University College London, London, UK, 4CNRS, INCIA, UMR 5287, Talence, FRANCE, 5CNRS, INRA, UM 5287, Talence, FRANCE.

OP-731 Dynamic absorbed dose calculations to the urinary bladder wall for the ICRP compartmental models of iodide and technetium
M. Andersson, S. Mattsson, J. Johansson; 1Medical Radiation Physics, Malmö, SWEDEN, 2Radiation Physics, Umeå University, Umeå, SWEDEN.

OP-732 Construction of Safety Standards for Short-half-life Alpha Emitters by Grant of Nuclear Regulatory Agency of Japan
M. Hosoio, T. Yamada, N. Onouchi, N. Ukon, K. Hayata, T. Takei, H. Yamashita, T. Matsumura, A. Hachisuka, Y. Nakamura; 1Kindai University Faculty of Medicine, Osaka-Sayama, JAPAN, 2Kindai University Atomic Energy Research Institute, Higashi-Osaka, JAPAN, 3Kakushima Medical University, Fukuoka, JAPAN, 4National Institute of Radiological Sciences, Chiba, JAPAN, 5National Institute of Health Sciences, Tokyo, JAPAN, 6Japan Radioisotope Association, Tokyo, JAPAN.

OP-733 Nationwide Survey in Finland: Optimisation Principle Should Not Be Forgotten
J. T. Liukkonen, J. Suutarinen, Radiation and Nuclear Safety Authority, Helsinki, FINLAND.

OP-734 Dynamic absorbed dose calculations to the urinary bladder wall for the ICRP compartmental models of iodide and technetium
M. Andersson, S. Mattsson, J. Johansson, 1Medical Radiation Physics, Malmö, SWEDEN, 2Radiation Physics, Umeå University, Umeå, SWEDEN.

OP-735 Eye Lens dose estimation in Peptide Receptor Radiodination Therapy: Monte Carlo simulations versus experimental measurements
F. Fioroni, F. Ferrani, E. Grassi, A. Chendi, M. Bertolini, V. Piccaglia, A. Filice, A. Varesi, F. Marioni, M. Iori; 1A.S. I.R.C.S. Regina Elena, ITALY, 2ENEA, Radiation Protection Institute, Bologna, ITALY, 3Postgraduate School in Medical Physics, University of Bologna, Bologna, ITALY.

OP-736 Novel Nanotech Antioxidant Cocktail for Protection from Ionizing Radiation during Bone Scans
M. Gorenberg, N. Eian, M. Ziv, Y. Haddad, I. Wolovic, A. Shalata; 1Bnai Zion Medical Center-Technion, Haifa, ISRAEL, 2Bnai Zion Medical Center, Haifa, ISRAEL.
OP-740 Supporting Fukushima - The Nuclear accident’s Consequences on the Region
K. Kanai, Faculty of Applied Sociology, Kindai University, Osaka, JAPAN.

OP-744 Special Aspects of Radiation Induced Paediatric Thyroid Cancer
C. Reiners, University Hospital Würzburg, Würzburg, GERMANY.

OP-745 Discussion

Joint Symposium 28 - Translational and Molecular Imaging Therapy + Oncology & Thersanotics Committee / WMIS Translational Aspects of PSMA Targeting
Wednesday, October 16, 2019, 10:00 - 11:30 Lecture Hall 312
Chair: M. Pomper, Baltimore, MD, UNITED STATES OF AMERICA.
Chair: M. Schottelius, Pharmacetical Radiochemistry, To Munich, Garching, GERMANY.

OP-746 Biology of PSMA
J. Grimm, Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA.

OP-747 Update on PSMA Tracers
M. Pomper, Johns Hopkins Hospital, Radiology, Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA.

OP-748 Clinical Relevance PSMA Targeting
F. Giesel, University of Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-749 Clinical Relevance PSMA Targeting
F. Giesel, University of Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-750 First in human dosimetry of [117mLu]BM2: A gastrin-releasing peptide receptor antagonist for targeted radiotherapy of metastasized castration resistant prostate cancer
J. Kurth, B. J. Krause, C. Bergner, S. M. Schwanenboeck, M. Heuschle, Rostock University Medical Center, Rostock, GERMANY.

OP-751 New PET Radiotracers for Lung Imaging
D. Albano, Spedali Civili of Brescia, Nuclear Medicine Department, Brescia, ITALY.

OP-752 Metabolic Volumes Delineation for External Beam Radiotherapy and its Prognostic Role in Lung Cancer
W. Cholewinski, The Greater Poland Cancer Centre, Nuclear Medicine Department, Poznan, POLAND.

OP-753a Radionuclide Features in Non-Small-Cell Lung Cancer FDG-PET/CT Studies
M. Kirienko, Humanitas University, Department of Biomedical Sciences, Milan, ITALY.

OP-753b Discussion

Joint Symposium 27 - Radiation Protection Committee / JSNM: Lessons from Fukushima - Low Dose Radiation from Environment Radioisotope
Wednesday, October 16, 2019, 10:00 - 11:30 Lecture Hall 117
T. T. Kudo, Joint Department of Physics, Royal Cornwall Hospitals Trust, Truro, ENGLAND.
F. Paycha; Bristol, UNITED KINGDOM.
R. Atkins, University of Tokyo, Tokyo, JAPAN.
M. Konijnenberg; ALVERCA DO RIBATEJO, PORTUGAL.
A. A. d. Santos, University for Lisbon, Lisbon, PORTUGAL.
N. S. Verkaik, 1Erasmus MC, Rotterdam, NETHERLANDS, 2Advanced Accelerator Applications, A Novartis Company, Colleretto Giacosa, ITALY.

OP-754 Intratumoral somatostatin receptor 2 heterogeneity confers differential radiouclide therapy response in preclinical neuroendocrine tumor models
D. Feijtel, 1D. Chicco, 1D. C. van der Graaf, 1J. C. Haeck, 1D. C. van der Meulen, 1L. Zhao, 2J. J. Wilson, 2D. L. J. Thorek, 5X. Chen, 1J. Kurth, 5X. Chen, 1N. S. Verkaik, 1Erasmus MC, Rotterdam, NETHERLANDS, 2Advanced Accelerator Applications, A Novartis Company, Colleretto Giacosa, ITALY.

OP-755 First in human dosimetry of [117mLu]BM2: A gastrin-releasing peptide receptor antagonist for targeted radiotherapy of metastasized castration resistant prostate cancer
J. Kurth, B. J. Krause, C. Bergner, S. M. Schwanenboeck, M. Heuschle, Rostock University Medical Center, Rostock, GERMANY.

OP-756 Chemical Conjugation Of Evans Blue Derivative Prolongs Blood Half-Life And Improves The Integrin αvβ3 -Targeted 111In-radiouclide Therapy In Patient-derived Xenograft Model Of Lung Adenocarcinoma
L. Zhao, 1J. Chen, 1K. Fu, 2D. Fan, 2Z. Guo, 1H. Wu, 1Q. Jacobsen, 1Q. Li, 1A. Chen, 1The First Affiliated Hospital of Xiamen University, Xiamen, CHINA, 1Beijing Tiantan Hospital, Beijing, CHINA, 1Center for Molecular Imaging and Translational Med, Xiamen, CHINA.

OP-757 Chelation of Radium-223 for Targeted Radionuclide Alpha Particle Therapy
D. Abou, 1M. A. Thieke, 1M. Longtin, 2A. L. Wilner, 1J. J. Wilson, 1D. L. J. Thorek, 1Washington University School of Medicine, Saint Louis, MO, UNITED STATES OF AMERICA, 1Genentech, BETHESDA, MD, UNITED STATES OF AMERICA.

OP-758 Alpha Particle Emitting Radium-223 in Combination Therapy: Potential and Pitfalls
D. L. Thorek, 1D. S. Abou, 1M. Longtin, 2P. Kustuwa, 1P. C. Todd, 1B. Baumann, 1Washington University School of Medicine, Saint Louis, MO, UNITED STATES OF AMERICA, 1Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

TARGETED ALPHA THERAPY IN METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: FIRST CLINICAL EXPERIENCE ON SAFETY AND EFFICACY (S. Ballal, M. P. Yadav, C. Bal, All India Institute of Medical Sciences, New Delhi, INDIA)

DO MORE - PARALLEL SESSION: PET/MR PHYSICS

Wednesday, October 16, 2019, 10:00 - 11:30 | Lecture Hall 112
Chair: G. S. Necola, Nuklearmedizinische Klinik, TU München, München, GERMANY
Chair: B. Sattler, Department of Nuclear Medicine, University Hospital Leipzig, LEIPZIG, GERMANY


PET/MRI ATTENUATION CORRECTION IN THE PELVIC REGION WITH A STATISTICAL DECOMPOSITION METHOD (E. Wallstén, J. J. Halvorsen, J. H. Rasmussen, C. Thellenberg Karlsson, T. Nyholm, A. Larsson; Department of radiation sciences, Umeå University, Umeå, SWEDEN)


COMPARISON OF SIMULTANEOUS ARTERIAL SPIN LABELING MRI AND 1D-H O PET MEASUREMENTS OF REGIONAL CEREBRAL BLOOD FLOW IN REST AND ALTERED PERFUSION STATES (O. Puig, O. M. Henriksson, M. B. Vestergaard, A. E. Hansen, F. L. Andersen, C. N. Ladesflodig, E. Reostrup, H. B. W. Larsson, U. Lindberg, I. Law; Department of Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen Ø, DENMARK)


DEEP DIRECT ATTENUATION CORRECTION OF BRAIN PET IMAGES USING EMISSION DATA AND DEEP CONVOLUTIONAL ENCODER-DECODER FOR APPLICATION TO PET/MR AND DEDICATED BRAIN PET SCANNERS (I. Shiri, P. Ghasarian, P. Geramifar, K. Ho-Yin Leung, M. Oveis, A. Rahimi, A. M. Ay; Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; PET/CT and Cyclotron Center, Mashhad Daneshvar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Research Center for Nuclear Physics, Osaka University, Suita, Osaka, JAPAN; Graduate School of Science, Osaka University, Suita, Osaka, JAPAN; Institute for Radiation Sciences, Osaka University, Suita, Osaka, JAPAN; Research Center for Nuclear Physics, Osaka University, Suita, Osaka, JAPAN)

PET/MRI ATTENUATION CORRECTION IN THE PELVIC REGION WITH A STATISTICAL DECOMPOSITION METHOD (E. Wallstén, J. J. Halvorsen, J. H. Rasmussen, C. Thellenberg Karlsson, T. Nyholm, A. Larsson; Department of radiation sciences, Umeå University, Umeå, SWEDEN)

DEEP DIRECT ATTENUATION CORRECTION OF BRAIN PET IMAGES USING EMISSION DATA AND DEEP CONVOLUTIONAL ENCODER-DECODER FOR APPLICATION TO PET/MR AND DEDICATED BRAIN PET SCANNERS (I. Shiri, P. Ghasarian, P. Geramifar, K. Ho-Yin Leung, M. Oveis, A. Rahimi, A. M. Ay; Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; PET/CT and Cyclotron Center, Mashhad Daneshvar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Research Center for Nuclear Physics, Osaka University, Suita, Osaka, JAPAN; Graduate School of Science, Osaka University, Suita, Osaka, JAPAN; Institute for Radiation Sciences, Osaka University, Suita, Osaka, JAPAN; Research Center for Nuclear Physics, Osaka University, Suita, Osaka, JAPAN)

PRELIMINARY RESULTS ON 225 AC-DOTATATE TARGETED ALPHA THERAPY IN METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: FIRST CLINICAL EXPERIENCE ON SAFETY AND EFFICACY (S. Ballal, M. P. Yadav, C. Bal, All India Institute of Medical Sciences, New Delhi, INDIA)


TARGETED ALPHA THERAPY IN METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: FIRST CLINICAL EXPERIENCE ON SAFETY AND EFFICACY (S. Ballal, M. P. Yadav, C. Bal, All India Institute of Medical Sciences, New Delhi, INDIA)


TARGETED ALPHA THERAPY IN METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: FIRST CLINICAL EXPERIENCE ON SAFETY AND EFFICACY (S. Ballal, M. P. Yadav, C. Bal, All India Institute of Medical Sciences, New Delhi, INDIA)
OP-770
PET/CT with 68Ga-Radiolabelled SST2 Analogues - Interactive Clinical Cases Presentation
V. Ambrosini, University of Bologna, S.Orsola-\Malpighi Hospital, Department of Experimental Diagnostic and Specialized Medicine, Nuclear Medicine, Bologna, Italy.

OP-771
PET/CT with [18F]FDOPA - Interactive Clinical Cases Presentation
S. Balogova, St. Elisabeth Oncology Institute, Comenius University of Bratislava, Slovak medicine, Bratislava, Slovakia.

OP-772
Wrap-up and Conclusions
P. Erba, Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

OP-773
Parallel comparison of 68Ga-Prostate Specific Membrane Antigen PET-CT and PRIMUS in primary prostate cancer diagnosis

OP-774
Prospective evaluation of 68Ga-PSMA PET/CT in primary prostate cancer diagnosis - final results of a dedicated trial

OP-775
Validation of galium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients
L. van Kalmthout, H. van Melick, J. Lavalaye, R. Meyer, A. Kassart, J. de Kleijn, A. Brand, P. Kiddewey, B. de Koning, M. Lamm; Academic Hospital, Utrecht, NETHERLANDS; St. Antonius Ziekenhuis, Nieuwegein, NETHERLANDS; Meander Medisch Centrum, Amersfoort, NETHERLANDS; UMC Utrecht, Utrecht, NETHERLANDS; St. Antonius Hospital, Nieuwegein, NETHERLANDS.

OP-776
Interobserver Agreement of 68 Ga-PSMA-11 PET/CT images interpretation
C. Derwaal, O. Lavergne, P. Lovinfosse, V. Nechifor, D. Woltering, R. Husni, A. Wetter, M. Meijer; CHU, Liège, BELGIUM; CHU, Liège, BELGIUM; Department of Nuclear Medicine, IRCCS Policlinico San Matteo, Pavia, ITALY; Rede Nucleraria, Instituto do Câncer do Estado do Rio de Janeiro, RIO DE JANEIRO, BRAZIL; Department of Nuclear Medicine, Clinic Kragujevac, Kragujevac, SERBIA; Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY; Department of Nuclear Medicine, University Hospital, Munich, Munich, GERMANY; Department of Nuclear Medicine, University of Turin, Turin, ITALY.

OP-777
Salvage radiotherapy guided by 68Ga-PSMA-11 PET/CT in patients with biochemical persistence (BCP) after radical prostatectomy for prostate cancer
F. Ceci, D. Nicolastri, E. Plati, A. Guarneri, S. Bartonnini, M. Fineschi, V. Liberati, G. Bri, U. Ricardi, D. Dearden; Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY; Radiation Oncology, Department of Oncology, University of Turin, Turin, ITALY.
OP-781 A comparison of the diagnostic value of MRI and Whole body 18F-FDG PET/CT in diagnosis of spondyloarthritis: A comparison of the diagnostic value of MRI and Whole body 18F-FDG PET/CT in diagnosis of spondyloarthritis
C. Altini, A. Bianca, R. Ruta, G. Santa, C. Ferma, A. Nicolò Asabella, N. Menendra, G. Rubini; Nuclear Medicine Unit, Interdisciplinary Department of Medicine – University of Bari “Vito Foria”, Bari, ITALY.

OP-782 Predictive Potential of Nonstandard Quantitative Imaging Features in Diabetic Foot Ulceration
A. Marciano, A. Bruekinger, J. Kedera, M. Karunh, R. Ziance, A. W. J. M. Glaudemans, P. A. Erba, A. H. J. A. Sartor; Regional Center of Nuclear Medicine, Department of Translational Research and New Technologies, Universita degli Studi di Roma “Tor Vergata”, Rome, ITALY; University Hospital of Groningen, University of Groningen, Groningen, NETHERLANDS, Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, ISRAEL.

OP-783 Handling of doubtful WBC scintigraphies in patients with prosthetic joint infections
G. Laueri, C. Lunt, D. Arola, S. Tetti, A. Signore; Nuclear Medicine Unit, Dept of Medical-Surgical Sciences and of Translational Medicine, “Sapienza” University of Rome, Rome, ITALY.

OP-784 Is the 18F-FDG PET/CT able to characterize fibrosing diseases?

OP-785 The Significance Of Inverted:“V” Shaped Prostatic FDG Uptake As A Diagnostic Clue for IgG4-Related Prostatitis
K. Nakatani, K. Yotsumi, T. Kayama; Kansai Medical University Hospital, Kansai, OSAKA, JAPAN.

OP-786 Diagnostic validity of (1S-4S)[18F]fluoropropyl-L-glutamic acid ([18F]FSPG) positron emission tomography/computed tomography (PET/CT) for the assessment of disease activity in patients with inflammatory bowel disease: a phase 2 pilot study
D. Lee, M. Seo, B. Ye, S. Park, S. Chae, S. Hwang, S. Lee, S. Oh, J. Kim, S. Na, N. Kogil, M. Berndt, A. Stephens, D. Moon; Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF; Department of Nuclear Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, KOREA, REPUBLIC OF; Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF; Department of Nuclear Medicine, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, KOREA, REPUBLIC OF; Department of Radiology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF; Life Molecular Imaging GmbH, Berlin, GERMANY.

OP-787 Noninvasive Diagnosis and Monitoring of Pneumonia using Pathogen-Specific 18F-Fluorodeoxyglucose (FDG) PET
U. Granados, A. A. Ordoñez; I. M. Wintzaco, C. A. Bridgby, S. Frey, J. D. Sanchez, P. R. D’Allesio, T. R. Ayvaz, D. P. Holt, R. F. Damnali, M. G. Raper, S. K. Jain; Universidad de Medicina Nuclear, Hospital Internacional de Colombia, Fundacion Cardiovascular de Colombia, Bucaramanga, COLOMBIA; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA; Radioimmunology, Universidad de las Ramblas, Universidad de Medicina Nuclear, Hospital Internacional de Colombia, Bucaramanga, COLOMBIA.
Russel H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-788 Real-Time Imaging of Human Skin Invasion by Fluorescently Labelled (Radiation-Attenuated) Schistosoma mansoni Parasites
C. de Korne, B. M. F. Winkler, M. R. Datschenko, D. M. van Wilgen; A. W. Hensbergen, E. C. de Jong, M. Roertgenber; F. W. B. van Leeuwen; LUMC, Leiden, NETHERLANDS; AMC, Amsterdam, NETHERLANDS.

1801/1804 Marie Curie Award

Plenary 4: Highlights Lecture

EP-001 Neuroimaging: Neurology

EP-0001 Disorders of Consciousness and visual fixation: a combined analysis with flash visual evoked potentials, MRI and PET/CT
G. Marotta, D. Sartori, L. D’Incerti, D. Rossi, Sebastian D’Tombo, S. Meloni, D. Dureni, S. Fermani, L. Minutri, A. Negri, C. Rosazza, M. Leonardi, R. Bertzi; Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, ITALY; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, ITALY.

EP-0002 Evaluation of reducing the [18F]FDG activity levels for clinical readings of PET/MRI scans of patients with non-lesional epilepsy
H. Kertesz, T. Traub-Wedinger, J. Cal-Gonzalez, J. Krause, O. Muzii, L. Shyamy Sundaram, T. Eyer; QIMR Berghofer Medical Research Institute, Brisbane, AUSTRALIA.

CC Closing Ceremony
**EP-0003**
Brain regions involved in cochlear implant user's speech comprehension: Insights from brain-perfusion-SPECT and EEG during a sentence discrimination task
M. L. Kessler, J. Scherthöhl, M. Mamadou, F. Wille, A. Hahn, J. Gevarski, F. M. Benes, P. Sandmann, G. Bending; 1, Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, 2, Department of Oto-Rhino-Laryngology, Hannover Medical School, Hannover, GERMANY, 3, Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, 4, Saxony Cochlear Implant Center, University Hospital, Dresden, GERMANY, 5, Department of Oto-Rhino-Laryngology, University of Cologne, Cologne, GERMANY.

**EP-0004**
Extratemporal metabolic profile on FDG-PET in temporal lobe epilepsy as a predictor of surgical failure
Y. Tang, G. Liao, J. Li, T. Long, Y. Li, S. Hu; Department of PET Center, XiangYa Hospital Central South University, Changsha, CHINA.

**EP-0005**
FDG-PET in the evaluation of patients with drug-resistant focal epilepsy
G. Capriotti, F. Franchi, L. Canide, G. Franchi, L. De Palma, D. Prosperi, P. Pizzichini, L. Carideo, G. Franchi, L. Carideo, A. Paccagnella; 1, Ospedale Pediatrico Bambino Gesù, Rome, ITALY, 2, Department of Biomedical and Neuroradiology Sciences, University of Bologna, Bologna, ITALY, 3, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, ITALY, 4, Pediatric Neurology, University Hospital of Toulouse, Toulouse, FRANCE, 5, Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY.

**EP-0006**
The Different Metabolic Patterns Of Brain 18F-FDG PET In Anti-nmda,anti-lgi1 And Anti-gabab Encephalitis
X. Zhao, X. Li, Z. Qiao, K. Wang, Q. Chen, L. Ai; Beijing Tiantan hospital, Beijing, CHINA.

**EP-0008**
FDG-PET assessment and metabolic patterns in Lafora disease: a multicenter retrospective study
A. Paccagnella, L. De Palma; 1,2, G. Capriotti; 1,3,4,5, G. Berding, D. Prosperi, P. Pizzichini, L. Geworski, A. Hahne; 1, Cluster of Excellence Hearing4all, Hannover, Bologna, Bologna, ITALY, 4,2, 1,4,2, 1,3, 1,2, 1,2, 1,3, 1,2, 1,2, 2, 1,2, 1,2.

**EP-0009**
Multimodal imaging approach in epilepsy: PET-MRI software coregistration in the assessment of localization the potential epileptogenic focus
A. Mestre Fucso, S. González-Ortiz, S. Medrano, M. Salinas-Vieitez, M. Ley, A. Pirzio, J. Capellades, R. Raco-Mas; 1, Nuclear Medicine, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN, 2, Radiotherapy, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN, 3, Epilepsy Unit - Neurology, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN.

**EP-0010**
Brain Metabolism changes in patients with diffuse axonal injury after intracerebral cell therapy
J. Mucientes, J. Vázquez, M. Zuniga, C. Fernandez, M. Mitjavila; Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, SPAIN.

**EP-0011**
18F-DOPA positron emission tomography features in brain tumefactive demyelinating lesions
S. Raffa, M. Bauckhendt, J. Raccoglitore, S. Capistranito, E. Sbragia, M. Pastorino, A. Lopuso, M. I. Donadio, A. A. Marchelli, A. Uccili, M. Inglesi, F. M. Napolito, S. G. Sambuceti, S. Morfett; 1, Department of Health sciences (DEISAL), University of Genoa, Genoa, ITALY, 2, Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 3, Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 4, Clinical Neurology, Department of neurosciences (DINOGMI), University of Genoa, Genoa, ITALY, 5, Clinical neurology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, Genoa, ITALY.

**EP-0012**
Cerebral perfusion measured by s-tyc-HMPAO SPECT in a simulated microgravity model using a 5-day dry immersion
L. Guillou, M. P. Barelle, E. Cassol, A. Beck, M. Beaurain, P. Perani, J. A. Lestote, A. Pasy, L. Traen, P. Payaux; 1, Nuclear Medicine Department of University Hospital of Toulouse, Toulouse, FRANCE, 2, Nuclear Medicine, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN, 3, Nuclear Medicine, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN.

**EP-0013**
Autoimmune encephalitis: utility of PET/CT with 18F-FDG as the first diagnostic step
E. Fajardo Ordonez, R. Hernandez, J. Chavez Torres, D. Pacheco Gonzalez; 1, Medica Sur, Ciudad de Mexico, MEXICO, 2, Rodrigo Hernandez, Ciudad de Mexico, MEXICO.

**EP-0014**
Cerebral perfusion measured by s-tc-HMPAO and SPECT-CT
A. Galiana, J. A. Lotterie, M. P. Bareille, M. P. Payoux; 1, Nuclear Medicine Department - Neurology, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN, 2, Nuclear Medicine Department - Neurology, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN, 3, Nuclear Medicine Department - Neurology, Hospital del Mar - Parc de Salut Mar, Barcelona, SPAIN.

**EP-0015**
Epilepsy and radiological features in brain tumefactive demyelinating lesions
S. Raffa, M. Bauckhendt, J. Raccoglitore, S. Capistranito, E. Sbragia, M. Pastorino, A. Lopuso, M. I. Donadio, A. A. Marchelli, A. Uccili, M. Inglesi, F. M. Napolito, S. G. Sambuceti, S. Morfett; 1, Department of Health sciences (DEISAL), University of Genoa, Genoa, ITALY, 2, Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 3, Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 4, Clinical Neurology, Department of neurosciences (DINOGMI), University of Genoa, Genoa, ITALY, 5, Clinical neurology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, Genoa, ITALY.

**EP-0016**
Feasibility and Effectiveness of SISCOM With SPM To Locate Epileptogenic Focus in Clinical Practice

**EP-0017**
Syndrome of the Trehpined: evaluating brain perfusion before and after craniosynostosis surgery
99m-Tc HMPAO and SPECT-CT
Y. Tang, G. Liao, J. Li, T. Long, Y. Li, S. Hu; Department of PET Center, XiangYa Hospital Central South University, Changsha, CHINA.

**EP-0018**
Cerebral perfusion SPECT imaging in comparison to brain MRI imaging and their correlation with clinical condition in patients with multiple sclerosis
M. Assadi, H. Shoodi, R. Nemati, N. Chahri, E. Jalali, H. Dadgiri; 1, Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, 2, Islamic Republic of Iran, 3, Imam Reza International University, Mashhad, IRAN, 4, Islamic Republic of Iran.

**EP-0019**
Effects of brain surgery on glucose metabolism and cognitive function: insight from dynamic FDG PET/CT study
EP-0022 The Evaluation of Brain FDG PET Images in Temporal Lobe Epilepsy by Data Mining Methods in Terms of Lateralization of Epileptogenic Focus

Ü. Akademir, J. Yıldırım, Ú. Aydön, S. Gulbahar Ateş, G. Kuru, L. Atay; ‘Gazi University Medical Faculty Department of Nuclear Medicine, Ankara, TURKEY.

EP-0023 Target Volume Definition With "GA-DOTATOC-PET/CT And MRI For Patients With Meningiomas


EP-02 Imaging. Movement Disorders

Display throughout the congress days © e-Poster Area

EP-0024 Reliability of Dopamine Transporter PET Measurements with "[F]F-EPE2I in Early Stage Parkinson’s Disease: A Preliminary Test-Retest Evaluation

V. Kersten, P. Faia, M. Sandgren1, G. J. Matheson, E. Franclén, C. Hallén, S. Cevenini, P. Siemningsgård, A. Ilmarinen; ‘Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN.

EP-0025 Dopaminergic and Metabolic Characteristics of Parkinson Early Onset Parkinson’s Disease: a Dual-tracer PET Study

J. Lu, F. Lu, J. Ge, P. Wu, J. Wang, C. Zuo; ‘PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EP-0026 Tc-99m TRODAT-1 SPECT Images in Diagnosis and Severity Evaluation of Parkinson’s Disease Using Deep Learning Model

R. Chuang, C. K. L., C. L. Y., R. Yen; ‘Department of Nuclear Medicine, National Taiwan University Hospital, Taipei City, TAIWAN.

EP-0027 Comparison of "[I]Iodofluor SPECT imaging between the Veritron™ 360° CZT camera with striatum focusing and a conventional gamma-camera

M. B. Chawki, M. Borronné, T. Zaragó, G. Klaecher, P. Marie, L. Imbert, A. Végé; CNRou de Nancy, Nuclear Medicine Department, Vandoise-EN-Nancy, FRANCE.

EP-0028 Cortico basal syndrome is "[F]F-DOPA PET a feasible tool to predict underlying Alzheimer’s pathology?


EP-0029 Presurgical cognitive phenotype and its relation to brain metabolic pattern in the evaluation of the clinical outcome of Deep Brain Stimulation in Parkinson’s Disease: an FDG-PET study

C. Polito, V. Berti, S. Ramat, F. Treana, G. Puccini, M. De Cristofaro, S. Sorbi, R. Scaglìa, Università di Firenze, Firenze, ITALY.

EP-0030 Utility of "FDG-brainPET for parkinsonism diagnosis in daily clinical practice: our experience in a non-dedicated hospital

P. Santos-Holgueiras, P. Gamostachou-Zuman, C. Alfonso, V. Boulouard, L. Romero, A. Cabrelo, F. Carle, R. Delgado, R. Ramirez; Nuclear Medicine and Molecular Imaging Division, San Pedro Hospital-CIBIR, Logroño, SPAIN.


G. Aghakhanyan1, M. Rullmann, J. Rumpf, M. Schröter, M. Paff1, J. Wassen1, O. Saber, H. Berthe; ‘Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY.

EP-0032 Preliminary Exploration of PET/MR Radiomics Features for Differential Diagnosis of Parkinson’s Disease and Multiple System Atrophy

X. Hu, X. Sun1, J. Gao, X. Lan1, R. An1; ‘Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ‘Huhe Key Laboratory of Molecular Imaging, Wuhan, CHINA, ‘GE Healthcare (CHINA), Shanghai, CHINA.

EP-0033 Assessment of dopamine transporter imaging and olfactory testing in patients with Parkinson’s disease: a semi-quantities analysis

M. Assadi1, M. E. Ferrari1, S. Cervenka; ‘Department of Nuclear Medicine, National Taiwan University Hospital, Taipei City, TAIWAN.

EP-0034 Comparison of semiquantitative analysis of dopaminergic brain imaging

R. Durmo1, B. Phaguna1, D. Alban1, M. Bonaona1, M. Gazz1, E. Sendui1, I. Dand1, A. Mazzetti1, F. Bertagnol1, G. Gubas1, P. Bellet1; ‘Nuclear Medicine, Spedali Civili Brescia, Brescia, ITALY, ‘Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, ITALY, ‘University of Brescia, Brescia, ITALY.

EP-0035 Characterization of the FDOPA Uptake of the Brainstem and Diencephalon in Parkinsonian Syndromes by PET / MRI

G. Demonceau1, A. Tett1, G. Demonceau1, V. Lebon1, I. CEA-INSYS Orsay, Paris, FRANCE, ‘Inserm UPS, Liège, BELGIUM, ‘University Paris Sud, Paris, FRANCE.

EP-0036 Prognostic Role Of FDG PET Before Deep Brain Stimulation in PD Patients: A Voxel-Based Study

G. Puccini, V. Berti, S. Ramat, F. Treana, C. Palato, M. De Cristofaro, S. Sorbi, R. Scaglìa; ‘Nuclear Medicine Unit - University of Florence, Florence, ITALY,’Neurology Unit - University of Florence, Florence, ITALY.

EP-03 Imaging. Psychiay and Neurotransmission

Display throughout the congress days © e-Poster Area

EP-0037 Brain Dysfunction in Active and Abstinent Smoked Cocaine Addicts from Brazil and Uruguay

R. Ferrando1, C. Paschoch, S. Pan2, M. Langhian, A. Silvencia, P. Filiat2, A. Negri, V. Imaioni, V. Martin, C. Rodriguez, F. Cadenaz2, E. Moreno1, M. Bidegain2, R. Ponde de León2, L. Hennes1, L. Mendes1, F. Omet2, V. Morecht1, N. Fares1, M. Carbó2, F. Kessler1; ‘Clínics Hospital, University of the Republic, Montevideo, URUGUAY, ‘Maciel Hospital, Montevideo, URUGUAY, ‘Catholic University, Montevideo, URUGUAY, ‘Clínicas Hospital of Porto Alegre, Porto Alegre, BRASIL, ‘University of Zurich, Zurich, SWITZERLAND.
EP-0038
Brain SPECT Perfusion Imaging With Brodmann Areas Mapping Of Psychotic Symptoms (Delusions And Hallucinations) In Patients With Alzheimer's Disease
V. V. Talasaintsev, N. Shifakhi, C. Traversy, E. Lykou, G. Angelakou, N. Trivan, V. Karmatsandik, T. Tsipougi, D. Pumda, S. Alexiou, S. Papageorgiou, P. Georgoulis, J. Papantonaitisfly, “Dept of Nuclear Medicine, University Hospital of Larissa, Larissa, GREECE, 1st Dept of Nuclear Medicine, “Alexandras” University Hospital, Athens, GREECE”, IASIS Third Age Center, Athens, GREECE, “Kypriotikan Hosp., 1st University Psychiatric Clinic of Athens, Athens, GREECE, 2nd University Neurological Opt., Attikon Hospital, Athens, GREECE.

EP-0039
Examination of brain perfusion and metabolism in metabolic diseases (focusing on diabetes and obesity)
Z. K. Zita, J. Varga, F. Nagy, M. Emri, M. Kaplair, C. Ananji, J. Ganai; “University of Debrecen, Debrecen, HUNGARY”, “Division of Nuclear Medicine and Translational Imaging, Medical Imaging Department, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY”, “Scannomed Ltd., Debrecen, HUNGARY”, “Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY.

EP-0040
Sciintigraphic low cerebral blood flow in initial episode psychosis
C. Sioka, G. Georgiou, A. Karappas, P. Petrisik, A. Papadopoulos, S. Tsironi, A. Fotopoulos; University Hospital of Ioannina, Ioannina, GREECE.

EP-0041
From metabolic connectivity to molecular connectivity: application to dopaminergic pathways
A. Verger, T. Horowitz, M. Chauvel, N. Gradir, E. Guerard; CHRU Nancy, Nancy, FRANCE, Timone, APMH, Marseille, FRANCE.

EP-0042
Factors influencing the cerebral 18F-DOPA uptake
A. Tebbei, N. D. Demiroussos, V. Lebon, G. Demiroussos; “CEA-Saclay, Orsay, FRANCE, Université Paris Sud, Paris, FRANCE, ‘Bains de l’Hôpital, Senart, BELGIUM

EP-0043
A Direct Comparison Between 18F-FDG PET and Arterial Spin Labelling Perfusion MRI in Patients Referred for Differential Diagnosis of Dementia Using Simultaneous PET/MR

EP-0044
SPM MRI-less 18F-FloretabetaT PET for amyloid burden quantification and potential AD patients selection in clinical trials
P. Alongi, R. Laudicina, D. Sardina, S. Gerventa, G. Russo, A. Stefano, R. Cappetta, M. Madri, L. Gerumai; 1’National Medicine Unit, Fondazione Istituto G Gaglia, Cefalù PA, ITALY, 2’University of Palermo, Palermo, ITALY, “Department of Biomedical and Dental Sciences’ and of Morphofunctional Imaging, University of Messina, Messina, ITALY, 3’National Medicine Unit, Fondazione Istituto G Gaglia, Cefalù PA, ITALY, 4’I.U.C. Neurology, Fondazione Istituto G Gaglia, Cefalù PA, ITALY”.

EP-0045
Task-specific regional cerebral metabolic activity according to amyloid deposition in MCI patients: SPM analysis with paired FDG PET images
E. Lee, H. Youn, S. Lee, J. Jeong, J. Ee; “Department of Nuclear Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF”, “Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF”, “Department of Biomedical Sciences, Korea University Graduate School, Seoul, KOREA, REPUBLIC OF”, “Korea University Research Institute of Mental Health, Seoul, KOREA, REPUBLIC OF”.

EP-0046
Comparison of MR-based and PET-only quantification of tau load using [11C]PBB3
E. Yousefzadeh-Nowshahr; G. Winter, P. Bohn, K. Kune, C. van Amerom, M. Ono, C. Sabach, S. Anderer, Strnad, M. Polubak, P. Fissler, P. Prazsl, P. Kletting, M. W. Riepe, H. Braski, K. Del Tredici, M. Houguchi, A. Ludolph, A. J. Beer, G. Glattling; 1’Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY”, “Department of Nuclear Medicine, Ulm University, Ulm, GERMANY”, “Department of Nuclear Medicine, University Hospital Cologne, Köln, GERMANY”, “Department of Nuclear Medicine, Ulm University, Ulm, GERMANY”, “Department of Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”, “NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, SWITZERLAND”, Memory Center and LANVIE – Laboratory of Neuroimaging of Aging, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND”, “Radiology Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”, “Neurodiagnostic and Interventional Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”.

EP-0052
In vivo Amyloid Plaques quantification using F18-Flutemetamol PET/CT in 31 healthy controls and 130 MCI; SUV-methods comparison and transposition in the centiloid scale
R. Lhonnert1, B. Marsault1, L. Deicke1, A. Ivanov1, “Cliniques Universitaires St-Luc, UCLouvain, Brussels, BELGIUM, Institute of Neuroscience (IONS), UCLouvain, Brussels, BELGIUM”.

EP-0053
Multimodal Imaging of X-linked Adrenoleukodystrophies with [18F]FloretabetaT PET/MRI
T. Gerhards, M. Rullmann, H. Rodeck, D. Lobieske, K. Hoffmann, J. Claessen, M. Put, O. Sabin, W. Koehler, H. Barchel; University Hospital Leipzig, Leipzig, GERMANY.

EP-0054
A Brain PET staging system using Amyloid and Neurodegeneration Biomarkers for Individual Assessment in the Context of the 2018 NIA-AA Research Framework: an approach exploring clinical-biomarker mismatches and socio-demographic parameters

EP-0055
Agreement between amyloid-PET early phase images and FDG-PET: a single subject validation in amyloid positive and amyloid negative subjects
P. Santos-Holgueras1, A. Raschli, P. Andryszak1, B. Rakotomassamanana1, M. Scheffler, K. Lückfeld, G. B. Frisoni1, V. Garabrieto1, “Nuclear Medicine and Molecular Imaging Division, San Pedro Hospital-CIBIR, Logroño, SPAIN”, “Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”, “NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, SWITZERLAND”, “Memory Center and LANVIE – Laboratory of Neuroimaging of Aging, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND”, “Radiology Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”, “Neurodiagnostic and Interventional Division, Diagnostic Department, Geneva University Hospitals, Geneva, SWITZERLAND”.

EP-0056
Using Simultaneous PET/MR for amyloidosis and in the SPECT/CT era: applications in Normal Pressure Hydrocephalus and in the detection of Cerebrospinal Fistulas in comparison with Magnetic Resonance Imaging techniques
Clinical progression over one year in mild cognitive impairment subjects with low β-amyloid neocortical retention levels
E. Giovannini, G. Gocoviciu, M. Riondato, S. Pastore, A. Pasteurino, Y. Duer, M. De Biase, C. Passeri, E. Carabelli, A. Maninno, L. Mani, A. Tartaglione, A. Cuvarello; AISI, La Spezia, ITALY, 2Memory Center, La Spezia, ITALY, 3University, Napoli, ITALY.

Quantification of tau load using [3F]PBB: a voxel-wise statistical analysis
E. Yousefzadeh-Nowshahr, G. Winter, P. Bohn, K. Kneer, C. van Ammon, M. Otter, C. Salbach, S. Andersen-Snuth, D. Polivka, P. Fissler, P. Kitting, U. Prasad, M. W. Repp, H. Basak, K. Del Tredici, M. Higuchi, A. Ludolph, A. J. Beer, G. Gattinger; 1Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, 2Department of Psychiatry and Psychotherapy, Ulm University, Ulm, GERMANY, 3National Institute of Radiological Sciences, Chiba, JAPAN.

Tremor and non-tremor Parkinson’s disease show different patterns of [11C]-CFT and [18F]-FDG PET/CT imaging
M. Xin, C. Wang, J. Lu, G. Huang, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.


EP-0075 A pilot study to assess the feasibility of utilising a dedicated cardiac gamma camera based on pin-hole collimated solid state detectors for Striatal Dopamine transporter imaging of the brain (DaTscan).


EP-0076 Visual and semiquantitative analysis of regional brain metabolism in patients with amnestic mild cognitive impairment assessed by 18 F-FDG PET/CT.

Q. Guo, J. Lu. Group-IDIVAL, University of Cantabria, Santander, Valdecilla University Hospital, Molecular Imaging and Medical Physics, University of Cantabria, Santander, España.

EP-0077 Changes of Cerebral Glucose Metabolism in Semantic Dementia: a 18 F-FDG PET Study

J. Lu, K. Cheret, J. Garé, Y. Zhu, J. Xiao, C. Zuo, Q. Guo, P. Wu, J. Li. PET Center, Huashan Hospital, Fudan University, Shanghai, China, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China, Department of Genetics, Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, China.

EP-0078 Are there limitations in reporting brain PET for suspected neurodegenerative dementia in diabetic patients?

K. Mullin. Belfast Health and Social Care Trust, Belfast, United Kingdom.

EP-0079 Amyloid PET/CT for the diagnosis of Alzheimer’s disease dementia and other dementias in patients with cognitive impairment and its relationship with cognitive functioning

L. Rodríguez-Bel, M. Martínez de la Barra, A. Solà, M. Sánchez-Salmón, R. Rodríguez, A. Sánchez-Salmón, J. Martínez-Rodríguez, P. Wu, J. Xiao, I. Martínez-Rodríguez, S. López-García. Hospital Puerta de Hierro, Majadahonda, Spain, Departamento de Neurología, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain, Departamento de Neurología, L’Hospitalet de Llobregat, Barcelona, Spain, Departamento de Neurología, L’Hospitalet de Llobregat, Barcelona, Spain.

EP-0080 Brain 18 F-FDG PET qualitative and quantitative analyses in Atypical Parkinsonian Syndromes (APS) with Cognitive Clinical Symptoms (CCS)


EP-0081 Assessment of the impact of Alternative 11C Ilofinane Imaging Protocols on Image Interpretation for Complex Patients

E. Heeskens, J. Taylor. Medical Imaging and Medical Physics, Sheffield, United Kingdom.

EP-0082 Contribution of the amyloid PET to diagnosis Alzheimer disease

S. Perez Quiros, R. Rodríguez Alfonsín, S. Isejas Miret, A. Santol Delgado, M. Milagros Casasnovas. Hospital Puerta de Hierro, Majadahonda, Spain.

EP-0083 Prognostic Value Of Brain Perfusion Spect In Patients With Attrial Fibrillation And Dementia

H. Hashimoto, R. Nishikuni, S. Mazumza, Y. Hashimoto, Y. Okumura, K. Yamakawa, T. Ide, Tohoku University, Faculty of Medicine, Tokyo, Japan, Domanoritho Otsukaku, Tokyo, Japan.

EP-0084 Application of the 2018 NIA-AA Research Framework to a large cohort of patients with cognitive impairment


EP-0085 A MRI-PET study between behavioral variant Frontotemporal Dementia and elderly Bipolar Disorder


EP-0086 A Comparative PET Study for Assessing Abnormal Metabolic Brain Network Activity in Dementia with Lewy Bodies and Parkinson’s Disease

R. Wu, J. Ge, L. Li, Y. Zhu, J. Xiao, G. Guo, C. Zou. PET center, Huashan Hospital, Fudan University, Shanghai, China, Department of Geriatrics, Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, China.

EP-0087 Retinal and brain tau deposition evaluated by 18 F-Flortaucipir and its correlation with AD biomarkers in CSF


EP-0088 Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy bodies


EP-0089 PET/CT brain imaging using 18 F-FDG in patients with Creutzfeldt-Jakob disease

M. Gremek, T. Rusi, M. Popović, M. Titač. Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Institute of Pathology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.

EP-0090 Integration of dynamic parameters in the analysis of 18 F-Dopa PET imaging improves the prediction of molecular features of gliomas

T. Zargari, A. Gicic, M. Panaite, V. Righi, C. Gauchotte, T. Rech, M. Blonski, Z. Lamič, L. Talinder, L. Imbert, A. Veger. Department of Nuclear Medicine & Nancyclotep Imaging platform, CRFU Nancy, Lorraine University, Nancy, France, IADI, INSERM U1254, Lorraine University, Nancy, France, INSERM U1176, lorraine University, Nancy, France, Department of Pathology, CRFU Nancy, France, INSERM U1256, Lorraine University, Nancy, France, Department of Neurosurgery, CRFU Nancy, Nancy, France, Centre de Recherche en Automatique de Nancy CRAN, CNRS UMR 7019, University of Lorraine, Nancy, France, Department of Neuro-Oncology, CRFU Nancy, Nancy, France.

EP-0091 Neuroimaging: Brain Malignant

Displayed throughout the congress days e-Poster Area
The pentose phosphate pathway in glioma - a promising target for nuclear medicine?

A. Kholyavin; N. P. Bechtereva

Institute of the Human Pathology - Universitary Hospital, Rennes, FRANCE.

Correlation of [11 C]Methionine PET Uptake With Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [1,3]Department of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [1]University of Lausanne, Lausanne, SWITZERLAND, [2]Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA.

15F-Fluorocholine PET/CT in the prediction of [18 F]FDG uptake in primary brain tumors

Y. G. Abdelhafiz1, N. Raghuram, W. Deha1, W. Abdel-Ghany2, M. El-Naggar2, M. Yasuda2, 3

1Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, 2Department of Neuroradiology Unit and CERMAC, IRCCS San Raffaele Scientific Institute, Milan, ITALY, 3Department of Pathology, Radiological Medical University Hospital, Monza, Italy, [1]Department of Pathology, Radiological Medical University International Medical Center, Hidaka, Saitama, JAPAN, [1]Department of Pathology, Radiological Medical University, Monza, Italy, [1-3]University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, [2]South Egypt cancer Institute, Assuit, Egypt, [3]Faculty of Medicine, Assuit University, Assuit, EGYPT.

Comparison of diagnostic value between PET/CT and PET/MRI in brain tumors: a preliminary study

Y. Xu, J. Wang, S. Wang, C. Li; Hangzhou Universal Imaging Diagnostic Center, Hangzhou, CHINA.

68 Ga-DOTANOC PET/CT in Meningioma

Y. G. Abdelhafiz1, E. Roychoudhury, H. Atta1, M. El-Naggar2, 3, M. Yasuda2, [1]University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA, [2]South Egypt cancer Institute, Assuit, Egypt, [3]Faculty of Medicine, Assuit University, Assuit, EGYPT, [1]Faculty of Medicine, Cairo University, Cairo, EGYPT.
EP-0109  Spatial relationship of 11C-Methionine PET and Gd-enhanced MRI in oncological brain lesions by using a fully hybrid PET/MRI system  
P. Magelli1, P. Sculli2, F. Fallanca2, V. Bettinardi2, A. Castellano1, M. Barbera1, A. Falini1, L. Ganzoni2, N. Anzalone2, M. Piacelli11  
1Vita-Salute San Raffaele University, Milan, ITALY; 2Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY;  
1Neuroradiology Unit and CERMAC, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

EP-0110  Relationship Of Hearing Preservation Of Patients With Neurofibromatosis Type 2 With Tumor Maximum Standardized Uptake From The 11c-met Pet/Ct Images  
X. Zhao, Z. Chen, S. Li, S. Zhang, C. Zhao, J. Zhang, X. Wang, F. Zhao, P. Liu, L. Ai; Beijing Tiantan hospital, Beijing, CHINA.

EP-05  Translational and Molecular Imaging Therapy: Optimisation of Tracer Kinetics

EP-0111  First Reported SPECT/CT to Investigate Pharmacokinetics of Host Defence Peptides  
K. Saatchi1, C. Y. V. Lopata1, D. Pietten1, C. Blackadar2, A. Rodriguez-Rodriguez1, R. E. W. Hancock1, U. D. Hallé1  
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CANADA; 2Centre for Microbial Disease and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, CANADA.

EP-0112  Comparison of the Physiological Uptake of 4Ga-PSMA Between Early and 60-min Post-injection PET/CT Scans  
T. Hekimsoy, S. Isgen, G. Daglar Gora, H. Demir; Kocaeli University School of Medicine, Department of Nuclear Medicine, Kocaeli, TURKEY.

EP-0113  Monitoring early vascular disrupting agent (VDA) treatment response with 68Ga-DOTA-Heptap, an albumin binding tracer, in vivo PET/CT imaging  
C. Huang1, G. Chang1, J. Liu1, S. Hsu2, W. Chang1, F. Huang1; 1Center for Advanced Molecular Imaging and Translation, Taipei, TAIWAN; 2National Taiwan University, Taipei, TAIWAN.

EP-0114  Influence of the degree of chelator conjugation on the physicochemical properties of Nanobody PET tracers  
P. Debie1, H. Baadhui1, J. Rutgers1, S. Hemrot1, C. Xavier2, T. Lahautre2; 1Vige University Brusel, Brusel, BELGIUM; 2Brussels Jette, Jette, BELGIUM.

EP-0115  Design and biodistribution of 64Cu labelled liposomes bearing anti-CD44 aptamer in triple negative breast cancer murine model  
F. Antoni1, H. Willaure2, F. Hontonnau1, B. Hosten1, N. Vignal1, L. Durand2, S. Denis1, V. Panetti1, C. Chomienne1, L. Sarda-Mariet1, E. Fart1; 1Univ Claude Bernard Lyon 1, INSA, Université Lyon 1, INSERM U1122, CNRS UMR 5247, INSA, Lyon, FRANCE; 2Institut Galien Paris-Sud, UMR CNRS 8612, Chalégy-Malabry, FRANCE.

EP-0116  Optimizing affibody-mediated PET imaging of HER3 expression using long-lived radioisotope for the next day PET image  
S. Rinne1, C. Dahlsson Leisner1, B. Milman1, V. Tilmachev1, S. Ståh1, J. Lofblom1, A. Orlova1; 1Uppsala University, Uppsala, SWEDEN; 2KTH - Royal Institute of Technology, Stockholm, SWEDEN.

EP-0117  Pretargeted Radioimmunotherapy and SPECT Imaging of Peritoneal Carcinomatosis Using Bioorthogonal Click Chemistry: Probe Selection and First Proof-of-Concept  
F. Degou1, A. Randori1, S. Schmitt1, A. Bhat1, N. Ty1, M. Quittana1, R. Membrino1, B. Ziegba2, J. NavarroTeulier1, J. Pouget1, J. Cheval1, E. Mist-Nearnault1, E. Moreno1; 1UMR 7240, Clermont-Ferrand, FRANCE; 2Department of Chemistry, Hunter College, City University of New York, New York, NY, UNITED STATES OF AMERICA; 3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA; 4Institut de Recherche en Cancérologie (IRCM), U1194 – Université Montpellier – ICM, Radiology and Targeted Radiotherapy, Montpellier, FRANCE.

EP-0118  Structural Modification of Indolino-Diene Analogues as Alpha-Synuclein Ligands and Its Structure-Activity Relationship Analysis  
J. Lee1, J. Han1, E. Nam1, K. Chung1, S. Lee2; Neuroscience Research Institute, Gachon University, Incheon, KOREA, REPUBLIC OF.

EP-0119  Identification of Peptide Ligands from Peptide Mixtures by Quantitative Analyses of Differential Cell Uptake Patterns  
M. Parzinger1, H. Wester2; 1Technical University of Munich, Garching bei München, GERMANY; 2Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

EP-0120  TyT Labeled Tetrazines for In Vivo Pretargeted Imaging  
L. Bohrmann1, P. Brueckl1, S. Krapieszcz1, C. Rodriguez-Rodriguez1, M. M. Herth1, K. Serach1, U. O. Hallé1; 1University of British Columbia, Vancouver, BC, CANADA; 2University of Copenhagen, Copenhagen, DENMARK.

EP-0121  A1/P-NOTA-octreotide PET imaging of the somatostatin receptor: preliminary results of a human biodistribution, dosimetry and safety study  
E. Pauwels1, F. Clemen1, T. Tishbarg1, M. Koeler1, K. Sundans1, K. Van Laere1, G. Biermans1, C. M. Deraese1; 1Nuclear Medicine - UZ Leuven, Nuclear Medicine and Molecular Imaging – RU Leuven, Leuven, BELGIUM; 2Radiopharmaceutical Research – KU Leuven, Leuven, BELGIUM.

EP-0122  Linker optimization to improve tumor uptake of PSMA binding radiopharmaceuticals  
H. Kuo1, Z. Zhang1, H. Mekens1, C. Zhang1, N. Gai1, K. Lin2; 1F. Bédard1, Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA.

EP-0123  4Gα-labeled N-Carboxymethyl-substituted PSMA ligands enhancing binding affinity  
B. Lee1, S. Choi2, W. Jung1, H. Moon1, H. Jeong1, H. Kim1, K. Kim2, K. Kim1, M. Kim1, Y. Lee1, K. Lee1, S. Lim1, D. Chi1, K. Song1; 1FutureChem, Seoul, KOREA, REPUBLIC OF; 2Korea Insti7uted of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF; 3Sogang University, Seoul, KOREA, REPUBLIC OF.

EP-0124  Application of 99mTc-3PRGD2 imaging for early predicting pathological response to neoadjuvant chemotherapy in breast tumors and axillary lymph nodes  
W. Miao1, Z. Chen1; 1The First Affiliated Hospital of Fuzhou Medical University, Fuzhou, CHINA.

H. Kuo1, Z. Zhang1, C. Urbe1, H. Mekens1, C. Zhang1, F. Bédard1, K. Lin2; 1Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA; 2Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.
EP-0126
Impact of global ultrasound-induced blood-brain barrier opening on the distribution of full monoclonal antibody cetuximab
C. Trullillet, V. Tran, A. Novella, M. Genitennemeyer, A. Bouroua, H. Maslak, B. Kuhnert, N. Tourrier, B. Larrat, CEA, Orsay, FRANCE, CNRS, Orsay, FRANCE.

EP-07
Oncology: PSMA Imaging and Therapy
Displayed throughout the congress days e-Poster Area

EP-0127
Unexpected high incidence of positive 68Ga-PSMA-11 PET/CT performed during androgen deprivation therapy in biochemical recurrent patients, showing low PSA values (<0.5 ng/mL)
P. L. Muraglia, F. Mattarini, A. Farelli, F. Ceci, P. Castellucci, L. Caldaroni, V. Cerri, R. Meo, S. Fanti, 1Università di Bologna, Bologna, ITALY, 2Metropolitan Nuclear Medicine, Policlinico Sant’Orsola-Malpighi, Bologna, ITALY, 3Università degli studi di Torino, Torino, ITALY.

EP-0128
Location of biochemical recurrences after robot-assisted radical prostatectomy with sentinel node biopsy and lymph node dissection: analysis with PSMA-PET/CT and comparison with initial SPECT/CT
O. R. Brouwer, E. Wit, P. J. van Leeuwen, F. W. B. van Leeuwen, H. G. van der Poel, 1The Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 2Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0129
Prospective evaluation of 68Ga-PSMA-11 PET/CT sensitivity in patients with early biochemical recurrence
O. Alonso Nunez, G. dos Santos, M. Rodriguez-Torres, E. Silveira, 1Uruguayan Centre of Molecular Imaging (CLUDIM), Montevideo, URUGUAY, 2Clinical Hospital, University of Uruguay, Montevideo, URUGUAY.

EP-0130
Potential of molecular imaging with 111In-EDDA/HYNIC-IPSMA SPECT in brain tumors
M. R. Siqueira, J. S. Andrade, C. C. Correia, P. Ferreira, C. Gomes, F. Costa, C. Araújo, 1Instituto de Medicina Molecular, Instituto de Biociências e Medicina Molecular, Universidade de Lisboa, Lisbon, PORTUGAL.

EP-0131
Potential of molecular imaging with 68Ga-PSMA-11 PET/CT in prostate cancer patients with suspected recurrence after definitive therapy
T. Langena, K. Kapkar, J. Lawal, T. Boshomane, M. Kolkama, M. Vorster, F. Gerszt, M. Sathegker, 1Department of Nuclear Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, SOUTH AFRICA, 2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY, 3Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY.

EP-0132
"Ga-PSMA uptake variability: A test-retest study
J. olde Heuvel, L. J. de Wit - van der Veen, M. L. Danuswijk, C. H. Stump, M. P. M. Stokkel, 1Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS.

EP-0133
Intersubject and Intraobserver Agreement for the Proposed mTNM Classification for the Interpretation of "GaPSMA I&T PET/CT Imaging
A. Gültekin, O. Yıldız, T. Şenego, D. Yuksel, H. Şenal, Pamukkale University Medical Faculty, Denizli, TURKEY.

EP-0134
Prospective comparison of hybrid 68Ga-PSMA PET/CT and PET/MRI in patients with biochemically recurrent prostate cancer

EP-0135
The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients With Suspected Recurrence After Definitive Bloodstream Relapse
T. Lengena, K. Kapkar, J. Lawal, T. Boshomane, M. Kolkama, M. Vorster, F. Gerszt, M. Sathegker, 1Department of Nuclear Medicine, Steve Biko Academic Hospital and University of Pretoria, Pretoria, SOUTH AFRICA, 2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, GERMANY, 3Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY.

EP-0136
Interobserver and Intraobserver Agreement for the Proposed mTNM Classification for the Interpretation of "GaPSMA I&T PET/CT Imaging
A. Gültekin, O. Yıldız, T. Şenego, D. Yuksel, H. Şenal, Pamukkale University Medical Faculty, Denizli, TURKEY.

EP-0137
"Ga-PSMA-11 PET surpasses clinical nomograms for prediction of lymph node metastasis in patients with intermediate to high-risk prostate cancer
A. D. Ferrara, U. I. Muhlhammer, H. J. Garcia Schüeler, N. J. Rupp, T. Herrmann, I. A. Burger, 1University Hospital of Zurich, Zurich, SWITZERLAND.

EP-0138
Head To Head Comparison Of 18f-fch And 18F-PSMA-1007 Pet/ct In Biochemically Relapsed Prostate Cancer Patients - Preliminary Results
E. Witkowska-Patena, A. Ganzowski, M. Czulp, J. Milko, A. Budzyska, A. Wolejko-Mazur, 1Military Institute of Medicine, Warsaw, POLAND, 2Affidea Mazovian PET/CT Medical Centre, Warsaw, POLAND.

EP-0139
Novel squaric acid coupled Ku-based PSMA inhibitors: Synthesis, radiolabelling with gallium68 and first in vitro and ex vivo evaluation
H. Lahnif, L. Greffenstete, T. Grus, R. Bergmann, M. Schenklenburger, M. Miedener, S. Pekár, F. Roach, 1Johannes Gutenberg University Mainz, Mainz, GERMANY, 2Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, 3University Medical Center Mainz, Mainz, GERMANY.

EP-0140
Use of 68Ga-PSMA-11 PET/CT in the detection of prostate cancer recurrence of non metastatic castrate-resistant patients: positivity rate and impact on patient management
M. Gauthé, F. Fournet, C. Avetross, F. Montavon, J. Talbot, Hôpital Tenon, Paris, FRANCE.

EP-0141
Interobserver agreement in 68Ga-PSMA PET/CT
I. Garcia Schüler, D. Eberli, T. Hermanns; University Hospital Göttingen, Göttingen, GERMANY.

EP-0142
Can patient selection based on 68Ga-PSMA I&T/CT improve the outcome of radical prostatectomy in prostate cancer patients?
I. A. Burger, D. A. Ferrara, U. I. Muhlhammer, H. J. Garcia Schüeler, D. Eberli, T. Herrmanns; University Hospital Zurich, Zurich, SWITZERLAND.

EP-0143
Advantages of "Ga-PSMA I&T/CT in primary staging of prostate cancer
W. Cytaxa, T. Bandurski, J. Tran-Gia, A. Schehbel, K. Tsuchishita, H. Wester, P. Cais, B. Brockhaus, W. Pek, A. K. Bucli, C. Lapot, 1Medical University of Gdansk, Gdansk, POLAND, 2University Hospital Würzburg, Würzburg, GERMANY, 3Technische Universität München, Munich, GERMANY.

EP-0144
"11c-PSMA-SPECT/CT in Patient With Prostate Cancer
I. Farkas, Z. Besemy, A. Manda, Z. Bajory, A. Palkó, G. Szabs, L. Udvardy, L.Palcu, University of Szegett, Szegett, HUNGARY.

EP-08
Inflammation & Infection: Molecular Imaging in Infection and Inflammation
Displayed throughout the congress days e-Poster Area

EP-0147
Clinical usefulness of 18F-FDG PET/CT in patient with cardiac implantable electronic device
C. Ferrari, A. Ungara, A. R. Pianu, A. Gaudiana, V. Leviti, C. Almis, A. G. Nappi, G. Rubino, Nuclear Medicine Unit, Interdisciplinary Department of Medicine – University of Bari “Aldo Moro”, Bari, ITALY.

EP-0148
11c-White Blood Cell Scintigraphy With SPECT/CT in the Diagnosis of Vascular Graft Infection

EP-0149
Role Of F-18 FDG PET-CT in The Evaluation of Patients With Fever Of Unknown Origin
J. Mandarapu, Continental Hospitals Limited, Hyderabad, Telangana, INDIA.

EP-0150
The role of “after washing imaging” in evaluation of tear drainage system by dacyrocystography
R. Sadeghi, T. Mazouki, H. Shayanji, Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.
EP-0151
Progressive Accumulation of Radiolabeled White Cells in Scans Performed for Suspected Vascular Prosthetic Graft Infections
J. Joona, A. G. G. Doruyter, J. M. Wiernick
Stellenbosch University, Cape Town, SOUTH AFRICA

EP-0152
18F-FDG PET/CT Assessment of Sarcoiodosis: Extension and Activity - A Single Center Experience

EP-0154
Novel monitoring indices of osteomyelitis of the jaw using SPECT quantitative analysis: Preliminary study for patients with ARONU
H. Hata, T. Kitai, K. Imamachi, J. Sato, A. Asaka, N. Ohara, K. Hara, T. Shiga, K. Tanaka, "Dentistry and oral surgery, Hokkaido Cancer Center, National Hospital Organization, Sapporo, JAPAN, 1Radiology Department, Hokkaido Cancer Center, National Hospital Organization, Sapporo, JAPAN, 1Oral diagnosis and medicine, Graduate school of dental medicine, Hokkaido University, Sapporo, JAPAN, 1Nuclear medicine, Graduate school of medicine, Hokkaido University, Sapporo, JAPAN, 1Hokkaido Cancer Center, National Hospital Organization, Sapporo, JAPAN.

EP-0155
Polyarthritis Rheumatica as Paraneoplastic syndrome on18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
G. Silvér, S. Karacavus, H. Gencer, Health Sciences University, Kayseri City Hospital, Department of Nuclear Medicine, Kayseri, TURKEY.

EP-0156
Diagnostic Role Of Three-phase Bone Scintigraphy In The Differentiated Choosing Of The Component Of Endoprosthesis In Patients With Septic And Aseptic Osteoarthrosis Of The Hip Joint
P. Korol, M. Tkachenko; "Clinical City Hospital #12, Kiev, UKRAINE, 1A. A. Boharanovs National Medical University, Kiev, UKRAINE.

EP-0158
Correlation between bone scan findings and echocardiography parameters in patients with cardiac amyloidosis
N. A. Martinez Amador1, O. Cuencas Vivas1, J. Martinez Rodriguez1, M. De Arcaseta Torres1, R. Quiroz1, J. Jiménez Borrás1, A. Sánchez Salmerón1, M. Zanauza Navarro2, G. Molina Mendoza1, J. Banza2; 1Department of Nuclear Medicine, Marqués de Valdecilla University Hospital. Molecular Imaging Group (GIMAV), University of Cantabria, Santander, SPAIN, 2Department of Cardiology, Marqués de Valderriña University Hospital, University of Cantabria, Santander, SPAIN.

EP-0159
"18F-Technetium Diphotophosphates in Transhyretin Cardiac Amyloidosis. Extracardiac Uptake Evaluation in Our Centre
A. Andres Gracia1, D. Noguera Saúto1, L. Tardín Cardoso1, M. Delgado Castro1, P. Razzela Atkins1, C. Latuerna Peyre2, M. Abal Arequez2, E. Piáts Rivera2, D. Abas Olivar2; 1Unidad Clínica Multihospitalaria de Medicina Nuclear de Aragon, Zaragoza, SPAIN, 2IS ARAGON, Zaragoza, SPAIN, 3Servicio de Bioquímica Clínica Hospital Universitario "Miguel Servet", Zaragoza, SPAIN, 4Servicio de Medicina Interna-Hospital Clínico Universitario "La Paz", Zaragoza, SPAIN.

EP-0160
Contribution Of "18F-FDG PET/CT In Patients With Suspected Cardiac Implantable Device Related Infection
B. Rodríguez-Alfonso1, A. Ramos-Martinez1, V. Castro Urdá1, M. Cobo-Marcos1, J. Sánchez-Romero1, J. Toquero-Ramos1, A. Restrepo-Casabó1, M. Mitjavila-Casanova1; Hospital Universitario Puerta de Hierro, Majadahonda, SPAIN.

EP-0161
Contribution of "18F-FDG PET/CT in Treatment Decision Making in Patients with Suspected Cardiac Implantable Device Infection
B. Rodríguez-Alfonso1, M. Mitjavila-Casanova1, L. Canales-Rodriguez1, V. Castro Urdá, M. Cobo-Marcos1, A. Ramos-Martinez1, Hospital Universitario Puerta de Hierro, Majadahonda, SPAIN.

EP-0162
Musculoskeletal infections: contribution to definitive diagnosis of the semiquantitative analysis with 99mTc-lesilesomab
P. Guardia Jimena1, A. Costa López1, M. Martínez del Valle Torres1, R. Arenas Aguaza1, M. Bermúdez Morales1, E. Moratalla Aranda1, R. Nieto Semana1, D. Becerra García1, San Cecilio University Clinical Hospital, Granada, SPAIN.

EP-0163
Odontogenic and non-odontogenic mandibular osteomyelitis: Differentiating findings on bone scintigraphy
K. Kawai1, M. Jingui1, M. Nakaj1, A. Tsai1, T. Yoshid1; 1Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN.

EP-0164
"18F-FDG PET-CT in patients with spondyloarthropitits: image, clinical and laboratory findings in 10 cases
J. Bernal1, M. Agudelo-Cifuentes1, B. Martínez-Sanchís1, A. Yepes-Agudelo1, A. Utrera-Costero1, J. Fragio1, P. Sopena-Navales1, B. Pello-Añgeres1; Hospital La Fe, Valencia, SPAIN.

EP-0165
Bone extension of histiocytosis: Assessment with bone scan and FDG-PET/CT
A. Palomar Muñoz1, M. Cortés-Romera1, A. Sabaté-Llobrí1, L. Rubio-Aviles1, X. Solà-Menénez1, J. A. Hernández-García1, J. J. Robles-Barba1, J. Mestre-Alsina1, A. Rodríguez-Gasen1, G. Gómez-Centeno1; 1Unit PET/CT (IO) - Department of Nuclear Medicine, Hospital U. de Bellvitge-IDIBELL, Hospital de Llobregat (Barcelona), SPAIN, 2Department of Internal Medicine, Hospital U. de Bellvitge-IDIBELL, Hospital de Llobregat (Barcelona), SPAIN.

EP-0166
SPECT/CT imaging in dacryocystography for the anatomical localization of nasolacrimal duct obstruction
C. C. M. Fernandez1, K. Rayando2, E. Sélvez1, S. Rodríguez1, A. Massó2, R. Hita-Tejada1, J. Vilà1, A. Fernández1; 1Clinical Hospital, University of the Republic, Montevideo, URUGUAY, 2Fernanda Paez Nuclear Medicine Clinic, Montevideo, URUGUAY.

EP-0167
"18F-FDG PET/CT with early and delayed imaging in infective endocarditis and implantable cardiac electronic device infection
H. Navalon Martínez1, L. Vida1, S. Rubi1, A. Morena1, A. Raposo1, N. Ortiz1, B. Lain1, M. Valiente1, C. Medina1, C. Pérez1; 1Hospital Universitario San Espasmas, Palma De Mallorca, SPAIN, 2IdISBa, Palma de Mallorca, SPAIN.

EP-0168
The potential clinical role of "18F-FDG-PET-derived metabolic parameters in extrapulmonary tuberculosis among HIV-infected patients: An explorative prospective study
G. Boshomane1, I. O. Lawali1, L. Gengana1, P. Rheeder1, K. M. G. Makadzi1, V. Matzer1, M. M. Sathelgife1; University of Pretoria, Pretoria, SOUTH AFRICA.

EP-0169
MRI-based validation of 99mTc-HDP SPECT/CT in sarcoidosis - preliminary results
Z. Besenyi1, A. Balázs1, G. Sipák1, J. Farkas1, S. Urán1, R. Heremel1, L. Kovács1, L. Pávics1; 1University of Szeged Department of Nuclear Medicine, Szeged, HUNGARY, 2University of Szeged Department of Rheumatology, Szeged, HUNGARY.

EP-0170
Diagnosis of infected hip and knee prostheses with Tc-99m Sulfomab: the utility of delayed (20-24hours) imaging
O. Mbakaza1, O. Ayen2, P. Karumba1, M. D. T. W. Vang1, University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0171
Cardiovascular: Vascular Imaging
"Displayed throughout the congress days e-Poster Area

EP-0172
Medical mimics and incidental findings diagnosed on PET/CT for investigation of possible giant cell arteritis: a pictorial review
S. L. Ayesa1, A. M. Sammet2, R. Laurent3, P. J. Roach4, E. S. L. Ayesa1; 1University of the Witwatersrand, Johannesburg, South Africa, 2University of Melbourne, Melbourne, AUSTRALIA, 3University of Cape Town, Cape Town, SOUTH AFRICA, 4Royal North Shore Hospital, St Leonards, Sydney, AUSTRALIA.
EP-0172 Relationships between the results of computed tomography coronary angiography and myocardial perfusion abnormalities on SPECT
K. Zavadovskiy, A. Maltesa, K. Kopena, A. Mochula, E. Gerasova, Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-0173 Usefulness of 18-Fluorodeoxyglucose PET/CT semi-quantification in the diagnosis of large vessel vasculitis: a retrospective study
D. Lisei Coscia, C. Viggli, O. Rodriguez, C. Salvat, A. González-García, Hospital Universitario Central de Asturias, Oviedo, SPAIN.

EP-0174 Arterial inflammation detected with PET-TC 18 F-FDG at staging and end of treatment after ABVD
A. L. Gutiérrez Cardo, 1

EP-0175 Molecular imaging of carotid artery atherosclerosis with pet: a systematic review
R. Piri, A. H. Jafarian, M. Assadi, Department of Radiology, Aga Khan University Hospital (AKUH), Karachi, PAKISTAN.

EP-0176 Short-term discontinuation of vagal nerve stimulation alters 18F-FDG blood pool activity in humans
E. Boswik, 1, R. Franssen, 2, G. H. E. J. Vijgen, 2, A. Caresia, 3, M. H. M. J. Mottaghy, 1

EP-0177 Utility Of PET-CT With 18F-FDG In The Study Of Large Vasculitis

EP-0178 18F-FDG PET/CT and CT angiography in the evaluation of immunosuppressive therapy in large vessel vasculitis
M. M. S. Maragas, 1

EP-0179 Measurement of epicardial adipose tissue with FDG-PET/CT in patients with type-2 diabetes mellitus
D. Deseo, 2 K. Zambón, 2 Z. Pitter, 2 Z. Bán, 2 J. Szabó, 2 B. Bódor, 2 I. Kanyi, 2 S. Szalóki, 2 T. Toth, 2 O. Nemés, 2 K. Ruzs, 2 S. Szójayi, 2 E. Medevi, 2 B. Kaposi, 2 E. Schmidt, 1 University of Pécs Department of Nuclear Medicine, Pécs, HUNGARY, 1 University of Pécs 1st Department of Medicine, Pécs, HUNGARY, 4 University of Pécs Department of Radiology, Pécs, HUNGARY.

EP-0180 Myocardial ischemic patterns in patients with idiopathic pulmonary arterial hypertension
A. A. Anshelev, 1 J. G. Gunaynov, 2 T. V. Martynyuk, 2 V. B. Senykinov, 1 National Medical Research Center of Cardiology, Moscow, RUSSIAN FEDERATION, 3 National Economics Research Institute, Moscow, RUSSIAN FEDERATION.

EP-0181 Visual identification of coronary calcifications on diagnostic chest CT improves diagnostic accuracy of TI-201 CZT SPECT myocardial perfusion imaging
H. Chen, Y. Chang, Y. Huang, Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN.

EP-0182 Evaluation of myocardial perfusion in patients with asymptomatic Beta-thalassemia major using myocardial perfusion SPECT and its possible association with severity of hemostasis
M. Assadi, P. Rahimighad, A. Omran, E. Jafarian, Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-0183 The evaluation of myocardial perfusion with CZT gamma camera in patients with immediately stenosed left anterior descending coronary artery and estimated fractional flow reserve
S. Piszczek, K. Tsaracovský, A. Mazurek, S. Oseckí, M. Dzika, Military Institute of Medicine, Warsaw, POLAND.

EP-0184 Left ventricular mass index measured by myocardial perfusion scan: Correlation with echocardiography
M. Abbadi, 1 Q. Nadj, 2 D. Djermane, 2 M. Habbach, 2 B. Said, 3 Centre d’Imagerie Scintigraphique, Blida, ALGERIA, 1 CHU Mustapha Bacha, Algiers, ALGERIA.

EP-0185 Lower Event Rate In Obese Patients With Transient Ischemic Dilatation Of LV Cavity on Gnp2: Is Obesity Friend or Foie
N. Fatima, 1 M. U. Zaman, 1 A. Zaman, 1 U. Zaman, 2 S. Zaman, 1 Department of Radiology, Aga Khan University Hospital (AKUH), Karachi, PAKISTAN, 1 Civil Hospital, Karachi, PAKISTAN, 2 Dow Medical College, Dow University of Health Sciences (DUGH), Karachi, PAKISTAN.

EP-0186 Prognostic Value of Stress Gated MPI SPECT and Coronary Artery Calcium Score in Patients with Diabetes Mellitus
M. Havel, 1 M. Kamei, 1, 2 P. Koranda, 1, 2, 3, 4, 5, I. Metelková, 1, 2, 3, 4, 5, M. Budiková, 1, 2, 3, 4, 5, L. Henzlová, 1, 2, 3, 4, 5, V. Kincz, 1 Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, CZECH REPUBLIC, 2 International Clinical Research Center, Center of Molecular Imaging, Brno, CZECH REPUBLIC.

EP-0188 Interpretation of coronary collateral by myocardial perfusion gated spect
S. Ozdemir, 1 A. Barutcu, 1 Y. Y. Tari, 1 E. Akar, 1 A. Duygu, 1 F. K. Gaturk, 1 Onkorya Man University Faculty of Medicine Department of Nuclear Medicine, Canakkale, TURKEY, 2 Onkorya Man University Faculty of Medicine Department of Radiology, Canakkale, TURKEY.

EP-0187 Evaluation of myocardial perfusion in patients with asymptomatic Beta-thalassemia major using myocardial perfusion SPECT and its possible association with severity of hemostasis
M. Assadi, P. Rahimighad, A. Omran, E. Jafarian, Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-018A Evaluation of myocardial perfusion in patients with asymptomatic Beta-thalassemia major using myocardial perfusion SPECT and its possible association with severity of hemostasis
M. Assadi, P. Rahimighad, A. Omran, E. Jafarian, Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF.
EP-0189
Interreader Reproducibility Between A Conventional And A CZT/SPECT Camera In The Myocardial Perfusion Scintigraphy (MPS): A Multicentric Study
N. Mansour, E. Reyer, G. Angeli, P. Geragthoulis, C. Anagnostopoulos, P. Bravo, J. Bruner, A. Guzman, A. Flotar, F. Fuentes-Ocaampo, R. Di Dato, F. Reng, L. Keseler, M. Papathanassiu, P. Soman, S. Nekolla, C. Rischpler. Nuclear Medicine Unit, Klinikums rechts der Isar, Munich, Germany; Royal Brompton Hospital, London, United Kingdom; Nuclear Medicine Department, University of Thessaly, Larissa, Greece; IRBFA - Biomedical Research Foundation Academy Of Athens, Athens, Greece; University of Pennsylvania, Philadelphia, PA, United States of America; Fondazione Policlinico Universitario Policlinico - IRCCS: “A. Gemelli”, Rome, Italy; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences “Mara Seno”, Florence, Italy; National Heart Centre, Singapore, Singapore; University Hospital Essen, Department of Nuclear Medicine, Essen, Germany; Department of Cardiology, Wes Geman Heart and Vascular Center, University Hospital, Essen, Germany; University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.

EP-0190
Investigation of clinical factors affecting the myocardial blood flow and flow reserve using TI-dynamic SPECT with a CZT gamma-camera limited patients with normal summed stress score

EP-0191
SPECT-CT 16 Slices Myocardial Perfusion Imaging vs Prone Acquisition In Minimizing Artifactual Defects Interpretation
E. Papadaki, N. Kapotsikis, O. Bourangien, M. Statthaki, A. Tsaroucha, M. Akrantas, S. Kotsiavari; Heraklion University Hospital, Iraklion - Crete, Greece.

EP-0192
Sensitivity of the treadmill stress test according to the risk stratification by clinical evaluation of the stable coronary artery disease, confirmed whether by myocardial perfusion scan and coronary angiography
M. Habbeche, G. Nabi, M. Abdal, B. Safi, D. Djermane, Centre d’imagerie scintigraphique, Blida, Algeria; Service de cardiologie CHU Mustapha Bacha, Algier, Algeria.

EP-0193
Could end-diastolic images in myocardial perfusion imaging performed on CZT camera determine significant changes in ischemia assessment in Patients with diastolic dysfunction compared to Patients with normal diastolic function?
M. Bonacina, D. Albano, M. Bertoli, F. Donà, R. D’Urmi, A. Mazzotti, E. Cerudelli, P. Bellini, M. Gazzelli, F. Bertagno, A. Stoddard, Civil, Brescia, Italy; Università degli Studi di Brescia, Brescia, Italy.

EP-0195
Clinical impact of the use of ultralight exercise with adenosine stress myocardial perfusion imaging
E. Tateishi, K. Kiso, Y. Kawahara, T. Nishii, University of Osaka, Osaka, Japan; E. Tateishi, K. Kiso, Y. Kawahara, T. Nishii, Cardiovascular Center, Suita, Osaka, Japan.

EP-0196
Does prone myocardial perfusion imaging improve inferior and anterior perfusion defects?
Z. Al Bimani, P. H. Whitnoff, R. Kilen, W. Zeng; University of Ottawa, Ottawa, ON, Canada; Ottoman Medical Speciality Board (OMSB), Muscat, Sultanate of Oman, Oman.

EP-0197
Incidental Findings on Myocardial Perfusion SPECT/CT Images
I. El Bez, R. Tulbah, I. Murn, F. Afghamis, M. Alkhali, XAMS, nuclear medicine department, Riyadh, Saudi Arabia.

EP-0198
Fast heterogeneous convolution algorithm used in absorbed dose calculation for beta emitters
A. Vergara Gil, J. Maria Ramírez, J. J. Pouget, P. Kozik; ASST Spedali Civili, Brescia, Italy; Università degli Studi di Brescia, Brescia, Italy.

EP-0199
Analysis of nuclide distributions of pre-therapeutic thyroid scintigraphies with I-131 and Tc-99m in comparison to intra-therapeutic I-131 scintigraphies in the context of radioidine therapy in benign thyroid dysfunctions by means of parametric evaluation and 3D imaging
U. Lützen, S. Meyerburg, Y. Zhao, M. Marx, M. Jüptner, M. Zwingenberger, UKF, Kiel, Germany.

EP-0200
Estimation Of The Absorbed Dose In Patients Treated With Ra223

EP-0201
Partition method-based treatment planning in radioembolization with microspheres: software for tumor to normal tissue ratio calculation
F. Márquez, D. Martínez, A. Fernández, I. Basagoiti, F. Caudelou, P. Estada, N. Fuentes Mellor, M. Rébélès, Complejo Hospitalario de Navarra, Pamplona, Spain.

EP-0202
Different settings for the calculation of absorbed doses in therapy with radioactive somatostatin analogues
E. Grassi, E. Pailer, D. Pinochett, A. Versani, A. Ficici, L. Bragali, M. Iori, J. Tipping, F. Fiorenzi; AUSL - IRCCS di Reggio Emilia, Reggio Emilia, Italy; The Christie NHS Foundation, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom; Università di Bologna, Bologna, Italy.

EP-0203
“Cu111-AC-DOTA-rituximab internal dosimetry in mice using image-based Monte Carlo simulation
S. Woo, W. Kim, C. Lee, I. Lim, K. Song, S. Lim; Division of applied R, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of, Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of, Department of Urology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of.

EP-0204
Accuracy of personalized kidney dosimetry in “Lu-DOTA-TATE based on a simplified single-time-acquisition with segmentation-free small-volume method
X. Hou, W. Zhou, J. Beauregard, A. Cellier; Radiology Department, University of British Columbia, Vancouver, BC, Canada; Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada, Department of Medical Imaging and Oncology Division of Research Center, CHU de Quebec – Université Laval, Quebec, QC, Canada; Department of Radiology and Nuclear Medicine and Cancer Research Center, Université Laval, Quebec, QC, Canada.

EP-0205
A Geant4-based Voxel S-value Generator For Radiopharmaceutical Therapy
B. Bednarz; University of Wisconsin, Madison, WI, United States of America.
**EP-0206**

PRRT: standardized activity and dose quantification for dosimetry of NETs patients treated with \(^{90}\)Y-Lu


Department of Physics and Earth Sciences, University of Ferrara, Ferrara, ITALY. Medical Physics Unit, Sant’Anna University Hospital, Ferrara, ITALY.

**EP-0207**

Thresholds in SPECT image for quantification in the planning of TheraSpheres\(^{90}\)Y 190 treatments

M. Barquero Sanz, C. Andreu, M. Martin Veganzones, R. Pausa, J. Velaosa, C. Caglioni, A. Sainz, J. Gomez, SACLY, Valladolid, SPAIN.

**EP-0209**

Torch: A Treatment Planning System for Personalized Radiopharmaceutical Therapy

J. Grudzinski, K. Soerenen, M. Graaz, B. Bednarz, P. Weckie, Vasimetry, Middleton, WI, UNITED STATES OF AMERICA.

**EP-0210**

Idac-alpha - An Alpha Dosimetry Program For Healthy Tissues

M. Andersson, Medical Radiation Physics, Malmo, SWEDEN.

**EP-0211**

Development and Verification of a Software Tool to Calculate Absorbed Doses at the Voxel Level in Molecular Radiotherapy Treatments

T. Monserrat, M. Fernández, N. Montenegro, D. Alvarez, J. Herero, D. Breaux, Hospital Universitario Central de Asturias, Oviedo, SPAIN.

**EP-0212**

Iodine Internal Dosimetry using Anthropomorphic Voxelized Phantom in GATE

N. G. Cavedini, C. M. Dotta, A. M. Marques da Silva; PUCRS, Porto Alegre, BRAZIL.

**EP-0213**

A Novel Patient-Based Dosimetric Approach for Y-90 Microsphere Treatment

F. Çakir, M. F. Bircakci, A. K. Cakici; Hacettepe University, Ankara, TURKEY. Hacettepe University Faculty of Medicine, Ankara, TURKEY.

**EP-0214**

Simple Bremsstrahlung SPECT Method for Whole Liver Dosimetry in Treatments with \(^{99m}\)Y-Microspheres - Comparison with \(^{90}\)PET

K. Knesarek, S. Heba, R. Ryzik, S. D. Pask, L. Kostaloglou, Ichan School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

**EP-0215**

Image-based 3D Dosimetry Techniques For Yttrium-90 SRT of HCC: Quantitative Comparison Of Tumor And Healthy Liver Absorbed Doses

J. Brosch, A. Goekeisch, H. von Zimmerman, L. Kaiser, P. Baroreit, H. Ihan, A. Todaka, G. Böning; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

**EP-0216**

The joint use of MAA SPECT/CT and CBCT enables better dosimetry planning for SIRT procedures


**EP-0217**

Comparision of 6 MeV electrons scattering at the edges of metal and 3D-printed plastic collimators at the edges of metal and 3D-printed plastic collimators

I. Carrio, M. Estorch, J. Duch, J. L. Eersels, V. Caveliers, I. Nilsson, D. A. Lopez Mora; Endocrinology, benign -> Non-oncology study -> Endocrinology -> Nuclear Medicine Research Centre, Kantonspital, Zurich, SWITZERLAND.

**EP-0218**

Normal organs and tumor absorbed doses of \(^{90}\)Y-human serum albumin microsphere in GP777 hepatoma model

L. Chen, W. Lee, C. Ha, Y. Chang, C. Chang, Institute of Nuclear Energy, Taoyuan City, TAIWAN.

**EP-0219**

Quantification of \(^{111}\)In activity in mouse kidneys using micro-SPECT and ex vivo gamma counting: experimental evaluation of uncertainties

C. Saldariaga Vargas, L. Streljes, L. Ehrenberg, J. L. Ermel, V. Cavelli, P. Govers, B. Castellano, M. C. Garganese, V. Cavallini; WCCS, Bambino Gesa Children’s Hospital, Rome, ITALY. Arcispedale Sant’Anna Hospital, Ferrara, ITALY.

**EP-0220**

An evaluation of a new TripleSPECT\(^{+}\) protocol for localisation of surgically proven parathyroid lesions, with assessment of both conventional and surface rendered image review

H. Ilyas, H. Ahmad, S. Hafeez, J. Fowler; Gay and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM. Darent Valley Hospital, Dartford, UNITED KINGDOM.

**EP-0221**

SPECT Computed Tomography in the Detection of Functional Pituitary Microadenoma with Inconclusive MRI Findings

S. Stuchebrov, I. Miloshchikova, Y. Cherepennikov, A. Kosykh, B. Gankwati; Tomsk polyechnic university, Tomsk, RUSSIAN FEDERATION. Cancer research institute of Tomsk national research medical center of the Russian academy of sciences, Radiotherapy department, Tomsk, RUSSIAN FEDERATION. Moscow city oncology hospital M2, 1st Radiological department, Istra, RUSSIAN FEDERATION.

**EP-0222**

Comparison of \(^{99m}\)Tc-sestamibi\(^{+}\)I subtraction SPECT/CT in parathyroid scintigraphy

V. Tunninen, M. Seppänen, T. Noponen; Department of Clinical Physiology and Nuclear Medicine, Satukia Central Hospital, Pori, FINLAND. Department of Clinical Physiology and Nuclear Medicine and PET centre, Turku University Hospital, Turku, FINLAND. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND.

**EP-0223**

Clinical - Diagnostic study -> Adult study -> Non-oncology study -> Endocrinology, benign

EP-0224**

**EP-0226**

Self-comparison of \(9\)FDG PET/MRI and \(9\)FDG PET/CT in the Detection of Functional Pituitary Microadenoma with Inconclusive MRI Findings

H. Sui, H. Wang, J. Zhang, L. Li, B. Hao, Q. Liu, Z. Zhu; Peking Union Medical College (PUMC) Hospital, Beijing, CHINA.

**EP-0227**

Preoperative accuracy in parathyroid adenoma localisation with contrast enhanced SPECT/CT

P. Sandqvist, I. Nilsson, P. Goby, A. Sanchez-Crespo, A. Sundin; Karolinska University Hospital, Stockholm, SWEDEN. Uppsala University Hospital, Uppsala, SWEDEN.

**EP-0228**

Detectional\(y\) of \(18\)F-Choline PET/MRI in Primary Hyperparathyroidism

D. A. Lopez Mora, M. Sarova, A. Florets, V. Camacho, A. Fernandez, J. Fuentes-Campbell, J. Duch, A. Domenech, A. Perez, A. Moran, M. Estorch; Endocrinology Research Centre, Moscow, RUSSIAN FEDERATION. Endocrinology Research Centre, Moscow, RUSSIAN FEDERATION.

**EP-0229**

Digital PET/CT with 18F-Fluorocholine improves the detection of Occult Parathyroid Adenoma

T. Jansen; M. Buizing1; M. Bossi; E. de Konning; M. Engelert; M. Nijkamp; O. Konranger; O. Eriksson; M. Bom; M. Gosthardt1; Radboud University medical center, Nijmegen, NETHERLANDS, KU Leuven, Leuven, BELGIUM, Leiden University Medical Center, Leiden, NETHERLANDS, Uppsala University, Uppsala, SWEDEN.

EP-0230 Imaging of chemokine receptor type4 expression in patients with aldosteronism using (21)Ga-pentixafor PET / CT
J. Ding; L. Huo; Y. Luo; F. Li; H. Xing; A. Tang; J. Wen1; T. Zhang1; X. Li; M. Hacker; Peking Union Medical College Hospital, Beijing, China, Vienna General Hospital, Vienna, AUSTRIA.

EP-0231 Assisted visual reading using semi-quantitative analysis of pachymyocytoma and paraganglioma (PPGL) with 18F-FDOPA PET/CT
F. L. Grisanti1; M. Bodesz-Lozana; J. J. Reseal; E. Hernández-Acero1; J. F. Bastidas; C. Perdomo; J. C. Fernández-Acero; V. Arribas; I. Bossert1; Dept. of nuclear medicine, Clinical center, Nijmegen, NETHERLANDS, Nuclear Medicine Research Department, Iason, Graz, AUSTRIA, Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacky University, Olomouc, CZECH REPUBLIC, Unit of Internal Medicine and Endocrinology, Istituti Clinici Scientifici Maugeri Sp A SB RICCS, Pavia, ITALY, Medical Physics Unit, Istituti Clinici Scientifici Maugeri Sp A SB RICCS, Pavia, ITALY, Endocrinology Unit, Istituto Clinica Città di Pavia, Pavia, ITALY.

EP-0237 Parathyroid imaging by (18)Fluorocholine PET/ MR in patients with hyperparathyroidism
B. Emsen; S. Mvé4; E. Evangelista1; B. Ibrahim1; L. Bannez1; J. Cholaye1; L. Lemarr1; M. Abullal1; C. Dubouchet1; D. Barry; C. Calvo-Besta1; S. Sakkani1; J. Israel; A. Lucan1; J. Fris1; Synaptom PET/MR platform, Henri Mondor Hospital, Creteil, FRANCE, Department of Endocrinology, Henri Mondor Hospital, Creteil, FRANCE.

EP-0238 Unsupervised Image Subtraction in Parathyroid Scintigraphy as a Prerequisite for Machine Learning
I. Mariliko1; J. Tinkov1; D. Chmoustov1; D. Zagovar1; M. Samal1; Charles University, 1st Faculty of Medicine, Prague, CZECH REPUBLIC, General University Hospital, Prague, CZECH REPUBLIC.

EP-0240 Optimizing (18)Fluorocholine PET/CT procedures in parathyroid imaging: a proposal
I. Bessert; M. Haddad1; S. Chytiri2; D. Armbrusso3; A. Marchetto; C. Veliani; L. Criviez1; V. Riveluta1; L. Chwat1; G. Tiferno1; Nuclear Medicine Unit, Istituti Clinici Scientifici Maugeri Sp A SB RICCS, Pavia, ITALY, Nuclear Medicine Research Department, Iason, Graz, AUSTRIA, Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacky University, Olomouc, CZECH REPUBLIC, Unit of Internal Medicine and Endocrinology, Istituti Clinici Scientifici Maugeri Sp A SB RICCS, Pavia, ITALY, Medical Physics Unit, Istituti Clinici Scientifici Maugeri Sp A SB RICCS, Pavia, ITALY, Endocrinology Unit, Istituto Clinica Città di Pavia, Pavia, ITALY.

EP-0241 Patients with Hashimoto Nodular Goiter: Relation to Differentiated Thyroid Carcinoma and Outcome
J. Mihailovic; J. Roganovic; V. Cimboljac2; D. Stojanovic; Institute of Oncology, Smederevska Kamenica, SERBIA.

EP-0242 The Role Of Regulatory T Cells In Pregnant And Postpartum Women With Autoimmune Thyroid Disease
T. Bogovic Crnic1; S. Grbac Ivankovic1; M. Abulizi1; R. Braham; S. Sahbai; 1Department of Oncology and Nuclear Medicine, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, 2Department of Nuclear Medicine, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0247 Scintigraphic findings in a patient with hylazinalizing trabecular tumour of the thyroid
J. Baumgartner; C. Hopp; K. Jung; D. Gröner; A. Sabet; F. Grunwald; University Hospital Frankfurt, Frankfurt, GERMANY.

EP-0248 Assessment of Somatostatin Receptor Expression in Thyroid Associated Orbitalitis by (18)Ga-DOTANOC PET/CT
N. Damle; M. Angamuthu; S. Arora, K. Lata, K. Shankar; R. Meid; S. Sharma, N. Tandon, C. Ball, M. Tripathi; All India Institute of Medical Sciences, New Delhi, INDIA.
EP-0249
Improving Diagnostic Accuracy by Application of SPECT/CT on Hepatobiliary Scintigraphy: Pictorial Essay
J. Kim, K. Yoo, S. Baek, S. Lee, J. Cho; Hanyang University Medical Center, Seoul, KOREA, REPUBLIC OF; Kangdong Sacred Heart Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0250
Dynamic liver scintigraphy - quantitative tool in chronic liver disease?
D. Jocius; D. Vapasaku; A. F. Tamosiunus; Winus University Hospital Santaros Alikiskes, Vilnius, LITHUANIA, Lithuanian University of Health Sciences, Kaunas, LITHUANIA.

EP-0251
Diagnosis of pleuropneumonic contamination as a complication of continuous ambulatory peritoneal dialysis by peritoneal scintigraphy - a case report
A. N. B. Marques, F. Abreu, C. Gaspar, S. Pintão; Hospital de Santa Cruz - Centro Hospital de Lisboa Ocidental, Camara de Lobos, PORTUGAL.

EP-0252
SPECT/CT - solving the dilemma of hepatic hemangioma
N. Manevski, S. Sopajski, T. Makaleena, N. Bavziavonka, D. Miladinova, Medical Faculty, Skopje, REPUBLIC OF MONTENEGRO.

EP-0253
Gastrointestinal transit scintigraphy in patients with chronic constipation: an uncommon test, complication, an uncommon test
M. Moreno-Caballero, J. Infante-de la Torre, A. Martinez-Esteve, J. Raya-Madrid, P. Jimenez-Graener, A. Cobo-Rodriguez, J. Semara-Vicente; Hospital Universitario de Badajoz, Badajoz, SPAIN.

EP-0254
Clinical Utility Of Gallbladder Ejection Fraction: Is It Reliable By Itself?
J. Seo, J. Oh, H. Kim, J. Park; Fatima Hospital, Daegu, KOREA, REPUBLIC OF; Raphael Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0255
Utility of Bile Acid Malabsorption Test 75SeHCAT in the Evaluation of Functional Chronic Diarrhea
V. Godigna Guilloteau, M. Marin-Ferrer, E. Martinez Albors, A. Gallana Moran, D. Vega Perez, A. Garetkini Guerra, S. Ruiz Sols, P. Paviotno W; J. Esteban Alfaro; Hospital universitario 12 de Octubre, Madrid, SPAIN.

EP-0256
The Reliability of Manual Drawing for Salivary Gland Segmentation of Quantitative Tc-99m pertechnetate Salivary Gland SPECT/CT
W. Lee, J. Oh, J. Kim, J. Han, J. Park, J. Lee; Seoul National University College of Medicine, Seong-Nam, KOREA, REPUBLIC OF; Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0257
Added value of SPECT/CT in localizing the correct site of gastrointestinal bleeding
F. Di Gregorio, M. Rezza, D. Capobianco, M. Povolato, G. Ferreri, F. Giromuzza; Nuclear Medicine Unit - University Hospital Udine, ITALY.

EP-0258
FDG PET/CT in evaluation of patients with monoclonal gammopathy of undetermined significance (MGUS)
T. Rudolfi-Solero, A. Sánchez Sánchez, A. González Jimenez, M. Rarhit, E. Trivinho-Blazé, J. Llanos Elvar, SAS, Granada, SPAIN.

EP-0259
Somatic volume assessment by heat denatured red blood cells SPECT: validation against unenhanced low-dose SPECT/CT volumetry by OsiriX MD
G. Arora, A. Szpakowski, L. Kirk, M. Gregore; A. Kalaiselvag, P. Michalakis, J. Katsampoukas, E. Moradi, L. Pentifilo, T. Vassiladis; 3rd Dept. of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, GREECE, 1st Dept. of Anatomy, Democritus University of Thrace School of Medicine, Alexandroupolis, GREECE, 1st Propedeutic Dept. of Internal Medicine, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, GREECE.

EP-0260
Comparison of blood volume calculation by radioisotopic dilution techniques with red blood cells abelled with Cr-51 and Tc-99m administered simultaneously
A. Agudo Martinez; L. León-Ruiz Morena, G. Sabatini-Hernández, M. Manceaga-Hernández, P. de la Riva-Pérez, F. García-Gómez, J. Martín-Meana, C. Calvo-Murillo; Virgen Macarena University Hospital, Seville, SPAIN.

EP-0261
Comparison of two calculation methods for isotopic measurement of plasma volume
P. Orhon, M. Templier, F. Cachin, S. Levesque; Centre Riva-Pérez, F. García-Gómez, I. Marín-Melero, C. Calvo-Murillo; Virgen Macarena University Hospital, Seville, SPAIN.

EP-0262
Determination of split renal function as assessed by MAG-3 SPECT imaging of the kidneys and PSMA PET imaging allows accurate determination of split renal function as compared with MAG-3 scintigraphy
M. Reis, P. Pauly, J. Reis, H. Kühn, A. Schäfer; S. Ezziddin; Universitätsklinikum des Saarlandes, Homburg, GERMANY.

EP-0263
FDG PET/CT Findings in Cavitary Form of IgG4-Related Lung Disease
S. Kesi, T. Onig, S. Gaya, K. Okuuzaki, S. White, H. T. Turgut, T. V. Endli; Marmara University Istanbul Pendik Education And Research Hospital, Istanbul, TURKEY.

EP-0264
Increase in number of undetermined studies with ventilation/perfusion SPECT
J. Deportes, V. Villalobos, S. LaFuent, M. Soler, J. Riba, G. Maragao; Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EP-0265
Evaluation of bronchopleural fistula with technegas ventilation scintigraphy
Z. AR Binani, S. Samaan, W. Zeng; University of Ottawa, Ottawa, ON, CANADA, Oman Medical Specialty Board (OMSB), Muscat, OMAN.

EP-0266
Spectrum of unitalar hyperperfusion or absent perfusion on pulmonary scintigraphy
N. Uyama; H. Chuou; Y. Ohara; M. Harada; Department of Radiology, Tokushima University Hospital, Tokushima, JAPAN, Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, JAPAN.

EP-0267
Analyzing the influence of bronchodilators in 99mTc-MAA imaging
V. Mendi Barcina, R. Rikkial Monzon, B. Martinez De Miguel, E. Cnhurele Pantoja, E. Dabara, H. Garcia Ruiz, E. Martinez Montafan; Hospital Universitario La Paz, Madrid, SPAIN.

EP-0268
PSMA PET/CT Imaging allows accurate determination of split renal function as compared with MAG-3 scintigraphy
M. Reis, P. Pauly, J. Reis, H. Kühn, A. Schäfer; S. Ezziddin; Universitätsklinikum des Saarlandes, Homburg, GERMANY.
EP-0269

Comparison of Relative Renal Function with Scintigraphy and Anger cameras

C. Ngoanu, A. Bouthiba1, N. Roth, N. Aide1, B. Eklöfber, C. Lassnair, D. Agostini1
1Nuclear Medicine Department, University Hospital, Caen, FRANCE
2Normandy University, EA 4650, Caen, FRANCE
3Spectrum Dynamics Medical Ltd., Canesana, ISAREG
4NUERM 1199 ANTICIPE, Normandy University, Caen, FRANCE

EP-0270

DMSA scintigraphy in orthotopic kidneys: Do we really need to perform geometric mean assessment?

I. El Bez1, R. Tsibebi, I. Mute, F. Alghamlas, M. Alharbi1, R. Tulbah, I. Munir, F. Alghamlas, M. Alharbi2
1KFMC, nuclear medicine department, Riyadh, SAUDI ARABIA.
2Medical University of Łódź, Łódź, POLAND.

EP-0271

SPECT/CT for detection of dye leakage in patients on continuous ambulatory peritoneal dialysis - a retrospective study

D. Chroustova, J. Tinka1, M. Haindl1
1General University Hospital and 1st Faculty of Medicine, Charles University Prague, CZECH REPUBLIC
21st Department of Internal Medicine, Faculty Hospital Kazlovke Vinohrady and Third Faculty of Medicine, Charles University Prague, CZECH REPUBLIC

EP-0272

Is geometric mean calculation of renal split function applicable to patients with impaired renal function?

O. K. I. Kotbi1, A. Abaltiy2, E. Leung1, A. Reil1, R. Klein1, R. Klein1, W. Zeng1
1The Ottawa hospital, Ottawa ON, CANADA
2King Abdullah medical city in Holy capital, Meccaah, SAUDI ARABIA
3Prince Sultan Military Medical City, Riyadh, SAUDI ARABIA

EP-0273

DMSA scan versus MR imaging in patients with pyelonephritis: A Meta-analysis

I. Sankaya, A. Sankaya, A. Abaltiy1, Kuwait University Faculty of Medicine, Kuwait, KUMAHT
2Turkya University Faculty of Medicine, Edirne, TURKEY

EP-0274

A comparison of the renographic results from living and cadaver donors in kidney transplantation

A. N. B. Marques, F. Abou, C. Gaspar, S. Pintão
Hospital de Santa Cruz - Centro Hospitalar Lisboa Ocidental, Carnaxide, PORTUGAL

EP-0275

Validation of the Glomerular Filtration Rate determination using Technetium-99m Diethylenetriaminopentaacetic acid instead of Chromium-51 Ethylenediaminetetraacetic acid

University of Medicine-PET Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN

EP-0276

Does volume of distribution make a contribution to QC of GFR measurement?

J. M. Warwick, J. L. Holness
Stellenbosch University, Cape Town, SOUTH AFRICA

EP-0277

SPECT/CT for Assessment of Clinical Usefulness of a New Dynamic Renal Scintigraphy Parameter

P. Cicchici, K. Filipczak1, M. Suma2, A. Plachskitsa2, J. Kuznierek1
1Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND
2Department of Quality Control and Radiological Protection, Medical University of Lodz, Lodz, POLAND

EP-0278

Can Glomerular Filtration Rate Estimation be Adapted for Local Oncology Patients?

J. L. Holness, H. M. Simonds, P. Barnardt, J. M. Warwick
Stellenbosch University, Cape Town, SOUTH AFRICA

EP-0279

Is there a role for renal perfusion on the evaluation of urinary tract obstruction?

M. Monteiro1, R. Silva2, T. Saravat, G. Costas1, J. Pedroso de Lima1,2,3
1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL
2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL
3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL

EP-0280

Simultaneous measurement of Glomerular Filtration Rate (GFR) with Tc-99m labelled diethylenetriaminopentaacetic acid (Tc-99m-DTPA) and Cr-51-labelled ethylenediaminetetraacetic acid (Cr-51-EDTA)

A. Agudo Martinez, A. Moreno-Ballesteros, F. Garcia-Gomez, T. Cambal-Molina, R. Fernandez-Sanz, C. Calvo-Moron, Virgen Macarena Hospital, Seville, SPAIN

EP-0281

Renal Clearance Function Index - Preliminary Assessment of Clinical Usefulness of a New Dynamic Renal Scintigraphy Parameter

O. K. I. Kotbi1, A. Sarikaya2, A. Bouthiba1
1General University Hospital and 1st Faculty of Medicine, Charles University Prague, CZECH REPUBLIC
21st Department of Internal Medicine, Faculty Hospital Kazlovke Vinohrady and Third Faculty of Medicine, Charles University Prague, CZECH REPUBLIC

EP-0282

Comparison Of Simultaneous Plasma Clearance of Tc-99m-DTPA And Cr-99m-EDTA And Its Contribution to QC of GFR measurement: is there a systematic difference?

M. Monteiro1, R. Silva2, T. Saravat, G. Costas1, J. Pedroso de Lima1,2,3
1Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL
2Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL
3Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL

EP-0283

Outcome of Kidney Function after Kidney Donation in Donors over 60 Years Old

University Hospital of Lausanne, Lausanne, SWITZERLAND

EP-0284

Gravity-dependent renography: A Rational Approach For Functional Evaluation Of Urinary Diversion

G. Tartaglione1, N. Foschi1, S. M. Recupero1, M. Parodi2, R. Bentimodi1, G. Palermo1, M. Ragonese1, L. Di Guarniero1, S. Zacchi1, F. P. Ferrai, F. Pesci, P. P. Basili2
1Nuclear Medicine, Croo Re Hospital, Rome, ITALY
2Department of Urology, Fondazione PoliChirurgica Universitaria “A. Gemelli” MIIC, Rome, ITALY.
3University, Universidade Catolica do Sacro Cuore, Rome, ITALY

EP-0285

Viability Of The Transplanted Renal Graft. Correlation Between Renal Biopsy And Isotopic Renogram 24h Post-Transplant

J. Gómez Hidalgo1, M. Ruiz-Gómez1, N. Álvarez Mera1, P. Turbay-Eijach1, B. Pérez-López1, C. Gamazo Lahérn1, M. Alonso Rodríguez1, A. Saina Esteban1, M. Méndez Pascual1, S. De Pablo-1, M. González Soto2, R. Ruizena Pérez2
1Hospital Clinico Universitario de Valladolid, Medicina Nuclear, Valladolid, SPAIN
2Hospital Clinico Universitario de Valladolid. Unidad de trasplante renal, Valladolid, SPAIN

EP-0286

Importance of 99mTc-DTPA renography in evaluating renal function in the pre-operative and post-operative elective F/BEVAR phases TAAA's

V. Frantellizzi1, L. Corso1, M. Ricci1, M. Omori1, N. Mangialardi1, M. Librati1,2,3,4,5,6,7,8,9,10,11,12
1Sapienza University of Rome, Rome, ITALY. 2 San Camillo Forlanini Hospital, Rome, ITALY.
3Catholic University of the Sacred Heart, Rome, ITALY.
4La Sapienza University, Rome, ITALY.
5Johns Hopkins University, Baltimore, USA.
6Emory University School of Medicine, Atlanta, USA.
7University of California, San Francisco, USA.
8Hospital Clinico Universitario de Valladolid, Valladolid, SPAIN.
9Hospital Universitario de Salamanca, Salamanca, SPAIN.
10IBIMA, Barcelona, SPAIN.
11Nuclear Medicine, Coimbra, PORTUGAL.
12School of Medicine, University of Porto, Porto, PORTUGAL

EP-0287

“Cr EDTA vs Tc-99m-DTPA vs inulin for GFR measurement: is there a systematic difference?”

H. McKeen1, F. Wickham1, M. Barnfield1, M. Burnstrom1
1Barns Health NHS Trust, London, UNITED KINGDOM
2Royal Free London NHS FT, London, UNITED KINGDOM
3Leeds Teaching Hospitals NHS Trust, London, UNITED KINGDOM

EP-0288

Comparison Of Simultaneous Plasma Clearance Of Tc-99m-DTPA And Cr-99m-EDTA - Can One Tracer Replace The Other?

L. Petersen, T. Andersen, L. Jødal, N. Nielsen1, L. Petersen
1Department of Nuclear Medicine, Aalborg, DENMARK.

EP-0289

Dynamic Renography: A Rational Approach For Functional Evaluation Of Urinary Diversion

G. Tartaglione1, N. Foschi1, S. M. Recupero1, M. Parodi2, R. Bentimodi1, G. Palermo1, M. Ragonese1, L. Di Guarniero1, S. Zacchi1, F. P. Ferrai, F. Pesci, P. P. Basili2
1Nuclear Medicine, Croo Re Hospital, Rome, ITALY
2Department of Urology, Fondazione PoliChirurgica Universitaria “A. Gemelli” MIIC, Rome, ITALY.
3University, Universidade Catolica do Sacro Cuore, Rome, ITALY
EP-0291 Accuracy of 4h Single Sample Measurement for Low GFR and Comparison with Same Day Slope-Intercept GFR

EP-0292 Glomerular filtration rate can be estimated from the total bladder activity measured by quantitative 99mTc-DTPA SPECT-CT
C. Kim, J. Char, Y. Kang, D. Cha, K. Kang; Korea University Ansan Hospital, Ansan, KOREA, REPUBLIC OF, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0293 Sentinel lymph node biopsy in prostate cancer: a modified injection technique targeting the tumor index lesion
A. Mestre Fusco, I. Mar - Parc de Salut Mar, Barcelona, SPAIN, Universitat Autònoma de Barcelona, Barcelona, SPAIN, Universitat de Barcelona Clínic, Barcelona, SPAIN.

EP-0294 Role Of Lymphoscintigraphy In The Assessment Of Lymphedema Of Extremities In Microsurgery Of Lymph Node Transfer
C. Sampol1, C. Roca1, J. Estrada, N. Orza1, A. Repetto1, M. Villar1, N. Orza2, J. Cifuentes3; Hospital Universitar San Espases, Palma De Mallorca, SPAIN, Hospital Universitari Sant Joan de Déu, Barcelona, SPAIN, Hospital Universitario La Fe, Valencia, SPAIN.

EP-0295 Feasibility Of The Radio-guided Surgery During Transaxillary Endoscopic Parathyroidectomy
C. Sampol1, J. Sánchez2, J. Julián3, J. Cifuentes4, A. Repetto3, N. Orza2, J. Cifuentes4, M. Villar1, C. Pérez5; Hospital Universitari Sant Joan de Déu, Barcelona, SPAIN, Hospital Universitario La Fe, Valencia, SPAIN, Hospital Universitario La Fe, Valencia, SPAIN, Hospital Universitario Miguel Servet, Zaragoza, SPAIN, Hospital Universitario Miguel Servet, Zaragoza, SPAIN.

EP-0296 Concordance Between Intracervical and Fundal Injections for Sentinel Node Mapping in Patients With Endometrial Cancer; A Study Using Intracervical Intradermocuticular and Fundal Blue Dye Injections
R. Sadeghi1, M. Hassanazad-Mohadd2, M. Farsaianzam1, Z. Yousefi1, S. Radkhahay2; Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, Women’s Health Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0297 Findings in sentinel lymph node biopsy in 19 patients with ovarian cancer
A. Utreta, M. Aguado-Cifuentes, J. Benalcazar, P. Bello-Arques, L. Martínez, V. Lago, A. Yerpes-Aguilera, G. Figueroa, V. Virella, Hospital La Fe, Valencia, SPAIN.

EP-0298 Sentinel node biopsy in breast ductal carcinoma in situ: our experience
P. Fernández-Rodriguez1, Á. De Bonilla Damián1, R. Álvarez Pérez1, R. Fernández López1, D. Tamayo Caraballo1, J. Jiménez-Hoyuela García1; Nuclear Medicine: University Hospital Virgen del Rocío, Sevilla, SPAIN.

EP-0299 Radionuclide-guided sentinel lymph node mapping in urachal cancer
W. Cytwa1, W. Pohon, B. Brochhaus, J. Loss1, M. Matuszewski1; Medical University of Gdansk, Gdansk, POLAND.


EP-0301 The comparative study of the validation for tc-99m tin-colloid and tc-99m Phytate in sentinel node detection in breast cancer patients
J. Seok, Chung-Ang University, Collège of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0302 The Axillary Node Staging After Neoadjuvant Systemic Therapy Using Sentinel Node biopsy and Radioiodine Seed Localization in Breast Cancer Patients. First Experiences in our Center
A. Gallina1, M. Tabuena, M. Marin, S. Aragón, E. Crivados1, I. Torres, S. Ruiz, F. Martínez, V. Godina1, J. Estenoz, Hospital Universitario 12 de Octubre, Madrid, SPAIN.

EP-0303 Comparison of 1 day protocol and 2 day protocol of lymphoscintigraphy by subareolar injection in the detection of sentinel lymph nodes in breast cancer patients
J. Seok, Chung-Ang University, Collège of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0304 Radioguided Occult Lesion Localization Plus Sentinel Node biopsy After Neoadjuvant Chemotherapy in Breast Cancer
I. Cepedello Boiso1, C. Ramirez Tortosa1, J. Jimenez Anula1, J. Ramirez Ferral1; Complejo Hospitalario De Jaen, Jaen, SPAIN.

EP-0305 Study of Recurrence in Cervical Cancer after Selective Lymph Node biopsy
M. Calderón Calvente1, J. Vela Morcillo1, G. Guzmán Prudencio2, M. Seguí Loeches1, P. Navarro Beltrán2, L. De la Cueva Barrón1, M. SangróSatirín1, S. Álvarez Ruiz2, D. Abós Olivares1; Hospital Universitario 12 de Octubre, Madrid, SPAIN.

EP-0306 Examination of the validation for Tc-99m Tc-99m Tc-99m Tc-99m Tin-colloid and Tc-99m Phytate in sentinel node detection in breast cancer patients
J. Seok, Chung-Ang University, Collège of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0307 The comparative study of the validation for tc-99m Tin-colloid and Tc-99m Phytate in sentinel node detection in breast cancer patients
J. Seok, Chung-Ang University, Collège of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0308 Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (A-NAC) in patients with locally advanced breast cancer (LABC). Preliminary results before validation of the technique
J. Espejo Niño, M. Nevares Herrera, R. Valverde Jorge, P. Caboa Baina, L. Andrés Álvarez, E. Roderigo Ortiz de Zatarate, Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-18 Clinical -> Diagnostic study -> Adult study -> Oncology study -> General oncology -> Therapy response assessment
Displayed throughout the congress days – e-Poster Area

EP-0309 Metabolic parameters at baseline 18-F-FDG PET/CT and MlC expression for the assessment of clinical outcome and treatment response in diffuse large B-cell lymphoma
M. Cuzzocrea, M. Spulíni1, L. De Panfilo5, L. Casaroli, S. Bolli1,1, C. Landoni, J. Gurm1; Nuclear Medicine Department, University Milan- Bicocca, Monza, ITALY, Medical Physics Department, San Gerardo Hospital ASST Monza, Monza, ITALY, Hematology Department, San Gerardo Hospital ASST Monza, Monza, ITALY.

EP-0310 Role Of Pet-ct In The Evaluation Of The Effect Of Stereotactic Body Radiotherapy (sbrt) In Patients With Lung Metastases
I. Kostadinova, G. Mateva, N. Nedev, M. Gancheva, A. Demiro, Clinic of nuclear medicine, Akademisk City Hospital-Oncology, Sofia, BULGARIA, 3 Clinic of Radiology, Akademisk City Hospital-Oncology, Sofia, BULGARIA.

EP-0311 Emphasizing role of post treatment surveillance PET/CT scan for radically treated non metastatic squamous cell carcinoma of head and neck (SCCHN): Single Institution preliminary outcome
S. Gavite, A. Kasat, F. Baxu, S. Parekh, A. Singh1; HCG Cancer Centre, Mumbai, INDIA.
EP-0312
The role of 18F-FDG-PET/CT in the response evaluation of primary systemic therapy in breast cancer
J. Torok, S. Zabel, T. Tókés, T. Gyorke1; Semmelweis University, Nuclear Medicine Center, Budapest, HUNGARY; Semmelweis University, Oncology Center, Budapest, HUNGARY

EP-0313
18F-FDG-PET/CT Is Useful In The Evaluation Of Treatment Response With Tocilizumab In Patients With Large Vessel Vasculitis
E. Geradelli1; G. Bosio2, R. Tőkés, R. Giubbini2, R. Cestari; 1Bellini, 2Ferrari, 3C. Lasnon, 4G. Ruiz Merino, 5Frutos Esteban, J. Andrés; Università degli studi di Brescia, Brescia, ITALY; 2Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, ITALY

EP-0317
Prognostic role of basal bone scintigraphy and 18F-Fluorocholine PET/CT in patients with prostate cancer treated with 223Ra
E. Casillas Sagrado1, A. M. Garcia Vicente1, M. Martinez Arozena, M. A. Salas, J. G. Galán1, J. Garcia Carbonero1, J. Cassinelli Espinosa1, R. Gómez Díaz1, J. Jiménez García1, E. Casillas Sagrado1; 1Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, 2Castilla-La Mancha University, Ciudad Real, SPAIN

EP-0318
Interim and end-of-treatment bone scintigraphy and 18F-Fluorocholine PET/CT in the prediction of response in patients with prostate cancer treated with 223Ra
E. Casillas Sagrado1, A. M. Garcia Vicente1, M. Martinez Arozena, M. A. Salas, J. G. Galán1, J. Garcia Carbonero1, J. Cassinelli Espinosa1, R. Gómez Díaz1, A. M. Sorano Castejón1; 1Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, 2Castilla-La Mancha University, Ciudad Real, SPAIN, 3Hospital Virgen de la Salud, Toledo, SPAIN, 4Hospital Universitario de Guadalajara, Guadalajara, SPAIN

EP-0319
A Prospective Study In 613 Patients Seeking For Predictive Factors Of Physiological FDG Anal Uptake To Improve Post Chemo-radiotherapy PET Scans Interpretation In Anal Cancer
C. Lasnon1, N. Kahl1, C. Nagamoto, B. Houli1, J. Kamberer1, M. Galas1, R. Capuccini1, L. Tainturier2, 1Department Français Bactériologique, Caen, FRANCE; ANTICIP, INSERM U1086, Caen, FRANCE; 2Caen University Hospital, Caen, FRANCE

EP-0320
18F-FDG-PET early response assessment of PD1-immunotherapy in melanoma patients
D. Papamichail1, R. Hug1, C. Schachtried1, J. Hassel1, A. Dimitrofalou-Stauss1; 1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, 2Universitystairhauklinik, Heidelberg, GERMANY

EP-0321
One versus five lesions for response assessment by PERCIST in patients with lung cancer
S. Kwon, J. Q. Yoo, S. Kim, Seoul Saint Mary's Hospital, Seoul, KOREA, REPUBLIC OF

EP-20
Clinical -> Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Bone and soft tissues cancer primary and metastatic cancers
Displayed throughout the congress days e-Poster Area

EP-0322
The Role Of 18F-Sodium Fluoride (NaF) PET/CT In The Evaluation Of Metastatic Bone Disease In Extremely Obese (super Obese) Patients
M. Usman1, F. Al-Kandari1, J. Hassel1, R. Hog2, J. C. Castro2, J. Martínez Asensio3, M. J. Tello Galán3, A. M. García Vicente1; 1Kuwait Cancer Center, Kuwait, KUWAIT, 2Jaber Al-Ahmad Molecular Imaging Center, Kuwait, KUWAIT, 3Royal Free Hospital NHS Trust, London, UK, LONDON, UNITED KINGDOM, 4Antwerp University Hospital Belgium, Antwerp, BELGIUM

EP-0323
Test-retest Reliability Of Quantitative Bone SPECT/CT Performed On Different Days
T. Yamane; S. Srisurapong, T. Okabe, K. Nishimoto, K. Kaneta, M. Oyama, A. Seta, K. Fujikawa, H. Kip; Department of Nuclear Medicine, Showa Medical University International Medical Center, Hidaka, JAPAN, 2Department of Uro-Oncology, Showa Medical University International Medical Center, Hidaka, JAPAN

EP-0324
Clinical Utility of hybrid versus planar images on bone scintigraphy for oncologic patients
I. El Bez; R. Tulkun, J. Mune, F. Aghaemias, M. Alkhali, King Faisal medical city, nuclear medicine department, Riyadh, SAUDI ARABIA

EP-0325
68Ga-PSMA-PET/CT vs Bone Scintigraphy in prostatic cancer; are we postponing the future?
S. Castro1; G. Ferrer2, L. Violante1, L. Fonseca3, J. Sampao1, C. Castro1, H. Duarte1; 1Instituto Português de Oncologia, Porto, PORTUGAL, 2Centros Hospitalar Universitário do Porto, Porto, PORTUGAL

EP-0326
Whole-body SPECT/CT: Could Replace Bone Scintigraphy in Cancer Patients?
F. Manchon Aduvar, R. Diaz Expósito, V. López Prov, Fundación Instituto Valenciano de Oncología, Valencia, SPAIN

EP-0327
Utility of SUVmax, SUVmean AND SUVpeak values measured on baseline 18F-FDG PET/CT to discriminate the high-grade from the low-grade soft tissue sarcomas

EP-0328
Role Of 18F-FDG PET/CT In Management Of Malignant Peripheral Nerve Sheath Tumors (MPNST)
D. Yadav; S. A. Sharma, S. Rastogi, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA

EP-21
Clinical -> Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Breast, malignant
Displayed throughout the congress days e-Poster Area

EP-0329
Prognostic Value Of F-18 FDG PET/CT In Invasive Ductal Carcinoma
S. Kang; Catholic University of Daegu School of Medicine, Daegu, KOREA, REPUBLIC OF

EP-0330
FDG PET Findings In Invasive Ductal Carcinoma Of The Breast With And Without Coexisting DCIS
I. Sarikaya; A. Sarikaya, A. Albatineh1, E. Tastekin2, Y. A. Sezer3; 1Kadir Has University, 2AMT Antwerp University Hospital Belgium, Antwerp, BELGIUM, 3Istanbul University Faculty of Medicine, Edirne, TURKEY
M. G. Hildebrandt1, M. Vogt2, S. Geneser3, M. Rasmussen4, M. Hjörne1. PREMO - Centre for Personalized Response Monitoring in Oncology,1 Odense University Hospital, Odense C, DENMARK, 2University of Southern Denmark, Odense, DENMARK, 3University of Southern Denmark, Odense, DENMARK, 4University of Southern Denmark, Odense, DENMARK.

EP-0332 Should prone 18FDG-PET/CT be used to improve lymph node staging in breast cancer? L. Sánchez Orduz1, M. Mordas-Lamana2, B. Andraos-Couture2, J. Roux1, J. Bayard1, J. Gourant1, M. Ochs1, M. Ribelles1, M. García-Veloso1, M. Rodríguez-Fraile1. SPECT medicina nuclear S.A.S, UNAB, Carrancas, COLOMBIA, 1Department of Nuclear Medicine, Clínica Universitaria de Navarra, Pamplona, Spain, 2Department of Nuclear Medicine, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 3Department of Public Health, Universidad Autonoma de Barcelona, Barcelona, Spain.

EP-0333 Should we insist on 18F-fluoride PET/CT for breast cancer patients? Review of experience and incidental findings E. Mehdi1, F. Nasravi1, J. Alpery1, L. Membehzad1, S. Vatankhah1. 1Department of Nuclear Medicine, National Centre of Oncoology, Baku, AZERBAIJAN, 2Department of Nuclear Medicine, National Centre of Oncology, Baku, AZERBAIJAN, 3Department of Diagnostic Radiology, National Centre of Oncology, Baku, AZERBAIJAN.

EP-0334 Comprehensive Analysis of Clinical Parameters used in Breast Cancer with F-18 FDG PET/CT Standardized Uptake Values E. Akgun1, O. Gökbulut1, H. Bor1, Sayman1, A. Cengiz1. 1Cerrahpasa Medical Faculty, Istanbul, TURKEY.

EP-0335 Prevalence of focal incidental breast uptake on FDG-PET/CT and risk of malignancy: A Systematic Review and Meta-analysis M. Naghavi-Bezd2, A. Kastad1, P. Nordhaus3, L. Bramms Larsen1, M. Vogt2, D. Gørke1, M. Grube-Hildebrandt1. 1Department of Clinical Research, University of Southern Denmark (SDU), Odense, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, 3Department of Radiology, Odense University Hospital, Odense, DENMARK.

EP-0336 Value Of Hybrid F-18 FDG PET/MIRI in BIRADS 4 And 5 Breast Lesions: Preliminary Results Of An On-Going Study L. L. Ulus1, R. Yılmaz1, M. Velidėdeoglu1, O. E. Sahn1, E. Akgün1, S. Sager1, H. B. Sayman2, K. Sonmezoglu2, 1Istanbul University-Cerrahpasa, Cerrahpaşa Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, 2Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TURKEY, 3Istanbul University-Cerrahpasa, Cerrahpaşa Medical Faculty, Department of General Surgery, Istanbul, TURKEY.

EP-0337 Added diagnostic value of FDG PET/CT in assessment of internal mammary nodal metastasis in breast cancer patients E. El-kholy1, M. Tahseen2, 1Department of General Surgery, Istanbul, TURKEY, 2Department of Clinical Research, University of Southern Denmark (SDU), Odense, DENMARK.

EP-0338 Correlation Between Primary Breast Tumor Size And Prevalence Of Nodal And Distant Metastasis On FDG-PET/CT at Initial Staging N. Fatima1, M. U. Zaman1, U. Zaman1, A. Zaman1, R. Tahseen1, S. Zaman1. 1Department of Radiology, Aga Khan University Hospital (AKUH), Karachi, PAKISTAN, 2Department of Medicine, Dr. Ruth Hospital, Karachi, PAKISTAN, 3Department of Radiation Oncology, Aya Khan University Hospital (AKUH), Karachi, PAKISTAN, 4Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN.


EP-0340 Clinical -> Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Colorectal, malignant Displayed throughout the congress days e-Poster Area

EP-0341 Value of 18F-FDG PET/CT metabolic parameters in patients with locally advanced rectal cancer L. García Zoghby1, M. Coronado Paggi1, A. Obesa de Diego1, A. Guzmán Cruz1, D. Monachello Arsuja1, D. Tavaglia Moxas1, S. Rastkalz Monzón1, J. Gádodo García1, S. Rodado Marín1, C. Lancha Hernández1, E. El-kholy1, P. J. Turbay Eljach1, C. Gamazo Laherrán1, M. Alonso Moralidis1, V. Mpalaris1, M. Lelegianni1, A. Cengiz1, D. Katsampoukas1, D. Albano1, Ö. Yersal1, E. Aarstad1, O. Gerke1, H. B. Sayman1, K. Sonmezoglu2, 1Department of Gastroenterology, Papageorgiou Gen Hospital, Thessaloniki, GREECE, 2Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgou Gen Hospital, Thessaloniki, GREECE.

EP-0342 Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer A. Cengiz1, I. Kurt Ömürlü1, Y. Yürekli1, 1Department of Clinical Research, University of Southern Denmark (SDU), Odense, DENMARK, 2Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, 3Department of Medical Oncology, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.


EP-0344 Diagnostic Accuracy Of Somatostatin Receptor Scintigraphy In Patients With Suspected Tumor Recurrence By Increase In Chromogranin A N. Alvarez Mena1, Á. Pérez López1, J. Gómez Hidalgo1, P. J. Turbay Eljach1, C. Gamazo Laherrán1, M. Alonso Moralidis1, V. Mpalaris1, M. Lelegianni1, A. Cengiz1, D. Katsampoukas1, D. Albano1, Ö. Yersal1, E. Aarstad1, O. Gerke1, H. B. Sayman1, K. Sonmezoglu2, 1Department of Gastroenterology, Papageorgiou Gen Hospital, Thessaloniki, GREECE, 2Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgou Gen Hospital, Thessaloniki, GREECE.

EP-0345 Comparison of 18F DOTATOC PET/CT with morphological imaging in staging of neuroendocrine tumors M. Finessi1, E. Pilati1, R. Passavento1, V. Liberini1, C. De Angelis1, E. Avati1, N. Biscaretti1, M. Brizzi1, D. Camprat1, G. Giardino1, M. Belli2, G. Bili2, D. Desmedt3. 1Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, 2Gastroenterology Unit, Department of General and Specialist Medicine, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, 3Medical Oncology, Department of Medical Oncology, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.
Relevance of different patterns of thyroid uptake of 18F-fluorocholine in patients who undergo 18F-fluorocholine PET/CT for detection of parathyroid disease

Athens, GREECE.
P. Valsamaki

Spindle Cell Variant of Medullary Thyroid Cancer

Lezaic; Department of Nuclear Medicine, University of Zagreb, Zagreb, CROATIA.

Impact of FDG PET/CT in directing management of neuroendocrine tumors

EP-0360

Prognostic validity of 18F-fluorocholine PET/CT in predicting neuroendocrine tumor recurrence

EP-0348

Pitfall upon 99mTc-EDDA/HYNIC-TOC scintigraphy with 68Ga-DOTATOC: Experience of 4 years

Presenting Exquisite Accuracy

BARCELONA, SPAIN | OCTOBER 12 – 16, 2019

BARCELONA, SPAIN | OCTOBER 12 – 16, 2019
EP-0368
FDG uptake in the mylohyoid muscle - a common misconception
D. Pizzuto; P. Stalman*, L. Husmann*, E. Onda*, C. Meiwen*, G. K. van Schutthoven*, M. W. Huitema*, Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, ZURICH, SWITZERLAND, 1Department of Orthopahnology, Head & Neck Surgery, University Hospital Zurich, University of Zurich, ZURICH, SWITZERLAND.

EP-24
Clinical - Diagnostic study - Adult study - Oncology study - Organ-based oncology - Head and neck, malignant
A. Repetto, C. Sampol, N. Oria, R. Navaroli, M. Valente, S. Ruda, C. Perti, University Hospital San Erazo, Nuclear Medicine Department, Palermo di Malora, SFIN.

EP-25
Clinical - Diagnostic study - Adult study - Oncology study - Organ-based oncology - Hemato-oncology- oncology- malignant
displayed throughout the congress days.

EP-0370
18F-FDG PET/CT-based Nomogram for Predicting Individual Conditional Risk of 5-Year Recurrence before Initial Treatment of Nasopharyngeal Carcinoma
B. Gu1,2,3, G. Ma1,2,3, Z. Zhang1,2,3, Y. Yang1,2,3, S. Song1,2,3, Y. Zhang1,2,3, 1Department of Nuclear Medicine, Fudan University Shangai Cancer Center, Shanghai, CHINA, 2Center for Biomedical Imaging, Fudan University, Shanghai, CHINA, 3Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, CHINA.

EP-0371
Clinical and prognostic value of staging 18F-FDG PET/CT in laryngeal cancer

EP-0372
18F-fluorodeoxyglucose PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
L. Zhao, H. Chen1, X. Fu, D. Fan1, H. Wu, Y. Zhuang2, Q. Liu1, 1The First affiliated hospital of Xiamen University, Xiamen, CHINA, 2Beijing Tsiantan Hospital, Beijing, CHINA, 3Xiamen Cancer Hospital, The First affiliated hospital of Xiamen University, Teaching hospital of Fujian Medical University, Xiamen, CHINA.

EP-0373
FDG uptake in the mylohyoid muscle - a common misconception
D. Pizzuto; P. Stalman*, L. Husmann*, E. Onda*, C. Meiwen*, G. K. van Schutthoven*, M. W. Huitema*, Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, ZURICH, SWITZERLAND, 1Department of Orthopahnology, Head & Neck Surgery, University Hospital Zurich, University of Zurich, ZURICH, SWITZERLAND.

EP-0375
Feasibility of Multiparametric Imaging with PET/MR in Nasopharyngeal Carcinoma: A Pilot Study
C. Cao, X. Fu, S. Wang1, C. Li*, Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, CHINA, 1Hangzhou University Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0376
Impact of 18F-FDG PET/CT in the initial staging and changing the management intent in head and neck squamous cell carcinoma

EP-0377
The impact of PSF reconstruction algorithm on the early therapeutic response of lymphoma patients
B. Magyar, E. Kinski, S. Csabai, L. Jangou, M. Bara, A. Fekecsarzy, Z. Varga, T. Gyore, Semmelweis University, Nuclear Medicine Center, Budapest, HUNGARY.

EP-0378
Metabolic Tumor Volume Measurement in Early Hodgkin Lymphoma. Preliminary Results
M. Cortes Romero, A. Palmar-Munoz, E. Domingo-Dorente, G. Reyes-Vampart, J. Vercher-Consperi, P. Ponsat, A. Sunol-Balsera, J. Mesroi-Marti, C. Galmes-Cenzano; 1Unit Pet CT IDIBELL, Department of Nuclear Medicine, Hospital U. de Bellvitge-IDIBELL, L’Hospitat de Llobregat (Barcelona), SPAIN, 2Department of Hematology, I.C.O. Hospital del Mar Duren i Reynals-IDIBELL, L’Hospitat de Llobregat (Barcelona), SPAIN, 3Department of Medical Physics, IDIBELL, Hospital U. de Bellvitge-IDIBELL, L’Hospitat de Llobregat (Barcelona), SPAIN.

EP-0379
18F-FDG PET/CT in the evaluation of metabolic behaviour of solitary plasmacytoma and the progression to Multiple Myeloma
M. Rashki, R. Sánchez-Sánchez, A. González Jiménez, T. Martínez Solana, E. Triviño-Bohés, J. Llamas Elías, Hospital Virgen de las Neves, Granada, SPAIN.

EP-0380
Diagnostic Value Of Red Cell Mass Measurements And JAK2 V617F Mutation In Patients With Polycythemia Vera
J. Stojanovic, M. Todorcev-Tirmanic, Center for Nuclear Medicine, Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.

EP-0381
Prognostic value of baseline metabolic heterogeneity on 18F-FDG PET/CT in primary mediastinal large B-cell lymphoma (PMBCL) treated with R-DAEPOCH chemotherapy

EP-0382
Hepatosplenic T-cell lymphoma: clinical characteristics and imaging findings
F. Chao, X. Han; The First Affiliated Hospital of Zhejiang University, Zhejiang, CHINA.

EP-0383
The Role Of PET/CT In Diagnosis And Follow Up Of Patients With Extranaional Localization Of Lymphoma
K. Mladenov1,3, V. Hadzhiyalka2, D. Vassileva1; 1Clinic o nuclear medicine University Hospital Aleksandrov, Sofia, BULGARIA, 2University Hospital Aleksandrov, Sofia, BULGARIA, 3National Specialised Hospital for Active Treatment of hematological diseases, Sofia, BULGARIA.

EP-0384
Application value of 18F-FDG PET/CT metabolic parameters in the prognostic prediction of Diffuse Large B-cell Lymphoma
J. Li, X. Sun, Y. Lu, J. Yang, Q. Zhao, P. Yang; General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0385
Prognostic value of total metabolc tumor volume and total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography / computed tomography in Hodgkin lymphoma. Preliminary Results
C. A. Achury, L. G. Diaz1, C. Monter2, R. Garcia2, M. Perahue2, S. Fernandez2, M. Vidal3, J. Quezada3, G. Hermida3, D. Caballero2, P. Tamayo4; 1Hospital Universitario de Salamanca, Salamanca, SPAIN, 2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, SPAIN, 3Hospital Universitario de Valladolid, Valladolid, SPAIN, 4Complexo Asistencial Universitario de Leon, Leon, SPAIN.

EP-0386
Role of 18F-FDG PET/CT in the evaluation of bone marrow involvement in 3 different lymphomas subtypes: diffuse large B-cell, follicular and Hodking lymphoma
M. Suarez-Piñeira1, E. Gemoero, I. Panayati, A. Mestre-Fuente2, J. Arell, L. Colares1, B. Sanchez3, A. Salazar4, 1Nuclear Medicine Department, Hospital del Mar, Parc de Salut Mar, Barcelona, SPAIN, 2Hematology, Hospital del Mar, Parc de Salut Mar, Barcelona, SPAIN, 3Nuclear Medicine Department, Hospital del Mar, Parc de Salut Mar, Barcelona, SPAIN, 4Radiology, Hospital del Mar, Parc de Salut Mar, Barcelona, SPAIN, 5Hematopathology, Hospital del Mar, Parc de Salut Mar, Barcelona, SPAIN.

EP-0387
Diagnostic value of FDG PET/CT in Assessment of Bone Marrow Infiltration in DLBCL
A. Doma, J. Jemielak, Avakov1, J. Zagor, Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.
EANM'19 | Final Programme

EP-0388
The Role Of 18F-FDG PET/CT In Detection Of Bone Marrow Involvement In Patients With Newly Diagnosed Non-Hodgkin’s Lymphoma

EP-0389
Comparison of Visual and Semiquantitative Methods in the Evaluation of Interim 18F-FDG PET/CT Findings in the Assessment of Therapeutic Response in Diffuse Large B-cell Lymphoma Patients
S. Czibor1, B. Bányai1, L. Jorgov1, M. Varga1, T. Gyorke2,1, 1Semmelweis University, Nuclear Medicine Center, Budapest, HUNGARY; 2Semmelweis University, Faculty of Medicine, Budapest, HUNGARY.

EP-0390
Prognostic role of Interim PET in adult Hodgkin lymphoma
S. Pacella,1, L. Rondanini2, C. Cinelli3, E. De Pandis4, M. Airossi2, F. Elisei2, S. Bovi1, L. Guerra2,1, 1University of Milano Bicocca, Milano, ITALY, 2Milano Medical Physics Department, ASST Monza San Gerardo Hospital, Monza, ITALY, 3Nuclear Medicine Department, ASST Monza San Gerardo Hospital, Monza, ITALY, 4Haematology Department, ASST Monza San Gerardo Hospital, Monza, ITALY.

EP-0391
Response Adapted Pet Ct Imaging In Hodgkin Lymphoma
K. Mladenov1, V. Hadzhikyurluk1, D. Vasileva1, 1University Hospital Aleksandrovitsa, Sofia, BULGARIA; 2National Specialized Hospital for Active Treatment of hematological diseases, Sofia, BULGARIA.

EP-0392
Efficacy of 18F-FDG PET/CT in detection of bone marrow involvement in patients with newly diagnosed indolent Non-Hodgkin’s Lymphoma

EP-0393
Opportunity Of #m1-thio-d-glucose SPECT Using In The Diagnosis And Staging Of Lymphomas
V. Chernov,1, E. Chatkovskov,1, R. Zelkhov,1, V. Goloborg1, T. Kravchuk1, A. Dzemyava1, A. Medvedev2, J. Simkina,2, O. Brajingga1, E. Stassyuk2, V. Sturde1,1, 1Cancer Research Institute, Tomsk, RUSSIAN FEDERATION; 2Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0394
Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis of baseline 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma
L. G. Diaz Gonzalez1,2, C. A. Achury1, C. Moneders1, A. Martin1,2, M. Perlatamara1, S. Fernandez1, M. Iyad1, J. Quezada1, G. Hermod1, D. Caballero1, P. Tamayo1,1, 1Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN; 2Healthcare Research Institute of Salamanca (IIS), Salamanca, SPAIN; 3Hospitale Clínico Universitario de Valladolid, Valladolid, SPAIN; 4Complejo Asistencial Universitario de Leon, Leon, SPAIN; 5Hospital de Segovia, Segovia, SPAIN; 6Hospital Universitario de Burgos, Burgos, SPAIN.

EP-0395
Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma: preliminary results
M. Raskhi1, E. Tinuviel-Brache1, J. López Ruiz1, A. González Jiménez1, T. Rudolph Salinas2, J. Llamas-Elvira1, Hospital Virgen de las Nieves, Granada, SPAIN.

EP-0396
Response Assessment of Rosai-Dorfman Disease with 18F-FDG PET/CT
S. Shamim1, S. Datta Gupta1, S. Tripathy1, J. Hussain1, G. Arora1, C. Bai2, All India Institute of Medical Sciences, Delhi, INDIA.

EP-0397
18F-FDG PET/CT imagingfeatures of renal lymphoma
Y. Yu,1 X. Han, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CHINA.

EP-0398
Validation of Multi-Foci Segmentation method for Measuring Metabolic Tumor Volume in Hodgkin’s Lymphoma
M. R. F. Camacho1, E. Estebanheche2, C. Ramos1,1, A. Verçosa1, T. N. Naredi1, I. M. Delamont1, M. Takahashi1, S. Brunetti1,1, I. Mietz2, J. Gorch2, 1MIN Campus, Campinas, Brazil; 2Department of Nuclear Medicine, Department of Radiology, University of Campinas, Campinas, Brazil; 3School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil; 4CAMP, Campinas, Brazil; 5Division of Hematology and Hemotherapy, Department of Internal Medicine, University of Campinas, Campinas, Brazil; 6Institute of Physics, University of Campinas (UNICAMP), Campinas, Brazil; 7Clinical and diagnostic Radiology, Timon, Brazil; 8Quanta Diagnosis and Therapy Clinic, Cambuí, BRAZIL.

EP-0399
Clinical and prognostic significance of FDG-PET derived biomarkers in high grade B cell lymphoma
Z. Ritter1, K. Zádor1, D. Dávid1, Z. Szabó1, Z. Bödő1,2, K. Farkas1, A. Somfai1, A. Hussain1, E. Schmidt1,1, 1University of Pécs, Department of Nuclear Medicine, Pécs, HUNGARY; 2University of Pécs, Department of Pathology, Pécs, HUNGARY; 3University of Pécs 1st Department of Internal Medicine, Pécs, HUNGARY.

EP-0400
Metabolic response of normal bone marrow in non-responders patients with Hodgkin Lymphoma: a 18F-FDG PET/CT study
A. Borra1, R. Lai1, M. Bauckholt2, S. Capitanio1, S. D. Morbelli2,1, V. Cenni1, F. Fenu1, S. Bruno1, M. Panza1,1, C. Centroni1,1, D. Scheneiker1, S. Moggi1, F. Frassaniti1,1, C. Manni1, G. Sambusetti1,1, 1Nuclear Medicine Department, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY; 2Spin Institute, CNR, Genoa, ITALY; 3Institute of Health Science, University of Genoa, Genoa, ITALY; 4Nuclear Medicine Unit, Department of Radiology, University of Turin, Turin, ITALY; 5Department of Experimental Medicine, University of Genoa, Genoa, ITALY; 6Department of Mathematics (DIMA), University of Genoa, Genoa, ITALY; 7Department of Mathematics (DIMADEC), Politecnico University of Padua, ITALY; 8Istituto Giannina Gaslini, Genoa, ITALY; 9CNR Institute of Molecular Biomaging and Physiology (BFM), Milan, ITALY.

EP-0401
Metabolic multiparametric analysis in PTLD baseline 18-FDG PET/CT: MTV, TLG, SUVmax, mean and peak can predict patient outcome after first line of treatment
R. V. A. Vicinelli1, R. Spolinar1, C. Dalò1, M. Nicholato1, A. F. Scardano1, M. Baronca1, E. Pazar1, E. Gay1, P. Mingia1, C. Rossetti1,2, 1Nuclear Medicine Department, University Milano-Bicocca, Milan, ITALY; 2ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-0402
Clinical- > Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Liver, upper GI and pancreatic (non-endocrine), malignant
Displayed throughout the congress area

EP-0403
Digital PET/CT Improves the Detection of Liver Lesions in Cancer Patients
F. Fuentes-Ocampo1, D. López-Mora1, A. Plata3, V. Camacho1, L. Alarcon-Lagares1, M. Sazava1, A. Fernández1, J. Duchi1, A. Donechetti1, M. Estorch1, J. Carre1, 1Hospital de la Santa Cruz y Santa Paul, Barcelona, SPAIN; 2Hospital Dr. Gustavo Frickel, Viña del Mar, CHILE.

EP-0404
Value of 18F-FDG PET/CT in diagnosing pancreatic lesions:Comparison with CA19-9, enhanced CT and MR
S. Huang1, H. Cheng1, Y. Zhang2, X. Lai1, 1Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CHINA; 2Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0405
Utility of Metabolic Parameters on Baseline FDG PET/CT for Prognostication in patients with operable Esophageal Adenocarcinoma
R. Kakade1, W. Purandare1, V. Ramgoopan, A. Agnew1, S. Shah1, A. Puranik1, Tata Memorial Hospital & Research Center, Mumbai, INDIA.
Parameters In Patients With Hepatocellular Carcinoma

**EP-0405**
Fluorodeoxyglucose Positron Emission Tomography and Computed tomography metabolic parameters in Oesophageal Carcinoma


**EP-0406**
The Role Of 18F-FDG PET/CT For Evaluation Of The Efficiency Of Radiofrequency Ablation (RFA) Of Primary And Metastatic Tumors Of The Liver

G. H. M. Mateva, I. Kastadinova, S. Handzhieva, A. Demirev. M. Gancheva - Tschechow. Acibadem City Clinic Oncology Center, Sofia, BULGARIA.

**EP-0408**
Detection Rate of Radiolabeled Choline PET or PET/CT in Hepatocellular Carcinoma: an Updated Meta-analysis

G. Treglia, G. Signori, M. Nicolad-Loalando, J. Q. Poir, B. Musi. L. Bertagnol. L. Gaivannie. Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona and Lugano, SWITZERLAND. Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND. Health Technology Assessment Unit, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND. School of Medicine, Universidade de Brasilia and Escola de Medicina. Universidade de Brasilia, Brasilia, ITALY. Department of Internal Medicine, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND. Department of Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, ITALY. Department of Nuclear Medicine, University Hospital Zurich and University of Zurich, Zurich, SWITZERLAND.

**EP-0409**
Baseline metabolic parameters assessed with [18]FDG-PET/CT are predictive of early unresetable relapse after curative intended liver surgery of colorectal liver metastases


**EP-0410**
Prognostic Value Of Pretreatment Dual-time-point PET/CT Lean Body Mass-corrected

**EP-0411**
Diagnostic Performance Of Psma Pet For The Detection Of Hepatocellular Carcinoma

B. Noto, A. Perni, S. Hutz, A. Karais, M. Wilderup, M. Schutter. Clinic of Nuclear Medicine, Muenster, GERMANY. Gerhard Domagk Institute for Pathology, Muenster, GERMANY. Department of Clinical Radiology, Muenster, GERMANY.

**EP-0412**
Metabolic Active Tumour Volume Quantified on [18F]FDG PET/CT Further Stratifies THM Stage IV Non-Small Cell Lung Cancer Patients

H. C. Martins, P. Lapiti, O. Oliveira, M. Silvar, A. Silva, T. Saraiva, R. Rostal, G. Cosio, E. Pedroso de Lima. Centro Hospitalar e Universitario de Coimbra, Coimbra, PORTUGAL. Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL. Laboratory of Biostatistics and Medical Informatics, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL. Institute for Biomedical Imaging and Life Sciences, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL. Institute of Nuclear Sciences Applied to Health-IENS, University of Coimbra, Coimbra, PORTUGAL.

**EP-0413**
Joint compensation for motion and partial volume effects in PET/CT images of lung cancer patients: impact on quantification for different image reconstruction methods

S. Rezaei, P. Ghafarian, A. Pir, A. Rahmani, S. Sahnai, M. Ayi. Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, WA, UNITED STATES OF AMERICA. Malanaknicht Institute of Radiology, Washington University in St. Louis, St. Louis, WA, UNITED STATES OF AMERICA.

**EP-0414**
SUV-derived Parameters Assessed on [18F]FDG PET/CT and Serum Tumor Markers Predict EGFR Mutation: a Retrospective Study of 191 Patients with Lung Adenocarcinoma

R. Wang, X. Laier, M. Liu, Y. Cui, A. Chen, J. Zhang. Peking University First Hospital, Beijing, CHINA. Peking University International Hospital, Beijing, CHINA.

**EP-0415**
[18F]FDG PET/CT in Pulmonary Sarcomatoid Carcinoma And Correlation With Clinicopathological And Genetic Results

L. Jiang. Shanghai Pulmonary Hospital, Shanghai, CHINA.

**EP-0416**
Molecular Imaging Of Pleomorphic Lung Carcinoma

L. Travani, M. Ferrai, M. Colandrea, G. Manfrinato, A. Penning, A. Rahmani, S. Sahnai, M. Ayi. Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, WA, UNITED STATES OF AMERICA. Malanaknicht Institute of Radiology, Washington University in St. Louis, St. Louis, WA, UNITED STATES OF AMERICA.

**EP-0417**
Inter-observer agreement of the FDG PET CT visual Herder score for the assessment of solitary pulmonary nodules

K. Ordidge, N. Gandy, M. Arpad, N. Soneji, K. Wallitt, S. Khan, T. Barwick. Charing Cross Hospital, London, UNITED KINGDOM.

**EP-0418**
Diagnostic value of PET/CT in the determination of nodal status in patients with non small cell lung carcinoma

R. Czepczynski, R. Gercz, M. Ruchalski. Poznan University of Medical Sciences, Poznan, POLAND. Dept. of Nuclear Medicine Affidea, Poznan, POLAND. Greater Poland Centre of Pulmonology and Thoracic Surgery, Poznan, POLAND.

**EP-0420**
Utility of 18F-FDG PET/CT preceding CT-guided percutaneous biopsy for pulmonary lesions

H. Iwasa, Y. Minatsu, H. Hayashita, T. Yamagami, Koki Medical School Hospital, Namakita, JAPAN.

**EP-0423**
Delineating Metabolic Tumor Volume In NSCLC: Which Thresholding Method Should Be Used ?

H. N. M. Anwar, T. J. Vogl, M. A. Abougabal, F. Grumwald, P. Kleene, S. Efremov, N. A. Nou-El Min, Cairo University, Cairo, EGYPT; Frankfurt University, Frankfurt, GERMANY.

**EP-0424**
Correlation of Tumor Metabolism with Circulating and Tissue Levels of PD-L1 in Patients with NSCLC

E. Lopedi, A. Castella, S. Rossi, E. Mazzotti, L. Toschi. Humanitas Clinical and Research Hospital – IRCCS, Milan, ITALY.
EP-0428 Predictive value of PET-FDG derived lesion glycolysis values in Stage I non-small-cell lung cancer patients for selecting high risk patients G. Santaguida1, V. Speranzoi1, M. Cuzzocrea1, V. Orunesu1, J. Thomas1, D. Castello1, 1Nuclear Medicine, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Milano, ITALY; 2Université degli Studi di Milano, Milano, ITALY; 3Thoracic Surgery, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, ITALY.

EP-0439 Association between PD-L1 expression and histology with SUVmax on "PET/CT in non small-cell lung cancer patients E. Martínez Albero1, J. Ruiz Solís1, L. Pampía Rubia2, V. M. Godigna Guilloteau1, A. Galinska Mateón2, D. Pérez Vega2, J. Pillington Wall2, P. Sarandeses Fernandez2, J. Esteban Allain1, Hospital Universitario 12 de octubre, Madrid, ESPAÑA.

EP-0442 Comparative analysis of lung perfusion scan with lung perfusion SPECT/CT for prediction of early postoperative lung function H. Suh1, S. Kim1, National Cancer Center, Goyang, KOREA, REPUBLIC OF.

EP-0443 Prognostic value of "FDG PET/CT in treatment monitoring and follow-up of lung tumors treated with stereotactic body radiotherapy J. Vercher-Concejero1, P. Nottji1, A. Navarro-Marten2, J. Sanchez-Rodriguez3, E. Andaia Navarr3, A. Palamar-Murfin1, I. Garcia-Sanchez4, S. Padrones-Sanchez4, C. Gomez-Cenarro5, 1Hospital Universitari de Bellvitge-IDIBELL, 2Hospital de Lleida (Barcelona), SPAIN, 3Institut Català d’Oncologia, El Hospital del Lleóbar (Barcelona), SPAIN.

EP-0437 Improved detection of small pulmonary lesions using a digital PET/CT system compared with conventional analog PET/CT A. Fernández León1, A. Ruiz1, V. Camacho1, M. Estorch2, A. Domenech3, M. Sizova1, I. J. G. Villanueva1, D. López-Mora1, 1Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN; 2Radioprotection Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN; 3Epidemiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0438 18F-FDG PET-CT quantitative parameters as prognostic factor in inoperable lung cancer M. Moreno-Caballero1, J. Cabrera-Arguedas2, J. Infante-de la Torre1, J. Ayoo-Madrid1, C. Cruz1, J. Sanmar-Vicente1, A. Martinez-Esteve1, P. Jiménez-Guarrero1, A. Cobo-Rodriguez1, Hospital Universitario-Valdapat, Badajoz, SPAIN.

EP-0433 Prognostic value of "FDG-FET PET/CT in patients with non small cell lung cancer treated with Stereotactic Body Radiation Therapy P. García-Talavera San Miguel1, E. González2, C. Caimi3, F. Gómez-Camino4, J. G. Villanueva1, C. Roa1, L. G. Daza1, E. Martín1, P. Tamayo1, 1Nuclear Medicine Department, Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN; 2Radiotherapy Department, Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

EP-0432 Diagnostic imaging of typical lung carcinoids: relationship between nuclear imaging and MDCT features and Ki-67 index F. Linguanti1, V. Berti1, E. Abenavoli1, G. Danti2, 1Radiology, Firenze, ITALY; 2Radiotherapy, Firenze, ITALY.

EP-0425 Study on SUV-derived parameters assessed on "PET/CT for predicting EGFR mutation status and prognosis in Lung Adenocarcinoma R. Wang1, K. Luo1, M. Liu1, X. Chen1, L. Yin2, B. Zhang2, Y. Du2, 1Peking University First Hospital, Beijing, CHINA; 2Peking University International Hospital, Beijing, CHINA.

EP-0426 FDG/PET SUVmax O F Percent Rate Of Subtype, size And Invasive Rate Of Pulmonary Adenocarcinoma K. Hayasaka1, T. Tatsot2, H. Itoe1, M. Fukasawa1, M. Hiraga1, Y. Shiono1, T. Tohgo1, M. Hiramatsu1, K. Shimoda1, K. Yashikawa2, K. Ohza1, Fukushima Hospital, Ant-tuberculosis Association, Tokyo, JAPAN.

EP-0423 The relationship between PET parameters (SUVMAX, SUVMEAN, MTV, TLG) and biomarkers which are effective in clinical applications (EGFR, ALK, MET, ROS-1, KRAS) in lung cancer patients A. Arçay1, A. Oner1, H. Çağman1, E. Sürer Budak1, M. Özcan1, F. Aydın1, 1Akdeniz University Nuclear Medicine Department, Antalya, TURKEY; 2Afyon Kocatepe University Nuclear Medicine Department, Afyon, TURKEY; 3Akdeniz University Clinic of Medical Oncology, Antalya, TURKEY; 4Antalya Training and Research Hospital, Clinic of Nuclear Medicine, Antalya, TURKEY; 5Akdeniz University Pathology Department, Antalya, TURKEY.

EP-0424 Relation Between Metabolic Parameters In 18F-FDG PET/CT And Hematological Markers In Non-Small Cell Lung Cancer S. Gök sel1, A. Cengiz2, H. Çaturluk1, Y. Yurekli2, 1Recep Tayyip Erdoğan University Medical Faculty Education and Research Hospital, Department of Nuclear Medicine, Rize, TURKEY; 2Adnan Menderes University Medical Faculty, Department of Nuclear Medicine, Aydın, TURKEY; 3Adnan Menderes University Medical Faculty, Department of Biostatistics, Aydın, TURKEY.

EP-0447 Role of texture parameters derived on "FDG PET/CT studies, in prediction of survival to therapy in lung carcinoma patients N. Rana1, R. Mittal1, K. Karpadi2, D. K. Dhar2, PGDAR, Chandigarh, INDIA.
Clinical -> Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Other malignant, including primary of unknown origin

Displayed throughout the congress days *e-Poster Area*

**EP-0447**
Qualitative Assessment of Pericardial Metastasis in Oncologic F-18 FDG PET/CT
H. Lee, J. Kim. Dongnam Institute of Radiological & Medical Sciences (IMARMS), Busan, KOREA, REPUBLIC OF.

**EP-0448**
FDG-PET/CT is far superior to the Danish national standard of care diagnostic strategy in suspected occult cancer
R. Horvat, E. Dissing, S. Hess. SYS Erlangen, Erlangen, GERMANY.

**EP-0449**
18F-FDG-PET/CT in Peritoneal Carcinomatosis. Correlation With CT And Surgery In Evaluation Of Peritoneal Carcinomatosis Index (PCI)
A. Vallejo-Lesmes, E. Rodriguez-Caceres, A. Santos-Buena, J. Marques-Fernandez, J. Prieto-Prieto, M. Guzie Maremsa, J. Vallval-Casas; University Hospital Renal Sofia, IMIBIC, Cordoba University, Cordoba, SPAIN.

**EP-0450**
F-18 FDG-PET/CT in evaluating of the mediastinal tumours: The role of the metabolic and volumetric parameters
I. Aksivrikos, M.C. Siminak, E. Duzceylan, E. Gokmen; ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TURKEY; Eskisehir Osmangazi University School of Medicine Department of Thoracic Surgery, Eskisehir, TURKEY.

**EP-0451**
FDG PET with Low Dose CT versus Contrast Enhanced CT as Quantification Method to Assess the Extent of Peritoneal Carcinomatosis previous Cytoreductive Surgery-HIFEC: a Pilot Study
A. Repetto, C. De Juan, M. Gimenez, J. Segura, R. Morales, M. Guillot, C. Perla; University Hospital Son Espases - Department of Nuclear Medicine, Palma de Mallorca, SPAIN; University Hospital Son Espases - Department of Radiology, Palma de Mallorca, SPAIN; University Hospital Son Espases - Department of Digestive and General Surgery, Palma de Mallorca, SPAIN; University Hospital Son Espases - Department of Oncology, Palma de Mallorca, SPAIN.

**EP-0452**
Positive Predictive Value of Suspected Primary Malignancy Localized on F-18 FDG PET-CT in Patients with Carcinoma of Unknown Primary (CUP)
B. Kumar, H. Singh, R. Kumar, A. Bhattacharyya, B. Mittal; Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, INDIA.

**EP-0453**
Clinical -> Diagnostic study -> Adult study -> Oncology study -> Organ-based oncology -> Prostate, malignant

Displayed throughout the congress days *e-Poster Area*

**EP-0459**
Impact of late PET/CT imaging with 18F-RM2 in the characterization of prostate cancer
R. Schollhammer1,2,3, M. De Clementi Galienard1, G. Robert1, M. Yassou1, F. Lumen1,3, N. Balkimli1, D. Vimont1, E. Hinder1,3, P. Fernandez1, C. Margat1,3, Service de Medicine Nucléaire, CHU Bordeaux, Bordeaux, FRANCE; University Hospital Haut-Lévêque, Bordeaux, FRANCE; University Hospital Georges Pompidou, Paris, FRANCE;

**EP-0460**
Novel F-18-sPSMA-14 shows favourable tracer kinetics for staging and restaging of prostate cancer patients
V. Prasad1, O. D’Cerral1, J. Mikocz1, G. Fischer1, F. Zengerling1, C. Salbach1, H. Wester1, A. J. Beer2, Department of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY; Department of Pharmaceutical Radiochemistry, Technical University Munich, Garching, GERMANY; Department of Urology, University Hospital Ulm, Ulm, GERMANY.

**EP-0461**
Prospective evaluation of 18F-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer
A. Lagara1, M. Diana2, M. Song2, C. Hansen2, K. Gupta2, B. Fran2, P. Manali2, G. Davidson; Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA.
Scientific e-Posters

EP-0462
Diagnostic accuracy of 68Ga-PSMAHBED PET/CT and pelvic mp-3Tesla MRI in primary staging of patients with intermediate/high-risk prostate adenocarcinoma
M. Celli1, G. Fenuenti, R. Gurelli, M. Castantini, V. D. Iorio, D. Barone, P. Caroli, L. Fantini, A. Moretti, R. Galastri, M. Giganti, G. Papag-exp1, F. Matteucci*, RIST, Metals, ITALY, *Morgagni-Panieri General Hospital, Forlì, ITALY, †Tenase University, Forlì, ITALY.

EP-0463
Diagnostic performance of 68Ga-HBED PSMA PET/CT in BCR prostate cancer: a single center study review
C. Reichel†, F. Locucio1, B. Tombai†, R. Lhommet†; *Nuclear medicine, Cliniques Universitaires Saint-Luc, UCL, Brussels, BELGIUM; †Medical imaging, Cliniques Universitaires Saint-Luc, UCL, Brussels, BELGIUM, ‡Urology Cliniques Universitaires Saint-Luc, UCL, Brussels, BELGIUM.

EP-0464
Role of (68Ga)-PSMA-11 PET/CT to target focal treatment in patients with biochemical relapse of prostate cancer
A. Skanjelii†; *A. Dhompri†, W. Soifai†, A. Ruffin†, O. Chopet1, J. Toras1; *Nuclear Medicine, Hospices Civils de Lyon, Lyon, France, †Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, ‡Department of Oncology, University Hospital Center Zagreb, Zagreb, CROATIA, §Department of Radiology, University Hospital Center Zagreb, Zagreb, CROATIA, ¶University of Zagreb School of Medicine, Zagreb, CROATIA.

EP-0465
Correlation among biochemical, biological characteristics and 18F-Choline PET/CT findings in a large cohort of 1225 prostate cancer patients
I. Ravelli*; *L. Cuppini1, P. Recacci, A. Cerina, M. Buret1, M. Manuro1, F. Zattò1, A. Gustia1, M. Gardi1, L. Evangelista1, *Department of Nuclear Medicine, University of Padua, Padua, ITALY, †Department of Nuclear Medicine, University, Veneto Institute of Oncology-IRCCS, Padua, ITALY, ‡Oncology Unit, Veneto Institute of Oncology-IRCCS, Padua, ITALY, §Department of Urology, Hospital of Udine, Udine, ITALY, ¶Department of Urology, Hospital of Camporosso, Padua, ITALY, ‰Department of Urology, Hospital of Sant'Antonia, Padua, ITALY.

EP-0466
Practical approach: description of three different patterns we found in 18 FCholine PET/CT in the diagnosis of bone metastasis for prostate carcinoma
M. Agosti, L. Solari, C. Aruga, Centro Medicina Nuclear, Parma, ARGENTINA.

EP-0467
68Ga-PSMA PET/CT in the evaluation of Prostate cancer patients with biochemical recurrence after radical therapy, a first multicentric study in Mexico
S. S. Medina*; *O. Garcia1, I. Soldevilla1, U. Canavos1, D. Cardoso1, S. Lopez1, A. Quintana1, O. Hernandez1, †Instituto Nacional De Cancerología, México City, MEXICO, ‡Hospital Angeles Lindavista, México City, MEXICO, §Hospital Médico Sur, Mexico City, MEXICO, ¶*Centro Medico ABC, Mexico City, MEXICO.

EP-0468
F-18-choline PET in initial staging of prostate cancer patients
A. T. Golubic*, M. Gumunić*, M. Salonić*, T. Kuljiz†, Z. Kazalinić‡; *Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, †Department of Oncology, University Hospital Center Zagreb, Zagreb, CROATIA, ‡Department of Oncology, University Hospital Center Zagreb, Zagreb, CROATIA, ¶University of Zagreb School of Medicine, Zagreb, CROATIA.

EP-0469
The added value of lumbopelvic SPECT/CT to negative planar 99mTc-Bone Scintigraphy in Prostate Cancer

EP-0471
Diagnostic Efficacy of 18F-PSMA-1007 in Staging of Prostate Cancer
K. Gourevich, A. Kavkoss, Z. Keidar, Rambam Healthcare Campus, Haifa, ISRAEL.

EP-0472
Assessment Of Bone Lesions With Ga68PSMA Uptake Without Visible Bone Density Change On Corresponding CT
S. Tatlıdil, F. Tamer, M. Gumus, Z. Ozcinar, Ege University, Izmir, TURKEY

EP-0473
Influence of urinary bladder activity on the detectability of local prostate cancer recurrence in “Ga68-PSMA-PET/CT
I. L. Alberts*, C. Sachapelski*, L. Dyjkstra*, E. Gouwm*, L. Heret*, R. Cacciatore*, S. Bakker*, T. Grazi, G. Thalmann1, A. Rominger*, A. Alshar*, †University clinic for Nuclear Medicine, Bern, SWITZERLAND, ‡University clinic for Nuclear Medicine, Bern, SWITZERLAND.

EP-0474
Correlation of Ga68 PSMA PET/CT parameters, mPHI parameters and histopathological grading in prostate cancer
A. Arçay, F. Aydin, M. Akus1, A. Kerem1, E. Süzü Budak1, C. Çevik1, A. Bo1; *Akdeniz University Faculty of Medicine, Nuclear Medicine Department, Antalya, TURKEY, ‡Akdeniz University Faculty of Medicine, Radiation Oncology Department, Antalya, TURKEY, ¶Akdeniz University Faculty of Medicine, Radiology Department, Antalya, TURKEY, ‰Antalya Training and Research Hospital, Clinic of Nuclear Medicine, Antalya, TURKEY.

EP-0475
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical persistence (BCP) after radical prostatectomy: Accuracy in localizing residual disease and impact on subsequent management
G. Polverari, F. Ceci†, M. Valder, P. Casteluzza1, F. Farroh1, L. Calderoni‡, F. Lodì†, S. Fant1; †Metropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, Bologna, ITALY, ‡Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY.

EP-0476
Biochemical recurrence with low values of PSA in prostate carcinoma after radical therapy: sensibility of 68Ga-PSMA PET/CT imaging for prostate cancer: three case reports
S. Erhamamci*, N. Aslan; †Baskent University, ‡Istanbul Health Practice and Research Center Hospital, Department of Nuclear Medicine, Istanbul, TURKEY, †Baskent Medical Center, Department of Nuclear Medicine, Istanbul, TURKEY.
EP-0485 Does "Ga-PSMA-11 PET/CT Detection Rate change during time? A single-center study
S. Telo,1, S. Veneva,1, A. Farolfi,2, L. Caldesano,1, R. Meti,1, P. Castellucci,1,2,3 C. Fonti,1,2, C. Ceci,1, S. Sanfi,1,2,3,1 Nuclear Medicine, I.Oralis Malpighi Hospital, Bologna, ITALY, 2OMES University of Bologna, Bologna, ITALY, 3University of Messina, Messina, ITALY.
Protection of personal data: Not applicable.
Clinical relevance: The results of our study suggest that the detection rate of "Ga-PSMA-11 PET/CT may change over time, with statistically significant differences observed at different time points in our study population. Further research is needed to determine the optimal timing for performing this imaging modality.

EP-0486 The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia
I. L. Alberts,1,2 D. Djakar,1, G. Pernos,1 E. Gourli,1 L. Met,2 R. Cascato,2 S. Bauder,2 T. Graess,2 C. Thadmann,2 K. Rahbar,2 A. Rominger,2 A. Alkhair,2 University Clinic for Nuclear Medicine, Bern, SWITZERLAND, 1University clinic for Urology, Bern, SWITZERLAND, 2University clinic for Nuclear Medicine, Munich, GERMANY.

EP-0487 Retrospective comparison of "Ga-PSMA-11 and 11C-Choline performances in a cohort of selected prostate cancer patients after radical prostatectomy, presenting with low PSA levels and undergoing imaging with both modalities within 8 weeks
A. Farina,1 J. De Nicolai,1 A. Lambertini,1 F. Ceci,1 P. Castellucci,2 S. Sanfi,1,2 Nuclear Medicine Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, 1Nuclear Medicine, 2Department of Medical Sciences, University of Turin, Turin, ITALY.

EP-0488 Performance of PSMA PET for Staging of Prostate Cancer
A. Gumer,1 K. Unal,1 H. Irzom,2 E. Kayaır,1 E. Vardareli,1 M. Tun,2 I. Dogan,1 Acıbadem University, Istanbul, TURKEY, Acıbadem University Nuc Med Dept, Istanbul, TURKEY, Acıbadem University Urology Dept, Istanbul, TURKEY.

EP-0489 Relationship Between PSA Levels and F-18 Sodium Fluoride Positron Emission Tomography Scan in Prostate Cancer Bone Metastasis
F. Abbaspour Raddakheili, F. Kazaee, P. Mahdha, N. Almanav, M. Leblanc, A. Alzohorabhi, V. Deneky, A. Ciarallà, R. Lisbona, J. Navalón Díaz, A. Afshar, M. Holenam, McGill University, Montreal, QC, CANADA.

EP-0490 Detection Rate of "F-labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Meta-analysis
G. Treglia1,2, S. Annunziata,2 D. A. Pozzato,1,2 Cerami1, J. G. Di Marco1,2,4, J. O. Priore,1 Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona and Lugano, SWITZERLAND, 2Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, 3Health Technology Assessment Unit, Generali Directorate, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND, 4Department of Nuclear Medicine, University of Messina, Messina, ITALY.

L. Baratto,1 M. Duan,2 R. Luscin,1,2 V. Fern,1, A. Tongana,1,2 N. Hitami,1, A. Iagaru2; Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

EP-0492 68Ga-PSMA PET/CT: review of a population of prostate cancer patients at initial diagnosis
C. V. Pinto,1 C. Loewenthal,1 R. Vieira,1 Hospital da Luz, Lisboa, PORTUGAL.

EP-0493 The impact of 68Ga-PSMA PET/CT in prostate cancer patients with earlier biochemical recurrence
D. Has Simsek,1,2 S. Sanfi1,2, Istanbul University, Istanbul Faculty of Medicine, Istanbul, TURKEY.

EP-0494 Choline-PET Radiomic features to predict survival outcome in prostate cancer
P. Alongi1, P. Stefano,1 P. Mappel2, R. Laudencia3, A. Gentile3, D. Sardina4, G. Russol5, G. Granducci3,1, A. Vento4,1, M. Vecchio4,1, S. Baldani2, M. Milian4,1, Nuclear Medicine Unit, Fondazione Istituto Gigi, Cefalù, ITALY, 2Department of Radiology, University of Palermo, Palermo, ITALY, 3Institute of Molecular Biomaging and Physiology, National Research Council (BFM- CNR), Cefalù, ITALY, 4Department of Nuclear Medicine, RCCS San Raffaele Scientific Institute, Milan, ITALY, 5Vita-Salute San Raffaele University, Milan, ITALY, 6Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, University of Palermo, University of Messina, Messina, ITALY, 7Department of Surgical Oncological and Stomatological Sciences, University of Palermo, Palermo, ITALY, 8Institute of Molecular Biomaging and Physiology, National Research Council (BFM-CNR), Cefalù, ITALY, 9Department of Biopathology e Biotecnologie Mediche, Policlinico Paolo Gallina, Palermo, ITALY, 10Department di Biopatologia e Biotecnologie Mediche, Policlinico Paolo Gallina, Palermo, ITALY.

EP-0495 18F-Choline PET/CT in the Susception of Prostate Cancer Recurrence. Our Experience
C. Riola-Parada,1 P. García-Talavera,1 J. Villanueva,4 F. Gómez-Caminero,4 C. Vázquez,4 J. Izaguirre,4 J. Rodríguez-Núñez,4 P. Tamayo4, Nuclear Medicine Department, Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

EP-0496 Negative predictive value of the finding of non-metastatic disease with whole body 99m-Tc HDP-SPECT-CT in prostate adenocarcinoma may be adequately high
E. E. Kauppila,1 Senokopi Central Hospital, South Ostrobothnian Health Care District, Senokopi, FINLAND.

EP-0497 "F-Choline PET/MRI On The Therapeutic Approach For Prostate Cancer Patients Treated With Prostatectomy And Rising PSA Below 1 ng/ml
J. R. García,1 A. Blanch,1 CTRT, Valsanomat (Barcelona), SPAIN.

EP-0498 Diagnostic accuracy of 60min & 120min 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence. Initial results
E. Panagiotidis,1 A. Paschali,2 P. Mitsakis, N. Papadopoulos,1 T. Kalivas,1 A. Papitoula,1 V. Chatzipavlou; PET/CT department, Theogaea Cancer Center, Thessaloniki, GREECE.

EP-0499 Comparison between sonoanatomic characteristics and cytopathologic findings of thyroid nodules detected incidentally at 18F-FDG PET/CT (18F-Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography)
M. Waitamin,1 P. D. Barbosa,2 C. A. T. D. Meldorff,2 C. A. Bucheguet,1 G. G. Cerr,1 C. D. Leite,3 Sino Libanês Hospital, São Paulo, BRAZIL.

EP-0500 Correlation between Ig levels and 18 F-FDG PET/CT findings in follow up the group of radioiodine refractory disease DTC patients with negative PET/CT findings
D. J. Srbovan,1 L. Vucic,1 P. J. Institute of oncology Wojasod, Sieiniski Kanemico, SERBIA.

EP-0501 Contribution Of 111I SPEC/CT To Planing Imaging In Post-Ablation Differentiated Thyroid Cancer
M. Quirce Pisano,1 J. Andre-Pacheco,1 J. Jimenez-Bonilla,1 I. Martinez-Rodriguez,1 N. Martinez-Amador,1 M. De Arcos-Torres,1 A. Sanchez-Salman,1 C. Cuencavega,1 G. Molina-Mendoza,1 J. Bonac,2 Department of Nuclear Medicine, Marques de Valdecilla University Hospital, Molecurar Imaging Group (IONAL), University of Cantabria, Santander, SPAIN.

EP-0502 Incremental value of cervico-thoracic SPECT/CT over planar imaging in postablution 131I scintigraphy for thyroid cancer
W. Amouri, E. Yakoob, S. Charfeddine, I. Jardak, B. Khnouf, M. Maaouia, F. Hamza, K. Kaflet, K. Chitouni, F. Guermaz; Nuclear medicine department, Habib Bourguiba Hospital, Sfax, TUNISIA.
EP-0503 FGK PET-positive incidental thyroid nodules - clinical implications and the role of thyroid scintigraphy
M. H. Reichkendler, K. Konradi, L. Asløv, P. Chun, Department of Clinical Physiology, Nuclear medicine and PET, Rigshospitalet Copenhagen University Hospital, Copenhagen, DENMARK.

EP-0504 How accurate is serum thyroglobulin measurement in patients with differentiated thyroid cancer?
M. Tuncel, T. Türkl, M. Çaldaş Tuncali, Hacettepe University, Ankara, TURKEY.

EP-0505 Comparison of Ga68 PSMA PET/CT and FGK PET/CT Findings In a Case with Follicular Thyroid Cancer
C. O. Engür, T. Öney, S. Kesen, N. Filizoğlu, S. Çagüven, K. Okçuözüg, S. Inanor, T. Y. Irlı, H. T. Türcü, Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

EP-0506 Usefulness Of Post Treatment SPECT/CT In Whole Body Scan For The TNM Re-Staging In Patients With Well Differentiated Thyroid Cancer (WDTC)
A. Yępes Agüelo, S. Praço Wilsenend, R. Sanchez Varia, M. Agüelo Cifuentes, J. Bernal Vergara, A. Urrera Castena, P. Olivan Sasot, P. Bello Arques, B. Martinez Sanchez, Hospital La Fe, Valencia, SPAIN.

EP-0507 Incidental Findings in the Thyroid Gland in PET-CT Studies with 18F-FDG
S. García Martínez, A. Boñon García, M. De Bonilla Canals, M. Cruz Montijano, J. Rodríguez-Rubio Canova, M. Pajares Vinardell, Puerta del Mar University Hospital, Cadiz, SPAIN.

EP-0508 18F-FDG PET-CT In Patients With Thyroid Cancer: Our Experience
A. Peñaherrera Cepeda, P. García-Talavera San Miguel, F. Gómez Camarero, C. Roa Paredes, J. Villamor Carrera, J. Martín Gómez, J. Carballosa Salazar, E. Achury Muncur, P. Tamayo Alonso, Madre Auxiliadora University Hospital, Salamanca, SPAIN; Madre Auxiliadora Nuclear Medicine, Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

EP-0509 Incidental discovery of thyroid cancer in scintigraphic studies of patients with hyperparathyroidism
V. Rodríguez Morales, B. Uñuea de Oliveira, F. Laina Bano, J. Muñoz, A. Renda, C. Martinez, D. Ruiz, Hospital ab de Menéndez, Vigo, SPAIN.

EP-0510 Integrative Analysis Of Glucose Metabolism Signatures and Differentiation Of Thyroid Cancer: Diagnostic and Therapeutic Implications

EP-0511 Correlation of mRNA-TSH and mRNA-Tg with radiiodine whole body scan and ultrasound findings in thyroid carcinoma patients
T. Makakieziewa, O. Vaskovska, T. Tripczynski, S. Stajniakowski, M. Manevskas, S. Ristevski, H. Javonovic, Z. Jakovski, A. Ethnoff, Institute of pathophysiology and nuclear medicine, Skopje, NORTH MACEDONIA; Institute for forensic medicine, criminology and medical deontology, Skopje, NORTH MACEDONIA; Institute of pathology, laboratory of molecular pathology, Skopje, NORTH MACEDONIA.

EP-0512 Preliminary results of serum thyroglobulin without TSH-stimulation measured by an ultrasensitive kit : a prospective study
H. Kim, S. Hah, Y. Park, K. Paeng, K. Kang, D. Lee, J. Chung, S. Chon, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF; National Cancer Center, Goyang, KOREA, REPUBLIC OF.

EP-0513 Treatment of Radio iodine-Refactory well Differentiated Thyroid carcinoma: Impact of PET-FDG on Decision Making
E. Lodí Rizzini, E. Tabachch, A. Faralli, A. Margariti, F. Manoni, S. Faniri, Nuclear Medicine Unit, S. Orsola Malpighi University Hospital, Bologna, ITALY; Radiatum Oncology Center, S. Orsola-Malpighi Hospital, Bologna, ITALY.

EP-0514 18F-18 Fluorodeoxyglucose Positron Emission Tomography Useful In Thyroid Papillary Cancer With Positive Follow-up Radioiodine Scan And Elevated Serum Thyroglobulin Level?
J. Oh, J. Seo, S. Baer, H. Kim, J. Baer, H. Jeong, W. Chang, H. Yoon; Raphaël Hospital, Daegu, KOREA, REPUBLIC OF; Daegu Fatima Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0515 Utility of Radioactive iodine 131 Seed as preoperative method for localization of cervical thyroid cancer recurrence
T. Cambil Molina, T. Martín Hernandez, C. Marin Velarde, J. Tenon León, P. De la Riva Perez, J. Garcia Gomez, C. Cabo Morlan, Virgen Macarena University Hospital, Sevila, SPAIN.

EP-0516 Radioactive iodine 131 Seed as preoperative method for localization of cervical thyroid cancer lymphadenopathy. Preliminary results
T. Cambil Molina, T. Martín Hernandez, J. Tenon Leon, C. Marin Velarde, P. De la Riva Perez, M. Molina Mora, J. Leon-Aiubana Moreno, C. Calvo Morlan, Virgen Macarena University Hospital, Sevila, SPAIN.

EP-0517 Evaluating Focal 18F-FDG Uptake In Thyroid Gland With Radionics
A. Aksoy, N. Kazar, Kazahane Şen, G. Çapa Kayas, Dokuz Eylül University, Izmir, TURKEY.

EP-0518 Is 18F-18 Fluorodeoxyglucose Positron Emission Tomography Useful In Thyroid Papillary Cancer With Positive Follow-up Radioiodine Scan And Elevated Serum Thyroglobulin Level?
J. Oh, J. Seo, S. Baer, H. Kim, J. Baer, H. Jeong, W. Chang, H. Yoon; Raphaël Hospital, Daegu, KOREA, REPUBLIC OF; Daegu Fatima Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0519 Utility of Radioactive iodine 131 Seed as preoperative method for localization of cervical thyroid cancer recurrence
T. Cambil Molina, T. Martín Hernandez, C. Marin Velarde, J. Tenon León, P. De la Riva Perez, J. Garcia Gomez, C. Cabo Morlan, Virgen Macarena University Hospital, Sevila, SPAIN.

EP-0520 Radioactive iodine 131 Seed as preoperative method for localization of cervical thyroid cancer lymphadenopathy. Preliminary results
T. Cambil Molina, T. Martín Hernandez, J. Tenon Leon, C. Marin Velarde, P. De la Riva Perez, M. Molina Mora, J. Leon-Aiubana Moreno, C. Calvo Morlan, Virgen Macarena University Hospital, Sevila, SPAIN.

EP-0521 Preliminary results of serum thyroglobulin without TSH-stimulation measured by an ultrasensitive kit : a prospective study
H. Kim, S. Hah, Y. Park, K. Paeng, K. Kang, D. Lee, J. Chung, S. Chon, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF; National Cancer Center, Goyang, KOREA, REPUBLIC OF.

EP-0522 Incremental value of intestinal transit scintigraphy in children with functional constipation
M. Pizzoferrro, R. Tamburri, M. F. Villari, T. Caldare, P. De Angelis, F. Fusaro, M. C. Gangiarena, Nuclear Medicine Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ITALY; Digestive Endoscopy and Surgery Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ITALY; Department of Medical and Surgical Neonatology, Naval Medical University-IrCCS, Rome, ITALY.

EP-0523 Urea breath test in children
I. El Bez, R. Tufahj, I. Moun, F. Alhamjas, M. Alkabti, KFMC, nuclear medicine department, Riyadh, SAUDI ARABIA.
EANM'19  WORLD LEADING MEETING
FINAL PROGRAMME

**EP-0524**
The applicability of the ICRP 128 kinetic model to pediatric patients at 3 hour time point post 99mTc-OMSSA injection
M. Pitkonen, O. Spiký, J. Hyyppänen, HUS Imaging Centre, Helsinki University Central Hospital, Helsinki, FINLAND.

**EP-034**
Clinical -> Diagnostic study -> Paediatric study -> Oncology (Diagnostic)
Displayed throughout the congress days – e-Poster Area

**EP-0352**
A Use Of Post-therapy 131I-mibg Scintigraphy In Pediatric Patients With High-risk Neuroblastoma
H. Watanabe, Y. Nguyen, H. Maeba, J. Kanazawa, M. Gavras, I. El Bez, R. Tulbah, I. Munir, F. Alghamlas, M. Alharbi; King Fahd Medical City, Nuclear Medicine Department, Riyadh, SAUDI ARABIA.

**EP-0526**
Influencing factors of the first 18FDG ablation therapy for children and adolescents differentiated thyroid cancer
L. Lina, T. Tian, L. Ren; West China Hospital, Sichuan University, Chengdu, CHINA.

**EP-0527**
PET/MR imaging of pediatric bone tumors: Case based review
K. Hawk, C. N. R. Farrow, A. Pareek, A. Muhe, A. Pribnov, R. Steffner, R. Avedian, H. E. Daldrup-Link; Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

**EP-0528**
MBIg Scintigraphy In Children With Neuroblastoma: Add Value Of Hybrid Images
I. El Bez, R. Tulbah, I. Munir, F. Alghamlas, M. Alharbi, King Fahd medical city, nuclear medicine department, Riyadh, SAUDI ARABIA.

**EP-0529**
Differentiated Thyroid Carcinoma in Children and Teenagers
I. El Bez, R. Tulbah, I. Munir, F. Alghamlas, M. Alharbi, King Fahd medical city, nuclear medicine department, Riyadh, SAUDI ARABIA.

**EP-0530**
The Association Between Pathological Featuers and Resistant Disease In Paediatric Patients With Differentiated Thyroid Cancer
K. Kucuker, Z. Yapar, I. Guney, G. Buyuklerdik; Gulhane University, Adana, TURKEY.

**EP-0531**
Response assessment in children with lymphoma under neoadjuvant checkpoint inhibitor therapy using 18 FDG-PET/CT
I. Vdovina, E. Kreva, K. Chasutiu, M. Chetuchova, I. Pataprev, N. Myakova, V. Liker, Dimitry Rojaschey National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

**EP-0532**
Prognostic value of 123I-MIBG scintigraphy in bone metastatic neuroblastoma
L. Nieto Morcillo, L. de la Curva Barras, M. Foligs Larcurea, M. Caldenín Calvente, G. Guzmán Prudencio; Zaragoza, SPAIN.

**EP-0533**
Spectrum of malignancies in patients with Neurofibromatosis (NF): role of FDG-PET/CT in detecting malignant transformation
M. Gavra, K. Rokat, I. Sevastidou, D. Veugelers, V. Veleris, M. Filippidou, I. Malamani, A. Katramis; Radiology, CT & MRI, Goudi, Athens, GREECE.

**EP-0534**
FDG PET/CT predictors of treatment response in patients with Osteosarcoma and Ewing’s sarcoma
D. Volterrani, M. Aghakhanyan, F. Guidoccio, L. D. Volterrani; Hospital Universitario de Granada, Granada, SPAIN.

**EP-0535**
Dosimetry in thyroid cancer paediatric patients
T. Kramarovna, V. L. Mikhailov, V. Simonov, K. Tabarska; University Hospital Motol, Prague, CZECH REPUBLIC.

**EP-0536**
Clinical -> Therapy study -> Adult study -> Other treatments -> Bone metastases -> pain palliation
Displayed throughout the congress days – e-Poster Area

**EP-0537**
Identifying Factors that Affect Patient Outcomes in Radium-223 Therapy: Retrospective Image Quantification of Bone Scans and Assessment of Blood Markers
J. Gray, J. Southam, V. Prakash, M. Shastry; Royal Surrey County Hospital NHS Foundation Trust, Guilford, UNITED KINGDOM.

**EP-0538**
Role of FDG PET/CT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride

**EP-0540**
Factors Contributing to Discontinuation of Radium-223 Dichloride Treatment in Patients with Castration Resistant Prostate Cancer (mCRPC) and Bone Metastasis. Single Center Experience
S. Kozak, O. Lang, R. Pichova, M. Mateju, Nemocnice Kraslice Vrchlabi, Klinika nuklearni mediciny, Prague, CZECH REPUBLIC.

**EP-0541**
A Single Centre Experience with 223-Radium-Dichloride (“223RaCl2”) Therapy
R. Laudicciella, M. Minutoli, A. D. Coim, A. Vento, H. Lanusstrome, B. Catalfamo, F. Paraiso, C. Mantara, S. A. Pagnotta, B. Pagona, S. Baldani; Unit of Nuclear Medicine, Messina, ITALY.

**EP-0542**
Value Of Dosimetry, Analytical Data And Imaging Tests In The Monitoring Of Bone Metastases Response Treated With “223Radium (Xofigo) In Patients With Metastatic Castration-Resistant Prostate Cancer
M. Alonso Rodriguez, C. Andrés Rodriguez, B. Pérez Urgest, C. Garrozo Louhéron, J. Gómez Hidalgo, M. A. Ruiz Gómez, V. De la Llana Granja, P. I. Turbay Eljach, N. Alvarez Mené, M. Ayuga Osler, R. Torres Cabrera, R. Ruano Paredes; Hospital Clínico Universidad de Valladolid, Valladolid, SPAIN.

**EP-0543**
Evaluation of the efficacy and safety of radio-223 dichloride in prostate Bone- metastatic Castration-resistant Prostate Cancer in our hospital
M. Asensio Ruiz, Á. García Almagro, A. Ribello Tarazona, M. Sara Sober, M. Claver Valdenos, M. Martínez Martínez; Hospital Clínico Universidad Virgen de la Arrixaca, Murcia, SPAIN, Hospital General Universitario Morales Meseguer, Murcia, SPAIN.
Unresectable Hepatocellular Carcinoma: Analysis of Prognostic Factors in Patients Who Displayed throughout the congress days e-Poster Area

Clinical -> Therapy study -> Adult study -> Other treatments -> Local radioembolization treatments

Radioembolization of refractory synovitis - Initial experience at Groote Schuur Hospital

St. Orsola Malpighi - Bologna, Bologna, ITALY,

Radioembolization of hepatic artery with 90Y itiro cristal microspheres, for the treatment of patients with inoperable liver lesions

Unresectable liver metastases from thyroid cancer: Dose-response relationship and estimate of the radiobiological alpha parameter

Comparison of best therapy response according to the intraarticular techniques performed in gEP NET treated patients in relation to the absorbed dose, Ki-67 index and tumor size using n.c.a. Lu-177 dotatate

Does clinical response to PRRT with 177Lu-DOTATATE influence lesion progression? A lesion-based approach

Does initial response to PRRT with 177Lu-DOTATATE predict long-term outcomes after high-dose I-131 Mibg therapy for high-risk neuroblastoma: A Japanese single-institution experience

Does initial response to PRRT with 177Lu-DOTATATE predict long-term outcomes after high-dose I-131 Mibg therapy for high-risk neuroblastoma: A Japanese single-institution experience

Efficacy and safety of PRRT in neuroendocrine tumors: a single center experience in Mexico

Efficacy and safety of PRRT in neuroendocrine tumors: a single center experience in Mexico

Efficacy and safety of PRRT in neuroendocrine tumors: a single center experience in Mexico
EP-0566
An uncommon “pseudo-progression” pattern of morphological response, as early as after one cycle of PRRT, in sNET patients
I. Karfh, G. Mann, P. Flanner; Jules Bordet Institute, Brussels, BELGIUM

EP-0567
Targeted Molecular Therapy Using Radiolabelled Somatostatin Analogue (Dotatate): Initial Experience From A Tertiary Hospital In Singapore
H. Huang, W. Thiam, D. W. M. Tai, D. C. E. Ng, S. X. Yen, K. Loke; Singapore General Hospital, Singapore, SINGAPORE.

EP-0568
Efficacy of 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Inoperable/Metastatic, Progressing Neuroendocrine Tumors: Results of Our First Clinical Experience
B. Gunalp, A. Uğur, U. Goker, M. Mahmudov, S. Ince, E. Alagöz; University of Health Sciences, Gulhane Medical Faculty, Ankara, TURKEY.

EP-0569
Cytoreductive Surgery And Lesion Excision As Treatment Of Choice In Intrapitoneal And Liver GEP NET Metastases Respectively. Followed By Radiopeptide Treatment
G. Limouris1, M. Papaith2, V. Kyrol2, M. Daloguz3, R. V. McCready3, J. Kynazanos4; Medical School, National and Kapodistrian University of Athens, Athens, GREECE, 1National Health System, Athens, GREECE, 2Nuclear Medicine Department “A Tyto”; Medical Radiological Research Center, Olimpos, RUSSIAN FEDERATION, 3Babkin; Russian Oncological Research Center, Moscow, RUSSIAN FEDERATION, 4Cancer Research Institute, Sutton Surrey & Royal Sussex County Hospital, Sutton-Surrey, UNITED KINGDOM, 5Surgery Dept, Army Naval Hospital, Athens, GREECE.

EP-0570
Ki-67 expression index and early post-PRRT chromogranin A levels in NETs - Is there any correlation? Preliminary results
A. Mazurek1, M. Zurak2, S. Pluczyn2, M. Kolodziej3, A. Goewie1, E. Wilkowska-Patena1, S. Ocie2, 1Military Institute of Medicine Department of Nuclear Medicine, Warsaw, POLAND, 2Military Institute of Medicine Department of Endocrinology and Isotope Therapy, Warsaw, POLAND.

EP-38
Clinical -> Therapy study -> Adult study -> Other treatments -> Other treatments
Displaced throughout the congress days

EP-0571
Peptide receptor radionuclide therapy for high-grade glioma brain tumors: Variable clinical response in a pilot study
M. Assadi1, R. Nemati2, H. Shoob3, M. Rekhtarpour4, A. Amini5, M. Rasavand2, A. Ahmadvandefahri2, 1Buehrli University of Medical Sciences (BUMS), Buehrli, IRAN, 2ISLAMIC REPUBLIC OF, 3University Hospital Bonn, Bonn, GERMANY.

EP-0572
Quantitative kinetic analysis of Lu-177-DOTA-ocacteotate/ocacteotreated patients with meningioma
L. Lehmoven1, E. Hippeläinen1, V. Ahkanen1, J. Vaastrap1, V. Reijonen1; 1Cancer Center, University Hospital University Hospital, Helsinki, FINLAND, 2Department of Physics, University of Helsinki, Helsinki, FINLAND, 3HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND.

EP-0573
177 Lu-DOTATATE therapy in progressive meningioma
W. Roll1, M. Muthter1, B. Zimbhando1, L. Stegger1, M. Schäfers1, M. Wlekser1, W. Stummer2; 1Department of Neurosurgery, University Hospital Münster, Münster, GERMANY, 2Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY.

EP-0574
[177 Lu]-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer: a prospective study
B. M. Prive3, S. Perez4, C. H. J. Muiselaer1, P. Zamaroulakis2, M. Jonasen1, J. W. J. Scheppe1, M. W. Koinenberg1, J. V. Veysbroeck2, W. R. Gennimans1, N. Mehas1; D. M. Somfaord3, J. P. M. Sedeliers3, I. M. von Dör1, J. O. Barentsz4, S. Hekamp1, M. Gotthard1, J. A. Wijten1, J. Nagoraad1; Radiotherapy Unit, Amsterdam, NETHERLANDS, 2Ravand Medical Center, Rotterdam, NETHERLANDS, 3Carusus Wilhelmina Hospital, Amsterdam, NETHERLANDS.

EP-0575
Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?
T. Langbein1, H. R. Kuukans2, A. Singh1, C. Schrattel3, J. Zhang1, R. P. Baum4; Technical University of Munich, School of Medicine, Department of Nuclear Medicine, Munich, GERMANY, 2Zentrumlink Böd Berka, Theranostics Center of Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY.

EP-0576
Correlation between PSA response and response assessment with [18F]-PSMA-11 PET/CT-derived metabolic parameters in patients treated with [18F]AC-PSMA-617 for metastatic prostate carcinoma
I. O. Lawal1, A. Morgenstein2, G. Knaeren1, M. Vorster1, G. O. Poppo2, J. Mahapane2, J. Lengana2, T. M. G. Bosshamner1, K. M. G. Mokoloko1, F. Bruchertseifer2, M. S. Sathekge1, 1Department of Nuclear Medicine, University of Ilorin, Ilorin, NIGERIA, 2Department of Nuclear Medicine, University Hospital, Ulm, GERMANY.

EP-0577
[177 Lu]-PSMA-617 Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer: Safety, Efficacy and Quality of Life Assessment
M. P. Yadav, C. Sal, S. Baid, M. Tripathi, N. A. Damci; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0578
[186mRa]-dichloride: Prognostic value of Baseline Quality of Life in mCRPC patients candidates to treatment
V. Frantellizzi, M. De Feo, C. De Angelis, G. De Vincenti, Sapienza University of Rome, Rome, ITALY.

EP-0580
High Activity [177 Lu]-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
C. Happel, W. T. Kramer, B. Bockisch, G. Gierner, K. H. Davies, J. Wichter, M. Stefanova, F. Grünwald, A. Sabet; University Medical Center Frankfurt / Department of Nuclear Medicine, Frankfurt, GERMANY.

EP-0581
Prognostic Value of Discordance Between [[18F]-PSMA PET/CT and [[99mTc]-HOP SPECT/CT Bone Sцинtigraphy in Metastatic Prostate Cancer Patients Treated with [186mRa]-Dichloride
N. Plouznikoff1, C. Artigas1, T. Grp, P. Flanner; 1Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB) Brussels, BELGIUM, 2Department of Nuclear Medicine, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, CANADA, 3Department of Oncology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

EP-0582
Potential value of neuroendocrine differentiation serum biomarkers in prediction of response to radioligand therapy with Lu-177 PSMA 617 for metastasized castrate resistant prostate cancer
V. Prasad, M. Gruener, F. Zengelinger, J. Mikosch1, C. Boland2, A. J. Beer2, 1Department of Nuclear Medicine, University Hospital, Ulm, GERMANY, 2Department of Urology, University Hospital, Ulm, GERMANY.
EP-0583
The 68Ga / 177Lu-Theragnostic Concept in PSA-MaTargeting of Metastatic Castration Resistant Prostate Cancer: Impact of Post-therapeutic Whole Body Scintigraphy in the Follow-Up
L. Scarpa, J. Maffey-Steffan, A. Suryandexia, B. Nica, S. Busbaum, C. Mair, J. Belkin, E. von Guggenberg, C. Uprimny, W. Henninger, J. Vanherpen, Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA; Medical University Innsbruck, Department of Radiology, Innsbruck, AUSTRIA

EP-0584
Radioiodinant Therapy with 177Lu-PSMA in Metastatic Castration Resistant Prostate Cancer: First case series in Iran
K. Aryana, Z. Zarehparvar Moghadam, G. A. Divband, Department of General Surgery, National Medical University of Bialystok, Bialystok, POLAND

EP-0585
225Ac-PSMA-617 treatment and follow up in advanced stage metastatic castration resistant prostate cancer: First clinical experience from Azerbaijan
F. Novruzov, A. Mjøyr, F. Guliyev, B. Abbasov, L. Metemnazarov, Department of Nuclear Medicine, National Centre Of Oncology, Baku, AZERBAIJAN; Department of General Surgery, National Centre Of Oncology, Baku, AZERBAIJAN

EP-0586
Radioiodinmunotherapy with 90Y-Ibritumomab. Twelve years experience
M. Lara Martinez, F. Medina Romea, I. Cabrera Velas, M. Carales Sabater, S. Lakhwani Lakhwani, F. Fernandez Belmonte, M. Gonzalez Diaz, M. Gomez Rodriguez, Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN

EP-0587
Correction Of Hyperfunctional Radiation Induced Stunning (CHIRS) In Pre-therapeutic Radiodiode-131 Uptake Test Of Patients Suffering From Multifunctional Autonomic Thyroid Nodules
C. Happel, J. Bieni, B. Bockisch, A. Sabet, D. Groener, W. T. Kramer, K. Hermann, F. Gneuscald, University Medical Center Frankfurt / Department of Nuclear Medicine, Frankfurt, GERMANY; University Medical Center Essen / Department of Nuclear Medicine, Essen, GERMANY

EP-0588
Analysis of factors influencing the effective half-life of radioactive iodine in patients with hyperthyroidism by pretreatment with lithium carbonate
R. Wang, B. Wu, Z. Yan, Y. Liu, X. Han, B. Liu, Nuclear Medicine Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, CHINA

EP-0589
Personal Ablative Doses of Radioiodine in Young Patients with Graves` disease in Respect of Level of Anti-thyroid Antibodies
M. Listewnik, K. Jasieczkiewicz, P. Ganczycza, H. Rawska-Boksia, B. Brzak, independent Public Clinical Hospital no 1, Szczecin, POLAND

EP-0590
An interim assessment of outcomes from long-term follow-up data of 12 years on radioiodine therapy in patients treated for Graves’ disease
G. Kumar, A. Bhattacharyya, B. Mittal, PGIMER, Chandigarh, INDIA

EP-0591
Radioiodine therapy and the induction of hyperthyroidism in patients with non-toxic goitre
S. Abdelrazek, P. Szumowski, J. Myśliwiec, M. Mąsajk, J. Zulewski, P. Liserowicz, M. Sankowski, N. Król, Department of Nuclear Medicine Medical University of Bialystok, Bialystok, POLAND

EP-0592
The efficacy of radioiodine therapy in patients with non-toxic nodular goitre with large cold nodule
S. Abdelrazek, P. Szumowski, J. Myśliwiec, M. Mąsajk, J. Zulewski, P. Liserowicz, M. Sankowski, N. Król, Department of Nuclear Medicine Medical University of Bialystok, Bialystok, POLAND

EP-0593
Quantitative assessment of hepatic uptake of I-131 during radiiodine therapy in patients with hyperthyroidism-related thyroid diseases
M. Jüptner, M. Marx, J. Ranjan, W. Schüler, M. Zühlsdorf, U. Lüster, University Hospital of Kiel, Kiel, GERMANY

EP-0594
Assessment of the results of I-131 radioiodine therapy in patients with autonomously functioning thyroid nodules
Z. Adamczewska, J. Miskiewicz, J. Kulmerek, M. Adamczewska, P. Jarek, Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, POLAND; Department of Nuclear Medicine and Endocrinology, Maria Sklodowska-Curie Memorial Hospital, Zgorzelec, POLAND; Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND

EP-0595
I-131 therapy for Graves’ disease with giant goiter
M. Jingui, M. Nakaj, A. Tan, Y. Yoshung, Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN

EP-0596
Outcome analysis after Radioactive Iodine-I131 Treatment in 424 patients with hyperthyroidism
M. Finisse, A. Boceghia, A. Passeri, R. Rossetto Giachetti, L. Pagano, G. Castellano, G. Bivi, D. Deandrea, Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienze, Turin, ITALY; Endocrinology, Diabetology and Metabolism Unit, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienze, Turin, ITALY

EP-0597
The effect of radioiodide therapy I-131 in patients with non-toxic nodular goitre
S. Abdelrazek, P. Szumowski, J. Myśliwiec, M. Mąsajk, J. Zulewski, M. Sankowski, N. Król, Department of Nuclear Medicine Medical University of Bialystok, Bialystok, POLAND
EP-0606 Efficacy Of Low And High Dose Of Radioiodine For The Ablation Of Thyroid Remnant In Patients With Differentiated Thyroid Cancer Coexisting Chronic Lymphocytic Thyroiditis
M. Chao, X. Xie, Z. Lu; Ninth People’s Hospital of Tongji University, Shanghai, CHINA.

EP-0607 Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
T. Tian, R. Huang, B. Liu; West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0608 Intraoperative 123I-radionavigation as a method of objective control of the completeness of thyroidectomy and rational planning of subsequent adjuvant radioiodine ablation in patients with differentiated thyroid cancer

EP-0609 The diagnostic value of serum TgAb value and its changes on the prognosis of DTC patients with positive TgAb
W. Hu, B. Liu; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CHINA.

EP-0610 200mg vs 400mg daily dose of Sorafenib in radioiodine refractory differentiated thyroid cancer: A comparison of response and adverse effects
A. Prashanth, M. Angamuthu, M. Prabhu, K. Reddy, D. Chakraborty, S. Arora, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0611 Analysis of outcome of low risk differentiated thyroid carcinoma: a retrospective review and our experience of 6.5 years
H. Ahmed, M. Al Qahtani, H. Ilyas, F. Ull Hassan, G. Guy’s and St. Thomas NHS Foundation, London, UNITED KINGDOM.

EP-0612 Preclinical evaluation of apoptosis radiotracer [18F]-ML-10 in triple negative breast cancer

EP-0613 Does I-131 uptake in the subhyoid portion or lymph nodes affect the outcome of low-dose ablation therapy for patients with differentiated thyroid carcinoma?
S. Ito, S. Kawan, K. Kato, S. Naganawas; “Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, “Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN.

EP-0614 The role of metabolic-receptor imaging in the selection of localized dedifferentiated thyroid carcinoma patients for peptide-receptor therapy
F. Velickovic, T. Andjelkovic, M. Vidanovic, M. Stesić, M. Rajić, M. Vlajković, M. Matović; “University of Niš, Faculty of Medicine, Niš, SERBIA, “University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SERBIA.

EP-0615 “Unexpected uptakes” in post 131I whole body scans in patients with differentiated thyroid cancer
D. Monachello Araujo, J. Sereñas, J. Xie, Z. Lv; Tenth People’s Hospital of Tongji University, Chengdu, CHINA.

EP-0616 An Impact of Microscopic Positive Margin on Incomplete Response after I-131 Therapy in Differentiated Thyroid Cancer: A Retrospective Cohort Study
Y. Raruenrom, Y. Blanter, K. Sawangsri, C. Somboonporn, D. Chankijvi; Khon Kaen University, Khon Kaen, THAILAND.

EP-0617 Does I-131 uptake in the subhyoid portion or lymph nodes affect the outcome of low-dose ablation therapy for patients with differentiated thyroid carcinoma?
S. Ito, S. Kawan, K. Kato, S. Naganawas; “Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, “Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN.

EP-0618 A Follow Up Dose-rate Measurement Strategy for Patients Post [131I]Iodine Ablation Therapy. Can We Improve the Post Treatment Restrictions Applied to the Patient on Discharge?
J. Weekes, M. Foley; New Cross Hospital, Wolverhampton, UNITED KINGDOM.

EP-0619 A dual-labelled anti-FAP antibody for imaging and targeted photodynamic therapy of cancer associated fibroblasts in a pancreatic cancer mouse model

EP-0620 "18F-FDG PET Imaging For Monitoring The Early Anti-tumor Effect Of Albendazole On Triple-negative Breast Cancer
H. Li, Y. Liu, T. Shi, D. Pan; The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, CHINA.

EP-0621 A Simple And Quantitative Method To Address The Synchronicity Between Uptake And Efflux Transporters In The Rat Liver Using 18F-Mebrofenin Scintigraphy
S. Marie, 1 J. Fernandez-Lozano; L. Breuil, 2 O. Langer, 2 A. Del Vecchio, 2 D. Audiat, 2 G. Caille, 2 N. Tourner, 2 UMR 1031, 1 “Service Hospitalier Frédéric Joliot, 1 CEA, 1 INSERM, 1 CNRS, Université Paris Sud, Université Paris-Saclay, Orsay, FRANCE, “Department of Clinical Pharmacology, Medical University of Vienna, Vienna, AUSTRIA, “1 Service de Chimie Bio-organique et de Marquage, 1 CEA-DRF-JOLIOT-SCBM, Université Paris-Saclay, Gif sur Yvette, FRANCE, “2 Service de Chimie Bio-organique et de Marquage, 1 CEA-DRF-JOLIOT-SCBM, Université Paris-Saclay, Gif sur Yvette, FRANCE.

EP-0622 Biodistribution of PSMA-R2 in mice bearing prostate cancer
V. Muzzio, L. Roviello, L. Sacchetti, L. Fagazza, S. Boschi, M. Debiossat, C. Ghezzi, L. Sacchetti; 1 Advanced Accelerator Applications, a Novartis company, Geneva, SWITZERLAND, 1 Univ Genoble Alpes, 2 INSERM, 1 CHU Genoble Alpes, Genoble, FRANCE.

EP-0623 Optimization and comparison of cell labelling strategy with [125I]Zr-complex for cell trafficking
M. Kim, D. Kim, S. Lee, S. Kim, H. Sohn, J. Ryui; K. Ohy; “Asan Medical Center, Seoul, KOREA, REPUBLIC OF, “Asan Institute for Life Sciences, Seoul, KOREA, REPUBLIC OF.
EP-0631 Feasibility of real-time in vivo 99mTc-DFO-labeled CAR T-cell tracking using PET imaging
S. Kim1, S. Lee1, H. Sohn1, J. Jung1, C. Choi1, J. Ryu1, J. Joo1, J. Shin1, H. Kim1, S. Oh2, S. Lee1, J. Jung1, J. Ryu1, J. Joo1
1Asan Medical Center, Seoul, KOREA, REPUBLIC OF; 2University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF; 3Hyundai University Kangnam Sacred Heart Hospital, Seoul, KOREA, REPUBLIC OF; 4National Cancer Center, Goyang-si, KOREA, REPUBLIC OF; 5Seoul National University, Seoul, KOREA, REPUBLIC OF.

EP-0632 Cancer diagnostic imaging using the novel T-cell that specifically attracted a cancer cell
Y. Nakagami1, D. Kanou1, S. Hosokawa1, Y. Kaji1, 1Tokyo Medical University, Tokyo, JAPAN, 2National Cancer Center Hospital, Kawasaki, JAPAN, 3Nihon University, Hirsano, JAPAN.

EP-0634 Toxicity, efficacy and tumour imaging of 18F-aptamer-cisplatin in mice
E. A. Aalbersberg1, L. de W1, van der Veen1, K. Castie1, van der Schelven1, O. Zwaagstra1, E. Verg1, W. Vage1, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 2Nuclear Research and consultancy Group, Petten, NETHERLANDS.

EP-0635 99mTc-dimercaptosuccinic acid renal scintigraphy is correlated to fibrosis in a model of Chronic Kidney Disease in rats
M. Bobot1, G. Hache2, S. Fernandez2, 1Nuclear Research and consultancy Group, Petten, NETHERLANDS; 2University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0636 Towards Imaging Cisplatin Resistance with 18F-PET
F. Al-saleem1, J. Bartnicka1, T. H. Witney1, P. J. Blower1, 1King’s College London, London, UNITED KINGDOM.

C. Lee1, K. Kim1, S. Wei, C. Kang, C. Kang, K. Lee, Y. Lee, J. Song2, S. Lim3, I. Rim4,5, 1Korea, REPUBLIC OF; 2Korea Research Institute of Radiological Medicine, Daejeon, KOREA, REPUBLIC OF; 3Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF; 4Pusan National University, Busan, KOREA, REPUBLIC OF; 5Busan National University, Busan, KOREA, REPUBLIC OF.

EP-0638 Early prognostic value of 99mTc-3PBGD2 scintimammography in acute Radiation-induced lung injury
L. Shi1, Q. Bai, W. Zhang, M. Yuan, L. Wte, Tangdu Hospital, Xian, CHINA

EP-0639 Synthesis of 99mTc-DOTA-TDM1 and preliminary evaluation as a potential companion diagnostic agent for T-DM1
H. Kim1, E. Lee1, E. Shin1, E. Lee, R. Yoo1, H. Chung1, J. Shin1, 1Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0641 Synthesis And Pre-clinical Evaluation Of 18F-labeled Mucin 1-folate Hybrid Peptide: Potential Theranostic Radiopharmaceuticals For Breast And Ovarian Cancers
I. Alijammaz1, B. Alotzad1, F. AlRumayyan1, A. Altabahi1, S. Ghanem1, King Faisal Spec. Hosp., Riyadh, SAUDI ARABIA.

EP-0642 In vivo longitudinal monitoring the permeability of the blood-spinal cord barrier in a dog hemisection spinal cord injury model using 11N-NH3-PET/CT
L. Zhang1, Y. Jiao1, Y. Chen1, X. Zhanga1, H. Xia1, 1Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan City, CHINA; 2Ningxia Human Stem Cell Research Institute, General Hospital of Ningxia Medical University, Yinchuan City, CHINA; 3Department of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan City, CHINA.

EP-0643 Potentiality of 18F-FDG easyPET-3D studies in mouse solid tumours
F. Ribeiro1, M. Lago-Ravi1, A. C. Santos1, C. Ramos1, A. Parma1, A. L. M. Silva1, I. F. Castro1, P. M. M. Correia1, P. M. C. C. Encarnação1, N. C. Ferreira1, D. A. S. J. Mahammedi1, C. Nicolucci1, D. Prioli1, J. F. C. A. Veloso1, 1University of Aveiro, Institute for Nanostructures, Nanomodelling and Nanofabrication (UNINN) – Department of Physics, Aveiro, PORTUGAL, 2Faculty of Sciences and Technology of University of Coimbra, Coimbra, PORTUGAL, 3Institute of Biophysics of University of Coimbra, Coimbra, PORTUGAL, 4Institute for Clinical and Biomedical Research (ICBR), Coimbra, PORTUGAL, 5Institute of Biophysics of University of Coimbra, Coimbra, PORTUGAL, 6University of Aveiro, Institute for Nanostructures, Nanomodelling and Nanofabrication (UNINN) – Department of Physics, Aveiro, PORTUGAL.

EP-0644 Radiofluorinated gases as regional ventilation markers: Application to a rat model of acute lung inflammation
J. Llop Roig1, V. Gómez-Vallejo1, U. Casas1, A. Lekunza1, CIC biomaGUNE, San Sebastián, SPAIN.

EP-0645 A Computational Phantom of the Adult Labrador for Use in Preclinical Nuclear Medicine Dosimetry Studies
W. Bolch1, M. Sands2, A. Parma1, P. Garrigue1, S. Burtey1, G. Hachet1, B. Guillet1, 1Aix Marseille Université - CERMEF, Marseille, FRANCE, 2University of Aveiro, Institute for Clinical and Biomedical Research (ICBR), Coimbra, PORTUGAL.

EP-0646 In vivo imaging of 18F-labelled NOTA-EGFRvIII aptamer
J. Park1, Y. Cha1, J. Chae1, W. Kang1, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0647 easyPET-3D with 18F-FDG: potentiality of quercetin in a cocaine exposure brain study in a mouse model
M. Pias1,2, F. M. Ribeiro1, C. Nicolucci1, D. Prioli1, C. Ramos1, A. Parma1, P. M. M. Correia1, A. L. M. Silva1, J. F. Castro1, P. M. C. C. Encarnação1, I. Mhammedi1, J. F. C. A. Veloso1, A. C. Santos1, 1Institute for Clinical and Biomedical Research (ICBR), Coimbra, PORTUGAL, 2Faculty of Sciences and Technology of University of Coimbra, Coimbra, PORTUGAL.

EP-0648 99mTc-DTPA cerebral scintigraphy is associated with cognitive impairment in models of chronic kidney diseases in rats
L. Thomas1, M. Bobot1, S. Fernandez1, L. Balasse1, A. Mayorowicz1, P. Garrigue1, S. Burtey1, G. Hachet1, B. Guillet1, 1Aix Marseille Université - CERMEF, Marseille, FRANCE, 2University of Aveiro, Institute for Clinical and Biomedical Research (ICBR), Coimbra, PORTUGAL.

EP-0650 MicroPET Imaging With 11C-TPP+ and DTBZ Reveals The Synergistic Neurotoxicity Of VMAT2 Inhibitor And MPTP To Dopaminergic Neurons
Y. Xu1, J. Tang1, C. Liu1, Z. Chen1, Y. Xue1, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0653 Optimisation of Conjugation for Radioimmunoconjugate Based Imaging of Intraneuronal Epitopes
M. Veal1, B. Cameron1, 1University of Oxford, Oxford, UNITED KINGDOM.
EANM'19 Scientific e-Posters

EP-0654 In vitro system model for biological quality control and functional research of radiopharmaceuticals used for Targeted Radionuclide Therapy
Z. Kalina; K. Shvirksts; E. M. Rubena; M. Grubel; T. Kuusmaa; R. Kovaldina; M. Jääskalainen; H. Razmeniene; A. Beraud; G. Kizan; A. Greibergs;
"Latvian Biomedical Research and Study Centre, Riga, Latvia, "Institute of Microbiology and Biotechnology, University of Latvia, Riga, Latvia, "Kadomus Medicinas Klinika Ltd, Riga, Latvia, "University of Latvia, Faculty of Biology, Riga, Latvia, "Riga East University Hospital, Clinical Department of Nuclear Medicine, Riga, Latvia, "University of Latvia, Faculty of Chemistry, Riga, Latvia, "Institute of Biomedical Engineering and Nonmedical Research, Riga Technical University, Riga, Latvia, "Institute of Chemical Physics, University of Latvia, Riga, Latvia.

EP-0655 In vitro Evidence of Abnormal Glutamate to Glutamine Conversion in Astrocytes harvested from a Mouse Model of Amytrophic Lateral Sclerosis: a potential Experimental Application of 14N-ammonia
V. Cossu; G. Sambrunzi; T. Bonifacino; S. Bruno; S. Ravera; V. Cenere; P. Piccoli; P. Castellani; M. Bauckhein; S. Capistrano; D. Gondet; M. Mieraine; A. Dermoiti; C. Ghesqi; G. Bannana; C. Manni; "Nanomedicine, Riga Technical University, Riga, Latvia, "Institute of Microbiology and Biotechnology, University of Latvia, Riga, Latvia, "University of Latvia, Faculty of Chemistry, Riga, Latvia, "Institute of Biomedical Engineering and Nonmedical Research, Riga Technical University, Riga, Latvia.

EP-0657 Radiobiological Evaluation of Copper-64 on Tumor Cells
D. Nicula; R. Leontie; R. Serban; L. Chilag; D. Draganeas; M. Temelie; D. Savu; Hana Huubi; National Institute for Physics and Nuclear Engineering, Bucharest (Magurele), Romania.

EP-0658 Radium-223 Inhibits Cancer Growth in Bone and Improves Survival in a Syngeneic Bladder Cancer Bone Metastasis Model
M. I. Suominen; T. E. Kallahinen; J. H. E. Mäki-Jauhola; S. Jokiainen; J. Ahonen; D. Mummery; K. Ziegelhofer; J. M. Walken; S. Kållkenen; A. Schäfer; "Pharmaceutical Services, Turku, Finland; "Aureo Life Sciences Ltd, Auckarun, Finland; "Vinci Oy, Turku, Finland; "Bayex AG, Berlin, Germany.

EP-0659 Imaging EGF receptor in malignant glioma models
S. L. Hopkins; M. Mosley; P. Bemeger; J. Bagunja; Torres; F. Guibbal; A. Patelii; R. Hueting; V. Gouverneur; B. Cameleussen; University of Oxford; Oxford, United Kingdom.

EP-0660 Radiosynoviorthesis Using Sn-117m Colloid to Treat Canine Elbow Osteoarthritis Demonstrates Efficacy and Safety
C. A. Doerfler; J. M. Donecker; N. R. Stevenson; G. R. Gonzalez; J. E. Latimer; Stereone, LLC; The Woodlands, TX, United States of America; "University of Missouri, Columbus, MO, United States of America.

EP-0661 Validation of 6281 as cancer stem cell marker for molecular imaging using 1850-1 mAb probes : A preliminary study on Hepatocellular Carcinoma
X. Guo; G. An; W. Zhao; Z. Zhang; H. Zhu; Z. Yang. Peking University Cancer Hospital & Institute, Beijing, China.

EP-0662 Using Radiolabelled APOMA® For Non-Invasive ImmunoPET Imaging of Tumour Cell Death Following Chemotherapy
V. Liapis; W. Tief; P. Takhar; A. Ekdolou; M. J. Brown; A. H. Staudacher; "University of South Australia, Adelaide, Australia; "Australis, "Molecular Imaging and Therapy Research Unit, South Australian Health and Medical Research Institute, Adelaide, Australia; "Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, Australia; "Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.

EP-0663 Combined PET and MR imaging of HET-CAM xenografts for evaluation of targetspecific binding of radioligand
G. Winter; A. B. F. Koch; J. Lüffer; C. Salbach; G. Gisting; V. Rasche; J. A. Bier; "Department of Nuclear Medicine, Ulm University; Ulm, Germany; "Center for Translational Imaging, Internal Medicine K, Ulm University, Ulm, Germany; "Medical Radiation Physics, Department of Nuclear Medicine, Ulm University; Ulm, Germany.

A. Bebila Tarazona; M. A. N. Rusu; A. Garcia Aliaga; T. Chivato Martin-Falquina; M. Martinez Martinez; "Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; "Hospital General Universitario Santa Lucía, Cartagena, Spain.

A. Prignon; Sorbonne Université, Paris, France.

EP-0666 In-vivo 18F-fluoro-thymidine Positron Emission Imaging For Disease Monitoring In A Mouse Model Of High-risk Myelodysplastic Syndrome
L. Sarde-Mandal; P. Hontonrout, B. Hosten; N. Vignola; C. Sant; M. Pi; F. Fenali; P. Kneif; C. Chomienne, R. Raudu; "Unité Claude Kellermann, IRS; Université Paris Diderot, APHP Labanviste Saint-Louis, Paris, France; "Unité Claude Kellermann, IRS; Université Paris Diderot, Paris, France; "Inserm U1132, IRS; Université Paris Diderot, Hôpital Saint-Louis, Paris, France.

EP-0667 Developing Peptide based Nanoconstructs as Potential Theranostic Agents
I. U. Khan; E. Alchial, R. Zahasra, A. Fatimal; M. Sohade; A. Shadiah; C. Flores; M. Garoszi; A. Jallanon; "Institute of Nuclear Medicine and Oncology (INAO), New Campus Road, Lahore, Pakistan; "Laboratorio de Materiales Biotecnologicos, Universidad Nacional de Quimica-IMBICET (CONICET), Benal, Argentina; "Department of Nuclear Science and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria.

EP-0668 Preclinical translational bridge studies supporting advancement of 18F-in-BDTPA-NLS-trastuzumab to Phase I clinical trial in patients with HER2-positive breast cancer
C. Chau; N. Dai; M. Done; R. Kelly; "Departments of Pharmaceutical Sciences and Medical Imaging, University of Toronto, Toronto, ON, Canada; "Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada, "Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; "Torchay Research Institute, University Health Network, Toronto, ON, Canada.

EP-0669 Evaluation specific infection in severe acute pancreatitiswith a novel probe 18FDG
Z. Zhu; Q. Peng; J. L.; X. Wang; X. Zhang; X. Su; S. Hu; "Department of PET Center, Xiangya Hospital, Central South University, Changsha, China; "National Clinical Research Center for Gastroenteric Disorders (XANGYA), Xiangya Hospital, Central South University, Changsha, China; "Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China; "School of Public Health, Xiamen University, Xiamen, China; "Department of Nuclear Medicine, Zhejiang Hospital, Xiamen University, Xiamen, China.
EP-44
Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Preclinical and translational aspects -> Preclinical aspects -> Biology, benign disease

EP-0674
On the reduction of uptake of radiolabeled DARPin in kidneys
A. Vorobyeva, M. Abott, J. Garavos, S. S. Rinne, A. Schulga, S. Dieye1,2,3; 1Uppsala University, Uppsala, SWEDEN, 2Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN FEDERATION, 3National Research Nuclear University “MEPhI”, Moscow, RUSSIAN FEDERATION.

EP-45
Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Preclinical and translational aspects -> Preclinical aspects -> Tumor biology

EP-0675
Application of 18F-FMISO in Determination of Hypoxia Level in Murine CT26 Tumors During Various Stages of Development
L. Kiraga, L. Chedir, B. Taciak, K. Rzaziks, K. Tarczylak, A. Said, R. Kilar, E. Gerk, Z. Rogulski, T. P. Rygiel; 1Warsaw University of Life Sciences, Warsaw, POLAND, 2University of Warsaw, Warsaw, POLAND, 3Medical University of Warsaw, Warsaw, POLAND.

EP-0676
In vivo investigation of APN/CD13 inhibitors in tumor bearing animal models using 68Ga-NODAGA-CNGR radiotracer
A. Kis, J. P. Szabo1, J. Nagy, N. Dénès, I. Ketész, S. Lakatos, K. Halma, E. Berényi, G. Terecsényi; 1Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, 2Division of Radiology and Imaging Sciences, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY.

EP-0677
Epigenetic Treatment with Histone Deacetylase Inhibitor Increases Uptake of [111In]DOTA-TATE by Neuroendocrine Tumor Cells
I. Klomp, S. U. Dalm, P. M. van Koetsveld, F. Drijger-Drui, M. de Jong, L. J. Heiland, Erasmus MC, Rotterdam, NETHERLANDS.

EP-0678
Radiogenomics in Ewing Sarcoma: Integration of Functional Imaging and Transcriptomics Characterizes Tumor Glucose Uptake
C. Prexler, M. S. Keppler, M. Mastla2, W. Seermann, C. Schmidt, K. Gell, K. Specht1, H. Recht, C. Krebs, K. Weisent, W. Weichert1, G. H. S. Richter1, M. Schweiger1,2,3, J. von Luetich2,3, W. Weber1,2,3, S. Burach1,2,3; 1Department of Pediatrics and Children’s Cancer Research Center, Kinderklinik München Schwabing, Klinikum rechts der Isar, Fakultät für Medizin, Technische Universität München, Munich, GERMANY, 2Institute of Pathology, Klinikum rechts der Isar, Fakultät für Medizin, Technische Universität München, Munich, GERMANY, 3Comprehensive Cancer Centre, Munich, GERMANY.

EP-0679
GRPR mRNA Expression Levels to Select Patients Suited for GRPR-mediated Radiolabeled Imaging and/or Therapy
S. Dalm, K. Bugaj-Ristie, C. M. Beaufort, J. W. M. Mentens, C. H. M. van Deurzen, M. de Jong, A. M. Siewers, Erasmus MC, Rotterdam, NETHERLANDS.

EP-0680
Loss of PSMA during neuroendocrine differentiation of prostate cancer is associated with elevation of metabolotropic glutamate receptors as an alternative diagnostic target
M. K. Bakht1,2,3, K. F. Stinger1, J. M. Louniviki1, A. Pilk1, F. Shaheen-Raj, J. J. Hayward1, S. Oh2, J. J. Frant3, G. Cheon4, C. Kwon3, K. Kang5, Y. Wang5, X. Deng5, L. A. Porter1; 1Department of Biological Sciences, University of Windsor, Windsor, ON, CANADA, 2Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, 3Department of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, UNITED STATES OF AMERICA, 4Department of Cancer Research, Institute of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, 5Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, UNITED STATES OF AMERICA, 6University of British Columbia, Vancouver, BC, CANADA, 7Department of Medicine and Biochemistry, University of Windsor, Windsor, ON, CANADA.

EP-0681
Metabolic changes of melanoma assessed by [18F]FDG and [18F]FLT PET during immune checkpoint inhibitor treatment: potential role as a predictive imaging biomarker
S. Oh, M. Youn, J. Paeng, Y. Kim, K. Kang, G. Cheon, J. Chung, Seoul National University, Seoul, KOREA, REPUBLIC OF.

EP-0682
SPECT Imaging of Endogenous Tumor Hypoxia Marker Carbonic Anhydrase IX with [111In]labeled VH1B 89
S. A. M. van Lith1, F. J. Huizing2, B. A. W. Hoeben1; 1Department of Radiology, Maastricht University Medical Center, Maastricht, NETHERLANDS, 2Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS.

EP-0683
The Elusive Link between [18F]FDG uptake and Glycolytic Flux explains the Preserved Diagnostic Accuracy of PET-CT in Diabetic Cancer Patients
V. Cossu1, M. Bauchneh2, S. Brunori, A. Orenzi, L. Emanante1, F. D. Guolo, S. Capitanio, E. Babiz, P. Castellani, P. Poccioli, A. Moro1, S. Raffa, A. Bonar3, M. Domenghi1, S. Morbelli, S. Rave1, G. Sambucetti1; 1Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 2Department of Health Sciences, University of Genoa, Genoa, ITALY, 3Department Experimental Medicine, University of Genoa, Genoa, ITALY, 4Animal Facility, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 5Cell Biology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 6CNR Institute of Molecular Imaging and Physiology (IBFM), Milan, ITALY.

EP-46
Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Preclinical and translational aspects -> Translational aspects -> Cardiology

EP-0684
"[18F]FDG-PET, MRI Relaxometry And Terahertz Reflectometry in a Multimodal Imaging Heart Study of a Cardiorenal Syndrome Small Animal Model"
L. Agrigoropaeia, D. Furac, C. Uru, G. Stanciu, C. Micu, I. Gaidakioiu, R. Iulcu, C. Stefanescu, M. Guta; 1University of Medicine and Pharmacy “Gr. T. Popa”, Iasi, ROMANIA, 2Advanced Center for Research and Development in Experimental Medicine CEGEMEX, Iasi, ROMANIA.
**EP-0689**
Effects of Chronic Alcohol Self-Administration on Striatal Phosphodiesterase 10A Availability Are Associated with Poor Decision-Making
J. Cecconari, Y. K. Limkinitis, Y. B. de Loaf, G. Schreyen, M. Coebergh, G. Biomart, K. Van Laer, M. Nuclear Medicine and Molecular Imaging, University Hospital Leuven; Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM; Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LEI), Center for Brain & Disease Research, Laboratory of Neurobiology, VIB-KU Leuven, Leuven, BELGIUM; Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM; Radiopharmaceutical Research Laboratory, KU Leuven, Leuven, BELGIUM.

**EP-0690**
F-18 labeled FAPi-74 in patients with lung cancer: biodistribution at 3 imaging time points
P. L. Giesel, J. Linder, S. Adeberg, F. Saudagni, P. Pechoug, H. Ratha, M. Rohner, J. Detur, U. Habenicht, C. Kroatowich, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY; Radiodiagnostic, University Hospital Heidelberg, Heidelberg, GERMANY.

**EP-0691**
In-111 Labeled Cd166-targeted Peptide For Detecting Colorectal Cancer Stem-like Tumor In Vivo
S. Guan, T. Lu, C. Peng, T. Luoa, Institute of Nuclear Energy Research, Longtan District, Taoyuan, TAIWAN.

**EP-0692**
Clinical translation of the PepProtect concept: Improved detection of cancer and metastases, applied in medullary thyroid cancer patients with [111In-MG11 staining during nephryl inhibition

**EP-0693**
PSMA-GaNODAGA-82 for imaging activated T-cells
I. Antunes, E. L. van der Weer, F. V. Swart, R. A. J. O. Dierickx, M. N. Lub-de Hooge, E. G. E. de Vries, E. F. J. de Vries, University of Groningen, University of Medical Center of Groningen, Dept of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS; University of Groningen, University of Medical Center of Groningen, Dept of Medical Oncology, Groningen, NETHERLANDS; University of Groningen, University of Medical Center of Groningen, Dept of Hospital and Clinical Pharmacy, Groningen, NETHERLANDS.

**EP-0694**
Radiolabelling and biodistribution in the tumour xenograft of [18F]-labelled anti-CXCR4 antibody for cancer stem cell targeted alpha-particle therapy
N. Oriuchi, S. Zhao, M. Aoki, C. Tan, S. Sagawa, K. Yuge, N. Shigematsu, K. Washiyama, K. Sakakibara, T. Iwase, H. Ito, A. Advanced Clinical Research Center, Fukushima Medical University, Fukushima, JAPAN; Department of Nuclear Medicine, Fukushima Medical University, Fukushima, JAPAN; Department of Hematology, Fukushima Medical University, Fukushima, JAPAN; Department of Radiology, Fukushima Medical University, Fukushima, JAPAN.

**EP-0695**
Translational proof-of-concept with 68Ga-Nobomb in the management of Gastrointestinal Stromal Tumor Liver Metastasis Treated with Interventional Radiotherapy Methods
R. De Juan Rubio, M. Pretzer, L. Reifert, F. Oltmann, J. Schmidpeter, S. Siegel, R. Kühler, N. Rathmann, S. Schneider, C. Decristofaro, P. Hohenberger, B. Wängler, Universitätsklinikum, Mannheim, GERMANY; Medical Faculty-Manheim, Heidelberg University, Mannheim, GERMANY; Advanced Accelerator Applications, Collicostra, Cassino, ITALY; Medical University, Innsbruck, AUSTRIA.

**EP-0696**
PSMA expression a promising biomarker to predict differentiated thyroid cancer aggressiveness and outcome
M. Sollini, L. Di Tommaso, M. Kiencko, C. Cordoni, M. E. M. A. Laia, L. Antunes, A. Ochi, Humanitas University, Pieve Emanuele, ITALY; Humanitas Clinical and Research Center, Rozzano, ITALY.

**EP-0697**
Entrace- treated mice show superior targeting of PC-3 xenografts vs. controls after injection of the SPECT tracer [99m Tc]DB4
P. Kanellopoulos, A. Kaloudis, M. Jorg, E. Frenkening, T. Mairn, B. A. Nock; Molecular Radiopharmacy, MIVASTES, NCSR "Demokritos", Athens, GREECE; Molecular Pharmacology, School of Medicine, University of Crete, Halki, GREECE; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS; Cyclotron Rotterdam BV, Erasmus MC, Rotterdam, NETHERLANDS.

**EP-0698**
Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Preclinical and translational aspects -> Therapy
Displayed throughout the congress days a-Poster Area
EP-0709
In Vivo Evaluation of [18F]FFFA as a Fatty Acid Synthase-targeting Imaging Agent for Breast Cancer and its In Vivo Whole-Body Biodistribution in Normal Mice
Y. Huang, C. Tsai, B. Ho, H. Ho, Y. Chang, C. Wu, R. Yen, C. Shiau
PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN; Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, TAIWAN; Molecular Imaging Center, National Taiwan University Hospital, Taipei, TAIWAN.

EP-0710
Structural Optimization of the Arecaidine Diphenylmethyl Estor Scaffold for Muscarinic Acetylcholine Receptor PET Tracer Development
M. Ozen; K. Pacher; C. Vaska; H. Spenrider; M. Hacker; M. Mitterhauser; W. Waisak; V. Pichler
1Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA; 2Department of Pharmaceutical Chemistry, University of Vienna, Vienna, AUSTRIA; 3Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA; 4Gismed GmbH – Center for Biomarker Research in Medicine, Graz, AUSTRIA.

EP-0711
Development of radiofluorinated CYP11B2-Inhibitors for the differential diagnosis of primary aldosteronism
A. Schirbel; B. Horner; P. Maier; M. Schneider; S. Samwick; A. K. Buck; B. Sermey; K. Mansfeld; S. Hahnert
1University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY; 2University Hospital Würzburg, Department of Endocrinology, Würzburg, GERMANY.

EP-0712
1,5-Disubstituted 1,3-Triazole-based peptidomimetics: Synthesis and Application to Minigastroin
I. Valverde; N. M. Grob; M. Bérne; T. L. Mindt
1Institut de Chimie Moléculaire de l’Université de Bourgogne, Dijon, FRANCE; 2Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, SWITZERLAND; 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, SWITZERLAND; 4Ludwig Boltzmann Institute of Applied Diagnostics, Vienna, AUSTRIA; 5Medical University of Vienna, Department of Biomedical Imaging and Image Guided Therapy, Vienna, AUSTRIA.

EP-0713
Biological evaluation of radiolabelled peptides for oestrogen positive tumour theranostics
M. Gano; P. Valtos; C. Fernandez; F. Silva; F. Mendes; J. D. G. Camara; Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Bacadela, PORTUGAL.

EP-0714
Development of O-[123C]Methyl Estor Derivative of Sacubitril for PET Imaging of Nephrils
V. Teysseir; J. Smant; D. Petrenyov; F. Touroume
1; 2; 3J. N. Duszak
1Université de Montréal, Montréal, QC, CANADA; 2Centre de recherche du centre hospitalier de l’Université de Montréal, Montréal, QC, CANADA; 3INSERM, Bordeaux, FRANCE.

EP-0715
Gallium-68 Labelled Radiotracer Based On Dopa-curcumin For Imaging Of Colon-rectal Carcinoma
M. Asti; G. Creteur; F. Pisaniello; S. Rubagotti; T. W. Liu; G. Igiatou; D. Pauwels-Worms; M. Iori; P. C. Cappone; E. Ferroni
1AUSL-IRCCS Reggio Emilia, Reggio Emilia, ITALY; 2Università dell’Aquila, Aquila, ITALY; 3University of Modena, Modena, ITALY; 4MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA; 5University of Firenze, Firenze, ITALY.

EP-0716
**11C-buprenorphine in humans**
A. Pinon; C. Leney; F. Cado, E. Gervais; S. Jan; C. Comar; S. Chalamalapati; F. Fernandez; M. Bottlaender; N. Touvier; 1UMR 1033 RAV, Service Hospitalier Frédéric Joliot, CEA, Inserm, CNRS, Université Paris Sud, Université Paris-Saclay, Orsay, FRANCE; 2GE Healthcare, Applications & Workflows, Orsay, FRANCE.
Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development. Radiopharmacy, radiochemistry, drug development. Displayed throughout the congress days. e-Poster Area
EP-0742 Investigation of automated radiofluorination methods for oxidatively sensitive aryl systems
A. McDonald, Y. W. Goh, J. M. White, A. Scott, U. Ackerman, J. Whitehead

EP-0748 Study of Chelator-Free Zr-89 Labeling of PAMAM Dendrimers
G. Kim, J. Lee, K. Yu, S. Kim, D. Dongguang Unh, Gyeonggi, KOREA, REPUBLIC OF; Dongguang Unh, Seoul, KOREA, REPUBLIC OF

EP-0749 Development of novel ⁶⁸Ga chelators for PET imaging

EP-0750 A simplified method for the radio-synthesis of [¹⁸F]-fluorazinidene
P. Kumar, R. Joshi, N. Rao, National Institute of Mental Health and Neuroscience, Bengaluru, INDIA

EP-0751 An Efficient Automated Radiosynthesis And Bioactivity Confirmation Of [⁹⁹mTc]−DTBZ As A VMAT2 Tracer
Z. Chen, C. Zhao, C. Liu, J. Tang, Y. Li, M. Xie, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA

EP-0752 An Efficient Automated Radiosynthesis And Bioactivity Confirmation Of [¹⁸FJFP−J−DTBZ As A VMAT2 Tracer
Z. Chen, C. Zhao, C. Liu, J. Tang, Y. Li, M. Xie, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA

EP-0753 AAZT®: squaramide ester: a promising tool for ¹⁸F-labelling of monoclonal antibodies under mild conditions concerning immune-based endoradiotherapeutic applications
B. Klasen, E. Meier, H. Rösch; Institute of Nuclear Chemistry, Mainz, GERMANY

EP-0754 Radiolabelled multifunctional hybrid magnetic nanoparticle probe for dual-mode imaging (SPECT and MRI) medical in vivo imaging
G. Dodi, C. M. Unu, I. Gandaksoy, C. T. Minha, L. A. Aguirre, M. Muresu, B. T. Tumul, C. Stefanelu,

EP-0755 Automated synthesis of [¹⁸F]SC560 with Synthra® synthesis module
C. Kuzera, F. Antunes, R. Zijlma, E. de Vries, Umcg, Groningen, NETHERLANDS

EP-54 Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiochemistry, drug development -> Radiopharmacy -> Quality control & quality assurance

EP-0756 Development of novel ⁶⁸Ga chelators for PET imaging
U. Ackermann, J. J. Lee, W. Grantham, A. McDonald, Hull, UNITED KINGDOM;

EP-0758 Risk management in a radiopharmacy: from safety and quality assurance to centralization and hospitalization
O. Neels, J. L. Jeris, M. Vrancken, O. Neels; University of Hul, Hul, UNITED KINGDOM, University of Edinburgh, Edinburgh, UNITED KINGDOM

EP-0761 Evaluation of the E-E-Tl-milancotech retention in different syringes at different times
C. Franco Monterrosa, B. Santos Montco, M. Hernández Fructuoso, E. Romero Herrera, S. Ruiz Llamas, J. Castell Cortés; University Hospital Vall d’Hebron, Barcelona, SPAIN, University Hospital Vall d’Hebron - ID, Barcelona, SPAIN

EP-0763 Patient-reported adverse events of diagnostic radiopharmaceuticals
N. Schreuder, P. L. Jager, J. J. W. Kosterink, F. van Puijelenbroek; University of Groningen, Groningen, NETHERLANDS; GE Healthcare Radiopharmacy Zwolle, Zwolle, NETHERLANDS, Isala Hospital, Zwolle, NETHERLANDS, University Medical Center Groningen, Groningen, NETHERLANDS, Netherlands Pharmacovigilance Centre Laren, Laren, NETHERLANDS

EP-0764 In vitro analysis of ⁹⁹mTc-EDDA/HYNIC-TOC bonding to blood clots and comparison with other radiopharmaceuticals
M. Valliente, M. Willer, F. Cepa, S. Rudi, B. Luna, H. Navaroli, C. Medina, F. Vega; Hospital Universitario San Espirito, Palma, SPAIN

EP-0766 Risk management in a radiopharmacy: from safety and quality assurance to centralization and hospitalization
M. Riondato, S. Pastore, G. Gavacchi, E. Borgia, A. Carmello, Nuclear Medicine Department, La Spezia, ITALY

EP-0768 Various Detection Techniques for ²²⁵Ac
E. Arponen, T. Oikari, V. Kalliajärvi, Håkan ÖI, Turku, FINLAND

EP-0770 Automated synthesis of [¹⁸F]SC560 with Synthra® synthesis module
C. Kuzera, F. Antunes, R. Zijlma, E. de Vries, Umcg, Groningen, NETHERLANDS

EP-0772 Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiochemistry, drug development -> Radiopharmacy -> Quality control & quality assurance

EP-0774 Time-lapse And Long-term Stability Of ⁶⁸RGD *tyophosphilated Kit
S. Lee, S. Ls, S. Wang, S. Ls, S. Chen, M. Li; Institute of Nuclear Energy Research Atomic Energy Council, Taysan, TAIWAN

EP-0776 Evaluation of the E-E-Tl-milancotech retention in different syringes at different times
C. Franco Monterrosa, B. Santos Montco, M. Hernández Fructuoso, E. Romero Herrera, S. Ruiz Llamas, J. Castell Cortés; University Hospital Vall d’Hebron, Barcelona, SPAIN, University Hospital Vall d’Hebron - ID, Barcelona, SPAIN

EP-0778 Risk management in a radiopharmacy: from safety and quality assurance to centralization and hospitalization
M. Riondato, S. Pastore, G. Gavacchi, E. Borgia, A. Carmello, Nuclear Medicine Department, La Spezia, ITALY

EP-0780 Various Detection Techniques for ²²⁵Ac
E. Arponen, T. Oikari, V. Kalliajärvi, Håkan ÖI, Turku, FINLAND
EP-0772
Non-invasive whole-body imaging of immune checkpoints using PET-labeled small molecules as predictive biomarker for response to therapy
M. Wazyńska, R. Butera, M. de Bruijn, A. S. Diamant, P. H. Elzinga, H. W. Nijman; University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, University of Groningen, Faculty of Science and Engineering, Groningen, NETHERLANDS.

EP-0773
First Phantom-based Quantitative Assessment of Scandium-44 in a Commercial PET Device
T. Lima, S. Gnesi, E. Nitschke, C. Müller, N. van der Meulen; Radiation Protection Group, Aarhus Hospital (Krankenhaus), Aarhus, SWITZERLAND, Institute of Radiation Physics, Universiteit Utrecht, Utrecht, SWITZERLAND, Institute of Nuclear Medicine and PET, Aarhus Hospital, Aarhus, SWITZERLAND, Center for Radiopharmaceutical Sciences ETH-PHI-USZ, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, Laboratory of Radiophysics, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND.

EP-0774
New approach to production and quality control of 180m (18F)fluorooestradiol (18F) FES: The effective functional molecular imaging probe for positive estrogen receptors breast cancer
Z. Dadashov, R. Shakurov, M. Valiyev, K. Bhalla; Balashov, Department of Nuclear Medicine, National Centre of Oncology, Baku, AZERBAIJAN.

EP-0775
Development of novel (11)F-thiosemicarbazone metal fluoride complexes as potential neuroimaging agents
D. Stimson, T. K. Verkochtachotn, G. K. Perrens, K. V. Beemhardt, K. Mardon, D. C. Reuters, R. Bhalla; Centre for Advanced Imaging, University of Queensland, Brisbane, AUSTRALIA, National Imaging Facility, University of Queensland, Brisbane, AUSTRALIA.

EP-0776
Establishing a GMP-compliant 89-Zirconium radiopharmaceutical production capability at the Royal Marsden Hospital Foundation Trust, UK
J. Tan, C. Da Pievè, G. Smith, D. Turner, W. J. G. Oyen; Royal Marsden Hospital Foundation Trust (RHM), Sutton, UNITED KINGDOM, Institute of Cancer Research (ICR), London, UNITED KINGDOM.

EP-0777
18F-Labeled PET Tracers Derived from Angiotensin II Type 1 Receptor Antagonists
X. Chen, M. Hoffmann, R. A. Werner, X. Armitou, H. Kimura, M. Becker, T. Higuchi, H. Watanabe; University Hospital of Würzburg, Würzburg, GERMANY, Julius Maximilian University Würzburg, Würzburg, GERMANY, Kyoto Pharmaceutical University, Kyoto, JAPAN.

EP-0778
Quantitative Clinical Imaging of 18Zr Developing the Patient Pathway
A. Fenwick, L. Bartley, D. Deddieh, W. Evans, K. M. Ferrara, S. Paisley, A. P. Robinson, C. Marshall; National Physical Laboratory, Teddington, UNITED KINGDOM, Wales Research & Diagnostic Positron Emission Tomography (PET) Imaging Centre, School of Medicine, Cardiff University, Cardiff, UNITED KINGDOM.

EP-0779
Instrumentation and infrastructure for setting up advanced PET/CT services beyond F18-FDG in a developing country
A. Fatima, A. Rizvi, J. Khan, A. Shahid; ANMOL Cancer Hospital, Lahore, PAKISTAN.

EP-0780
In vivo visualisation of GLP-1 receptor expression with PET/CT in patients with morbid obesity undergoing bariatric surgery
L. Deden, M. Bass, F. Berends, M. Brom, E. Hazerbroek, M. Gothard, J. Rijnstate, Vitalis, Arnhem, NETHERLANDS, RadboudUMC, Nijmegen, NETHERLANDS, Rijnstate, Arnhem, NETHERLANDS.

EP-0781
81Zr labelled nanoparticle coating with biotin inserted cell membrane as a biomaterial for enhancing long-term circulation and tumor targeting
J. Lee, P. Choi, M. Hur, S. Yang, Y. Kang, E. Lee, H. Song, J. Park; Korea Atomic Energy Research Institute, Jeongeup-do, Jeongeup, KOREA, REPUBLIC OF.

EP-0782
Application of production and quality control procedures of 18F-PSMA-1007: dominant in Preclinical and translational aspects, including radiopharmacy, radiochemistry, drug development -> Radiochemistry, drug development -> Radiopharmacy, radiochemistry, drug development -> PET
Displayed throughout the congress days e-Poster Area
R. Shakurov, M. Balashov, Z. Dadashov, M. Valiyev, E. Mehd, F. Niasrat; Department of Nuclear Medicine, National Centre of Oncology, Baku, AZERBAIJAN.

EP-0783
Preclinical and translational aspects, including radiopharmacy, radiochemistry, drug development -> Radiochemistry, drug development -> Radiopharmacy, radiochemistry, drug development -> PET
Displayed throughout the congress days e-Poster Area
M. Wazyńska, R. Butera, M. de Bruijn, A. S. Diamant, P. H. Elzinga, H. W. Nijman; University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, University of Groningen, Faculty of Science and Engineering, Groningen, NETHERLANDS.

EP-0784
Preparation and biological assessment of 18F-NOTA-anti EGFR as a Radioimmunoconjugate for Diagnosis of EGFR* ESCC by PET
B. Allirezapour, H. Yousefnia, A. Bahrami Samani; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0785
Radioimmunocigraphy of EGFR with pretargeting Cetuximab in triple negative breast cancer
X. Lan, L. Yuan, Y. Gai, R. Yan, Y. Zhang; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0786
Comparison of two HAES sedimentation agents for leukocyte separation in radiolabeling procedure
A. Socan, F. Debeski, M. Kroej, P. Kocen Pet; University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-0787
Non-invasive whole-body imaging of immune checkpoints using PET-labeled small molecules as predictive biomarker for response to therapy
M. Wazyńska, R. Butera, M. de Bruijn, A. S. Diamant, P. H. Elzinga, H. W. Nijman; University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, University of Groningen, Faculty of Science and Engineering, Groningen, NETHERLANDS.

EP-0788
Establishing a GMP-compliant 89-Zirconium radiopharmaceutical production capability at the Royal Marsden Hospital Foundation Trust, UK
J. Tan, C. Da Pievè, G. Smith, D. Turner, W. J. G. Oyen; Royal Marsden Hospital Foundation Trust (RHM), Sutton, UNITED KINGDOM, Institute of Cancer Research (ICR), London, UNITED KINGDOM.

EP-0789
In vivo visualisation of GLP-1 receptor expression with PET/CT in patients with morbid obesity undergoing bariatric surgery
L. Deden, M. Bass, F. Berends, M. Brom, E. Hazerbroek, M. Gothard, J. Rijnstate, Vitalis, Arnhem, NETHERLANDS, RadboudUMC, Nijmegen, NETHERLANDS, Rijnstate, Arnhem, NETHERLANDS.

EP-0790
81Zr labelled nanoparticle coating with biotin inserted cell membrane as a biomaterial for enhancing long-term circulation and tumor targeting
J. Lee, P. Choi, M. Hur, S. Yang, Y. Kang, E. Lee, H. Song, J. Park; Korea Atomic Energy Research Institute, Jeongeup-do, Jeongeup, KOREA, REPUBLIC OF.

EP-0791
Application of production and quality control procedures of 18F-PSMA-1007: dominant in Preclinical and translational aspects, including radiopharmacy, radiochemistry, drug development -> Radiochemistry, drug development -> Radiopharmacy, radiochemistry, drug development -> PET
Displayed throughout the congress days e-Poster Area
R. Shakurov, M. Balashov, Z. Dadashov, M. Valiyev, E. Mehd, F. Niasrat; Department of Nuclear Medicine, National Centre of Oncology, Baku, AZERBAIJAN.

EP-0792
Preparation and biological assessment of 18F-NOTA-anti EGFR as a Radioimmunoconjugate for Diagnosis of EGFR* ESCC by PET
B. Allirezapour, H. Yousefnia, A. Bahrami Samani; Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0793
Radioimmunocigraphy of EGFR with pretargeting Cetuximab in triple negative breast cancer
X. Lan, L. Yuan, Y. Gai, R. Yan, Y. Zhang; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0794
Comparison of two HAES sedimentation agents for leukocyte separation in radiolabeling procedure
A. Socan, F. Debeski, M. Kroej, P. Kocen Pet; University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-0795
Non-invasive whole-body imaging of immune checkpoints using PET-labeled small molecules as predictive biomarker for response to therapy
M. Wazyńska, R. Butera, M. de Bruijn, A. S. Diamant, P. H. Elzinga, H. W. Nijman; University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, University of Groningen, Faculty of Science and Engineering, Groningen, NETHERLANDS.
EP-0797

Contribution of 131-I-ND-99 Planar and SPECT/CT Imaging in Patients with Hypersecretory Adrenal Syndromes and Incidentally Discovered Adrenal Masses


EP-0798

The Possibility of 99mTc-1-thio-d-glucose Spect for Detection of Residual Tumor Tissue After Non-radical Surgical Treatment and Use for Detection of Residual Tumor Tissue After Non-radical Surgical Treatment and Visualization Of Recurrence in Patients With a Brain Tumor

R. Zelcaia, A. Medvedeva, J. Srinivi, O. Bragina, A. Rybdaia, E. Staya, A. Ragor, V. Skudinkaia, V. Chernina, E. Chaynazarov, E. Mishina, Tomsk National Research Medical Center of the Russian Academy of Sciences includes the following Research Institute, Tomsk, RUSSIAN FEDERATION, 2Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Siberian State Medical University, Tomsk, RUSSIAN FEDERATION.

EP-0799

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiopharmacy, drug development -> Radiopharmacy -> Radiopharmaceuticals - Therapy

A. Orlova, U. Rosenström; Uppsala University, Uppsala, SWEDEN, A. Chernov, A. Abouzayed, B. Mitani, V. Talmachova, A. Orlova, U. Rosenström; Uppsala University, Uppsala, SWEDEN.

EP-0800

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiopharmacy, drug development -> Radiopharmacy -> Radiopharmaceuticals - Multimodal / optical probes

Displayed throughout the congress days: e-Poster Area.

EP-0801

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiopharmacy, drug development -> Radiopharmacy -> Radiopharmaceuticals - Multimodal / optical probes

Endepols, M. Oroujeni, 2Uppsala University, Uppsala, SWEDEN, 1M. Álvarez Mena, M. González Soto, B. Pérez López, M. Alonso Rodríguez, R. Ruaño Pérez, Hospital Clinico Universitarios, Valladolid, SPAIN.

EP-0802

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiopharmacy, drug development -> Radiopharmacy -> Radiopharmaceuticals - Multimodal / optical probes

Endepols, M. Oroujeni, 2Uppsala University, Uppsala, SWEDEN, 1M. Álvarez Mena, M. González Soto, B. Pérez López, M. Alonso Rodríguez, R. Ruaño Pérez, Hospital Clinico Universitarios, Valladolid, SPAIN.

EP-0803

Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development -> Radiopharmacy, radiopharmacy, drug development -> Radiopharmacy -> Radiopharmaceuticals - Multimodal / optical probes

Endepols, M. Oroujeni, 2Uppsala University, Uppsala, SWEDEN, 1M. Álvarez Mena, M. González Soto, B. Pérez López, M. Alonso Rodríguez, R. Ruaño Pérez, Hospital Clinico Universitarios, Valladolid, SPAIN.
### EP-0808

**Reinforcement Learning for Automated PET Image Segmentation**

R. L. Smith, L. Bartley, S. Paisey, C. Marshall; Cardiff University, Cardiff, UNITED KINGDOM.

#### Abstract

Deep Learning has been used extensively for semi-automated segmentation of medical images. However, the performance of these tools can be confounded by varying patient anatomies. We evaluated a deep reinforcement learning (DRL) approach to PET image segmentation in patients with low or intermediate risk prostate cancer.

**Keywords:** Deep Learning, Reinforcement Learning, Prostate Cancer

### EP-0809

**Low Dose CT to Assess Performance of Deep Learning Pre-Clinical Medical Image Segmentation for Automated Organ-wise Delineation of PET**

R. L. Smith, N. Evans, V. Florence, S. Paisey; Cardiff University, Cardiff, UNITED KINGDOM. Polytech Marseille, Marseille, FRANCE.

#### Abstract

The use of low dose CT scans for delineation of organs in PET-CT imaging is common practice. However, the accuracy of such delineation is not well studied. We have developed a pre-clinical tissue phantom to assess the performance of a deep learning approach to such delineation in a low dose CT setting.

**Keywords:** Low Dose CT, Deep Learning, Organ-wise Delineation

### EP-0810

**Determining the influence of patient's positioning in prone/supine breast PET/CT examination on the selection of the contouring algorithm using radiomics features**

D. Berys, J. Gorczewska, K. Matsuki, M. Jarasah; A. d'Amico; Department of PET Diagnostics, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND, Department of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND.

#### Abstract

The correct positioning of a patient during PET/CT examination is crucial to acquire high-quality images and accurate radiomics features. We aimed to investigate the influence of patient positioning (prone vs. supine) on the selection of the contouring algorithm using radiomics features.

**Keywords:** Breast Cancer, PET/CT, Radiomics, Patient Positioning

### EP-0811

**Stability of PET Radiomic Features: A Preclinical Study**

E. Aleyre; R. Smith, C. Marshall, S. Paisey, E. Spear; School of Engineering, Cardiff University, Cardiff, UNITED KINGDOM. Wales Research & Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM. Velindre Cancer Centre, Cardiff, UNITED KINGDOM.

#### Abstract

Radiomics is a powerful tool for extracting quantitative features from medical images. The stability of radiomics features is crucial for their clinical utility. We aimed to evaluate the stability of radiomics features across multiple PET/CT scans.

**Keywords:** Radiomics, PET, Stability

### EP-0812

**Precision and Accuracy of Radiomics Analysis at Poor Noise Conditions: a Phantom Study Using 3D Printed ‘Tumor’ Inserts**

A. Somasundaram, E. Plehier, J. van Sloot, O. Vos; Institute of Nuclear Energy Research, Tsinghua University, TAIWAN. Department of Biomedical Engineering, Tsinghua University, TAIWAN.

#### Abstract

Radiomics analysis is a promising tool for extracting information from medical images. However, the accuracy of radiomics analysis at poor noise conditions is important to consider. We performed a phantom study using 3D printed ‘tumor’ inserts to evaluate the precision and accuracy of radiomics analysis.

**Keywords:** Radiomics, Phantom, Noise, Insert

### EP-0813

**Image-based biomarkers for resectable NSCLC using F-18 FDG PET/CT: evaluation of a novel Matlab based algorithm for better characterisation of radiomics features**

K. Kneer, J. Steinacker, E. Eberhardi, E. Houtsadefad-Nosхват, J. Racel, S. Rüdiger, C. Krypf-Sánchez, M. Beer, V. Prasad, G. Glätting; A. Beer; University Hospital, Department of Nuclear Medicine, Ulm, GERMANY, University Hospital, Department of Diagnostic and Interventional Radiology, Ulm, GERMANY, University Hospital, Department of Interventional Radiology, Ulm, GERMANY.

#### Abstract

Image-based biomarkers can provide valuable information for the management of resectable NSCLC patients. We developed a novel Matlab-based algorithm for better characterisation of radiomics features in F-18 FDG PET/CT images.

**Keywords:** NSCLC, PET/CT, Radiomics, Image-based biomarkers

### EP-0814

**The comparison of radiomics features on FDG PET/CT acquisition between supine and prone position**

I. Gorczewska, D. Berys, M. Jarasah, A. d’Amico; Department of PET Diagnostics, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND, Department of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND.

#### Abstract

The position of a patient during PET/CT examination can affect the accuracy of radiomics features. We compared the radiomics features acquired in supine and prone positions to evaluate the impact of patient positioning.

**Keywords:** PET/CT, Radiomics, Patient Positioning

### EP-0815

**Validation of an open source Natural Language Processing (NLP) and an in-house developed python script for named entity recognition from Image-based biomarkers for resectable NSCLC using F-18 FDG PET/CT: evaluation of a novel Matlab based algorithm for better characterisation of radiomics features**

S. Mathew, A. K. Jha, U. B. Sherkhane, V. Jaiswar, A. V. Prasad, C. M. Ortiz, S. Pal, V. Rangarajan; A. Decker, L. Wee; Tata Memorial Hospital, Mumbai, INDIA, Philips innovation campus, Philips INDIA, Bangalore, INDIA, Netherlands eScience Center, Amsterdam, NETHERLANDS, MAASTRO Clinic, Maastricht, NETHERLANDS, Department of Radiation Oncology, MAASTRO Clinic, Maastricht, NETHERLANDS.

#### Abstract

Natural Language Processing (NLP) and named entity recognition are important tools for extracting information from radiomics analysis. We evaluated the performance of an open source NLP tool and an in-house developed python script for named entity recognition.

**Keywords:** NLP, Named Entity Recognition, Radiomics, NSCLC

### EP-0816

**Is there any correlation between the radiomic features extracted from CT and PET Images**

A. K. Jha, S. Mathew, U. B. Sherkhane, V. Jaiswar, N. Eberhardt; A. Decker; L. Wee; Tata Memorial Hospital, Mumbai, INDIA, Philips Innovation Campus, Philips INDIA, Bangalore, INDIA, Netherlands eScience Center, Amsterdam, NETHERLANDS, MAASTRO Clinic, Maastricht, NETHERLANDS, Department of Radiation Oncology, MAASTRO Clinic, Maastricht, NETHERLANDS.

#### Abstract

Radiomics features extracted from CT and PET images can provide valuable information for the management of NSCLC patients. We aimed to investigate the correlation between these features.

**Keywords:** Radiomics, CT, PET, Correlation
EP-0821
Al-Based PET-to-PET Alignment Enabling Individual Tumour Tracking and Multi-Tracker Analysis
1Department of Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 2Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 3Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 4Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 5Radiology, Oncology and Human Pathology, Department of Medicine and Urgency, Unit of Cardiology, Odense Universitetssygehus, Odense, DENMARK.

EP-0822
Evaluation of radiomics quantification using a multi-compartment multimodality imaging phantom
K. Meijer, J. Hendriks-Gielen, W. M. Brink, A. Bongers, C. H. Slump, T. de Gruy-Oen, E. V. Kuznetsov, D. R. Schaart, 1
1Department of Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 2Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 3Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 4Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 5Radiology, Oncology and Human Pathology, Department of Medicine and Urgency, Unit of Cardiology, Odense Universitetssygehus, Odense, DENMARK.

EP-0823
A Novel Automated Deep Learning Algorithm for Segmentation of the Skeletal in Low-Dose CT for [18F]DCFPyL PET/CT Hybrid Imaging in Patients with Metastatic Prostate Cancer
K. Gjertsson, R. Johnson, J. Richter, K. Stenström, L. Edenbrandt, A. Anand, E. Chiorino, F. Guana, S. Vaz, 1
1Department of Medicine and Urgency, Unit of Cardiology, Odense Universitetssygehus, Odense, DENMARK.

EP-0824
Favorable Image Reconstruction for Adequate Myocardial Perfusion Imaging Using Rubidium-82 on a Digital PET System
S. S. Koenders, F. F. P. M. Oliveira, S. S. Koenders, 1
1Department of Cardiology, University of Medicine, Odense, DENMARK.

EP-0825
The influence of Attenuation Artefacts Caused by Metallic Injection Ports in Breast Tissue Expanders on the Calculation of LVFE in MUGA Studies
A. Hughes, M. Christe Medical Physics & Engineering, Royal Preston Hospital, Preston, UNITED KINGDOM.

EP-0826
Prevalence, Characteristic And Pronostic Value Of Extra-cardiac Uptake Of 99mTc-hydroxyethylene Diphosphonate In Cardiac Amyloidosis
1Department of Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 2Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 3Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 4Radiation Science, Electronic and Mechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, 5Radiology, Oncology and Human Pathology, Department of Medicine and Urgency, Unit of Cardiology, Odense Universitetssygehus, Odense, DENMARK.

EP-0827
Evaluation of washout rate with crosstalk correction between 18F-EMIPP and 18F-TICI for triglyceride deposit cardiomyovasculopathy (TGCV)
K. Kamiya, T. Kusari, K. Fujino, M. Chiumi, K. Hiraoka, K. Sakatsuki, J. Hatazawa, 1
1Osaka University Graduate School of Medicine, Osaka, JAPAN.

EP-0828
Improved accuracy in diagnosing cardiac amyloidosis through increased myocardial 99mTc-DPD uptake associated with increased LV mass
L. Monaco, A. Scazzetti, R. Sarri, C. Popescu, M. Spallino, C. Dalci, M. Cuzzocrea, E. Guay, M. Melleo, F. Musca, F. Candelori, C. Rossetti, 1
1University degli studi di Milano-Bicocca, Milano, ITALY; 2ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY; 3University of Zurich, UZH, Department of Medicine, Section of Nuclear Medicine, Vienna, AUSTRIA; 4Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND; 5Cure@ge University Hospital, Florence, ITALY; 6Galeazzi University Hospital, Oderzo, ITALY.

EP-0829
Assessment of three software packages in the estimation of left ventricular volumes and ejection fraction with resolution recovery algorithm in gated myocardial perfusion SPECT vs CT: preliminary results of a single centre
E. Calandri, F. Guanat, L. Conversano, S. Gallina, S. Leuz, E. Soligo, S. Debenedetti, M. Liberatore, G. Chirona, M. Putrane, 1
1Department of Medicine and Urology, University of Bari, Bari, ITALY.

EP-0830
Noninvasive Tracer Kinetic Analysis of Brain 18F-Florbetaben PET: a Comparison of Kinetic Models
1Hospital de Saude, Department of Nuclear Medicine, Lisbon, LISBOA.

EP-0831
Tool and Urgency, Nuclear Medicine Unit, Ospedale degli Infermi, Ponderano, ITALY, 2Department of Radiology, Oncology and Human Pathology, Nuclear Medicine Unit, Sapienza University, Rome, ITALY.

EP-0832
Nonstandardized PET MBF Quantification through Development of a One-for-all Software Tool
S. Nesterov, R. Buechen, J. Dolkos, V. Diliszenko, H. Gewirtz, A. Mianouque, J. O. Priot, R. Scagapi, M. Smith, A. Thomasen, J. Knudt, 1
1Turku PET Centre, Turku, FINLAND; 2IPETH RAS, St Petersburg, RUSSIAN FEDERATION; 3University of Zurich, ZURICH, ZURICH, SWITZERLAND; 4University College London, Institute of Nuclear Medicine, London, UNITED KINGDOM; 5University of Maryland School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA; 6Holland Medical School, Boston, MA, UNITED STATES OF AMERICA; 7Université Caen Normandie, CHU de Caen, GIP Caresse, Caen, FRANCE; 8Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND.

EP-0833
Can SPECT Resolution Be Considered Invariant in Partial Volume Correction?
R. Gillen, M. A. Denis-Bacelar, S. J. McCaugh, I. S. Keradis, J. Badel, 1
1Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM; 2School of Physical Laboratory, Teddington, UNITED KINGDOM.

EP-0834
Using phase space for SPECT Monte-Carlo simulation
D. Sarrut, T. Baudier, J. Labour, 1
1Centre Léon Bérard, Lyon, FRANCE; 2Centre Léon Bérard, Lyon, FRANCE.

EP-0835
Pertinent Image Reconstruction for Adequate Myocardial Perfusion Imaging Using Rubidium-82 on a Digital PET System
S. S. Koenders, F. F. P. M. Oliveira, S. S. Koenders, 1
1Department of Cardiology, University of Medicine, Odense, DENMARK.

EP-0836
Standardization of PET MBF Quantification through Development of a One-for-all Software Tool
S. Nesterov, R. Buechen, J. Dolkos, V. Diliszenko, H. Gewirtz, A. Mianouque, J. O. Priot, R. Scagapi, M. Smith, A. Thomasen, J. Knudt, 1
1Turku PET Centre, Turku, FINLAND; 2IPETH RAS, St Petersburg, RUSSIAN FEDERATION; 3University of Zurich, ZURICH, ZURICH, SWITZERLAND; 4University College London, Institute of Nuclear Medicine, London, UNITED KINGDOM; 5University of Maryland School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA; 6Holland Medical School, Boston, MA, UNITED STATES OF AMERICA; 7Université Caen Normandie, CHU de Caen, GIP Caresse, Caen, FRANCE; 8Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND.

EP-0837
Can SPECT Resolution Be Considered Invariant in Partial Volume Correction?
R. Gillen, M. A. Denis-Bacelar, S. J. McCaugh, I. S. Keradis, J. Badel, 1
1Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM; 2School of Physical Laboratory, Teddington, UNITED KINGDOM.
EP-0835 Reproducibility Study of Lesion Features Extracted from 18F-FDG PET Images of the Same Patients Acquired on Two Philips PET/CT Scanners: Digital VEREO versus GEMINI TF

EP-0836 Is it valid to simulate a decrease in the administered activity by a reduction in the acquisition time of a PET scan?
J. M. Marti-Climent, P. Prieto, P. Aguilar, A. Garcia, V. Moreda, 1Clínica Universidad de Navarra, Pamplona, SPAIN, 2Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0837 Impact of the Bayesian Penalized Likelihood (BPL) algorithm on hypoxia PET/CT in patients with lung neoplasia
S. Hadpey, E. Teste, P. Gouet, B. Barnes, P. Bahr, S. Thuesen, P. Viera, 1Nuclear Medicine dept, Centre Bréquemard & QuantIF-LITIS EA 4108, Rouen Medical University, Rouen, FRANCE, 2Nuclear Medicine dept, Centre Bréquemard, Rouen, FRANCE, 3Nuclear Medicine dept, Centre J. Perier, Clermont-Ferrand, FRANCE, 4Radiotherapy dept, Centre Bréquemard & QuantIF-LITIS EA 4108, University of Rouen, Rouen, FRANCE.

EP-0838 Constructing Bland-Altman plots in small to moderate sample sizes: use rather a factor between 2 and 2.4 than 1.96
O. Gerke, Odense Agreement Working Group, Odense University Hospital, Odense C, DENMARK.

EP-0839 Nonparametric alternatives to Bland-Altman Limits of Agreement in case of non-normally distributed data
O. Gerke, 1M. E. Frey, H. C. Petersen, Odense Agreement Working Group, Odense University Hospital, Odense C, DENMARK, 2University of Southern Denmark, Odense M, DENMARK.

EP-0840 What are the effects of respiratory gating method on measurement accuracy of SUVmax with respect to lesion size? An anthropomorphic phantom study
B. Serrano, M. Salvar, Y. Ben Ahmed, N. Garneri, R. Ambiahi, B. Paulmeri, R. Villeneuve, F. Hugunet, V. Natof, M. Faraggi, 1Princess Grace Hospital Center, Medical Physics Department, Monaco, MONACO, 2Princess Grace Hospital Center, Nuclear Medicine Department, Monaco, MONACO.

EP-0841 Software development and validation for Salivary Gland Scintigraphy using Gamma Camera
A. K. Jha, S. Mitrun, A. D. Parandeh, S. Shih, A. Agarwal, N. C. Purandare, V. Rangarajan, Tata Memorial Hospital, Mumbai, INDIA.

EP-0842 Evaluation of Atlas Based Attenuation Correction in Bone Scintigraphy

EP-0843 Study of different quantitative uptake metrics in F18-FDG PET/CT imaging in breast cancer: impact of workstation and segmentation method

EP-0844 Study of different quantitative uptake metrics in 18F-FDG PET/CT imaging from malignant lymph node in breast cancer: impact of workstation and segmentation method

EP-0845 Comparison of different quantitative uptake metrics in 18F-FDG PET/CT imaging in breast cancer according to voxel size using different workstation and segmentation method

EP-0846 Partial Volume Correction for Lymph Nodes in 18F-PSSMA PET Images
J. Schaafkerkoetter, C. Ortega, P. Veit-Habich, L. Metten, University Health Network, Toronto, ON, CANADA.

EP-0847 New Nuclear Functional Imaging Data in NET:Theragnostic Approach
C. R. Stolnicenaru, C. Ungureanu, C. Preda, C. Volariu, S. Holovat, T. Ionescu, T. Chofor, A. Satosenaru, M. Gatu, M. Matoe, C. Stefanescu, 1University of Medicine and Pharmacy U M F, Grigore T. Popa, Iasi, ROMANIA, 2University emergency hospital “Sf. Spiridon”, Iasi, ROMANIA, 3Center of Nuclear Medicine, Craiova, ROMANIA, 4Center of Nuclear Medicine, Iasi, ROMANIA.

EP-0848 Study of different quantitative uptake metrics in 18F-FDG PET/CT imaging from malignant lymph node in breast cancer: impact of workstation and segmentation method

EP-0849 Quantitative assessment of joints affected by rheumatoid arthritis using 11C/CDPA713 PET
M. Yaqub, N. Verheij, S. Peplienbach, R. Boelgaard, C. van der Linden, A. A. Lammersma, 1Amsterdam UMC, Vrije Universiteit Amsterdam, department of radiology and nuclear medicine, Amsterdam, NETHERLANDS, 2Amsterdam UMC, Vrije Universiteit Amsterdam, department of radiology, Amsterdam, NETHERLANDS.

EP-0850 Development of PET in Europe
A. N. Stevens, Medical Options, London, UNITED KINGDOM.

EP-0851 Multicenter study of rapid bone-SPECT/CT image acquisition
K. Miwa, T. Murata, N. Miyagi, T. Kamiya, Y. Owaki, T. Okamoto, R. Emura, M. Takahashi, R. Kobayashi, T. Imai, 1Department of Radiological Sciences, International University of Health and Welfare, Tochigi, JAPAN, 2Department of Radiology, China University Hospital, Chiba, JAPAN, 3Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN, 4Department of Medical Technology, Osaka University Hospital, Osaka, JAPAN, 5Center of Radiation Technology, Keio University Hospital, Tokyo, JAPAN, 6Department of Radiology, Tsuchi General Hospital, Aomori, JAPAN, 7Department of Radiology, Keimtsu Central Hospital, Chiba, JAPAN, 8Department of Central Radiological Technology, Satama Medical University Hospital, Satama, JAPAN.
EP-62
Technical aspects -> Instrumentation and data analysis -> Data analysis -> Image reconstruction

EP-0852
Added Value of Siemens xSPECT Bone Algorithm in Reading Musculoskeletal SPECT/CT

Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-0853
Optimized PET reconstructions: Can they be harmonized as well?

H. Vossoughi, P. Gerasimov, A. Rahmim, F. Emami, M. Haji, M. Momennejad
Department of Medical Physics, Masahid University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.
Nuclear Medicine Department, Raziav Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF.
Research Center for Nuclear Medicine, Shiraz University Hospital, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.
Departments of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA.

EP-0856
Impact of Radiation Dose Reduction of CT component in Whole-Body PET/CT Protocols on CT image quality

Zagazig university faculty of medicine, Zagazig, EGYPT, Cairo university faculty of medicine, Cairo, EGYPT, Cairo university hospitals, Cairo, EGYPT, Cairo university Hospitals, Cairo, EGYPT.

EP-0858
A preliminary assessment of metallic artefact reduction strategies for quantifying FDG activity around cardiac implantable electronic devices

M. Memmott, J. S. Armsrong, J. Jones, V. J. Panini
Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM.
Siemens Medical Solutions USA, Inc. Medical Imaging, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0859
The Effect of Different Time Per Bed Position on Image Quality and Semi-Quantitative Measurements in "Ga-RM" and "Ga-P5MA11" PET/MR images

L. Baratto, H. Duan, H. Gandhi, M. Khalighi, A. Iagaru
Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

EP-0860
Optimisation of TOF and PSF PET Reconstruction for the Detection and Quantification of Metastatic Tumour Lesions in the Liver

Y. Bouchareb, N. Tag, H. Suliman, M. El-zenain, A. Al-Sabri, Z. Jawad, H. Al-Dhah, S. Qadous
University, Muscat, OMAN.

EP-0861
Comparison of two strategies for mitigation of gross misregistration of CT and PET in PET/CT imaging

T. Pan, B. Simar, P. Wilcoxon
The University of Texas, Houston, TX, UNITED STATES OF AMERICA.

EP-0864
Scan time optimisation of PET/CT examinations in case of patients in pain

A. Zagorska, V. Koyoun, A. Tsonnenko
Acibadem City Clinic Cancer Center, Sofia, BULGARIA.

EP-0865
Partial volume corrected image derived input functions for kinetic modelling of FDG PET brain studies

H. Kelzera, S. V. G. Olga, M. Yaqub, N. Settemo, P. Schelten, M. Hofman, R. Boellaard
Amsterdam UMC, Amsterdam, NETHERLANDS.

EP-0866
Validation of reference regions for "[18F]"Flortaucipir and "[18F]Florbetapir brain PET studies using non-invasive simplified metrics

S. S. Golla, M. de Vries, T. Timmen, E. E. Wolten, P. Osenkappe, S. Valtzs, R. C. Schut, P. Schelten, W. M. van der Flier, A. D. Windhoudt, B. N. van Berckel, R. Boellaard
Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS.

EP-0867
A quantitative approach for the diagnosis of nonconvulsive status epilepticus from brain perfusion SPECT images

Nuclear Medicine-PET Department. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN.
Neurology department. Hospital Universitari de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN.

EP-0871
Estimation of the spatial resolution of [18F]FDG brain PET/MI scans using phantom measurements and human scan data


EP-0868
The Impact Of Reference Region Choice On The Apparent Ordering Of Amyloid Deposition

F. Heeman, M. Yaqub, L. Colly, S. Ngakui, G. Salvadori, A. Wink, P. Vater, B. N. M. van Berckel, J. D. Giger López, F. Berkel, J. A. Lammertsma, J. Lager Alves, A. Alzheimer research consortium.; Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, NETHERLANDS.
Bioklinika Brain Research Center, Barcelona, SPAIN.

EP-0870
MRI-guided partial volume correction of 3D PET images using a split Bregman optimized parallel level set framework

Y. Zha, A. Rahmim, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.
University of British Columbia, Vancouver, BC, CANADA.

EP-0871
MRI-guided voxel-based Automatic Semi-quantification of Dopamine Transporter Imaging

J. Trmka, P. Dusek, D. Zogala, V. Prcakl; General University Hospital and Charles University, Prague, CZECH REPUBLIC.

EP-0872
Estimation of the spatial resolution of [18F]FDG brain PET/MI scans using phantom measurements and human scan data

EP-0890
Thrombosis as incidental finding in 18F-FDG PET/CT scan performed in oncologic patients: usefulness of intravenous contrast-enhanced CT

EP-0891
Imaging Protocol Optimisation for 223Ra on SPAIN.
Carreras Delgado; San Carlos Clinical Hospital, Madrid; M. Garcia Garcia-Esquinas, M. J. Pérez Castejón, J. L. Landaeta Kancev, A. Blanes, R. Valhondo Rama, C. G. Wakfie Corieh, E. Rodriguez Gallo, Cardiovascular Center, Gunma, JAPAN.

EP-0892
Intercomparison of radionuclide calibrators used in the main Lithuanian hospitals with the secondary standard ionization chamber K. Skovorodko; A. Gužul; Vincas University Hospital Santarino Klinikos, Vinus, LITHUANIA; State research institute the Center for Physical Sciences and Technology (FTMC), Vilnius, LITHUANIA.

EP-0893
Acceptance and Quality Tests in Thyroid Uptake EP-0894
Systems
Technology (FTMC), Vilnius, LITHUANIA.

EP-0895
Improving the Assessment of Dose Calibrator Linearity for the Clinical Activity Range D. O’Keeffe. Medical Physics and Bioengineering, Christchurch Hospital, Christchurch, NEW ZEALAND.

EP-0896
Proposal for National Quarterly Quality Control Tests for the SPECT/CT Systems
R. Y. Almazrou, S. F. Alnazer, T. O. Almatawi, A. K. Aloissi,
“King Faisal Specialist Hospital and Research center, Riyadh, SAUDI ARABIA, “Prince Mohammad Bin Abdulaziz Hospital, Riyadh, SAUDI ARABIA, “King Abdulaziz Hospital, Bisha, SAUDI ARABIA, “King Faisal Medical City for Southern Region, Abha, SAUDI ARABIA.

EP-0897
Is there any “Y”-FDG PET/CT BAT pattern in oncological patients? W. Jalloh, E. Chiña, A. Tava, M. Gúri, D. Chetser, C. Štětina, A. Naum, Nuclear Medicine Laboratory, County Emergency Hospital, Székesfehérvár, HUNGARY, Romania, ROMANIA.

EP-0898
Technical aspects -> Instrumentation and data analysis -> Instrumentation -> General aspects

EP-0899
Development of Simulation Environment for bone SPECT imaging using SIMIND H. Daisaki; M. Shimizu, T. Kazuki, H. Shiodani, T. Inou, T. Sato, I. Kanmori, H. Masuko, S. Fukun; K. Shimizu, T. Nakahara; K. Kashikura; Gunma Prefectural College of Health Sciences, Gunma, JAPAN; Fukuoka General Hospital, Gunma, JAPAN; Gunma University Hospital, Gunma, JAPAN; Gunma Cardiovascular Center, Gunma, JAPAN; The Cancer Institute Hospital of JFCR, Tokyo, JAPAN; “Kose University Hospital, Tokyo, JAPAN.

EP-0900
A web-based platform for collecting, researching and presenting molecular hybrid imaging artefacts O. Roemser, M. Mullmann, B. Sattler, G. Sabe; University Hospital Leipzig, Department for Nuclear Medicine, Leipzig, GERMANY.

EP-0901
Assessment of image quality comparing 2 acquisitions speeds in whole body bone scan with new generation of collimators and processing software G. García; N. Gehrman, H. Santer, R. Muteganyi, M. Tondari; OLAPi, Traunma, BELGIUM, CHUB Hospital, Krakow, Université Libre de Bruxelles, Bruxelles, BELGIUM, Centre Hospitalier Universitaire Yalgada Ouedraogo, Ouagadougou, Burkina Faso, “Clinique de l’Europe, Bruxelles, BELGIUM, “CHU Saint-Pierre, Université Libre de Bruxelles, Bruxelles, BELGIUM.

EP-0902

EP-0903
Atomlab 100plus dose calibrator adjustment with 177Lu calibrated source in a phase III/II study for treatment of NIH lymphoma with 177Lu-DOTA-HH1 P. Saletti; S. Carboni, S. Raspani, G. Bell, AOI Careggi, Florence, ITALY, “University of Florence, Florence, ITALY.

EP-0904

EP-0905
Simultaneous 18F- and 11C-guided breast cancer surgery: from probes characterization to clinical trial C. Hoog, P. Kuikabul, J. Gal, T. Desouza, C. Dieper, C. Charpeller, J. Haugeois, J. Durand, B. Mamanter, Antoine Lacassagne Center, Nice, FRANCE.

EP-0906
Technical aspects -> Instrumentation and data analysis -> Instrumentation -> Metric and intervention

EP-0907

EP-0908
Use of The Silicon Photomultiplier (SiPM)- based PET/CT Results in lower FDG Uptake in Mediastinal Blood Pool Compared to The Conventional PET/CT Y. Toyama, Tohoku university, Sendai city, JAPAN.
EP-0910 Phantom-based image quality assessment of clinical 18F-FDG protocols in digital PET/CT and comparison with conventional PMT-based PET/CT devices
S. Gnesin, C. Keffert, K. Zempekis, J. Papazyan, R. Guignard, J. O. Poir, F. R. Verdier, T. V. M. Linds, Institute of Radiation Physics, Lausanne University Hospital, Lausanne, SWITZERLAND. 1Department of nuclear medicine, Zürich Universitätsspital, Zurich, SWITZERLAND. 2Department of Nuclear medicine, La Tour Medical Group, Meyrin, SWITZERLAND. 3Department of nuclear medicine and molecular imaging, Lausanne University Hospital, Lausanne, SWITZERLAND. 4Department of nuclear medicine, Aarau Kantonsspital, Aarau, SWITZERLAND.

EP-0911 Monolithic PET detectors with sub-mm transverse and 6 layer DOI identification for next generation high resolution clinical PET scanners
M. Stockhoff, R. Van Haelen, S. Vandenberghe, Ghent University, Gent, BELGIUM.

EP-0912 PET2020: Combination of clinical routine PET and molecular research in one compact and cost-efficient high resolution long axial FOV PET scanner

EP-0913 Physical Performance of a PET Scanner Prototype with Extended Axial Field of View using Sparse Detector Module Rings
Configuration: A Monte Carlo simulation study
S. Zein, N. A. Karakatsanis, A. Gupta, J. R. Osborne, S. A. Nettenh, Weil Cornel Medical College, New York, NY, UNITED STATES OF AMERICA.

W. Jentzen, J. Bu, R. Hoffner, P. Coster, R. Winters, J. Rauschi, A. Berger, T. Beyer, M. Corri, F. Hermann, 1Clinic of Nuclear Medicine, University of Dussburch-Essen, Essen, GERMANY. 2Siemens Medical Solutions USA, Inc, Knoxville, TN, UNITED STATES OF AMERICA. 3Department of Nuclear Medicine, Maastricht University Medical Centre, Department of Radiology and Nuclear Medicine, Maastricht, NETHERLANDS. 4QIM Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.

EP-0915 Recovery of Missing Data in Partial Geometry Dedicated Breast PET Scanner Using Compressive Sensing
A. Emami, 1,2 P. Gharabali, 1 H. Ghadrif, 3, 4 P. Grassia, 1 M. Ay, 1, 2 Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 1Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 2International Campus, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 3Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shariati Research Center for Nuclear Medicine, Tehran, IRAN, ISLAMIC REPUBLIC OF. 4Pet/CT and Cyclotron Center, Mash Dameshk Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 1Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND. 2Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

EP-0916 Quantitative gated PET and CT imaging of mice and rats using a fully integrated animal monitoring system
P. Mollet, S. Neyt, B. Vandaghrist, Molecubes NV, Gent, BELGIUM.

EP-0917 Metabolic Response Assessment Following Stereotactic Ablative Radiotherapy (SABR) in oligo lung metastases - How early we get to see!
A. Kasat, S. Gouveia, H. Rashid, A. Singh, S. Yangjunren, HCG Cancer Centre, Mumbai, INDIA.

EP-0918 Systematic Error On The Displayed Delivered Activity Of The Medrad® Intego Pet Infusion System
A. Wenger, C. Weyermann, M. Hoffbauer, M. Christen, K. Ziempekis, Universitätsklinik Zürich, Zurich, SWITZERLAND.

EP-0919 Phase la intra-individual comparison study of osteoelastic metastases using rapid high definition whole-body Na18F digital photon counting PET/CT
C. L. Wright, K. Brunat, J. Zhang, E. Fole Rae, D. A. Diaz Pardo, D. G. Stover, J. P. Monk III, M. V. Knopp, The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

A. Moreno, E. Iain, M. Luchtenrik, Uppsala University Hospital, Uppsala, SWEDEN.

EP-0921 Accuracy of the Siemens Biograph Vision 600 for Radiotherapy planning: technical aspects and extra acceptance testing
E. Raaijmakers, S. Schip, van Het, E. Gerrits, Institute UMR-1154, Nancy, FRANCE. 2INSERM UMR-1116 DCAC, Nancy, FRANCE. 3Vandurde Center, Université Lorraine, Nancy, FRANCE. 4CHRU-Nancy, Radiology, France

EP-0922 Use of insulin to avoid false-negative for FDG-PET Imaging in cancer patients with high blood glucose level: a prospective cross-over study
H. Gauthier, E. Golbert, V. Pinet, Centre Oscar Lambret, Lille Cedex, FRANCE.

EP-0923 Performance Evaluation of a Newly Designed SiPM-based Preclinical Scanner Based on NEMA-Nu 2008
M. Amirrashedi, 1,2 S. Sarvari, 1,2 P. Ghalanian, 1,2 R. Hashemi (Shahed), 1,2 P. Geramifar, 1,2 P. Ghafarian, 1,2 Iran University of Medical Sciences, Tehran, Iran, ISLAMIC REPUBLIC OF. 2Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 3Department of Nuclear Medicine, Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF. 4Research Center for Nuclear Medicine, Shariati Research Center, Tehran, Iran, ISLAMIC REPUBLIC OF. 5Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND. 6Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

EP-0924 Assessment of a Monte Carlo simulation of PET recordings from the fully-digital Vereos camera
J. Salvadori, 1,2 P. Miane, 1,2 G. Karcher, 1,2 L. Imbert, 1,2 IAC UMR-1154, Nancy, France, 2INSERM UMR-1116 DCAC, Nancy, France, 3CHRU-Nancy, Nuclear Medicine, Nancy, France.

EP-0925 Qualitative and Quantitative Assessment of Reducing the Scan Time for 18F-fluorodeoxyglucose (18F-FDG) Wholebody PET/CT to 2 min/bed
A. McCann, D. Maguire, A. Dawling, L. Harris, R. P. Kilren, L. Lusty, OGD-SUNH PET CT Research Centre, St Vincent’s University Hospital, Dublin, IRELAND.
EP-0926
In vitro detection limit of 99mTc-labelled cells using a human PET system
L. Lechermann, R. Manosvak1, T. D. Fryer2, B. Antl1, D. Lass1, B. J. Jarvis1, I. Aboy2, B. Basu1, N. Patel1, M. Cliche2, J. L. Jones1, F. J. Argiby1, F. A. Gallagher1; 1Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM, 2Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UNITED KINGDOM.

EP-0927
Optimization of CT acquisition protocol in brain 18F-FDG PET/CT
A. L. M. Silva1,2, T. D. Fryer1, N. Patel1, A. Courteau1, M. Moreau1, P. M. Walker1, M. Guillemin1, C. Decro1, A. Oudot1, L. Larcher1, S. Roux1, J. McGrath1, R. Ganpate1, R. Crochet1, F. Brunaut1, J. M. Vigneault1; 1ImViMA laboratory, EA 7535, University of Burgundy, Dijon, FRANCE, 2Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6102, Dijon, FRANCE, 3CHU Franois Mitterand, Dijon, FRANCE, 4Georges-François Leclerc Cancer Center, Universite d'Orleans, Dijon, FRANCE, 5Georges-François Leclerc Cancer Center, UMR-CNRS, Dijon, FRANCE.

EP-0928
Low Dose 68 Ga DOTA Zoledronate Bone PET/CT Scan on a High Definition Digital PET Scanner: First Technical Feasibility Study Done in Kuwait
B. M. Alenezi; John Al Ahmad For Molecular Imaging Center, Kuwait, KUWAIT.

EP-0929
EasyPET-3D, a super high spatial resolution and cost-effective PET scanner for training and preclinical applications
F. Castro1, P. M. C. Correia1, P. M. C. Encarnação1, A. M. L. Silva1, F. M. Ribeiro1, J. Mohammad1, A. I. Velosa1, A. C. Santos1, J. F. C. Velosa1; 1Departamento de Fisica da Universidade de Aveiro, Aveiro, PORTUGAL, 2R-TE Radiation Imaging Technologies, Ltda, Braga, PORTUGAL, 3iGMA, Universidade de Aveiro, Aveiro, PORTUGAL.

EP-0926
EP-0927
EP-0928
EP-0929
EP-0930
Technical aspects -> Instrumentation and data analysis -> Instrumentation -> PET/MR Displaced throughout the congress days e-Poster Area

EP-0930
PET/MR, the optimal imaging tool for quantitative biodistribution studies in nanoparticle research
A. Courteau1, M. Moreau1, P. M. Walker1, M. Guillemin1, C. Decro1, A. Oudot1, L. Larcher1, S. Roux1, J. McGrath1, R. Ganpate1, R. Crochet1, F. Brunaut1, J. M. Vigneault1; 1ImViMA laboratory, EA 7535, University of Burgundy, Dijon, FRANCE, 2Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6102, Dijon, FRANCE, 3CHU Franois Mitterand, Dijon, FRANCE, 4Georges-François Leclerc Cancer Center, Universite d'Orleans, Dijon, FRANCE, 5Georges-François Leclerc Cancer Center, UMR-CNRS, Dijon, FRANCE.

EP-0931
The effects of 18F-FDG dose reductions on quantification and diagnosis in whole body PET/MRI
Y. Xu1, J. Guo1, F. Li1, C. Li1; Hangzhou University Imaging Diagnostic Center, Hangzhou, CHINA, 2GE HealthcareChina/GE, Hangzhou, CHINA.

EP-0932
Feasibility of Ultra-Low Dose Ultra-High Definition PET/MR for Assessment of ACL Graft Healing
K. Binzel1, C. Karding1, R. Magnusson1, D. C. Flanigan1, B. Sanders2; 1The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA, 2Department of Orthopaedics, University of Cambridge, Cambridge, UNITED KINGDOM.

EP-0933
EPI distortion correction for Lung PET-MRI oncology
F. L. Besson1, B. Fernandez1, S. Faure1, A. Sefran1, O. Mercier1, F. Parent1, S. Buldain1, D. Montani1, S. Mussat1, F. Fadel1, D. Meliot1, E. Blanchet1, A. Chetouani1, F. Boudjena1, H. Chenkai1, D. Planchard1, C. Naltet1, C. Le Pechoux1, C. Camellia1, B. Besse1, C. Comtat1, F. Gervais1, V. Lebair1, E. Daurat1; 1Department of Nuclear Medicine Hopitaux Universitaires Paris Sud, AP-HP, Le Kremlin-Bicetre, FRANCE, 2FRM unit UMR8081 Paris Sud-CNRS, Orsay, FRANCE, 3GE Healthcare, Orsay, FRANCE, 4EURS UMR 8081, Université Paris Sud Institut de Mathematique d'Orsay, Orsay, FRANCE, 5Department of respiratory medicine, Hopitaux Universitaires Paris Sud, AP-HP, Le Kremlin-Bicetre, FRANCE, 6Thoracic Oncology Institute, Université Paris-Sud, Hospital Mairie Longjumeau, le Plessis-Robinson, FRANCE, 7Department of Nuclear Medicine, Service hospitalier Frédéric Joliot, Université Paris Sud, CEFA, Orsay, FRANCE, 8Neurosop, CEA, Orsay, FRANCE, 9Thoracic Oncology Institute, Université Paris-Sud, Gustave Roussy, Villejuif, FRANCE, 10MIVI, CEA, Orsay, FRANCE.

EP-0934
Quantitative T1 and T2 mapping for multimodal PET-MRI lung oncology purpose
F. L. Besson1, B. Fernandez1, S. Faure1, A. Guillaud1, A. Vignaud1, O. Mercier1, A. Sefran1, S. Mussat1, E. Blanchet1, D. Meliot1, A. Chetouani1, S. Buldain1, F. Fadel1, D. Montani1, C. Le Pechoux1, D. Mansati1, D. Mantoani1, D. Montrouillet1, A. Levy1, F. Fadel1, D. Planchard1, B. Besse1, F. Gervais1, C. Comtat1, V. Lebair1, E. Daurat1; 1Department of Nuclear Medicine Hopitaux Universitaires Paris Sud, AP-HP, Le Kremlin-Bicetre, FRANCE, 2FRM unit UMR8081 Paris Sud-CNRS, Orsay, FRANCE, 3GE Healthcare, Orsay, FRANCE, 4Laboratoire de mathématiques Université Paris Sud-CNRS, Orsay, FRANCE, 5Moléculaire de l'Université de Bourgogne, UMR CNRS 6213, Université de Bourgogne, Dijon, FRANCE, 6Institut UTINAM, UMR CNRS 6213, Université de Franche-Comté, Besançon, FRANCE, 7MIVI Solutions Ltd, Guildford, UNITED KINGDOM.

EP-0935
Ultra-fast Dynamic Perfusion 18F-NaF PET in Prostate Cancer as Enabled by Digital Photon Counting PET/CT - A Feasibility Demonstration
K. Binzel1, T. Porter1, C. L. Wright1, E. Fadel1, J. P Monk1, D. D. Scott1, D. G. Staven1, J. Haken1, M. V. Knap1; The Ohio State University Wexner Medical Center, Columbus, OH, UNITED STATES OF AMERICA.

EP-0936
Metal artifact reduction in 18F-PSMA-11 PET/MRI for prostate cancer patients with hip joint replacement using multiaquisition variable-resonance image combination
K. Kudura; Nuclear Medicine Department, Zurich, SWITZERLAND.

EP-0937
Technical limitations of 18F-FDG PET/MR in pediatric oncology: Case-based review of false positive findings
K. Hawke1, M. Muhe1, F. Sindel1, A. J. Theruvath1, H. E. Dalkey1; Link, Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

EP-0938
Validation Of Aseptic Filling Process Of A New Automated Dispenser, Karl 100
S. Emery; C. Rémy1, M. Razouk-Cadet1, C. Grangeon-Chopin1, CHU1, Nice, FRANCE.

EP-0939
Technical aspects -> Instrumentation and data analysis -> Instrumentation -> PET/SPECT/CT

EP-0940
Simultaneous Ventilation/Perfusion SPECT Acquisition: Diagnostic Accuracy
N. Gandy; N. Saney1, J. Phillips1, L. M. Perry1, M. Woodward1, K. Walitt8, T. Ham1, D. Gopalan1; Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-0941
Phantom study for activity quantification of 11Lu SPECT/CT imaging
O. Ferrando1, A. Chimeno1, M. Randate1, G. Rambaldi1, F. Foppiano1, A. Ciaramelli1; 1Department of Medical Physics - ASL Spezzano, La Spezia, ITALY, 2Department of Nuclear Medicine - ASL Spezzano, La Spezia, ITALY.
EP-0942 Sensitivity comparison between normal, fast and super-fast Low Dose SPECT/CT in order to localize and discriminate the nature of doubtful findings to complete whole-body bone scintigraphy in cancer patients
A. Farina, R. Bonfiglioli, M. Mascagnani, S. Zoboli, S. Fanti; Nuclear Medicine Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

EP-0943 Fast” SPECT/CT: a new possibility for the assessment of bone metastases as add-on to planar bone scintigraphy. Preliminary study in 31 patients
A. Baena, M. Cruz-Montijano, S. Garcia-Martinez, M. Pagares-Varndell, J. Frene-Macias, M. De Bonilla, F. Partida-Palma, T. Gutierrez-Amares; Hospital Universitario Puerta del Mar, Cadiz, SPAIN, Hospital Universitario Puerta del Mar, Cadiz, SPAIN.

EP-0944 Performance characteristics of $^{185}$Ac-produced gamma and X-rays SPECT imaging with medium-energy collimator
S. Woo, W. Kim, H. Sheen, C. Lee, A. Song, S. Lim, J. Lim; Division of applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, Department of Urology, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0945 Beyond Nema For Modern Spect Cameras
A. Alosaimi, C. Miller, Y. Shimizu, K. Ichikawa, N. Yoshida, K. Debordeaux, L. Bordenave; CHU, Bordeaux, FRANCE.

EP-0946 Dual-isotope Peptide Receptor Radionuclide Therapies with $^{188}$Lu and $^{177}$Lu: Is Quantitative Imaging Possible?
C. Miller; A. Rahimzadeh, A. Cellier; Department of Physics, University of British Columbia, Vancouver, BC, CANADA, Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, CANADA.

EP-0947 Shorter Dynamic Planar Sctintigraphy to Estimate Myocardial $^{177}$Lu-MIBG Washout Rates
Y. Kumakura, Y. Shimizu, K. Akihikawa, N. Yoshida, K. Nishima, Saitama Medical Center, Saitama Medical University, Saitama, JAPAN.

EP-0948 Fast” SPECT/CT: a new possibility for the assessment of bone metastases as add-on to planar bone scintigraphy. Preliminary study in 31 patients
A. Baena, M. Cruz-Montijano, S. Garcia-Martinez, M. Pagares-Varndell, J. Frene-Macias, M. De Bonilla, F. Partida-Palma, T. Gutierrez-Amares; Hospital Universitario Puerta del Mar, Cadiz, SPAIN, Hospital Universitario Puerta del Mar, Cadiz, SPAIN.

EP-0949 A rapid protocol to evaluate myocardial flow reserve with myocardial scintigraphy using CZT camera and Regadenoson
J. Pinyaqui, G. Ceyrat, T. Cuvelhain, H. Dourad, F. Debodebat, L. Bordenave; CHU, Bordeaux, FRANCE.

EP-0950 Evaluation of Veriton$^{360}$ 360° CZT-camera performances for quantitative Dopamine Transporter (DaT) Imaging: a SPECT study based on quality and anthropomorphic phantoms
E. Cassol, P. Garette, P. Payau, Department of Nuclear Medicine, University Hospital of Toulouse Purpan, Toulouse, FRANCE, TSGC, Toulouse Neuroimaging Center, Toulouse University, Inserm, Toulouse, FRANCE.

EP-0951 Impact of acquisition and reconstruction parameters on cardiac perfusion imaging using the new 360° CZT VERITON camera
A. Manrique, A. Bouthib, B. Enlazar, P. Tager, C. N’Ganoa, H. Kertesz, I. Rausch, D. Agostini, ToNIC Toulouse

EP-0952 GATE-based simulations of the performance of the Symbia Intevo SPECT/CT system for evaluating novel image reconstruction algorithms
H. Kertesz, N. Demiava, M. Ondar, J. Cal-Gonzalez, J. Kraus, P. Schaffarcik, T. Bayerer; QM Team, Center for Medical Physics and Biomedical Engineering, Vienna, AUSTRIA, Whistansoow Institute of Theoretical and Applied Mechanics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, RUSSIAN FEDERATION, Novosibirsk State Technical University, Novosibirsk, RUSSIAN FEDERATION.

EP-0953 Head to head comparison of General Electric Swithinbank solution versus Siemens Symbia in bone scintigraphy on Nal-camera
M. Bailly, F. Thibault, G. Le Roux, G. Mattrand, CHR Orleans, Orleans, FRANCE.

EP-0954 Effects of acquisition time, energy window width and matrix size on image quality in bone SPECT acquired using a general-purpose CZT gamma camera
S. Arvola, M. Seppänen, T. Noponen; Department of Nuclear Medicine, Turku University Hospital, Turku, FINLAND, Turku PET Centre, Turku, FINLAND, Department of Medical Physics, Turku University Hospital, Turku, FINLAND.

EP-0955 Monte Carlo simulations of pre-clinical SPECT systems with $^{99m}$Tc and $^{188}$Lu resources
M. Belli, K. Van Heder, T. Cardinaels, S. Vandenberghen; SCKCEN, Mol, BELGIUM, Ghent University, Ghent, BELGIUM, KU Leuven, Leuven, BELGIUM.

EP-0956 Image quality and SUV accuracy evaluation of bone SPECT/CT imaging using new available techniques: $^{x}$SPECT Bone$^{x}$ and $^{x}$SPECT Quant$^{x}$
V. Moran, P. Aguilar, E. Pretor, E. Gallén, L. Sanchez, J. Richter, J. Martí-Clementi; Clinica Universidad De Navarra, Madrid, SPAIN, Clinica Universidad De Navarra, Pamplona, SPAIN.

EP-0957 Synthetic planar bone scans reprojected from SPECT/CT data have better image quality than original planar bone scans
S. Arvola, A. Sohnberg, M. Seppänen, T. Noponen; Department of Nuclear Medicine, Turku University Hospital, Turku, FINLAND, Laboratory of Clinical Physiology and Nuclear Medicine, Joint Authority for Pajatu-Hame Social and Health Care, Lahti, FINLAND, Turku PET Centre, Turku, FINLAND, Department of Medical Physics, Turku University Hospital, Turku, FINLAND.

EP-0958 Effect of reconstruction iterations on the SUVs of $^{111}$In-HDP SPECT/CT
S. Arvola, J. Jambor, M. Seppänen, T. Noponen; Department of Nuclear Medicine, Turku University Hospital, Turku, FINLAND, Department of Diagnostic Radiology, University of Turku, Turku, FINLAND, Turku PET Centre, Turku, FINLAND, Department of Medical Physics, Turku University Hospital, Turku, FINLAND.

EP-0959 Feasibility and time reduction of 1-123 MIBG planar imaging using a CZT-based whole-body camera: phantom study, and clinical study for patients with suspected or known Lewy body diseases
N. Okano, J. Osawa, S. Tsuchihashi, N. Fukushina, J. Rui, J. Matsunari; Department of Radiology, Saitama Medical University Hospital, Saitama, JAPAN, Department of Nuclear Medicine, International Medical Center, Saitama Medical University, Saitama, JAPAN, Division of Nuclear Medicine, Department of Radiology, Saitama Medical University Hospital, Saitama, JAPAN.

EP-0960 Comparison Of The Quality Of Brain Images Obtained With $^{99m}$Tc-HMPAO Acquired Using Either The Veriton 360° CTA Camera Or A Conventional Anger Camera, And With An “$^{18}$F-FDG Analog PET System
M. Bordonne, M. Chawki, T. Zaragori, V. Reich, R. Grignon, G. Kracher, P. Marie, L. Umbert, A. Verget; CHRU Nancy, Nuclear Medicine Department, Vandoeuvre les Nancy, FRANCE.

H. Sachani; Narayana Hrudayalaya, Bangalore, INDIA.

EP-0962 Comparing the use of IQ-SPECT versus LEHR-SPECT on the influence of abdominal radiotracer uptake in myocardial perfusion SPECT-CT
A. de Vries, J. van Rijn, J. E. Huybrechts; Gelre Hospitals, Apeldoorn, NETHERLANDS.
EP-0903 A whole-body bone SPECT of a high quality may be recorded in less than 20 minutes with the Veriton 360° CZT-camera


EP-0964 Diagnostic performance of 360° CZT SPECT compared to a conventional camera in lung perfusion scintigraphy

K. Anindita, K. Drivcart, B. Mahdad, K. Dayen, F. Rouzet1,2; *Inserm 1144*, Paris Didier University, Paris, FRANCE, 1*EYENAM Paris Tech*, Paris, FRANCE, 2*Paris Didier University, Paris, FRANCE*, Department of Nuclear Medicine, Bichat Claude Bernard University Hospital, APHP Paris, FRANCE.

EP-72 Technical aspects -> Radiation protection and dosimetry -> Dosimetry and radiobiology -> Clinical studies -> Clinical and dosimetry

Displayed throughout the congress days: *e-Poster Area*

EP-0965 Dosimetric aspects with TL dosimetry in 99mTc-radiobiology -> Clinical studies -> Clinical and dosimetry

Karcher, P. Saletti; Nanocoll lymphoscintigraphy in pregnant women Dosimetric aspects with TL dosimetry in 99mTc-radiobiology -> Clinical studies -> Clinical and dosimetry

F. Rouzet1,2; *Inserm 1144*, Paris Didier University, Paris, FRANCE, 1*EYENAM Paris Tech*, Paris, FRANCE, 2*Paris Didier University, Paris, FRANCE*, Department of Nuclear Medicine, Bichat Claude Bernard University Hospital, APHP Paris, FRANCE.

EP-0966 Establishment of National DRL for CT in Hybrid Imaging Studies "The First National NM CT (PET) Dose Audit for Kw population"

M. Masaomi1, A. Shamen2, A. Shammer1, M. Libhman1, J. Fanevanyo Hospital - Kuwait, 3 Mubarak Al Kabeer Hospital - Kuwait, 4 J. A. Jaha Hospital - Kuwait, 5 J. C. Ocampo Ramos - Hospital Federico Laredo Brú - Panama, 6 E. Mora-Ramírez1; *Universidad Nacional, Colombia*, 2*Misión de Fuerzas Armadas Nacionales, Colombia*, 3*Hospital Universitario de Bielsa*, 4*Hospital Universitario Virgen de las Nieves*, 5*King Saud University*, 6*Universidad de Costa Rica, Escuela de Fisica, OCAUNAM*, San Jose, COSTA RICA.

EP-0969 Assessment the activity incorporated by the patient's caregivers after iodine-131 therapy


EP-73 Technical aspects -> Radiation protection and dosimetry -> Dosimetry and radiobiology

Displayed throughout the congress days: *e-Poster Area*

EP-0971 The Evaluation of Bone Marrow Suppression and Secondary Malignancy Risk after Radioiodine Treatment in Patients with Thyroid Cancer after 10 Years Follow Up

K. Toplutas, S. Sager, R. Ulu, B. Kiliç, S. Asa, S. Khosrostchakh, M. Sayman, J. Ulu, K. Somuncuoglu; *Istanbul University, Cerrahpaşa Medical Faculty Department of Nuclear Medicine, Istanbul, TURKEY*.

EP-0974 Personal dose equivalent $H_{eff}(10)$ in patient’s family members after $^{131}I$ therapy in thyroid cancer and benign thyroid diseases


EP-0975 Radiation Exposure to Carers and Comforters from patients undergoing $^{131}I$-FDG PET/CT

E. Kalogianii1, O. Levrat, N. Henghjty, S. Soares, A. Cheetham, B. Corcoran, N. Mathalland, M. Vadrucci, G. Vianon; *King’s College Hospital*, London, UNITED KINGDOM.

EP-0977 Life quality improvement in Pediatric Patients submitted to Radiiodine Therapy for a return to daily life As Fast As Reasonably Achievable

M. Pizzoferro1, C. Pizzera2, B. Casarino3, M. F. Villani1, M. Longo, G. Gentovese4, A. Castellano2, A. Guzzetti, M. C. Gangarossa, *Nuclear Medicine Unit, Bambino Gesù Children's Hospital-BIHFCS, Rome, ITALY*, Medical Physics Unit, Bambino Gesù Children's Hospital-BIHFCS, Rome, ITALY, 2*Ionicology Unit, Bambino Gesù Children's Hospital-BIHFCS, Rome, ITALY*, 3*Endocrine Unit, Bambino Gesù Children's Hospital-BIHFCS, Rome, ITALY*.

EP-0978 Optimal shielding specification for $^{131}I$-Gallium - validation by Monte Carlo Simulations and Empirical Measurements

A. McCann1,2, S. Courrard3, A. Dowling, M. Maguire, R. P. Kilren, J. Lucey, L. J. Vintor1,2; *UCD-SVH PET CT Research Center, St. Vincent's University Hospital*, Dublin, IRELAND, 1*School of Physics, University College Dublin*, Dublin, IRELAND.

EP-0979 External radiation exposure to the patient's environment after treatment with Cu-67 SARITATE

J. Preston1, E. Lengyelová, C. Biggin, M. Parker, M. Hains, E. van Dam1, E. Bailey, B. Bailey, G. Schenker, C.严密 Pharmaceuticals, Epping, AUSTRALIA, 2*Royal North Shore Hospital*, St Leonards, AUSTRALIA.

EP-0980 Developing of a quantitative annual risk assessment model for Nuclear Medicine: simulating radiation doses to hospital staff cohorts and members of the public

S. Courname1, M. McKirdle, J. McCruon; St Vincent's University Hospital, Dublin 4, IRELAND.

EP-0982 Evolution and evaluation of effective dose in the context of diagnostic nuclear medicine

EP-0980 Comparison of correction factors for assessment of skin exposure of workers’ hands in specific operations with selected radiopharmaceuticals

J. Hudzietzova, M. Fulop, J. Sahal, J. Doležal, J. Kubinová, D. Krah, P. Pávnik, A. Vondrák, E. Faltánová; Czech Technical University in Prague, Kladno, CZECH REPUBLIC, Slovak Medical University, Bratislava, SLOVAKIA, Faculty of Security Management PRCH, Prague, CZECH REPUBLIC, Department of Nuclear Medicine, Hospital Frankfurt, Department of Nuclear Medicine, University Hospital Hradec Králové, Hradec Králové, CZECH REPUBLIC, IZOTOCENTRUM, s.r.o, Nitra, SLOVAKIA, Department of Nuclear Medicine, University Hospital Ostrava, Ostrava, CZECH REPUBLIC, PET centre BCNIT, s.r.o, Bratislava, SLOVAKIA, IZOTOCENTRUM, s.r.o, Bratislava, SLOVAKIA, LEBA, University of Economics in Bratislava, Bratislava, SLOVAKIA.

EP-0981 Comparison of eye lens and hand skin exposures during handling of 99mTc and 68Ga radiopharmaceuticals

M. Fulop, J. Hudzietzova, J. Sahal, P. Pávnik, A. Vondrák, E. Faltánová; Slovak Medical University, Bratislava, SLOVAKIA, Czech Technical University in Prague, Kladno, CZECH REPUBLIC, Faculty of Security Management PRCH, Prague, CZECH REPUBLIC, IZOTOCENTRUM, s.r.o, Nitra, SLOVAKIA, LEBA, University of Economics in Bratislava, Bratislava, SLOVAKIA.

EP-0982 Incorporation Of 111Lu During Care Of 111Lu-PSMA And 177Lu-DOTATATE Therapy Patients


EP-0983 Iodine 131 Excretion In Saliva And Bronchial Secretion In Differentiated Thyroid Carcinoma

B. Bockisch, A. Sauter, M. Ezelt, W. T. Kranert, S. Wagner, A. Sabot, F. Gruenwald, C. Happel; University Hospital Frankfurt, Department of Nuclear Medicine, Frankfurt, GERMANY, Kreisklinikum Darmstadt-Dieburg, Darmstadt, GERMANY, Radiologie Darmstadt, Darmstadt, GERMANY.

EP-0984 CT optimisation and LDRRLs for SPECT/CT in a Paediatric Hospital

E. Morris; A. Rose; E. Easty; L. Bassano; Bart’s Health NHS Trust, London, UNITED KINGDOM, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UNITED KINGDOM.

EP-0985 Challenging Radiopharmaceuticals: The art of not tripping over your feet whilst looking up at the stars

R. Fernandez, A. Nunez, F. Hassan, V. Levinsing, S. J. Allen; Guy’s & St Thomas’ Hospital, London, UNITED KINGDOM.

EP-0986 Management Of Extravasation Of Lutetium 177 Dotatoc

A. C. Bekker, P. F. Stuurman, H. Blume, A. K. Arvencoehaus, Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, DENMARK.

EP-0987 Pattern Of Myocardial 18F-FDG Uptake Related To Radiation Dose Before And After Radiotherapy In Patients With Esophageal Cancer

X. Sha, E. Hart, G. Gong, Y. Yin; Department of Radiation Oncology, Shandong Cancer Hospital and Institute of Radiation Medicine, Shandong First Medical University, Jinan, CHINA, Turku PET Centre, Turku University Hospital, Turku, FINLAND.


J. Ranjan, U. Luchten, Y. Zhao, M. Jüppner, M. Marx, M. Zuhayri; Nuclear Medicine, UKSH, Kiel, GERMANY.

EP-0989 Common Errors and Misconceptions in Radiation Protection

J. Cartes; British Columbia Institute of Technology, Burnaby, BC, CANADA.

EP-0990 Absorbed Dose Estimation To Co-Habitants And Co-Travellers Of Patients Treated With Radioiodine For Differentiated Thyroid Carcinoma

I. Iakovou, E. Hatzirenaou, K. Badaviris, E. Papapanagiotou, A. Zapantis, G. Arapi; 3rd Nuclear Medicine Laboratory, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, GREECE, Medical Physics Department, Papageorgiou General Hospital, Thessaloniki, GREECE, Medical Physics Laboratory, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GREECE.

EP-0991 Radiation Exposure of Nurses Including Eye Lens In PET Facility in Association with Performance Status of Patients

M. Hosono, T. Takahara, Y. Yakushiji, K. Sakaguchi, Y. Tamada, H. Kaida, K. Ishi, Y. Nishimura; Kinki University Faculty of Medicine, Osaka, SAIYAMA, JAPAN.

EP-0992 Radiation safety instructions given to all household contacts significantly reduce radiation exposure from illiterate patients treated with low dose radioactive iodine (I-131)

K. Salman, G. Wageila, A. Bakhr, M. Al-Ezz, M. Mamby; King Abdullah Medical City-Makkah, Makkah, SAUDI ARABIA, King Abdullah Medical City-Makkah (Carcinology Centre), Jeddah, SAUDI ARABIA.

EP-0993 Dosimetric evaluation to medical workers operating in a PET/CT department after the use of in house production of Ga-68 peptides

K. Dalianis, K. Gogos, E. Dikonomou, G. Kollias, R. Efthimiadou, V. Prapartoulou; Medical Physics Department, Hygeia SA, Athens, MAROUSI, GREECE, PET/CT Department, Hygeia SA, Athens, MAROUSI, GREECE.

EP-0994 Absorption of 131I in Ascorbic Acid Following Radioiodine Therapy (RIT).

B. Bockisch, M. Ezelt, A. Sabot, C. Happel, W. T. Kranert, W. Mader, A. Sabot, F. Gruenwald; University Hospital Frankfurt, Department of Nuclear Medicine, Frankfurt, GERMANY, Radiologie Darmstadt, Darmstadt, GERMANY, Kreisklinikum Darmstadt-Dieburg, Darmstadt, GERMANY.

EP-0995 Effective finger dose for the staff performing in house production of 68Ga-PSMA and 68Ga-DOTATOC

K. Dalianis, K. Gogos, G. Kollias, E. Dikonomou, A. Efthimiadou, V. Prapartoulou; Medical Physics Department, Hygeia SA, Athens, MAROUSI, GREECE, PET/CT Department, Hygeia SA, Athens, MAROUSI, GREECE.

EP-0996 Absorption of 131I in Ascorbic Acid Following Radioiodine Therapy (RIT).

B. Bockisch, M. Ezelt, A. Sabot, C. Happel, W. T. Kranert, W. Mader, A. Sabot, F. Gruenwald; University Hospital Frankfurt, Department of Nuclear Medicine, Frankfurt, GERMANY, Radiologie Darmstadt, Darmstadt, GERMANY, Kreisklinikum Darmstadt-Dieburg, Darmstadt, GERMANY.

EP-0997 Rotating duties among nurses to reduce occupational radiation exposure during PET/CT procedures

Y. Nishi, Y. Murata, N. Hayashi, N. Akagi, H. Iwasa, C. Komatsu, M. Hamada, T. Yamagami; Kochi Medical School Hospital, Kochi, JAPAN.

EP-0998 Uptake of I-131 to the thyroid of infant mice administered to mothers and substances affecting the uptake

T. Hongyo, Y. Sawa, Y. Ueda; Osaka University, Suita, JAPAN.

EP-1000 A Useful Pump To Inject Lutathera®

C. Rouet, M. Chassat, C. Blamert, R. Gaston, M. Couturier, A. François, Joubert, Centre Hospitalier Métropole Savoie, Chambery, FRANCE.

EP-1001 Assessment of Occupational Radiation Doses in Different Diagnostic and Interventional Radiology and Molecular Imaging Services

Y. Bouchareb, A. El-Masery, H. Al-Zehemi, A. Al-Razibi, N. Al-Mashmali, A. Al-Hayji, A. Al-Ouhaini; Sultan Qaboos University Hospital, Muscat, OMAN, Sultan Qaboos University Hospital, Muscat, OMAN.

EP-1002 The Quantitative Analysis of Uranium Isotopes in the Urine of an Ammunition Clean-up Worker deployed on Dutch North Sea Islands

F. Klimaschewski, Uranium Medical Research Institute, Llandilo, UK, UNITED KINGDOM.

EP-1003 Absorption of 131I in Ascorbic Acid Following Radioiodine Therapy (RIT).

B. Bockisch, M. Ezelt, A. Sabot, C. Happel, W. T. Kranert, W. Mader, A. Sabot, F. Gruenwald; University Hospital Frankfurt, Department of Nuclear Medicine, Frankfurt, GERMANY, Radiologie Darmstadt, Darmstadt, GERMANY, Kreisklinikum Darmstadt-Dieburg, Darmstadt, GERMANY.
### INDUSTRY PROGRAMME

on the occasion of the 32nd Annual Congress of the European Association of Nuclear Medicine

Barcelona, Spain | October 12 – 16, 2019

<table>
<thead>
<tr>
<th>Satellite Symposia</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 13, 2019</td>
<td>292</td>
</tr>
<tr>
<td>Monday, October 14, 2019</td>
<td>294</td>
</tr>
<tr>
<td>Tuesday, October 15, 2019</td>
<td>296</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>List of Exhibitors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorted by Name</td>
<td>298</td>
</tr>
<tr>
<td>Sorted by Booth No.</td>
<td>304</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exhibition Hall</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 310</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company Profiles</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 312</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Corporate Members</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 382</td>
<td></td>
</tr>
</tbody>
</table>
Satellite Symposia

Sunday, October 13, 2019 | 13:00 - 14:30, Lecture Hall 112, Level P1
Symposium by Bayer AG: Targeted Alpha Therapy with Radium-223: Your Questions Answered
Chairs: Prof. Stefano Fanti (Bologna, Italy)

13:00 – 13:15 Welcome and introduction
Prof. Stefano Fanti (Bologna, Italy)

13:15 – 13:30 Radium-223: the right patient at the right time
Prof. Stefano Fanti (Bologna, Italy)

13:30 – 13:45 Supporting patients to receive maximum benefit from treatment
Prof. Daniel Heinrich (Lørenskog, Norway)

13:45 – 14:05 Achieving operational excellence with radium-223
Prof. Daniel Heinrich (Lørenskog, Norway)

14:05 – 14:15 Over to you: your questions answered
Prof. Joe O’Sullivan (Belfast, Northern Ireland), Dr. Harun Ilhan (Germany)

Sunday, October 13, 2019 | 13:00 - 14:30, Lecture Hall 115, Level P1
Symposium by BTG: Make a Real Difference - Drive HCC Curative Intent Strategies with Personalised Dosimetry
Chairs: Prof. Derek Manas (Newcastle, United Kingdom)

Multidisciplinary Panel
Prof. Eline Deforche (Brussels, Belgium), Dr. Mark Konijneng (Rotterdam, The Netherlands), Prof. Jan Stijnen (Utrecht, The Netherlands)

Clinical and dosimetric considerations for Y-90 glass microspheres: recommendations from an international multidisciplinary working group
Prof. Jan Stijnen (Utrecht, The Netherlands)

The DOSISPHERE study - Bringing the concept of SIRT with TheraspHERE™ to reality and beyond
Prof. Eline Deforche (Brussels, Belgium)

Build a local SIRT community with the right dosimetry tools
Dr. Mark Konijneng (Newcastle, United Kingdom)

SIRT HOT TOPICS! A multidisciplinary panel discussion

Sunday, October 13, 2019 | 13:00 - 14:30, Lecture Hall 116, Level P1
Symposium by Bruker: The Continued Value of Hybrid Imaging in Nuclear Molecular Research
Chairs: Dr. Geoffrey Wainock, Dr. Michael Heidenreich

13:00 – 13:10 Welcome & Introduction
Dr. Wulf-Ingo Jung, Dr. Michael Heidenreich

13:10 – 13:30 Molecular Imaging with pPET/SPECT/CT: An essential tool for clinical translation
Dr. David Vert (Lausanne, Switzerland), Prof. John O. Prior (Lausanne, Switzerland)

13:35 – 13:55 Recent experiences with small-bore simultaneous PET/MR
Peter Caravan, PhD (Charlestown, United States)

14:00 – 14:20 Looking on the bright side of the brain – Integration of molecular quantification and functional neuroimaging
Prof. Rupert Lanzenberger, MD, PhD (Vienna, Austria)

Sunday, October 13, 2019 | 13:00 - 14:30, Lecture Hall 111, Level P1
Symposium by Spectrum Dynamics Medical: Routine Digital Imaging in Nuclear Medicine: Clinical Impact
Chairs: Pr. Denis Agostini, MD, PhD (Caen, France)

D-SPECT: Continuing Innovation in Nuclear Cardiology

360° CZT™ VERITON-CT® Clinical Impact
Performance of 360° CZT VERITON-CT System: Analog to Digital Transition
Clinical Experience with 360° CZT VERITON-CT: Routine Clinical Utilization

Guest Presenters:
Dr. Laetitia Imbert, PhD (Nancy, France)
Pr. Pierre-Yves Maire (Nancy, France)
Pr. Piotr Stomka (United States)
### Symposium by GE Healthcare: Elevating Molecular Imaging for Precision Diagnostics, Therapy and Monitoring

**Chairs:** Prof. Ora Israel (Haifa, Israel)

<table>
<thead>
<tr>
<th>Time</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>13:05 – 13:25</td>
<td>The future role of PET Imaging in Immuno-Oncology</td>
</tr>
<tr>
<td>Prof. Eric O. Aboagye (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>13:25 – 13:45</td>
<td>Current and future perspectives of SPECT quantification</td>
</tr>
<tr>
<td>Dr. John Dickson (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>13:45 – 13:55</td>
<td>Nuclear medicine and prostate cancer management</td>
</tr>
<tr>
<td>Prof. Stefano Fanti (Bologna, Italy)</td>
<td></td>
</tr>
<tr>
<td>13:55 – 14:10</td>
<td>Clinical PET/MR - The Neurologist’s Perspective</td>
</tr>
<tr>
<td>Dr. Stéphane Epelbaum (Paris, France)</td>
<td></td>
</tr>
<tr>
<td>14:10 – 14:25</td>
<td>The future role of PET Imaging in Immuno-Oncology</td>
</tr>
<tr>
<td>Prof. Eric O. Aboagye (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>14:25 – 14:30</td>
<td>Current and future perspectives of SPECT quantification</td>
</tr>
<tr>
<td>Dr. John Dickson (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>Nuclear medicine and prostate cancer management</td>
</tr>
<tr>
<td>Prof. Stefano Fanti (Bologna, Italy)</td>
<td></td>
</tr>
<tr>
<td>14:45 – 14:55</td>
<td>Clinical PET/MR - The Neurologist’s Perspective</td>
</tr>
<tr>
<td>Dr. Stéphane Epelbaum (Paris, France)</td>
<td></td>
</tr>
</tbody>
</table>

### Symposium by Siemens Healthineers: Digitalizing Healthcare with Molecular Imaging

**Chairs:** Bruce Spottiswoode, Ph.D. (Knoxville, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>13:05 – 13:25</td>
<td>Defining the clinical value of quantitative SPECT/CT</td>
</tr>
<tr>
<td>Prof. Torsten Kuwert (Erlangen, Germany), Dr.-Ing. Philipp Ritt (Erlangen, Germany)</td>
<td></td>
</tr>
<tr>
<td>13:25 – 13:40</td>
<td>Improved accuracy and performance on Biograph Vision™</td>
</tr>
<tr>
<td>Prof. Pierre-Yves Salaru (Brest, France)</td>
<td></td>
</tr>
<tr>
<td>13:40 – 13:55</td>
<td>Improved accuracy and performance on Biograph Vision™</td>
</tr>
<tr>
<td>Prof. Pierre-Yves Salaru (Brest, France)</td>
<td></td>
</tr>
<tr>
<td>13:55 – 14:10</td>
<td>Improved clinical outcomes for mNET patients using SIRT after PRRT</td>
</tr>
<tr>
<td>Dr. A. Britz</td>
<td></td>
</tr>
</tbody>
</table>

### Symposium by Terumo Interventional Systems: Holmium SIRT - The First Complete, Innovative Solution with Promising Combinations

**Chairs:** Prof. M Lam, Dr. C. Chiesa

<table>
<thead>
<tr>
<th>Time</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:15</td>
<td>Accurate personalised dosimetry is the future of SIRT</td>
</tr>
<tr>
<td>Dr. C. Chiesa</td>
<td></td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>How does QuiremSpheres® integrated with QuiremScout® and Q-Suite™ help advance treatment planning and patient selection in SIRT</td>
</tr>
<tr>
<td>Dr. I. Barghi &amp; Dr. G. Boni</td>
<td></td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Improving clinical outcomes for mNET patients using SIRT after PRRT</td>
</tr>
<tr>
<td>Dr. A. Britz</td>
<td></td>
</tr>
<tr>
<td>13:45 – 13:55</td>
<td>Investing in the future of SIRT</td>
</tr>
<tr>
<td>Prof. M Lam</td>
<td></td>
</tr>
<tr>
<td>13:55 – 14:10</td>
<td>Open panel discussion</td>
</tr>
<tr>
<td>14:10 – 14:25</td>
<td>Session Summary and Close</td>
</tr>
<tr>
<td>Dr. C. Chiesa</td>
<td></td>
</tr>
</tbody>
</table>
Symposium by Advanced Accelerator Applications, a Novartis company: How has Theragnostics Changed the Management of Patients with GEP-NETs?

Chairs: Prof. Ken Herrmann (Essen, Germany)

Welcome and introduction
Prof. Ken Herrmann (Essen, Germany)

Selecting patients suitable for 177Lu-oxodotreotide treatment
Lisa Bodei

Considerations for treatment administration
Ken Herrmann

Exploring the 177Lu-oxodotreotide safety profile
Christos Toumpanakis

Understanding efficacy data from NETTER-1 and the impact on quality of life
Philippe Ruszniewski

Question & answer session
### List of Exhibitors (A – Z)

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6th Theranostics World Congress/Oncidium Foundation</td>
<td>35</td>
</tr>
<tr>
<td>A.C.O.M. Advanced Center Oncology Macerata S.r.l.</td>
<td>98</td>
</tr>
<tr>
<td>ABX GmbH</td>
<td>80</td>
</tr>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>128</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, a Novartis company</td>
<td>57</td>
</tr>
<tr>
<td>Advanced Cyclotron Systems Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Advancing Nuclear Medicine, with NIRI &amp; Partners</td>
<td>50</td>
</tr>
<tr>
<td>AIMN – Italian Association of Nuclear Medicine</td>
<td>SV9</td>
</tr>
<tr>
<td>AMPLITUDEUDA</td>
<td>124</td>
</tr>
<tr>
<td>ANMI SA</td>
<td>72</td>
</tr>
<tr>
<td>Antaya Science &amp; Technology</td>
<td>9</td>
</tr>
<tr>
<td>ANZSNM - Australian and New Zealand Society of Nuclear Medicine</td>
<td>SV23</td>
</tr>
<tr>
<td>AOFNMB - Asia Oceania Federation of Nuclear Medicine and Biology</td>
<td>SV11a</td>
</tr>
<tr>
<td>Arronax</td>
<td>94</td>
</tr>
<tr>
<td>ARTMS Products Inc.</td>
<td>78</td>
</tr>
<tr>
<td>ASNC - American Society of Nuclear Cardiology</td>
<td>SV24</td>
</tr>
<tr>
<td>Atlante Biotherapies</td>
<td>94</td>
</tr>
<tr>
<td>att, Applied Theranostics GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Bayer AG</td>
<td>49b</td>
</tr>
<tr>
<td>Becquerel &amp; Serviet Co. Ltd.</td>
<td>37</td>
</tr>
<tr>
<td>Berthold Technologies GmbH</td>
<td>112</td>
</tr>
<tr>
<td>Best Cyclotron Systems Ltd. / Best ABT</td>
<td>5</td>
</tr>
<tr>
<td>Biodev Medical Systems, Inc.</td>
<td>122</td>
</tr>
<tr>
<td>BIOEMTECH</td>
<td>13</td>
</tr>
<tr>
<td>Blue Earth Diagnostics Ltd.</td>
<td>10</td>
</tr>
<tr>
<td>BNMS - British Nuclear Medicine Society</td>
<td>SV5</td>
</tr>
<tr>
<td>Bracco Diagnostics Inc.</td>
<td>102</td>
</tr>
<tr>
<td>Bruker Biophyn</td>
<td>63</td>
</tr>
<tr>
<td>BTG – Boston Scientific</td>
<td>100</td>
</tr>
<tr>
<td>BV Cyclotron VU</td>
<td>83</td>
</tr>
<tr>
<td>Cambridge Isotope Laboratories, Inc.</td>
<td>137</td>
</tr>
<tr>
<td>CANM – Canadian Association of Nuclear Medicine</td>
<td>SV25</td>
</tr>
<tr>
<td>Capnec, Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Chezatec</td>
<td>94</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>34</td>
</tr>
<tr>
<td>China Isotope &amp; Radiation Corporation</td>
<td>21</td>
</tr>
<tr>
<td>Cisbio</td>
<td>132</td>
</tr>
<tr>
<td>Clarity Pharmaceuticals</td>
<td>32</td>
</tr>
<tr>
<td>CLERAD</td>
<td>47</td>
</tr>
<tr>
<td>CMR - Center of Molecular Research</td>
<td>108</td>
</tr>
<tr>
<td>CMR Molecular Imaging</td>
<td>36</td>
</tr>
<tr>
<td>COMECER</td>
<td>89</td>
</tr>
<tr>
<td>Croatian Society of Nuclear Medicine</td>
<td>SV6</td>
</tr>
<tr>
<td>Crystal Photonics</td>
<td>1</td>
</tr>
<tr>
<td>CSNM - Chinese Society of Nuclear Medicine</td>
<td>SV22</td>
</tr>
<tr>
<td>ČSNM - Czech Society of Nuclear Medicine</td>
<td>SV3</td>
</tr>
<tr>
<td>Curium</td>
<td>54</td>
</tr>
<tr>
<td>Cyclomedica Europe Ltd.</td>
<td>84</td>
</tr>
<tr>
<td>DDO-Diagnostic A/S</td>
<td>113</td>
</tr>
<tr>
<td>DGN e.V. - German Society of Nuclear Medicine</td>
<td>SV10</td>
</tr>
<tr>
<td>Diverse SA</td>
<td>74</td>
</tr>
<tr>
<td>dXit s.r.l.</td>
<td>14</td>
</tr>
<tr>
<td>Dongcheng Pharmaceutical</td>
<td>123</td>
</tr>
<tr>
<td>DOSYS</td>
<td>109</td>
</tr>
<tr>
<td>DSD Pharma GmbH</td>
<td>83</td>
</tr>
<tr>
<td>EANM – Patient &amp; Public Involvement</td>
<td>SV14</td>
</tr>
<tr>
<td>e²C Software Solutions</td>
<td>130</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler Strahlen- und Medizintechnik AG</td>
<td>53</td>
</tr>
<tr>
<td>Eczacibasi-Monrol Nuclear Products Co.</td>
<td>111</td>
</tr>
<tr>
<td>EFRS - European Federation of Radiographer Societies</td>
<td>SV13</td>
</tr>
<tr>
<td>ETA - European Isotopes Transport Association</td>
<td>48</td>
</tr>
<tr>
<td>Elysa-raytest</td>
<td>70</td>
</tr>
<tr>
<td>Epsilon Radioactive Sources· ERS</td>
<td>17</td>
</tr>
<tr>
<td>Euromedical Instruments</td>
<td>83</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>69</td>
</tr>
<tr>
<td>Global Morpho Pharma SAS</td>
<td>101</td>
</tr>
<tr>
<td>Hermes Medical Solutions</td>
<td>88</td>
</tr>
<tr>
<td>Hidex Oy</td>
<td>96</td>
</tr>
</tbody>
</table>

**List of Exhibitors**

**Industry Programme**

**List of Exhibitors**
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOY Scandinavian ApS</td>
<td>83</td>
</tr>
<tr>
<td>HSNMM&amp;MI - Hellenic Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV18</td>
</tr>
<tr>
<td>Huayi Isotopes Co.</td>
<td>22</td>
</tr>
<tr>
<td>IAEA - International Atomic Energy Agency</td>
<td>SV17</td>
</tr>
<tr>
<td>JASON GmbH</td>
<td>81</td>
</tr>
<tr>
<td>IBA</td>
<td>55</td>
</tr>
<tr>
<td>IDI Holland bv</td>
<td>57</td>
</tr>
<tr>
<td>ImoGamma Ltd</td>
<td>11</td>
</tr>
<tr>
<td>Institute of Isotopes Co. Ltd</td>
<td>68</td>
</tr>
<tr>
<td>Inter Medical Medizintechnik GmbH</td>
<td>105</td>
</tr>
<tr>
<td>INVI Medical Imaging Solutions</td>
<td>6</td>
</tr>
<tr>
<td>Inviro</td>
<td>12</td>
</tr>
<tr>
<td>inviscan</td>
<td>2</td>
</tr>
<tr>
<td>Institut de Radiofarmacia Aplicada de Barcelona (IRAB)</td>
<td>25</td>
</tr>
<tr>
<td>iPHASE technologies</td>
<td>29</td>
</tr>
<tr>
<td>IRE ELIT</td>
<td>71</td>
</tr>
<tr>
<td>Isotopia Molecular Imaging Ltd.</td>
<td>77</td>
</tr>
<tr>
<td>ITEL Telecomunicazioni</td>
<td>44</td>
</tr>
<tr>
<td>ITM Isotopen Technologien München AG</td>
<td>95</td>
</tr>
<tr>
<td>JSC Isotope / Rusatom Healthcare</td>
<td>103</td>
</tr>
<tr>
<td>JSNM - Japanese Society of Nuclear Medicine</td>
<td>SV16</td>
</tr>
<tr>
<td>jubilant DraxImage Inc.</td>
<td>76</td>
</tr>
<tr>
<td>Keosys</td>
<td>94</td>
</tr>
<tr>
<td>LabLogic Systems Ltd.</td>
<td>96</td>
</tr>
<tr>
<td>LaCalhene</td>
<td>18</td>
</tr>
<tr>
<td>Lerner Pax</td>
<td>94</td>
</tr>
<tr>
<td>Life Healthcare</td>
<td>52</td>
</tr>
<tr>
<td>Lynax s.r.o.</td>
<td>24</td>
</tr>
<tr>
<td>M&amp;I Materials Ltd (Wolfmet Tungsten)</td>
<td>83</td>
</tr>
<tr>
<td>MAP Medical Technologies Oy</td>
<td>75</td>
</tr>
<tr>
<td>MDPI Diagnostics</td>
<td>5V24a</td>
</tr>
<tr>
<td>Medi-Radiopharma Ltd.</td>
<td>82</td>
</tr>
<tr>
<td>Medisys</td>
<td>66/67</td>
</tr>
<tr>
<td>Medisystem</td>
<td>94</td>
</tr>
<tr>
<td>MEDraysintell</td>
<td>73</td>
</tr>
<tr>
<td>MedSTEP</td>
<td>5V15</td>
</tr>
<tr>
<td>MedTrace Pharma</td>
<td>49c</td>
</tr>
<tr>
<td>ME medical imaging electronics GmbH</td>
<td>110</td>
</tr>
<tr>
<td>MIlabs BV</td>
<td>134</td>
</tr>
<tr>
<td>MIM Software</td>
<td>59</td>
</tr>
<tr>
<td>Mirada Medical</td>
<td>126</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>107</td>
</tr>
<tr>
<td>MR Solutions Ltd</td>
<td>87</td>
</tr>
<tr>
<td>NICEOSoft</td>
<td>83</td>
</tr>
<tr>
<td>Norgine Ltd</td>
<td>3</td>
</tr>
<tr>
<td>NSNM - Norwegian Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV7</td>
</tr>
<tr>
<td>Nuclear Medicine Europe - The Industry Association</td>
<td>139</td>
</tr>
<tr>
<td>Nuclear Shields BV</td>
<td>85</td>
</tr>
<tr>
<td>Nucler</td>
<td>73</td>
</tr>
<tr>
<td>NUKEM Isotopes GmbH</td>
<td>40</td>
</tr>
<tr>
<td>NUVIA (MED Nuclear-Medizintechnik Dresden)</td>
<td>83</td>
</tr>
<tr>
<td>OGHMB - Austrian Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV1</td>
</tr>
<tr>
<td>OncorBeta GmbH</td>
<td>28</td>
</tr>
<tr>
<td>Oncodesign</td>
<td>34</td>
</tr>
<tr>
<td>ORA-NEPTIS</td>
<td>115</td>
</tr>
<tr>
<td>Pars Isotope Co.</td>
<td>104</td>
</tr>
<tr>
<td>Pepscan Presto BV</td>
<td>97</td>
</tr>
<tr>
<td>Philips</td>
<td>65</td>
</tr>
<tr>
<td>PI Medical Diagnostic Equipment B.V.</td>
<td>83</td>
</tr>
<tr>
<td>PMB-ALCEN</td>
<td>62</td>
</tr>
<tr>
<td>PMOD Technologies Ltd.</td>
<td>61</td>
</tr>
<tr>
<td>POLATOM, Radiosotope Centre of National Centre for Nuclear Research</td>
<td>93</td>
</tr>
<tr>
<td>Polish Society of Nuclear Medicine</td>
<td>SV4</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals, Inc.</td>
<td>91</td>
</tr>
<tr>
<td>Qubitec Health Intelligence, S.L.</td>
<td>8</td>
</tr>
<tr>
<td>RADIOPROTECH</td>
<td>20</td>
</tr>
<tr>
<td>RadQual Global Sources</td>
<td>43</td>
</tr>
<tr>
<td>Rotem GmbH</td>
<td>114</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth No.</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ROTOPIA Pharma GmbH</td>
<td>92</td>
</tr>
<tr>
<td>RoveMed AG - Medical 4 Life</td>
<td>42</td>
</tr>
<tr>
<td>Scannix</td>
<td>73</td>
</tr>
<tr>
<td>Scintomics GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Sedecal Molecular Imaging - SMI</td>
<td>121</td>
</tr>
<tr>
<td>SFMNI - French Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV2</td>
</tr>
<tr>
<td>ShandongMadic Technology Co. Ltd</td>
<td>60</td>
</tr>
<tr>
<td>SHNE Medical Technologies, LLC</td>
<td>23</td>
</tr>
<tr>
<td>Sichuan Tianle Photonics Co., Ltd</td>
<td>19</td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>58</td>
</tr>
<tr>
<td>Sirteq Medical Europe GmbH</td>
<td>86</td>
</tr>
<tr>
<td>SNM India - Society of Nuclear Medicine India</td>
<td>SV21</td>
</tr>
<tr>
<td>SNMMI - Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV20</td>
</tr>
<tr>
<td>Southern Scientific Ltd.</td>
<td>96</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>SV11b</td>
</tr>
<tr>
<td>Sumitomo Heavy Industries, Ltd.</td>
<td>41</td>
</tr>
<tr>
<td>Syntermed, Inc.</td>
<td>39</td>
</tr>
<tr>
<td>SYNTHRA GmbH</td>
<td>49a</td>
</tr>
<tr>
<td>Taiyo Nippon Senso Corporation</td>
<td>30</td>
</tr>
<tr>
<td>Tecnicas Radiologicas S.L.</td>
<td>38</td>
</tr>
<tr>
<td>Tekis Pharmaceuticals Ltd.</td>
<td>72</td>
</tr>
<tr>
<td>Tema Snergie S.p.A.</td>
<td>56</td>
</tr>
<tr>
<td>Terumo Interventional Systems</td>
<td>51</td>
</tr>
<tr>
<td>Theagnostic Ltd</td>
<td>4</td>
</tr>
<tr>
<td>TRAVIS S.A.</td>
<td>79</td>
</tr>
<tr>
<td>Triskem International</td>
<td>94</td>
</tr>
<tr>
<td>TSNM - Turkish Society of Nuclear Medicine</td>
<td>SV12</td>
</tr>
<tr>
<td>U.S. Department of Energy Isotope Program</td>
<td>27</td>
</tr>
<tr>
<td>VANDERWILT Techniques b.v.</td>
<td>83</td>
</tr>
<tr>
<td>Varian Medical Systems International AG</td>
<td>7</td>
</tr>
<tr>
<td>Vent-medis GmbH</td>
<td>90</td>
</tr>
<tr>
<td>Von Gahlen Niederland B.V.</td>
<td>117</td>
</tr>
<tr>
<td>Vortal</td>
<td>73</td>
</tr>
<tr>
<td>Wallonia Export &amp; Investment Agency</td>
<td>73</td>
</tr>
<tr>
<td>WFNMB - World Federation of Nuclear Medicine and Biology</td>
<td>SV17</td>
</tr>
<tr>
<td>WIS - World Infinity Services</td>
<td>73</td>
</tr>
<tr>
<td>Wistpress Medical Bookshop</td>
<td>SV18</td>
</tr>
<tr>
<td>Wuxi Jiangyuan Industrial Technology and Trade Corporation</td>
<td>26</td>
</tr>
<tr>
<td>Zionexa</td>
<td>106</td>
</tr>
</tbody>
</table>
List of Exhibitors (sorted by Booth No.)

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystal Photonics GmbH</td>
<td>1</td>
</tr>
<tr>
<td>inviscan</td>
<td>2</td>
</tr>
<tr>
<td>Norgine Ltd</td>
<td>3</td>
</tr>
<tr>
<td>Theragnostics Ltd</td>
<td>4</td>
</tr>
<tr>
<td>Best Cyclotron Systems Ltd./ Best ABT</td>
<td>5</td>
</tr>
<tr>
<td>INVIA Medical Imaging Solutions</td>
<td>6</td>
</tr>
<tr>
<td>Varian Medical Systems International AG</td>
<td>7</td>
</tr>
<tr>
<td>Qubiatech Health Intelligence, S.L.</td>
<td>8</td>
</tr>
<tr>
<td>Antaya Science &amp; Technology</td>
<td>9</td>
</tr>
<tr>
<td>Blue Earth Diagnostics Ltd.</td>
<td>10</td>
</tr>
<tr>
<td>InnoGamma Ltd</td>
<td>11</td>
</tr>
<tr>
<td>Invicro</td>
<td>12</td>
</tr>
<tr>
<td>BioEMTECH</td>
<td>13</td>
</tr>
<tr>
<td>dXit s.r.l.</td>
<td>14</td>
</tr>
<tr>
<td>Captronic, Inc.</td>
<td>15</td>
</tr>
<tr>
<td>att, Applied Theranostics GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Scintomics GmbH</td>
<td>17</td>
</tr>
<tr>
<td>Epison Radioactive Sources- ERS</td>
<td>18</td>
</tr>
<tr>
<td>LaCalhene</td>
<td>19</td>
</tr>
<tr>
<td>Sichuan Tianle Photonics Co., Ltd.</td>
<td>20</td>
</tr>
<tr>
<td>RADIOPROTECT</td>
<td>21</td>
</tr>
<tr>
<td>China Isotope &amp; Radiation Corporation</td>
<td>22</td>
</tr>
<tr>
<td>Huai Isotopes Co.</td>
<td>23</td>
</tr>
<tr>
<td>SHINE Medical Technologies, LLC</td>
<td>24</td>
</tr>
<tr>
<td>Lynax s.r.o.</td>
<td>25</td>
</tr>
<tr>
<td>Institut de Radiofarmacia Aplicada de Barcelona (IRAB)</td>
<td>26</td>
</tr>
<tr>
<td>Wuxi Jiangyuan Industrial Technology and Trade Corporation</td>
<td>27</td>
</tr>
<tr>
<td>U.S. Department of Energy Isotope Program</td>
<td>28</td>
</tr>
<tr>
<td>Oncolabta GmbH</td>
<td>29</td>
</tr>
<tr>
<td>pHASE technologies</td>
<td>30</td>
</tr>
<tr>
<td>Taiyo Nippon Sanso Corporation</td>
<td>31</td>
</tr>
<tr>
<td>Clarity Pharmaceuticals</td>
<td>32</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>33</td>
</tr>
<tr>
<td>Oncodesign</td>
<td>34</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6th Theranostics World Congress/Oncidium Foundation</td>
<td>35</td>
</tr>
<tr>
<td>CMR Molecular Imaging</td>
<td>36</td>
</tr>
<tr>
<td>Becquereul &amp; Sievert Co., Ltd.</td>
<td>37</td>
</tr>
<tr>
<td>Tecnicas Radiofisicas S.L.</td>
<td>38</td>
</tr>
<tr>
<td>Syntermed, Inc.</td>
<td>39</td>
</tr>
<tr>
<td>NUKEM Isotopes GmbH</td>
<td>40</td>
</tr>
<tr>
<td>Sumitomo Heavy Industries, Ltd.</td>
<td>41</td>
</tr>
<tr>
<td>RoveMed AG - Medical 4 Life</td>
<td>42</td>
</tr>
<tr>
<td>RadDual Global Sources</td>
<td>43</td>
</tr>
<tr>
<td>ITEL Telecomunicazioni</td>
<td>44</td>
</tr>
<tr>
<td>CHERAD</td>
<td>45</td>
</tr>
<tr>
<td>IEIA - European Isotopes Transport Association</td>
<td>46</td>
</tr>
<tr>
<td>SYNT-HRA GmbH</td>
<td>47</td>
</tr>
<tr>
<td>Bayer AG</td>
<td>48</td>
</tr>
<tr>
<td>MedTrace Pharma</td>
<td>49</td>
</tr>
<tr>
<td>Advancing Nuclear Medicine, with NRG &amp; Partners</td>
<td>50</td>
</tr>
<tr>
<td>Terumo Interventional Systems</td>
<td>51</td>
</tr>
<tr>
<td>Life Healthcare</td>
<td>52</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler Strahlen- und Medizintechnik AG</td>
<td>53</td>
</tr>
<tr>
<td>Curium</td>
<td>54</td>
</tr>
<tr>
<td>InA</td>
<td>55</td>
</tr>
<tr>
<td>Tema Snergie S.p.A</td>
<td>56</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, a Novartis company</td>
<td>57</td>
</tr>
<tr>
<td>DDR Holland bv</td>
<td>57</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>58</td>
</tr>
<tr>
<td>MIM Software</td>
<td>59</td>
</tr>
<tr>
<td>ShandongMedic Technology Co., Ltd.</td>
<td>60</td>
</tr>
<tr>
<td>PMOD Technologies Ltd</td>
<td>61</td>
</tr>
<tr>
<td>PMB-ALCEIN</td>
<td>62</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>63</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Philips</td>
<td>65</td>
</tr>
<tr>
<td>Mednovo</td>
<td>66/67</td>
</tr>
<tr>
<td>Institute of Isotopes Co. Ltd.</td>
<td>68</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth No.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>69</td>
</tr>
<tr>
<td>Elysia-raytest</td>
<td>70</td>
</tr>
<tr>
<td>IRE ELIT</td>
<td>71</td>
</tr>
<tr>
<td>ANW1 SA</td>
<td>72</td>
</tr>
<tr>
<td>Telix Pharmaceuticals Ltd.</td>
<td>72</td>
</tr>
<tr>
<td>MEDaysintell</td>
<td>73</td>
</tr>
<tr>
<td>Nucleus</td>
<td>73</td>
</tr>
<tr>
<td>Scannix</td>
<td>73</td>
</tr>
<tr>
<td>Vortal</td>
<td>73</td>
</tr>
<tr>
<td>Wallonia Export &amp; Investment Agency</td>
<td>73</td>
</tr>
<tr>
<td>WIS - World Infinity Services</td>
<td>73</td>
</tr>
<tr>
<td>Diasource SA</td>
<td>74</td>
</tr>
<tr>
<td>MAP Medical Technologies Oy</td>
<td>75</td>
</tr>
<tr>
<td>Jubilant DraxImage Inc.</td>
<td>76</td>
</tr>
<tr>
<td>Isotopia Molecular Imaging Ltd.</td>
<td>77</td>
</tr>
<tr>
<td>ARTMS Products Inc.</td>
<td>78</td>
</tr>
<tr>
<td>TRASIS S.A.</td>
<td>79</td>
</tr>
<tr>
<td>ABX GmbH</td>
<td>80</td>
</tr>
<tr>
<td>JASON GmbH</td>
<td>81</td>
</tr>
<tr>
<td>Medi-Radiopharma Ltd.</td>
<td>82</td>
</tr>
<tr>
<td>BV Cyclotron VI</td>
<td>83</td>
</tr>
<tr>
<td>DSD Pharma GmbH</td>
<td>83</td>
</tr>
<tr>
<td>Euromedical Instruments</td>
<td>83</td>
</tr>
<tr>
<td>HOY Scandinavian ApS</td>
<td>83</td>
</tr>
<tr>
<td>M&amp;B Materials Ltd. (Wolfmet Tungsten)</td>
<td>83</td>
</tr>
<tr>
<td>NICESOFT</td>
<td>83</td>
</tr>
<tr>
<td>NUVA (MCD Nuklear-Medizintechnik Dresden)</td>
<td>83</td>
</tr>
<tr>
<td>PI Medical Diagnostic Equipment B.V.</td>
<td>83</td>
</tr>
<tr>
<td>VANDERWALT techniques b.v.</td>
<td>83</td>
</tr>
<tr>
<td>Cyclomedica Europe Ltd.</td>
<td>84</td>
</tr>
<tr>
<td>Nuclear Shields BV</td>
<td>85</td>
</tr>
<tr>
<td>Sirex Medical Europe GmbH</td>
<td>86</td>
</tr>
<tr>
<td>MR Solutions Ltd.</td>
<td>87</td>
</tr>
<tr>
<td>Hermes Medical Solutions</td>
<td>88</td>
</tr>
<tr>
<td>COMECER</td>
<td>89</td>
</tr>
<tr>
<td>vent-medis GmbH</td>
<td>90</td>
</tr>
<tr>
<td>Progenics Pharmaceuticals, Inc.</td>
<td>91</td>
</tr>
<tr>
<td>ROTOP Pharmaka GmbH</td>
<td>92</td>
</tr>
<tr>
<td>POLATOM, Radiosotope Centre of National Centre for Nuclear Research</td>
<td>93</td>
</tr>
<tr>
<td>Lerner Pax</td>
<td>94</td>
</tr>
<tr>
<td>Aronax</td>
<td>94</td>
</tr>
<tr>
<td>Atlanpole Biotherapies</td>
<td>94</td>
</tr>
<tr>
<td>Chemetec</td>
<td>94</td>
</tr>
<tr>
<td>Keosys</td>
<td>94</td>
</tr>
<tr>
<td>Medisystem</td>
<td>94</td>
</tr>
<tr>
<td>Triskem International</td>
<td>94</td>
</tr>
<tr>
<td>ITM Isotopen Technologien München AG</td>
<td>95</td>
</tr>
<tr>
<td>HideX Oy</td>
<td>96</td>
</tr>
<tr>
<td>LabLogic Systems Ltd.</td>
<td>96</td>
</tr>
<tr>
<td>Southern Scientific Ltd.</td>
<td>96</td>
</tr>
<tr>
<td>Pepsican Presto BV</td>
<td>97</td>
</tr>
<tr>
<td>A.C.O.M. Advanced Center Oncology Macenata S.r.l.</td>
<td>98</td>
</tr>
<tr>
<td>Advanced Cyclotron Systems Inc.</td>
<td>99</td>
</tr>
<tr>
<td>BTG – Boston Scientific</td>
<td>100</td>
</tr>
<tr>
<td>Global Morpho Pharma SAS</td>
<td>101</td>
</tr>
<tr>
<td>Bracco Diagnostics Inc.</td>
<td>102</td>
</tr>
<tr>
<td>JSC Isotope / Russian Healthcare</td>
<td>103</td>
</tr>
<tr>
<td>Pars Isotope Co.</td>
<td>104</td>
</tr>
<tr>
<td>Inter Medical Medizintechnik GmbH</td>
<td>105</td>
</tr>
<tr>
<td>Zienexa</td>
<td>106</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>107</td>
</tr>
<tr>
<td>CMR - Center of Molecular Research</td>
<td>108</td>
</tr>
<tr>
<td>DOSiSoft SA</td>
<td>109</td>
</tr>
<tr>
<td>MIE medical imaging electronics GmbH</td>
<td>110</td>
</tr>
<tr>
<td>Eczacibasi-Monrol Nuclear Products Co.</td>
<td>111</td>
</tr>
<tr>
<td>Berthold Technologies GmbH</td>
<td>112</td>
</tr>
<tr>
<td>DDD-Diagnostic A/S</td>
<td>113</td>
</tr>
<tr>
<td>Rotem GmbH</td>
<td>114</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth No.</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ORA-NEPTIS</td>
<td>115</td>
</tr>
<tr>
<td>Von Gahlen Nederland B.V.</td>
<td>117</td>
</tr>
<tr>
<td>Sedecal Molecular Imaging - SMI</td>
<td>121</td>
</tr>
<tr>
<td>Biodex Medical Systems, Inc.</td>
<td>122</td>
</tr>
<tr>
<td>Dongcheng Pharmaceutical</td>
<td>123</td>
</tr>
<tr>
<td>AMPLITUDA</td>
<td>124</td>
</tr>
<tr>
<td>Mirada Medical</td>
<td>126</td>
</tr>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>128</td>
</tr>
<tr>
<td>ec2 Software Solutions</td>
<td>130</td>
</tr>
<tr>
<td>Cisbio</td>
<td>132</td>
</tr>
<tr>
<td>IILabs BV</td>
<td>134</td>
</tr>
<tr>
<td>Cambridge Isotope Laboratories, Inc.</td>
<td>137</td>
</tr>
<tr>
<td>Nuclear Medicine Europe - The Industry Association</td>
<td>139</td>
</tr>
<tr>
<td>ÖGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV1</td>
</tr>
<tr>
<td>SFMNN - French Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV2</td>
</tr>
<tr>
<td>ČSNM - Czech Society of Nuclear Medicine</td>
<td>SV3</td>
</tr>
<tr>
<td>Polish Society of Nuclear Medicine</td>
<td>SV4</td>
</tr>
<tr>
<td>BNMS - British Nuclear Medicine Society</td>
<td>SV5</td>
</tr>
<tr>
<td>Croatian Society of Nuclear Medicine</td>
<td>SV6</td>
</tr>
<tr>
<td>NSNM - Norwegian Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV7</td>
</tr>
<tr>
<td>HSNM&amp;MIMI - Hellenic Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV8</td>
</tr>
<tr>
<td>AIMNN - Italian Association of Nuclear Medicine</td>
<td>SV9</td>
</tr>
<tr>
<td>ÖGN e.V. - German Society of Nuclear Medicine</td>
<td>SV10</td>
</tr>
<tr>
<td>AORINMB – Asia Oceania Federation of Nuclear Medicine and Biology</td>
<td>SV11a</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>SV11b</td>
</tr>
<tr>
<td>TSNM - Turkish Society of Nuclear Medicine</td>
<td>SV12</td>
</tr>
<tr>
<td>EPRS - European Federation of Radiographer Societies</td>
<td>SV13</td>
</tr>
<tr>
<td>EANM - Patient &amp; Public Involvement</td>
<td>SV14</td>
</tr>
<tr>
<td>MedSTEP</td>
<td>SV15</td>
</tr>
<tr>
<td>JSNMM - Japanese Society of Nuclear Medicine</td>
<td>SV16</td>
</tr>
<tr>
<td>IAEA - International Atomic Energy Agency</td>
<td>SV17</td>
</tr>
<tr>
<td>WFNMB - World Federation of Nuclear Medicine and Biology</td>
<td>SV17</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>SV18</td>
</tr>
<tr>
<td>SNMNM - Society of Nuclear Medicine and Molecular Imaging</td>
<td>SV20</td>
</tr>
<tr>
<td>SNM India - Society of Nuclear Medicine India</td>
<td>SV21</td>
</tr>
<tr>
<td>CSNM - Chinese Society of Nuclear Medicine</td>
<td>SV22</td>
</tr>
<tr>
<td>ANZSNM - Australian and New Zealand Society of Nuclear Medicine</td>
<td>SV23</td>
</tr>
<tr>
<td>ASNC - American Society of Nuclear Cardiology</td>
<td>SV24</td>
</tr>
<tr>
<td>MDPI Diagnostics</td>
<td>SV24a</td>
</tr>
<tr>
<td>CANM - Canadian Association of Nuclear Medicine</td>
<td>SV25</td>
</tr>
</tbody>
</table>
Regarding 6th Theranostics World Congress (TWC)

We are honored to invite you to join us on March 19-21, 2021 in Santiago, Chile to celebrate the 10th anniversary of TWC. During this international forum encompassing scientific and educational contributions regarding Theranostics, the aim will be to exchange about the remarkable growth of this field, shown by the exponential increase in the number of publications on matters such as new clinical applications, the introduction of promising innovative radiopharmaceuticals and novel radiochemical concepts.

Regarding The Oncidium Foundation

Created in 2011 by Dr. Richard Zimmermann, PhD, The Oncidium Foundation focuses on promoting Radiotheranostics for cancer therapy to accelerate and facilitate global access. The priorities include raising awareness about Radiotheranostics among patients and physicians, investing in research and scholarships, promoting clinical trials and the developments of new radiopharmaceuticals for therapy, supporting clinical best practice and improving access to patients.

ABX GmbH

ABX is the leading manufacturer of PET precursors and peptides as well as reagent kits and cassettes.

An excerpt from our portfolio:
- FDG reagent kits and cassettes for nearly all FDG modules
- Mannose Triflate (DMF US and Europe)
- Cryptand222 (kryptofix)
- F-18 PSMA-1007 precursors, reagents, and cassettes for GE MIX, GE FX, GE FASTlab, OPA NPS, IBA Synthera, Synthetis, and Trisio AIO modules
- Nucleophilic and electrophilic F-DOPA precursors as well as reagents and cassettes
- F-FET, F-Choline, F-MISO, FET, and NAF precursors, reagents, and cassettes
- Comprehensive range of "scientific" precursors for oncology such as Fluorostarol, FAPA... and neurology like Raclopride, Fallypride, PK11195, Flumazenil, beta-CIT, PI... - SPECT precursors, e.g. Cu64MB (DMF US and Europe), MB, ECD
- Peptides, e.g. PSMA-11, DOTA-TOC, DOTA-TATE, and DOTA-NOC for Gallium68 labelling
- Gallium-68 reagents kits and cassettes
- Lu-177 reagents kits and cassettes
- O-18 WATER
- Performance of stability studies
- Development of radionuclides and labelling as well as purification strategies

We are well experienced in GMP productions and also do offer custom syntheses according to Q7 chapter 19 for clinical PET studies (APIs). Our laboratories and clean rooms are GMP certified and meet pharmaceutical standards. We are GMP and ISO13485 certified.

ABX-CRO advanced pharmaceutical services

ABX-CRO is a globally operating clinical research organization with a strong focus on pre-clinical and clinical molecular imaging and molecular radiotherapy.

Based on over 15 years’ experience in diagnostic and therapeutic oncology, neurology and other disease areas, ABX-CRO provides you with unique opportunities to test your drug candidates in complex pre-clinical disease models, assessed quantitatively using molecular and functional imaging (PET, SPECT, CT, MRI). We translate preclinical results into first-in-man studies and support you with design and execution of efficient late stage clinical trials, minimizing your costs and time to marketing authorization. ABX-CRO makes translational medicine a visible reality.

ABX-CRO is very proud to present QDOS©, the only comprehensive dosimetry solution, featuring seamless integration of the new ICRP-endorsed EAC-Dose 2.1 dose calculator enabling anatomically realistic phantom-based dose calculation using the official ICRP Adult Reference Computational Phantoms (CRP).

QDOS© is a comprehensive internal dosimetry software suite for both, systemic and selective internal radiation therapy (IRT). QDOS© is platform-independent, clinically validated, and user-friendly.

It enables state-of-the-art evaluation of safety and efficacy (e.g. tumour) dosimetry.

ABX-CRO, paving your way into the theranostics landscape
Advanced Accelerator Applications, a Novartis company

Advanced Accelerator Applications (AAA), a Novartis company, is developing precision targeted radioligand therapies and diagnostics. Our vision is to transform patients’ lives by leading innovation in nuclear medicine.

We are committed to improving patient management by merging targeted therapeutics and diagnostics (an approach known as theragnostics) to advance assessment, treatment, and monitoring of disease. AAA’s theragnostic platform is based on developing therapeutic and diagnostic drug pairings based on targeting agents with high affinity for specific receptors expressed on tumor cells.

AAA’s first theragnostic pairing includes diagnostic dotatate, approved for use in Europe and the United States, respectively.

Advanced Cyclotron Systems Inc

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 25 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production and distribution of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are the reasons why many of the world’s most prestigious universities and research centres, as well as some of the most successful commercial radiopharmaceutical producers have chosen ACSI cyclotrons to meet their radiopharmaceutical production needs.

For more information, please visit www.advancedcyclotron.com

Advancing Nuclear Medicine by NRG & Partners

A few years ago NRG decided to focus its strategy on the development of new medical isotopes and to extend its activities from irradiation to the preparation of radiochemicals, or radioactive starting materials for the production of radiopharmaceuticals. With this adjusted course we started cooperations with academic medical centres to joint-develop mentioned radiopharmaceuticals, based on promising isotopes.

The identified need of speeding-up the development and enabling affordable projects led to the birth of FIELD-LAB, an innovative joint R&D centre for Nuclear Medicine!

FIELD-LAB aims at accelerating, encouraging and facilitating collaborative innovation projects in the nuclear medicine sector with the goal to develop and introduce the next generation of radiopharmaceutical products to combat serious diseases like cancer. FIELD-LAB’s goals are supported by renowned Dutch Academic Medical Centres and dedicated industry partners, a complete network of academic medical centres to joint-develop materials for the production of radiopharmaceuticals or radioactive starting materials, or radioactive starting materials for the production of radiopharmaceuticals.

For more information, visit www.advancingnuclearmedicine.com

American Society of Nuclear Cardiology - ASNC

For over 25 years, the American Society of Nuclear Cardiology and its more than 4,300 members in the USA and 65 countries worldwide have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development.

ASNC’s members are comprised of cardiologists, radiologists, physicians, scientists, technologists, imaging specialists and other professionals committed to the science and practice of nuclear cardiology. ASNC provides peer-reviewed original articles through its official publication Journal of Nuclear Cardiology and operates the USA’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. Two upcoming ASNC meetings: ASNC’s 25th Annual Scientific Session will be held in Washington, D.C., September 24-27, 2020 and NCToday will be held in the Washington, DC metropolitan area, April 17-19, 2020.

For more information, visit www.asnc.org
ANMI SA is an innovative pharmaceutical company developing novel radiopharmaceutical solutions, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of “theranostic” radiopharmaceuticals and to streamline routine production in hospitals and radio-pharmacies. ANMI’s mission is to increase patient access to new highly specific theranostic radiopharmaceuticals through efficient and cost-effective production processes. ANMI is a wholly-owned subsidiary of Telix Pharmaceuticals.

ARTMS manufactures proprietary, state-of-the-art hardware and disposable target plates to enable the production of high-value radiopharmaceutical isotopes on medical cyclotrons. ARTMS has proven concept, conducted clinical trials and commercialized globally its QUANTM Irradiation System which includes all the necessary hardware, disposable solid target plates, and dissolution products and processing procedures for isotope production. Leveraging initial success of intellectual property developed for producing Technetium-99m (Tc-99m), ARTMS is now expanding commercial operations to other high value isotopes such as Gallium-68 (Ga-68), Zirconium-89 (Zr-89) and Copper-64 (Cu-64).

Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB) was established in 1969 to promote nuclear medicine in Asia and Oceania. AOFNMB’s goal is the achievement of excellence in academic and technological fields of nuclear medicine in Asia Oceania region. AOFNMB congresses have been held every 4 years since the first inaugural congress in Sidney, Australia. Sites of previous congresses were Manila (Philippines), Seoul (Korea), Taipei (Taiwan), Jakarta (Indonesia), Kyoto (Japan), Istanbul (Turkey), Beijing (China), New Delhi (India), Jeju (Korea), Yokohama (Japan) and Shanghai (China) in order of the year. The next AOCNMB will be held in Amman, Jordan, in 2021. We are expecting that many young physicians, technologists, and scientists who are not only in the field of nuclear medicine but also in various other fields will join the AOFNMB and create a future Asia Oceania NM network.

Associazione Italiana di Medicina Nucleare (AIMN). It is the Italian Association of Nuclear Medicine. It is the only representative society of the Italian Nuclear Medicine discipline.
Australian and New Zealand Society of Nuclear Medicine
PO Box 6178
Vermont South
3133 Victoria
1300330402
secretariat@anzsnm.org.au
https://www.anzsnm.org.au/

Founded in 1969, the ANZSNM is the major professional society for those practising Nuclear Medicine in Australia and New Zealand. The Society uniquely includes Technologists, Physicians, Radiopharmacists, Physicians, Nurses, Chemists and others interested in the practice of Nuclear Medicine. It has close ties with other professional groups in Nuclear Medicine, most particularly, the Australasian Association of Nuclear Medicine Specialists (AANMS) which represents all practicing medical doctors, Radiologists, Cardiologists, and Oncologists may also participate and be involved in this area of healthcare.

Berthold Technologies GmbH & Co. KG
Calmbacher Straße 22
75323 Bad Wildbad
+49 7081 177 0
nuclear@berthold.com
http://www.berthold.com

The Berthold radiation protection division supplies advanced and reliable detection technology for measurement of radioactive contamination, dose and dose rate, activity and airborne radioactivity concentrations.

The portfolio ranges from handheld instruments up to large customer-tailored systems for research, nuclear medicine, nuclear energy and decommissioning.

For many decades customers have trusted Berthold to support their efforts in creating a healthier world, a safer environment and more efficient manufacturing processes. Our deep understanding of science combined with leading-edge technology empowers our clients with tools and solutions to pursue the most challenging applications - we improve life in meaningful ways.

Best Cyclotron Systems Ltd. / Best ABT
413 March Road
K2K0E4 Ottawa
613-591-2100
marketing@teambest.com
http://www.bestcyclotron.com

Best Cyclotron Systems, Inc., TeamBest®, through Best Cyclotron Systems, Inc. (BCSI), offers radioscopy and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. BCSI’s mission is to create technology to provide healthcare options for various needs around the world. The company is a subsidiary of Best Medical Internatia, a company renowned in the field of medical instrumentation and radiation therapy.

Cyclotrons are manufactured and tested at Best Theratronics in Ottawa, Ontario, Canada. BCSI is currently focused on five different energy cyclotrons: the 15, 25, 30 and 70 MeV negative hydrogen ion accelerators.

Best ABT Molecular Imaging is a medical imaging company marketing the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT’s investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund. The company is headquartered in Knoxville, Tennessee.

Biodex Medical Systems, Inc.
20 Ramsey Road
11967 Shirley, NY
+1 631.924.9000
info@biodex.com
http://www.biodex.com/nuclearmedicine

Biodex Medical Systems, Inc. continues to support the nuclear medicine and molecular imaging community with various imaging solutions including their Atomlab product line.

The Atomlab™ 500Plus combines the Atomlab™ 500 Dose Calibrator and Wipe Test Counter, offering a cost-effective solution for all of your molecular imaging needs. It’s a complete Hot Lab Management System. The intuitive Atomlab 500Plus provides fast, accurate radionuclide activity measurements with performance that complies with stringent regulatory requirements.

The Atomlab™ 960 Thyroid Uptake System features a unique Positioning LED for accurate thyroid centering – a first in Thyroid Uptake System design. The combination of positioning LED and distance measurement rod assures accurate, repeatable patient positioning and uptake measurements. The optional DICOM Interface integrates the Atomlab 960 with your hospital management system, streamlining workflow and improving communication.

Clear-Lead™ Mobile X-Ray Barriers are designed for use around any imaging procedure using ionizing radiation. They offer durable and shatter resistant protection wherever it’s needed. The unique hourglass contour of the Clear-Lead™ Personal Mobile Barrier provides “hands-on” patient access while providing radiation protection (0.5 mm LE).

The Biodex commitment to innovative excellence spans more than 60 years. Their customer-driven support is why leading medical facilities around the globe call Biodex first.
Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluorine 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. Fluorine 18 has also a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology.

The company’s pipeline includes innovative Prostate Specific Membrane Antigen (PSMA)-targeted radiopharmaceuticals, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging. For more information, visit www.blueearthdiagnostics.com.

Bracco Diagnostics Inc. (BDI), the U.S.-based subsidiary of Bracco Imaging SpA, is part of the Bracco Group, a leader in innovative contrast imaging agents in the U.S. BDI, established in 1994, with headquarters and research offices in Monroe Township, NJ, offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers.

The diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology.

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS represents all craft groups in nuclear medicine and provides advice and guidelines for all those who practice nuclear medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK.

The official journal of the Society is Nuclear Medicine Communications. Officers of the Society: Dr John Buscombe, President, Mrs. Jilly Croasdale, Honorary Treasurer, Dr Richard Graham, President-Elect, Dr Stewart Redman, Honorary Secretary.

At the BNMS booth, delegates can find:

- Information on BNMS membership - discount to new members signing up at the meeting.
- Information about future meetings in the UK
- BNMS Brochures and Publications
- Answers to any other questions regarding the BNMS

Pass by our stand for a chance to win free attendance at our Spring Meeting 2020 which will be held at the ACC Liverpool, UK on 18 - 20 May.
Cambridge Isotope Laboratories, Inc.

137

3 Highwood Drive
1876 Tewksbury
978-251-2841
cilsales@isotope.com
http://www.isotope.com

Cambridge Isotope Laboratories, Inc. (CIL) is one of the world’s leading suppliers of 18O water and the preferred supplier to premier FDG providers.

In response to the increasing needs of the PET community, CIL has undertaken multiple expansions of its 18O separation facility over the past few years. The combined synthetic expertise, cGMP experience and reputation for high-quality cGMP and non-cGMP nuclear medicine compounds and precursors allows CIL and its subsidiary, ABX Advanced Biochemicals, to offer complete PET chemistry solutions for the molecular imaging community. ABX is the leading supplier of PET precursors worldwide and also offers cGMP custom synthesis and development of labeling strategies for new tracers.

To learn more about BTG Interventional Oncology, please visit: btg-io.com.

BTG Interventional Oncology is transforming the way cancer is treated with our wide-ranging solutions of minimally-invasive, highly targeted cancer therapies. We are leaders in developing intelligent, loco-regional treatments that can be personalised to each patient's needs. Our treatments include elegant and innovative new medicines, improved device technology and ground-breaking delivery techniques.

Our products are used to treat and provide symptomatic relief for people with cancer and benign tumours. By specifically targeting diseased cells, we can limit the impact on healthy tissue. Our solutions include embolisation beads, drug-eluting beads, radiotherapy treatment that uses yttrium-90 glass microspheres, and cryoablation delivery systems.

By partnering with the brightest minds in medicine and technology, we are committed to better serving healthcare professionals and delivering improved healthcare for those who deserve it the most, the patients. Healthcare is evolving and at BTG Interventional Oncology we believe intelligent science is the way forward.

To learn more about BTG Interventional Oncology, please visit: btg-io.com.
Capintec Inc.

7 Vreeland Road
7932 Florham Park, NJ
001-201-8259500
getinfo@capintec.com
http://www.capintec.com

Capintec is a leading worldwide supplier of energy measurement products and services. Capintec is dedicated to continuous quality improvement that leads to uncompromising quality in the development of the most advanced technology and services in the industry.

For over 50 years, Capintec has been recognized as a world leader in the development, manufacturing and marketing of state-of-the-art radiation measurement and monitoring instrumentation. With thousands of instruments in use worldwide, the company continually provides new and innovative solutions to radiation measurement applications. By offering products with applications in Nuclear Medicine, Diagnostic Radiology, and Radiation Therapy, the company continues to grow.

Center of Molecular Research (CMR)

Leninsky Prospect 113/1
117198 Moscow

70056572228
sales@isotope-cmr.com
http://www.isotope-cmr.com

Center of Molecular Research or CMR is a Russian isotopes production company which is included into the group of companies, founded in 1993.

Nowadays our company is one of the world's largest manufacturers and suppliers of Oxygen-18 water and other stable and radioactive isotopes worldwide. For more than twenty years Center of Molecular Research has been a reliable supplier of isotopes for our customers in different industries, basically nuclear medicine, science and others.

CMR is a globally represented manufacturer of GMP certified stable isotope Oxygen-18 water of the premium quality. Moreover, we offer a wide range of reagent kits, chemicals for PET-tomography, PET precursors and kits for Tc-99m Generator. We offer enriched stable isotopes for cyclotron and reactor targets. This list includes the following elements: Xe-124, Te-124, Ni-64, Ti-203 and many others.

CMR is ready to accept orders for almost full range of isotopes elements of Periodic Table. We offer high quality products due to the fact that manufacture process totally complies with applicable international standards as well as national and is certified by GMP authorities.

Our company is oriented to build a successful long-term relationship with clients. We are striving to provide our customers with the highest quality products and services. We offer reasonable prices, efficient logistic services and an individual approach to each client.
Cisbio Bioassays is a privately held life sciences company committed to improving human healthcare. With more than 30 years of experience in vitro diagnostics and drug discovery, we provide creative technological solutions and partnerships to the global scientific community.

With more than 30 years of development in immunoassays (RIA and ELISA) in Oncology and Endocrinology, Cisbio Bioassays is a partner of choice for medical device in ELISA for specialized testing, like Chromogranin A, N terminal Procollagen Ill Peptide and S100A12.

Cisbio is a choice for medical device in ELISA for specialized testing, like Chromogranin A, N terminal Procollagen Ill Peptide and S100A12.

Cisbio Bioassays has facilities in France, the United States, China and Japan, and a network of distributors across the globe. The company is now part of PerkinElmer, Inc.

The Exhibiting COMPANY’s main areas of activity are:
- Endocrinology
- Fertility
- Autoimmunity
- Tumor markers
- Inflammation
- Fibrosis

Visit www.cisbio.com/locations to find a list of our regional distributors.

Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

Clarity utilises its strong imaging capability and proprietary technology to develop novel radiopharmaceuticals. Its in-house drug development program is focused on developing targeted therapeutics in oncology using a theranostic approach, which combines diagnostics and therapy. Clarity’s lead compound, SARTATE™, has entered Cu-64/Cu-67 theranostic trials in meningioma. This new agent will also potentially allow better treatment of paediatric cancers and is entering clinical trials for neuroblastoma. Clarity is in a number of negotiations to expand its program and tap into new markets that can be better served with the SAR-Technology. As such, the prostate cancer market remains a key focus for the Company.

Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current technologies. Clarity is also in early preclinical development with a small range of other therapeutic oncology indications. In other serious diseases, Clarity is developing imaging-based companion diagnostics in areas including cardiovascular disease and fibrosis.

Clarity Pharmaceuticals
4 Cornwallis St
National Innovation Centre
2015 Eveleigh
+61 (0)2 9209 4037
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CISBIO
Parc Marcel Boiteux
BP 84175
30200 Codolet
+33(0)466 796 700
fservent@cisbio.com
http://www.cisbio.com

Clarity Pharmaceuticals
4 Cornwallis St
National Innovation Centre
2015 Eveleigh
+61 (0)2 9209 4037
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/

Since 2000, CLERAD company has become a main leader in imaging agents detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.

We are present in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other intraoperative treatment solutions in Radiology, Chemotherapy and Radiotherapy.

Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CLERAD
15 rue Patrick Depailler
63000 Clermont Ferrand
+33(0)473 81 37 37
bd@claritypharmaceuticals.com
https://www.claritypharmaceuticals.com/
Comecer is an Italian company based in Castel Bolognese and established in the mid-1970s. Comecer develops and manufactures high technology systems for aseptic treatment and containment in the pharmaceutical and nuclear medicine industries, specializing in isolation technology solutions for regenerative medicine and tissue engineering. Since 2019 Comecer is part of AFS Automation Tooling Systems Inc., a Canadian company listed on the Toronto Stock Exchange and a leading provider of industrial automation solutions for manufacturing companies in all production sectors. Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. In particular, Comecer excels in the field of radiopharmacy where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. In the Nuclear Medicine sector, Comecer’s products are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide. Thanks to its production flexibility, the continuous investments in research, the synergies between its various divisions and the sharing of know-how, Comecer always develops highly innovative products, from both the operator safety and product protection standpoints.

Curi um is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

With manufacturing facilities across Europe and the United States, Curi um delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name Curi um honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. An innovative and supportive employer to our valued team.

To learn more, visit curiumpharma.com

Czech Society of Nuclear Medicine (CSNM) is a non-profit medical association, part of the Czech Medical Association of J. E. Purkyně and a member of the European Association of Nuclear Medicine. CSNM is one of the oldest European nuclear medicine societies originally established in 1965 as the Czechoslovak Society of Nuclear medicine and Radiation Hygiene (CSNMRH). Czechoslovak dissolution in 1993 resulted in the division of the CSNMRH into Czech and Slovak Nuclear Medicine Societies.

CSNM is a multidisciplinary forum connecting professionals within the field of nuclear medicine. The aim of our Society is to maintain high-quality nuclear medicine practice throughout the Czech Republic, develop the guidelines in clinical nuclear medicine, foster interdisciplinary co-operation with other medical societies, facilitate knowledge exchange in the nuclear medicine and related sciences and be the full-bodied part of the modern development in field of nuclear medicine, personalised healthcare, molecular imaging and therapy.

CSNM holds an annual national congress called “Days of Nuclear Medicine” (this year already 56th annual) offering educational lectures and presentations on the latest achievements in a basic and clinical nuclear medicine research. Moreover, each of the five CSNM sections (clinical, radiopharmaceutical, immunonuclear, technologist’s and physicist’s section) holds its own, at least annual, meeting. All healthcare professionals are more than welcome there!

The Czech Society of Nuclear Medicine (CSNM) is a non-profit medical association, part of the Czech Medical Association of J. E. Purkyně and a member of the European Association of Nuclear Medicine. CSNM is one of the oldest European nuclear medicine societies originally established in 1965 as the Czechoslovak Society of Nuclear medicine and Radiation Hygiene (CSNMRH). Czechoslovak dissolution in 1993 resulted in the division of the CSNMRH into Czech and Slovak Nuclear Medicine Societies.

CSNM is a multidisciplinary forum connecting professionals within the field of nuclear medicine. The aim of our Society is to maintain high-quality nuclear medicine practice throughout the Czech Republic, develop the guidelines in clinical nuclear medicine, foster interdisciplinary co-operation with other medical societies, facilitate knowledge exchange in the nuclear medicine and related sciences and be the full-bodied part of the modern development in field of nuclear medicine, personalised healthcare, molecular imaging and therapy.

CSNM holds an annual national congress called “Days of Nuclear Medicine” (this year already 56th annual) offering educational lectures and presentations on the latest achievements in a basic and clinical nuclear medicine research. Moreover, each of the five CSNM sections (clinical, radiopharmaceutical, immunonuclear, technologist’s and physicist’s section) holds its own, at least annual, meeting. All healthcare professionals are more than welcome there!

DDD Diag nost ic A/S, based in Denmark, manufactures a range of gamma cameras from organ specific cameras to general purpose cameras. Until 2012, DDD was an OEM manufacturer of some of the most successful gamma camera systems worldwide. DDD has been in the market since 1987, and presently more than 2500 DDD-manufactured gamma cameras have been installed worldwide.

Today, DDD develops and markets the gamma camera systems described below under its own brand name. DDD cameras are durable and reliable with small footprint and superb image quality.

• QuantumCam, a dual-head general purpose SPECT camera for routine nuclear medicine procedures and useful in hospitals with limited space

• CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging

• Solo, a small FOV system for planar imaging for low and high energy isotopes

• Solo Mobile, a mobile small FOV gamma camera that runs on battery and easily can be moved around

• QuantumCam, a dual-head general purpose SPECT camera for routine nuclear medicine procedures and useful in hospitals with limited space

• CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging

• Solo, a small FOV system for planar imaging for low and high energy isotopes

• Solo Mobile, a mobile small FOV gamma camera that runs on battery and easily can be moved around

• nephroCam, a large Field of View, single-detector camera for Radiosotope Renography

DDD Diagnostic A/S is represented worldwide by distributors with exclusive rights for sales, marketing and servicing of products under DDD Diagnostic’s own brand.

Web site: www.ddd-diagnostic.dk
Contact: Jakob Mouridsen, VP Sales & Marketing (jmo@ddd-diagnostic.dk)

DDD-Diagnostic, a Danish company with more than a century of industry experience, is a leading provider of industrial automation solutions for manufacturing companies in all production sectors. Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. Comecer excels in the field of radiopharmacy where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. In the Nuclear Medicine sector, Comecer’s products are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide. Thanks to its production flexibility, the continuous investments in research, the synergies between its various divisions and the sharing of know-how, Comecer always develops highly innovative products, from both the operator safety and product protection standpoints.

Curi um is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

With manufacturing facilities across Europe and the United States, Curi um delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name Curi um honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A innovative and supportive employer to our valued team.

To learn more, visit curiumpharma.com

Czech Society of Nuclear Medicine (CSNM) is a non-profit medical association, part of the Czech Medical Association of J. E. Purkyně and a member of the European Association of Nuclear Medicine. CSNM is one of the oldest European nuclear medicine societies originally established in 1965 as the Czechoslovak Society of Nuclear medicine and Radiation Hygiene (CSNMRH). Czechoslovak dissolution in 1993 resulted in the division of the CSNMRH into Czech and Slovak Nuclear Medicine Societies.

CSNM is a multidisciplinary forum connecting professionals within the field of nuclear medicine. The aim of our Society is to maintain high-quality nuclear medicine practice throughout the Czech Republic, develop the guidelines in clinical nuclear medicine, foster interdisciplinary co-operation with other medical societies, facilitate knowledge exchange in the nuclear medicine and related sciences and be the full-bodied part of the modern development in field of nuclear medicine, personalised healthcare, molecular imaging and therapy.

CSNM holds an annual national congress called “Days of Nuclear Medicine” (this year already 56th annual) offering educational lectures and presentations on the latest achievements in a basic and clinical nuclear medicine research. Moreover, each of the five CSNM sections (clinical, radiopharmaceutical, immunonuclear, technologist’s and physicist’s section) holds its own, at least annual, meeting. All healthcare professionals are more than welcome there!

DDD Diag nost ic A/S, based in Denmark, manufactures a range of gamma cameras from organ specific cameras to general purpose cameras. Until 2012, DDD was an OEM manufacturer of some of the most successful gamma camera systems worldwide. DDD has been in the market since 1987, and presently more than 2500 DDD-manufactured gamma cameras have been installed worldwide.

Today, DDD develops and markets the gamma camera systems described below under its own brand name. DDD cameras are durable and reliable with small footprint and superb image quality.

• QuantumCam, a dual-head general purpose SPECT camera for routine nuclear medicine procedures and useful in hospitals with limited space

• CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging

• Solo, a small FOV system for planar imaging for low and high energy isotopes

• Solo Mobile, a mobile small FOV gamma camera that runs on battery and easily can be moved around

• QuantumCam, a dual-head general purpose SPECT camera for routine nuclear medicine procedures and useful in hospitals with limited space

• CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging

• Solo, a small FOV system for planar imaging for low and high energy isotopes

• Solo Mobile, a mobile small FOV gamma camera that runs on battery and easily can be moved around

• nephroCam, a large Field of View, single-detector camera for Radiosotope Renography

DDD Diagnostic A/S is represented worldwide by distributors with exclusive rights for sales, marketing and servicing of products under DDD Diagnostic’s own brand.

Web site: www.ddd-diagnostic.dk
Contact: Jakob Mouridsen, VP Sales & Marketing (jmo@ddd-diagnostic.dk)
Based in beautiful Turin, the first capital city of Italy and a technological hub, Dixit is a company focused on building efficient medical applications and services. Its main product, WIDEN (www.widen.it), is a Web Service designed to make the management, quality assurance and review of imaging studies in clinical trials simpler, more effective and more reliable. Trials can then easily scale in size and statistical significance can be achieved in a short time.

Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET/CT, in their cancer treatment protocols.

Since 2012, WIDEN has been used in more than 25 multi-centre clinical trials, whose coordinating bodies reside in Austria, France, Switzerland, Italy and Australia. WIDEN users are located in 25 different countries and more than 230 clinical centres.

WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Their data can be quickly analysed, to assess the results and design more ambitious, prospective trials to validate them.

Dongcheng Pharmaceuticals

Established in 1998, went public in May 2012, Dongcheng Pharmaceutical has developed into an enterprise group which combines pharmaceutical R&D, production and sales, covering four fields of biochemical API, traditional Chinese medicine, chemical drug and nuclear medicine. Dongcheng Pharmaceutical stepped into the high-tech barrier and high growth nuclear medicine industry with a high starting point in 2014, completed industrial chain layout from diagnostics to therapeutics by acquisition of Chengdu Yunke Pharmaceutical, Yitai Pharmaceutical, Dongcheng Xinke and AMS, further consolidate the leading position in China nuclear medicine market and grow into a total solution supplier for nuclear medicine.

DOSIsoft

Discover our patient-specific dosimetry for 90Y-SRT/177Lu Molecular RadioTherapy (MRT)


PLANET® Onco: Oncology software for Molecular Imaging & Radiotherapy. It helps clinical team to optimize disease diagnosis and therapy through registration, contouring, advanced quantification and patient response from multimodal imaging. Texture analysis for diagnosis, follow-up and radionics is also provided.

PLANET® Dose: Dosimetry software dedicated to Molecular Radiotherapy providing fully integrated 3D and hybrid 3D/2D dosimetry for 90Yttrium 6177Lutetium. It allows medical team to personalize patient therapy through pre & post-implementation dosimetry, automatic structure propagation, calculation of residence time and comparison between treatment planning and validation control dose maps. Consolidation of multi-treatment stages is also available.

PLANET® Neuro: Neurology software for diagnosis of Neurological and Dementia Diseases. It is designed to improve analysis accuracy and increase medical confidence for neurodegenerative diseases such as Alzheimer, dementia with Lewy bodies, Parkinson and Epilepsy. Normality database can be created with your own SPECT/PET data.

DSD Pharma

DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. Our headquarter is located near Vienna and approachable easily by public and private transportation. Our suppliers are international companies and partners, our strength is the innovative development of integrated solutions together with our customers.

Our Mission

DSD Pharma offers a product portfolio developed together at the bleeding edge of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.

Our Vision

We contribute significantly to improve diagnostics, theranostics, therapy and the quality of life of patients. From the provision of radioactive nuclids including logistics to laboratory equipment, DSD Pharma is the competent partner in all questions of nuclear medicine.

Our Values

Innovation on a strong scientific base is the core value of DSD Pharma and an important element of our strategy and success.

Only based on a high quality of products we can ensure a reliable supply and gain confidence with our customers. Our consequent focus on highest quality includes improved standards and technologies as well as education and training of our staff.
ec² Software Solutions

ec² Software Solutions is the leading provider of software solutions for the Molecular Imaging community for over 30 years. Along with our partner company, Numa, we have over 5,000 customers worldwide using our products to manage records, meet regulatory requirements and improve patient care.

Nuclear Medicine Information System (NMIS) and BioDose. These programs are used to manage inventory, patient doses and other records required for regulatory compliance in molecular imaging departments.

BioTrax QMS. This 21 CFR Part 11 validated quality management system is used in PET and Pharmaceutical manufacturing facilities. BioTrax QMS contains a document repository with SOP revision control, inventory management, production batch records, employee training and instrument QC.

Radiopharmacy Management Information System (RMIS) and BioRx. These programs are used in radiopharmacies worldwide to manage the production and distribution of radioactive isotopes. They contain prescription control, inventory management, health physics, invoicing and transportation documentation.

Rescue Dose. Rescue Dose is an automated unit dose dispensing system. Rescue Dose is integrated with the BioRx and RMIS radiopharmaceutical programs.

NumaStatus. NumaStatus integrates with NMIS/Biodose to provide a web-based user interface to display the patient's status and export Dose Reports in DICOM formats.

NumaLink. Provides multi-vendor compatibility for imaging systems.

Eckert & Ziegler Strahlen- und Medizintechnik AG

Eckert & Ziegler Radiopharma – info@radiopharma@ezag.de

Radiopharma is specialized in the provision of pharmaceutical services, versatile, innovative and high-quality technical solutions. Our product portfolio consists of radiochemicals, radiopharmaceuticals (Ytriga and Gallapharm®), a wide range of radiosynthesis technology (ModularLab, KitLab), radiochromatography equipment and accessories.

Eckert & Ziegler Isotope Products – isotopes@ezag.com

Isotope Products offers the world’s largest range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications. Products include Co-57 flood sources, OEM-quality replacement Ge-68 and Gd-153 sources for PET and SPECT, a complete range of multi-modal markers and other reference or calibration products necessary for nuclear medicine departments.

Eckert & Ziegler Isotope Technologies Dresden – id-info@ezag.com

Isotope Technologies Dresden solve safety and process challenges for manufacturers and users of radioactive material in the form of sealed sources, radiochemicals and radiopharmaceuticals. IDT’s product spectrum comprises facilities and devices needed for the handling of radioactive material including hot cells, mini-cells, dispensing cells, radiochemical fume hoods, aseptic workplaces, shielding equipment, specific solutions for radiation protection for α-, β- and γ-radiation as well as facilities to produce and process radiochemicals and radiopharmaceuticals.

Eczacıbaşı Monrol Nuclear Products

Eczacıbaşı Monrol Nuclear Products has been leading the development of the Turkish Nuclear Medicine market with the production of high-quality radiopharmaceuticals as a market leader and is the first company carrying out radioisotope R&D activities in Turkey.

Eczacıbaşı Monrol has 11 world-class production facilities, 5 in Turkey and 6 international (Bulgaria, Romania, Egypt) employing modern and environment-friendly technologies. The company also has been operating cyclotrons in Kuwait, United Arab Emirates, Pakistan and Erbil. Both local and international facilities are utilized by a range of PET and SPECT products complying fully with national and international regulations related to its manufacturing and service activities, including current GMP to ensure that its products are of the highest quality.

Along with its production capabilities Eczacıbaşı Monrol also offers global brands to Turkish Nuclear Medicine Market via its strong distribution channels. For the international market, Eczacıbaşı Monrol does not only export over 43 countries but also is the solution partner supplying start-up, operational and hand-over services.

EFS European Federation of Radiographer Societies

The role of the EFRS is to represent, promote and develop the profession of Radiography in Europe, within the whole range of medical imaging, nuclear medicine and radiotherapy.
Elysia-raytest is a solution provider for radio-pharmaceutical producers and nuclear medicine. We provide IMS solutions, services, chromatography and quality control systems to the pharmaceutical, agrochemical and nuclear/PET industries.

We design, manufacture, sell and service instruments used for measurement of radioactivity and quality control. We work in close collaboration with radiopharmaceutical and cyclotron providers to develop new products and improve existing solutions.

In 2015 Elysia has purchased the Raytest Isotopenmessegerate GmbH to increase the R&D, service and production capacity.

Since the integration of raytest, Elysia has extended the product line with casette based synthesis module especially for the peptide labelling with Ga68, Lu177 and other radio-metals.

This allows us to plan and offer complete GMP solutions for the quality control of a huge variety of PET and SPECT tracers.

Our mission is to make the measurement of radioactivity, the peptide labeling and quality control of radiopharmaceuticals easier, faster and safer.

Radiopharmaceuticals should be accessible worldwide and affordable. We help our customers accelerate their R&D and to validate QC methods for existing and new molecules.

Our team is customer-oriented and composed of radiochemists, IT and QA specialists.

Their professional background ensures high-efficacy answers for all radiopharmaceutical, software and instrument questions.
GE Healthcare is the $19.8 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics, and monitoring through intelligent devices, data analytics, applications, and services.

With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world.

Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website https://corporate.gehealthcare.com/ for more information.

German Society of Nuclear Medicine (DGN e.V.)

The German Society of Nuclear Medicine (DGN e.V.) is a scientific society with headquarters in Göttingen. Its goal is to promote nuclear medicine in basic and applied research in the fields of diagnostics, therapy, and radiation protection. This is done at national and increasingly at international level too.

The DGN e.V. has about 1,500 members, including not only specialists in nuclear medicine and physician from other disciplines but also engineers and scientists. Its president is Prof. Dr. Bernd Joachim Krause from the Department of Nuclear Medicine, University Hospital Rostock. For more information, please visit www.nuklearmedizin.de.

Global Morpho Pharma SAS is a French company created early 2018 that aims at developing, manufacturing, distributing and selling radionuclides and radiopharmaceuticals under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. Global Morpho Pharma intends to become one of the major suppliers of pharmaceutical grade doses of therapeutic radionuclides for the pharmaceutical industry.

Global Morpho Pharma believes in the important short term growth of the radiotheranostic market at a worldwide level. The company selected a few radionuclides of interest for which existing sources have not yet guaranteed redundant worldwide supply when radiolabeled drugs addressing larger indications will reach the market (starting with nca 177Lu and 227Ac-free 225Ac). There is largely room for several players active in this field, but Global Morpho Pharma took in account that major customers in this field (pharmaceutical companies as newcomers) will always need access to at least two totally independent suppliers for their final product.

Global Morpho Pharma is presently building a network of centers covering the entire supply chain, from the original target to the pharmaceutical grade radionuclide for human use, eventually to the final ready-to-use drug. This network includes for each step backup solutions in both the US and EU to avoid rupture of supply in case of maintenance or temporary shutdowns.

Hellenic Society of Nuclear Medicine and Molecular Imaging (HNS&M&I)

Our Society of Nuclear Medicine and Molecular Imaging (HNS&M&I) was founded in 1968, as Greek Society of Nuclear Medicine and Biology, by the renowned Honoured Member of the Academy of Athens for Sciences and Philosophy, Professor of Medicine Vassilios Malamos. It is one of the oldest European societies in nuclear medicine and its membership now numbers approximately 400.

In order to fulfill our mission, the society has established a number of committees, including committees for education, continuing medical education in nuclear medicine, radioprotection.

Mission:

• Expert Consulting for the Greek State that guides and constructs Regulations and Institutions in Nuclear Medicine, like Education, Retraining, Radiation Protection and Dosimetry.
• Actions to ensure the education to Nuclear Medicine Doctors offering trainings in the highest possible level and creating the right conditions for continuous education and training of its members. Simultaneously ensure the continuous training of the trainers and to create training programs of all health professionals working in the field of nuclear medicine.
• Creates committees which are referring and recommending to the Board of Directors issues and solutions affecting the Nuclear Medicine.
• Protecting and establishing the spiritual property of its members.

Nuclear Medicine Departments in Greece:

• 25 departments in the public hospitals and even more in private hospitals
• 11 PET-CT cameras (in both public and private sector)
Hermes Medical Solutions

Recognised for over 40 years for clinical excellence and innovation, Hermes Medical Solutions provides vendor neutral software for nuclear medicine. Our solutions enable physicians to provide faster and more accurate diagnosis, improving patient outcomes and increasing efficiency. We provide the clinical workflow for integration, visualisation, processing, reporting and archiving of image data from multiple modalities within nuclear medicine and radiology.

At EANM 2019 we are proud to launch our new Multimodality Viewer for clinical imaging. Designed to be the fastest and most intuitive product on the market. Driven by extremely responsive and fast handling, framed with a modern and efficient user interface, tailored to fit the needs of sophisticated and demanding users.

We will showcase our comprehensive range of systems and custom solutions based on your needs. New developments include automated HpGe instrument offers.

Hermes Medical Solutions’ leadership within nuclear medicine has been built upon technological innovation, strong customer service, and historical success. We offer the most comprehensive enterprise class software suite for nuclear medicine diagnosis and treatment planning, making precision personalised medicine a reality.

Hidex Oy

Hidex is a high technology company which develops and manufactures high performance analysis equipment for pharmaceutical research, radiation measurement and nuclear medicine. Our products utilize modern technology and excellent tradition of workmanship. With strong links to the scientific community we continue to innovate and develop to improve scientific research and safety of everyday life.

Hidex offers automated system for Oxygen-15 water production and injection. Oxygen-15 water is the gold standard for blood flow analysis with PET. Our system is compatible with all cyclotrons and can be installed with PET/MR scanners. With close to 50 installations we are the world leader in Oxygen-15 water.

Hidex AMG automatic gamma counter is an unrivalled instrument for nuclear medicine and radiopharmaceutical development. The system has small footprint, touch screen software, on board balance with convenience and ease of use no other instrument offers.

New developments include automated HpGe detectors, automated radiochemistry extraction systems and custom solutions based on your needs.

Huayi Isotopes Co.

Huayi Isotopes Co. (HIC), a manufacturer of Oxygen-18 water, biochemical compounds and sterile components, is dedicated to leading-edge development of new biochemistry platforms critical for the advancement of diagnostic imaging.

We provide a broad catalog of products designed to meet the needs of our basic and applied research customers, as well as commercial cGMP products and services.

We also offer custom synthesis, consulting expert and custom manufacturing services related to radiopharmacy and molecular imaging.

We provide a broad catalog of products designed to meet the needs of our basic and applied research customers, as well as commercial cGMP products and services.

We also offer custom synthesis, consulting expert and custom manufacturing services related to radiopharmacy and molecular imaging.

IASON GmbH

IASON, with its head office in Graz, was founded by its Managing Director Mr Christoph Artner in 1994 and has its origins in the trade of innovative medical technology products. As a specialist for the production of radioactive pharmaceuticals, IASON helped to bring the method of positron-emission-tomography (PET) to Austria in the late 1990ies.

The IASON headquarters were established near Graz, and three company-owned and operated, state-of-the-art radiopharmaceutical production sites are today located in Linz, Klagenfurt (both AUT) and in Settebagni near Rome (IT).

IASON’s core competence lies in the development, production and distribution (even by air logistical) of radiopharmaceuticals for application in Positron-Emission-Tomography. Our USPs are clearly our Marketing Authorizations (MAs) which we hold for our products in several European countries. Our products Edega®, IASOcholine®, IASOflu®, IASOglio® and IASOpip® are mostly applied for imaging of cancer patients.

New PET radiopharmaceuticals are constantly being developed into a marketable commodity in the R&D department at all sites of the company group. The company policy is to bring a new product to Marketing Authorization every two years.

Further business segments of IASON include conducting clinical research programs and know-how transfers, the production of O-18 water as a raw material for production of radiopharmaceuticals (at the site in Graz, measuring the radiation exposure of flight person.)
IBA RadioPharma Solutions
Cheim du cyclotron 3
1348 Louvain la Neuve
3210201275
info-cycle@iba-group.com
https://www.iba-radiopharmasolutions.com

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotope production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP quality technology production equipment.

IBA is a global medical technology company focused on bringing integrated and innovative solutions for radioisotope and radiopharmaceutical production centers.

IBA RadioPharma Solutions

Institute of Isotopes Co. Ltd.
Korunky-Thege M. u. 29-33
1121 Budapest
+36 1 392 2577
commerce@izotop.hu
http://www.izotop.hu

IZOTOP is the major Hungarian centre for the research, development and production of radioisotopes and other products for a broad range of application areas, especially healthcare, research and industry. Hundreds of products manufactured in our facilities and distributed worldwide. Company operates in accordance with ISO 9001 and ISO 14001 QA system. We have GMP Certificate for Radiopharmaceutical preparations. We developed an in-depth experience in setting up GMP quality disease production equipment. The company offers GMP quality technology production equipment, IBA has developed in-depth experience in setting up GMP quality technology production equipment.

IBA RadioPharma Solutions

Inter Medical Medizintechnik GmbH
Dainlerstr. 34-36
32312 Luebecke
+49 5741 2359 0
sales@IntMed.de
https://www.IntMed.eu/

The Inter Medical Medizintechnik GmbH Company is specialized in medical devices and hardware with the focal point in Nuclear Medicine technique.

Long time experience in product innovations, development and production of Nuclear systems make Inter Medical a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.

Quality on each step of our business is our main goal, also expressed through the certifications for the European ISO standard given to Inter Medical.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras.

Inter Medical Medizintechnik GmbH

International Atomic Energy Agency
Wagramer strasse 5
1400 Vienna
+43 1260021670
g.Ladaa-Horet@iaea.org
http://iaea.org

The IAEA is a worldwide focal point for cooperation in the nuclear field. Set up in 1957 as an independent intergovernmental, science and technology-based organization, the IAEA is known as the world’sAtoms for Peace organization within the United Nations family. The Agency works together with over 160 Member States and multiple partners worldwide to promote the safe, secure and peaceful use of nuclear technologies and seeks “to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world”, as stated in Article II of its statute.

The goal of the IAEA programme in Human Health is to enhance capabilities of Member States to address health needs related to the prevention, diagnosis and treatment of health problems through the application of radiation medicine.

The Nuclear Medicine and Diagnostic Imaging (NMDI) Section focuses in particular on enhancing Member States’ capabilities by providing various areas of support and activities related to Education, Research, Services and Quality Management in order to develop the practice of NMDD and ultimately improve patient care. In addition, the NMDI Section keeps a close watch on technological trends and new clinical applications in order to continuously evaluate the needs of Member States in the fields of nuclear medicine and radiology as well as reinforcing capabilities of Member States to use existing and new therapeutic applications of radionuclides and interventional
**Invicro**

27 Drydock Avenue  
7th Floor West  
2210 Boston  
info@invicro.com  
http://www.invicro.com

Invicro applies extraordinary resources to answer complex questions with industry leading imaging biomarkers, core lab services, advanced analytics, and software solutions across all drug phases and therapeutic areas.

**inviscan**

23 rue du Loess  
Bat. 25  
67200 Strasbourg  
info@inviscan.fr  
http://www.inviscan.fr

Inviscan Imaging Systems is a high technology company located in France. inviscan manufacture preclinical imaging systems used in Medical Research. The products of inviscan include PET and CT systems for imaging small animal models. inviscan is also providing novel PET/MRI technology and developing innovative digital PET detection modules based on new photodetector components. inviscan is partner in international projects with academic partners to develop MRI compatible PET imaging instrumentation for research on the human brain and neurodegenerative diseases.

Inviscan has research offices and laboratory area located in Strasbourg, France.

Our products/services:

- Research imaging tools and services for in-vivo and ex-vivo studies
- microPET scanners
- microCT scanners
- PET/CT scanners
- PET/MRI insert solutions
- Multi-modality imaging solutions for preclinical research in oncology, neurology, cardiac studies
- Analysis softwares for preclinical studies
IRE ELIT, IRE’s innovation subsidiary, is a pharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy. In 2018, IRE ELIT devoted 18% of its turnover to R&D. IRE ELIT currently employ 218 people.

Our company places quality, reliability and services at the center of all its concerns to secure the supply and easy use of radiopharmaceuticals for its customers worldwide. IRE ELIT’s portfolio of customer-oriented solutions includes radioisotopes for diagnosis or treatment purposes, as well as equipment dedicated to their preparation.

Our main product is a Ga-68/GeV 68 generator, Galli Ad. It’s a simple and innovative PET imaging solution used, mainly, for NET tumors and recurrent prostate cancers.

Galli Ad is a fully integrated and closed system to get rapidly highly concentrated and very pure radiopharmaceutical preparations minimizing loss of activity. Its innovative design, specific for cold kit reconstitution, limits the risk of misuse and contamination. This generator can be used manually or connected to a synthesis module.

Last year, we have received the Marketing Authorization in 13 European countries for our Ga-68 Generator. In the US & Canada, DMF is available.

We work with more than 100 hospitals worldwide, especially in Europe and in the US. Get more info on our booth!

ISOTOP4LIFE

Château de la Chantrerie
95 Route de Gachet
44307 NANTES
+33 2 40 25 13 99
https://www.atlanpolebiotherapies.com/
radiopharmaceutiques-isotop4life/

Atlanpole Biotherapies is a competitiveness cluster on the bio-medicine value chain from target discovery to clinical evaluation. One of its thematic, called ISOTOP4LIFE, is Radios isotopes applications, aiming at mutualisation and coordination of skills and actors concerned by the use of radioisotopes for health in order to overcome hurdles to innovation in the radiopharmaceutical domain. The main goal of ISOTOP4LIFE is to facilitate the use of Radiopharmaceuticals for diagnostic and therapeutic applications.

ISOTOP4LIFE is a one-stop offer providing R&D, technology transfer and industrialization capacities, with academic, clinical, industrial partners as well as a high-energy, high-intensity cyclotron ARCHANA. It is also a commercial coordination offer with an identified gate for Pharmaceutical industry.

Isotopia molecular imaging

39 Alexander Yanai St. Segula Industrial Park
4927735 Petach Tikva

Isotopia is a Radio Pharmaceutical Company established in 2006, since than has become an essential supplier for the growing field of nuclear medicine in Israel.

Isotopia was founded by a highly trained group of senior professionals, experienced in all aspects of radio-pharmaceutical operations, in collaboration with a group of Canadian investors.

Isotopia operates a PETtrace Cyclotron (GE Healthcare), supplying both PET and SPECT tracers, manufactured under strict Quality Control Procedures.

Apart from FDG, there are newly available 18F-labeled products, including 18-F-DOPA, 18-F-PSMA and 18-F-Choline. Being aware of new advancements in nuclear therapy, Isotopia is also providing 177 Lu treatments for prostate cancer and neuroendocrine tumors.

Since 2014, Isotopia supply 68- Ga- PSMA to the local market, being the first company responding to this emerging technique in prostate cancer management.

In our pipeline, soon will be available for marketing a cold kit for 68-Ga-PSMA-11 synthesis.

As of now, Isotopia is taking steps for becoming a major worldwide supplier of 177- Lutetium to be used in the field of molecular radiotherapy.

As part of Isotopia’s vision, we are looking for collaboration with companies and academic institutes to develop new markers, radiopharmaceuticals production and international sales.

ITEL Telecomunicazioni S.r.l.

Via Labriola snc
70037 Ruvo di Puglia
+33 2 40 25 13 99
itel@itelte.it
https://www.itelte.it/

Established 30 years ago in the telecommunications sector, thanks to the expertise acquired in electromagnetic waves, fields and radiations, ITEL Telecommunications® today works in the medical, pharmaceutical and electromagnetic compatibility fields, offering high-tech products and services that have in common the application of ionizing and non-ionizing radiations: electromagnetic and magnetic field shielding for diagnostic and intraoperative imaging and industrial environments, medical site auditing, integrated project planning and design of complex healthcare facilities, radiopharmaceuticals and services for nuclear medicine (division ITELPHARMA), research and development of medical mechatronics technologies, electromagnetic compatibility tests & measurements (division EMC TEST LAB).

As part of these activities, ITEL has developed a wide range of services for Radiopharmacies, both those already operational and those of new construction. From Sterility Tests, to Bioburden Analysis, to advice and training on GMP. ITEL is configured as a global partner for each Radiopharmacy and Nuclear Medicine Department.

Of course ITEL can be configured as a “full service provider” able to follow the planned construction of a radiopharmacy from design, to commissioning, qualification and validation activities and preparation of the quality system, with full knowledge and competence in relation to GMP requirements.
ITM AG

Schleissheimerstrasse 91
85748 Munich
089 329 8986 600
info@itm.ag
https://isotope-technologies-munich.com

About the ITM Group

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

Japanese Society of Nuclear Medicine

The JSNM was established in 1964 which currently has over 3,600 members. The JSNM has been working hard to promote the development of nuclear medicine through the collaboration with the SNM/WFNMB, EANM, ASNMB (Asia and Oceania Federation of Nuclear Medicine and Biology), ARCNM (Asian Regional Cooperative Council for Nuclear Medicine), World Federation of Nuclear Medicine and Biology (WFNMB) and individual societies of many countries. The JSNM is proud to announce that the 2022 Congress of the WFNMB will be held in Kyoto, Japan. We have been working to set up the congress, the international committee will be assembled meanwhile, and we sincerely appreciate you if you propose any idea to make the congress successful. Check the web site at http://www.jsnm.org/english/

The Annals of Nuclear Medicine (ANNM) is the official journal indexed in the most of major sites such as Journal Citation Reports/Science Edition, PubMed/ Medline. ANNM is now one of the most popular journals in the field. The Best papers are selected every year and the winners are awarded with grant. Please come to the web site at http://www.springer.com/medicine/nuclear+medicine/journal/12149.

We are waiting for you to treat you with a variety of Japanese traditions at our booth with the utmost hospitality. Join us!

JSC Isotope / Rusatom Healthcare

Popodinskaya street 22
119435 Moscow
+7 (495) 981-96-16
isotope@isotop.ru
http://www.isotop.ru/

JSC Isotope is a 100% subsidiary of Rusatom Russian State Atomic Energy Corporation, responsible for distribution and marketing of isotope products manufactured at Rosatom production sites. We guarantee reliable supplies of high quality unique isotope products to the international market.

JSC Isotope is a team of professionals that provides supplies of a wide range of products for nuclear medicine, in particular: radiochemicals (Mo-99, Tc-99m, Sm-153, Lu-177, Ac-225), radiopharmaceuticals (Mo-99/Tc-99m, W-188/Re-188, Ge-68/Ga-68) and many others.

JSC “Isotope” is a partner to more than 100 foreign customers in over 30 countries and more than 600 organisations in Russia.

JSC Rusatom Healthcare is the integrator for nuclear medicine within Rosatom Russian State Atomic Energy Corporation, established for purposes of development and production of equipment and radionuclide products for nuclear medicine and medical radiology, as well as industrial equipment based on radiation technologies.

Rusatom Healthcare unites companies that supply nuclear medicine and medical radiology solutions. These enterprises possess rich expertise and knowledge of hundreds qualified professionals, numerous patents and licensees on innovative products.

Jubilant Radiopharma

790 Township Line Rd.
19067 Yardley
2155502810
donna.schork@jdi.jubl.com
http://www.jubilantradiopharma.com

Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine. They are focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of improving Lives Through Nuclear Medicine on a global scale.

The business is backed by dedicated research and development teams, cGMP manufacturing, and strong regulatory and quality systems.

They provide high quality and reliable specialty products to hospital-based customers and radio-pharmacies worldwide and ultimately through them patients. The areas of specialization include cardiology, pulmonology, skeletal, and endocrine therapies. Jubilant Radiopharma is a wholly-owned subsidiary of Jubilant Pharma.

Therapy. Jubilant Radiopharma is a wholly-owned subsidiary of Jubilant Pharma.
Since its founding in the 1960’s Getinge La Calhène (part of the Getinge group) has developed innovative solutions complying with safety, security, reliability and performance constraints. The equipment designed, manufactured and serviced by the company contributes to the protection of operators in the nuclear and pharmaceutical industries and safe transport of fissile materials / pharmaceutical materials.

Getinge’s DPTE® patented transfer solutions are installed in hot cells, on isolators and pharmaceutical production lines throughout the world. Our DPTE® equipment ensures secure transfer of sterile and/or toxic materials, into and out of contaminated or clean zones. It is the industry standard for transfer of toxic / aseptic products in nuclear and biomedical research institutions and the pharmaceutical industry globally.

Leak-tight bi-directional transfer is assured with our wide range of Beta parts including re-usable containers (PE, stainless steel), tubing and DPTE® BetaBag® in a variety of diameters, volumes and materials to suit a variety of applications.

La Calhène supplies the nuclear industry and nuclear medicine laboratories with a complete range of remote manipulators for all standard and specific applications, from the small capacity MA 30 to the large capacity MT 200 (telescopic type), including the medium capacity MT 200 TACO computer-assisted remote manipulator with robotic function.

Shielded transport casks (PADRAC and AGNES) and glove box equipment complete the range.

LabLogic has over 35 years’ experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications.

We will be showcasing our Trace-QC system at EANM’19. Developed in conjunction with TraceAbility this instrument is already being seen as the future of PET QC. Certainly TraceAbility’s years of experience in the PET industry, combined with LabLogic’s expertise in software development, has created a unique instrument which can perform the essential PET QC tests with just ‘single touch’ operation and all in compliance with FDA 21 CFR Part 11 (Electronic Signatures) and Part 212 (GMP) regulations. The instrument has already undergone successful trials with a major US healthcare provider and was recently the subject of an FDA funded validation project at the University of California, San Francisco, which was also successfully completed.

Our range of market leading products for PET and Nuclear Medicine applications also includes QC equipment such as r-TLC and r-HPLC instruments, plus our single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic.

Furthermore we offer two dedicated LIMS systems for PET and Nuclear Medicine applications: PETra, a PET LIMS system designed to improve efficiency and compliance and SPECTra, a dedicated Radiochemistry LIMS.

Visit booth n°96 to see demonstrations of the Trace-QC and other products in our nuclear medicine range.

Discover a complete offer of effective radiation protection solutions from preparation to injection of any radionuclides with Lemer Pax & Medisystem - come visit us on booth n°94.

The two French historic leaders in the radiation protection industry joined forces in 2016 to serve you better and to offer you a full array of innovative solutions, incorporating the most advanced technologies to protect you efficiently against ionizing radiations.

Among many innovative products, you will discover the latest version of Posijet®, an independent fractionation and injection unit for high energy radiopharmaceuticals which has been co-developed by the Lemer Pax engineering department in partnership with nuclear medicine operators and which offers a unique and very user-friendly voice driven interface. This new version includes new therapy injection protocols (177-Lu).

You will also discover the smart version of the Easypharma Compact® Vision+, our low and medium energy radiopharmaceutical ultra-compact preparation hotcell, which offers new user friendly voice recognition interface, an innovative unique solution to ensure total visibility of the work area and comfort of use in a perfectly safe environment.

Feel free to visit our experts on booth n°94 to benefit from a recognized know-how in the field of nuclear medicine and identify the most adapted solutions to your requirements, local regulations and standards.
**Mediso Ltd.**

**24**

Pulkovskaja 158/3
16000 Praha 6

77201667
kralik.j@lynax.cz
http://www.lynax.eu

The target of the company is to provide continuously innovative solutions of shielding and manipulating systems in order to limit the risk of exposing the medical health care staff to radiation and contamination when handling radioactive materials.

Especially Lynax automatic dose drawing stations reduces the doses fundamentally. Lynax offers complete solutions of manipulation and shielding systems of nuclear medicine departments including laminar flow cells, shielded hoods, dispensing devices and other shielding equipment.

---

**Mediso Ltd.**

**66/67**

Laborc u.3.
1037 Budapest

361999030

Mediso with its almost three-decade expertise in nuclear medicine and molecular imaging, is one of the global leaders in the development, manufacturing and servicing of multi-modality in-vivo imaging systems.

The company offers complete solutions from fully integrated hardware design to fusional software applications, both for clinical patient care and high-level life science research purposes. For clinical use Mediso offers not only the conventional SPECT, SPECT-CT and PET-CT systems but has launched the unique triple-modality SPECT-CT-PET AnyScan® and AnyScan TRIO family.

Mediso introduced the world’s first pre-clinical integrated PET-MRI and SPECT-MRI cameras as members of the nanoScan® high-end small animal imager family, consisting of SPECT, PET, CT, as well as low and high field MRI modalities. The portable MultiScan® LFER PET/CT cameras represent the new-generation in dynamic brain imaging, even for primates. Further to these core activities, Mediso successfully runs two complex clinical diagnostic, research and education centres, offering clinical and evaluation software application trainings for the international medical community.

During its long history, the company issued numerous academic publications, started scientific collaborations with recognized medical university clinics, scientific institutes, and can proudly declare that by today, more than 97 countries use Mediso produced equipment.

---

**Medstep- Vivai Software AG**

**SV15**

Betenstr. 13-15
44137 Dortmund

4921399500
bewerbung@medstep.de

MedSTEP is a career consultant in the medical sector specialized in the field of radiology and nuclear medicine successfully presented since 1997.

As an expert for German inbound placement we support doctors and radiology technicians in their next career step. Our focus lies on our personal trustful services. We accompany the candidates from the first contact on by organizing job interviews, any required documents, helping with housing facilities and so on.

Welcome to Germany ! You are a doctor, specialist, radiographer or any medical profession? You think about working and living in Germany? You have already German language knowledge?

Don’t hesitate to contact us. This service is for free!

---

**MIE GmbH**

**110**

Hauptstrasse 112
23845 Seth

419499770
mie@mieg-germany.de

http://www.mieg.de/

MIE has produced nuclear medicine systems (SPECT & PET) and accessories for the complete customer needs since 1981. During this time MIE have gained extensive experience in user specific requirements and have adapted it to the market and specific user needs. All our products are CE certified and FDA cleared, thus new with full warranty and min. 10 years guaranteed spare part support.

Our workstation name SCINTRON is developed to close the gap between shortened development cycles and more durable mechanics and electronics. This computer is design to acquire data as well as process and view studies from our new or already installed Gamma Camera and PET systems.

The in-house research, development, electronic and mechanic department ensure that we provide always the latest technologies. This allows us to meet the specific needs of our customers.

The MIE company works in accordance with EN ISO 13485, so all products are CE certified. Also, MIE is registered at the FDA - all systems are 510(k) approved since 1995. This extensive certification is the basis for the manufacturing and distribution of new medical products on the world market.
MILabs provides high performance standalone and integrated SPECT, PET, CT, and Optical Imaging systems for molecular imaging and in vivo imaging research. Our 4x4D multimodal imaging technology, each with four-dimensional imaging capabilities enables researchers to improve diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality by itself gives data beyond the capabilities of any other stand-alone system.

Our mission is to make molecular imaging clear. Through our continuous innovation and supportive service, the team at MILabs is dedicated to ‘providing small details for big discoveries’ for a wide range of applications that are well-equipped to manage the latest advanced segmentation and image registration when in collaborative settings like tumor boards or when combining all three CUBES.

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine’s important role in the patient care pathway. MIM Software products emphasize the importance of quantification, collaboration, and data management in order to provide physicians with the necessary information needed to generate confident clinical guidance and to inform effective treatments.

MIM SurePlan™ MRT provides voxel-based dosimetry for molecular radiotherapy, deformable registration, and timesaving tools for organ and tumor segmentation. MIM SurePlan™ Liver/PET provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using 99mTc-PET and Bremsstrahlung SPECT. SPECTRA™ Quant offers a vendor-neutral SPECT reconstruction method including iterative reconstruction, attenuation correction, energy window-based scatter correction, resolution recovery, and conversion of counts to activity (Bq/ml and SUs).

MIM Assistant® allows for centralizing images and related data to a single repository, while flexible deployment options allow other MIM Software products to be accessed from anywhere. The result is greater access to important patient information when in collaborative settings like tumor boards or for use in dictated reports. MIM Encore® provides advanced segmentation and image registration tools that are well-equipped to manage the latest advances in theranostics and other fields.

Mirada Medical

New Ballard House 234 Botley Road Oxford OX2 0HP Oxford

+44 1865871600 annamaria.albano@mirada-medical.com

Mirada develops software applications that provide simple and accessible solutions to complex image analysis problems in the diagnosis and treatment of cancer and other diseases. Through automation, our products improve consistency and productivity while enabling clinicians to deliver more personalized care. By combining deep learning technology with our thorough understanding of the challenges faced, Mirada is leading the development of next generation imaging software and decision support products.

Mirada offers vendor-neutral applications for reading Nuclear Medicine, SPECT/CT, PET/CT, and PET/MR, with flexible display protocols and workflows. Deformable registration is performed for image comparison and quantitative response to therapy is assessed with comprehensive tools for PERCIST, WHO, and RECIST analysis.

Mirada’s portfolio also includes knowledge-sharing solutions providing referring physicians access to rich images and reports, plus software designed exclusively for efficient preparation and elegant presentation of images at tumor board.

Working in collaboration with BTG, Mirada develops interventional medicine solutions to optimize radioembolization therapy. Simplicit90YTM is a customized, easy-to-use dosimetry application that helps physicians to personalize treatment with 90Y therapies for patients with liver cancer.

Molecules

Ottergemsesteenweg-Zuid 808 b125 9000 Gent

+3292777728 steven.cool@molecules.com

Based in Ghent, Belgium, MOLECUBES is an innovative company, developing and manufacturing scanners for preclinical imaging. MOLECUBES enables researchers in pharma and biotech to obtain high resolution images in vivo. An efficient workflow and intuitive user interface provide 3D images in a turkkey solution. With its truly benchtop design, total ease-of-use and a breakthrough application support service, MOLECUBES paves the way with its next generation of whole-body small animal imagers.

The X-CUBE, best-in-class micro-CT, is designed for modularity and simplicity of use. Whole-body mouse and rat applications benefit from fast acquisition speed and low animal dose, while iterative reconstruction guarantees high image quality.

The y-CUBE, best-in-class micro-SPECT, is unique in terms of modularity and simplicity of use. It offers high sensitivity and sub-millimeter resolution for whole-body mouse and rat imaging. Patented parallel-hole technology supports cube compactness. State-of-the-art reconstruction guarantees excellent image quality.

The β-CUBE is the best-in-class micro-PET, providing sub-millimeter image resolution thanks to monolithic scintillators with depth of interaction, advanced photon detection and iterative image reconstruction. The β-CUBE is optimally designed for whole body rodent imaging, from high-throughput to advanced workflows.

The intuitive software and functional animal bed allow for easy and reliable multimodal imaging when combining all three CUBES.
MR Solutions Ltd
Ashbourne House
The Guildway, Old Portsmouth Road
Artington
GU3 1UR, Guildford
7807955901
katietre-vett@hotmail.com
http://www.mrsolutions.com

MR SOLUTIONS is the worldwide leader in superconducting cryogen-free, preclinical MRI systems with multiple proven installations of its 3T, 7T, 7T, 9.4T. MR SOLUTIONS has a large installed base of high-field PET/MRI systems for simultaneous mice and rats imaging. A new high-resolution benchtop CT is available and allows for PET/CT and SPECT/CT imaging or stand-alone CT imaging. PET/CT and SPECT/CT in-line configurations are available as benchtop devices.

Depending on the MR model, the system is available with adjustable magnetic field strengths ranging from 0.1T to 9.4T.

For multi-modality imaging, MR SOLUTIONS has developed extremely compact PET, SPECT and CT scanners. The unique and innovative design allows users to interchange these scanners between the MR and the CT without duplicating them. Therefore, with one device for each, all PET-SPECT-MR-CT configurations are possible.

MR SOLUTIONS performs service, refurbishment and MRI upgrades including high performance gradients.

MR Solutions holds the prestigious Queen’s awards for enterprise 2017 and Innovation 2016, the innovation award 2017 from the Institute of Physics and is the winner in the global R&D 100 awards. MR SOLUTIONS has over 33 years of imaging technology development and manufactures all its product in-house.

National Centre for Nuclear Research RC POLATOM
Andrzej Sołtan str. 7
5400 Otwock
+48 22 2731820
iliana.chwalinska@polatom.pl
http://www.polatom.pl

Radioisotope Centre POLATOM is manufacturer and distributor of the radioisotopes applied in medicine, research and development, industry and environment protection.

In the nuclear medicine field, POLATOM offers the radiopharmaceuticals for diagnosis and therapy; 131I-Sodium iodide capsules, 131I-solution for injection, 131I-Hippurate, 131I-MIBG, 131I-MIBG, 89Sr-Sodium chloride, scintigraphy kits for technetium labelling (Tektrotyd, PoltechMIBI, PoltechCollod, PoltechDMSA, PoltechDTPA, PoltechMIBG, PoltechMDP, PoltechHRIC), 99mTc / 99mTc- generators, Hipat 90Y and Lutapal 177Lu for peptides labelling and accessories for nuclear medicine.

POLATOM offers wide range of the products for research purposes – GMP grade: DOTATATE kits and substance, PSMA-11 kit and substance, ascorbic acid.

Our products are exported to more than 70 countries all over the world.

The company is engaged in scientific research and development programs in application of radioisotopes in nuclear medicine.

The medical production is certified for compliance with (GMP), the area of manufacturing, sales, dispatching and transport of radioactive materials is certified according to PN-EN ISO 9001:2015.

POLATOM is a world famous supplier of high quality radiopharmaceuticals and diagnostic kits for nuclear medicine and important manufacturer of radiochemical products.
Nuclear Shields B.V.

NUKEM Isotopes GmbH

NUVIA (MED Nuclear-Medizintechnik Dresden GmbH)

O.R.A. - NEPTIS (Optimized Radiochemical Applications)

Nuclear Shields has over 40 years of experience in producing lead products for nuclear medical purposes. Nuclear Shields is the go-to place for transparent, quick & reliable purchasing of high-quality radiation-related products. Nuclear Shields offers a wide range of products, including shielding hot lab cabinets, radiation monitoring products, personal radiation protection products, waste and storage solutions, and custom-made solutions. Next to this, Nuclear Shields also offers a wide range of collimators to suit your imaging needs.

Nuclear Shields is a manufacturer of radiation shielding and collimators for medical and industrial imaging with over 40 years of experience. We manufacture solutions from long-term serial production to one-off custom projects.

Our solutions include:
- syringe & vial shields
- shielded containers
- lead-lined cabinets
- shielded gloveboxes
- low-background shielding
- lead & tungsten collimators
- anti-scatter grids

Visit booth #85 or visit our website at www.Nuclear-Shields.com

NUKEM Isotopes GmbH offers markets Oxygen-17, Xenon-129 and Nitrogen-15 products for use in MRI as well as Oxygen-18 for use in PET.

- Oxygen-18 in the form of water is used to create tailored organochemical compounds labelled with the radio isotope 18F (for example, 2-fluoro-2-deoxy glucose [18FDG]). These are used for Positron Emission Tomography (PET), the most common cancer diagnostic technique.

- Xenon-129 in the form of gas is one of the most promising non-invasive and non-radioactive gases for MRI-imaging of the lung. Xenon-129 offers full view and is available as pure gas and gas mixture (1% or 3%) Xe-129, 10%, N2, 89% (or 87%) He.

- Oxygen-17 is the only non-radioactive isotope to measure oxygen consumption and metabolism in real-time by using MRI systems for diagnostic application and medical research and provides a breakthrough of Magnetic Resonance Imaging using state-of-the-art clinical MRI scanners.

- Oxygen-17 is available in the form of gas and water with different enrichments up to 90 at %.

- Nitrogen-15 in the form of gas could have a potential as lung imaging agent especially in high field MRI scanners due to its similar behaviour to air. Additionally, Nitrogen-15 is available in the form of Ammonium salts and Nitrates.

Our products are manufactured under conditions in compliance with cGMP requirements of 21 Code of Federal Regulations: Parts 210 and 211.

NUKEM Isotopes GmbH
Rodensbacher Straße 47
63755 Alzenau

NUVIA Instruments GmbH
Dombühlstrasse 14 A
1277 Dresden

O.R.A. - NEPTIS (Optimized Radiochemical Applications)
Rue de la Salette, 15
5600 Neuville

O.R.A. is an innovation-driven Belgian company. At O.R.A., we have developed an extensive range of PET synthesizers for existing and new radiopharmaceutical laboratories, collaborating with major research institutions and pharmaceutical companies worldwide.

The various range of NEPTIS® synthesizers are dedicated for the production of PET radiopharmaceuticals, and have aimed since their inception to address the various challenges a user faces in today’s field. NEPTIS® synthesizers are different by nature, equipped with an innovative patented technology, a unique control system software and a reliable and strong performance are all factors which have proven that NEPTIS® does belong in your hotcell lab.

For additional information about NEPTIS® please visit our webpage at www.neptis-vsa.com.

About the NUVIA Group:
NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility’s lifecycle design, construction, operations, maintenance, decommissioning. The NAVIATECH HEALTHCARE brand was created in 2017 to offer the Group’s complete portfolio of instruments, systems and solutions for healthcare applications.

For more information about the NUVIA Group and its activities in the healthcare sector, please visit www.nuviatech-healthcare.com.
The OGNMB represents the field of nuclear medicine and molecular imaging in Austria with more than 250 individual and supporting members. It welcomes researchers and employees of all fields involved, including radiochemists, medical physicists, technologists, radiopharmacists and of course trained nuclear medicine specialists as well as those in training.

The OGNMB organizes annually symposia in Zell am See (Austria). You are cordially invited to attend the next International Austrian Winter Symposium, taking place from Jan 22 - 25, 2020. Please check the website for further information.

OncoBeta GmbH

OncoBeta GmbH, located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company. The OncoBeta® GmbH is specialized in the development and commercialization of innovative therapies utilizing epidermal radioisotope applications as well as the supply of 188W/188Re generator platforms.

OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers (NMSC). The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs. Due to the specially designed devices and accessories the Rhenium-SCT compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician.

Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

Oncodesign

Oncodesign is a leading French biopharmaceutical company that meets the needs of innovation in the health industry through precision medicine. The company has built an industrial model of innovation to orientate new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment: through services, partnerships and licensing. Oncodesign offers access to its drug discovery platform to qualify, at a very early stage, each molecule’s potential to become an effective therapeutic drug.

Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB.

Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 225 employees and subsidiaries in Canada and the USA.

Oncodesign is a leading French biopharmaceutical company that meets the needs of innovation in the health industry through precision medicine. The company has built an industrial model of innovation to orientate new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment: through services, partnerships and licensing. Oncodesign offers access to its drug discovery platform to qualify, at a very early stage, each molecule’s potential to become an effective therapeutic drug.

Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB.

Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 225 employees and subsidiaries in Canada and the USA.
PI Medical Diagnostic Equipment B.V.

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market in the Netherlands and Flanders. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, laser systems for PET/CT, patient positioning devices, etc.

PI Medical is specialized in gamma probes for the sentinel node procedure. The company has been deeply involved in the development of these products. Next to probes, the company also supplies 125I seeds for tumor localization purposes.

The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

PMB-ALCEN

Located near Aix-en-Provence, in France, PMB is a 130-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency...), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.

PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room, complete with an automated quality control device. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Quality control is then carried out through an automated process to test the synthesized molecule.

AVGâNE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, AVGâNE improves patient care.

Pepscan BV

Pepscan is a premium service provider for Life Sciences with more than 25 years expertise in providing custom peptide and epitope mapping services. Pepscan-team is the inventor of combinatorial peptide-based libraries and expert in providing custom peptide including chelator-conjugated peptides (DTPA, DOTA and etc.) and disulfide containing peptides (folded peptides).

We are fully capable of meeting the growing needs for peptides in research purposes and clinical peptides for neosaragen projects.

Pepscan is based in Lelystad, the Netherlands, and can be reached via info@pepscan.com or www.pepscan.com.

Philips

Enabling better health and better care at lower cost – Philips is a leading health technology company focused on improving people’s lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people’s health and enable better outcomes.

Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced.

The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

Philips

Amstelplein 2
Breitner Center
PO Box 77900
1070 MX Amsterdam
+31 20 59 77777
http://www.philips.com

Enabling better health and better care at lower cost – Philips is a leading health technology company focused on improving people’s lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people’s health and enable better outcomes.

Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced.

The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

PMB-ALCEN

Route des Michels CD56
Chemin de la Corneillre
13790 Peynier
(33)442531313
contact@pmb-alcen.com

Located near Aix-en-Provence, in France, PMB is a 130-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency...), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.

PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room, complete with an automated quality control device. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Quality control is then carried out through an automated process to test the synthesized molecule.

AVGâNE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, AVGâNE improves patient care.

Pepscan BV

Zuidersluisweg 2
8243 RC Lelystad
+31 320 225300
http://www.pepscan.com

Pepscan is a premium service provider for Life Sciences with more than 25 years expertise in providing custom peptide and epitope mapping services. Pepscan-team is the inventor of combinatorial peptide-based libraries and expert in providing custom peptide including chelator-conjugated peptides (DTPA, DOTA and etc.) and disulfide containing peptides (folded peptides).

We are fully capable of meeting the growing needs for peptides in research purposes and clinical peptides for neosaragen projects.

Pepscan is based in Lelystad, the Netherlands, and can be reached via info@pepscan.com or www.pepscan.com.

Philips

Amstelplein 2
Breitner Center
PO Box 77900
1070 MX Amsterdam
+31 20 59 77777
http://www.philips.com

Enabling better health and better care at lower cost – Philips is a leading health technology company focused on improving people’s lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people’s health and enable better outcomes.

Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced.

The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

PMB-ALCEN

Route des Michels CD56
Chemin de la Corneillre
13790 Peynier
(33)442531313
contact@pmb-alcen.com

Located near Aix-en-Provence, in France, PMB is a 130-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency...), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.

PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room, complete with an automated quality control device. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Quality control is then carried out through an automated process to test the synthesized molecule.

AVGâNE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, AVGâNE improves patient care.
Qubiotech Health Intelligence is a medical imaging start-up dedicated to the development and commercialization of cloud software for improving the diagnostic of neurodegenerative diseases by means of advanced image processing.

Our cloud platform provides quantitative and visual information of PET, SPECT and MRI images in few minutes, allowing natural integration within the clinical workflow. An easy web access fosters communication among different specialties physicians, reducing barriers for team work. Neurocloud helps to improve diagnostic confidence, reducing diagnosis subjectivity and improving time per patient.

Polish Association of Nuclear Medicine (PTMN) is a scientific society with app. 300 members: physicians, technicans, nurses, physicists and radiochemists. Its main activities include promotion of nuclear medicine in Poland, organization of scientific meetings and education. Biannual meetings are organized to discuss latest research performed in the country and abroad. The next national PTMN meeting will be held on May 20-23rd, 2020 in the city of Białystok, near the border to Lithuania, Belarus and Russia. Participants from neighbouring countries are welcome.

The Association runs its scientific journal named Nuclear Medicine Review. Contribution from all over the world are welcome to publish in NMR. Currently, the PTMN coordinates the editorial work on the first comprehensive and up-to-date textbook of nuclear medicine in Polish language.

For the first time, PTMN opens its booth at the ‘World’s leading meeting’ to inform the international public about its activities and projects. See you at our booth!
Rotem GmbH

RoweMed AG - Medical 4 Life

ROTOP Pharmaka GmbH

Scintomics GmbH

Rotem GmbH

RoweMed AG – Medical 4 Life is an innovative MedTech company. Our focus is on developing and producing customized medical plastic systems, especially for the handling of sensitive pharmaceuticals.

R&D: The development of systems is closely coordinated with the customer, from first sketch up to a market-ready product, including CAD construction, prototyping, first series and product tests.

Production: We offer injection molding, assembling & packaging under one-roof. In the cleanroom production facility (ISO class 7) in Parchim our employees carry out single-part, small series & automated mass production. At the assembling department all common welding & gluing technologies are implemented.

Regulatory Affairs: In addition to the technical services we offer the complete technical documentation according to the requirements of the Medical Device Directive 93/42/EEC.

Rotem, a longtime world leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product line is centered on Oxygen-18 enriched water, plastic cassettes, precursors and full reagent kits for various synthesis modules. All products are produced in accordance with cGMP requirements according to the EU & PIC/S and are manufactured at our US FDA-inspected facility. Rotem’s cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM. Production is supported by Rotem’s in-house certified analytical lab with a wide array of equipment and QC method development capabilities. Users enjoy full technical and regulatory support from our highly qualified staff along with excellent customer service.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, the result of a longstanding and close cooperation with radiopharmacies worldwide.

Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Eire.

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOPI continuously expands its product portfolio by developing new products and entering new strategic partnerships.

Our portfolio includes:
- A comprehensive range of Tc-99m kits
- GMP-compliant production of agents for Tc-99m kits
- Quality control sets for Tc-99m radiopharmaceuticals
- Distribution of pharmaceuticals that are produced by subcontractors for ROTOPI
- Pharmaceutical Development

We will be happy to welcome you at our booth #92.

Scintomics GmbH is a worldwide leading company in the clinical translation of innovative radiopharmaceuticals for theranostics. As a worldwide operating subsidiary of Scintomics, ATT (SCINTOMICS Molecular Applied Theranostics Technologies) continues Scintomics’ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy, such as PSMA TO-1.

At this year’s EANM conference, SCINTOMICS and ATT launch [18F]siPSMA, a series of Silicon Fluoride Acceptor- (SiFA-) based Glutamate carboxypeptidase II Inhibitors (PSMA-Inhibitors) that are produced in <15 min at room temperature by means of very simple cassettes and downsized, highly cost-effective modules.
Super Argus PET/CT is the Argus PET/CT scanners evolution. The new scanner combine the “Unique Phoswich DOI Technology” from the Argus family with the highest FOV of the market (axial and transversal), which permits extending PET/CT studies to bigger animals. The configurations available in axial FOV are (2, 4 or 6 rings) depending on customers needs and with the option of to be upgrade later on.

Super Argus has been designed with the aim of satisfy the professionals needs, such as user-friendly option and multi-animal bed system which allows a high throughput (up to 10 mices at the same time).

The new CT, is also focused on new market demands, such as low dose, fast scanning time, high resolution mode and advanced applications (dual energy and dual exposure).

In particular in these areas, the SFMN ensures the national organization of continuous training and evaluation of professional practices. The means of action of the Society are publications, lectures, courses, exhibitions, study groups, conventions, meetings, awarding of prizes and any means of dissemination, education or technical training in the French language.

The dual modality configuration delivers faster scan times with superior image resolution, improved localization and quantifiable data.

SHINE Medical Technologies, LLC is dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements.

SHINE began construction of its first production facility in 2019 in Janesville, WI, USA and has announced plans to build a second plant in Europe.

SHINE will use a patented, proprietary manufacturing process to produce medical tracers and cancer treatment elements such as molybdenum-99, iodine-131, xenon-133, and lutetium-177. SHINE already has three definitive supply agreements with Mo-99 distributors for over 10 million doses. The SHINE technology offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste, and is compatible with the existing global supply chain for Mo-99.

SHINE also recently announced the signing of a license agreement for the exclusive, global rights to a novel Lu-177 separation method which will allow production and separation of Lu-177 before the completion of its primary medical isotope production facility in the United States.
Siemens Healthcare GmbH

At Siemens, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalizing healthcare.

An estimated 5 million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,500 patents worldwide. With more than 50,000 dedicated colleagues in more than 75 countries, we will continue to innovate and shape the future of healthcare.

Sirtex Medical Europe GmbH

Sirtex is a global life-sciences company actively engaged in the field of liver-directed therapies for cancer patients. The innovative technology SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, to treat inoperable liver tumours. High doses of radiation are directly delivered to the site of tumour(s) whilst conserving normal liver parenchyma.

Our business revolves around helping medical professionals understand and use our product to improve clinical outcomes and the quality of life for patients with liver tumours.

Over 100,000 SIR-Spheres microspheres have been supplied to treat patients in over 1,300 certified hospitals in more than 50 countries.

SIR-Spheres® microspheres were approved in 2002 for use in the treatment of a variety of unresectable liver tumours within the European Union under a CE Mark.

The 2016 European Society for Medical Oncology (ESMO) guidelines for physicians recommend the use of SIR-Spheres Y-90 resin microspheres to treat liver tumours that have spread from the bowel and do not respond anymore to chemotherapy.

Please come to our booth to see new and exciting things!

Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization, founded in 1954, that promotes the science, technology and practical application of nuclear medicine and molecular imaging and therapy. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 16,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

In addition to publishing journals, newsletters and books, the Society also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine and molecular imaging practitioners and to promote new advances in the science of nuclear medicine, molecular imaging and therapy. The Society maintains an active advocacy program to promote and encourage research and the advancement of nuclear medicine science and produces a number of programs to help physicians and technologists remain current with the latest advances. The Society also sponsors education programs for consumers to help them understand nuclear medicine, molecular imaging and therapy and the constructive role it can play in both diagnostic and therapeutic therapies.

Southern Scientific Limited

Southern Scientific manufacture a range of probes and contamination monitors for medical applications, including the Care Wise C-Trak Galaxy Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.

Southern Scientific will be showcasing the brand new C-Trak Apollo Gamma Probe System and the iodine-125 diagnostic seeds at EANM’19.

The C-Trak Apollo is the only system on the market allowing wireless or wired connectivity with the same probe. The well-known Omni Probe, provides an optimal balance between directionality and sensitivity. With the Apollo, surgeons can easily switch between wired and wireless eliminating any instrument downtime.

The iodine-125 seeds, currently available in the UK through Southern Scientific, are a safe, effective and increasingly popular technique for the preoperative localisation of non-palpable breast lesions.

With the seeds available in pre-loaded needles, this saves time, skill, and effort for radiologists and minimizes risk of dropping or losing a seed compared to manual loading of needles.

Our contamination monitor range includes the Radhound - available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes - and the Handhound voice-activated hand monitor.

We are looking for distributors in certain countries. If you are interested, please visit us on stand 96.
Since 1998, the company has been developing and manufacturing radiation safety devices and equipment. They include a lot of various types of products – from measuring instruments for ionizing radiation and radioisotopic products of metronomological and other purposes to technological radiation protection equipment designed to work with radioactive substances and other sources of ionizing radiation.

Sumitomo Heavy Industries, Ltd. (“SUMITOMO”) is one of the largest heavy machinery companies in Japan and manufactures various machinery and equipment, such as VLCC tanker, power boilers, plastic machinery, power transmission equipment and accelerator.

In the field of accelerator, with long experiences, Sumitomo produces medical related equipment, i.e. proton therapy system and PET (“Positron Emission Tomography”) radio-tracer production system. Regarding PET radio-tracer production system, Sumitomo is the leading manufacture of cyclotrons as well as various synthesizers, hot cell and ancillary equipment with majority of market share in Asia.

Sumitomo has an experience of delivering the PET cyclotron system over 30 years and delivered more than 200 PET systems in Asian countries, i.e. Japan, South Korea, China, Taiwan, Thailand, Malaysia, India, Philippines and Iraq.

Syntermed, Inc.

Syntermed, Inc., an Atlanta-based imaging and informatics software company, is a global leader in providing Cardiac and NeuroRadiology solutions. Syntermed complies with the requirements of ISO 13485:2016 and our products carry required CE marks. Syntermed solutions power over 50% of the nuclear medicine departments worldwide. Signature products include Emory Toolbox™ with AI, NeuroQ™, Syntermed Live™, FlowTool™, and SmartReport™. Please visit stand #39 to learn more about new innovations including the industry’s first and only AI solution for Nuclear Cardiology, plus the most comprehensive and widely used solution for quantitation of NeuroRadiology PET/SPECT studies. Syntermed software is compatible with virtually any nuclear medicine workstation or PC/MAC that supports Microsoft® Windows® operating systems and is available direct or from leading OEMs, PACs and EMR Vendors, and Systems Integrators. We are always seeking reseller/distributor partnerships and is available direct or from leading OEMs, PACs and EMR Vendors, and Systems Integrators. We are committed to automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises C-11, F-18, N-13, Ga-68, Lu-177, I-123, I-124, I-131 and other radioisotopes. It includes targets, radio synthesizers (including customized modules), quality control equipment, e.g. HPLC and TLC, spare parts and service.

Our radio synthesizers combine high performance and efficiency with high flexibility that enable the production of radio pharmaceuticals. Besides the attractive design, our software and synthesizers are highly user-friendly and meet the latest GMP regulations. Most commonly our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals. It also offers an automated self-cleaning system which is a far more ecofriendly and a time-efficient feature.

For more information about Syntermed Innovation, or to inquire about reseller/distributor partnerships, please visit www.syntermed.com, or email mlee@syntermed.com

Brands: NeuroQ™, Emory Toolbox™, with AI, Syntermed Live™, Syntermed IDS™, SmartReport™, Sync tools™, Adreview™ Tools PET tools™, FlowTool™.
Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR).

The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Telix is listed on the Australian Securities Exchange (ASX:TLX).

Tecnica Radiofisicas

Tecnica Radiofisicas (TRF) is a Healthcare company based in Spain with expertise in the following areas.

Medical Physics Consulting, (Nuclear Medicine, Radiotherapy & Radiology)

Manufacturing of Radiation Protection Equipment

Development of Software for Healthcare Applications

TRF was established in 1985. TRF has performed Medical Physics consulting for installations throughout Europe, Asia and Latin America. TRF has designed and implemented Medical Physics Projects in both the Healthcare & Science Sectors. A core component of the TRF business is the design and manufacturing of Decay Tank Systems (DTS) for handling and disposal of radioactive waste that is generated during Nuclear Medicine procedures.

TRF also manufactures and markets a full featured Radiation Area Monitor, (TRF GM Rady) and Radiation Monitoring System, (RMS) that includes centralized control and monitoring via the TRF RadyNet software product. Another area where TRF excels is in the manufacturing and supply of Nuclear Medicine Hot Lab products that are designed to provide Radiation Protection for the safe handling, preparation and storage of Radiopharmaceuticals.
Terumo Interventional Systems

Interleuvenlaan 40
3001 Leuven
https://www.terumo-europe.com/

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years’ experience in developing best in class medical devices. At Terumo Interventional Systems, we constantly work to refine and perfect our products so that healthcare professionals can do more to support their patients.

Within Interventional Oncology, Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medicine to ensure they have access to high quality tools for their patients. This partnership is based on Terumo’s comprehensive range of technology and services to support healthcare professionals with their patient needs.

QuiremSpheres® are advancing the future of SIRT through developing the first commercially available microspheres that contains the radioactive isotope Holmium-166. QuiremSpheres® are also the only microspheres that contains the radioactive isotope through developing the first commercially available QuiremSpheres® are advancing the future of SIRT needs.

Theragnostics Ltd

2 Arlington Square
Bracknell
RG12 1WA Bracknell
+44 330 606 7437
hello@theragnostics.com
https://theragnostics.com/

Theragnostics is an innovative radiopharmaceutical company with a portfolio of products in development. Our mission is to drive innovation in the fight against cancer, enhancing patients’ lives with precision radiopharmaceuticals for personalized medicine.

Theragnostics are developing a first-in-class molecular radiotherapy based on a PARP inhibitor (PARPi) which has the potential to treat a wide range of cancers. The equivalent PET diagnostic molecule (18F-PARPi) recently completed recruitment in a Phase I clinical trial and plans for Phase II trials are currently underway.

Theragnostics most advanced clinical program, THG-001, is in Phase II clinical trials for the assessment of prostate cancer. THG-001 utilizes our GalliP® platform to prepare Ga-68 TIP-PSMA from a single vial kit.

GalliP® technology simplifies the production of gallium labelled compounds allowing elution of a generator directly into the kit vial to yield a product in 5 minutes without heating or preparation of buffer vials.

For further details please visit www.theragnostics.com or stop by booth number 4 at EANM 2019 to meet our team.

Trasis

Rue Gilles Magnée 90
4430 Ans
info@trasis.com
http://www.trasis.com

Trasis is specialized in the development and the manufacturing of innovative and high quality radiopharmaceutical equipment.

By carefully listening to professional users and markets trends, Trasis provides practical and reliably designed systems for automated synthesis, dispensing and packaging of radio-pharmaceuticals.

AllinOne is a multiple purpose radiochemistry unit featuring synthesizer, HPLC & reformulation in a single compact box, able to efficiently produce the most complex compounds such as nucleophilic FOPa, Thymosine, HF1 as well as FDG in multiple runs. AllInOne’s versatility also helps researchers address the growing need for new tracers.

MiniAIO is designed for simpler processes and to cost efficiently produce compounds such as FDG, Ga68/Lu177-peptide conjugates or NaF and requires less space in the hot cell.

EasyOne is the latest of the AllinOne family. It has been simplified to the extreme for routine production of most radiometals labelled pharmaceuticals. Compatible with all Ga68 Generators, its ultra-compact design and ease of use are its major assets.

Undose, a high speed dose dispenser dedicated to hospitals, simplifies the procedures and reduces drastically the exposure to the technologists.

Trasis offers custom development services for chemistry, reagents and disposables.

TRISKEM

3 RUE DES CHAMPS GEONS ZAC DE l’EPERON
35170 Bruz
https://www.triskem-international.com/

Triskem International is a leading provider of extraction chromatographic resins and solutions for the separation of radioactive elements.

Triskem’s main product line consists of a wide selection of different extraction chromatographic resins which allow the separation of radionuclides from various samples and matrices (irradiated targets, environmental, medical and biosassay as well as waste and decommissioning samples). Our products are standard technology in radiochemistry and they are used by international accredited laboratories and monitoring agencies such as the IAEA, AREVA, IRSN, CEA, BR…).

Our resins are increasingly finding application in the production and quality control of radionuclides (such as Cu-64/7, Sc-44/7, Zr-89, Ge-68, Ga-67, Ti-44, alpha emitters…) for medical use, and are employed by leading radionuclide manufacturers worldwide.

Triskem International places a strong focus on the development of new resins and separation methods to meet your separation needs. If you’d like to receive more detailed information, or if you’d like to discuss a specific separation problem please contact us under: contact@triskem.fr.
The Turkish Society of Nuclear Medicine (TSNM) was founded in 1975 and is dedicated to the education and promotion of nuclear medicine for the benefit of public health. The society aims to provide a common platform for nuclear medicine physicians, physicists, pharmacists, and technologists to share knowledge and engage in collaborative projects.

Current TSNM membership includes 859 members, including physicians, physicists, pharmacists, and technologists. The society hosts several scientific activities each year, such as winter schools, online workshops, and industrial supplier symposiums, in addition to national congresses and a symposium dedicated to a different topic of interest.

Currently, TSNM offers various educational programs for residents and young physicians by experts in the field. The society’s educational offerings are designed to enhance understanding and promote clinical practice and research in the field of nuclear medicine.

The official journal of TSNM is “Molecular Imaging and Radiation Oncology” (MIRT), which is a peer-reviewed, international journal dedicated to research and advancements in nuclear medicine. MIRT is indexed in PubMed, PubMed Central, EBSCO, and other databases to increase access to its content.

The society is also proud of its electronic journal, “Nuclear Medicine Seminars,” which is dedicated to educational articles on specific topics by the invited editors in each issue. The society publishes these educational articles in Turkish, dedicated to educational articles for residents and young physicians by the experts of the scientific task groups involved in the society.

The Turkish Society of Nuclear Medicine aims to promote clinical practice, research, and education in nuclear medicine for the benefit of public health. TSNM also holds a unique position in the field of national health authorities, departments of nuclear medicine in universities, and training and research hospitals, as well as industrial suppliers and other medical societies.

TSNM also has a significant role in providing collaboration between national health authorities and the scientific community, allowing for the development of production techniques and the advancement of international collaborations. The society is a member of the European Association of Nuclear Medicine (EANM), which is a leading international organization in the field of nuclear medicine.
At this EANM annual congress, AWEX has gathered more than 400 employees in nearly 100 countries internationally via our website. In our network of international agents, we support you. Around the world, there is always someone ready to advise in every stage of their development. We work closely with them to inform, convince, and deliver worldwide. The agency’s vast network of connections ensures that the best advisors are always by your side. Our local offices and agents are capable of providing unparalleled insight to take your company to the next level.

The Wallonia Export-Investment Agency (AWEX) is the institution in charge of the development and management of Wallonia’s international economic relations.

Through a personalized, innovative, and sustainable approach, AWEX supports companies – regardless of their size or sector – in every step of their search for suppliers and partners from Wallonia. This includes exports, technological partnerships, and development abroad.

The agency’s vast network of connections ensures the best advisors are always by your side. Our local offices and agents are capable of providing unparalleled insight to take your company to the next level.

AWEX is also committed to strengthening Wallonia’s position as the top gateway for international investors seeking success in the heart of Europe. We work closely with them to inform, convince, and advise in every stage of their development.

Feel free to get in touch with one of our local or international agents via our website. In our network of more than 400 employees in nearly 100 countries around the world, there is always someone ready to support you.

At this EANM annual congress, AWEX has gathered nine companies active in nuclear medicine. Come discover their products and services in booths 70 to 74.

**Wisepress LTD**

**15 Lyon Road**

Merton

SW19 2RL London

+44 2087151812

olivia.thomas@wisepress.com

http://www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide.

In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

**Wolfmet (M&I Materials Ltd)**

**M&I Materials Ltd**

Hibernia Way

Trafford Park

M32 0ZD Manchester

0161 864 5453

stevejeffery@mimaterials.com

http://www.wolfmet.com/

Wolfmet 3D Printed Tungsten Collimators

Wolfmet tungsten alloy has been the automatic choice for radiation shielding and collimators in nuclear medicine for many years.

Over the last 5 years Wolfmet has been opening up a world of possibilities with the introduction of Wolfmet 3D printed tungsten. This revolutionary process makes complex, high-precision tungsten collimators a reality. The benefits of this ever developing technology include:

- High density components which reduce septal penetration and therefore improve imaging
- Collimator compatibility with the new generation of SPECT/MRI scanners
- Reduced development costs – no tooling charges
- Rapid production of prototypes
- Easy modifications of designs
- Reduced time from development to actual production

Wolfmet (M&I Materials Ltd) is part of the Pavilion consortium (Stand 83), come and visit us to learn more about our exciting new developments.

In addition, we will have examples of our standard shields for nuclear medicine – FDG pots, vial shields and customised shields.
Zionexa

42 Avenue de la Grande Armée
75017 Paris
contact@zionexa.com
https://www.zionexa.com

Founded in 2018, Zionexa is an international leader in the development of in-vivo biomarkers guiding targeted therapies that will transform oncology by improving the patient’s pathway and quality of life.

Within a PET Scan (Positron Emission Tomography) exam, biomarkers help Oncologists and Nuclear Medicine Physicians to personalize the treatment, based on a whole body image which provides the localization and characteristics of the tumors.

Annual Congress of the European Association of Nuclear Medicine
October 17 – 21, 2020
Vienna, Austria
eanm20.eanm.org
Corporate Members

EANM wishes to thank the following companies for their support as Corporate Members (alphabetical order):

- Advanced Accelerator Applications, a Novartis company
- Advancing Nuclear Medicine, with NRG & Partners
- Avid Radiopharmaceuticals (Lilly)
- BTG – Boston Scientific
- Bracco Diagnostics Inc.
- Bruker BioSpin
- COMECER
- Curium
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- GE Healthcare
- Hermes Medical Solutions
- IBA
- JSC Isotope / Rusatom Healthcare
- Lemer Pax
- Life Healthcare
- Mediso
- MR Solutions Ltd.
- Norgine Ltd
- Pars Isotope Co.
- Philips
- Siemens Healthineers
- Sirtex Medical Europe GmbH
- Spectrum Dynamics Medical Inc.
- Tema Sinergie S.p.A.
- Terumo Interventional Systems
- Zionexa